FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Du, XL
Qian, XL
Papageorge, A
Vass, WC
Braverman, R
Lowy, DR
AF Du, Xiaoli
Qian, Xiaolan
Papageorge, Alex
Vass, William C.
Braverman, Richard
Lowy, Douglas R.
TI Complex formation between the DLC1 START domain and Cav1 contributes to
the tumor suppressor function of DLC1
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Du, Xiaoli; Qian, Xiaolan; Papageorge, Alex; Vass, William C.; Braverman, Richard; Lowy, Douglas R.] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2184
DI 10.1158/1538-7445.AM2011-2184
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402278
ER
PT J
AU Edelman, DC
Stevenson, H
Suuriniemi, M
Singh, P
Rodriguez-Canales, J
Hanson, JC
Walker, R
Emmert-Buck, MR
Meltzer, P
AF Edelman, Daniel C.
Stevenson, Holly
Suuriniemi, Miiia
Singh, Parvati
Rodriguez-Canales, Jamie
Hanson, Jeffery C.
Walker, Robert
Emmert-Buck, Michael R.
Meltzer, Paul
TI Whole genome amplification allows for testing of valuable specimens by
array comparative genomic hybridization
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Edelman, Daniel C.; Stevenson, Holly] NCI, NIH, Gaithersburg, MD USA.
[Suuriniemi, Miiia; Singh, Parvati; Rodriguez-Canales, Jamie; Hanson, Jeffery C.; Walker, Robert; Emmert-Buck, Michael R.; Meltzer, Paul] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4862
DI 10.1158/1538-7445.AM2011-4862
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701403442
ER
PT J
AU El Meskini, R
Lacovelli, A
Kulaga, A
Gumprecht, M
Martin, P
Baran, M
Song, YR
Ohler, ZW
Van Dyke, T
AF El Meskini, Rajaa
Lacovelli, Anthony
Kulaga, Alan
Gumprecht, Michelle
Martin, Philip
Baran, Maureen
Song, Yurong
Ohler, Zoe Weaver
Van Dyke, Terry
TI A preclinical orthotopic mouse model for human GBM: Recapitulation of
features of GEM model of origin and potency of PI3K inhibitors
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [El Meskini, Rajaa; Lacovelli, Anthony; Kulaga, Alan; Gumprecht, Michelle; Martin, Philip; Baran, Maureen; Ohler, Zoe Weaver] SAIC NCI Frederick, Frederick, MD USA.
[Song, Yurong; Van Dyke, Terry] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4322
DI 10.1158/1538-7445.AM2011-4322
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301332
ER
PT J
AU Emre, NCT
Shaffer, AL
Wright, GW
Kohlhammer, H
Staudt, LM
AF Emre, N. C. Tolga
Shaffer, Arthur L.
Wright, George W.
Kohlhammer, Holger
Staudt, Louis M.
TI IRF4 as a critical regulator and potential therapeutic target in ABC
type diffuse large B-cell lymphoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Emre, N. C. Tolga] Bogazici Univ, Istanbul, Turkey.
[Shaffer, Arthur L.; Wright, George W.; Staudt, Louis M.] NIH, Bethesda, MD 20892 USA.
[Kohlhammer, Holger] Univ Ulm Klinikum, Ulm, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA LB-248
DI 10.1158/1538-7445.AM2011-LB-248
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303051
ER
PT J
AU Ericson, ME
Nye, S
Bode, A
Grubbs, C
Lubet, R
AF Ericson, Marna E.
Nye, Steffan
Bode, Ann
Grubbs, Clinton
Lubet, Ron
TI Degree or extent of radially-aligned collagen fibrils in the
tumor-stromal interface of rodent mammary tumor tissue is an indicator
of chemotherapeutic potential of the EGFr inhibitor, Gefitinib
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Ericson, Marna E.; Nye, Steffan] Univ Minnesota, Minneapolis, MN USA.
[Bode, Ann] Univ Minnesota, Austin, MN USA.
[Grubbs, Clinton] Univ Alabama Birmingham, Birmingham, AL USA.
[Lubet, Ron] NCI, Bethesda, MD 20892 USA.
RI ericson, marna/C-9591-2017
OI ericson, marna/0000-0003-1862-4957
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 441
DI 10.1158/1538-7445.AM2011-441
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301026
ER
PT J
AU Eyans, LM
Woditschka, S
Fitzgerald, DP
Palmieri, D
Badve, S
Sledge, GW
Steeg, PS
AF Eyans, Lynda M.
Woditschka, Stephan
Fitzgerald, Daniel P.
Palmieri, Diane
Badve, Sunil
Sledge, George W.
Steeg, Patricia S.
TI L1CAM neural adhesion molecule is overexpressed in human brain
metastases of breast cancer and contributes to colony formation
efficiency
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Eyans, Lynda M.; Woditschka, Stephan; Fitzgerald, Daniel P.; Palmieri, Diane; Steeg, Patricia S.] NCI, NIH, Bethesda, MD 20892 USA.
[Badve, Sunil; Sledge, George W.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2667
DI 10.1158/1538-7445.AM2011-2667
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300302
ER
PT J
AU Fitzgerald, DP
Palmieri, D
Qian, YZ
Deshpande, M
Subramanian, P
Graves, C
Davis, S
Meltzer, P
Camphausen, K
Becerra, PS
Steeg, PS
AF Fitzgerald, Daniel P.
Palmieri, Diane
Qian, Yongzhen
Deshpande, Monika
Subramanian, Pretti
Graves, Christian
Davis, Sean
Meltzer, Paul
Camphausen, Kevin
Becerra, Patricia S.
Steeg, Patricia S.
TI Pigment epithelium-derived factor (PEDF) functions as a brain metastasis
suppressor of breast cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Fitzgerald, Daniel P.; Palmieri, Diane; Graves, Christian; Davis, Sean; Meltzer, Paul; Camphausen, Kevin; Steeg, Patricia S.] NCI, Bethesda, MD 20892 USA.
[Qian, Yongzhen] NCI, Lab Sci Anim Program, Frederick, MD 21701 USA.
[Deshpande, Monika; Subramanian, Pretti; Becerra, Patricia S.] NEI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2846
DI 10.1158/1538-7445.AM2011-2846
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303321
ER
PT J
AU Flavell, DJ
Holmes, SE
Gibbs, EL
Adcott, JE
Flavell, SU
Bachran, C
Fuchs, H
Weng, A
Bachran, D
Melzig, MF
AF Flavell, David J.
Holmes, Suzanne E.
Gibbs, Emily L.
Adcott, Jennifer E.
Flavell, Sopsamorn U.
Bachran, Christopher
Fuchs, Hendrik
Weng, Alexander
Bachran, Diana
Melzig, Matthias F.
TI Gypsophila saponins significantly augment the cytotoxicity of
saporin-based anti-CD19,-CD22,-CD38 and-CD71 immunotoxins in human
leukemia and lymphoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Flavell, David J.; Flavell, Sopsamorn U.] Univ Southampton, Southampton, Hants, England.
[Holmes, Suzanne E.; Gibbs, Emily L.; Adcott, Jennifer E.] Leukaemia Busters, Southampton, Hants, England.
[Bachran, Christopher] NIAID, NIH, Bethesda, MD 20892 USA.
[Fuchs, Hendrik; Weng, Alexander; Bachran, Diana] Charite, Zent Inst Lab Med & Pathobiochem, D-13353 Berlin, Germany.
[Melzig, Matthias F.] Free Univ Berlin, Inst Pharm, Berlin, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 767
DI 10.1158/1538-7445.AM2011-767
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303163
ER
PT J
AU Fortner, RT
Eliassen, AH
Xu, X
Schairer, C
Veenstra, TD
Ziegler, RG
Hankinson, SE
AF Fortner, Renee Turzanski
Eliassen, A. Heather
Xu, Xia
Schairer, Catherine
Veenstra, Timothy D.
Ziegler, Regina G.
Hankinson, Susan E.
TI Association between reproductive factors and urinary estrogen
metabolites in premenopausal women
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Fortner, Renee Turzanski; Eliassen, A. Heather; Hankinson, Susan E.] Harvard Univ, Boston, MA 02115 USA.
[Xu, Xia; Veenstra, Timothy D.] SAIC Frederick Inc, Frederick, MD USA.
[Schairer, Catherine; Ziegler, Regina G.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4634
DI 10.1158/1538-7445.AM2011-4634
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406052
ER
PT J
AU Gan, ZY
Kodela, R
Goswami, S
Chattopadhyay, M
Boring, D
Crowell, JA
Kashfi, K
AF Gan, Zong Yuan
Kodela, Ravinder
Goswami, Satindra
Chattopadhyay, Mitali
Boring, Daniel
Crowell, James A.
Kashfi, Khosrow
TI All three positional isomers of acetyl salicylic acids are equally
potent in inhibiting colon cancer cell growth: Differences in mode of
COX inhibition
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Gan, Zong Yuan; Kodela, Ravinder; Goswami, Satindra; Chattopadhyay, Mitali; Kashfi, Khosrow] CUNY, Sch Med, New York, NY 10031 USA.
[Boring, Daniel; Crowell, James A.] NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5560
DI 10.1158/1538-7445.AM2011-5560
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305317
ER
PT J
AU Gan, ZY
Chattopadhyay, M
Kodela, R
Boring, D
Crowell, JA
Kashfi, K
AF Gan, Zong Yuan
Chattopadhyay, Mitali
Kodela, Ravinder
Boring, Daniel
Crowell, James A.
Kashfi, Khosrow
TI Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic
Jurkat cells and modulates beta-catenin expression
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Gan, Zong Yuan; Chattopadhyay, Mitali; Kodela, Ravinder; Kashfi, Khosrow] CUNY, Sch Med, New York, NY 10031 USA.
[Boring, Daniel; Crowell, James A.] NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4608
DI 10.1158/1538-7445.AM2011-4608
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303030
ER
PT J
AU Gandini, S
di Pietro, A
Maisonneuve, P
Autier, P
Fargnoli, MC
Garcia-Borron, JC
Han, JL
Kanetsky, PA
Landi, MT
Little, J
Newton-Bishop, J
Sera, F
Raimondi, S
AF Gandini, Sara
di Pietro, Alessandra
Maisonneuve, Patrick
Autier, Philippe
Fargnoli, Maria Concetta
Garcia-Borron, Jose C.
Han, Jiali
Kanetsky, Peter A.
Landi, Maria Teresa
Little, Julian
Newton-Bishop, Julia
Sera, Francesco
Raimondi, Sara
TI The M-SKIP Project: an international pooled-analysis on melanocortin-1
receptor (MC1 R) variants and skin carcinogenesis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Gandini, Sara; di Pietro, Alessandra; Maisonneuve, Patrick; Raimondi, Sara] IEO European Inst Oncol, Milan, Italy.
[Autier, Philippe] Int Prevent Res Inst, Lyon, France.
[Fargnoli, Maria Concetta] Univ Aquila, IEO European Inst Oncol, Dept Dermatol, I-67100 Laquila, Italy.
[Garcia-Borron, Jose C.] Univ Murcia, Dept Biochem & Mol Biol, Murcia, Spain.
[Han, Jiali] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA.
[Han, Jiali] Harvard Univ, Sch Med, Boston, MA USA.
[Kanetsky, Peter A.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Landi, Maria Teresa] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Little, Julian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada.
[Newton-Bishop, Julia] Univ Leeds, Epidemiol & Biostat Sect, Leeds Inst Mol Med, Leeds, W Yorkshire, England.
[Sera, Francesco] UCL Inst Child Hlth, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2244
DI 10.1158/1538-7445.AM2011-2244
PG 2
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405217
ER
PT J
AU Gao, Y
Chow, WH
AF Gao, Ying
Chow, Wong-Ho
TI Leukocyte LINE1 and Alu DNA methylation and gastric cancer risk in the
Shanghai Women's Health Study cohort
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Gao, Ying; Chow, Wong-Ho] NCI, DCEG, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3747
DI 10.1158/1538-7445.AM2011-3747
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305064
ER
PT J
AU Garimella, SV
Gehlhaus, K
Grandin, M
Caplen, N
Lipkowitz, S
AF Garimella, Sireesha V.
Gehlhaus, Kristie
Grandin, Magda
Caplen, Natasha
Lipkowitz, Stanley
TI A functional genomic approach to identify novel molecular regulators of
the TRAIL pathway in breast cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Garimella, Sireesha V.; Lipkowitz, Stanley] NCI, LCMB, CCR, NIH, Bethesda, MD 20892 USA.
[Gehlhaus, Kristie; Grandin, Magda; Caplen, Natasha] NCI, Genet Branch, CCR, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4106
DI 10.1158/1538-7445.AM2011-4106
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402080
ER
PT J
AU Gaudet, MM
Falk, R
Stevens, RD
Pfeiffer, R
Potischman, N
Brinton, LA
Garcia-Closas, M
Sherman, ME
Bain, JR
Muehlbauer, MJ
Newgard, CB
Gunter, MJ
Lissowska, J
Peplonska, B
AF Gaudet, Mia M.
Falk, Roni
Stevens, Robert D.
Pfeiffer, Ruth
Potischman, Nancy
Brinton, Louise A.
Garcia-Closas, Montserrat
Sherman, Mark E.
Bain, James R.
Muehlbauer, Michael J.
Newgard, Christopher B.
Gunter, Marc J.
Lissowska, Jolanta
Peplonska, Beata
TI Serum metabolic profiles and endometrial cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Gaudet, Mia M.] Amer Canc Soc, Atlanta, GA 30329 USA.
[Falk, Roni; Pfeiffer, Ruth; Potischman, Nancy; Brinton, Louise A.; Garcia-Closas, Montserrat; Sherman, Mark E.] NCI, Bethesda, MD 20892 USA.
[Stevens, Robert D.; Bain, James R.; Muehlbauer, Michael J.; Newgard, Christopher B.] Duke Univ, Durham, NC USA.
[Gunter, Marc J.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Lissowska, Jolanta] Ctr Canc, Warsaw, Poland.
[Lissowska, Jolanta] M Sklodowska Curie Inst Oncol, Warsaw, Poland.
[Peplonska, Beata] Nofer Inst Occupat Med, Lodz, Poland.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA LB-454
DI 10.1158/1538-7445.AM2011-LB-454
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406036
ER
PT J
AU Geczy, T
Valle, CJ
Selezneva, JS
Kedei, N
Lewin, NE
Lim, L
Mannam, P
Garfield, SH
Peach, ML
Blumberg, PM
AF Geczy, Tamas
Valle, Christopher J.
Selezneva, Julia S.
Kedei, Noemi
Lewin, Nancy E.
Lim, Langston
Mannam, Poonam
Garfield, Susan H.
Peach, Megan L.
Blumberg, Peter M.
TI Identification of crucial residues at the rim of the binding cleft of
the C1 domain of Vav1 that determine its ligand sensitivity
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Geczy, Tamas; Valle, Christopher J.; Selezneva, Julia S.; Kedei, Noemi; Lewin, Nancy E.; Lim, Langston; Mannam, Poonam; Garfield, Susan H.; Blumberg, Peter M.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Peach, Megan L.] NCI, Ctr Canc Res, NIH, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3854
DI 10.1158/1538-7445.AM2011-3854
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401464
ER
PT J
AU Geiger, TR
Mattaini, K
Williams, M
Walker, R
Alsarraj, J
Borges, RN
Hunters, K
AF Geiger, Thomas R.
Mattaini, Katie
Williams, Mia
Walker, Renard
Alsarraj, Jude
Borges, Rosan Nieves
Hunters, Kent
TI Mechanistic insights into regulation of metastasis by Sipal
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Geiger, Thomas R.; Walker, Renard; Alsarraj, Jude; Borges, Rosan Nieves; Hunters, Kent] NCI, CCR, Bethesda, MD 20892 USA.
[Mattaini, Katie] MIT, Cambridge, MA 02139 USA.
[Williams, Mia] Cleveland Clin, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5269
DI 10.1158/1538-7445.AM2011-5269
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301059
ER
PT J
AU Gijsen, M
Kramer-Marek, G
Bennett, R
Harris, A
Capala, J
Kong, A
AF Gijsen, Mere
Kramer-Marek, Gabriela
Bennett, Ruth
Harris, Adrian
Capala, Jacek
Kong, Anthony
TI Trastuzumab treatment induces ADAM17 and HER ligands in vivo
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Gijsen, Mere; Bennett, Ruth; Harris, Adrian; Kong, Anthony] Univ Oxford, Oxford, England.
[Kramer-Marek, Gabriela; Capala, Jacek] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1530
DI 10.1158/1538-7445.AM2011-1530
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302158
ER
PT J
AU Gills, JJ
Zhang, CY
Abu-Asab, MS
Castillo, SS
Marceau, C
Kozikowski, A
Tsokos, M
Goldkorn, T
Dennis, PA
AF Gills, Joel J.
Zhang, Chunyu
Abu-Asab, Mones S.
Castillo, S. Sianna
Marceau, Caleb
Kozikowski, Alan
Tsokos, Maria
Goldkorn, Tzipora
Dennis, Phillip A.
TI Ceramide-dependent release of nanovesicles is a class effect
oflipid-based Akt inhibitors
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Gills, Joel J.; Zhang, Chunyu; Abu-Asab, Mones S.; Marceau, Caleb; Tsokos, Maria; Dennis, Phillip A.] NCI, Bethesda, MD 20892 USA.
[Castillo, S. Sianna; Goldkorn, Tzipora] Univ Calif Davis, Sacramento, CA 95817 USA.
[Kozikowski, Alan] Univ Illinois, Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 960
DI 10.1158/1538-7445.AM2011-960
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701400277
ER
PT J
AU Glinskii, OV
Li, F
Rittenhouse-Olson, K
Barchi, J
Glinsky, VV
AF Glinskii, Olga V.
Li, Feng
Rittenhouse-Olson, Kate
Barchi, Joseph
Glinsky, Vladislav V.
TI Endothelial integrin alpha 3 beta 1 stabilizes TF antigen/Galectin-3
mediated metastatic cell adhesion to the endothelium
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Glinskii, Olga V.; Li, Feng; Glinsky, Vladislav V.] Univ Missouri, Columbia, MO USA.
[Glinskii, Olga V.; Li, Feng; Glinsky, Vladislav V.] Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA.
[Rittenhouse-Olson, Kate] Univ Buffalo, Buffalo, NY USA.
[Barchi, Joseph] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2436
DI 10.1158/1538-7445.AM2011-2436
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301079
ER
PT J
AU Goldberger, NE
Kim, CH
Walker, R
Hunter, K
AF Goldberger, Natalie E.
Kim, Chang Hee
Walker, Renard
Hunter, Kent
TI Identification of miR-132 and miR-290-3p as putative tumor and
metastasis suppressor microRNAs in breast cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Goldberger, Natalie E.; Walker, Renard; Hunter, Kent] NCI, Bethesda, MD 20892 USA.
[Kim, Chang Hee] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3988
DI 10.1158/1538-7445.AM2011-3988
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404026
ER
PT J
AU Grade, M
Spitzner, M
Emons, G
Kramer, F
Gaedcke, J
Rave-Frank, M
Scharf, JG
Burfeind, P
Becker, H
Beissbarth, T
Ghadimi, BM
Ried, T
AF Grade, Marian
Spitzner, Melanie
Emons, Georg
Kramer, Frank
Gaedcke, Jochen
Rave-Fraenk, Margret
Scharf, Jens-Gerd
Burfeind, Peter
Becker, Heinz
Beissbarth, Tim
Ghadimi, B. Michael
Ried, Thomas
TI Identification of potential relevant pathways and genes for resistance
to chemoradiotherapy in colorectal cancer cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Grade, Marian; Spitzner, Melanie; Emons, Georg; Kramer, Frank; Gaedcke, Jochen; Rave-Fraenk, Margret; Burfeind, Peter; Becker, Heinz; Beissbarth, Tim; Ghadimi, B. Michael] Univ Gottingen, D-37073 Gottingen, Germany.
[Scharf, Jens-Gerd] HELIOS Klinikum Erfurt, Erfurt, Germany.
[Ried, Thomas] NCI, Genet Branch, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2508
DI 10.1158/1538-7445.AM2011-2508
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302047
ER
PT J
AU Gril, B
Vidal-Vanaclocha, F
Qian, Y
Liewehr, DJ
Steinberg, SM
Palmieri, D
Steeg, PS
AF Gril, Brunilde
Vidal-Vanaclocha, Fernando
Qian, Yong
Liewehr, David J.
Steinberg, Seth M.
Palmieri, Diane
Steeg, Patricia S.
TI Pazopanib inhibits a subpopulation of PDGFR plus astrocytes in the
neuro-inflammatory microenvironment of breast cancer brain metastases
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Gril, Brunilde; Qian, Yong; Liewehr, David J.; Steinberg, Seth M.; Palmieri, Diane; Steeg, Patricia S.] NCI, Bethesda, MD 20892 USA.
[Vidal-Vanaclocha, Fernando] CEU San Pablo Univ, Sch Med Urb Monteprincipe, Madrid, Spain.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3561
DI 10.1158/1538-7445.AM2011-3561
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401127
ER
PT J
AU Grubbs, CJ
Boring, D
Steele, VE
Verney, ZM
Lu, Y
You, M
Lubet, RA
AF Grubbs, Clinton J.
Boring, Daniel
Steele, Vernon E.
Verney, Zoe M.
Lu, Yian
You, Ming
Lubet, Ronald A.
TI Chemopreventive efficacy of naproxen, sulindac, and their nitric oxide
derivatives in the hydroxylbutyl(butyl)nitrosamine induced model of
urinary bladder cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Grubbs, Clinton J.; Verney, Zoe M.] Univ Alabama Birmingham, Birmingham, AL USA.
[Boring, Daniel; Steele, Vernon E.; Lubet, Ronald A.] NCI, Bethesda, MD 20892 USA.
[Lu, Yian; You, Ming] Washington Sch Med, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1849
DI 10.1158/1538-7445.AM2011-1849
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303161
ER
PT J
AU Gu, FY
Caporaso, NE
Eliassen, AH
Xu, X
Hankinson, SE
Ziegler, RG
AF Gu, Fangyi
Caporaso, Neil E.
Eliassen, A. Heather
Xu, Xia
Hankinson, Susan E.
Ziegler, Regina G.
TI Associations between cigarette smoking and urinary estrogens/estrogen
metabolites (EM) in premenopausal women
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Gu, Fangyi; Caporaso, Neil E.; Ziegler, Regina G.] NCI, Rockville, MD USA.
[Eliassen, A. Heather; Hankinson, Susan E.] Harvard Univ, Sch Med, Boston, MA USA.
[Xu, Xia] SAIC Inc, Frederick, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3738
DI 10.1158/1538-7445.AM2011-3738
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405446
ER
PT J
AU Gupta, GN
Lin, KY
Sourbier, C
Baba, M
Guichard, S
Linehan, WM
Srinivasan, R
AF Gupta, Gopal N.
Lin, Kelly Y.
Sourbier, Carole
Baba, Masaya
Guichard, Sylvie
Linehan, W. Marston
Srinivasan, Ramaprasad
TI Preclinical efficacy of AZD8055, an ATP-competitive mammalian target of
rapamycin (mTOR) kinase inhibitor, in vitro in clear cell renal cell
carcinoma (RCC)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Gupta, Gopal N.; Lin, Kelly Y.; Sourbier, Carole; Baba, Masaya; Linehan, W. Marston; Srinivasan, Ramaprasad] NCI, NIH, Bethesda, MD 20892 USA.
[Guichard, Sylvie] AstraZeneca, Chester, Cheshire, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 645
DI 10.1158/1538-7445.AM2011-645
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401335
ER
PT J
AU Gurpinar, E
Sun, Y
Keeton, A
Tinsley, H
Gary, B
Butler, BL
Binkowski, BF
Kopelovich, L
Athar, M
Piazza, GA
AF Gurpinar, Evrim
Sun, Yanjie
Keeton, Adam
Tinsley, Heather
Gary, Bernard
Butler, Braeden L.
Binkowski, Brock F.
Kopelovich, Levy
Athar, Mohammad
Piazza, Gary A.
TI NO-NSAIDs inhibit colon tumor cell growth by a cGMP-independent
mechanism
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Gurpinar, Evrim; Tinsley, Heather; Athar, Mohammad; Piazza, Gary A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Sun, Yanjie; Keeton, Adam; Gary, Bernard] So Res Inst, Birmingham, AL 35255 USA.
[Butler, Braeden L.; Binkowski, Brock F.] Promega Corp, Birmingham, AL USA.
[Kopelovich, Levy] NCI, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4610
DI 10.1158/1538-7445.AM2011-4610
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303032
ER
PT J
AU Harada, T
Wang, YS
Yatabe, Y
Takeshita, M
Koga, T
Yano, T
Giaccone, G
AF Harada, Taishi
Wang, Yisong
Yatabe, Yasushi
Takeshita, Masafumi
Koga, Takaomi
Yano, Tokujiro
Giaccone, Giuseppe
TI Role and relevance of TrkB mutations and expression in non-small cell
lung cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Harada, Taishi; Wang, Yisong; Giaccone, Giuseppe] NCI, Bethesda, MD 20892 USA.
[Yatabe, Yasushi] Aichi Canc Ctr, Nagoya, Aichi 464, Japan.
[Takeshita, Masafumi; Koga, Takaomi; Yano, Tokujiro] Kyushu Univ, Fukuoka 812, Japan.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1120
DI 10.1158/1538-7445.AM2011-1120
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701403342
ER
PT J
AU Hayman, TJ
Williams, ES
Camphausen, K
Tofilon, PJ
AF Hayman, Thomas J.
Williams, Eli S.
Camphausen, Kevin
Tofilon, Philip J.
TI eIF4E is a potential tumor specific target for radiosensitization
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Hayman, Thomas J.] Univ S Florida, Tampa, FL USA.
[Williams, Eli S.] Emory Univ, Sch Med, Decatur, GA 30033 USA.
[Camphausen, Kevin] NCI, Radiat Oncol Branch, Bethesda, MD 20892 USA.
[Tofilon, Philip J.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2510
DI 10.1158/1538-7445.AM2011-2510
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302050
ER
PT J
AU Held, N
Rangel, C
Castro, N
Gonzales, M
Nagaoka, T
Karasawa, H
Salomon, DS
Bianco, C
AF Held, Natalie
Rangel, Cristina
Castro, Nadia
Gonzales, Monica
Nagaoka, Tadahiro
Karasawa, Hideaki
Salomon, David S.
Bianco, Caterina
TI Role of p38 MAPK in regulating Cripto-1 expression and signaling in
human embryonal carcinoma cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Held, Natalie; Rangel, Cristina; Castro, Nadia; Gonzales, Monica; Nagaoka, Tadahiro; Karasawa, Hideaki; Salomon, David S.; Bianco, Caterina] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2175
DI 10.1158/1538-7445.AM2011-2175
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402184
ER
PT J
AU Hirsch, D
Stapleton, M
Ried, T
Camps, J
Gaiser, T
AF Hirsch, Daniela
Stapleton, Mark
Ried, Thomas
Camps, Jordi
Gaiser, Timo
TI Isothermal whole genome amplification of FFPE samples to detect copy
number changes in the progression from colonic adenoma to carcinoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Hirsch, Daniela; Ried, Thomas; Camps, Jordi; Gaiser, Timo] NCI, NIH, Washington, DC USA.
[Stapleton, Mark] NuGEN Technol, San Carlos, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3073
DI 10.1158/1538-7445.AM2011-3073
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402033
ER
PT J
AU Holbeck, SL
Collins, JM
Doroshow, JH
AF Holbeck, Susan L.
Collins, Jerry M.
Doroshow, James H.
TI NCI-60 combination screening matrix of approved anticancer drugs
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Holbeck, Susan L.; Collins, Jerry M.; Doroshow, James H.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2547
DI 10.1158/1538-7445.AM2011-2547
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401226
ER
PT J
AU Holczbauer, A
Factor, VM
Marguardt, JU
Kleiner, D
Seo, D
Raggi, C
Kitade, M
Andersen, JB
Durkin, M
Thorgeirsson, SS
AF Holczbauer, Agnes
Factor, Valentina M.
Marguardt, Jens U.
Kleiner, David
Seo, Daekwan
Raggi, Chiara
Kitade, Mitsuteru
Andersen, Jesper B.
Durkin, Marian
Thorgeirsson, Snorri S.
TI Generation of hepatocellular carcinomas with cancer stem cell properties
from primary mouse hepatocytes
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Holczbauer, Agnes; Factor, Valentina M.; Marguardt, Jens U.; Kleiner, David; Seo, Daekwan; Raggi, Chiara; Kitade, Mitsuteru; Andersen, Jesper B.; Durkin, Marian; Thorgeirsson, Snorri S.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2452
DI 10.1158/1538-7445.AM2011-2452
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301352
ER
PT J
AU Hosgood, HD
Zhang, LP
Tang, XJ
Vermeulen, R
Shen, M
Smith, M
Qiu, CY
Ge, YC
Ji, ZY
Xiong, J
Reiss, B
Hao, ZY
Liu, SW
Xie, YX
Guo, WH
Galvan, N
Li, LY
Rothman, N
Huang, HL
Lan, Q
AF Hosgood, H. Dean
Zhang, Luoping
Tang, Xiaojiang
Vermeulen, Roel
Shen, Min
Smith, Martyn
Qiu, Chuangyi
Ge, Yichen
Ji, Zhiying
Xiong, Jun
Reiss, Boris
Hao, Zhenyue
Liu, Songwang
Xie, Yuxuan
Guo, Weihong
Galvan, Noe
Li, Laiyu
Rothman, Nat
Huang, Hanlin
Lan, Qing
TI Decreased CD4+naive and effector memory T cell counts, and CD8+naive T
cell counts, are associated with trichloroethylene exposure
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Hosgood, H. Dean; Shen, Min; Rothman, Nat; Lan, Qing] NCI, Bethesda, MD 20892 USA.
[Zhang, Luoping; Tang, Xiaojiang; Smith, Martyn; Ji, Zhiying; Guo, Weihong; Galvan, Noe] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
[Vermeulen, Roel; Reiss, Boris] Univ Utrecht, Utrecht, Netherlands.
[Qiu, Chuangyi; Ge, Yichen; Xie, Yuxuan; Li, Laiyu; Huang, Hanlin] Guangdong Poison Control Ctr, Guangzhou, Guangdong, Peoples R China.
[Xiong, Jun] Dongguan Ctr Dis Control & Prevent, Dongguan, Guangdong, Peoples R China.
[Hao, Zhenyue] Inst Breast Canc Res, Toronto, ON, Canada.
[Hao, Zhenyue] Univ Hlth Network, Toronto, ON, Canada.
[Liu, Songwang] Qiaotou Hosp, Dongguan, Guangdong, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4645
DI 10.1158/1538-7445.AM2011-4645
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406063
ER
PT J
AU Houghton, PJ
Lock, RB
Carol, H
Morton, CL
Gorlick, R
Kolb, EA
Kier, ST
Reynolds, CP
Kang, MH
Maris, JM
Billups, CA
Smiths, MA
AF Houghton, Peter J.
Lock, Richard B.
Carol, Hernan
Morton, Christopher L.
Gorlick, Richard
Kolb, E. Anders
Kier, Stephen T.
Reynolds, C. Patrick
Kang, Min H.
Maris, John M.
Billups, Catherine A.
Smiths, Malcolm A.
TI Pediatric preclinical testing program (PPTP) evaluation of the
non-camptothecin topoisomerase 1 targeted agent Genz644282
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Houghton, Peter J.] Nationwide Childrens Hosp, Columbus, OH USA.
[Lock, Richard B.; Carol, Hernan] Childrens Canc Inst Australia Med Res, Randwick, NSW, Australia.
[Morton, Christopher L.; Billups, Catherine A.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
[Gorlick, Richard] Childrens Hosp Montefiore, Bronx, NY USA.
[Kolb, E. Anders] Alfred I DuPont Hosp Children, Wilmington, DE USA.
[Kier, Stephen T.] Duke Univ, Med Ctr, Durham, NC USA.
[Reynolds, C. Patrick; Kang, Min H.] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA.
[Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Smiths, Malcolm A.] NCI, Canc Therapy Evaluat Program, Bethesda, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5358
DI 10.1158/1538-7445.AM2011-5358
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301420
ER
PT J
AU House, CD
Samaan, M
Irby, RB
Lee, NH
AF House, Carrie D.
Samaan, May
Irby, Rosalyn B.
Lee, Norman H.
TI Voltage-gated Na+ channel activation leads to increased invasion
potential through persistent MAPK signaling involving PKA, Src, and Rap1
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [House, Carrie D.; Lee, Norman H.] George Washington Univ, Washington, DC USA.
[Samaan, May] Natl Inst Dent & Craniofacial Res, Bethesda, MD USA.
[Irby, Rosalyn B.] Penn State Hershey Canc Inst, Hershey, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1418
DI 10.1158/1538-7445.AM2011-1418
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304146
ER
PT J
AU Huang, WY
Su, JL
Hayes, RB
Moore, LE
Katki, HA
Berndt, SI
Weissfeld, JL
Yegnasubramanian, S
Purdue, MP
AF Huang, Wen-Yi
Su, Joseph L.
Hayes, Richard B.
Moore, Lee E.
Katki, Hormuzd A.
Berndt, Sonja I.
Weissfeld, Joel L.
Yegnasubramanian, Srinivasan
Purdue, Mark P.
TI Prospective study of genomic hypomethylation of leukocyte DNA and
colorectal cancer risk
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Huang, Wen-Yi; Su, Joseph L.; Moore, Lee E.; Katki, Hormuzd A.; Berndt, Sonja I.; Purdue, Mark P.] NCI, Bethesda, MD 20892 USA.
[Hayes, Richard B.] NYU, Sch Med, New York, NY USA.
[Weissfeld, Joel L.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Yegnasubramanian, Srinivasan] Johns Hopkins Univ, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3755
DI 10.1158/1538-7445.AM2011-3755
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305072
ER
PT J
AU Hudson, RS
Yi, M
Esposito, D
Stephens, RM
Croce, CM
Ambs, S
AF Hudson, Robert S.
Yi, Ming
Esposito, Dominic
Stephens, Robert M.
Croce, Carlo M.
Ambs, Stefan
TI Tumor suppressor role of microRNA-1 in prostate cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Hudson, Robert S.; Ambs, Stefan] NCI, Human Carcinogenesis Lab, Bethesda, MD 20892 USA.
[Yi, Ming; Stephens, Robert M.] NCI, Adv Biomed Comp Ctr, SAIC Frederick Inc, Frederick, MD 21701 USA.
[Esposito, Dominic] NCI, Prot Express Lab, SAIC Frederick Inc, Frederick, MD 21701 USA.
[Croce, Carlo M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 140
DI 10.1158/1538-7445.AM2011-140
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404065
ER
PT J
AU Huppi, K
Pitt, J
Wahlberg, B
Jones, TL
Mushinski, JF
Janz, S
Caplen, NJ
AF Huppi, Konrad
Pitt, Jason
Wahlberg, Brady
Jones, Tamara L.
Mushinski, J. Frederic
Janz, Siegfried
Caplen, Natasha J.
TI Expression studies from the PVT1 region of 8q24
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Huppi, Konrad; Pitt, Jason; Wahlberg, Brady; Jones, Tamara L.; Mushinski, J. Frederic; Caplen, Natasha J.] NCI, Bethesda, MD 20892 USA.
[Janz, Siegfried] Univ Iowa, Iowa City, IA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1181
DI 10.1158/1538-7445.AM2011-1181
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404218
ER
PT J
AU Ibarrondo, J
Comin-Anduix, B
Lee, Y
Chodon, T
Sazegar, H
Jalil, J
Chmielowski, B
Koya, RC
Gomez-Navarro, J
Jamieson, BD
Ribas, A
AF Ibarrondo, Javier
Comin-Anduix, Begona
Lee, Yohan
Chodon, Thinle
Sazegar, Hooman
Jalil, Jason
Chmielowski, Bartosz
Koya, Richard C.
Gomez-Navarro, Jesus
Jamieson, Beth D.
Ribas, Antoni
TI Characterization of invariant natural killer T cells in patients with
advanced melanoma treated with CTLA4 blockade and dendritic cell
vaccination
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Ibarrondo, Javier; Comin-Anduix, Begona; Chodon, Thinle; Sazegar, Hooman; Jalil, Jason; Chmielowski, Bartosz; Koya, Richard C.; Jamieson, Beth D.; Ribas, Antoni] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Lee, Yohan] NIMH, NIH, Bethesda, WA USA.
[Gomez-Navarro, Jesus] Pfiser Global Res & Dev, New London, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5518
DI 10.1158/1538-7445.AM2011-5518
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301103
ER
PT J
AU Ierano, C
To, KW
Robey, RW
Bates, SE
Scala, S
AF Ierano, Caterina
To, Kin Wah
Robey, Robert W.
Bates, Susan E.
Scala, Stefania
TI Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4
migration
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Ierano, Caterina; Robey, Robert W.; Bates, Susan E.] NCI, Bethesda, MD 20892 USA.
[To, Kin Wah] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
[Scala, Stefania] Natl Canc Inst G Pascale, Naples, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2633
DI 10.1158/1538-7445.AM2011-2633
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401118
ER
PT J
AU Issa, S
Braggio, E
Molnar, S
Jimenez-Zepeda, VH
Van Wier, S
Keats, JJ
Kuehl, MW
Ahmann, GJ
Carpten, J
Stewart, K
Bergsagel, L
Chng, WJ
Fonseca, R
AF Issa, Samar
Braggio, Esteban
Molnar, Soledad
Jimenez-Zepeda, Victor Hugo
Van Wier, Scott
Keats, Jonathan J.
Kuehl, Michael W.
Ahmann, Gregory J.
Carpten, John
Stewart, Keith
Bergsagel, Leif
Chng, Wee Joo
Fonseca, Rafael
TI TP53 loss: An overriding marker of disease progression in Multiple
Myeloma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Issa, Samar; Braggio, Esteban; Molnar, Soledad; Jimenez-Zepeda, Victor Hugo; Van Wier, Scott; Ahmann, Gregory J.; Stewart, Keith; Bergsagel, Leif; Fonseca, Rafael] Mayo Clin Arizona, Scottsdale, AZ USA.
[Keats, Jonathan J.; Carpten, John] TGEN, Phoenix, AZ USA.
[Kuehl, Michael W.] NCI, Genet Branch, Bethesda, MD 20892 USA.
[Chng, Wee Joo] Natl Univ Singapore, Singapore 117548, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 219
DI 10.1158/1538-7445.AM2011-219
PG 2
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402371
ER
PT J
AU Iyer, S
Perera, F
Zhang, BZ
Chanock, S
Wang, S
Tang, DL
AF Iyer, Shoba
Perera, Frederica
Zhang, Bingzhi
Chanock, Stephen
Wang, Shuang
Tang, Deliang
TI Interactions between PAH exposure and genetic polymorphisms on BaP-DNA
adducts in a NYC cohort of African American and Dominican mothers and
newborns
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Iyer, Shoba; Perera, Frederica; Zhang, Bingzhi; Wang, Shuang; Tang, Deliang] Columbia Mailman Sch Publ Hlth, New York, NY USA.
[Chanock, Stephen] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2753
DI 10.1158/1538-7445.AM2011-2753
PG 2
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406101
ER
PT J
AU Janakiram, NB
Mohammed, A
Qian, L
Venkateshwar, M
Reddy, MP
Steele, VE
Rao, CV
AF Janakiram, Naveena B.
Mohammed, Altaf
Qian, Li
Venkateshwar, Madka
Reddy, Manasa P.
Steele, Vernon E.
Rao, Chinthalapally V.
TI Chemopreventive effects of selective estrogen receptor modulator (SERM)
raloxifene on intestinal neoplasia of APC(Min/+) mice
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Janakiram, Naveena B.; Mohammed, Altaf; Qian, Li; Venkateshwar, Madka; Reddy, Manasa P.; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Ctr Canc, Ctr Chemoprevent & Drug Dev,Hem Onc Sect, Oklahoma City, OK USA.
[Steele, Vernon E.] NCI, Chemoprevent Agent Dev Res Grp, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 831
DI 10.1158/1538-7445.AM2011-831
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303082
ER
PT J
AU Janakiram, NB
Mohammed, A
Qian, L
Steele, VE
Rao, CV
AF Janakiram, Naveena B.
Mohammed, Altaf
Qian, Li
Steele, Vernon E.
Rao, Chinthalapally V.
TI miRNA profiling and target identification during normal pancreata
transformation to PanINs to pancreatic ductal cancer progression in
p48(Cre/+)-LSL-KrasG(12D/+) mice: Implication for human pancreatic
cancer chemoprevention and treatment
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Janakiram, Naveena B.; Mohammed, Altaf; Qian, Li; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Ctr Chemoprevent & Drug Dev, Canc Ctr,Dept Med Hem Onc Sect, Oklahoma City, OK USA.
[Steele, Vernon E.] NCI, Chemoprevent Agent Dev Res Grp, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 821
DI 10.1158/1538-7445.AM2011-821
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303071
ER
PT J
AU Jansen, R
Robinson, D
Stolzenberg-Solomon, R
Bamlet, W
Cunningham, J
Rider, D
Oberg, A
Hammer, T
Rabi, K
Anderson, K
Olson, J
Sinha, R
Petersen, G
AF Jansen, Rick
Robinson, Dennis
Stolzenberg-Solomon, Rachael
Bamlet, William
Cunningham, Julie
Rider, David
Oberg, Ann
Hammer, Traci
Rabi, Kari
Anderson, Kristin
Olson, Janet
Sinha, Rashmi
Petersen, Gloria
TI Polymorphisms in metabolism genes may mediate the effect of dietary
intake on pancreatic cancer risk
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Jansen, Rick; Robinson, Dennis; Bamlet, William; Cunningham, Julie; Rider, David; Oberg, Ann; Hammer, Traci; Rabi, Kari; Olson, Janet; Petersen, Gloria] Mayo Clin, Rochester, MN USA.
[Stolzenberg-Solomon, Rachael; Sinha, Rashmi] NCI, Bethesda, MD 20892 USA.
[Anderson, Kristin] Univ Minnesota, Minneapolis, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3749
DI 10.1158/1538-7445.AM2011-3749
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305066
ER
PT J
AU Ji, JP
Lee, MP
Kadota, M
Zhang, YP
Parchment, RE
Tomaszewski, JE
Doroshow, JH
AF Ji, Jiuping
Lee, Maxwell P.
Kadota, Mitsutaka
Zhang, Yiping
Parchment, Ralph E.
Tomaszewski, Joseph E.
Doroshow, James H.
TI Pharmacodynamic and pathway analysis of three presumed inhibitors of
poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Ji, Jiuping; Zhang, Yiping; Parchment, Ralph E.] NCI Frederick, SAIC Frederick Inc, Appl Dev Res Directorate, Frederick, MD USA.
[Lee, Maxwell P.; Kadota, Mitsutaka; Doroshow, James H.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
[Tomaszewski, Joseph E.; Doroshow, James H.] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4527
DI 10.1158/1538-7445.AM2011-4527
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300151
ER
PT J
AU Jia, JP
Frank, N
Parikh, H
Flandez, M
Collins, I
Hussain, P
Lo, K
Petersen, GM
Real, F
Ammundadottir, L
AF Jia, Jinping
Frank, Naomi
Parikh, Hemang
Flandez, Marta
Collins, Irene
Hussain, Perwez
Lo, Ken
Petersen, Gloria M.
Real, Francisco
Ammundadottir, Laufey
TI Genome analysis of a pancreatic cancer susceptibility locus in the NR5A2
gene on chromosome 1q32.1
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Jia, Jinping; Frank, Naomi; Parikh, Hemang; Collins, Irene; Ammundadottir, Laufey] NCI, Lab Translat Genom, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Flandez, Marta; Real, Francisco] Ctr Nacl Invest Oncol, Mol Pathyol Programme, Madrid, Spain.
[Hussain, Perwez] NCI, Lab Human Carcinogenesis, CCR, NIH, Bethesda, MD 20892 USA.
[Lo, Ken] Roche Nimblegen, Madison, WI USA.
[Petersen, Gloria M.] Mayo Clin, Ctr Canc, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4965
DI 10.1158/1538-7445.AM2011-4965
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404186
ER
PT J
AU Jin, GX
Zhao, H
Cong, Y
Fu, CH
Chang, J
Lewis, M
Wong, S
AF Jin, Guangxu
Zhao, Hong
Cong, Yang
Fu, Changhe
Chang, Jenny
Lewis, Michael
Wong, Stephen
TI Network-based signatures for drug repositioning and combination for the
breast tumor initiating cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Jin, Guangxu; Zhao, Hong; Cong, Yang; Fu, Changhe; Wong, Stephen] Methodist Hosp, NCI Ctr Modeling Canc Dev, Bioengn & Bioinformat Program, Res Inst, Houston, TX 77030 USA.
[Chang, Jenny] Methodist Hosp, Methodist Canc Ctr, Houston, TX 77030 USA.
[Lewis, Michael] Baylor Coll Med, Sue Smith Breast Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4370
DI 10.1158/1538-7445.AM2011-4370
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302105
ER
PT J
AU Jochems, C
Poole, DJ
Vergati, M
Gulley, JL
Schlom, J
Tsang, KY
AF Jochems, Caroline
Poole, Diane J.
Vergati, Matteo
Gulley, James L.
Schlom, Jeffrey
Tsang, Kwong Yok
TI Generation of cellular immune responses to MUC1-C to target the portion
of MUC1 that is most biologically relevant to the transformation process
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Jochems, Caroline; Poole, Diane J.; Vergati, Matteo; Gulley, James L.; Schlom, Jeffrey; Tsang, Kwong Yok] NCI, Bethesda, MD 20892 USA.
RI Gulley, James/K-4139-2016
OI Gulley, James/0000-0002-6569-2912
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5524
DI 10.1158/1538-7445.AM2011-5524
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301158
ER
PT J
AU Johansson, P
Wei, JS
Chen, QR
Bowden, N
Badgett, TC
Song, YK
Wen, XY
Holman, C
Yeh, S
Khan, J
AF Johansson, Peter
Wei, Jun S.
Chen, Qingrong
Bowden, Nikola
Badgett, Tom C.
Song, Young K.
Wen, Xinyu
Holman, Catherine
Yeh, Susan
Khan, Javed
TI A genomic portrait of tumor progression using next-generation sequencing
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Johansson, Peter; Wei, Jun S.; Chen, Qingrong; Badgett, Tom C.; Song, Young K.; Holman, Catherine; Yeh, Susan; Khan, Javed] NCI, Gaithersburg, MD USA.
[Bowden, Nikola] Univ Newcastle, Sch Biomed Sci & Pharm, Newcastle, NSW 2300, Australia.
[Wen, Xinyu] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4833
DI 10.1158/1538-7445.AM2011-4833
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701403278
ER
PT J
AU Jong, L
Chao, WR
Green, C
Kapetanovic, I
Sambucetti, L
Collins, N
AF Jong, Ling
Chao, Wan-Ru
Green, Carol
Kapetanovic, Izet
Sambucetti, Lidia
Collins, Nathan
TI SR13668, a selective 12-lipoxygenase inhibitor, suppresses tumor growth
by modulating the Akt signaling pathway
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Jong, Ling; Chao, Wan-Ru; Green, Carol; Sambucetti, Lidia; Collins, Nathan] SRI Int, Menlo Pk, CA 94025 USA.
[Kapetanovic, Izet] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4483
DI 10.1158/1538-7445.AM2011-4483
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404267
ER
PT J
AU Kaira, N
Zhang, JL
Yu, YK
Ho, M
Cao, L
Hassan, R
AF Kaira, Neetu
Zhang, Jingli
Yu, Yunkai
Ho, Mitchell
Cao, Liang
Hassan, Raffit
TI Anti-tumor efficacy of IMC-A12, a fully human anti-insulin like growth
factor 1 receptor (IGF-1R) antibody, against malignant mesothelioma (MM)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kaira, Neetu; Zhang, Jingli; Yu, Yunkai; Ho, Mitchell; Cao, Liang; Hassan, Raffit] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 646
DI 10.1158/1538-7445.AM2011-646
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401340
ER
PT J
AU Kales, SC
Lipkowitz, S
AF Kales, Stephen C.
Lipkowitz, Stanley
TI Enigma blocks Cbl-c-mediated RET ubiquitination and degradation
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kales, Stephen C.; Lipkowitz, Stanley] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1220
DI 10.1158/1538-7445.AM2011-1220
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401466
ER
PT J
AU Kang, ZG
Chen, JJ
Yu, YK
Zhang, BL
Cao, L
AF Kang, Zhigang
Chen, Junjie
Yu, Yunkai
Zhang, Baolin
Cao, Liang
TI A human antibody to death receptor 5 has potent antitumor activity
against rhabdomyosarcoma with the expression of caspase-8 predictive of
response
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kang, Zhigang; Yu, Yunkai; Cao, Liang] NCI, Bethesda, MD 20892 USA.
[Chen, Junjie; Zhang, Baolin] US FDA, Bethesda, MD 20014 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4094
DI 10.1158/1538-7445.AM2011-4094
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402066
ER
PT J
AU Karasawa, H
Nagaoka, T
Rangel, MC
Castro, NP
Held, N
Gonzales, M
Bianco, C
Salomon, DS
AF Karasawa, Hideaki
Nagaoka, Tadahiro
Rangel, Maria Cristina
Castro, Nadia P.
Held, Natalie
Gonzales, Monica
Bianco, Caterina
Salomon, David S.
TI Phospholipid scramblase 1 and 3 as novel effectors of cripto-1 signaling
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Karasawa, Hideaki; Nagaoka, Tadahiro; Rangel, Maria Cristina; Castro, Nadia P.; Held, Natalie; Gonzales, Monica; Bianco, Caterina; Salomon, David S.] NCI, MBTL, CCR, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1944
DI 10.1158/1538-7445.AM2011-1944
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401439
ER
PT J
AU Katiyar, S
Casimiro, M
Dettin, L
Ju, XM
Wagner, E
Tanaka, H
Pestell, R
AF Katiyar, Sanjay
Casimiro, Mathew
Dettin, Luis
Ju, Xiaoming
Wagner, Erwin
Tanaka, Hirokazu
Pestell, Richard
TI Endogenous c-jun inhibits mammary epithelial cellular apoptosis in vivo
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Katiyar, Sanjay] Univ Delhi, Delhi 110007, India.
[Casimiro, Mathew; Ju, Xiaoming; Pestell, Richard] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
[Dettin, Luis] NIH, Ctr Sci Review, Bethesda, MD 20892 USA.
[Wagner, Erwin] CNIO Canc Cell Biol Programme, Madrid, Spain.
[Tanaka, Hirokazu] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 202
DI 10.1158/1538-7445.AM2011-202
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402356
ER
PT J
AU Kaur, I
Kosak, KM
Sweeley, JC
Terrazas, M
Saavedra, JE
Keefer, LK
Herron, JN
Shami, PJ
AF Kaur, Imit
Kosak, Ken M.
Sweeley, John C.
Terrazas, Moises
Saavedra, Joseph E.
Keefer, Larry K.
Herron, James N.
Shami, Paul J.
TI Protein Interaction and Binding Studies of the Nitric Oxide-Generating
Antineoplastic Agent JS-K
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kaur, Imit; Herron, James N.] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT USA.
[Kosak, Ken M.; Terrazas, Moises; Shami, Paul J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
[Sweeley, John C.] Univ Utah, Dept Pediat, Salt Lake City, UT USA.
[Saavedra, Joseph E.] SAIC Frederick, Frederick, MD USA.
[Keefer, Larry K.] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4392
DI 10.1158/1538-7445.AM2011-4392
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401361
ER
PT J
AU Kawabata, S
Mercado, J
Hollander, MC
Wilson, W
Regales, L
Pao, W
Janne, PA
Wong, KK
Dennis, PA
AF Kawabata, Shigeru
Mercado, Jose
Hollander, M. Christine
Wilson, Willie
Regales, Lucia
Pao, William
Janne, Pasi A.
Wong, Kwok-Kin
Dennis, Phillip A.
TI Rapamycin prolongs overall survival and progression-free survival in a
mouse model of lung cancer in never smokers resistant to erlotinib
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kawabata, Shigeru; Mercado, Jose; Hollander, M. Christine; Wilson, Willie; Dennis, Phillip A.] NCI, Med Oncol Branch, CCR, Bethesda, MD 20892 USA.
[Regales, Lucia] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Pao, William] Vanderbilt Univ, Nashville, TN 37235 USA.
[Janne, Pasi A.; Wong, Kwok-Kin] Dana Farber Canc Inst, Boston, MA 02115 USA.
OI wong, kwok kin/0000-0001-6323-235X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2836
DI 10.1158/1538-7445.AM2011-2836
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302368
ER
PT J
AU Kawabata, S
Hollander, MC
Munasinghe, JP
Mercado, J
Brinster, LR
Butman, JA
Lonser, RR
Regales, L
Pao, W
Janne, PA
Wong, KK
Dennis, PA
AF Kawabata, Shigeru
Hollander, M. Christine
Munasinghe, Jeeva P.
Mercado, Jose
Brinster, Lauren R.
Butman, John A.
Lonser, Russell R.
Regales, Lucia
Pao, William
Janne, Pasi A.
Wong, Kwok-Kin
Dennis, Phillip A.
TI A new mouse model for epithelial ear neoplasms based upon expression of
mutant EGFRL858R/T790M
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kawabata, Shigeru; Hollander, M. Christine; Mercado, Jose; Dennis, Phillip A.] NCI, Med Oncol Branch, CCR, Bethesda, MD 20892 USA.
[Munasinghe, Jeeva P.] NINDS, MRI Res Facil, Bethesda, MD 20892 USA.
[Brinster, Lauren R.] Div Vet Resources, Bethesda, MD USA.
[Butman, John A.] Ctr Clin, Radiol & Imaging Sci, Bethesda, MD USA.
[Lonser, Russell R.] NINDS, Surg Neurol Branch, Bethesda, MD 20892 USA.
[Regales, Lucia] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Pao, William] Vanderbilt Univ, Nashville, TN 37235 USA.
[Janne, Pasi A.; Wong, Kwok-Kin] Dana Farber Canc Inst, Boston, MA 02115 USA.
OI wong, kwok kin/0000-0001-6323-235X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2417
DI 10.1158/1538-7445.AM2011-2417
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300458
ER
PT J
AU Kayode, O
Reid, JM
Satele, DV
Tang, H
Haluska, P
Peethambaram, PP
Ames, MM
Chen, A
Kaufmann, SH
Northfelt, DW
Erlichman, C
Menefee, ME
AF Kayode, Olumide
Reid, Joel M.
Satele, Danel V.
Tang, Hui
Haluska, Paul
Peethambaram, Prema P.
Ames, Matthew M.
Chen, Alice
Kaufmann, Scott H.
Northfelt, Donald W.
Erlichman, Charles
Menefee, Michael E.
TI Investigation of a potential pharmacokinetic interaction between ABT-888
and topotecan in a phase I trial
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kayode, Olumide; Reid, Joel M.; Satele, Danel V.; Tang, Hui; Haluska, Paul; Peethambaram, Prema P.; Ames, Matthew M.; Kaufmann, Scott H.; Erlichman, Charles] Mayo Clin, Rochester, MN USA.
[Chen, Alice] NCI, Rockville, MD USA.
[Northfelt, Donald W.] Mayo Clin Arizona, Scottsdale, AZ USA.
[Menefee, Michael E.] Mayo Clin Florida, Jacksonville, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1301
DI 10.1158/1538-7445.AM2011-1301
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405294
ER
PT J
AU Kedei, N
Telek, A
Lubart, ES
Lewin, NE
Yang, DZ
Chen, JQ
Herrmann, MA
Goldsmith, PK
Lim, L
Mannam, P
Garfield, SH
Blumberg, PM
AF Kedei, Noemi
Telek, Andrea
Lubart, Emanuel S.
Lewin, Nancy E.
Yang, Dazhi
Chen, Jinqiu
Herrmann, Michelle A.
Goldsmith, Paul K.
Lim, Langston
Mannam, Poonam
Garfield, Susan H.
Blumberg, Peter M.
TI Diverse patterns of biological response to phorbol esters and related
protein kinaseC activators in LNCaP human prostate cancer cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kedei, Noemi; Telek, Andrea; Lubart, Emanuel S.; Lewin, Nancy E.; Yang, Dazhi; Chen, Jinqiu; Herrmann, Michelle A.; Goldsmith, Paul K.; Lim, Langston; Mannam, Poonam; Garfield, Susan H.; Blumberg, Peter M.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4058
DI 10.1158/1538-7445.AM2011-4058
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404309
ER
PT J
AU Keir, ST
Morton, CL
Kolb, EA
Gorlick, R
Caroi, H
Lock, R
Kang, MH
Reynolds, CP
Maris, JM
Wu, JR
Smith, MA
Houghton, PJ
AF Keir, Stephen T.
Morton, Christopher L.
Kolb, E. Anders
Gorlick, Richard
Caroi, Hernan
Lock, Richard
Kang, Min H.
Reynolds, C. Patrick
Maris, John M.
Wu, Jianrong
Smith, Malcolm A.
Houghton, Peter J.
TI Pediatric preclinical testing program (PPTP) evaluation of the DNA
methylating agent temozolomide
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Keir, Stephen T.] Duke Univ, Med Ctr, Durham, NC USA.
[Morton, Christopher L.; Wu, Jianrong] St Jude Childrens Res Hosp, Memphis, TN USA.
[Kolb, E. Anders] Alfred I DuPont Hosp Children, Wilmington, DE USA.
[Gorlick, Richard] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Caroi, Hernan; Lock, Richard] Childrens Canc Inst Australia, Randwick, NSW, Australia.
[Kang, Min H.; Reynolds, C. Patrick] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA.
[Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Smith, Malcolm A.] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA.
[Houghton, Peter J.] Nationwide Childrens Hosp, Columbus, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5356
DI 10.1158/1538-7445.AM2011-5356
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301418
ER
PT J
AU Kelly, L
Bryan, K
Kim, SY
Debiec-Rychter, M
O'Sulliyan, MJ
AF Kelly, Lorna
Bryan, Kenneth
Kim, Su Young
Debiec-Rychter, Maria
O'Sulliyan, Maureen J.
TI An investigation into the role of miRNAs in the pathogenesis of
pediatric gastrointestinal stromal tumor
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kelly, Lorna; O'Sulliyan, Maureen J.] Univ Dublin Trinity Coll, Dublin 2, Ireland.
[Bryan, Kenneth] Royal Coll Surgeons Ireland, Dublin 2, Ireland.
[Kim, Su Young] NCI, Bethesda, MD 20892 USA.
[Debiec-Rychter, Maria] Katholieke Univ Leuven, Leuven, Belgium.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 169
DI 10.1158/1538-7445.AM2011-169
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404094
ER
PT J
AU Kendziorra, E
Ahlborn, K
Spitzner, M
Rave-Frank, M
Gaedcke, J
Emons, G
Kramer, F
Beissbarth, T
Ebner, R
Becker, H
Ghadimi, BM
Pukrop, T
Ried, T
Grade, M
AF Kendziorra, Emil
Ahlborn, Kerstin
Spitzner, Melanie
Rave-Fraenk, Margret
Gaedcke, Jochen
Emons, Georg
Kramer, Frank
Beissbarth, Tim
Ebner, Reinhard
Becker, Heinz
Ghadimi, B. Michael
Pukrop, Tobias
Ried, Thomas
Grade, Marian
TI Silencing of TCF7L2 sensitizes Wnt/beta-catenin signaling-dependent
colorectal cancer cells to radiation
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kendziorra, Emil; Ahlborn, Kerstin; Spitzner, Melanie; Gaedcke, Jochen; Emons, Georg; Becker, Heinz; Ghadimi, B. Michael; Grade, Marian] Univ Med Ctr Gottingen, Dept Gen & Visceral Surg, Gottingen, Germany.
[Rave-Fraenk, Margret] Univ Med Ctr Gottingen, Dept Radiotherapy & Radiooncol, Gottingen, Germany.
[Kramer, Frank; Beissbarth, Tim] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany.
[Ebner, Reinhard; Ried, Thomas] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Pukrop, Tobias] Univ Med Ctr Gottingen, Dept Hematol Oncol, Gottingen, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2490
DI 10.1158/1538-7445.AM2011-2490
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302028
ER
PT J
AU Khan, MH
deGraffenried, LA
Sanders, BG
Ciolino, HP
AF Khan, Maruf H.
deGraffenried, Linda A.
Sanders, Bob G.
Ciolino, Henry P.
TI Induction of apoptosis and cell cycle arrest in renal cancer cells by
phenethyl isothiocyanate (PEITC) and the mechanisms involved
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Khan, Maruf H.; deGraffenried, Linda A.; Sanders, Bob G.] Univ Texas Austin, Austin, TX 78712 USA.
[Ciolino, Henry P.] NCI, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4222
DI 10.1158/1538-7445.AM2011-4222
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305105
ER
PT J
AU Kim, HK
Chanock, SJ
Fang, J
Collins, I
Amundadottir, L
AF Kim, Hye Kyung
Chanock, Stephen J.
Fang, Jun
Collins, Irene
Amundadottir, Laufey
TI MicroRNA gene polymorphisms in cancer susceptibility loci 5p12, 8q24 and
11q13
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kim, Hye Kyung; Chanock, Stephen J.; Fang, Jun; Collins, Irene; Amundadottir, Laufey] NIH, Gaithersburg, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1170
DI 10.1158/1538-7445.AM2011-1170
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404130
ER
PT J
AU Kim, JS
Chrysovergis, K
Kosak, J
Kissling, G
Eling, T
AF Kim, Jong-Sik
Chrysovergis, Kaliopi
Kosak, Justin
Kissling, Grace
Eling, Thomas
TI Transgenic expression of NSAID-activated gene-1 (NAG-1) protects mice
from high fat diet-induced obesity
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kim, Jong-Sik] Andong Natl Univ, Dept Biol Sci, Andong, Gyeongbuk, South Korea.
[Chrysovergis, Kaliopi; Kosak, Justin; Kissling, Grace; Eling, Thomas] NIEHS, Res Triangle Pk, NC 27709 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 982
DI 10.1158/1538-7445.AM2011-982
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305354
ER
PT J
AU Kohaar, I
Fu, YP
Tang, W
Tarway, M
Muchmore, B
Porter-Gill, P
Prokunina-Olsson, L
AF Kohaar, Indu
Fu, Yi-Ping
Tang, Wei
Tarway, McAnthony
Muchmore, Brian
Porter-Gill, Patricia
Prokunina-Olsson, Ludmila
TI Allele-specific mRNA and protein expression on genetic variants of CCNE1
associated with risk of bladder cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kohaar, Indu; Fu, Yi-Ping; Tang, Wei; Tarway, McAnthony; Muchmore, Brian; Porter-Gill, Patricia; Prokunina-Olsson, Ludmila] NCI, NIH, Gaithersburg, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4974
DI 10.1158/1538-7445.AM2011-4974
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404195
ER
PT J
AU Kramer-Marek, G
Shenoy, N
Seidel, J
Griffiths, G
Choyke, P
Capala, J
AF Kramer-Marek, Gabriela
Shenoy, Nalini
Seidel, Jurgen
Griffiths, Gary
Choyke, Peter
Capala, Jacek
TI Ga-68-radiolabeled DOTA-affibody molecule for in vivo assessment of HER2
expression with PET
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kramer-Marek, Gabriela; Seidel, Jurgen; Choyke, Peter; Capala, Jacek] NCI, NIH, Bethesda, MD 20892 USA.
[Shenoy, Nalini; Griffiths, Gary] NHLBI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5284
DI 10.1158/1538-7445.AM2011-5284
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301149
ER
PT J
AU Kratz, CP
Greene, MH
Shi, JX
AF Kratz, Christian P.
Greene, Mark H.
Shi, Jianxin
TI A stratified genetic risk assessment for testicular cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kratz, Christian P.; Greene, Mark H.; Shi, Jianxin] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 871
DI 10.1158/1538-7445.AM2011-871
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405454
ER
PT J
AU Krueger, A
Dehdashti, S
Southhall, N
Patnaik, S
Marugan, J
Zheng, W
Ford, H
Zhao, R
AF Krueger, Aaron
Dehdashti, Seameen
Southhall, Noel
Patnaik, Samarjit
Marugan, Juan
Zheng, Wei
Ford, Heide
Zhao, Rui
TI Identification and characterization of small molecule inhibitors
targeting Eya phosphatase activity for anti-breast cancer therapy
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Krueger, Aaron; Zhao, Rui] Univ Colorado, Dept Biochem & Mol Genet, Aurora, CO USA.
[Dehdashti, Seameen; Southhall, Noel; Patnaik, Samarjit; Marugan, Juan; Zheng, Wei] NIH, Chem Genom Ctr, Rockville, MD USA.
[Ford, Heide] Univ Colorado, Dept Obstet & Gynecol, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1378
DI 10.1158/1538-7445.AM2011-1378
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304223
ER
PT J
AU Kunnumakkara, AB
Memmott, RM
Maier, CR
Kawabata, S
Quinn, B
Gills, J
Dallos, M
Hollander, CM
Dennis, PA
AF Kunnumakkara, Ajaikumar B.
Memmott, Regan M.
Maier, Colleen R.
Kawabata, Shigeru
Quinn, Brendan
Gills, Joell
Dallos, Matthew
Hollander, Christine M.
Dennis, Phillip A.
TI Efficacy of metformin in two mouse models of Li-Fraumeni syndrome
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Kunnumakkara, Ajaikumar B.; Memmott, Regan M.; Maier, Colleen R.; Kawabata, Shigeru; Quinn, Brendan; Gills, Joell; Dallos, Matthew; Hollander, Christine M.; Dennis, Phillip A.] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 614
DI 10.1158/1538-7445.AM2011-614
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401011
ER
PT J
AU Lai, G
Park, Y
Hartge, P
Hollenbeck, A
Schatzkin, A
Freedman, N
AF Lai, Gabriel
Park, Yikyung
Hartge, Patricia
Hollenbeck, Albert
Schatzkin, Arthur
Freedman, Neal
TI The association between diabetes and cancer incidence and mortality in
the NIH-AARP study
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lai, Gabriel; Park, Yikyung; Hartge, Patricia; Schatzkin, Arthur; Freedman, Neal] NCI, Rockville, MD USA.
[Hollenbeck, Albert] AARP, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 947
DI 10.1158/1538-7445.AM2011-947
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406031
ER
PT J
AU Lee, MP
Kadota, M
AF Lee, Maxwell P.
Kadota, Mitsutaka
TI Transcriptome analysis and the identification of novel somatic mutations
in breast cancer by the next-generation sequencing
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lee, Maxwell P.; Kadota, Mitsutaka] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4971
DI 10.1158/1538-7445.AM2011-4971
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404191
ER
PT J
AU Lee, S
Zhu, L
Mansfield, JR
Chen, XY
AF Lee, Seulki
Zhu, Lei
Mansfield, James R.
Chen, Xiaoyuan
TI Real-time video imaging of protease expression in vivo
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lee, Seulki; Zhu, Lei; Chen, Xiaoyuan] NIH, Bethesda, MD 20892 USA.
[Mansfield, James R.] CRi, Woburn, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5313
DI 10.1158/1538-7445.AM2011-5313
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301178
ER
PT J
AU Lee, YH
Andersen, JB
Judge, AD
Seo, D
Raggi, C
Jens, MU
Conner, EA
MacLachlan, I
Factor, VM
Thorgeirsson, SS
AF Lee, Yun-Han
Andersen, Jesper B.
Judge, Adam D.
Seo, Daekwan
Raggi, Chiara
Jens, Marquardt U.
Conner, Elizabeth A.
MacLachlan, Ian
Factor, Valentina M.
Thorgeirsson, Snorri S.
TI siRNA targeting of cell cycle kinase Wee1 inhibits hepatocullar
carconima growth in vitro and in vivo
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lee, Yun-Han; Andersen, Jesper B.; Seo, Daekwan; Raggi, Chiara; Jens, Marquardt U.; Conner, Elizabeth A.; Factor, Valentina M.; Thorgeirsson, Snorri S.] NCI, Bethesda, MD 20892 USA.
[Judge, Adam D.; MacLachlan, Ian] Tekmira Pharmaceut, Burnaby, BC, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1644
DI 10.1158/1538-7445.AM2011-1644
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401057
ER
PT J
AU Li, HZ
Liu, WL
Zhu, JQ
Rodriguez-Canales, J
Hanson, JC
Emmert-Buck, MR
Rodgers, GP
AF Li, Hongzhen
Liu, Wenli
Zhu, Jianqiong
Rodriguez-Canales, Jaime
Hanson, Jeffrey C.
Emmert-Buck, Michael R.
Rodgers, Griffin P.
TI Detections of olfactomedin 4 gene expression by qRT-PCR in human
prostatic samples and cell lines
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Li, Hongzhen; Liu, Wenli; Zhu, Jianqiong; Rodgers, Griffin P.] NHLBI, NIH, Bethesda, MD 20892 USA.
[Rodriguez-Canales, Jaime; Hanson, Jeffrey C.; Emmert-Buck, Michael R.] NIH, CCR, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2168
DI 10.1158/1538-7445.AM2011-2168
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402177
ER
PT J
AU Li, JX
Cho, YY
Ericson, M
Lubet, R
Grubbs, CJ
Bode, AM
AF Li, Jixia
Cho, Yeon-Yong
Ericson, Marna
Lubet, Ronald
Grubbs, Clinton J.
Bode, Ann M.
TI Lapatinib suppresses RTK-mediated signaling through multiple signaling
pathways in the chemically-induced ER plus model of mammary cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Li, Jixia; Cho, Yeon-Yong; Grubbs, Clinton J.; Bode, Ann M.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA.
[Ericson, Marna] Univ Minnesota, Minneapolis, MN USA.
[Lubet, Ronald] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1050
DI 10.1158/1538-7445.AM2011-1050
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701400094
ER
PT J
AU Li, ZJ
Ramalingam, S
Yan, S
Thiele, CJ
AF Li, Zhijie
Ramalingam, Sridevi
Yan, Shuang
Thiele, Carol J.
TI The allosteric Akt inhibitor MK-2206 inhibits neuroblastoma tumor cell
growth in vitro and in vivo
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Li, Zhijie; Ramalingam, Sridevi; Yan, Shuang; Thiele, Carol J.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4342
DI 10.1158/1538-7445.AM2011-4342
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405255
ER
PT J
AU Lin, KY
Gupta, GN
Sourbier, C
Williams, H
Guichard, S
Linehan, WM
Srinivasan, R
AF Lin, Kelly Y.
Gupta, Gopal N.
Sourbier, Carole
Williams, Heinric
Guichard, Sylvie
Linehan, W. Marston
Srinivasan, Ramaprasad
TI Preclinical efficacy of AZD8055, an ATP-competitive mammalian target of
rapamycin (mTOR) kinase inhibitor, in vitro in urothelial carcinoma of
the bladder
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lin, Kelly Y.; Gupta, Gopal N.; Sourbier, Carole; Williams, Heinric; Linehan, W. Marston; Srinivasan, Ramaprasad] NCI, NIH, Bethesda, MD 20892 USA.
[Guichard, Sylvie] AstraZeneca, Chester, Cheshire, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4493
DI 10.1158/1538-7445.AM2011-4493
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404278
ER
PT J
AU Liu, W
Sharma, A
Phang, JM
AF Liu, Wei
Sharma, Anit
Phang, James M.
TI Tumor cell survival under microenvironmental stress: Hypoxia and/or low
glucose upregulate poline oxidase
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Liu, Wei; Sharma, Anit; Phang, James M.] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2067
DI 10.1158/1538-7445.AM2011-2067
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701403425
ER
PT J
AU Liu, Y
Chen, KG
Yao, XH
Gong, WH
Yoshimura, T
Ford, J
McVicar, D
Wang, JM
AF Liu, Ying
Chen, Kegiang
Yao, Xiaohong
Gong, Wanghua
Yoshimura, Teizo
Ford, Jill
McVicar, Daniel
Wang, Ji Ming
TI The G protein-coupled receptor mFPR2 promotes antitumor host defense
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Liu, Ying; Chen, Kegiang; Yao, Xiaohong; Gong, Wanghua; Yoshimura, Teizo; Ford, Jill; McVicar, Daniel; Wang, Ji Ming] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1562
DI 10.1158/1538-7445.AM2011-1562
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302268
ER
PT J
AU Liu, ZH
Rader, J
Thiele, C
AF Liu, Zhihui
Rader, JulieAnn
Thiele, Carol
TI CASZ1 suppresses neuroblastoma cell growth by restoring Rb activity in
G1 and regulating kinases involved in G2/M progression
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Liu, Zhihui; Rader, JulieAnn; Thiele, Carol] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2115
DI 10.1158/1538-7445.AM2011-2115
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402007
ER
PT J
AU Lu, AJ
Yu, YL
Merlino, G
AF Lu, Andrew J.
Yu, Yanlin
Merlino, Glenn
TI Role of Fc gamma RIIB in metastatic melanoma and rhabdomyosarcoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lu, Andrew J.; Yu, Yanlin; Merlino, Glenn] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1475
DI 10.1158/1538-7445.AM2011-1475
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301454
ER
PT J
AU Lu, H
Si, H
Yang, XP
Burnett, J
Davis, S
Sun, HW
Xiao, WM
Wei, L
Meltzer, P
Van Waes, C
Chen, Z
AF Lu, Hai
Si, Han
Yang, Xinping
Burnett, Jeffery
Davis, Sean
Sun, Hongwei
Xiao, Wenming
Wei, Lai
Meltzer, Paul
Van Waes, Carter
Chen, Zhong
TI TNF-alpha promotes genome-wide replacement of TAp73 chromatin occupancy
by cREL and DeltaNp63
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lu, Hai; Si, Han; Yang, Xinping; Burnett, Jeffery; Van Waes, Carter; Chen, Zhong] NIDCD, NIH, Bethesda, MD USA.
[Davis, Sean; Meltzer, Paul] NCI, NIH, Bethesda, MD 20892 USA.
[Sun, Hongwei] NIAMS, NIH, Bethesda, MD USA.
[Xiao, Wenming] CIT, NIH, Bethesda, MD USA.
[Wei, Lai] NEI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4968
DI 10.1158/1538-7445.AM2011-4968
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404188
ER
PT J
AU Lu, H
Brown, M
Hu, M
Unger, G
Van Waes, C
Chen, Z
AF Lu, Hai
Brown, Matthew
Hu, Michael
Unger, Gretchen
Van Waes, Carter
Chen, Zhong
TI Protein kinase CK2 modulates TAp73 phosphorylation and suppresses
apoptosis in head and neck cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lu, Hai; Brown, Matthew; Hu, Michael; Unger, Gretchen; Van Waes, Carter; Chen, Zhong] NIDCD, NIH, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4788
DI 10.1158/1538-7445.AM2011-4788
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402480
ER
PT J
AU Lu, J
Ikejiri, B
Yang, CZ
Thompson, E
Mushlin, H
Kovach, JS
Lonser, R
Zhuang, ZP
AF Lu, Jie
Ikejiri, Barbara
Yang, Chunzhang
Thompson, Eli
Mushlin, Harry
Kovach, John S.
Lonser, Russell
Zhuang, Zhengping
TI An inhibitor of phosphatase PP2A enhances in vivo anticancer activity of
a phospho (ADP-ribosyl) polymerase inhibitor (PARPi) combined with
temozolomide (TMZ)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lu, Jie; Ikejiri, Barbara; Yang, Chunzhang; Thompson, Eli; Mushlin, Harry; Lonser, Russell; Zhuang, Zhengping] NINDS, Bethesda, MD 20892 USA.
[Kovach, John S.] Lixte Biotechnol Holdings Inc, East Setauket, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5497
DI 10.1158/1538-7445.AM2012-5497
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300208
ER
PT J
AU Lu, Y
Liu, PY
Grubbs, C
Lubet, R
You, M
AF Lu, Yan
Liu, Pengyuan
Grubbs, Clinton
Lubet, Ronald
You, Ming
TI Modulation of gene expression and cell cycle signaling pathways in
Iressa-treated urinary bladder cancer in rats
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lu, Yan; Liu, Pengyuan; You, Ming] Med Coll Wisconsin, Miwaukee, WI USA.
[Grubbs, Clinton] Univ Alabama Birmingham, Birmingham, AL USA.
[Lubet, Ronald] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 818
DI 10.1158/1538-7445.AM2011-818
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303068
ER
PT J
AU Lu, YN
Ma, HY
Malone, KE
Norman, SA
Sullivan-Halley, J
Strom, BL
Marchbanks, PA
Spirtas, R
Burkman, RT
Deapen, D
Folger, SG
Simon, MS
Press, MF
McDonald, JA
Bernstein, L
AF Lu, Yani
Ma, Huiyan
Malone, Kathleen E.
Norman, Sandra A.
Sullivan-Halley, Jane
Strom, Brian L.
Marchbanks, Polly A.
Spirtas, Robert
Burkman, Ronald T.
Deapen, Dennis
Folger, Suzanne G.
Simon, Michael S.
Press, Michael F.
McDonald, Jill A.
Bernstein, Leslie
TI Obesity and mortality among black women and white women with invasive
breast cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lu, Yani; Ma, Huiyan; Sullivan-Halley, Jane; Bernstein, Leslie] City Hope Natl Med Ctr, Duarte, CA USA.
[Malone, Kathleen E.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Norman, Sandra A.; Strom, Brian L.] Univ Penn, Philadelphia, PA 19104 USA.
[Marchbanks, Polly A.; Folger, Suzanne G.; McDonald, Jill A.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Spirtas, Robert] NICHD, Bethesda, MD USA.
[Burkman, Ronald T.] Tufts Univ, Sch Med, Springfield, MA 01199 USA.
[Burkman, Ronald T.] Baystate Med Ctr, Springfield, MA USA.
[Deapen, Dennis; Press, Michael F.] Univ So Calif, Los Angeles, CA USA.
[Simon, Michael S.] Wayne State Univ, Detroit, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3720
DI 10.1158/1538-7445.AM2011-3720
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406086
ER
PT J
AU Lubet, RA
Bode, A
Szabo, E
Grubbs, CJ
AF Lubet, Ronald A.
Bode, Ann
Szabo, Eva
Grubbs, Clinton J.
TI Alternative dosing regimens with the EGFr inhibitors (Gefitinib and
Lapatinib) in a mammary cancer model: Prevention efficacy
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Lubet, Ronald A.; Szabo, Eva] NCI, Bethesda, MD 20892 USA.
[Bode, Ann] Hormel Inst, Minnesota, MO USA.
[Grubbs, Clinton J.] Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 854
DI 10.1158/1538-7445.AM2011-854
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303106
ER
PT J
AU Luchenko, VL
Litman, T
Devor, C
Heffner, A
Robey, RW
Wilkerson, J
Chakraborty, AR
Bangiolo, L
Levens, D
Bates, SE
AF Luchenko, Victoria L.
Litman, Thomas
Devor, Christopher
Heffner, Aaron
Robey, Robert W.
Wilkerson, Julia
Chakraborty, Arup R.
Bangiolo, Lois
Levens, David
Bates, Susan E.
TI Identification of cell context specific and pleiotropic effects of the
histone deacetylase inhibitors romidepsin (depsipeptide) and vorinostat
(SAHA)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Luchenko, Victoria L.; Litman, Thomas; Devor, Christopher; Heffner, Aaron; Robey, Robert W.; Wilkerson, Julia; Bangiolo, Lois; Levens, David; Bates, Susan E.] NCI, NIH, Bethesda, MD 20892 USA.
[Chakraborty, Arup R.] Texas Tech Univ, Lubbock, TX 79409 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2620
DI 10.1158/1538-7445.AM2011-2620
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401104
ER
PT J
AU Maier, C
Hollander, MC
Dennis, P
AF Maier, Colleen
Hollander, M. Christine
Dennis, Phillip
TI Nicotine does not promote tumor growth in preclinical mouse models of
lung cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Maier, Colleen; Hollander, M. Christine; Dennis, Phillip] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1336
DI 10.1158/1538-7445.AM2011-1336
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304250
ER
PT J
AU Marchio, S
Di Paolo, D
Loi, M
Soster, M
Bartolini, A
Cilli, M
Sun, J
Gambini, C
Longhi, R
Curnis, F
Corti, A
Arap, W
Pasqualini, R
Ponzoni, M
Pastorino, F
AF Marchio, Serena
Di Paolo, Daniela
Loi, Monica
Soster, Marco
Bartolini, Alice
Cilli, Michele
Sun, Jessica
Gambini, Claudio
Longhi, Renato
Curnis, Flavio
Corti, Angelo
Arap, Wadih
Pasqualini, Renata
Ponzoni, Mirco
Pastorino, Fabio
TI Novel phage-display derived peptides for tumor- and vasculature-targeted
therapies in neuroblastoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Marchio, Serena; Soster, Marco; Bartolini, Alice] Univ Turin, IRCC, Dept Oncol Sci, Turin, Italy.
[Di Paolo, Daniela; Loi, Monica; Ponzoni, Mirco; Pastorino, Fabio] G Gaslini Childrens Hosp, Lab Oncol, Genoa, Italy.
[Cilli, Michele] Natl Canc Inst, Anim Res Facil, Genoa, Italy.
[Sun, Jessica; Arap, Wadih; Pasqualini, Renata] Univ Texas MD Anderson Canc Ctr, GU Med Oncol, Houston, TX 77030 USA.
[Gambini, Claudio] G Gaslini Childrens Hosp, Pathol Lab, Genoa, Italy.
[Longhi, Renato] CNR, Ist Chim Riconoscimento Mol, I-20133 Milan, Italy.
[Curnis, Flavio; Corti, Angelo] San Raffaele Inst, Dept Mol Oncol, Milan, Italy.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3625
DI 10.1158/1538-7445.AM2011-3625
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401262
ER
PT J
AU Marino, N
Marshall, JCA
Collins, J
Zhou, M
Veenstra, T
Steeg, PS
AF Marino, Natascia
Marshall, Jean-Claude A.
Collins, Joshua
Zhou, Ming
Veenstra, Timothy
Steeg, Patricia S.
TI The interaction of two metastasis suppressor genes, Nm23-H1 and
Gelsolin, results in synergistic phenotypes
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Marino, Natascia; Marshall, Jean-Claude A.; Collins, Joshua; Steeg, Patricia S.] NCI, Bethesda, MD 20892 USA.
[Zhou, Ming; Veenstra, Timothy] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4753
DI 10.1158/1538-7445.AM2011-4753
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303290
ER
PT J
AU Marsh, CA
Patel, V
El Dinali, M
Seiwert, T
Molinolo, AA
Gutkind, JS
AF Marsh, Christina A.
Patel, Vyomesh
El Dinali, Mohamed
Seiwert, Tanguy
Molinolo, Alfredo A.
Gutkind, J. Silvio
TI HPV-associated HNSCC: Widespread mTOR pathway activity and preclinical
evaluation of mTOR inhibitors rapamycin and RAD-001
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Marsh, Christina A.; Patel, Vyomesh; Molinolo, Alfredo A.; Gutkind, J. Silvio] NIDCR, Bethesda, MD USA.
[El Dinali, Mohamed; Seiwert, Tanguy] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA LB-7
DI 10.1158/1538-7445.AM2011-LB-7
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305413
ER
PT J
AU Marshall, JCA
Collins, J
Zhou, M
Veenstra, T
Khanna, C
Steeg, P
AF Marshall, Jean-Claude A.
Collins, Joshua
Zhou, Ming
Veenstra, Timothy
Khanna, Chand
Steeg, Patricia
TI An unbiased screen for Nm23-H1 interacting proteins identifies the
cytoskeletal crosslinking protein Ezrin
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Marshall, Jean-Claude A.; Collins, Joshua; Zhou, Ming; Veenstra, Timothy; Khanna, Chand; Steeg, Patricia] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1447
DI 10.1158/1538-7445.AM2011-1447
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301263
ER
PT J
AU Mayeenuddin, L
Yu, YK
Kang, ZG
Helman, L
Cao, L
AF Mayeenuddin, Linnia
Yu, Yunkai
Kang, Zhigang
Helman, Lee
Cao, Liang
TI Insulin-like growth factor 1 receptor antibody induces rhabdomyosarcoma
cell death via a process involving AKT and Bcl-xL
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Mayeenuddin, Linnia; Yu, Yunkai; Kang, Zhigang] NCI, Frederick SAIC Inc, Bethesda, MD 20892 USA.
[Helman, Lee; Cao, Liang] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 651
DI 10.1158/1538-7445.AM2011-651
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401346
ER
PT J
AU McCormick, DL
Horn, TL
Johnson, WD
Lubet, RA
Steele, VE
AF McCormick, David L.
Horn, Thomas L.
Johnson, William D.
Lubet, Ronald A.
Steele, Vernon E.
TI Inhibition of oral carcinogenesis in rats by the histone deacetylase
inhibitor, suberoylanilide hydroxamic acid (SAHA)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [McCormick, David L.; Horn, Thomas L.; Johnson, William D.] IIT, Res Inst, Chicago, IL 60616 USA.
[Lubet, Ronald A.; Steele, Vernon E.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1858
DI 10.1158/1538-7445.AM2011-1858
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303172
ER
PT J
AU Miller, NR
Huang, RL
Xia, MH
AF Miller, Nicole R.
Huang, Ruili
Xia, Menghang
TI Identification and characterization of small molecule inhibitors of the
activator protein-1 pathway
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Miller, Nicole R.; Huang, Ruili; Xia, Menghang] NIH, Chem Genom Ctr, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1377
DI 10.1158/1538-7445.AM2011-1377
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304222
ER
PT J
AU Mineo, M
Garfield, SH
Alessandro, R
Kohn, EC
AF Mineo, Marco
Garfield, Susan H.
Alessandro, Riccardo
Kohn, Elise C.
TI Exosomes released by K562 chronic myeloid leukemia cells promote
endothelial cell tubular differentiation through uptake and cell-to-cell
transfer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Mineo, Marco; Kohn, Elise C.] NCI, Mol Signaling Sect, Med Oncol Branch, CCR, Bethesda, MD 20892 USA.
[Garfield, Susan H.] NCI, Confocal Microscopy Core Facil, Expt Carcinogenesis Lab, CCR, Bethesda, MD 20892 USA.
[Alessandro, Riccardo] Univ Palermo, Dipartimento Biopatol & Biotecnol Med & Forensi, Sez Biol & Genet, Palermo, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5135
DI 10.1158/1538-7445.AM2011-5135
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303494
ER
PT J
AU Mirabello, L
Sun, C
Ghosh, A
Rodriguez, AC
Schiffman, M
Wentzensen, N
Wacholder, S
Lorincz, A
Burk, RD
AF Mirabello, Lisa
Sun, Chang
Ghosh, Arpita
Rodriguez, Ana C.
Schiffman, Mark
Wentzensen, Nicolas
Wacholder, Sholom
Lorincz, Attila
Burk, Robert D.
TI Methylation of the HPV16 L1 gene is associated with disease progression
in a prospective population-based cohort
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Mirabello, Lisa; Ghosh, Arpita; Schiffman, Mark; Wentzensen, Nicolas; Wacholder, Sholom] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA.
[Sun, Chang; Burk, Robert D.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Rodriguez, Ana C.] Fdn INCIENSA, Epidemiol Guanacaste, San Jose, Costa Rica.
[Lorincz, Attila] Univ London, Wolfson Inst Prevent Med, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1991
DI 10.1158/1538-7445.AM2011-1991
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402481
ER
PT J
AU Mitsunaga, M
Ogawa, M
Kosaka, N
Choyke, PL
Kobayashi, H
AF Mitsunaga, Makoto
Ogawa, Mikako
Kosaka, Nobuyuki
Choyke, Peter L.
Kobayashi, Hisataka
TI Target-specific photo-activatable immunotherapy (PIT) for cancer based
on a monoclonal antibody-photosensitizer conjugate
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Mitsunaga, Makoto; Ogawa, Mikako; Kosaka, Nobuyuki; Choyke, Peter L.; Kobayashi, Hisataka] NCI, CCR, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3618
DI 10.1158/1538-7445.AM2011-3618
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401254
ER
PT J
AU Mohammed, A
Janakiram, NB
Ely, M
Lightfoot, S
Steele, VE
Rao, CV
AF Mohammed, Altaf
Janakiram, Naveena B.
Ely, Misty
Lightfoot, Stan
Steele, Vernon E.
Rao, Chinthalapally V.
TI Licofelone, a novel dual COX-LOX inhibitor prevents progression of PanIN
lesions to pancreatic carcinoma by targeting miRNAs and cancer stem
cells in p48(Cre/+)-LSL-Kras(G12D/+) transgenic mice
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Mohammed, Altaf; Janakiram, Naveena B.; Ely, Misty; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Ctr Chemoprevent & Canc Drug Dev, Dept Med,Hemonc Sect,Canc Inst, Oklahoma City, OK USA.
[Lightfoot, Stan] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA.
[Steele, Vernon E.] NCI, Canc Prevent Div, Chemoprevent Agent Dev Res Grp, Bethesda, MD 20892 USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2839
DI 10.1158/1538-7445.AM2011-2839
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302371
ER
PT J
AU Mondul, AM
Yu, K
Weinstein, SJ
Virtamo, J
Jacobs, KB
Kraft, P
Chanock, SJ
Albanes, D
AF Mondul, Alison M.
Yu, Kai
Weinstein, Stephanie J.
Virtamo, Jarmo
Jacobs, Kevin B.
Kraft, Peter
Chanock, Stephen J.
Albanes, Demetrius
TI Genetic determinants of serum retinol: A genome-wide association study
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Mondul, Alison M.; Yu, Kai; Weinstein, Stephanie J.; Jacobs, Kevin B.; Chanock, Stephen J.; Albanes, Demetrius] NCI, DCEG, Rockville, MD USA.
[Virtamo, Jarmo] Natl Inst Hlth & Welf, Helsinki, Finland.
[Kraft, Peter] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4726
DI 10.1158/1538-7445.AM2011-4726
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701400244
ER
PT J
AU Monks, A
Hose, CD
Doroshow, JH
AF Monks, Anne
Hose, Curtis D.
Doroshow, James H.
TI Sunitinib induces anti-angiogenic splice-variant VEGF165b through
induction of CLK1 and CLK4 kinases in prostate cell line DU-145
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Monks, Anne; Hose, Curtis D.] SAIC Frederick Inc, Frederick, MD USA.
[Doroshow, James H.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2853
DI 10.1158/1538-7445.AM2011-2853
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303266
ER
PT J
AU Moody, TW
Osefo, N
Sancho, V
DiFlorio, A
Mantey, S
Jensen, RT
AF Moody, Terry W.
Osefo, Nauramy
Sancho, Veronica
DiFlorio, Alessia
Mantey, Samuel
Jensen, Robert T.
TI Lung cancer epidermal growth factor receptors are transactivated by
neurotensin
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Moody, Terry W.; Osefo, Nauramy] NCI, CCR, Bethesda, MD 20892 USA.
[Sancho, Veronica; DiFlorio, Alessia; Mantey, Samuel; Jensen, Robert T.] NIDDK, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4534
DI 10.1158/1538-7445.AM2011-4534
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701400224
ER
PT J
AU Morozova, O
Birol, I
Corbett, R
Mungall, K
Attiyeh, EF
Asgharzadeh, S
Zhao, YJ
Moore, RA
Hirst, M
Jones, S
Hogarty, MD
Diskin, S
Mosse, YP
Diamond, M
Sposto, R
Ji, LY
Gerhard, DS
Smith, MA
Khan, J
Seeger, RC
Marra, MA
Maris, JM
AF Morozova, Olena
Birol, Inanc
Corbett, Richard
Mungall, Karen
Attiyeh, Edward F.
Asgharzadeh, Shahab
Zhao, Yongjun
Moore, Richard A.
Hirst, Martin
Jones, Steven
Hogarty, Michael D.
Diskin, Sharon
Mosse, Yael P.
Diamond, Maura
Sposto, Richard
Ji, Lingyun
Gerhard, Daniela S.
Smith, Malcolm A.
Khan, Javed
Seeger, Robert C.
Marra, Marco A.
Maris, John M.
CA NCI TARGET Initiative
TI Whole genome and transcriptome sequencing defines the spectrum of
somatic changes in high-risk neuroblastoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Morozova, Olena; Birol, Inanc; Corbett, Richard; Mungall, Karen; Zhao, Yongjun; Moore, Richard A.; Hirst, Martin; Jones, Steven; Marra, Marco A.] BC Canc Agcy, Genome Sci Ctr, Vancouver, BC, Canada.
[Attiyeh, Edward F.; Hogarty, Michael D.; Diskin, Sharon; Mosse, Yael P.; Diamond, Maura; Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Attiyeh, Edward F.; Hogarty, Michael D.; Diskin, Sharon; Mosse, Yael P.; Diamond, Maura; Maris, John M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Asgharzadeh, Shahab; Sposto, Richard; Ji, Lingyun; Seeger, Robert C.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Asgharzadeh, Shahab; Sposto, Richard; Ji, Lingyun; Seeger, Robert C.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Gerhard, Daniela S.; Smith, Malcolm A.; Khan, Javed] NCI, Bethesda, MD 20892 USA.
[Marra, Marco A.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada.
RI Birol, Inanc/G-5440-2011
OI Birol, Inanc/0000-0003-0950-7839
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 926
DI 10.1158/1538-7445.AM2011-926
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305334
ER
PT J
AU Muchmore, B
Park, H
Dickensheets, H
O'Brien, T
Rehermann, B
Donnelly, R
Prokunina-Olsson, L
AF Muchmore, Brian
Park, Heiyoung
Dickensheets, Harold
O'Brien, Thomas
Rehermann, Barbara
Donnelly, Raymond
Prokunina-Olsson, Ludmila
TI Expression analysis of the IL28A, IL28B, IL29 and IL28L genes in primary
human peripheral blood mononuclear cells and hepatocytes: Effects of
activation mode, time-course and genotypes
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Muchmore, Brian; Prokunina-Olsson, Ludmila] NCI, Lab Translat Genom, DCEG, NIH, Gaithersburg, MD USA.
[Park, Heiyoung; Rehermann, Barbara] NIDDK, Immunol Sect, Liver Dis Branch, NIH, Bethesda, MD 20892 USA.
[Dickensheets, Harold; Donnelly, Raymond] US FDA, Div Therapeut Prot, CDER, Bethesda, MD 20014 USA.
[O'Brien, Thomas] NCI, Infect & Immunoepidemiol Branch, DCEG, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3751
DI 10.1158/1538-7445.AM2011-3751
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305068
ER
PT J
AU Murthy, SRK
Lee, TK
Cawley, NX
Pacak, K
Loh, P
AF Murthy, Saravana R. K.
Lee, Terence K.
Cawley, Niamh X.
Pacak, Karel
Loh, Peng
TI Carboxypeptidase E splice isoform is a novel tumor inducer and biomarker
for predicting future metastasis in human cancers
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Murthy, Saravana R. K.; Cawley, Niamh X.; Pacak, Karel; Loh, Peng] NICHD, NIH, Bethesda, MD USA.
[Lee, Terence K.] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5162
DI 10.1158/1538-7445.AM2011-5162
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304021
ER
PT J
AU Nakayama, J
Marshall, JCA
Murone, M
Steeg, PS
AF Nakayama, Joji
Marshall, Jean-Claude A.
Murone, Maximilien
Steeg, Patricia S.
TI LPA1 regulated pathways that mediate breast cancer dormancy in the liver
and lung
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Nakayama, Joji; Marshall, Jean-Claude A.; Steeg, Patricia S.] NCI, Bethesda, MD 20892 USA.
[Murone, Maximilien] Debiopharm, Lausanne, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1454
DI 10.1158/1538-7445.AM2011-1454
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301270
ER
PT J
AU Nasser, MW
Qamri, Z
Deol, YS
Leone, G
Zou, XH
Wolf, R
Yuspa, SH
Ganju, RK
AF Nasser, Mohd W.
Qamri, Zahida
Deol, Yadwinder S.
Leone, Gustavo
Zou, Xianghong
Wolf, Ronald
Yuspa, Stuart H.
Ganju, Ramesh K.
TI Overexpression of S100A7 enhances mammary tumorigenesis through
upregulation of inflammatory pathways
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Nasser, Mohd W.; Qamri, Zahida; Deol, Yadwinder S.; Leone, Gustavo; Zou, Xianghong; Ganju, Ramesh K.] Ohio State Univ, Columbus, OH 43210 USA.
[Wolf, Ronald] Univ Munich, Munich, Germany.
[Yuspa, Stuart H.] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 403
DI 10.1158/1538-7445.AM2011-403
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300347
ER
PT J
AU Nesbitt, DE
Chattopadhyay, M
Kodela, R
Boring, D
Crowell, JA
Kashfi, K
AF Nesbitt, Diandra E.
Chattopadhyay, Mitali
Kodela, Ravinder
Boring, Daniel
Crowell, James A.
Kashfi, Khosrow
TI Hydrogen sulfide-releasing naproxen inhibits HT-29 human colon cancer
cell growth: Modulation of NF-kappa B
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Nesbitt, Diandra E.; Chattopadhyay, Mitali; Kodela, Ravinder; Kashfi, Khosrow] CUNY, Sch Med, New York, NY 10031 USA.
[Boring, Daniel; Crowell, James A.] NCI, Canc Prevent Div, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1353
DI 10.1158/1538-7445.AM2011-1353
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304267
ER
PT J
AU Newman, EM
Morgan, RJ
Beumer, JH
Blanchard, SM
EI-Khoueiry, AB
Kummar, S
Carroll, MI
Synold, TW
Lenz, HJ
Doroshow, JH
AF Newman, Edward M.
Morgan, Robert J.
Beumer, Jan H.
Blanchard, Suzette M.
EI-Khoueiry, Anthony B.
Kummar, Shivaani
Carroll, Mary I.
Synold, Timothy W.
Lenz, Heinz J.
Doroshow, James H.
TI Phase I and pharmacokinetic evaluation of the DNA methyltransferase
inhibitor 5-fluoro-2 '-deoxycytidine: A California Cancer Consortium
study
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Newman, Edward M.; Morgan, Robert J.; Blanchard, Suzette M.; Carroll, Mary I.; Synold, Timothy W.] City Hope Natl Med Ctr, Duarte, CA USA.
[Beumer, Jan H.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[EI-Khoueiry, Anthony B.; Lenz, Heinz J.] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
[Kummar, Shivaani; Doroshow, James H.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1283
DI 10.1158/1538-7445.AM2011-1283
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405275
ER
PT J
AU Niedan, S
Kauer, M
Jug, G
Walker, RL
Meltzer, PS
Kovar, H
AF Niedan, Stephan
Kauer, Maximilian
Jug, Gunhild
Walker, Robert L.
Meltzer, Paul S.
Kovar, Heinrich
TI A repressive EWS-FLI1 subsignature is the result of FOXO1 suppression
and nuclear exclusion
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Niedan, Stephan; Kauer, Maximilian; Jug, Gunhild; Kovar, Heinrich] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria.
[Walker, Robert L.; Meltzer, Paul S.] NCI, Genet Branch, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5338
DI 10.1158/1538-7445.AM2011-5338
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301399
ER
PT J
AU Nishizuka, SS
Ishida, K
Uesugi, N
Chiba, T
Matsuo, T
Yamada, N
Otsuka, K
Koeda, K
Sugai, T
Wakabayashi, G
AF Nishizuka, Satoshi Stephen
Ishida, Kazushige
Uesugi, Noriyuki
Chiba, Takehiro
Matsuo, Teppei
Yamada, Noriyuki
Otsuka, Koki
Koeda, Keisuke
Sugai, Tamotsu
Wakabayashi, Go
TI An isolation strategy for biomarkers that predict cancer relapse after
5-FU based adjuvant chemotherapy
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Nishizuka, Satoshi Stephen; Uesugi, Noriyuki; Chiba, Takehiro; Matsuo, Teppei; Yamada, Noriyuki; Otsuka, Koki; Koeda, Keisuke; Sugai, Tamotsu; Wakabayashi, Go] Iwate Med Univ, Sch Med, Morioka, Iwate 020, Japan.
[Ishida, Kazushige] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4129
DI 10.1158/1538-7445.AM2011-4129
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405395
ER
PT J
AU O'Connell, MP
Nelson, JL
Fiori, JL
Subaran, SS
Indig, FE
Weeraratna, AT
AF O'Connell, Michael P.
Nelson, Janelle L.
Fiori, Jennifer L.
Subaran, Sarah S.
Indig, Fred E.
Weeraratna, Ashani T.
TI Switching from an ROR1-positive phenotype to an ROR2-positive phenotype
promotes melanoma progression
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [O'Connell, Michael P.; Nelson, Janelle L.; Fiori, Jennifer L.; Subaran, Sarah S.; Indig, Fred E.; Weeraratna, Ashani T.] NIA, NIH, Baltimore, MD 21224 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2346
DI 10.1158/1538-7445.AM2011-2346
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304181
ER
PT J
AU O'Konek, JJ
Illarinov, P
Khursigara, DS
Ambrosino, E
Izhak, L
Castillo, BF
Raju, R
Khalili, M
Kim, HY
Howell, A
Besra, GS
Porcelli, SA
Berzofsky, JA
Terabe, M
AF O'Konek, Jessica J.
Illarinov, Petr
Khursigara, Deborah Stewart
Ambrosino, Elena
Izhak, Liat
Castillo, Bernard F.
Raju, Ravinder
Khalili, Maryam
Kim, Hee-Yong
Howell, Amy
Besra, Gurdyal S.
Porcelli, Steven A.
Berzofsky, Jay A.
Terabe, Masaki
TI Type I NKT cells mediate anti-tumor immunity through a TNF-a- and
NOS-dependent pathway when stimulated with p-M an Ce
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [O'Konek, Jessica J.; Khursigara, Deborah Stewart; Ambrosino, Elena; Izhak, Liat; Berzofsky, Jay A.; Terabe, Masaki] NCI, Bethesda, MD 20892 USA.
[Illarinov, Petr; Besra, Gurdyal S.] Univ Birmingham, Birmingham, W Midlands, England.
[Castillo, Bernard F.; Raju, Ravinder; Khalili, Maryam; Howell, Amy] Univ Connecticut, Storrs, CT USA.
[Kim, Hee-Yong] NIAAA, Rockville, MD 20852 USA.
[Porcelli, Steven A.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4746
DI 10.1158/1538-7445.AM2011-4746
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301291
ER
PT J
AU Olivo-Marston, SE
Hursting, S
Schetter, A
Khan, M
Harris, C
Lavigne, J
AF Olivo-Marston, Susan E.
Hursting, Stephen
Schetter, Aaron
Khan, Mohammed
Harris, Curtis
Lavigne, Jackie
TI Genetic reduction of circulating insulin-like growth factor (IGF)-1
inhibits obesity-promoted colon tumorigenesis in mice and alters
microRNA expression
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Olivo-Marston, Susan E.] Ohio State Univ, Columbus, OH 43210 USA.
[Hursting, Stephen] Univ Texas Austin, Austin, TX 78712 USA.
[Schetter, Aaron; Khan, Mohammed; Harris, Curtis; Lavigne, Jackie] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 823
DI 10.1158/1538-7445.AM2011-823
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303073
ER
PT J
AU Ou, LH
Huppi, K
Gehlhaus, K
Jones, T
Caplen, N
AF Ou, Lihui
Huppi, Konrad
Gehlhaus, Kristen
Jones, Tamara
Caplen, Natasha
TI Large-scale RNAi screening identifies PCTK3/CDK18 as a putative cancer
related molecular target
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Ou, Lihui; Huppi, Konrad; Gehlhaus, Kristen; Jones, Tamara; Caplen, Natasha] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2041
DI 10.1158/1538-7445.AM2011-2041
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701403170
ER
PT J
AU Paes, MF
Cerri, MF
Daltoe, RD
Dias, LCR
Herlinger, AL
Madeira, KP
Silva, D
Bacchi, CE
Duarte, IX
Morin, PJ
Silva, IV
Rangel, LB
AF Paes, Marcela F.
Cerri, Murilo F.
Daltoe, Renata D.
Dias, Lucas C. R.
Herlinger, Alice L.
Madeira, Klesia P.
Silva, Debora
Bacchi, Carlos E.
Duarte, Ivison X.
Morin, Patrice J.
Silva, Ian V.
Rangel, Leticia B.
TI Retrospective analysis of Claudin-16 (CLDN16) overexpression in ovarian
cancer (OVCA): Evaluation of a biomarker candidate and a novel potential
therapeutic target
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Paes, Marcela F.; Cerri, Murilo F.; Daltoe, Renata D.; Dias, Lucas C. R.; Herlinger, Alice L.; Madeira, Klesia P.; Silva, Debora; Silva, Ian V.; Rangel, Leticia B.] Univ Fed Espirito Santo, Vitoria, ES, Brazil.
[Bacchi, Carlos E.; Duarte, Ivison X.] Consultoria Patol, Botucatu, SP, Brazil.
[Morin, Patrice J.] NIH, Es, MD USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3812
DI 10.1158/1538-7445.AM2011-3812
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701400043
ER
PT J
AU Parikh, HM
Wang, ZM
Pettigrew, K
Jia, JP
Daugherty, S
Yeager, M
Jacobs, K
Hutchinson, A
Burdett, L
Cullen, M
Qi, LQ
Boland, J
Collins, I
Albert, T
Vatten, L
Hveem, K
Njolstad, I
Cancel-Tassin, G
Cussenot, O
Valeri, A
Virtamo, J
Thun, M
Feigelson, HS
Diver, WR
Chatterjee, N
Thomas, G
Albanes, D
Chanock, S
Hunter, D
Hoover, R
Hayes, R
Berndt, S
Sampson, J
Amundadottir, L
AF Parikh, Hemang M.
Wang, Zhaoming
Pettigrew, Kerry
Jia, Jinping
Daugherty, Sarah
Yeager, Meredith
Jacobs, Kevin
Hutchinson, Amy
Burdett, Laura
Cullen, Michael
Qi, Liqun
Boland, Joseph
Collins, Irene
Albert, Thomas
Vatten, Lars
Hveem, Kristian
Njolstad, Inger
Cancel-Tassin, Geraldine
Cussenot, Olivier
Valeri, Antoine
Virtamo, Jarmo
Thun, Michael
Feigelson, Heather Spencer
Diver, W. Ryan
Chatterjee, Nilanjan
Thomas, Gilles
Albanes, Demetrius
Chanock, Stephen
Hunter, David
Hoover, Robert
Hayes, Richard
Berndt, Sonja
Sampson, Joshua
Amundadottir, Laufey
TI Fine mapping the KLK3 locus on chromosome 19q13.33 associated with
prostate cancer susceptibility and PSA levels
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Parikh, Hemang M.; Wang, Zhaoming; Pettigrew, Kerry; Jia, Jinping; Daugherty, Sarah; Yeager, Meredith; Jacobs, Kevin; Hutchinson, Amy; Burdett, Laura; Cullen, Michael; Qi, Liqun; Boland, Joseph; Collins, Irene; Chatterjee, Nilanjan; Thomas, Gilles; Albanes, Demetrius; Chanock, Stephen; Hoover, Robert; Berndt, Sonja; Sampson, Joshua; Amundadottir, Laufey] NCI, DCEG, Bethesda, MD 20892 USA.
[Albert, Thomas] Roche NimbleGen, Madison, WI USA.
[Vatten, Lars; Hveem, Kristian] Norwegian Univ Sci & Technol, N-7034 Trondheim, Norway.
[Njolstad, Inger] Univ Tromso, Tromso, Norway.
[Cancel-Tassin, Geraldine; Cussenot, Olivier; Valeri, Antoine] AP HP, Paris, France.
[Virtamo, Jarmo] Natl Inst Hlth & Welf, Helsinki, Finland.
[Thun, Michael; Feigelson, Heather Spencer; Diver, W. Ryan] Amer Canc Soc, Atlanta, GA 30329 USA.
[Hunter, David] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Hayes, Richard] NYU, Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2778
DI 10.1158/1538-7445.AM2011-2778
PG 2
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701400193
ER
PT J
AU Parise, RA
Beumer, J
Clausen, D
Egorin, M
Covey, J
Eiseman, J
AF Parise, Robert A.
Beumer, Jan
Clausen, Dana
Egorin, Merrill
Covey, Joseph
Eiseman, Julie
TI Modulation of DMS612 (BEN) pharmacokinetics and metabolism in mice by
disulfiram, and aldehyde dehydrogenase inhibitor
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Parise, Robert A.; Beumer, Jan; Clausen, Dana; Egorin, Merrill; Eiseman, Julie] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Covey, Joseph] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5465
DI 10.1158/1538-7445.AM2011-5465
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300090
ER
PT J
AU Park, Y
Hollenbeck, A
Schatzkin, A
AF Park, Yikyung
Hollenbeck, Albert
Schatzkin, Arthur
TI Prediagnosis body mass index and smoking in relation to colon cancer
survival: The NIH-AARP Diet and Health Study
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Park, Yikyung; Schatzkin, Arthur] NCI, DCEG, Rockville, MD USA.
[Hollenbeck, Albert] AARP, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4667
DI 10.1158/1538-7445.AM2011-4667
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401207
ER
PT J
AU Pastorino, F
Dewilde, S
Loi, M
Tosti, S
Ricci, L
Cilli, M
Ribatti, D
Sapio, R
Bucci, E
Barone, D
Ponzoni, M
AF Pastorino, Fabio
Dewilde, Sarah
Loi, Monica
Tosti, Sara
Ricci, Laura
Cilli, Michele
Ribatti, Domenico
Sapio, Roberto
Bucci, Enrico
Barone, Domenico
Ponzoni, Mirco
TI Oligonucleotide-based inhibition of the pro-angiogenic activity of
Hepatoma-derived growth factor related protein 3 in neuroblastoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Pastorino, Fabio; Loi, Monica; Ponzoni, Mirco] G Gaslini Childrens Hosp, Genoa, Italy.
[Dewilde, Sarah; Sapio, Roberto; Bucci, Enrico; Barone, Domenico] BioNucleon Srl, Naples, Italy.
[Tosti, Sara; Ricci, Laura] Bioind Pk Canavese, Colleretto Giacosa, TO, Italy.
[Cilli, Michele] Natl Canc Inst, Anim Res Facil, Genoa, Italy.
[Ribatti, Domenico] Univ Bari, Dept Human Anat & Histol, Bari, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5144
DI 10.1158/1538-7445.AM2011-5144
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304005
ER
PT J
AU Patel, JP
Kuang, YH
Sodani, K
Wu, CP
Liao, LQ
Tiwari, AK
Dai, CL
Chen, X
Fu, LW
Ambudkar, SV
Korlipara, VL
Chen, ZS
AF Patel, Jay P.
Kuang, Ye-Hong
Sodani, Kamlesh
Wu, Chun-Pu
Liao, Li-Qiu
Tiwari, Amit K.
Dai, Chun-ling
Chen, Xiang
Fu, Li-Wu
Ambudkar, Suresh V.
Korlipara, Vijaya L.
Chen, Zhe-Sheng
TI Analogs of OSI-930 as potent ABCG2-mediated multidrug resistance
reversal agents
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Patel, Jay P.; Kuang, Ye-Hong; Sodani, Kamlesh; Tiwari, Amit K.; Dai, Chun-ling; Korlipara, Vijaya L.; Chen, Zhe-Sheng] St Johns Univ, Coll Pharm & Allied Hlth Profess, Queens, NY USA.
[Wu, Chun-Pu; Ambudkar, Suresh V.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Liao, Li-Qiu; Chen, Xiang] Cent S Univ, Xiang Ya Hosp, Chanhsha, Peoples R China.
[Fu, Li-Wu] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1740
DI 10.1158/1538-7445.AM2011-1740
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300088
ER
PT J
AU Patiolla, JMR
Lubet, R
Ely, M
Zhang, YT
Janakiram, NB
Madka, V
Mohammed, A
Steele, VE
Rao, CV
AF Patiolla, Jagan Mohan Reddy
Lubet, Ronald
Ely, Misty
Zhang, Yuting
Janakiram, Naveena B.
Madka, Venkateshwar
Mohammed, Altaf
Steele, Vernon E.
Rao, Chinthalapally V.
TI Chemoprevention of colon cancer by DFMO, sulindac and NO-sulindac
administered individually or in combinations in male F344 rats
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Patiolla, Jagan Mohan Reddy; Ely, Misty; Zhang, Yuting; Janakiram, Naveena B.; Madka, Venkateshwar; Mohammed, Altaf; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Lubet, Ronald; Steele, Vernon E.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 808
DI 10.1158/1538-7445.AM2011-808
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303058
ER
PT J
AU Peng, HZ
Hou, ZY
He, M
Kebebew, E
Orntoft, TF
Herlyn, M
Caton, AJ
Fredericks, WJ
Malkowicz, B
Rauscher, FJ
AF Peng, Hongzhuang
Hou, Zhaoyuan
He, Mei
Kebebew, Electron
Orntoft, Torben F.
Herlyn, Meenhard
Caton, Andrew J.
Fredericks, William J.
Malkowicz, Bruce
Rauscher, Frank J.
TI The LIM protein LIMD2 functions as an effector and biomarker for
metastasis in multiple tumor types
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Peng, Hongzhuang; Hou, Zhaoyuan; Herlyn, Meenhard; Caton, Andrew J.; Rauscher, Frank J.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.
[He, Mei; Kebebew, Electron] NCI, Bethesda, MD 20892 USA.
[Orntoft, Torben F.] Skejby Sygehus, Aarhus Univ Hosp, Aarhus, Denmark.
[Fredericks, William J.; Malkowicz, Bruce] Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5219
DI 10.1158/1538-7445.AM2011-5219
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300393
ER
PT J
AU Persson, EC
Shiels, MS
Bhatia, K
Dawsey, SM
Engels, EA
AF Persson, E. Christina
Shiels, Meredith S.
Bhatia, Kishor
Dawsey, Sanford M.
Engels, Eric A.
TI Risk of esophageal and stomach malignancies in people with AIDS
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Persson, E. Christina; Shiels, Meredith S.; Bhatia, Kishor; Dawsey, Sanford M.; Engels, Eric A.] NIH, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3744
DI 10.1158/1538-7445.AM2011-3744
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305061
ER
PT J
AU Petrini, L
Zucali, PA
Lee, HS
Luo, J
Killian, KJ
Melzer, PS
Wang, YH
Wang, YS
Giaccone, G
AF Petrini, Lacopo
Zucali, Paolo A.
Lee, Hye Seung
Luo, Ji
Killian, Keith J.
Melzer, Paul S.
Wang, Yonghong
Wang, Yisong
Giaccone, Giuseppe
TI Array comparative genomic hybridization of thymic epithelial tumors
identifies loss of CDKN2A as a prognostic factor and BCL2 family members
as targets for therapy
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Petrini, Lacopo; Lee, Hye Seung; Luo, Ji; Killian, Keith J.; Melzer, Paul S.; Wang, Yonghong; Wang, Yisong; Giaccone, Giuseppe] NCI, Bethesda, MD 20892 USA.
[Zucali, Paolo A.] IRCCS, Humanitas Clin Inst, Dept Oncol, Milan, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA LB-314
DI 10.1158/1538-7445.AM2011-LB-314
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405405
ER
PT J
AU Plyler, RJ
Wang, WX
Ghobrial, IM
Roccaro, AM
Korde, N
Zingone, A
Landgren, O
Calvo, KR
AF Plyler, Ryan J.
Wang, Weixin
Ghobrial, Irene M.
Roccaro, Aldo M.
Korde, Neha
Zingone, Adriana
Landgren, Ola
Calvo, Katherine R.
TI Cytokine profiles in bone marrow supernatant and peripheral blood of
patients with multiple myeloma and Waldenstrom's macroglobulinemia
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Plyler, Ryan J.] Georgetown Sch Med, Georgetown, DC USA.
[Wang, Weixin; Calvo, Katherine R.] NIH, Bethesda, MD 20892 USA.
[Ghobrial, Irene M.; Roccaro, Aldo M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Korde, Neha; Zingone, Adriana; Landgren, Ola] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 802
DI 10.1158/1538-7445.AM2011-802
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302342
ER
PT J
AU Porter-Gill, PA
Fu, YP
Kaushiva, A
Price, D
Dahut, W
Figg, W
Prokunina-Olsson, L
AF Porter-Gill, Patricia A.
Fu, Yi-Ping
Kaushiva, Alpana
Price, Douglas
Dahut, William
Figg, William
Prokunina-Olsson, Ludmila
TI Tissue and serum miRNA profiling for detection of bladder, breast and
prostate cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Porter-Gill, Patricia A.; Fu, Yi-Ping; Kaushiva, Alpana; Prokunina-Olsson, Ludmila] NCI, DCEG, Gaithersburg, MD USA.
[Price, Douglas; Dahut, William; Figg, William] NCI, MOB, Bethesda, MD 20892 USA.
RI Figg Sr, William/M-2411-2016
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA LB-350
DI 10.1158/1538-7445.AM2011-LB-350
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701306042
ER
PT J
AU Poruchynsky, MS
Gramza, AW
Wells, SA
Fojo, T
AF Poruchynsky, Marianne S.
Gramza, Ann W.
Wells, Samuel A.
Fojo, Tito
TI Treatment of human medullary thyroid carcinoma (MTC) with either
proteasome (Pr) or histone deacetylase (HDAC) inhibitors leads to a fall
in RET mRNA levels and, in turn, a decrease in RET protein expression
providing alternate strategies to reduce RET expression in a
tyrosine-kinase driven disease
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Poruchynsky, Marianne S.; Gramza, Ann W.; Wells, Samuel A.; Fojo, Tito] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4547
DI 10.1158/1538-7445.AM2011-4547
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701400209
ER
PT J
AU Prickett, TD
Wei, XM
Viloria, CG
Molinolo, A
Lin, JC
Cruz, P
Rosenberg, SA
Davies, MA
Gershenwald, JE
Lopez-Otin, C
Samuels, Y
AF Prickett, Todd D.
Wei, Xiaomu
Viloria, Cristina G.
Molinolo, Alfredo
Lin, Jimmy C.
Cruz, Pedro
Rosenberg, Steven A.
Davies, Michael A.
Gershenwald, Jeffrey E.
Lopez-Otin, Carlos
Samuels, Yardena
TI Mutational and functional analysis reveals ADAMTS18 metalloproteinase as
a novel driver in melanoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Prickett, Todd D.; Wei, Xiaomu; Cruz, Pedro; Samuels, Yardena] NHGRI, NIH, Bethesda, MD 20892 USA.
[Viloria, Cristina G.; Lopez-Otin, Carlos] Univ Oviedo, Oviedo, Spain.
[Molinolo, Alfredo] NIDCR, NIH, Bethesda, MD USA.
[Lin, Jimmy C.] Johns Hopkins Kimmel Canc Ctr, Baltimiore, MD USA.
[Rosenberg, Steven A.] NCI, NIH, Bethesda, MD 20892 USA.
[Davies, Michael A.; Gershenwald, Jeffrey E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4970
DI 10.1158/1538-7445.AM2011-4970
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404190
ER
PT J
AU Pugh, TJ
Lawrence, M
Sougnez, C
Getz, G
Attiyeh, E
Hogarty, M
Diskin, S
Yaei, M
Diamond, M
Asgharzadeh, S
Sposto, R
Wei, JS
Badgett, T
London, WB
Gastier-Foster, J
Smith, MA
Gerhard, DS
Seeger, R
Khan, J
Meyerson, ML
Maris, JM
AF Pugh, Trevor J.
Lawrence, Michael
Sougnez, Carrie
Getz, Gad
Attiyeh, Edward
Hogarty, Michael
Diskin, Sharon
Yaei, Mosse
Diamond, Maura
Asgharzadeh, Shahab
Sposto, Richard
Wei, Jun S.
Badgett, Thomas
London, Wendy B.
Gastier-Foster, Julie
Smith, Malcolm A.
Gerhard, Daniela S.
Seeger, Robert
Khan, Javed
Meyerson, Matthew L.
Maris, John M.
CA NCI Therapeutically Applicable Res
TI Exome sequencing of 81 neuroblastomas identifies a wide diversity of
somatic mutation
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Pugh, Trevor J.; Lawrence, Michael; Sougnez, Carrie; Getz, Gad; Meyerson, Matthew L.; NCI Therapeutically Applicable Res] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Attiyeh, Edward; Hogarty, Michael; Diskin, Sharon; Yaei, Mosse; Diamond, Maura; Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Asgharzadeh, Shahab; Sposto, Richard; Seeger, Robert] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Wei, Jun S.; Badgett, Thomas; Smith, Malcolm A.; Gerhard, Daniela S.; Khan, Javed] NCI, Bethesda, MD 20892 USA.
[London, Wendy B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[London, Wendy B.] Childrens Oncol Grp, Stat & Data Ctr, Boston, MA USA.
[Gastier-Foster, Julie] Nationwide Childrens Hosp, Columbus, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4756
DI 10.1158/1538-7445.AM2011-4756
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303278
ER
PT J
AU Puntervoll, HE
Yang, R
Vetti, HH
Bachmann, IM
Avrii, MF
Ghiorzo, P
Grammatico, P
Harland, M
Hayward, N
Pjanova, D
Soufir, N
Newton-Bishop, J
Goldstein, A
Akslen, LA
Molven, A
AF Puntervoll, Hanne E.
Yang, R.
Vetti, Hildegunn H.
Bachmann, Ingeborg M.
Avrii, Marie-Francoise
Ghiorzo, Paola
Grammatico, Paola
Harland, Mark
Hayward, Nick
Pjanova, Daze
Soufir, Nadem
Newton-Bishop, Julia
Goldstein, Alisa
Akslen, Lars A.
Molven, Anders
TI Characterization of malignant melanoma families with CDK4 germ-line
mutation
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Puntervoll, Hanne E.; Akslen, Lars A.; Molven, Anders] Univ Bergen, Gade Inst, Sect Pathol, Bergen, Norway.
[Yang, R.; Goldstein, Alisa] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Vetti, Hildegunn H.] Haukeland Hosp, Dept Med Gentet & Mol Med, N-5021 Bergen, Norway.
[Bachmann, Ingeborg M.] Haukeland Hosp, Dept Dermatol, N-5021 Bergen, Norway.
[Avrii, Marie-Francoise] Univ Paris, Hop Cochin, F-75252 Paris, France.
[Ghiorzo, Paola] UoGenova, Dept Oncol Biol & Genet, Genoa, Italy.
[Grammatico, Paola] Univ Roma La Sapienza, Rome, Italy.
[Harland, Mark; Newton-Bishop, Julia] UoLeeds, Leeds Inst Mol Med & GenoMEL, Leeds, W Yorkshire, England.
[Hayward, Nick] Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
[Pjanova, Daze] Latvian Biomed Res & Study Ctr, Riga, Latvia.
[Soufir, Nadem] Hop Bichat Claude Bernard, F-75877 Paris 18, France.
RI Akslen, Lars /C-1202-2017
OI Akslen, Lars /0000-0003-2710-9543
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 869
DI 10.1158/1538-7445.AM2011-869
PG 2
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405452
ER
PT J
AU Qin, J
Calado, R
AF Qin, James
Calado, Rodrigo
TI Development of a quick sensitive real-time PCR assay for measuring
telomere length
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Qin, James] QIAGEN Inc, Germantown, MD USA.
[Calado, Rodrigo] NHLBI, Nihon Univ, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1234
DI 10.1158/1538-7445.AM2011-1234
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401477
ER
PT J
AU Raggi, C
Marguardt, JU
Andersen, JB
Factor, VM
Thorgeirsson, SS
AF Raggi, Chiara
Marguardt, Jens U.
Andersen, Jesper B.
Factor, Valentina M.
Thorgeirsson, Snorri S.
TI Tumorigenic potential is independent of sphere phenotype in liver cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Raggi, Chiara; Marguardt, Jens U.; Andersen, Jesper B.; Factor, Valentina M.; Thorgeirsson, Snorri S.] NCI, LEC, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2460
DI 10.1158/1538-7445.AM2011-2460
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301360
ER
PT J
AU Rath, BH
Camphausen, K
Tofilon, PJ
AF Rath, Barbara H.
Camphausen, Kevin
Tofilon, Philip J.
TI Astrocytes enhance the migration potential of glioblastoma stem-like
cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Rath, Barbara H.; Tofilon, Philip J.] H Lee Moffitt Canc & Res Ctr, Tampa, FL USA.
[Camphausen, Kevin] NCI, Radiat Oncol Branch, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 533
DI 10.1158/1538-7445.AM2011-533
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302150
ER
PT J
AU Reece, KM
Pisle, ST
Richardson, ED
Cook, KM
Price, DK
Figg, WD
AF Reece, Kelie M.
Pisle, Stephen T.
Richardson, Emily D.
Cook, Kristina M.
Price, Douglas K.
Figg, William D.
TI The molecular, cellular, and physiological consequences of disrupting
the HIF-1 alpha interaction
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Reece, Kelie M.; Richardson, Emily D.; Cook, Kristina M.; Price, Douglas K.; Figg, William D.] NCI, NIH, Bethesda, MD 20892 USA.
[Pisle, Stephen T.] NCI, Clin Pharmacol Program, SAIC Frederick, Frederick, MD 21701 USA.
RI Figg Sr, William/M-2411-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3095
DI 10.1158/1538-7445.AM2011-3095
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402239
ER
PT J
AU Reinhold, WC
Erliandri, I
Liu, HF
Zoppoli, G
Pommier, Y
Larionov, V
AF Reinhold, William C.
Erliandri, Indri
Liu, Hongfang
Zoppoli, Gabriele
Pommier, Yves
Larionov, Vladimir
TI Identification of a predominant pattern of co-regulation among
kinetochore genes; prospective regulatory elements, and association with
genomic instability
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Reinhold, William C.; Erliandri, Indri; Zoppoli, Gabriele; Pommier, Yves; Larionov, Vladimir] NCI, Bethesda, MD 20892 USA.
[Liu, Hongfang] Georgetown Univ, Med Ctr, Washington, DC 20007 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3074
DI 10.1158/1538-7445.AM2011-3074
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402217
ER
PT J
AU Rossi, GR
Vahanian, NN
Morris, JC
Ramsey, JW
Tennant, L
Link, CJ
AF Rossi, Gabriela R.
Vahanian, Nicholas N.
Morris, John C.
Ramsey, Jay W.
Tennant, Lucinda
Link, Charles J.
TI Immunological findings in a phase II immunotherapy study using
allogeneic lung cancer cells modified to express
alpha(1,3)galactosyltransferase in advanced non-small cell lung cancer
(NSCLC)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Rossi, Gabriela R.; Vahanian, Nicholas N.; Ramsey, Jay W.; Tennant, Lucinda; Link, Charles J.] NewLink Genet, Ames, IA USA.
[Morris, John C.] NCI, Metab Branch, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5507
DI 10.1158/1538-7445.AM2011-5507
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300472
ER
PT J
AU Rotunno, M
Lam, TK
Caporaso, NE
Landi, MT
AF Rotunno, Melissa
Lam, Tram K.
Caporaso, Neil E.
Landi, Maria Teresa
TI Gene expression signatures of meat intake in lung cancer tissues
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Rotunno, Melissa; Lam, Tram K.; Caporaso, Neil E.; Landi, Maria Teresa] NIH, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2748
DI 10.1158/1538-7445.AM2011-2748
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406097
ER
PT J
AU Ryan, BM
Robles, AI
Bowman, E
McClary, AC
Harris, CC
AF Ryan, Brid M.
Robles, Ana I.
Bowman, Elise
McClary, Andrew C.
Harris, Curtis C.
TI From genotypes to phenotypes: genetic variation in microRNA-related
genes and lung cancer risk
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Ryan, Brid M.; Robles, Ana I.; Bowman, Elise; McClary, Andrew C.; Harris, Curtis C.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1171
DI 10.1158/1538-7445.AM2011-1171
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404131
ER
PT J
AU Saber, B
Zhang, CY
Wilson, W
Gills, J
Dennis, P
AF Saber, Barbara
Zhang, Chunyu
Wilson, Willie
Gills, Joell
Dennis, Phillip
TI Application of a novel cell-based dual luciferase assay to identify
inducers of the tumor suppressor RhoB
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Saber, Barbara; Zhang, Chunyu; Wilson, Willie; Gills, Joell; Dennis, Phillip] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2193
DI 10.1158/1538-7445.AM2011-2193
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402288
ER
PT J
AU Saleh, A
Savage, JE
Harris, CC
Mitchell, JB
Simone, NL
AF Saleh, Anthony
Savage, Jason E.
Harris, Curtis C.
Mitchell, James B.
Simone, Nicole L.
TI miRs are altered by caloric restriction: Therapeutic implications
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Saleh, Anthony; Savage, Jason E.; Harris, Curtis C.; Mitchell, James B.; Simone, Nicole L.] NCI, CCR, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2075
DI 10.1158/1538-7445.AM2011-2075
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404238
ER
PT J
AU Salvucci, O
Maric, D
Zhang, F
Li, XR
Basik, M
Buchanan, M
Tosato, G
AF Salvucci, Ombretta
Maric, Dragan
Zhang, Fan
Li, Xuri
Basik, Mark
Buchanan, Marguerite
Tosato, Giovanna
TI EphrinB2 promotes endothelial cell survival and vascular integrity
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Salvucci, Ombretta; Tosato, Giovanna] NCI, NIH, Bethesda, MD 20892 USA.
[Maric, Dragan] NINDS, NIH, Bethesda, MD 20892 USA.
[Zhang, Fan] NEI, NIH, Rockville, MD USA.
[Li, Xuri] NEI, NIH, Bethesda, MD 20892 USA.
[Basik, Mark; Buchanan, Marguerite] McGill Univ, Montreal, PQ, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3469
DI 10.1158/1538-7445.AM2011-3469
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302231
ER
PT J
AU Samimi, G
Wong, C
Spong, SM
Birrer, MJ
AF Samimi, Goli
Wong, Carol
Spong, Suzanne M.
Birrer, Michael J.
TI The CTGF antibody FG-3019 blocks CTGF-stimulated migration in ovarian
cancer cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Samimi, Goli] NCI, Bethesda, MD 20892 USA.
[Wong, Carol; Spong, Suzanne M.] FibroGen Inc, San Francisco, CA USA.
[Birrer, Michael J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 509
DI 10.1158/1538-7445.AM2011-509
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302124
ER
PT J
AU Sanda, T
Tyner, JW
Gutierrez, A
Ngo, VN
Moriggl, R
Ahn, Y
Glover, J
Chang, BH
Willis, SG
Zhou, WJ
Gray, NS
Staudt, LM
Druker, BJ
Look, AT
AF Sanda, Takaomi
Tyner, Jeffrey W.
Gutierrez, Alejandro
Ngo, Vu N.
Moriggl, Richard
Ahn, Yebin
Glover, Jason
Chang, Bill H.
Willis, Stephanie G.
Zhou, Wenjun
Gray, Nathanael S.
Staudt, Louis M.
Druker, Brian J.
Look, A. Thomas
TI Pathway dependence on the tyrosine kinase TYK2 in T-cell acute
lymphoblastic leukemia
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Sanda, Takaomi; Gutierrez, Alejandro; Ahn, Yebin; Zhou, Wenjun; Gray, Nathanael S.; Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tyner, Jeffrey W.; Glover, Jason; Chang, Bill H.; Willis, Stephanie G.; Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Ngo, Vu N.] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Moriggl, Richard] Ludwig Boltzmann Inst Canc Res, Vienna, Austria.
[Staudt, Louis M.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2809
DI 10.1158/1538-7445.AM2011-2809
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304483
ER
PT J
AU Satpathy, M
Qian, WP
Capala, J
Yang, L
AF Satpathy, Minati
Qian, Weiping
Capala, Jacek
Yang, Lily
TI Development of theranostic nanoparticles for targeted tumor imaging and
treatment of HER-2/neu positive cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Satpathy, Minati; Qian, Weiping; Yang, Lily] Emory Univ, Atlanta, GA 30322 USA.
[Capala, Jacek] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5314
DI 10.1158/1538-7445.AM2011-5314
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301179
ER
PT J
AU Sawyer, SJ
Myers, K
Anthony, D
Benkesser, R
Fombonne, B
Litwack, D
Thomas, M
Lockhart, N
Rogers, J
Vaught, J
Compton, C
AF Sawyer, Sherilyn J.
Myers, Kimberly
Anthony, Dickherber
Benkesser, Rachel
Fombonne, Benjamin
Litwack, David
Thomas, Mary
Lockhart, Nicole
Rogers, Joyce
Vaught, Jim
Compton, Carolyn
TI The National Cancer Human Biobank: CaHUB
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Sawyer, Sherilyn J.; Myers, Kimberly; Anthony, Dickherber; Benkesser, Rachel; Fombonne, Benjamin; Litwack, David; Thomas, Mary; Lockhart, Nicole; Rogers, Joyce; Vaught, Jim; Compton, Carolyn] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4660
DI 10.1158/1538-7445.AM2011-4660
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406077
ER
PT J
AU Scheel, C
NgEaton, E
Li, SHJ
Chaffer, CL
Reinhardt, F
Kah, KJ
Bell, G
Guo, WJ
Rubin, J
Richardson, A
Weinberg, RA
AF Scheel, Christina
NgEaton, Elinor
Li, Sophia Hsin-Jung
Chaffer, Christine L.
Reinhardt, Ferenc
Kah, Kong-Jie
Bell, George
Guo, Wenjun
Rubin, Jeffrey
Richardson, Andrea
Weinberg, Robert A.
TI Formation and maintenance of mesenchymal and stem-cell states in the
breast by paracrine and autocrine signals
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Scheel, Christina; NgEaton, Elinor; Li, Sophia Hsin-Jung; Chaffer, Christine L.; Reinhardt, Ferenc; Kah, Kong-Jie; Bell, George; Guo, Wenjun; Weinberg, Robert A.] MIT, Whitehead Inst Biomed Res, Cambridge, MA USA.
[Rubin, Jeffrey] NCI, Bethesda, MD 20892 USA.
[Richardson, Andrea] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA LB-108
DI 10.1158/1538-7445.AM2011-LB-108
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303343
ER
PT J
AU Schetter, AJ
Welsh, JA
Bowman, ED
Harris, CC
AF Schetter, Aaron J.
Welsh, Judith A.
Bowman, Elise D.
Harris, Curtis C.
TI Association of inflammation related microRNA gene expression in
inflammatory bowel disease and IBD-associated colon cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Schetter, Aaron J.; Welsh, Judith A.; Bowman, Elise D.; Harris, Curtis C.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3945
DI 10.1158/1538-7445.AM2011-3945
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701403378
ER
PT J
AU Schlom, J
Gulley, JL
Madan, RA
Tsang, KY
Greiner, JW
Palena, C
Hodge, JW
AF Schlom, Jeffrey
Gulley, James L.
Madan, Ravi A.
Tsang, Kwong-Yok
Greiner, John W.
Palena, Claudia
Hodge, James W.
TI Development of recombinant vaccines for the prevention and therapy of
human carcinomas
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Schlom, Jeffrey; Gulley, James L.; Madan, Ravi A.; Tsang, Kwong-Yok; Greiner, John W.; Palena, Claudia; Hodge, James W.] NCI, Bethesda, MD 20892 USA.
RI Gulley, James/K-4139-2016
OI Gulley, James/0000-0002-6569-2912
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA SY24-02
DI 10.1158/1538-7445.AM2011-SY24-02
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300262
ER
PT J
AU Schumacher, FR
Berndt, SI
Siddig, A
Jacobs, K
Wang, ZM
Lindstrom, S
Stevens, VL
Chen, C
Mondul, AM
Travis, RC
Straml, DO
Eeles, RA
Easton, DF
Giles, G
Severi, G
Gronberg, H
Wiklund, F
Allen, NE
Andriolell, GL
Barricarte, A
Boeing, H
de Mesquita, HBB
Crawford, ED
Divers, WR
Gonzalez, CA
Garziano, JM
Giovannucci, EL
Johansson, M
Le Marchand, L
Ma, J
Sier, S
Stattin, P
Stampfer, MJ
Tjonneland, A
Vineis, P
Virtamo, J
Voge, U
Weinstein, SJ
Yeager, M
Thun, MJ
Kolonel, LN
Henderson, BE
Albanes, D
Hayes, RB
Feigelson, HS
Riboli, E
Hunter, DJ
Chanock, SJ
Haimanl, CA
Kraft, P
AF Schumacher, Fredrick R.
Berndt, Sonja I.
Siddig, Afshan
Jacobs, Kevin
Wang, Zhaoming
Lindstrom, Sara
Stevens, Victoria L.
Chen, Constance
Mondul, Alison M.
Travis, Ruth C.
Straml, Daniel O.
Eeles, Rosalind A.
Easton, Douglas F.
Giles, Graham
Severi, Gianluca
Gronberg, Henrik
Wiklund, Fredrik
Allen, Naomi E.
Andriolell, Gerald L.
Barricarte, Aurelio
Boeing, Heiner
de Mesquita, H. Bas Bueno
Crawford, E. David
Divers, W. Ryan
Gonzalez, Carlos A.
Garziano, J. Michael
Giovannucci, Edward L.
Johansson, Mattias
Le Marchand, Loic
Ma, Jing
Sier, Sabina
Stattin, Par
Stampfer, Meir J.
Tjonneland, Anne
Vineis, Paolo
Virtamo, Jarmo
Voge, Ulla
Weinstein, Stephanie J.
Yeager, Meredith
Thun, Michael J.
Kolonel, Laurence N.
Henderson, Brian E.
Albanes, Demetrius
Hayes, Richard B.
Feigelson, Heather Spencer
Riboli, Elio
Hunter, David J.
Chanock, Stephen J.
Haimanl, Christopher A.
Kraft, Peter
TI Genome-wide association study identifies new prostate cancer
susceptibility loci
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Schumacher, Fredrick R.; Straml, Daniel O.; Henderson, Brian E.; Haimanl, Christopher A.] Univ So Calif, Los Angeles, CA USA.
[Berndt, Sonja I.; Jacobs, Kevin; Wang, Zhaoming; Mondul, Alison M.; Weinstein, Stephanie J.; Yeager, Meredith; Albanes, Demetrius; Chanock, Stephen J.] NCI, Bethesda, MD 20892 USA.
[Siddig, Afshan; Vineis, Paolo; Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, London, England.
[Lindstrom, Sara; Chen, Constance; Giovannucci, Edward L.; Hunter, David J.; Kraft, Peter] Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
[Stevens, Victoria L.; Divers, W. Ryan; Thun, Michael J.] Amer Canc Soc, Atlanta, GA 30329 USA.
[Travis, Ruth C.; Allen, Naomi E.] Univ Oxford, Oxford, England.
[Eeles, Rosalind A.] Inst Canc Res, Sutton, Surrey, England.
[Easton, Douglas F.] Univ Cambridge, Cambridge, England.
[Giles, Graham; Severi, Gianluca] Canc Council Victoria, Melbourne, Vic, Australia.
[Gronberg, Henrik; Wiklund, Fredrik] Karolinska Inst, Stockholm, Sweden.
[Andriolell, Gerald L.] Washington Univ, Sch Med, St Louis, MO USA.
[Barricarte, Aurelio] Navarre Publ Hlth Inst, Pamplona, Spain.
[Boeing, Heiner] Deutsch Inst Ernahrungsforsch, Potsdam, Germany.
[de Mesquita, H. Bas Bueno] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
[Crawford, E. David] Univ Colorado, Aurora, CO USA.
[Gonzalez, Carlos A.] Hosp Llobregat, Barcelona, Spain.
[Garziano, J. Michael; Ma, Jing; Stampfer, Meir J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Johansson, Mattias] Int Agcy Res Canc, F-69372 Lyon, France.
[Le Marchand, Loic; Kolonel, Laurence N.] Canc Res Ctr Hawaii, Honolulu, HI USA.
[Sier, Sabina] IRCCS Ist Nazl Tumori, Milan, Italy.
[Stattin, Par] Umea Univ, Umea, Sweden.
[Tjonneland, Anne] Danish Canc Soc, Copenhagen, Denmark.
[Virtamo, Jarmo] Natl Inst Hlth & Welf, Helsinki, Finland.
[Voge, Ulla] Natl Res Ctr Working Environm, Copenhagen, Denmark.
[Hayes, Richard B.] NYU, Inst Canc, New York, NY USA.
[Feigelson, Heather Spencer] Kaiser Permanente, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA LB-448
DI 10.1158/1538-7445.AM2011-LB-448
PG 2
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406047
ER
PT J
AU Schwentner, R
Kauer, M
Bilke, S
Jug, G
Meltzer, PS
Kovar, H
AF Schwentner, Raphaela
Kauer, Maximilian
Bilke, Sven
Jug, Gunhild
Meltzer, Paul S.
Kovar, Heinrich
TI Combinatorial regulation of E2F target genes by the oncogenic ETS
transcription factor EWS-FLI1
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Schwentner, Raphaela; Kauer, Maximilian; Jug, Gunhild; Kovar, Heinrich] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria.
[Bilke, Sven; Meltzer, Paul S.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5341
DI 10.1158/1538-7445.AM2011-5341
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301401
ER
PT J
AU Shah, GV
Tamrakar, P
Thomas, S
Lakshmikanthan, V
Parajuli, P
Sathyanarayanajois, S
Bahouth, S
Fanning, A
Anderson, J
AF Shah, Girish V.
Tamrakar, Pratistha
Thomas, Shibu
Lakshmikanthan, Vijaybasker
Parajuli, Parash
Sathyanarayanajois, Seetharama
Bahouth, Suleiman
Fanning, Alan
Anderson, James
TI Calcitonin receptor-zonnula occludens-1 interaction is critical for
calcitonin-induced destabilization of tight junctions and s prostate
cancer metastasis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Shah, Girish V.; Tamrakar, Pratistha; Thomas, Shibu; Lakshmikanthan, Vijaybasker; Parajuli, Parash; Sathyanarayanajois, Seetharama] Univ Louisiana, Sch Pharm, Monroe, LA USA.
[Bahouth, Suleiman] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA.
[Fanning, Alan] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Anderson, James] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA LB-13
DI 10.1158/1538-7445.AM2011-LB-13
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305419
ER
PT J
AU Shah, P
Katuri, V
Awad, O
Gul, N
Metzer, PS
Loeb, D
AF Shah, Preeti
Katuri, Varalakshmi
Awad, Ola
Gul, Naheed
Metzer, Paul S.
Loeb, David
TI Establishment and characterization of a primary chordoma xenograft
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Shah, Preeti; Katuri, Varalakshmi; Awad, Ola; Gul, Naheed; Loeb, David] Johns Hopkins Univ, Baltimore, MD USA.
[Metzer, Paul S.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2418
DI 10.1158/1538-7445.AM2011-2418
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300459
ER
PT J
AU Sharma, S
Zou, MX
Lee, J
Steele, VE
AF Sharma, Sheela
Zou, Minxu
Lee, Jin
Steele, Vernon E.
TI Chemopreventive efficacy of vandetanib, a multikinase inhibitor, in a
primary respiratory tract epithelial cell transformation assay
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Sharma, Sheela; Zou, Minxu; Lee, Jin] Hamner Inst Hlth Sci, Res Triangle Pk, NC USA.
[Steele, Vernon E.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3703
DI 10.1158/1538-7445.AM2011-3703
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303144
ER
PT J
AU Shi, KR
Parekh, V
Roy, S
Agarwal, SK
AF Shi, Kerong
Parekh, Vaishali
Roy, Swarnava
Agarwal, Sunita K.
TI Menin-mediated regulation of pancreatic beta-cell differentiation
factors
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Shi, Kerong; Parekh, Vaishali; Roy, Swarnava; Agarwal, Sunita K.] NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA LB-140
DI 10.1158/1538-7445.AM2011-LB-140
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305488
ER
PT J
AU Shilkaitis, A
Green, A
Bratescu, L
Peng, XJ
Steele, V
Christov, KT
AF Shilkaitis, Anne
Green, Albert
Bratescu, Laura
Peng, Xinjian
Steele, Vernon
Christov, Konstantin T.
TI Rexinoids induce cellular senescence in ER-negative breast cancer cells
and in MMTV-Neu mammary tumors
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Shilkaitis, Anne; Green, Albert; Bratescu, Laura; Christov, Konstantin T.] Univ Illinois, Chicago, IL USA.
[Peng, Xinjian] IIT, Res Inst, Chicago, IL 60616 USA.
[Steele, Vernon] NCI, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 836
DI 10.1158/1538-7445.AM2011-836
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303087
ER
PT J
AU Shirota, H
Klinman, DM
AF Shirota, Hidekazu
Klinman, Dennis M.
TI Role of Interferon Regulatory Factor (IRF)-3 in lung tumor
microenvironment
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Shirota, Hidekazu; Klinman, Dennis M.] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 412
DI 10.1158/1538-7445.AM2011-412
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300357
ER
PT J
AU Sholler, GLS
Kahn, J
Ferguson, W
Bergendahl, G
Currier, E
Lenox, S
Bond, J
Roberts, W
Mitchell, D
Eslin, D
Kraveka, J
Kaplan, J
Parikh, N
Malempati, S
Hanna, G
Kamen, B
Webb, C
AF Sholler, Giselle L. Saulnier
Kahn, Javed
Ferguson, William
Bergendahl, Genvieve
Currier, Erika
Lenox, Shannon
Bond, Jeffrey
Roberts, William
Mitchell, Deanna
Eslin, Don
Kraveka, Jacqueline
Kaplan, Joel
Parikh, Nehal
Malempati, Suman
Hanna, Gina
Kamen, Barton
Webb, Craig
TI A pilot trial testing the feasibility of using molecular-guided therapy
in patients with refractory or recurrent neuroblastoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Sholler, Giselle L. Saulnier; Bergendahl, Genvieve; Currier, Erika; Lenox, Shannon; Bond, Jeffrey] Univ Vermont, Burlington, VT USA.
[Kahn, Javed] NIH, Bethesda, MD 20892 USA.
[Ferguson, William] St Louis Univ, Sch Med, St Louis, MO USA.
[Roberts, William] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA.
[Mitchell, Deanna] Michigan State Univ, Grand Rapids, MI USA.
[Eslin, Don] MD Anderson Canc Ctr Orlando, Orlando, FL USA.
[Kraveka, Jacqueline] Med Univ S Carolina, Charleston, SC 29425 USA.
[Kaplan, Joel] Levine Childrens Hosp, Charlotte, NC USA.
[Parikh, Nehal] Connecticut Childrens Med Ctr, Hartford, CT USA.
[Malempati, Suman] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Hanna, Gina] Inova Fairfax Hosp Children & Women, Falls Church, VA USA.
[Kamen, Barton] Canc Inst New Jersey, New Brunswick, NJ USA.
[Webb, Craig] Van Andel Res Inst, Grand Rapids, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3942
DI 10.1158/1538-7445.AM2011-3942
PG 2
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701403265
ER
PT J
AU Sissung, TM
Kirkland, CT
Reece, K
Arnold, JT
Figg, WD
AF Sissung, Tristan M.
Kirkland, C. Tyler
Reece, Kelie
Arnold, Julia Tyler
Figg, William D.
TI Thalidomide inhibits the TGF beta-mediated synthesis of testosterone
from DHEA in prostate cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Sissung, Tristan M.; Kirkland, C. Tyler; Reece, Kelie; Figg, William D.] NCI, Bethesda, MD 20892 USA.
[Arnold, Julia Tyler] Natl Ctr Complementary & Alternat Med, Bethesda, MD USA.
RI Figg Sr, William/M-2411-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4535
DI 10.1158/1538-7445.AM2011-4535
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701400235
ER
PT J
AU Smith, SM
Chiao, LJ
Nogueria, L
Usary, J
Perou, CM
Varticovski, L
Hursting, SD
AF Smith, Sarah M.
Chiao, Lucia J.
Nogueria, Leticia
Usary, Jerry
Perou, Charles M.
Varticovski, Lyuba
Hursting, Stephen D.
TI Obesity drives epithelial/mesenchymal transition and tumor progression
in a novel Wnt-1 mammary cancer model
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Smith, Sarah M.; Chiao, Lucia J.; Nogueria, Leticia; Hursting, Stephen D.] UT Austin, Austin, TX USA.
[Usary, Jerry; Perou, Charles M.] Univ N Carolina, Chapel Hill, NC USA.
[Varticovski, Lyuba] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3332
DI 10.1158/1538-7445.AM2011-3332
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304081
ER
PT J
AU Song, YR
Zhang, Q
Bash, R
Yin, CY
Yang, CY
Gilbert, D
Wang, S
Bullitt, E
Kafri, T
McCarthy, KD
Louis, DN
Miller, CR
Van Dyke, T
AF Song, Yurong
Zhang, Qian
Bash, Ryan
Yin, Chaoying
Yang, Chunyu
Gilbert, Debra
Wang, Sophie
Bullitt, Elizabeth
Kafri, Tal
McCarthy, Ken D.
Louis, David N.
Miller, C. Ryan
Van Dyke, Terry
TI Delineation of grade-specific molecular drivers in inducible preclinical
mouse models of astrocytoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Song, Yurong; Zhang, Qian; Gilbert, Debra; Wang, Sophie; Van Dyke, Terry] Natl Canc Inst Frederick, Frederick, MD USA.
[Bash, Ryan; Yin, Chaoying; Yang, Chunyu; Bullitt, Elizabeth; Kafri, Tal; McCarthy, Ken D.; Miller, C. Ryan] Univ N Carolina, Chapel Hill, NC USA.
[Louis, David N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Louis, David N.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2854
DI 10.1158/1538-7445.AM2011-2854
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303267
ER
PT J
AU Sourbier, C
Ratnayake, R
Scroggins, B
Lee, MJ
Lee, S
Trepel, J
Beutler, J
Neckers, L
Linehan, WM
AF Sourbier, Carole
Ratnayake, Ranjala
Scroggins, Brad
Lee, Min-Jung
Lee, Sunmin
Trepel, Jane
Beutler, John
Neckers, Len
Linehan, W. Marston
TI Targeting renal cell carcinoma with englerin A
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Sourbier, Carole; Scroggins, Brad; Lee, Min-Jung; Lee, Sunmin; Trepel, Jane; Beutler, John; Neckers, Len; Linehan, W. Marston] NCI, Bethesda, MD 20892 USA.
[Ratnayake, Ranjala] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 959
DI 10.1158/1538-7445.AM2011-959
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701400276
ER
PT J
AU Street, CR
Chattopadhyay, M
Kodela, R
Boring, D
Crowell, JA
Kashfi, K
AF Street, Cherease R.
Chattopadhyay, Mitali
Kodela, Ravinder
Boring, Daniel
Crowell, James A.
Kashfi, Khosrow
TI Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing
enzymes in vitro and in vivo
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Street, Cherease R.; Chattopadhyay, Mitali; Kodela, Ravinder; Kashfi, Khosrow] CUNY, Sch Med, New York, NY 10031 USA.
[Boring, Daniel; Crowell, James A.] NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 807
DI 10.1158/1538-7445.AM2011-807
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303057
ER
PT J
AU Sturgeon, SR
Balasubramanian, R
Schairer, C
Ziegler, R
Muss, H
Arcaro, K
AF Sturgeon, Susan R.
Balasubramanian, Raji
Schairer, Catherine
Ziegler, Regina
Muss, Hyman
Arcaro, Kathleen
TI Detection of promoter methylation of tumor supressor genes in serum DNA
of breast cancer patients and controls
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Sturgeon, Susan R.; Balasubramanian, Raji; Arcaro, Kathleen] Univ Massachusetts, Amherst, MA 01003 USA.
[Schairer, Catherine; Ziegler, Regina] NCI, Bethesda, MD 20892 USA.
[Muss, Hyman] UNC Lineberger Canc Ctr, Chapel Hill, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 85
DI 10.1158/1538-7445.AM2011-85
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701403066
ER
PT J
AU Su, WH
Tse, KP
Yang, ML
Shugart, YY
Chang, YS
AF Su, Wen-Hui
Tse, Ka-Po
Yang, Min-Lee
Shugart, Yin Yao
Chang, Yu-Sun
TI Copy number variation analysis identified multiple genetic variants
related to nasopharyngeal carcinoma predisposition
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Su, Wen-Hui; Tse, Ka-Po; Yang, Min-Lee; Chang, Yu-Sun] Chang Gung Univ, Tao Yuan, Taiwan.
[Shugart, Yin Yao] NIMH, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 882
DI 10.1158/1538-7445.AM2011-882
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405466
ER
PT J
AU Suh, N
Reddy, BS
Paul, S
DeCastro, A
Lee, HJ
Smolarek, AK
So, JY
Simi, B
Wang, CX
Janakiram, NB
Steele, VE
Rao, CV
AF Suh, Nanjoo
Reddy, Bandaru S.
Paul, Shiby
DeCastro, Andrew
Lee, Hong Jin
Smolarek, Amanda K.
So, Jae Young
Simi, Barbara
Wang, Chung Xiou
Janakiram, Naveena B.
Steele, Vernon E.
Rao, Chinthalapally V.
TI Combination of atorvastatin with sulindac or naproxen profoundly
inhibits colonic adenocarcinomas by suppressing the
p65/beta-catenin/cyclin D1 signaling pathway in rats
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Suh, Nanjoo; Reddy, Bandaru S.; Paul, Shiby; DeCastro, Andrew; Lee, Hong Jin; Smolarek, Amanda K.; So, Jae Young; Simi, Barbara; Wang, Chung Xiou] Rutgers State Univ, Piscataway, NJ USA.
[Janakiram, Naveena B.; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Steele, Vernon E.] NCI, Chemoprevent Agent Dev Res Grp, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 833
DI 10.1158/1538-7445.AM2011-833
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303084
ER
PT J
AU Suzuki, T
Kosaka-Suzuki, N
Morse, HC
Loukinov, D
Lobanenkov, V
AF Suzuki, Teruhiko
Kosaka-Suzuki, Natsuki
Morse, Herbert C.
Loukinov, Dmitri
Lobanenkov, Victor
TI BORIS directly regulates in vivo expression of the cancer testis
antigen, testes-specific protease 50 (TSP50)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Suzuki, Teruhiko; Kosaka-Suzuki, Natsuki; Morse, Herbert C.; Loukinov, Dmitri; Lobanenkov, Victor] NIH, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2043
DI 10.1158/1538-7445.AM2011-2043
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701403174
ER
PT J
AU Takai, S
Schlom, J
Greiner, JW
AF Takai, Shinji
Schlom, Jeffrey
Greiner, John W.
TI Distinctive effects of the Src-inhibitor, saracatinib (AZD0530), on
T-cell activation and differentiation: A basic study to combine
Src-inhibitor and vaccine based cancer immunotherapy
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Takai, Shinji; Schlom, Jeffrey; Greiner, John W.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1783
DI 10.1158/1538-7445.AM2011-1783
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302048
ER
PT J
AU Tang, LY
Yamashita, M
Tang, Y
Zhang, YE
AF Tang, Liu-Ya
Yamashita, Motozo
Tang, Yi
Zhang, Ying E.
TI Mono-ubiquitination of Smad2/3 by Smurf2 regulates TGF-beta
transcriptional response
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Tang, Liu-Ya; Yamashita, Motozo; Tang, Yi; Zhang, Ying E.] NCI, CCR, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4057
DI 10.1158/1538-7445.AM2011-4057
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404308
ER
PT J
AU Tang, W
Fu, YP
Liu, LY
Orduz, N
Kaushiva, A
Mumy, A
Porter-Gill, P
Meyers, T
Garcia-Closas, M
Malats, N
Chanock, S
Real, FX
Kogevinas, M
Rothman, N
Silverman, D
Prokunina-Olsson, L
AF Tang, Wei
Fu, Yi-Ping
Liu, Luyang
Orduz, Natalia
Kaushiva, Alpana
Mumy, Adam
Porter-Gill, Patricia
Meyers, Timothy
Garcia-Closas, Montserrat
Malats, Nuria
Chanock, Stephen
Real, Francisco X.
Kogevinas, Manolis
Rothman, Nathaniel
Silverman, Debra
Prokunina-Olsson, Ludmila
TI Exploring the relationships between genetic variants within the UGT1A
locus, cellular detoxification and risk of bladder cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Tang, Wei; Fu, Yi-Ping; Liu, Luyang; Orduz, Natalia; Kaushiva, Alpana; Mumy, Adam; Porter-Gill, Patricia; Meyers, Timothy; Garcia-Closas, Montserrat; Chanock, Stephen; Rothman, Nathaniel; Silverman, Debra; Prokunina-Olsson, Ludmila] NCI, Gaithersburg, MD USA.
[Malats, Nuria; Real, Francisco X.] CNIO, Madrid, Spain.
[Kogevinas, Manolis] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain.
RI Kogevinas, Manolis/C-3918-2017
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4680
DI 10.1158/1538-7445.AM2011-4680
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401220
ER
PT J
AU Tarim, J
Sowers, RS
Piperdi, S
Khanna, C
Gorlick, RG
AF Tarim, John
Sowers, Rebecca S.
Piperdi, Sajida
Khanna, Chand
Gorlick, Richard G.
TI Evaluation of GD2 expression in patients with osteosarcoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Tarim, John; Sowers, Rebecca S.; Piperdi, Sajida; Gorlick, Richard G.] Childrens Hosp Montefiore, Bronx, NY USA.
[Khanna, Chand] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5332
DI 10.1158/1538-7445.AM2011-5332
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301393
ER
PT J
AU Tarway, MD
Tang, W
Fu, YP
Liu, LY
Porter-Gill, P
Hall, J
Ambs, S
Prokunina-Olsson, L
AF Tarway, McAnthony D.
Tang, Wei
Fu, Yi-Ping
Liu, Luyang
Porter-Gill, Patricia
Hall, Jennifer
Ambs, Stefan
Prokunina-Olsson, Ludmila
TI Genetic variants within JAZF1 are associated with differential binding
of androgen receptor, altered mRNA expression and risk of prostate
cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Tarway, McAnthony D.; Tang, Wei; Fu, Yi-Ping; Liu, Luyang; Porter-Gill, Patricia; Ambs, Stefan; Prokunina-Olsson, Ludmila] NIH, Bethesda, MD 20892 USA.
[Hall, Jennifer] Lillehei Heart Inst, Minneapolis, MN USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3816
DI 10.1158/1538-7445.AM2011-3816
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701400048
ER
PT J
AU Thyparambil, S
Hembrough, T
Cao, L
Krizman, D
Darfler, M
Burrows, J
Helman, L
AF Thyparambil, Sheeno
Hembrough, Todd
Cao, Liang
Krizman, David
Darfler, Marlene
Burrows, Jon
Helman, Lee
TI Quantitative analysis of IGF-1R expression and signaling pathway
activation in FFPE xenograft and human tumor tissues
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Thyparambil, Sheeno; Hembrough, Todd; Krizman, David; Darfler, Marlene; Burrows, Jon] Express Pathol Inc, Rockville, MD USA.
[Cao, Liang; Helman, Lee] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2211
DI 10.1158/1538-7445.AM2011-2211
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405163
ER
PT J
AU Tiwari, AK
Shi, Z
Shukla, S
Robey, RW
Singh, S
Kim, IW
Bates, SE
Peng, XX
Abraham, I
Ambudkar, SV
Talele, TT
Fu, LW
Chen, ZS
AF Tiwari, Amit K.
Shi, Zhi
Shukla, Suneet
Robey, Robert W.
Singh, Satyakam
Kim, In-Wha
Bates, Susan E.
Peng, Xing-xiang
Abraham, Ioana
Ambudkar, Suresh V.
Talele, Tanaji T.
Fu, Li-wu
Chen, Zhe-Sheng
TI Reversal of ABCB1-and ABCG2-mediated drug resistance by sildenafil
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Tiwari, Amit K.; Shi, Zhi; Singh, Satyakam; Peng, Xing-xiang; Abraham, Ioana; Talele, Tanaji T.; Chen, Zhe-Sheng] St Johns Univ, Queens, NY USA.
[Shukla, Suneet; Robey, Robert W.; Kim, In-Wha; Bates, Susan E.; Ambudkar, Suresh V.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Fu, Li-wu] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1739
DI 10.1158/1538-7445.AM2011-1739
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300087
ER
PT J
AU Townsend, RR
Rohrs, H
LeDuc, R
Malone, JP
Erdman-Gilmore, P
Hill, DL
Grubbs, CJ
You, M
Lubet, RA
AF Townsend, Reid R.
Rohrs, Henry
LeDuc, Richard
Malone, James P.
Erdman-Gilmore, Petra
Hill, Donald L.
Grubbs, Clinton J.
You, Ming
Lubet, Ronald A.
TI Proteomic credentialing in a model for chemoprevention studies of
urinary bladder cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Townsend, Reid R.; Rohrs, Henry; LeDuc, Richard; Malone, James P.; Erdman-Gilmore, Petra; You, Ming] Washington Sch Med, St Louis, MO USA.
[Hill, Donald L.; Grubbs, Clinton J.] UAB Chemoprevent Ctr, Birmingham, AL USA.
[Lubet, Ronald A.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3700
DI 10.1158/1538-7445.AM2011-3700
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303141
ER
PT J
AU Tripathi, BK
Lowy, DR
Zelenka, PS
AF Tripathi, Brajendra K.
Lowy, Douglas R.
Zelenka, Peggy S.
TI The Cdk5 activator p39 specifically links muskelin to myosin and
regulates stress fiber organization and contraction
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Tripathi, Brajendra K.; Lowy, Douglas R.] NCI, NIH, Bethesda, MD 20892 USA.
[Zelenka, Peggy S.] NEI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1436
DI 10.1158/1538-7445.AM2011-1436
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304164
ER
PT J
AU Tripathi, V
Zimonjic, DB
Popescu, NC
AF Tripathi, Veenu
Zimonjic, Drazen B.
Popescu, Nicholas C.
TI DLC1 and alpha-catenin protein interaction enhances DLC1 antioncogenic
activity by stabilizing adherens junctions and suppressing NF kappa B
signaling
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Tripathi, Veenu; Zimonjic, Drazen B.; Popescu, Nicholas C.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4017
DI 10.1158/1538-7445.AM2011-4017
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404168
ER
PT J
AU Tsang, DP
Lau, SS
Lee, TL
Wong, N
Cheng, AS
AF Tsang, Daisy P.
Lau, Suki S.
Lee, Tin L.
Wong, Nathalie
Cheng, Alfred S.
TI EZH2-mediated H3K27 trimethylation silencing of microRNAs in
hepatocellular carcinoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Tsang, Daisy P.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.
[Lau, Suki S.; Cheng, Alfred S.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.
[Lee, Tin L.] NICHHD, NIH, Bethesda, MD 20892 USA.
[Wong, Nathalie] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1185
DI 10.1158/1538-7445.AM2011-1185
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404222
ER
PT J
AU Tsuji, PA
Carlson, BA
Yoo, MH
Xu, XM
Naranjo-Suarez, S
Fomenko, D
Gladyshev, VN
Hatfield, DL
Davis, CD
AF Tsuji, Petra A.
Carlson, Bradley A.
Yoo, Min-Hyuk
Xu, Xue-Ming
Naranjo-Suarez, Salvador
Fomenko, Dmitri
Gladyshev, Vadim N.
Hatfield, Dolph L.
Davis, Cindy D.
TI Sep15 knockout in mice provides protection against chemically-induced
aberrant crypt formation
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Tsuji, Petra A.; Davis, Cindy D.] NCI, DCP, Bethesda, MD 20892 USA.
[Carlson, Bradley A.; Yoo, Min-Hyuk; Xu, Xue-Ming; Naranjo-Suarez, Salvador; Hatfield, Dolph L.] NCI, LCP, Bethesda, MD 20892 USA.
[Fomenko, Dmitri] Univ Nebraska, Lincoln, NE USA.
[Gladyshev, Vadim N.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1868
DI 10.1158/1538-7445.AM2011-1868
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303183
ER
PT J
AU Uckun, FM
Qazi, S
Garner, A
Ma, H
Ozer, Z
Pitt, J
Janda, K
AF Uckun, Fatih M.
Qazi, Sanjive
Garner, Amanda
Ma, Hong
Ozer, Zahide
Pitt, Jason
Janda, Kim
TI Unfolded protein response regulator BIP/HSPA5 as a chemoresistance
biomarker and molecular target in acute lymphoblastic leukemia
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Uckun, Fatih M.; Ma, Hong; Ozer, Zahide] USC Childrens Hosp Los Angeles, Los Angeles, CA USA.
[Qazi, Sanjive] Gustavus Adolphus Coll, St Peter, MN 56082 USA.
[Garner, Amanda; Janda, Kim] Scripps Res Inst, Worm Inst Med Res WIRM, La Jolla, CA 92037 USA.
[Pitt, Jason] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA LB-365
DI 10.1158/1538-7445.AM2011-LB-365
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303410
ER
PT J
AU Uppalapati, LD
Ohta, N
Zhang, YQ
Pyle, M
Becker, KG
Troyer, DL
Tamura, M
AF Uppalapati, Lakshmi D.
Ohta, Naomi
Zhang, Yongqing
Pyle, Marla
Becker, Kevin G.
Troyer, Deryl L.
Tamura, Masaaki
TI Identification of unique tumoricidal genes in rat umbilical cord matrix
stem cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Uppalapati, Lakshmi D.; Ohta, Naomi; Pyle, Marla; Troyer, Deryl L.; Tamura, Masaaki] Kansas State Univ, Manhattan, KS 66506 USA.
[Zhang, Yongqing; Becker, Kevin G.] NIA, NIH, Baltimore, MD 21224 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3355
DI 10.1158/1538-7445.AM2011-3355
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304104
ER
PT J
AU Vergati, M
Cereda, V
Intrivici, C
Huen, NY
Di Bari, MG
Jochems, C
Gulley, JL
Apelian, D
Schlom, J
Tsang, KY
AF Vergati, Matteo
Cereda, Vittore
Intrivici, Chiara
Huen, Ngar-Yee
Di Bari, Maria Giovanna
Jochems, Caroline
Gulley, James L.
Apelian, David
Schlom, Jeffrey
Tsang, Kwong Y.
TI Cancer vaccine immunotherapy employing Saccharomyces cerevisiae (yeast)
as a vector can modulate the balance between CD4+T cells and regulatory
T cells (Tregs) and enhance the specific antitumor immune response
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Vergati, Matteo; Cereda, Vittore; Intrivici, Chiara; Huen, Ngar-Yee; Di Bari, Maria Giovanna; Jochems, Caroline; Gulley, James L.; Schlom, Jeffrey; Tsang, Kwong Y.] NCI, NIH, Bethesda, MD 20892 USA.
[Apelian, David] GlobeImmune, Louisville, CO USA.
RI Gulley, James/K-4139-2016
OI Gulley, James/0000-0002-6569-2912
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 758
DI 10.1158/1538-7445.AM2011-758
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303085
ER
PT J
AU Vistica, DT
Kenney, S
Scudiero, DA
Reinhart, RA
Selby, MH
Butcher, DO
Shoemaker, RH
AF Vistica, David T.
Kenney, Susan
Scudiero, Dominic A.
Reinhart, Russell A.
Selby, Michael H.
Butcher, Donna O.
Shoemaker, Robert H.
TI The proprotein convertase PCSK1 is a novel drug target in alveolar soft
part sarcoma (ASPS)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Vistica, David T.; Kenney, Susan; Scudiero, Dominic A.; Reinhart, Russell A.; Selby, Michael H.; Butcher, Donna O.; Shoemaker, Robert H.] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1621
DI 10.1158/1538-7445.AM2011-1621
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401033
ER
PT J
AU Wang, C
Henkes, L
Doughty, LB
He, M
Wang, DF
Meyer-Almes, FJ
Newman, DJ
Cheng, YQ
AF Wang, Cheng
Henkes, Leonhard
Doughty, Leah B.
He, Min
Wang, Difei
Meyer-Almes, Franz-Josef
Newman, David J.
Cheng, Yi-Qiang
TI Thailandepsins: Novel bacterial natural products with potent histone
deacetylase inhibition activities and promising anticancer activities
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Wang, Cheng; Doughty, Leah B.; Cheng, Yi-Qiang] Univ Wisconsin, Milwaukee, WI 53201 USA.
[Henkes, Leonhard; Meyer-Almes, Franz-Josef] Univ Appl Sci Darmstadt, Darmstadt, Germany.
[He, Min; Newman, David J.] US NCI, Frederick, MD USA.
[Wang, Difei] US NCI, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5418
DI 10.1158/1538-7445.AM2011-5418
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305282
ER
PT J
AU Wang, CG
Zhou, J
Wu, KM
Tozeren, A
Zhao, KJ
Pestell, RG
AF Wang, Chenguang
Zhou, Jie
Wu, Kongming
Tozeren, Aydin
Zhao, Keji
Pestell, Richard G.
TI DACH1 (Dachshund homolog 1) attenuates forkhead signaling through
recruiting transcription elongation regulator 1 (TCERG1)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Wang, Chenguang; Zhou, Jie; Wu, Kongming; Pestell, Richard G.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
[Tozeren, Aydin] Drexel Univ, Philadelphia, PA 19104 USA.
[Zhao, Keji] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 269
DI 10.1158/1538-7445.AM2011-269
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402201
ER
PT J
AU Wang, LD
Bi, XL
Pohl, N
Cheng, YL
Zhou, YX
Shears, S
Wang, SM
Xu, XC
Huang, P
Chen, Z
Wang, L
Hong, JY
Xie, H
Wei, QY
Meltzer, S
Ding, I
Okunieff, P
Yang, WC
AF Wang, Li-Dong
Bi, Xiuli
Pohl, Nicole
Cheng, Yulan
Zhou, Yixing
Shears, Stephen
Wang, Shaomeng
Xu, Xiao-Chun
Huang, Peng
Chen, Zhong
Wang, Liang
Hong, Jun-Yan
Xie, Heng
Wei, Qingyi
Meltzer, Stephen
Ding, Ivan
Okunieff, Paul
Yang, Wancai
TI A sequence variant in the phospholipase C epsilon C2 domain is
associated with esophageal carcinoma and esophagitis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Wang, Li-Dong] Xinxiang Med Univ, Xinxiang, Peoples R China.
[Bi, Xiuli; Pohl, Nicole; Yang, Wancai] Univ Illinois, Chicago, IL USA.
[Bi, Xiuli] Liaoning Univ, Sch Life Sci, Shenyang 110036, Peoples R China.
[Cheng, Yulan; Meltzer, Stephen] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Zhou, Yixing; Shears, Stephen] NIEHS, NIH, Res Triangle Pk, NC 27709 USA.
[Wang, Shaomeng] Univ Michigan, Ann Arbor, MI 48109 USA.
[Xu, Xiao-Chun; Huang, Peng; Wei, Qingyi] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Chen, Zhong] Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD USA.
[Wang, Liang] Mayo Clin, Coll Med, Rochester, MN USA.
[Hong, Jun-Yan] Univ Med & Dent New Jersey, Piscataway, NJ 08854 USA.
[Xie, Heng; Ding, Ivan] NCI, NIH, Bethesda, MD 20892 USA.
[Okunieff, Paul] Univ Florida, Shands Canc Ctr, Gainesville, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4704
DI 10.1158/1538-7445.AM2011-4704
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305187
ER
PT J
AU Wang, XY
Xu, ZL
Chrysoyergis, K
Bienstock, R
Shim, M
Bensen, JT
Fontham, E
Smith, GJ
Mohler, J
Taylor, J
Eling, TE
AF Wang, Xingya
Xu, Zongli
Chrysoyergis, Kali
Bienstock, Rachelle
Shim, Minsub
Bensen, Jeannette T.
Fontham, Elizabeth
Smith, Gary J.
Mohler, James
Taylor, Jack
Eling, Thomas E.
TI The dual effects of H6D polymorphism of NAG-1/GDF15 in prostate cancer
carcinogenesis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Wang, Xingya; Xu, Zongli; Chrysoyergis, Kali; Bienstock, Rachelle; Shim, Minsub; Taylor, Jack; Eling, Thomas E.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA.
[Bensen, Jeannette T.] Univ N Carolina, Chapel Hill, NC USA.
[Fontham, Elizabeth] LSU Hlth Sci Ctr, New Orleans, LA USA.
[Smith, Gary J.] Roswell Pk Canc Inst, Bullalo, NY USA.
[Mohler, James] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5541
DI 10.1158/1538-7445.AM2011-5541
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701305300
ER
PT J
AU Wang, Y
James, M
Wen, WD
Lu, Y
Szabo, E
Lubet, RA
You, M
AF Wang, Yian
James, Michael
Wen, Weidong
Lu, Yan
Szabo, Eva
Lubet, Ronald A.
You, Ming
TI Chemopreventive efficacy of pioglitazone on lung cancer in mice
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Wang, Yian; James, Michael; Wen, Weidong; Lu, Yan; You, Ming] Washington Univ, St Louis, MO USA.
[Szabo, Eva; Lubet, Ronald A.] NCI, Canc Prevent Div, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3698
DI 10.1158/1538-7445.AM2011-3698
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701303138
ER
PT J
AU Welzel, TM
Graubard, BI
Davila, JA
El-Serag, HB
McGlynn, KA
AF Welzel, Tania M.
Graubard, Barry I.
Davila, Jessica A.
El-Serag, Hashem B.
McGlynn, Katherine A.
TI Metabolic syndrome increases the risk of primary liver cancer in the
United States
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Welzel, Tania M.; Graubard, Barry I.; McGlynn, Katherine A.] NCI, Bethesda, MD 20892 USA.
[Davila, Jessica A.; El-Serag, Hashem B.] Baylor Coll Med, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 945
DI 10.1158/1538-7445.AM2011-945
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406029
ER
PT J
AU Wentzensen, IM
Mirabello, L
Pfeiffer, RM
Savage, SA
AF Wentzensen, Ingrid M.
Mirabello, Lisa
Pfeiffer, Ruth M.
Savage, Sharon A.
TI Telomere length as a biomarker of cancer risk: Review and meta-analysis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Wentzensen, Ingrid M.; Mirabello, Lisa; Pfeiffer, Ruth M.; Savage, Sharon A.] NIH, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4654
DI 10.1158/1538-7445.AM2011-4654
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406073
ER
PT J
AU Wentzensen, NA
Walker, J
Zuna, R
Smith, K
Mathews, C
Moxley, K
Tenney, M
Zhang, R
Gold, M
Schiffman, M
AF Wentzensen, Nicolas A.
Walker, Joan
Zuna, Rosemary
Smith, Katie
Mathews, Cara
Moxley, Katherine
Tenney, Meaghan
Zhang, Roy
Gold, Michael
Schiffman, Mark
TI Misclassification of cervical precancer: Impact of a new colposcopy
protocol on disease ascertainment and biomarker performance
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Wentzensen, Nicolas A.; Schiffman, Mark] NCI, DCEG, Bethesda, MD 20892 USA.
[Walker, Joan; Zuna, Rosemary; Smith, Katie; Mathews, Cara; Moxley, Katherine; Tenney, Meaghan; Zhang, Roy] Univ Oklahoma, Oklahoma City, OK USA.
[Gold, Michael] Vanderbilt Univ, Nashville, TN 37235 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3189
DI 10.1158/1538-7445.AM2011-3189
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404414
ER
PT J
AU Winter, SF
Hunter, KW
AF Winter, Scott F.
Hunter, Kent W.
TI Arid4b: A germline breast cancer progression modifier
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Winter, Scott F.; Hunter, Kent W.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1458
DI 10.1158/1538-7445.AM2011-1458
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301274
ER
PT J
AU Woditschka, S
Palmieri, D
Flores, NM
Sledge, GW
Badve, S
Steeg, PS
AF Woditschka, Stephan
Palmieri, Diane
Flores, Natasha M.
Sledge, George W.
Badve, Sunil
Steeg, Patricia S.
TI The DNA double-strand break repair genes BARD1 and RAD51 as molecular
targets for brain metastases from breast cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Woditschka, Stephan] NCI, Canc Prevent Fellowship Program, Rockville, MD USA.
[Palmieri, Diane; Flores, Natasha M.; Steeg, Patricia S.] NCI, Womens Canc Sect, Mol Pharmacol Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
[Sledge, George W.] Indiana Univ Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA.
[Badve, Sunil] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1478
DI 10.1158/1538-7445.AM2011-1478
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301457
ER
PT J
AU Wood, LV
Dahut, W
Gulley, JL
Madan, RA
Arlen, P
Parnes, HL
Roberson, BD
Steinberg, SM
Terabe, M
Berzofsky, JA
AF Wood, Lauren V.
Dahut, William
Gulley, James L.
Madan, Ravi A.
Arlen, Philip
Parnes, Howard L.
Roberson, Brenda D.
Steinberg, Seth M.
Terabe, Masaki
Berzofsky, Jay A.
TI Therapeutic vaccination with epitope-enhanced and wild-type TARP
peptides in stage DO prostate cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Wood, Lauren V.; Dahut, William; Gulley, James L.; Madan, Ravi A.; Arlen, Philip; Parnes, Howard L.; Roberson, Brenda D.; Steinberg, Seth M.; Terabe, Masaki; Berzofsky, Jay A.] NCI, Bethesda, MD 20892 USA.
RI Gulley, James/K-4139-2016
OI Gulley, James/0000-0002-6569-2912
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5520
DI 10.1158/1538-7445.AM2011-5520
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405096
ER
PT J
AU Wu, YZ
Antony, S
Lu, JM
Juhasz, A
Liu, H
Jiang, GJ
Roy, K
Doroshow, JH
AF Wu, Yongzhong
Antony, Smitha
Lu, Jiamo
Juhasz, Agnes
Liu, Han
Jiang, Guojian
Roy, Krishnendu
Doroshow, James H.
TI ERK activation mediated by Duox2 expression and reactive oxygen
production is responsible for HIF-1 alpha accumulation and VEGF
induction in IFN-gamma-treated BxPC-3 pancreatic cancer cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Wu, Yongzhong; Antony, Smitha; Lu, Jiamo; Juhasz, Agnes; Liu, Han; Jiang, Guojian] NCI, Bethesda, MD 20892 USA.
[Roy, Krishnendu; Doroshow, James H.] NCI, DCTD, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 2082
DI 10.1158/1538-7445.AM2011-2082
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404245
ER
PT J
AU Xie, Q
Bradley, R
Kang, L
Koeman, J
Worschech, A
De Giorgi, V
Wang, E
Kefene, L
Su, YL
Essenburg, C
Kaufman, D
DeKoning, T
Enter, M
O'Rourke, TJ
Marincola, F
Vande Woude, GF
AF Xie, Qian
Bradley, Robert
Kang, Liang
Koeman, Julie
Worschech, Andrea
De Giorgi, Valeria
Wang, Ena
Kefene, Lisa
Su, Yanli
Essenburg, Curt
Kaufman, Dafna
DeKoning, Tom
Enter, Mark
O'Rourke, Timothy J.
Marincola, Francesco
Vande Woude, George F.
TI Dissecting the therapeutic determinants of MET inhibition in
Glioblastoma: HGF-autocrine loop predicts sensitivity to MET inhibitor
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Xie, Qian; Bradley, Robert; Kang, Liang; Koeman, Julie; Kefene, Lisa; Su, Yanli; Essenburg, Curt; Kaufman, Dafna; DeKoning, Tom; Vande Woude, George F.] Van Andel Res Inst, Grand Rapids, MI USA.
[Worschech, Andrea; De Giorgi, Valeria; Wang, Ena; Marincola, Francesco] NIH, Infect Dis & Immunogenet Sect, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.
[Enter, Mark; O'Rourke, Timothy J.] Spectrum Hlth, Grand Rapids, MI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA LB-223
DI 10.1158/1538-7445.AM2011-LB-223
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701400304
ER
PT J
AU Xie, YL
Camps, J
Awad, KS
Wangsa, D
Yang, JH
Yoo, N
Ried, T
Kwong, KF
AF Xie, Yili
Camps, Jordi
Awad, Keytam S.
Wangsa, Danny
Yang, Jianhui
Yoo, Nina
Ried, Thomas
Kwong, King F.
TI MicroRNA repression of BIRC4/XIAP in lung cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Xie, Yili; Camps, Jordi; Awad, Keytam S.; Wangsa, Danny; Yang, Jianhui; Yoo, Nina; Ried, Thomas; Kwong, King F.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 135
DI 10.1158/1538-7445.AM2011-135
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701404059
ER
PT J
AU Xin, HW
Hari, DM
Mullinax, JE
Ambe, CM
Ray, S
Koizumi, T
Wiegand, GW
Miller, T
Andersen, AJ
Garfield, SH
Thorgeirsson, SS
Avital, I
AF Xin, Hongwu
Hari, Danielle M.
Mullinax, John E.
Ambe, Chenwi M.
Ray, Satyajit
Koizumi, Tomotake
Wiegand, Gordon W.
Miller, Tyler
Andersen, Andrew J.
Garfield, Susan H.
Thorgeirsson, Snorri S.
Avital, Itzhak
TI Human solid organ cancers contain stem-like label-retaining cancer cells
that undergo asymmetric cell division and have superior tumor initiating
capacity
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Xin, Hongwu; Hari, Danielle M.; Mullinax, John E.; Ambe, Chenwi M.; Ray, Satyajit; Koizumi, Tomotake; Wiegand, Gordon W.; Miller, Tyler; Andersen, Andrew J.; Garfield, Susan H.; Thorgeirsson, Snorri S.; Avital, Itzhak] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 478
DI 10.1158/1538-7445.AM2011-478
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302060
ER
PT J
AU Yan, C
Nottingham, L
Allen, C
Cheng, TF
Pattatheyil, A
Yang, XP
Gius, D
Dang, LN
Chen, Z
Van Waes, C
AF Yan, Carol
Nottingham, Liesl
Allen, Clint
Cheng, Tsu-Fan
Pattatheyil, Arun
Yang, Xinping
Gius, David
Dang, Lenny
Chen, Zhong
Van Waes, Carter
TI Combined targeting of IKK alpha and beta effectively suppresses NF-kappa
B activation, cell survival and migration in head and neck squamous cell
cancers
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Yan, Carol; Nottingham, Liesl; Allen, Clint; Cheng, Tsu-Fan; Pattatheyil, Arun; Yang, Xinping; Chen, Zhong; Van Waes, Carter] NIDCD, NIH, Bethesda, MD USA.
[Gius, David] NCI, NIH, Bethesda, MD 20892 USA.
[Dang, Lenny] Millennium Pharmaceut Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5005
DI 10.1158/1538-7445.AM2011-5005
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402099
ER
PT J
AU Yang, HP
Trabert, B
Murphy, MA
Sherman, ME
Sampson, JN
Brinton, LA
Hartge, P
Hollenbeck, A
Schatzkin, A
Wentzensen, N
AF Yang, Hannah P.
Trabert, Britton
Murphy, Megan A.
Sherman, Mark E.
Sampson, Joshua N.
Brinton, Louise A.
Hartge, Patricia
Hollenbeck, Albert
Schatzkin, Arthur
Wentzensen, Nicolas
TI Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet
and Health Study
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Yang, Hannah P.; Trabert, Britton; Murphy, Megan A.; Sherman, Mark E.; Sampson, Joshua N.; Brinton, Louise A.; Hartge, Patricia; Schatzkin, Arthur; Wentzensen, Nicolas] NCI, Rockville, MD USA.
[Hollenbeck, Albert] AARP, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3712
DI 10.1158/1538-7445.AM2011-3712
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701406079
ER
PT J
AU Yang, J
Kinyamu, HH
Archer, TK
AF Yang, Jun
Kinyamu, Harriet H.
Archer, Trevor K.
TI Exploring LIN28 mRNA targets in breast cancer cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Yang, Jun; Kinyamu, Harriet H.; Archer, Trevor K.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3082
DI 10.1158/1538-7445.AM2011-3082
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402226
ER
PT J
AU Yang, M
Gao, HK
Sun, XL
Quan, QM
Mohamedali, KA
Rosenblum, MG
Niu, G
Chen, XY
AF Yang, Min
Gao, Haokao
Sun, Xilin
Quan, Qimeng
Mohamedali, Khalid A.
Rosenblum, Michael G.
Niu, Gang
Chen, Xiaoyuan
TI Multiplexed PET probes for imaging breast cancer early response to
VEGF(121)/rGel treatment
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Yang, Min; Gao, Haokao; Sun, Xilin; Quan, Qimeng; Niu, Gang; Chen, Xiaoyuan] NIH, Bethesda, MD 20892 USA.
[Mohamedali, Khalid A.; Rosenblum, Michael G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5273
DI 10.1158/1538-7445.AM2011-5273
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301137
ER
PT J
AU Yang, YA
Weng, J
Welsh, M
Ford, HL
Lonning, SM
Wakefield, L
AF Yang, Yu-an
Weng, Jia
Welsh, Michael
Ford, Heide L.
Lonning, Scott M.
Wakefield, Lalage
TI Development of predictive biomarkers for anti-TGF-beta therapy
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Yang, Yu-an; Weng, Jia; Welsh, Michael; Wakefield, Lalage] NCI, Bethesda, MD 20892 USA.
[Ford, Heide L.] Univ Colorado, Sch Med, Aurora, CO USA.
[Lonning, Scott M.] Genzyme Corp, Framingham, MA 01701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1090
DI 10.1158/1538-7445.AM2011-1090
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701403310
ER
PT J
AU Yoshikawa, N
Young, MR
Hegamyer, G
Baker, AR
Santhanam, AN
Wei, Q
Colburn, NH
AF Yoshikawa, Noriko
Young, Matthew R.
Hegamyer, Glenn
Baker, Alyson R.
Santhanam, Arti N.
Wei, Qiou
Colburn, Nancy H.
TI Identification of the translational targets of tumor suppressor Pdcd4
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Yoshikawa, Noriko; Young, Matthew R.; Hegamyer, Glenn; Baker, Alyson R.; Santhanam, Arti N.; Wei, Qiou; Colburn, Nancy H.] NCI, Frederick, MD 21701 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 3079
DI 10.1158/1538-7445.AM2011-3079
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701402223
ER
PT J
AU Yoshimura, T
Howard, OMZ
Matsukawa, A
Chen, KQ
Liu, Y
Wang, JM
Oppenheim, JJ
AF Yoshimura, Teizo
Howard, O. M. Zack
Matsukawa, Akihiro
Chen, Keqiang
Liu, Ying
Wang, Ji Ming
Oppenheim, Joost J.
TI Monocyte chemoattractant protein-1 (MCP-1)/CCL2 produced by non-tumor
cells in tumor stroma promotes lung metastasis of 4T1 murine breast
cancer cells
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Yoshimura, Teizo; Howard, O. M. Zack; Chen, Keqiang; Liu, Ying; Wang, Ji Ming; Oppenheim, Joost J.] NCI, Frederick, MD 21701 USA.
[Matsukawa, Akihiro] Okayama Univ, Okayama 7008530, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 385
DI 10.1158/1538-7445.AM2011-385
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701304208
ER
PT J
AU Yu, HP
Zhao, H
Wang, LE
Han, YH
Wei, VC
Amos, CI
Rafnar, T
Sulem, P
Stefansson, K
Landi, MT
Caporaso, N
Albanes, D
Thun, M
Mckay, JD
Brennan, P
Wang, YF
Houlston, RS
Spitz, MR
Wei, QY
AF Yu, Hongping
Zhao, Hui
Wang, Li-E
Han, Younghun
Wei, Chen, V
Amos, Christopher I.
Rafnar, Thorunn
Sulem, Patrick
Stefansson, Kari
Landi, Maria Teresa
Caporaso, Neil
Albanes, Demetrius
Thun, Michael
McKay, James D.
Brennan, Paul
Wang, Yufei
Houlston, Richard S.
Spitz, Margaret R.
Wei, Qingyi
TI An analysis of single nucleotide polymorphisms of 125 DNA repair genes
in the Texas genome-wide association study of lung cancer with a
replication for the XRCC4 SNPs
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Yu, Hongping; Zhao, Hui; Wang, Li-E; Han, Younghun; Wei, Chen, V; Amos, Christopher I.; Spitz, Margaret R.; Wei, Qingyi] UT MD Anderson Canc Ctr, Houston, TX USA.
[Rafnar, Thorunn; Sulem, Patrick; Stefansson, Kari] DeCODE Genet, Reykjavik, Iceland.
[Landi, Maria Teresa] NCI, Bethesda, MD 20892 USA.
[Caporaso, Neil; Albanes, Demetrius] NIH, Bethesda, MD 20892 USA.
[Thun, Michael] Amer Canc Soc, Atlanta, GA 30329 USA.
[McKay, James D.; Brennan, Paul] Int Agcy Res Canc, F-69372 Lyon, France.
[Wang, Yufei; Houlston, Richard S.] Inst Canc Res, Sutton, Surrey, England.
OI Houlston, Richard/0000-0002-5268-0242
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 889
DI 10.1158/1538-7445.AM2011-889
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701405471
ER
PT J
AU Yu, YL
Liu, ZY
Yu, YX
Mendoza, A
Khanna, C
Merlino, G
AF Yu, Yanlin
Liu, Ziyang
Yu, Yixin
Mendoza, Arnulfo
Khanna, Chand
Merlino, Glenn
TI Dissecting the role of PTEN/Akts in metastatic melanoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Yu, Yanlin; Liu, Ziyang; Yu, Yixin; Mendoza, Arnulfo; Khanna, Chand; Merlino, Glenn] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1446
DI 10.1158/1538-7445.AM2011-1446
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301262
ER
PT J
AU Zeng, HM
Yu, H
Lu, LG
Jain, D
Kidd, MS
Saif, MW
Chanock, SJ
Hartge, P
Risch, HA
AF Zeng, Hongmei
Yu, Herbert
Lu, Lingeng
Jain, Dhanpat
Kidd, Mark S.
Saif, M. Wasif
Chanock, Stephen J.
Hartge, Patricia
Risch, Harvey A.
TI Genetic effects and modifiers of radiotherapy and chemotherapy on
survival in pancreatic cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Zeng, Hongmei] Peking Univ, Key Lab Carcinogenesis & Translat Res, Beijing Canc Hosp & Inst, Minist Educ,Dept Canc Epidemiol,Sch Oncol, Beijing 100871, Peoples R China.
[Yu, Herbert; Lu, Lingeng; Risch, Harvey A.] Yale Univ, Dept Epidemiol & Publ Hlth, Sch Publ Hlth, New Haven, CT 06520 USA.
[Yu, Herbert; Lu, Lingeng; Risch, Harvey A.] Yale Univ, Sch Med, New Haven, CT USA.
[Jain, Dhanpat] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
[Kidd, Mark S.] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA.
[Saif, M. Wasif] Columbia Univ Coll Phys & Surg, Dept Med, Div Hematol Oncol, New York, NY USA.
[Chanock, Stephen J.; Hartge, Patricia] NCI, Lab Translat Genom, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 4668
DI 10.1158/1538-7445.AM2011-4668
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401208
ER
PT J
AU Zhang, JY
Thorgeirsson, SS
Jessup, JM
AF Zhang, Jingyu
Thorgeirsson, Snorri S.
Jessup, J. Milburn
TI Nanog family members are essential for spherogenicity and metastasis in
colorectal carcinoma
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Zhang, Jingyu; Thorgeirsson, Snorri S.] NCI, CCR, Bethesda, MD 20892 USA.
[Jessup, J. Milburn] NCI, Canc Diag Prog, DCTD, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5206
DI 10.1158/1538-7445.AM2011-5206
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701300380
ER
PT J
AU Zhang, SL
Pruitt, M
Tran, D
DuBois, W
Robinson, R
Mock, BA
AF Zhang, Shuling
Pruitt, Margaret
Dena Tran
DuBois, Wendy
Robinson, Richard
Mock, Beverly A.
TI mTORC protein levels affect class switch recombination, somatic
hypermutation, and antibody production
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Zhang, Shuling; Pruitt, Margaret; Dena Tran; DuBois, Wendy; Robinson, Richard; Mock, Beverly A.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 805
DI 10.1158/1538-7445.AM2011-805
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701302345
ER
PT J
AU Zhu, BK
Khozoie, C
Bility, M
Blazanin, N
Glick, AB
Gonzalez, FJ
Peters, JM
AF Zhu, Bokai
Khozoie, Combiz
Bility, Moses
Blazanin, Nicholas
Glick, Adam B.
Gonzalez, Frank J.
Peters, Jeffrey M.
TI Anti-oncogenic role of Peroxisome proliferator-activated
receptor-beta/Delta (Ppar beta/Delta) involves regulation of viral Hras1
(v-Hras1)-induced senescence and endoplasmic reticulum (ER) stress in
mouse primary keratinocytes
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Zhu, Bokai; Khozoie, Combiz; Bility, Moses; Blazanin, Nicholas; Glick, Adam B.; Peters, Jeffrey M.] Penn State Univ, University Pk, PA 16802 USA.
[Gonzalez, Frank J.] NCI, Lab Metab, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 1227
DI 10.1158/1538-7445.AM2011-1227
PG 1
WC Oncology
SC Oncology
GA V43SP
UT WOS:000209701401470
ER
PT J
AU Zhu, ZQ
Singh, V
Bronte, V
Feigenbaum, L
Hurwitz, A
AF Zhu, Ziqiang
Singh, Vinod
Bronte, Vincenzo
Feigenbaum, Lionel
Hurwitz, Arthur
TI CD4+T cell help differentially influences anti-tumor immunity as a
function of T cell avidity
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Zhu, Ziqiang; Singh, Vinod; Feigenbaum, Lionel; Hurwitz, Arthur] NCI, Frederick, MD 21701 USA.
[Bronte, Vincenzo] Univ Padua, Padua, Italy.
RI Bronte, Vincenzo/K-7902-2016
OI Bronte, Vincenzo/0000-0002-3741-5141
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 473
DI 10.1158/1538-7445.AM2011-473
PG 1
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301251
ER
PT J
AU Zielinski, RJ
Lyakhov, I
Moinuddin, H
Chernomordik, V
Garcia-Glaessner, A
Ardeshirpour, Y
Gandjbakhche, A
Capala, J
AF Zielinski, Rafal J.
Lyakhov, Ilya
Moinuddin, Hassan
Chernomordik, Victor
Garcia-Glaessner, Alejandra
Ardeshirpour, Yasaman
Gandjbakhche, Amir
Capala, Jacek
TI Affibody - NIR conjugate for optical imaging of HER2-expressing tumors
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Zielinski, Rafal J.; Garcia-Glaessner, Alejandra; Capala, Jacek] NCI, NIH, Bethesda, MD 20892 USA.
[Lyakhov, Ilya] NCI, NIH, Frederick, MD 21701 USA.
[Moinuddin, Hassan; Chernomordik, Victor; Ardeshirpour, Yasaman; Gandjbakhche, Amir] NICHHD, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2011
VL 71
SU 8
MA 5298
DI 10.1158/1538-7445.AM2011-5298
PG 2
WC Oncology
SC Oncology
GA V43SO
UT WOS:000209701301163
ER
PT J
AU Webb, SW
Grillet, N
Andrade, LR
Xiong, W
Swarthout, L
Della Santina, CC
Kachar, B
Muller, U
AF Webb, Stuart W.
Grillet, Nicolas
Andrade, Leonardo R.
Xiong, Wei
Swarthout, Lani
Della Santina, Charley C.
Kachar, Bechara
Mueller, Ulrich
TI Regulation of PCDH15 function in mechanosensory hair cells by
alternative splicing of the cytoplasmic domain
SO DEVELOPMENT
LA English
DT Article
DE Hair cells; PCDH15; Deafness; Mouse
ID SYNDROME TYPE 1F; INNER-EAR; USHER-SYNDROME; PLANAR POLARITY; WALTZER
MICE; TIP-LINK; PROTOCADHERIN GENE; HEARING-LOSS; MUTATIONS; CADHERIN-23
AB Protocadherin 15 (PCDH15) is expressed in hair cells of the inner ear and in photoreceptors of the retina. Mutations in PCDH15 cause Usher Syndrome (deaf-blindness) and recessive deafness. In developing hair cells, PCDH15 localizes to extracellular linkages that connect the stereocilia and kinocilium into a bundle and regulate its morphogenesis. In mature hair cells, PCDH15 is a component of tip links, which gate mechanotransduction channels. PCDH15 is expressed in several isoforms differing in their cytoplasmic domains, suggesting that alternative splicing regulates PCDH15 function in hair cells. To test this model, we generated three mouse lines, each of which lacks one out of three prominent PCDH15 isoforms (CD1, CD2 and CD3). Surprisingly, mice lacking PCDH15-CD1 and PCDH15-CD3 form normal hair bundles and tip links and maintain hearing function. Tip links are also present in mice lacking PCDH15-CD2. However, PCDH15-CD2-deficient mice are deaf, lack kinociliary links and have abnormally polarized hair bundles. Planar cell polarity (PCP) proteins are distributed normally in the sensory epithelia of the mutants, suggesting that PCDH15-CD2 acts downstream of PCP components to control polarity. Despite the absence of kinociliary links, vestibular function is surprisingly intact in the PCDH15-CD2 mutants. Our findings reveal an essential role for PCDH15-CD2 in the formation of kinociliary links and hair bundle polarization, and show that several PCDH15 isoforms can function redundantly at tip links.
C1 [Webb, Stuart W.; Grillet, Nicolas; Xiong, Wei; Mueller, Ulrich] Scripps Res Inst, Dorris Neurosci Ctr, La Jolla, CA 92037 USA.
[Webb, Stuart W.; Grillet, Nicolas; Xiong, Wei; Mueller, Ulrich] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.
[Andrade, Leonardo R.; Kachar, Bechara] Natl Inst Deafness & Other Commun Disorders, Lab Cell Struct & Dynam, NIH, Bethesda, MD 20892 USA.
[Swarthout, Lani; Della Santina, Charley C.] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg & Biomed Engn, Baltimore, MD 21287 USA.
RP Webb, SW (reprint author), Scripps Res Inst, Dorris Neurosci Ctr, La Jolla, CA 92037 USA.
EM swwebb@scripps.edu; kacharb@nidce.nih.gov; umueller@scripps.edu
RI Andrade, Leonardo/C-9554-2011; Wang, Shirong/G-1698-2011; Xiong,
Wei/A-6170-2012
OI Andrade, Leonardo/0000-0002-0004-5677;
FU NIDCD [DC007704, DC005965, DC005965-S1, DC9255, DC2390,
NIDCD-DIR-Z01DC000002]; Skaggs Institute for Chemical Biology; Dorris
Neuroscience Center; Ruth Kirschstein Predoctoral Fellowship; CIRM
FX This work was funded by NIDCD grants DC007704, DC005965, DC005965-S1 (U.
M.), DC9255, DC2390 (C. D. S.) and NIDCD-DIR-Z01DC000002 (B. K.); by the
Skaggs Institute for Chemical Biology (U. M.); by the Dorris
Neuroscience Center (U. M.); by a Ruth Kirschstein Predoctoral
Fellowship award (S. W. W.); and by a CIRM training grant (S. W. W.).
Deposited in PMC for release after 12 months.
NR 51
TC 43
Z9 43
U1 0
U2 10
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 0950-1991
J9 DEVELOPMENT
JI Development
PD APR 15
PY 2011
VL 138
IS 8
BP 1607
EP 1617
DI 10.1242/dev.060061
PG 11
WC Developmental Biology
SC Developmental Biology
GA 738OI
UT WOS:000288649400016
PM 21427143
ER
PT J
AU Sangeetha, M
Pillai, MS
Philip, L
Lakatta, EG
Shivakumar, K
AF Sangeetha, M.
Pillai, Malini S.
Philip, Linda
Lakatta, Edward G.
Shivakumar, K.
TI NF-kappa B inhibition compromises cardiac fibroblast viability under
hypoxia
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Cardiac fibroblasts; Hypoxia; NF-kappa B; clAP-2; Bcl-2; Cell survival
ID PROGRAMMED CELL-DEATH; SMOOTH-MUSCLE-CELLS; INDUCED APOPTOSIS;
MYOCARDIAL-INFARCTION; VENTRICULAR MYOCYTES; ENDOTHELIAL-CELLS;
OXIDATIVE STRESS; ACTIVATION; SURVIVAL; PATHWAY
AB Cardiac fibroblasts are reported to be relatively resistant to stress stimuli compared to cardiac myocytes and fibroblasts of non-cardiac origin. However, the mechanisms that facilitate their survival under conditions of stress remain unclear. We explored the possibility that NF-kappa B protects cardiac fibroblasts from hypoxia-induced cell death. Further, we examined the expression of the antiapoptotic clAP-2 and Bcl-2 in hypoxic cardiac fibroblasts, and their possible regulation by NF-kappa B. Phase contrast microscopy and propidium iodide staining revealed that cardiac fibroblasts are more resistant than pulmonary fibroblasts to hypoxia. Electrophoretic Mobility Shift Assay showed that hypoxia activates NF-kappa B in cardiac fibroblasts. Supershift assay indicated that the active NF-kappa B complex is a p65/p50 heterodimer. An I-kappa B-super-repressor was constructed that prevented NF-kappa B activation and compromised cell viability under hypoxic but not normoxic conditions. Similar results were obtained with Bay 11-7085, an inhibitor of NF-kappa B. Western blot analysis showed constitutive levels of Bcl-2 and hypoxic induction of clAP-2 in these cells. NF-kappa B inhibition reduced clAP-2 but not Bcl-2 levels in hypoxic cardiac fibroblasts. The results show for the first time that NF-kappa B is an important effector of survival in cardiac fibroblasts under hypoxic stress and that regulation of clAP-2 expression may contribute to its pro-survival role. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Sangeetha, M.; Pillai, Malini S.; Philip, Linda; Shivakumar, K.] Sree Chitra Tirunal Inst Med Sci & Technol, Div Cellular & Mol Cardiol, Trivandrum 695011, Kerala, India.
[Lakatta, Edward G.] NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA.
RP Shivakumar, K (reprint author), Sree Chitra Tirunal Inst Med Sci & Technol, Div Cellular & Mol Cardiol, Trivandrum 695011, Kerala, India.
EM shivak@sctimst.ac.in
FU NIH; National Institute on Aging; Life Science Research Board, DRDO,
Government of India; CSIR, Government of India
FX This work was supported in part by the Intramural Research Program of
the NIH, National Institute on Aging, and in part by a research grant to
K Shivakumar from the Life Science Research Board, DRDO, Government of
India. Sangeetha Mohan gratefully acknowledges the Courtesy
Associateship from the NIH, USA Linda Philip is recipient of a Junior
Research Fellowship from the CSIR, Government of India. The authors
thank Dr. Li Lin of the Laboratory of Cardiovascular Science, GRC,
NIA/NIH, for providing the super-repressor used in this study, and Dr.
Ranjan Sen of the Laboratory of Cellular and Molecular Biology, GRC,
NIA/NIH, for critical reading of the manuscript
NR 42
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD APR 15
PY 2011
VL 317
IS 7
BP 899
EP 909
DI 10.1016/j.yexcr.2010.12.024
PG 11
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 740VN
UT WOS:000288822600001
PM 21211536
ER
PT J
AU Zhang, X
Brann, TW
Zhou, M
Yang, J
Oguariri, RM
Lidie, KB
Imamichi, H
Huang, DW
Lempicki, RA
Baseler, MW
Veenstra, TD
Young, HA
Lane, HC
Imamichi, T
AF Zhang, Xing
Brann, Terrence W.
Zhou, Ming
Yang, Jun
Oguariri, Raphael M.
Lidie, Kristy B.
Imamichi, Hiromi
Huang, Da-Wei
Lempicki, Richard A.
Baseler, Michael W.
Veenstra, Timothy D.
Young, Howard A.
Lane, H. Clifford
Imamichi, Tomozumi
TI Cutting Edge: Ku70 Is a Novel Cytosolic DNA Sensor That Induces Type III
Rather Than Type I IFN
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID LAMBDA; RECOGNITION; INTERFERON; CYTOKINE; VIRUS; RECOMBINATION;
REPLICATION; MACROPHAGES; EXPRESSION; INFECTION
AB Cytosolic foreign DNA is detected by pattern recognition receptors and mainly induces type I IFN production. We found that transfection of different types of DNA into various untreated cells induces type III IFN (IFN-lambda 1) rather than type I IFN, indicating the presence of uncharacterized DNA sensor(s). A pull-down assay using cytosolic proteins identified that Ku70 and Ku80 are the DNA-binding proteins. The knockdown studies and the reporter assay revealed that Ku70 is a novel DNA sensor inducing the IFN-lambda1 activation. The functional analysis of IFNL1 promoter revealed that positive-regulatory domain I and IFN-stimulated response element sites are predominantly involved in the DNA-mediated IFNL1 activation. A pull-down assay using nuclear proteins demonstrated that the IFN-l1 induction is associated with the activation of IFN regulatory factor-1 and -7. Thus, to our knowledge, we show for the first time that Ku70 mediates type III IFN induction by DNA. The Journal of Immunology, 2011, 186: 4541-4545.
C1 [Imamichi, Tomozumi] NCI, Appl & Dev Res Directorate, Lab Human Retrovirol, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21702 USA.
[Zhou, Ming; Veenstra, Timothy D.] NCI, Adv Technol Program Directorate, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21702 USA.
[Imamichi, Hiromi; Lane, H. Clifford] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
[Young, Howard A.] NCI, Expt Immunol Lab, Ctr Canc Res, Frederick, MD 21702 USA.
RP Imamichi, T (reprint author), NCI, Appl & Dev Res Directorate, Lab Human Retrovirol, Sci Applicat Int Corp Frederick Inc, Bldg 550,Room 126,POB B, Frederick, MD 21702 USA.
EM timamichi@mail.nih.gov
RI Zhang, Xing/F-8230-2011; Lempicki, Richard/E-1844-2012
OI Lempicki, Richard/0000-0002-7059-409X
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]; National Institute of Allergy and Infectious
Disease
FX This work was supported by the National Cancer Institute, National
Institutes of Health (Contract HHSN261200800001E) and the National
Institute of Allergy and Infectious Disease.
NR 25
TC 73
Z9 81
U1 1
U2 11
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD APR 15
PY 2011
VL 186
IS 8
BP 4541
EP 4545
DI 10.4049/jimmunol.1003389
PG 5
WC Immunology
SC Immunology
GA 744FY
UT WOS:000289081500003
PM 21398614
ER
PT J
AU Metenou, S
Dembele, B
Konate, S
Dolo, H
Coulibaly, YI
Diallo, AA
Soumaoro, L
Coulibaly, ME
Coulibaly, SY
Sanogo, D
Doumbia, SS
Traore, SF
Mahanty, S
Klion, A
Nutman, TB
AF Metenou, Simon
Dembele, Benoit
Konate, Siaka
Dolo, Housseini
Coulibaly, Yaya I.
Diallo, Abdallah A.
Soumaoro, Lamine
Coulibaly, Michel E.
Coulibaly, Siaka Y.
Sanogo, Dramane
Doumbia, Salif S.
Traore, Sekou F.
Mahanty, Siddhartha
Klion, Amy
Nutman, Thomas B.
TI Filarial Infection Suppresses Malaria-Specific Multifunctional Th1 and
Th17 Responses in Malaria and Filarial Coinfections
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID T-CELL RESPONSES; PLASMODIUM-FALCIPARUM MALARIA; TUMOR-NECROSIS-FACTOR;
IMMUNE-RESPONSES; HELMINTH INFECTION; GAMMA-INTERFERON;
MYCOBACTERIUM-TUBERCULOSIS; LYMPHATIC FILARIASIS; PROTECTIVE IMMUNITY;
CYTOKINE RESPONSES
AB The mechanisms underlying the modulation of both the malaria-specific immune response and the course of clinical malaria in the context of concomitant helminth infection are poorly understood. We used multiparameter flow cytometry to characterize the quality and the magnitude of malaria-specific T cell responses in filaria-infected and -uninfected individuals with concomitant asymptomatic Plasmodium falciparum malaria in Mali. In comparison with filarial-uninfected subjects, filarial infection was associated with higher ex vivo frequencies of CD4(+) cells producing IL-4, IL-10, and IL-17A (p = 0.01, p = 0.001, and p = 0.03, respectively). In response to malaria Ag stimulation, however, filarial infection was associated with lower frequencies of CD4 + T cells producing IFN-gamma, TNF-alpha, and IL-17A (p, 0.001, p = 0.04, and p = 0.04, respectively) and with higher frequencies of CD4(+)IL10(+) T cells (p = 0.0005). Importantly, filarial infection was associated with markedly lower frequencies of malaria Ag-specific Th1 (p < 0.0001), Th17 (p = 0.012), and "TNF-alpha" (p = 0.0008) cells, and a complete absence of malaria-specific multifunctional Th1 cells. Filarial infection was also associated with a marked increase in the frequency of malaria-specific adaptive regulatory T/Tr1 cells (p = 0.024), and the addition of neutralizing anti-IL-10 Ab augmented the amount of Th1-associated cytokine produced per cell. Thus, among malaria-infected individuals, concomitant filarial infection diminishes dramatically the frequencies of malaria-specific Th1 and Th17 T cells, and alters the quality and magnitude of malaria-specific T cell responses. The Journal of Immunology, 2011, 186: 4725-4733.
C1 [Metenou, Simon; Mahanty, Siddhartha; Klion, Amy; Nutman, Thomas B.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.
[Dembele, Benoit; Konate, Siaka; Dolo, Housseini; Coulibaly, Yaya I.; Diallo, Abdallah A.; Soumaoro, Lamine; Coulibaly, Michel E.; Coulibaly, Siaka Y.; Sanogo, Dramane; Doumbia, Salif S.; Traore, Sekou F.] Univ Bamako, Filariasis Unit, Fac Med Pharm & Dent, Bamako, Mali.
RP Metenou, S (reprint author), NIAID, Parasit Dis Lab, NIH, 4 Ctr Dr,Room B1-05, Bethesda, MD 20892 USA.
EM metenous@niaid.nih.gov
RI Metenou, Simon/C-1101-2013;
OI Klion, Amy/0000-0002-4986-5326; Mahanty, Siddhartha/0000-0003-1068-0524
FU Division of Intramural Research, National Institute of Allergy and
Infectious Diseases, National Institutes of Health
FX This work was supported by the Intramural Research Program of the
Division of Intramural Research, National Institute of Allergy and
Infectious Diseases, National Institutes of Health.
NR 65
TC 33
Z9 33
U1 1
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD APR 15
PY 2011
VL 186
IS 8
BP 4725
EP 4733
DI 10.4049/jimmunol.1003778
PG 9
WC Immunology
SC Immunology
GA 744FY
UT WOS:000289081500024
PM 21411732
ER
PT J
AU Bray, M
AF Bray, Mike
TI Understanding Smallpox Vaccination
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Editorial Material
ID PROGRESSIVE VACCINIA; STRAIN
C1 NIAID, Off Director, Div Clin Res, NIH, Bethesda, MD 20892 USA.
RP Bray, M (reprint author), NIAID, Off Director, Div Clin Res, NIH, Bethesda, MD 20892 USA.
EM mbray@niaid.nih.gov
NR 17
TC 1
Z9 1
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD APR 15
PY 2011
VL 203
IS 8
BP 1037
EP 1039
DI 10.1093/infdis/jiq164
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 745MC
UT WOS:000289168500001
PM 21450992
ER
PT J
AU Troxler, S
Lalonde, T
Wilson, JR
AF Troxler, Steven
Lalonde, Trent
Wilson, Jeffrey R.
TI Exact logistic models for nested binary data
SO STATISTICS IN MEDICINE
LA English
DT Article
DE correlated; dependent; clustering; hierarchical; multilevel; small
sample
ID REGRESSION MODELS
AB The use of logistic models for independent binary data has relied first on asymptotic theory and later on exact distributions for small samples. However, the use of logistic models for dependent analysis based on exact analysis is not as common. Moreover, attention is usually given to one-stage clustering. In this paper, we extend the exact techniques to address hypothesis testing (estimation is not addressed) for data with second-stage and probably higher levels of clustering. The methods are demonstrated through a somewhat generic example using C++ program. Copyright (C) 2011 John Wiley & Sons, Ltd.
C1 [Wilson, Jeffrey R.] Arizona State Univ, NIH, Alzheimers Res Ctr, Tempe, AZ 85287 USA.
[Troxler, Steven] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA.
[Lalonde, Trent] Univ No Colorado, Dept Appl Stat, Greeley, CO 80634 USA.
RP Wilson, JR (reprint author), Arizona State Univ, NIH, Alzheimers Res Ctr, BAC 565, Tempe, AZ 85287 USA.
EM jeffrey.wilson@asu.edu
FU National Institute of Health, Arizona Alzheimer Center at the Arizona
State University
FX The authors thank the two referees and the editor for helping to add
clarity to the issues addressed in this paper. This research was
supported in part by a National Institute of Health Alzheimer's Grant in
the Arizona Alzheimer Center at the Arizona State University.
NR 12
TC 1
Z9 1
U1 2
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0277-6715
J9 STAT MED
JI Stat. Med.
PD APR 15
PY 2011
VL 30
IS 8
BP 866
EP 876
DI 10.1002/sim.4157
PG 11
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA 741JH
UT WOS:000288859500006
PM 21432880
ER
PT J
AU Chatterjee, S
Lardinois, O
Bhattacharjee, S
Tucker, J
Corbett, J
Deterding, L
Ehrenshaft, M
Bonini, MG
Mason, RP
AF Chatterjee, Saurabh
Lardinois, Olivier
Bhattacharjee, Suchandra
Tucker, Jeff
Corbett, Jean
Deterding, Leesa
Ehrenshaft, Marilyn
Bonini, Marcelo G.
Mason, Ronald P.
TI Oxidative stress induces protein and DNA radical formation in follicular
dendritic cells of the germinal center and modulates its cell death
patterns in late sepsis
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Oxidative stress; Follicular dendritic cell; Caspase-3; Xanthine
oxidase; Apoptosome; Necrosis; Plasma cell; Free radicals
ID POLYMICROBIAL SEPSIS; SEPTIC SHOCK; B-CELLS; APOPTOSIS; ACTIVATION;
IMMUNOSUPPRESSION; PROLIFERATION; INFLAMMATION; ANTIOXIDANTS; TRYPTOPHAN
AB Profound depletion of follicular dendritic cells (FDCs) is a hallmark of sepsis-like syndrome, but the exact causes of the ensuing cell death are unknown. The cell death-driven depletion contributes to immunoparalysis and is responsible for most of the morbidity and mortality in sepsis. Here we have utilized immuno-spin trapping, a method for detection of free radical formation, to detect oxidative stress-induced protein and DNA radical adducts in FDCs isolated from the spleens of septic mice and from human tonsil-derived HK cells, a subtype of germinal center FDCs, to study their role in FDC depletion. At 24 h post-lipopolysaccharide administration, protein radical formation and oxidation were significantly elevated in vivo and in HK cells as shown by ELISA and confocal microscopy. The xanthine oxidase inhibitor allopurinol and the iron chelator desferrioxamine significantly decreased the formation of protein radicals, suggesting the role of xanthine oxidase and Fenton-like chemistry in radical formation. Protein and DNA radical formation correlated mostly with apoptotic features at 24 h and necrotic morphology of all the cell types studied at 48 h with concomitant inhibition of caspase-3. The cytotoxicity of FDCs resulted in decreased CD45R/CD138-positive plasma cell numbers, indicating a possible defect in B cell differentiation. In one such mechanism, radical formation initiated by xanthine oxidase formed protein and DNA radicals, which may lead to cell death of germinal center FDCs. Published by Elsevier Inc.
C1 [Chatterjee, Saurabh; Lardinois, Olivier; Bhattacharjee, Suchandra; Corbett, Jean; Ehrenshaft, Marilyn; Bonini, Marcelo G.; Mason, Ronald P.] NIEHS, Free Rad Metab Grp, Lab Toxicol & Pharmacol, NIH, Res Triangle Pk, NC 27709 USA.
[Tucker, Jeff] NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA.
[Deterding, Leesa] NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA.
RP Chatterjee, S (reprint author), NIEHS, Free Rad Metab Grp, Lab Toxicol & Pharmacol, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
EM chatterjees2@niehs.nih.gov
FU National Institutes of Health; National Institute of Environmental
Health Sciences [Z01 ES050139-13]
FX The authors sincerely acknowledge Tiwanda Marsh, Jeoffrey Hurlburt, and
Holly Rutledge for excellent technical assistance. We also thank Dr.
Carl Bortner for help in analyzing flow cytometry data and Dr. Shyamal
Peddada of the Statistics Branch, NIEHS, for generous help in
statistical analysis. We also sincerely thank Dr. Ann Motten and Mary
Mason for help in the careful editing of the manuscript. This work was
supported by the Intramural Research Program of the National Institutes
of Health and the National Institute of Environmental Health Sciences
(Z01 ES050139-13).
NR 45
TC 13
Z9 16
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD APR 15
PY 2011
VL 50
IS 8
BP 988
EP 999
DI 10.1016/j.freeradbiomed.2010.12.037
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 740TU
UT WOS:000288818100010
PM 21215311
ER
PT J
AU Sologuren, I
Boisson-Dupuis, S
Pestano, J
Vincent, QB
Fernandez-Perez, L
Chapgier, A
Cardenes, M
Feinberg, J
Garcia-Laorden, MI
Picard, C
Santiago, E
Kong, XF
Janniere, L
Colino, E
Herrera-Ramos, E
Frances, A
Navarrete, C
Blanche, S
Faria, E
Remiszewski, P
Cordeiro, A
Freeman, A
Holland, S
Abarca, K
Valeron-Lemaur, M
Goncalo-Marques, J
Silveira, L
Garcia-Castellano, JM
Caminero, J
Perez-Arellano, JL
Bustamante, J
Abel, L
Casanova, JL
Rodriguez-Gallego, C
AF Sologuren, Ithaisa
Boisson-Dupuis, Stephanie
Pestano, Jose
Vincent, Quentin Benoit
Fernandez-Perez, Leandro
Chapgier, Ariane
Cardenes, Maria
Feinberg, Jacqueline
Isabel Garcia-Laorden, M.
Picard, Capucine
Santiago, Esther
Kong, Xiaofei
Janniere, Lucile
Colino, Elena
Herrera-Ramos, Estefania
Frances, Adela
Navarrete, Carmen
Blanche, Stephane
Faria, Emilia
Remiszewski, Pawel
Cordeiro, Ana
Freeman, Alexandra
Holland, Steven
Abarca, Katia
Valeron-Lemaur, Monica
Goncalo-Marques, Jose
Silveira, Luisa
Manuel Garcia-Castellano, Jose
Caminero, Jose
Luis Perez-Arellano, Jose
Bustamante, Jacinta
Abel, Laurent
Casanova, Jean-Laurent
Rodriguez-Gallego, Carlos
TI Partial recessive IFN-gamma R1 deficiency: genetic, immunological and
clinical features of 14 patients from 11 kindreds
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GAMMA-RECEPTOR DEFICIENCY; STEM-CELL TRANSPLANTATION; CALMETTE-GUERIN
INFECTION; HUMAN STAT1 DEFICIENCY; INTERFERON-GAMMA; IFN-GAMMA;
IL-12R-BETA-1 DEFICIENCY; CRYPTOSPORIDIUM-PARVUM; MEDIATED IMMUNITY;
CRYSTAL-STRUCTURE
AB We report a series of 14 patients from 11 kindreds with recessive partial (RP)- interferon (IFN)-gamma R1 deficiency. The I87T mutation was found in nine homozygous patients from Chile, Portugal and Poland, and the V63G mutation was found in five homozygous patients from the Canary Islands. Founder effects accounted for the recurrence of both mutations. The most recent common ancestors of the patients with the I87T and V63G mutations probably lived 1600 (875-2950) and 500 (200-1275) years ago, respectively. The two alleles confer phenotypes that are similar but differ in terms of IFN-gamma R1 levels and residual response to IFN-gamma. The patients suffered from bacillus Calmette-Guerin-osis (n = 6), environmental mycobacteriosis (n = 6) or tuberculosis (n = 1). One patient did not suffer from mycobacterial infections but had disseminated salmonellosis, which was also present in two other patients. Age at onset of the first environmental mycobacterial disease differed widely between patients, with a mean value of 11.25 +/- 9.13 years. Thirteen patients survived until the age of 14.82 +/- 11.2 years, and one patient died at the age of 7 years, 9 days after the diagnosis of long-term Mycobacterium avium infection and the initiation of antimycobacterial treatment. Up to 10 patients are currently free of infection with no prophylaxis. The clinical heterogeneity of the 14 patients was not clearly related to either IFNGR1 genotype or the resulting cellular phenotype. RP-IFN-gamma R1 deficiency is, thus, more common than initially thought and should be considered in both children and adults with mild or severe mycobacterial diseases.
C1 [Sologuren, Ithaisa; Cardenes, Maria; Isabel Garcia-Laorden, M.; Santiago, Esther; Herrera-Ramos, Estefania; Rodriguez-Gallego, Carlos] Gran Canaria Dr Negrin Univ Hosp, Dept Immunol, Las Palmas Gran Canaria, Spain.
[Manuel Garcia-Castellano, Jose] Gran Canaria Dr Negrin Univ Hosp, Mol Oncol Lab, Res Unit, Las Palmas Gran Canaria, Spain.
[Caminero, Jose] Gran Canaria Dr Negrin Univ Hosp, Dept Resp Dis, Las Palmas Gran Canaria, Spain.
[Boisson-Dupuis, Stephanie; Vincent, Quentin Benoit; Chapgier, Ariane; Feinberg, Jacqueline; Picard, Capucine; Janniere, Lucile; Bustamante, Jacinta; Abel, Laurent; Casanova, Jean-Laurent] Univ Paris 05, Lab Human Genet Infect Dis, Necker Fac, Necker Med Sch,INSERM,U980, Paris, France.
[Boisson-Dupuis, Stephanie; Kong, Xiaofei; Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, New York, NY 10021 USA.
[Pestano, Jose] Univ Las Palmas Gran Canaria, Dept Biochem Mol Biol Physiol Genet & Immunol, Las Palmas Gran Canaria, Spain.
[Fernandez-Perez, Leandro] Univ Las Palmas Gran Canaria, Dept Clin Sci Pharmacol Unit, Mol & Translat Endocrinol Grp, Las Palmas Gran Canaria, Spain.
[Luis Perez-Arellano, Jose; Rodriguez-Gallego, Carlos] Univ Las Palmas Gran Canaria, Sch Med, Dept Med & Surg Sci, Las Palmas Gran Canaria, Spain.
[Cardenes, Maria; Rodriguez-Gallego, Carlos] Canarian Inst Canc Res, San Cristobal la Laguna, Santa Cruz Tene, Spain.
[Picard, Capucine] Hop Necker Enfants Malad, Study Ctr Primary Immunodeficiencies, Paris, France.
[Blanche, Stephane; Casanova, Jean-Laurent] Hop Necker Enfants Malad, AP HP, Pediat Immunol & Hematol Unit, Paris, France.
[Colino, Elena] Insular Materno Infantil Hosp, Dept Pediat, Infect Dis Unit, Las Palmas Gran Canaria, Spain.
[Frances, Adela; Luis Perez-Arellano, Jose] Insular Materno Infantil Hosp, Dept Infect Dis, Las Palmas Gran Canaria, Spain.
[Valeron-Lemaur, Monica] Insular Materno Infantil Hosp, Pediat Intens Care Unit, Las Palmas Gran Canaria, Spain.
[Manuel Garcia-Castellano, Jose] Insular Materno Infantil Hosp, Dept Orthoped Surg, Las Palmas Gran Canaria, Spain.
[Navarrete, Carmen] Hosp Ninos Roberto del Rio, Dept Immunol, Santiago, Chile.
[Faria, Emilia] Coimbra Pediat Hosp, Coimbra, Portugal.
[Cordeiro, Ana] Coimbra Pediat Hosp, Dept Med, Coimbra, Portugal.
[Remiszewski, Pawel] Natl TB & Chest Dis Res Inst, Dept Lung Dis 3, Warsaw, Poland.
[Freeman, Alexandra; Holland, Steven] NIH, Lab Clin Infect Dis, Bethesda, MD USA.
[Abarca, Katia] Pontificia Univ Catolica Chile, Sch Med, Dept Pediat, Santiago, Chile.
[Goncalo-Marques, Jose] Lisboa Norte Hosp, Santa Maria Ctr Hosp, Dept Pediat Infect Dis, Lisbon, Portugal.
[Silveira, Luisa] Santo Espirito Angra Heroismo EPE Hosp, Dept Pediat, Angra Do Heroismo, Portugal.
RP Rodriguez-Gallego, C (reprint author), Hosp Univ Gran Canaria Dr Negrin, Serv Inmunol, Barranco Ballena S-N, Las Palmas Gran Canaria 35010, Spain.
EM jrodgal@gobiernodecanarias.org
RI KONG, Xiao-Fei/G-3437-2011; Fernandez-Perez, Leandro/H-1493-2015;
Pestano Brito, Jose Juan/A-9640-2017;
OI Fernandez-Perez, Leandro/0000-0001-7802-465X; Pestano Brito, Jose
Juan/0000-0001-6454-4785; Vincent, Quentin/0000-0001-6030-5912
FU Institute of Health Carlos III, Ministry of Health
[RedRespira-ISCiii-RTIC-03/11, FIS 06/1031]; Fundacion Canaria de
Investigacion y Salud (Canarian Government) [INREDCAN 05/06]; Foundation
Caja Rural de Canarias-Chil y Naranjo 2004; Canarian Institute for
Cancer Research [ISCiii-RTICCC-C03/10]; Proyecto Biorregion 2006;
Universidad de Las Palmas de Gran Canaria
FX This work was supported by grants from the Institute of Health Carlos
III, Ministry of Health (RedRespira-ISCiii-RTIC-03/11, FIS 06/1031, with
the funding of European Regional Development Fund-European Social
Fund-FEDER-FSE); Fundacion Canaria de Investigacion y Salud (Canarian
Government, INREDCAN 05/06); Research Prize of Foundation Caja Rural de
Canarias-Chil y Naranjo 2004; Canarian Institute for Cancer Research
(ISCiii-RTICCC-C03/10 to M. C.); Proyecto Biorregion 2006 to M. I.
G.-L.; and Universidad de Las Palmas de Gran Canaria (fellowship to
E.H.-R.). J.-L.C. was an International Scholar of the Howard Hughes
Medical Institute. The sponsors of the study had no role in designing
the study, collecting, analyzing and interpreting the data, or writing
the paper.
NR 55
TC 38
Z9 39
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD APR 15
PY 2011
VL 20
IS 8
BP 1509
EP 1523
DI 10.1093/hmg/ddr029
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 740NC
UT WOS:000288800500005
PM 21266457
ER
PT J
AU Tebbenkamp, ATN
Swing, D
Tessarollo, L
Borchelt, DR
AF Tebbenkamp, Andrew T. N.
Swing, Debbie
Tessarollo, Lino
Borchelt, David R.
TI Premature death and neurologic abnormalities in transgenic mice
expressing a mutant huntingtin exon-2 fragment
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID YAC128 MOUSE MODEL; KNOCK-IN MICE; NEURONAL INTRANUCLEAR INCLUSIONS;
N-TERMINAL FRAGMENTS; MOTOR DYSFUNCTION; NUCLEAR-LOCALIZATION;
NERVOUS-SYSTEM; STRIATAL CELLS; HD MUTATION; CAG REPEAT
AB Huntington's disease (HD) is a fatal neurodegenerative disease characterized pathologically by aggregates composed of N-terminal fragments of the mutant form of the protein huntingtin (htt). The role of these N-terminal fragments in disease pathogenesis has been questioned based in part on studies in transgenic mice. In one important example, mice that express an N-terminal fragment of mutant htt terminating at the C-terminus of exon 2 (termed the Shortstop mouse) were reported to develop robust inclusion pathology without developing phenotypic abnormalities seen in the R6/2 or N171-82Q models of HD, which are also based on expression of mutant N-terminal htt fragments. To further explore the capacity of mutant exon-2 htt fragments to produce neurologic abnormalities (N-terminal 118 amino acids; N118), we generated transgenic mice expressing cDNA that encodes htt N118-82Q with the mouse prion promoter vector. In mice generated in this manner, we demonstrate robust inclusion pathology accompanied by early death and failure to gain weight. These phenotypes are the most robust abnormalities identified in the R6/2 and N171-82Q models. We conclude that the lack of an overt phenotype in the initial Shortstop mice cannot be completely explained by the properties of mutant htt N118 fragments.
C1 [Tebbenkamp, Andrew T. N.; Borchelt, David R.] Univ Florida, McKnight Brain Inst, Dept Neurosci, SantaFe HealthCare Alzheimers Dis Res Ctr, Gainesville, FL 32610 USA.
[Swing, Debbie; Tessarollo, Lino] NCI, Mouse Canc Genet Program, Neural Dev Sect, Frederick, MD 21702 USA.
RP Borchelt, DR (reprint author), Univ Florida, McKnight Brain Inst, Dept Neurosci, SantaFe HealthCare Alzheimers Dis Res Ctr, 100 Newell Dr,Rm L1-100, Gainesville, FL 32610 USA.
EM borchelt@mbi.ufl.edu
OI Tebbenkamp, Andrew/0000-0002-9015-3427
FU Huntington's Disease Society of America; CHDI Coalition for a Cure; NIH,
Center for Cancer Research, National Cancer Institute; SantaFe
HealthCare Alzheimer's Disease Research Center
FX This work was supported by the Huntington's Disease Society of America
and the CHDI Coalition for a Cure (A.T.N.T. and D. R. B.) and the
Intramural Research Program of the NIH, Center for Cancer Research,
National Cancer Institute (for D. S. and L. T.). Funding to pay the Open
Access publication charges for this article was provided by SantaFe
HealthCare Alzheimer's Disease Research Center.
NR 46
TC 12
Z9 12
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD APR 15
PY 2011
VL 20
IS 8
BP 1633
EP 1642
DI 10.1093/hmg/ddr040
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 740NC
UT WOS:000288800500015
PM 21307087
ER
PT J
AU Wahl, SM
Redford, M
Christensen, S
Mack, W
Cohn, J
Janoff, EN
Mestecky, J
Jenson, HB
Navazesh, M
Cohen, M
Reichelderfer, P
Kovacs, A
AF Wahl, Sharon M.
Redford, Maryann
Christensen, Shawna
Mack, Wendy
Cohn, Jon
Janoff, Edward N.
Mestecky, Jiri
Jenson, Hal B.
Navazesh, Mahvash
Cohen, Mardge
Reichelderfer, Patricia
Kovacs, Andrea
CA DATRI 009 Study Grp
TI Systemic and Mucosal Differences in HIV Burden, Immune, and Therapeutic
Responses
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE adaptive immunity; HIV-1; mucosa; innate immunity; IgA; SLPI
ID HUMAN-IMMUNODEFICIENCY-VIRUS; LEUKOCYTE PROTEASE INHIBITOR;
EPITHELIAL-CELLS; GENITAL-TRACT; TYPE-1 TRANSMISSION; IMMUNOGLOBULIN-A;
HUMAN SALIVA; BREAST-MILK; INFECTION; IGA
AB Background: Mucosal tissues represent major targets for HIV transmission but differ in susceptibility and reservoir function by unknown mechanisms.
Methods: In a cross-sectional study, HIV RNA and infectious virus were compared between oral and genital compartments and blood in HIV-infected women, in association with clinical parameters, copathogens, and putative innate and adaptive HIV inhibitors.
Results: HIV RNA was detectable in 24.5% of women from all 3 compartments, whereas 45% had RNA in only 1 or 2 sites. By comparison, infectious HIV, present in blood of the majority, was rare in mucosal sites. Innate mediators, secretory leukocyte protease inhibitor and thrombospondin, were highest in mucosae. Highly active antiretroviral therapy was associated with an 80% decreased probability of shedding. Multivariate logistic regression models revealed that mucosal HIV RNA was associated with higher plasma RNA, infectious virus, and total mucosal IgA, but not IgG. There was a 37-fold increased probability of detecting RNA in both genital and oral specimens (P = 0.008; P = 0.02, respectively) among women in highest versus lowest IgA tertiles.
Conclusions: Mucosal sites exhibit distinct characteristics of infectious HIV, viral shedding, and responses to therapy, dependent upon both systemic and local factors. Of the putative innate and adaptive mucosal defense factors examined, only IgA was associated with HIV RNA shedding. However, rather than being protective, there was a striking increase in probability of detectable HIV RNA shedding in women with highest total IgA.
C1 [Wahl, Sharon M.; Redford, Maryann] Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA.
[Christensen, Shawna; Kovacs, Andrea] Univ So Calif, Keck Sch Med, Maternal Child & Adolescent Ctr Infect Dis & Viro, Los Angeles, CA 90033 USA.
[Mack, Wendy] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Cohn, Jon] Wayne State Univ, Div Infect Dis, Detroit, MI USA.
[Janoff, Edward N.] Univ Colorado, Mucosal & Vaccine Res Program Colorado MAVRC, VA Med Ctr, Denver, CO 80202 USA.
[Mestecky, Jiri] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA.
[Jenson, Hal B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA.
[Navazesh, Mahvash] USC, Herman Ostrow Sch Dent, Div Periodontol Diagnost Sci & Dent Hyg, Los Angeles, CA USA.
[Cohen, Mardge] Stroger Cook Cty Hosp, Dept Med, Chicago, IL USA.
[Reichelderfer, Patricia] NICHHD, NIH, Bethesda, MD 20892 USA.
RP Wahl, SM (reprint author), Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, NIH, 30 Convent Dr,MSC4352,Bldg 30,Room 320, Bethesda, MD 20892 USA.
EM smwahl@dir.nidcr.nih.gov
OI Jenson, Hal/0000-0002-6549-860X
FU Division of AIDS Treatment Research Initiative (DATRI), NIAID, NIH,
Bethesda MD [NO1-AI-15123]; Program Support Center, DHHS [282-98-0015,
21]; NIAID; NIDCR; NCI; NICHD; NIDAA; Centers for Disease Control and
Prevention [U01-AI-35004, U01-AI-31834, U01-AI-34994, AI-34989,
U01-HD-32632, U01-AI-34993, U01-AI-42590, NO1-DE-72621, P01-AI-28147];
NIH, NIDCR; Agency for Health Care Policy and Research
FX This study was supported by the Division of AIDS Treatment Research
Initiative (DATRI) program, NIAID, NIH, Bethesda MD (Contract
NO1-AI-15123); the Program Support Center, DHHS (Contract 282-98-0015,
Task Order Number 21); and the Women's Interagency HIV Study, funded by
NIAID, NIDCR, NCI, NICHD, NIDAA, the Agency for Health Care Policy and
Research, the Centers for Disease Control and Prevention (Contracts
U01-AI-35004, U01-AI-31834, U01-AI-34994, AI-34989, U01-HD-32632,
U01-AI-34993, U01-AI-42590, NO1-DE-72621, and P01-AI-28147), and by the
Intramural Research Program of the NIH, NIDCR.
NR 54
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 15
PY 2011
VL 56
IS 5
BP 401
EP 411
DI 10.1097/QAI.0b013e31820cdfdb
PG 11
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 733DP
UT WOS:000288241800010
PM 21239996
ER
PT J
AU Mirochnick, M
Best, BM
Stek, AM
Capparelli, EV
Hu, CC
Burchett, SK
Rossi, SS
Hawkins, E
Basar, M
Smith, E
Read, JS
AF Mirochnick, Mark
Best, Brookie M.
Stek, Alice M.
Capparelli, Edmund V.
Hu, Chengcheng
Burchett, Sandra K.
Rossi, Steven S.
Hawkins, Elizabeth
Basar, Michael
Smith, Elizabeth
Read, Jennifer S.
CA IMPAACT 1026s Study Team
TI Atazanavir Pharmacokinetics With and Without Tenofovir During Pregnancy
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE atazanavir; HIV; mother to child transmission; pharmacokinetics;
pregnancy; tenofovir
ID LOPINAVIR EXPOSURE; WOMEN; RITONAVIR; SAQUINAVIR; NELFINAVIR; SAFETY;
INDINAVIR; EFFICACY; ZIDOVUDINE; LAMIVUDINE
AB Background: Few data are available describing atazanavir exposure during pregnancy, especially when used in combination with tenofovir, whose coadministration with atazanavir results in decreased atazanavir exposure.
Design: International Maternal Pediatric Adolescent AIDS Clinical Trials 1026s is an ongoing, prospective, nonblinded study of antiretroviral pharmacokinetics in HIV-infected pregnant women that included 2 cohorts receiving atazanavir/ritonavir 300 mg/100 mg once daily, either with or without tenofovir.
Methods: Intensive steady-state 24-hour pharmacokinetic profiles were performed during the third trimester and at 6-12 weeks postpartum. Atazanavir was measured by reverse-phase high-performance liquid chromatography (detection limit 0.047 mcg/mL). Pharmacokinetic targets were the estimated 10th percentile atazanavir area under the concentration versus time curve [(AUC): 29.4 mcg.hr.mL(-1)] in nonpregnant historical controls (mean AUC = 57 mcg.hr.mL(-1)) and a trough concentration of 0.15 mcg/mL, the concentration target used in therapeutic drug monitoring programs.
Results: Median atazanavir AUC was reduced during the third trimester compared with postpartum for subjects not receiving tenofovir (41.9 vs. 57.9 mcg.hr.mL(-1), P = 0.02) and for subjects receiving tenofovir (28.8 vs. 39.6 mcg.hr.mL(-1), P = 0.04). During the third trimester, AUC was below the target in 33% (6 of 18) of women not receiving tenofovir and 55% (11 of 20) of women receiving tenofovir. Trough concentration was below the target in 6% (1 of 18) of women not receiving tenofovir and 15% (3 of 20) of women receiving tenofovir. The median (range) ratio of cord blood/maternal atazanavir concentration in 29-paired samples was 0.18 (0-0.45).
Conclusions: Atazanavir exposure is reduced by pregnancy and by concomitant tenofovir use. A dose increase of atazanavir/ritonavir to 400 mg/100 mg may be necessary in pregnant women to ensure atazanavir exposure equivalent to that seen in nonpregnant adults.
C1 [Mirochnick, Mark] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA.
[Best, Brookie M.; Capparelli, Edmund V.; Rossi, Steven S.] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA.
[Best, Brookie M.; Capparelli, Edmund V.; Rossi, Steven S.] Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA USA.
[Stek, Alice M.] Univ So Calif, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA.
[Hu, Chengcheng] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA.
[Burchett, Sandra K.] Harvard Univ, Sch Med, Boston, MA USA.
[Burchett, Sandra K.] Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Hawkins, Elizabeth] Social & Sci Syst, Silver Spring, MD USA.
[Basar, Michael] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA.
[Read, Jennifer S.] NICHD, Maternal AIDS Branch, NIH, DHHS, Bethesda, MD USA.
[Smith, Elizabeth] NIAID, Bethesda, MD 20892 USA.
RP Mirochnick, M (reprint author), Boston Med Ctr, 771 Albany St,Dowling 4N,Room 4111, Boston, MA 02043 USA.
EM markm@bu.edu
RI Hu, Chengcheng/A-8391-2017
FU National Institute of Allergy and Infectious Diseases (NIAID) [U01
AI068632]; Eunice Kennedy Shriver National Institute of Child Health and
Human Development (NICHD); National Institute of Mental Health (NIMH)
[AI068632]; Statistical and Data Analysis Center at Harvard School of
Public Health under NIAID [5 U01 AI41110]; Pediatric AIDS Clinical
Trials Group (PACTG); IMPAACT Group [1 U01 AI068616]; NICHD
International and Domestic Pediatric and Maternal HIV Clinical Trials
Network [N01-DK-9-001/HHSN267200800001C]
FX Overall support for the International Maternal Pediatric Adolescent AIDS
Clinical Trials Group (IMPAACT) was provided by the National Institute
of Allergy and Infectious Diseases (NIAID) [U01 AI068632], the Eunice
Kennedy Shriver National Institute of Child Health and Human Development
(NICHD), and the National Institute of Mental Health (NIMH) [AI068632].
Supported by the Statistical and Data Analysis Center at Harvard School
of Public Health, under NIAID cooperative agreement #5 U01 AI41110 with
the Pediatric AIDS Clinical Trials Group (PACTG) and #1 U01 AI068616
with the IMPAACT Group. Support of the sites was provided by NIAID and
by the NICHD International and Domestic Pediatric and Maternal HIV
Clinical Trials Network (contract number
N01-DK-9-001/HHSN267200800001C).
NR 26
TC 44
Z9 44
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 15
PY 2011
VL 56
IS 5
BP 412
EP 419
DI 10.1097/QAI.0b013e31820fd093
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 733DP
UT WOS:000288241800011
PM 21283017
ER
PT J
AU Fink, VI
Shepherd, BE
Cesar, C
Krolewiecki, A
Wehbe, F
Cortes, CP
Crabtree-Ramirez, B
Padgett, D
Shafaee, M
Schechter, M
Gotuzzo, E
Bacon, M
McGowan, C
Cahn, P
Masys, D
AF Fink, Valeria I.
Shepherd, Bryan E.
Cesar, Carina
Krolewiecki, Alejandro
Wehbe, Firas
Cortes, Claudia P.
Crabtree-Ramirez, Brenda
Padgett, Denis
Shafaee, Maryam
Schechter, Mauro
Gotuzzo, Eduardo
Bacon, Melanie
McGowan, Catherine
Cahn, Pedro
Masys, Daniel
CA IeDEA Program
TI Cancer in HIV-Infected Persons From the Caribbean, Central and South
America
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT 18th International AIDS Conference
CY JUL 13-18, 2010
CL Vienna, AUSTRIA
DE Caribbean; cohort studies; HIV; Latin America; neoplasms
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY;
AIDS-DEFINING MALIGNANCIES; NON-HODGKIN-LYMPHOMA; HUMAN-PAPILLOMAVIRUS;
UNITED-STATES; COHORT; RISK; ASSOCIATION; TRENDS
AB Background: HIV-infected individuals have heightened cancer risk. With the advent of highly active antiretroviral therapy (HAART), the frequency of some AIDS-defining cancers (ADC) has decreased although certain non-AIDS-defining cancers (NADC) are becoming more frequent. Cancers among HIV-infected individuals in Latin American and the Caribbean have not yet been carefully studied.
Methods: Cancer cases among the Caribbean, Central and South American network for HIV Research (CCASAnet) cohort were identified reviewing clinical records and pre-existing databases.
Results: There were 406 cancers reported: 331 ADC (224 Kaposi sarcomas and 98 non Hodgkin lymphomas). Most frequent NADC (n = 75) were Hodgkin lymphoma and skin cancers. Seventy-three percent of NADC and 45% of ADC were diagnosed >1 year after HIV diagnosis. Fifty-six percent of ADC occurred before HAART start. Median time from HAART start until cancer diagnosis was 2.5 years for NADC and 0.5 years for ADC (P = <0.001). Within 3372 HAART starters, 158 were diagnosed with 165 cancers (82.4% ADC); 85 cases were previous to or concomitant with HAART initiation. Incidence of cancer after HAART initiation in 8080 person-years of follow-up was 7.2 per 1000 person-years (95% confidence interval = 5.5 to 9.3) for ADC and 2.7 (95% confidence interval = 1.8 to 4.1) for NADC; incidence was higher in the first 2 months, particularly for ADC (47.6). A pre-HAART ADC was a predictor of mortality after adjusting for age, sex, and CD4 at HAART initiation.
Conclusions: ADC were the most frequent cancers in this region and were often diagnosed close to HIV diagnosis and HAART start. Incidence of cancer was highest around HAART initiation.
C1 [Fink, Valeria I.; Cesar, Carina; Krolewiecki, Alejandro; Cahn, Pedro] Fdn Huesped Invest Clin, Buenos Aires, DF, Argentina.
[Shepherd, Bryan E.; Wehbe, Firas; McGowan, Catherine; Masys, Daniel] Vanderbilt Univ, Nashville, TN USA.
[Cortes, Claudia P.] Univ Chile Fdn Arriaran, Santiago, Chile.
[Crabtree-Ramirez, Brenda] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
[Padgett, Denis] Inst Hondureno Seguro Social, Tegucigalpa, Honduras.
[Padgett, Denis] Hosp Escuela Tegucigalpa, Tegucigalpa, Honduras.
[Shafaee, Maryam] Cornell Univ, Weill Med Coll, GHESKIO, Port Au Prince, Haiti.
[Schechter, Mauro] Univ Fed Rio de Janeiro, Projeto Praca Onze, Rio De Janeiro, Brazil.
[Gotuzzo, Eduardo] Inst Med Trop Alexander von Humboldt, Lima, Peru.
[Bacon, Melanie] NIAID, HJF, DAIDS, Bethesda, MD 20892 USA.
RP Fink, VI (reprint author), Pasaje Peluffo 3932,C1202ABB, Buenos Aires, DF, Argentina.
EM valeria.fink@huesped.org.ar
OI Cortes, Claudia P./0000-0001-9101-9783; Wehbe, Firas/0000-0002-3984-9584
FU NCRR NIH HHS [UL1 RR024975, 1-UL1-RR024975]; NIAID NIH HHS [U01
AI069923, U01 AI069923-05, 1-U01-AI069923]
NR 42
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 15
PY 2011
VL 56
IS 5
BP 467
EP 473
DI 10.1097/QAI.0b013e31820bb1c3
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 733DP
UT WOS:000288241800018
PM 21239992
ER
PT J
AU Benton, G
Kleinman, HK
George, J
Arnaoutova, I
AF Benton, Gabriel
Kleinman, Hynda K.
George, Jay
Arnaoutova, Irina
TI Multiple uses of basement membrane-like matrix BME/Matrigel) in vitro
and in vivo with cancer cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Review
DE cancer cells; tumor cells; basement membrane; invasion; xenograft; 3D
culture; dormancy
ID BREAST-CANCER; TUMOR-CELLS; EXTRACELLULAR-MATRIX; CHEMOINVASION ASSAY;
GENE-EXPRESSION; MELANOMA-CELLS; NUDE-MICE; TGF-BETA; INVASION; GROWTH
AB Significant advances in our understanding of cancer cell behavior, growth, and metastasis have been facilitated by studies using a basement membrane- like extracellular matrix extract, also known as Matrigel. The basement membrane is a thin extracellular matrix that is found in normal tissues and contacts epithelial and endothelial cells, smooth muscle, fat, Schwann cells, etc. It is composed of mainly laminin- 111, collagen IV, heparan sulfate proteoglycan, entactin/ nidogen, and various growth factors ( fibroblast growth factor, transforming growth factor beta, epidermal growth factor, etc.). Most tumors of epithelial origin produce significant amounts of basement membrane matrix and interact with it particularly during metastasis. Cancer cells metastasize via degradation of the vessel basement membrane matrix to extravasate into the blood stream and colonize distant sites. This review will focus on the interaction of cancer cells and cancer stem cells with the basement membrane- like matrix and the various uses of this interaction to accelerate tumor growth in vivo and to develop in vitro assays for invasion, morphology, and dormancy. Such assays and methods have advanced our understanding of the process of cancer progression, the genes and pathways that are involved, the potential of various therapeutic agents, the effects of neighboring cells, and the role of stem cells. Mini Review
C1 [Benton, Gabriel; George, Jay; Arnaoutova, Irina] Trevigen Inc, Gaithersburg, MD 20877 USA.
[Kleinman, Hynda K.] NIDCR, NIH, Bethesda, MD USA.
RP Benton, G (reprint author), Trevigen Inc, 8405 Helgerman Ct, Gaithersburg, MD 20877 USA.
EM gbenton@trevigen.com
OI Benton, Gabriel/0000-0003-4244-5764
NR 55
TC 63
Z9 67
U1 6
U2 38
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2011
VL 128
IS 8
BP 1751
EP 1757
DI 10.1002/ijc.25781
PG 7
WC Oncology
SC Oncology
GA 730MM
UT WOS:000288037400001
PM 21344372
ER
PT J
AU Crea, F
Serrat, MAD
Hurt, EM
Thomas, SB
Danesi, R
Farrar, WL
AF Crea, Francesco
Duhagon Serrat, Maria A.
Hurt, Elaine M.
Thomas, Suneetha B.
Danesi, Romano
Farrar, William L.
TI BMI1 silencing enhances docetaxel activity and impairs antioxidant
response in prostate cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE docetaxel; Polycomb; prostate
ID SELF-RENEWAL; CELL-LINES; STEM-CELLS; EXPRESSION; RESISTANCE; APOPTOSIS;
CHEMOSENSITIVITY; CHEMORESISTANCE; CHEMOTHERAPY; MITOXANTRONE
AB The BMI1 oncogene promotes prostate cancer (PC) progression. High B- cell- specific Moloney murine leukemia virus integration site 1 (BMI1) expression predicts poor prognosis in PC patients. Recent evidence suggests that BMI1 may also play a role in docetaxel chemoresistance. However, mechanisms and clinical significance of BMI1- related chemoresistance have not been investigated. For this purpose, BMI1 was silenced in 2 PC cell lines (LNCaP and DU 145). Cell proliferation and apoptosis after docetaxel treatment were measured. Guanine oxidation was assessed by in- cell western. Global gene expression analysis was performed on BMI1 silenced cells. Oncomine database was used to compare in vitro data with gene expression in PC samples. BMI1 silencing had no effect on cell proliferation but significantly enhanced docetaxel- induced antitumor activity. Gene expression analysis demonstrated that BMI1 silencing downregulates a set of antioxidant genes. Docetaxel treatment increased guanine oxidation, whereas the antioxidant N- acetyl cysteine rescued docetaxel- induced cell death. Examination of clinical datasets revealed a positive correlation of BMI1 and antioxidant gene expression. BMI1controlled antioxidant genes were predictive of poor prognosis in PC patients. In conclusion, BMI1 enhances antioxidant response, thereby allowing PC survival after docetaxel- based chemotherapy. BMI1- controlled antioxidant genes are overexpressed in aggressive PC and should be tested as predictors of chemotherapy failure. Cancer Therapy
C1 [Crea, Francesco; Duhagon Serrat, Maria A.; Hurt, Elaine M.; Farrar, William L.] NCI Frederick, Canc Stem Cell Sect, Lab Canc Prevent, Ctr Canc Res, Frederick, MD 21702 USA.
[Crea, Francesco] Scuola Super Sant Anna, Pisa, Italy.
[Duhagon Serrat, Maria A.] UDELAR, Lab Interacc Mol, Fac Ciencias, Dept Genet,Fac Med, Montevideo, Uruguay.
[Thomas, Suneetha B.] NCI Frederick, Basic Sci Program, SAIC Frederick Inc, Frederick, MD 21702 USA.
[Danesi, Romano] Pisa Med Sch, Div Pharmacol, Dept Internal Med, Pisa, Italy.
RP Farrar, WL (reprint author), NCI Frederick, Canc Stem Cell Sect, Lab Canc Prevent, Ctr Canc Res, Bldg 560,Room 21-81, Frederick, MD 21702 USA.
EM farrar@mail.ncifcrf.gov
RI Crea, Francesco /I-8383-2015;
OI Crea, Francesco/0000-0002-4903-2973
FU National Institutes of Health [N01-CO-12400]
FX Grant sponsor: National Institutes of Health; Grant numbers:
N01-CO-12400, Intramural Research Program
NR 37
TC 37
Z9 43
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2011
VL 128
IS 8
BP 1946
EP 1954
DI 10.1002/ijc.25522
PG 9
WC Oncology
SC Oncology
GA 730MM
UT WOS:000288037400021
PM 20568112
ER
PT J
AU Makhnovskii, YA
Berezhkovskii, AM
Bogachev, LV
Zitserman, VY
AF Makhnovskii, Yu. A.
Berezhkovskii, A. M.
Bogachev, L. V.
Zitserman, V. Yu.
TI Driven Diffusion in a Periodically Compartmentalized Tube: Homogeneity
versus Intermittency of Particle Motion
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID CROSS-SECTION; BOUNDARY HOMOGENIZATION; TRANSPORT; ARRAYS; PORE;
SURFACES; MEDIA
AB We study the effect of a driving force F on drift and diffusion of a point Brownian particle in a tube formed by identical cylindrical compartments, which create periodic entropy barriers for the particle motion along the tube axis. The particle transport exhibits striking features: the effective mobility monotonically decreases with increasing F, and the effective diffusivity diverges as F-->infinity, which indicates that the entropic effects in diffusive transport are enhanced by the driving force. Our consideration is based on two different scenarios of the particle motion at small and large F, homogeneous and intermittent, respectively. The scenarios are deduced from the careful analysis of statistics of the particle transition times between neighboring openings. From this qualitative picture, the limiting small-F and large-F behaviors of the effective mobility and diffusivity are derived analytically. Brownian dynamics simulations are used to find these quantities at intermediate values of the driving force for various compartment lengths and opening radii. This work shows that the driving force may lead to qualitatively different anomalous transport features, depending on the geometry design.
C1 [Makhnovskii, Yu. A.] Russian Acad Sci, AV Topchiev Petrochem Synth Inst, Moscow 119991, Russia.
[Berezhkovskii, A. M.] NIH, Math & Stat Comp Lab, Div Computat Biosci, Ctr Informat Technol, Bethesda, MD 20892 USA.
[Bogachev, L. V.] Univ Leeds, Dept Stat, Sch Math, Leeds LS2 9JT, W Yorkshire, England.
[Zitserman, V. Yu.] Russian Acad Sci, Joint Inst High Temp, Moscow 125412, Russia.
RP Makhnovskii, YA (reprint author), Russian Acad Sci, AV Topchiev Petrochem Synth Inst, Leninsky Prospect 29, Moscow 119991, Russia.
EM yuam@ips.ac.ru
RI Makhnovskii, Yurii/B-1223-2014
OI Makhnovskii, Yurii/0000-0002-1517-536X
FU Russian Foundation for Basic Research [10-03-00393]; DFG [436 RUS
113/722]; NIH, Center for Information Technology; Leverhulme
FX We are grateful to Sergio Albeverio, Igor Goychuk, Peter Hanggi, Yuri
Kondratiev, Fabio Marchesoni, Peter Talkner, and Gerhard Schmidt for the
helpful discussions. Yu.A.M. and V.Yu.Z. thank the Russian Foundation
for Basic Research for support (Grant No. 10-03-00393). Yu.A.M. was also
partially supported by DFG (Grant 436 RUS 113/722). A.M.B. was supported
by the Intramural Research Program of the NIH, Center for Information
Technology. L.V.B. was partially supported by a Leverhulme Research
Fellowship.
NR 58
TC 9
Z9 9
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD APR 14
PY 2011
VL 115
IS 14
BP 3992
EP 4002
DI 10.1021/jp112393q
PG 11
WC Chemistry, Physical
SC Chemistry
GA 746BI
UT WOS:000289215600028
PM 21417298
ER
PT J
AU Sato, N
Sabzevari, H
Fu, S
Ju, W
Petrus, MN
Bamford, RN
Waldmann, TA
Tagaya, Y
AF Sato, Noriko
Sabzevari, Helen
Fu, Song
Ju, Wei
Petrus, Michael N.
Bamford, Richard N.
Waldmann, Thomas A.
Tagaya, Yutaka
TI Development of an IL-15-autocrine CD8 T-cell leukemia in
IL-15-transgenic mice requires the cis expression of IL-15R alpha
SO BLOOD
LA English
DT Article
ID NATURAL-KILLER; TRANSGENIC MICE; IL-15 ACTIVITY; NK CELL;
INTERLEUKIN-15; IL-15/IL-15R-ALPHA; DIFFERENTIATION; PROLIFERATION;
HOMEOSTASIS; CYTOKINE
AB IL-15 has growth-promoting effects on select lymphoid subsets, including natural killer (NK) cells, NK T cells, intraepithelial lymphocytes (IELs), CD8 T cells, and gamma delta-T cells. Constitutive expression of murine IL-15 in IL-15-transgenic mice was reported to cause T-NK leukemia. We investigated whether IL-15 expression is sufficient for leukemic transformation using a human IL-15-transgenic (IL-15Tg) mouse model. We noted that 100% of the mice observed over a 2-year period (n > 150) developed fatal expansions of CD8 T cells with NK markers, and determined that these cells expressed IL-15 receptor alpha (IL-15R alpha). The expression of IL-15R alpha on CD8 T cells appears to be required for uncontrolled aggressive lymphoproliferation, because none of the IL-15R alpha(-/-)-IL-15Tg mice that we followed for more than 2 years developed the fatal disease despite controlled expansion of CD8 T cells. In addition, in contrast to IL-15Tg mice, in which leukemia-like CD8 T cells expressed IL-15R alpha persistently, acutely activated normal CD8 T cells only transiently expressed IL-15R alpha. Inhibition of DNA methylation enabled sustained IL-15R alpha expression induced by activation. We present a scenario for IL-15Tg mice in which CD8 T cells that acquire constitutive persistent IL-15R alpha expression are at a selective advantage and become founder cells, outgrow other lymphocytes, and lead to the establishment of a leukemia-like condition. (Blood. 2011;117(15):4032-4040)
C1 [Sato, Noriko; Fu, Song; Ju, Wei; Petrus, Michael N.; Waldmann, Thomas A.; Tagaya, Yutaka] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Sabzevari, Helen] NCI, Lab Tumor Biol & Immunol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Bamford, Richard N.] Transponics, Jacobus, PA USA.
RP Waldmann, TA (reprint author), NCI, Metab Branch, Ctr Canc Res, NIH, Bldg 10,Rm 4N115,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM tawald@mail.nih.gov; ytagaya@ihv.umaryland.edu
FU Center for Cancer Research, National Cancer Institute, National
Institutes of Health, Bethesda, MD
FX This work was supported by intramural research funds of the Center for
Cancer Research, National Cancer Institute, National Institutes of
Health, Bethesda, MD.
NR 29
TC 12
Z9 13
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD APR 14
PY 2011
VL 117
IS 15
BP 4032
EP 4040
DI 10.1182/blood-2010-09-307504
PG 9
WC Hematology
SC Hematology
GA 749YF
UT WOS:000289507200019
PM 21304101
ER
PT J
AU Findeisen, HM
Pearson, KJ
Gizard, F
Zhao, Y
Qing, H
Jones, KL
Cohn, D
Heywood, EB
de Cabo, R
Bruemmer, D
AF Findeisen, Hannes M.
Pearson, Kevin J.
Gizard, Florence
Zhao, Yue
Qing, Hua
Jones, Karrie L.
Cohn, Dianne
Heywood, Elizabeth B.
de Cabo, Rafael
Bruemmer, Dennis
TI Oxidative Stress Accumulates in Adipose Tissue during Aging and Inhibits
Adipogenesis
SO PLOS ONE
LA English
DT Article
ID INSULIN SENSITIVITY; ADIPOCYTE PRECURSORS; BODY-COMPOSITION; ANATOMIC
SITE; RISK-FACTORS; PPAR-GAMMA; AGE; GLUTATHIONE; OBESITY;
DIFFERENTIATION
AB Aging constitutes a major independent risk factor for the development of type 2 diabetes and is accompanied by insulin resistance and adipose tissue dysfunction. One of the most important factors implicitly linked to aging and age-related chronic diseases is the accumulation of oxidative stress. However, the effect of increased oxidative stress on adipose tissue biology remains elusive. In this study, we demonstrate that aging in mice results in a loss of fat mass and the accumulation of oxidative stress in adipose tissue. In vitro, increased oxidative stress through glutathione depletion inhibits preadipocyte differentiation. This inhibition of adipogenesis is at least in part the result of reduced cell proliferation and an inhibition of G(1)-> S-phase transition during the initial mitotic clonal expansion of the adipocyte differentiation process. While phosphorylation of the retinoblastoma protein (Rb) by cyclin/cdk complexes remains unaffected, oxidative stress decreases the expression of S-phase genes downstream of Rb. This silencing of S phase gene expression by increased oxidative stress is mediated through a transcriptional mechanism involving the inhibition of E2F recruitment and transactivation of its target promoters. Collectively, these data demonstrate a previously unrecognized role of oxidative stress in the regulation of adipogenesis which may contribute to age-associated adipose tissue dysfunction.
C1 [Findeisen, Hannes M.; Gizard, Florence; Zhao, Yue; Qing, Hua; Jones, Karrie L.; Cohn, Dianne; Heywood, Elizabeth B.; Bruemmer, Dennis] Univ Kentucky, Coll Med, Saha Cardiovasc Res Ctr, Lexington, KY 40536 USA.
[Pearson, Kevin J.; Zhao, Yue; Bruemmer, Dennis] Univ Kentucky, Coll Med, Grad Ctr Nutr Sci, Lexington, KY USA.
[de Cabo, Rafael] NIA, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA.
RP Findeisen, HM (reprint author), Univ Kentucky, Coll Med, Saha Cardiovasc Res Ctr, Lexington, KY 40536 USA.
EM Dennis.Bruemmer@uky.edu
RI de Cabo, Rafael/J-5230-2016;
OI de Cabo, Rafael/0000-0002-3354-2442; , rafael/0000-0003-2830-5693
FU American Diabetes Association (ADA) [1-09-CD-02]; National Institutes of
Health COBRE on Obesity and Cardiovascular Diseases [P20 RR021954]; NIA,
NIH
FX These studies were supported by the American Diabetes Association (ADA
Award No.: 1-09-CD-02), the National Institutes of Health COBRE on
Obesity and Cardiovascular Diseases (P20 RR021954) and in part by the
Intramural Research Program of the NIA, NIH. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 48
TC 41
Z9 41
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 14
PY 2011
VL 6
IS 4
AR e18532
DI 10.1371/journal.pone.0018532
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 749XQ
UT WOS:000289505600008
PM 21533223
ER
PT J
AU Sim, BKL
Narum, DL
Chattopadhyay, R
Ahumada, A
Haynes, JD
Fuhrmann, SR
Wingard, JN
Liang, H
Moch, JK
Hoffman, SL
AF Sim, B. Kim Lee
Narum, David L.
Chattopadhyay, Rana
Ahumada, Adriana
Haynes, J. David
Fuhrmann, Steven R.
Wingard, Jennifer N.
Liang, Hong
Moch, J. Kathleen
Hoffman, Stephen L.
TI Delineation of Stage Specific Expression of Plasmodium falciparum
EBA-175 by Biologically Functional Region II Monoclonal Antibodies
SO PLOS ONE
LA English
DT Article
ID ERYTHROCYTE BINDING ANTIGEN; MALARIA PARASITES; RECEPTOR-BINDING;
INFECTED ERYTHROCYTES; MEROZOITE INVASION; PROTEINS; SURFACE; VACCINE;
FAMILY; DOMAIN
AB Background: The malaria parasite Plasmodium falciparum EBA-175 binds its receptor sialic acids on glycophorin A when invading erythrocytes. The receptor-binding region (RII) contains two cysteine-rich domains with similar cysteine motifs (F1 and F2). Functional relationships between F1 and F2 domains and characterization of EBA-175 were studied using specific monoclonal antibodies (mAbs) against these domains.
Methods and Findings: Five mAbs specific for F1 or F2 were generated. Three mAbs specific for F2 potently blocked binding of EBA-175 to erythrocytes, and merozoite invasion of erythrocytes (IC(50) 10 to 100 mu g/ml IgG in growth inhibition assays). A mAb specific for F1 blocked EBA-175 binding and merozoite invasion less effectively. The difference observed between the IC(50) of F1 and F2 mAbs was not due to differing association and disassociation rates as determined by surface plasmon resonance. Four of the mAbs recognized conformation-dependent epitopes within F1 or F2. Used in combination, F1 and F2 mAbs blocked the binding of native EBA-175 to erythrocytes and inhibited parasite invasion synergistically in vitro. MAb R217, the most potent, did not recognize sporozoites, 3-day hepatocyte stage parasites, nor rings, trophozoites, gametocytes, retorts, ookinetes, and oocysts but recognized 6-day hepatocyte stage parasites, and schizonts. Even though efficient at blocking binding to erythrocytes and inhibiting invasion into erythrocytes, MAb R217 did not inhibit sporozoite invasion and development in hepatocytes in vitro.
Conclusions: The role of the F1 and F2 domains in erythrocyte invasion and binding was elucidated with mAbs. These mAbs interfere with native EBA-175 binding to erythrocyte in a synergistic fashion. The stage specific expression of EBA-175 showed that the primary focus of activity was the merozoite stage. A recombinant RII protein vaccine consisting of both F1 and F2 domains that could induce synergistic activity should be optimal for induction of antibody responses that interfere with merozoite invasion of erythrocytes.
C1 [Sim, B. Kim Lee; Ahumada, Adriana; Hoffman, Stephen L.] Prot Potential LLC, Rockville, MD USA.
[Narum, David L.] NIAID, Lab Malaria Immunol & Vaccinol, NIH, Rockville, MD USA.
[Chattopadhyay, Rana; Hoffman, Stephen L.] Sanaria Inc, Rockville, MD USA.
[Haynes, J. David; Moch, J. Kathleen] US Mil Malaria Vaccine Program, Silver Spring, MD USA.
[Fuhrmann, Steven R.] Intercell USA, Gaithersburg, MD USA.
[Wingard, Jennifer N.] Univ Virginia, Dept Mol Physiol & Biophys, Charlottesville, VA USA.
[Liang, Hong] Infect Dis Res Inst, Seattle, WA USA.
RP Sim, BKL (reprint author), Prot Potential LLC, Rockville, MD USA.
EM ksim@protpot.com
FU Phase II National Institute of Allergy and Infectious Diseases (NIAID)
Small Business Innovative Research [AI36758]; EntreMed Inc; Protein
Potential; Sanaria Inc.
FX This work was partially funded by a Phase II National Institute of
Allergy and Infectious Diseases (NIAID) Small Business Innovative
Research Grant, AI36758 supplement awarded to BKLS. The authors BKLS,
DLN, SRF, JNW and HL were employees of EntreMed Inc (funder). Currently
BKLS, AA and SLH are employees of Protein Potential (funder) and the
role they played on this manuscript was funded by Protein Potential. As
the authors BKLS, DLN, SRF, JNW and HL were employees of EntreMed Inc.
and BLKS, AA and SLH are employees of Protein Potential, the funders
EntreMed and Protein Potential did have a role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript. RC and SLH are also employees of Sanaria Inc. (funder) but
their role on this manuscript was funded by Protein Potential. SRF is
currently an employee of Intercell but only reviewed the manuscript at
this time. Intercell provided no support for this project.
NR 41
TC 9
Z9 9
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 14
PY 2011
VL 6
IS 4
AR e18393
DI 10.1371/journal.pone.0018393
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 749XQ
UT WOS:000289505600004
PM 21533224
ER
PT J
AU Tang, J
Maddali, K
Metifiot, M
Sham, YY
Vince, R
Pommier, Y
Wang, ZQ
AF Tang, Jing
Maddali, Kasthuraiah
Metifiot, Mathieu
Sham, Yuk Y.
Vince, Robert
Pommier, Yves
Wang, Zhengqiang
TI 3-Hydroxypyrimidine-2,4-diones as an Inhibitor Scaffold of HIV Integrase
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; DYNAMIC PHARMACOPHORE MODEL; DIKETO ACID
PHARMACOPHORE; DNA STRAND TRANSFER; REVERSE-TRANSCRIPTASE;
1-<(2-HYDROXYETHOXY)METHYL>-6-(PHENYLTHIO)THYMINE HEPT; ANTI-HIV-1
ACTIVITY; RATIONAL DESIGN; DUAL INHIBITORS; RALTEGRAVIR
AB Integrase (IN) represents a clinically validated target for the development of antivirals against human immunodeficiency virus (HIV). Inhibitors with a novel structure core are essential for combating resistance associated with known IN inhibitors (IN Is). We have previously disclosed a novel dual inhibitor scaffold of HIV IN and reverse transcriptase (RT). Here we report the complete structure activity relationship (SAR), molecular modeling, and resistance profile of this inhibitor type on IN inhibition. These studies support an antiviral mechanism of dual inhibition against both IN and RT and validate 3-hydroxypyrimidine-2,4-diones as an IN inhibitor scaffold.
C1 [Tang, Jing; Sham, Yuk Y.; Vince, Robert; Wang, Zhengqiang] Univ Minnesota, Acad Hlth Ctr, Ctr Drug Design, Minneapolis, MN 55455 USA.
[Maddali, Kasthuraiah; Metifiot, Mathieu; Pommier, Yves] NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA.
RP Wang, ZQ (reprint author), Univ Minnesota, Acad Hlth Ctr, Ctr Drug Design, Minneapolis, MN 55455 USA.
EM wangx472@umm.edu
FU Center for Drug Design at the University of Minnesota; Center for Cancer
Research; National Cancer Institute; NIH
FX This research was supported by the Center for Drug Design at the
University of Minnesota, the Center for Cancer Research, Intramural
Program of the National Cancer Institute, and an NIH grant from IATAP
(Intramural AIDS Targeted Antiviral Program). We thank Roger Ptak at
Southern Research Institute for the antiviral assay and the Minnesota
Supercomputing Institute for computing resources.
NR 51
TC 29
Z9 32
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD APR 14
PY 2011
VL 54
IS 7
BP 2282
EP 2292
DI 10.1021/jm1014378
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 746BJ
UT WOS:000289215700025
PM 21381765
ER
PT J
AU Zhao, XC
AF Zhao, Xiongce
TI Self-Assembly of DNA Segments on Graphene and Carbon Nanotube Arrays in
Aqueous Solution: A Molecular Simulation Study
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID BIOMEDICAL APPLICATIONS; FULLERENE DERIVATIVES; C-60 DERIVATIVES;
DYNAMICS; ADSORPTION; BIOSENSORS; INSERTION; TOXICITY; DELIVERY; WATER
AB Molecular dynamics simulations were performed to study the interaction of double-stranded DNA segments with the surfaces of graphene and carbon nanotube arrays in aqueous solution. Several different kinds of self-assembly phenomena were observed. First, it is found that a DNA segment can 'stand up' on the carbon surfaces with its helix axis perpendicular to the surfaces of graphene or nanotube arrays to form a forestlike structure. Second, a DNA segment can also lie on the carbon surface with its axis parallel to the surface if both of its ends can form stable structure with the carbon surfaces. In the latter case, the ending basepairs of the DNA are broken due to severe deformations. Third, it is observed that short DNA segments can concatenate to each other to form a longer DNA when they are placed in the grooves of nanotube bundles. The self-assembly observed in this study usually happens in less than 50 ns. Exploration on the molecular details and self-assembly mechanism indicates the primary driving force is the pi stacking interaction between the ending basepairs of DNA and the carbon rings. This study confirms the dominant role of hydrophobic pi stacking in the interaction between nucleotides and carbon-based nanosurfaces in aqueous environment.
C1 [Zhao, Xiongce] Oak Ridge Natl Lab, Ctr Nanophase Mat Sci, Oak Ridge, TN 37831 USA.
RP Zhao, XC (reprint author), NIH, Bldg 10, Bethesda, MD 20892 USA.
EM xiongce.zhao@nih.gov
RI sriram, dodda/F-1952-2011
FU Oak Ridge National Laboratory by the Division of Scientific User
Facilities, U.S. Department of Energy; Office of Science of the U.S.
Department of Energy [DE-AC02-05CH11231]
FX The author thanks Peter T. Cummings for many helpful discussions. This
research was conducted at the Center for Nano phase Materials Sciences,
which is sponsored at Oak Ridge National Laboratory by the Division of
Scientific User Facilities, U.S. Department of Energy. This research
used resources of the National Energy Research Scientific Computing
Center, which is supported by the Office of Science of the U.S.
Department of Energy under Contract No. DE-AC02-05CH11231.
NR 44
TC 45
Z9 46
U1 2
U2 54
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD APR 14
PY 2011
VL 115
IS 14
BP 6181
EP 6189
DI 10.1021/jp110013r
PG 9
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 746BG
UT WOS:000289215400002
ER
PT J
AU Zhou, Z
Feng, HQ
Zhou, BR
Ghirlando, R
Hu, KF
Zwolak, A
Jenkins, LMM
Xiao, H
Tjandra, N
Wu, C
Bai, YW
AF Zhou, Zheng
Feng, Hanqiao
Zhou, Bing-Rui
Ghirlando, Rodolfo
Hu, Kaifeng
Zwolak, Adam
Jenkins, Lisa M. Miller
Xiao, Hua
Tjandra, Nico
Wu, Carl
Bai, Yawen
TI Structural basis for recognition of centromere histone variant CenH3 by
the chaperone Scm3
SO NATURE
LA English
DT Article
ID FISSION YEAST SCM3; SACCHAROMYCES-CEREVISIAE; SEDIMENTATION-VELOCITY;
ANALYTICAL ULTRACENTRIFUGATION; PROTEIN; NMR; NUCLEOSOMES; CHROMATIN;
HJURP; CSE4
AB The centromere is a unique chromosomal locus that ensures accurate segregation of chromosomes during cell division by directing the assembly of a multiprotein complex, the kinetochore(1). The centromere is marked by a conserved variant of conventional histone H3 termed CenH3 or CENP-A (ref. 2). A conserved motif of CenH3, the CATD, defined by loop 1 and helix 2 of the histone fold, is necessary and sufficient for specifying centromere functions of CenH3 (refs 3, 4). The structural basis of this specification is of particular interest. Yeast Scm3 and human HJURP are conserved non-histone proteins that interact physically with the (CenH3-H4) 2 heterotetramer and are required for the deposition of CenH3 at centromeres in vivo(5-13). Here we have elucidated the structural basis for recognition of budding yeast (Saccharomyces cerevisiae) CenH3 (called Cse4) by Scm3. We solved the structure of the Cse4-binding domain (CBD) of Scm3 in complex with Cse4 and H4 in a single chain model. An alpha-helix and an irregular loop at the conserved amino terminus and a shorter alpha-helix at the carboxy terminus of Scm3(CBD) wraps around the Cse4-H4 dimer. Four Cse4-specific residues in the N-terminal region of helix 2 are sufficient for specific recognition by conserved and functionally important residues in the N-terminal helix of Scm3 through formation of a hydrophobic cluster. Scm3(CBD) induces major conformational changes and sterically occludes DNA-binding sites in the structure of Cse4 and H4. These findings have implications for the assembly and architecture of the centromeric nucleosome.
C1 [Zhou, Zheng; Feng, Hanqiao; Zhou, Bing-Rui; Xiao, Hua; Wu, Carl; Bai, Yawen] NCI, Biochem & Mol Biol Lab, Bethesda, MD 20892 USA.
[Ghirlando, Rodolfo] NIDDKD, Mol Biol Lab, Bethesda, MD 20892 USA.
[Hu, Kaifeng] Univ Wisconsin, Natl Magnet Resonance Facil Madison, Madison, WI 53706 USA.
[Zwolak, Adam; Tjandra, Nico] NHLBI, Lab Mol Biophys, NIH, Bethesda, MD 20892 USA.
[Jenkins, Lisa M. Miller] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA.
RP Bai, YW (reprint author), NCI, Biochem & Mol Biol Lab, Bethesda, MD 20892 USA.
EM yawen@helix.nih.gov
RI Ghirlando, Rodolfo/A-8880-2009; Zhou, Bing-Rui/D-4766-2009
FU NCI; NIDDK; NHLBI
FX We thank J. Ying, K. Varney, J. F. Ellena and J. Gruschus for help
collecting NMR spectra, A. Bax for discussion, C. Klee and M. Lichten
for comments on the manuscript, and D. Cleveland for plasmids of human
CENP-A and H4 histones. This work is supported by the intramural
research programs of NCI, NIDDK and NHLBI.
NR 39
TC 66
Z9 68
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD APR 14
PY 2011
VL 472
IS 7342
BP 234
EP 237
DI 10.1038/nature09854
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 749LR
UT WOS:000289469100046
PM 21412236
ER
PT J
AU Huskins, WC
Huckabee, CM
O'Grady, NP
Murray, P
Kopetskie, H
Zimmer, L
Walker, ME
Sinkowitz-Cochran, RL
Jernigan, JA
Samore, M
Wallace, D
Goldmann, DA
AF Huskins, W. Charles
Huckabee, Charmaine M.
O'Grady, Naomi P.
Murray, Patrick
Kopetskie, Heather
Zimmer, Louise
Walker, Mary Ellen
Sinkowitz-Cochran, Ronda L.
Jernigan, John A.
Samore, Matthew
Wallace, Dennis
Goldmann, Donald A.
CA STAR ICU Trial Investigators
TI Intervention to Reduce Transmission of Resistant Bacteria in Intensive
Care
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PREVENTING NOSOCOMIAL TRANSMISSION; STAPHYLOCOCCUS-AUREUS MRSA; ACTIVE
SURVEILLANCE; NASAL CARRIAGE; GOWN-USE; ENTEROCOCCI; ACQUISITION; UNIT;
IMPACT; CHLORHEXIDINE
AB BACKGROUND
Intensive care units (ICUs) are high-risk settings for the transmission of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE).
METHODS
In a cluster-randomized trial, we evaluated the effect of surveillance for MRSA and VRE colonization and of the expanded use of barrier precautions (intervention) as compared with existing practice (control) on the incidence of MRSA or VRE colonization or infection in adult ICUs. Surveillance cultures were obtained from patients in all participating ICUs; the results were reported only to ICUs assigned to the intervention. In intervention ICUs, patients who were colonized or infected with MRSA or VRE were assigned to care with contact precautions; all the other patients were assigned to care with universal gloving until their discharge or until surveillance cultures obtained at admission were reported to be negative.
RESULTS
During a 6-month intervention period, there were 5434 admissions to 10 intervention ICUs, and 3705 admissions to 8 control ICUs. Patients who were colonized or infected with MRSA or VRE were assigned to barrier precautions more frequently in intervention ICUs than in control ICUs (a median of 92% of ICU days with either contact precautions or universal gloving [51% with contact precautions and 43% with universal gloving] in intervention ICUs vs. a median of 38% of ICU days with contact precautions in control ICUs, P<0.001). In intervention ICUs, health care providers used clean gloves, gowns, and hand hygiene less frequently than required for contacts with patients assigned to barrier precautions; when contact precautions were specified, gloves were used for a median of 82% of contacts, gowns for 77% of contacts, and hand hygiene after 69% of contacts, and when universal gloving was specified, gloves were used for a median of 72% of contacts and hand hygiene after 62% of contacts. The mean (+/- SE) ICU-level incidence of events of colonization or infection with MRSA or VRE per 1000 patient-days at risk, adjusted for baseline incidence, did not differ significantly between the intervention and control ICUs (40.4 +/- 3.3 and 35.6 +/- 3.7 in the two groups, respectively; P = 0.35).
CONCLUSIONS
The intervention was not effective in reducing the transmission of MRSA or VRE, although the use of barrier precautions by providers was less than what was required.
C1 [Huskins, W. Charles] Mayo Clin, Div Pediat Infect Dis, Rochester, MN 55905 USA.
[Huckabee, Charmaine M.; Kopetskie, Heather; Zimmer, Louise; Wallace, Dennis] Rho Fed Syst Div, Chapel Hill, NC USA.
[O'Grady, Naomi P.; Murray, Patrick] NIH, Ctr Clin, Bethesda, MD 20892 USA.
[Walker, Mary Ellen] Univ Alabama, Birmingham, AL USA.
[Sinkowitz-Cochran, Ronda L.; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Infect Dis, Atlanta, GA USA.
[Samore, Matthew] Univ Utah, Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA.
[Goldmann, Donald A.] Harvard Univ, Sch Med, Boston, MA USA.
[Goldmann, Donald A.] Inst Healthcare Improvement, Cambridge, MA USA.
RP Huskins, WC (reprint author), Mayo Clin, Div Pediat Infect Dis, 200 1st Ave SW, Rochester, MN 55905 USA.
EM huskins.charles@mayo.edu
OI Huskins, W. Charles/0000-0002-9989-175X
FU National Institute of Allergy and Infectious Diseases [N01 AI-15440, N01
AI-15441]; National Center for Research Resources [M01-RR-00585,
UL1-RR024150, M01-RR-00039]; General Clinical Research Center at Emory
University; Merck; Elan Pharmaceuticals; Roche Diagnostics; Kimberly
Clark; Medegen
FX Supported by contracts (N01 AI-15440 and N01 AI-15441) from the National
Institute of Allergy and Infectious Diseases to the Bacteriology and
Mycology Study Group clinical research network and the Bacteriology and
Mycology Statistical and Operations Unit data coordinating center; by
institutional grants (M01-RR-00585, UL1-RR024150, and M01-RR-00039) from
the National Center for Research Resources to the Mayo Clinic Center for
Translational Science Activities and the General Clinical Research
Center at Emory University; and by Merck, Elan Pharmaceuticals, Roche
Diagnostics, and Kimberly Clark.; Dr. Huskins reports receiving
consulting fees from Roche Diagnostics and serving on an advisory board
for GlaxoSmithKline; and Dr. Goldmann, receiving consulting fees from
Medegen and serving on an advisory board for BioNeutral Group. No other
potential conflict of interest relevant to this article was reported.
NR 39
TC 172
Z9 180
U1 1
U2 27
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD APR 14
PY 2011
VL 364
IS 15
BP 1407
EP 1418
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 749LD
UT WOS:000289467200005
PM 21488763
ER
PT J
AU Ungerleider, LG
Bell, AH
AF Ungerleider, Leslie G.
Bell, Andrew H.
TI Uncovering the visual "alphabet": Advances in our understanding of
object perception
SO VISION RESEARCH
LA English
DT Review
DE Object recognition; Inferior temporal cortex; fMRI; Electrophysiology;
Monkey; Vision
ID INFERIOR TEMPORAL CORTEX; MONKEY INFEROTEMPORAL CORTEX; HUMAN
EXTRASTRIATE CORTEX; LATERAL OCCIPITAL COMPLEX; MACAQUE CEREBRAL-CORTEX;
FUSIFORM FACE AREA; LONG-TERM-MEMORY; RHESUS-MONKEY; HUMAN BRAIN;
CORTICAL CONNECTIONS
AB The ability to rapidly and accurately recognize visual stimuli represents a significant computational challenge. Yet, despite such complexity, the primate brain manages this task effortlessly. How it does so remains largely a mystery. The study of visual perception and object recognition was once limited to investigations of brain-damaged individuals or lesion experiments in animals. However, in the last 25 years, new methodologies, such as functional neuroimaging and advances in electrophysiological approaches, have provided scientists with the opportunity to examine this problem from new perspectives. This review highlights how some of these recent technological advances have contributed to the study of visual processing and where we now stand with respect to our understanding of neural mechanisms underlying object recognition. Published by Elsevier Ltd.
C1 [Ungerleider, Leslie G.; Bell, Andrew H.] NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA.
RP Ungerleider, LG (reprint author), NIMH, Lab Brain & Cognit, NIH, 10 Ctr Dr,4C104, Bethesda, MD 20892 USA.
EM ungerlel@mail.nih.gov
RI Ren, Huorong/C-9810-2012;
OI Bell, Andrew/0000-0001-8420-4622
FU Intramural NIH HHS [Z99 MH999999]
NR 177
TC 24
Z9 24
U1 2
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
J9 VISION RES
JI Vision Res.
PD APR 13
PY 2011
VL 51
IS 7
SI SI
BP 782
EP 799
DI 10.1016/j.visres.2010.10.002
PG 18
WC Neurosciences; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA 757CI
UT WOS:000290061300012
PM 20971130
ER
PT J
AU Botos, I
Segal, DM
Davies, DR
AF Botos, Istvan
Segal, David M.
Davies, David R.
TI The Structural Biology of Toll-like Receptors
SO STRUCTURE
LA English
DT Review
ID INNATE IMMUNE-RESPONSE; GLYCOPROTEIN IB-ALPHA; LEUCINE-RICH REPEATS;
CRYSTAL-STRUCTURE; TIR-DOMAIN; BACTERIAL FLAGELLIN; PATHOGEN
RECOGNITION; ANTIGEN RECOGNITION; V(D)J RECOMBINATION; TLR4-MD-2 COMPLEX
AB The membrane-bound Toll-like receptors (TLRs) trigger innate immune responses after recognition of a wide variety of pathogen-derived compounds. Despite the wide range of ligands recognized by TLRs, the receptors share a common structural framework in their extracellular, ligand-binding domains. These domains all adopt horseshoe-shaped structures built from leucine-rich repeat motifs. Typically, on ligand binding, two extracellular domains form an "m"-shaped dimer sandwiching the ligand molecule bringing the transmembrane and cytoplasmic domains in close proximity and triggering a downstream signaling cascade. Although the ligand-induced dimerization of these receptors has many common features, the nature of the interactions of the TLR extracellular domains with their ligands varies markedly between TLR paralogs.
C1 [Botos, Istvan; Davies, David R.] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
[Segal, David M.] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.
RP Davies, DR (reprint author), NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
EM david.davies@nih.gov
FU National Institutes of Health (NIDDK); National Institutes of Health
(NCI); NIAID
FX This work was supported by the Intramural Research Program of the
National Institutes of Health (NIDDK and NCI) and by a National
Institutes of Health/Food and Drug Administration intramural biodefense
award from NIAID.
NR 82
TC 146
Z9 153
U1 4
U2 42
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0969-2126
EI 1878-4186
J9 STRUCTURE
JI Structure
PD APR 13
PY 2011
VL 19
IS 4
BP 447
EP 459
DI 10.1016/j.str.2011.02.004
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 751BN
UT WOS:000289592600004
PM 21481769
ER
PT J
AU Shiels, MS
Pfeiffer, RM
Hall, HI
Li, JM
Goedert, JJ
Morton, LM
Hartge, P
Engels, EA
AF Shiels, Meredith S.
Pfeiffer, Ruth M.
Hall, H. Irene
Li, Jianmin
Goedert, James J.
Morton, Lindsay M.
Hartge, Patricia
Engels, Eric A.
TI Proportions of Kaposi Sarcoma, Selected Non-Hodgkin Lymphomas, and
Cervical Cancer in the United States Occurring in Persons With AIDS,
1980-2007
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID NERVOUS-SYSTEM LYMPHOMA; INCIDENCE PATTERNS; SURVEILLANCE DATA; HIV;
TRENDS; ADULTS; RISK; RECOMMENDATIONS; ADOLESCENTS; MALIGNANCIES
AB Context Given the higher risk of AIDS-defining malignancies that include Kaposi sarcoma (KS), certain non-Hodgkin lymphomas (NHLs), and cervical cancer in persons with human immunodeficiency virus (HIV) infection, the HIV epidemic has likely contributed to the overall numbers of these cancers in the United States.
Objective To quantify the proportions of KS, AIDS-defining NHLs, and cervical cancer in the United States that occurred among persons with AIDS from 1980 to 2007.
Design, Setting, and Participants The HIV/AIDS Cancer Match Study (19802007) linked data from 16 US HIV/AIDS and cancer registries to identify cases with and without AIDS for KS, AIDS-defining NHLs (ie, diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL], and central nervous system [CNS] lymphoma), and cervical cancer. Using linked data, we derived cancer rates for persons with and without AIDS. To estimate national counts, the rates were applied to national AIDS surveillance and US Census data.
Main Outcome Measure Proportion of AIDS-defining malignancies in the United States occurring in persons with AIDS.
Results In the United States, an estimated 81.6% (95% confidence interval [CI], 81.2%-81.9%) of 83 252 KS cases, 6.0% (95% CI, 5.8%-6.1%) of 351 618 DLBCL cases, 19.9% (95% CI, 18.1%-21.7%) of 17 307 BL cases, 27.1% (95% CI, 26.1%-28.1%) of 27 265 CNS lymphoma cases, and 0.42% (95% CI, 0.37%-0.47%) of 375 452 cervical cancer cases occurred among persons with AIDS during 1980-2007. The proportion of KS and AIDS-defining NHLs in persons with AIDS peaked in the early 1990s (1990-1995: KS, 90.5% [95% CI, 90.2%-90.8%]; DLBCL, 10.2% [95% CI, 9.9%-10.5%]; BL, 27.8% [95% CI, 25.0%-30.5%]; and CNS lymphoma, 48.3% [95% CI, 46.7%-49.8%]; all P < .001 [compared with 1980-1989]) and then declined (2001-2007: KS, 70.5% [95% CI, 68.1%-73.0%]; DLBCL, 4.7% [95% CI, 4.3%-5.2%]; BL, 21.5% [95% CI, 17.7%-25.4%]; and CNS lymphoma, 12.9% [95% CI, 10.5%-15.3%]; all P < .001 [compared with 1990-1995]). The proportion of cervical cancers in persons with AIDS increased over time (1980-1989: 0.11% [95% CI, 0.09%-0.13%]; 2001-2007: 0.71% [95% CI, 0.51%-0.91%]; P < .001).
Conclusions In the United States, the estimated proportions of AIDS-defining malignancies that occurred among persons with AIDS were substantial, particularly for KS and some NHLs. Except for cervical cancer, the proportions of AIDS-defining malignancies occurring among persons with AIDS peaked in the mid-1990s and then declined. JAMA. 2011;305(14):1450-1459 www.jama.com
C1 [Shiels, Meredith S.] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20892 USA.
[Hall, H. Irene; Li, Jianmin] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Shiels, MS (reprint author), NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS 7059, Rockville, MD 20892 USA.
EM shielsms@mail.nih.gov
RI Morton, Lindsay/B-5234-2015
OI Morton, Lindsay/0000-0001-9767-2310
FU National Cancer Institute
FX This study was funded by the Intramural Research Program of the National
Cancer Institute.
NR 37
TC 60
Z9 61
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 13
PY 2011
VL 305
IS 14
BP 1450
EP 1459
DI 10.1001/jama.2011.396
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 748WQ
UT WOS:000289424100022
PM 21486978
ER
PT J
AU Marthas, ML
Van Rompay, KKA
Abbott, Z
Earl, P
Buonocore-Buzzelli, L
Moss, B
Rose, NF
Rose, JK
Kozlowski, PA
Abel, K
AF Marthas, Marta L.
Van Rompay, Koen K. A.
Abbott, Zachary
Earl, Patricia
Buonocore-Buzzelli, Linda
Moss, Bernard
Rose, Nina F.
Rose, John K.
Kozlowski, Pamela A.
Abel, Kristina
TI Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV
challenge in infant macaques
SO VACCINE
LA English
DT Article
DE Pediatric HIV vaccine; Mucosal immunity; SIV
ID SIMIAN IMMUNODEFICIENCY VIRUS; VESICULAR STOMATITIS-VIRUS; CD4(+)
T-CELLS; NEWBORN RHESUS MACAQUES; AGE-RELATED-CHANGES; LYMPHOCYTE
SUBSETS; HEALTHY-CHILDREN; PROTECT INFANT; INFECTION; TRANSMISSION
AB Despite antiretroviral medications, the rate of pediatric HIV-1 infections through breast-milk transmission has been staggering in developing countries. Therefore, the development of a vaccine to protect vulnerable infant populations should be actively pursued. We previously demonstrated that oral immunization of newborn macaques with vesicular stomatitis virus expressing simian immunodeficiency virus genes (VSV-SIV) followed 2 weeks later by an intramuscular boost with modified vaccinia ankara virus expressing SIV (MVA-SIV) successfully induced Sly-specific T and B cell responses in multiple lymphoid tissues, including the tonsil and intestine [13]. In the current study, we tested the oral VSV-SIV prime/systemic MVA-SIV boost vaccine for efficacy against multiple oral SIVmac251 challenges starting two weeks after the booster vaccination. The vaccine did not prevent Sly infection. However, in vaccinated infants, the level of SIV-specific plasma IgA (but not IgG) at the time of challenge was inversely correlated with peak viremia. In addition, the levels of Sly-specific IgA in saliva and plasma were inversely correlated with viral load at euthanasia. Animals with tonsils that contained higher frequencies of Sly-specific TNF-alpha- or IFN-gamma-producing CD8(+) T cells and central memory T cells at euthanasia also had lower viremia. Interestingly, a marked depletion of CD25(+)FoxP3(+)CD4(+) T cells was observed in the tonsils as well as the intestine of these animals, implying that T regulatory cells may be a major target of SIV infection in infant macaques. Overall, the data suggest that, in infant macaques orally infected with Sly, the co-induction of local antiviral cytotoxic T cells and T regulatory cells that promote the development of IgA responses may result in better control of viral replication. Thus, future vaccination efforts should be directed towards induction of IgA and mucosal T cell responses to prevent or reduce virus replication in infants. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Abel, Kristina] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
[Marthas, Marta L.; Van Rompay, Koen K. A.; Abbott, Zachary] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA.
[Earl, Patricia; Moss, Bernard] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
[Buonocore-Buzzelli, Linda; Rose, Nina F.; Rose, John K.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
[Kozlowski, Pamela A.] Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA USA.
RP Abel, K (reprint author), Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Genet Med Bldg,Rm 2047,120 Mason Farm Rd,CB 7042, Chapel Hill, NC 27599 USA.
EM abelk@med.unc.edu
FU NIH/NIAID [R01 AI062518]; Louisiana Vaccine Center; Louisiana Board of
Regents; National Center for Research Resources (NCRR; a component of
the National Institutes of Health (NIH)) [RR00169]
FX This work was supported by the NIH/NIAID grant R01 AI062518 to MM, and,
in part, by the Louisiana Vaccine Center and the South Louisiana
Institute for Infectious Disease Research sponsored by the Louisiana
Board of Regents. The animal studies at the CNPRC were supported by
grant RR00169 from the National Center for Research Resources (NCRR; a
component of the National Institutes of Health (NIH)). SIVmac251 was
obtained from the Analytical Core of the CNPRC. The SIV gag peptide pool
was from the AIDS Research and Reference Reagent Program (Division of
AIDS, NIAID, NIH). Dr. Jeff Lifson (AIDS and Cancer Virus Program,
National Cancer Institute at Frederick, Frederick, MD) provided
aldrithiol-2 inactivated SIVmac239 particles. We also thank the
Qualitative Molecular Diagnostics Core of the AIDS Vaccine Program at
SAIC Frederick/NCI for assistance with the quantitation of plasma viral
RNA. In addition, we are indebted to the veterinary staff at the CNPRC,
and would like to thank Yongzhi Geng and Robert L. Wilson for technical
assistance in the studies, and Jeffrey Americo for preparation of the
MVA viruses. The contents of this publication though are solely the
responsibility of the authors and do not necessarily represent the
official views of NCRR or NIH.
NR 43
TC 20
Z9 21
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD APR 12
PY 2011
VL 29
IS 17
BP 3124
EP 3137
DI 10.1016/j.vaccine.2011.02.051
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 764BJ
UT WOS:000290603100008
PM 21377510
ER
PT J
AU Talaat, KR
Karron, RA
Luke, CJ
Thumar, B
McMahon, BA
Chen, GL
Lamirande, EW
Jin, H
Coelingh, KL
Kemble, G
Subbarao, K
AF Talaat, Kawsar R.
Karron, Ruth A.
Luke, Catherine J.
Thumar, Bhagvanji
McMahon, Bridget A.
Chen, Grace L.
Lamirande, Elaine W.
Jin, Hong
Coelingh, Kathy L.
Kemble, George
Subbarao, Kanta
TI An open label Phase I trial of a live attenuated H6N1 influenza virus
vaccine in healthy adults
SO VACCINE
LA English
DT Article
DE H6N1; Avian influenza; Vaccine; Live attenuated
ID A H5N1 VIRUS; HUMAN INFECTION; SOUTHERN CHINA; HONG-KONG; H9N2;
RESPONSES; ANTIBODY; HUMANS; VOLUNTEERS; CHICKENS
AB Background: We describe the results of an open label Phase I trial of a live attenuated H6N1 influenza virus vaccine (ClinicalTrials.gov Identifier: NCT00734175).
Methods and findings: We evaluated the safety, infectivity, and immunogenicity of two doses of 10(7) TCID50 of the H6N1 Teal HK 97/AA ca vaccine, a cold-adapted and temperature sensitive live, attenuated influenza vaccine (LAIV) in healthy seronegative adults.
Twenty-two participants received the first dose of the vaccine, and 18 received the second dose of vaccine 4 weeks later. The vaccine had a safety profile similar to that of other investigational LAIVs bearing avian hemagglutinin (HA) and neuraminidase (NA) genes. The vaccine was highly restricted in replication: two participants had virus detectable by rRT-PCR beyond day 1 after each dose. Antibody responses to the vaccine were also restricted: 43% of participants developed a serum antibody response as measured by any assay: 5% by hemagglutination-inhibition assay, 5% by microneutralization assay, 29% by ELISA for H6 HA-specific IgG and 24% by ELISA for H6 HA specific IgA after either 1 or 2 doses. Following the second dose, vaccine specific IgG and IgA secreting cells as measured by ELISPOT increased from a mean of 0.6 to 9.2/10(6) PBMCs and from 0.2 to 2.2/10(6) PBMCs, respectively.
Conclusion: The H6N1 LAIV had a safety profile similar to that of LAIV bearing other HA and NA genes, but was highly restricted in replication in healthy seronegative adults. The H6N1 LAIV was also not as immunogenic as the seasonal LAIV. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Talaat, Kawsar R.; Karron, Ruth A.; Thumar, Bhagvanji; McMahon, Bridget A.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD 21205 USA.
[Luke, Catherine J.; Chen, Grace L.; Lamirande, Elaine W.; Subbarao, Kanta] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
[Jin, Hong; Coelingh, Kathy L.; Kemble, George] MedImmune, Mountain View, CA 94043 USA.
RP Talaat, KR (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD 21205 USA.
EM ktalaat@jhsph.edu
FU NIAID, NIH; Laboratory of Infectious Diseases, NIAID [AI-0155];
MedImmune
FX We wish to thank Ruval Comendador, Jasmine Jennings and Paula
Williams-Soro for expert clinical assistance, Susan DiLorenzo and Nicole
Yoder for expert technical assistance. We would also like to thank
Zhongying Chen, Weidong Cui, Kathy Wang, Silas Nwagwu, Alfred Pan, Lynne
Fitch, Patricia Ryan, So-Ching Brazer, David Prichett, and Edith
Matsuyama of MedImmune for vaccine manufacturing and testing. This
research was supported by the Intramural Research Program of the NIAID,
NIH. This research was performed as a Cooperative Research and
Development Agreement (CRADA) (CRADA No: AI-0155) between the Laboratory
of Infectious Diseases, NIAID and MedImmune.
NR 32
TC 23
Z9 23
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 12
PY 2011
VL 29
IS 17
BP 3144
EP 3148
DI 10.1016/j.vaccine.2011.02.043
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 764BJ
UT WOS:000290603100010
PM 21377509
ER
PT J
AU Brocca-Cofano, E
McKinnon, K
Demberg, T
Venzon, D
Hidajat, R
Xiao, P
Daltabuit-Test, M
Patterson, LJ
Robert-Guroff, M
AF Brocca-Cofano, Egidio
McKinnon, Katherine
Demberg, Thorsten
Venzon, David
Hidajat, Rachmat
Xiao, Peng
Daltabuit-Test, Mara
Patterson, L. Jean
Robert-Guroff, Marjorie
TI Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B
cells in rhesus macaque peripheral blood correlate with functional
antibody responses and reduced viremia
SO VACCINE
LA English
DT Article
DE Memory B cells; Rhesus macaque; Simian immunodeficiency virus; Vaccine;
Replication-competent adenovirus; recombinant
ID DEPENDENT CELLULAR CYTOTOXICITY; HELPER T-CELLS; PROTECTIVE EFFICACY;
PLASMA-CELLS; SHIV89.6P CHALLENGE; ANTIGEN; NAIVE; SIVMAC251; CD27;
IMMUNIZATION
AB An effective HIV vaccine requires strong systemic and mucosal, cellular and humoral immunity. Numerous non-human primate studies have investigated memory T cells, but not memory B cells. Humoral immunologic memory is mediated by long-lived antibody-secreting plasma cells and differentiation of memory B cells into short-lived plasma blasts following re-exposure to immunizing antigen. Here we studied memory B cells in vaccinated rhesus macaques. PBMC were stimulated polyclonally using CD40 Ligand, IL-21 and CpG to induce B cell proliferation and differentiation into antibody secreting cells (ASCs). Flow cytometry was used for phenotyping and evaluating proliferation by CFSE dilution. B cell responses were quantified by ELISPOT. Methodology was established using PBMC of vaccinated elite-controller macaques that exhibited strong, multi-functional antibody activities. Subsequently, memory B cells elicited by two replicating Ad-recombinant prime/envelope boost regimens were retrospectively evaluated pre- and post-Sly and SHIV challenges. The vaccine regimens induced SIV and HIV Env-specific IgG and IgA memory B cells. Prior to challenge, IgA memory B cells were more numerous than IgG memory B cells, reflecting the mucosal priming immunizations. Pre- and post-challenge memory B cells were correlated with functional antibody responses including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell-mediated viral inhibition (ADCVI) and transcytosis inhibition. Post-challenge, Env-specific IgG and IgA memory B cells were correlated with reduced chronic viremia. We conclude that functional antibody responses elicited by our prime/boost regimen were effectively incorporated into the memory B cell pool where they contributed to control of viremia following re-exposure to the immunizing antigen. Published by Elsevier Ltd.
C1 [Brocca-Cofano, Egidio; McKinnon, Katherine; Demberg, Thorsten; Hidajat, Rachmat; Xiao, Peng; Daltabuit-Test, Mara; Patterson, L. Jean; Robert-Guroff, Marjorie] NCI, Vaccine Branch, NIH, Bethesda, MD 20892 USA.
[Venzon, David] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA.
RP Robert-Guroff, M (reprint author), NCI, Vaccine Branch, NIH, 41 Medlars Dr,Bldg 41,Room D804, Bethesda, MD 20892 USA.
EM guroffm@mail.nih.gov
FU National Institutes of Health, National Cancer Institute
FX We thank Dr. Shane Crotty for sharing reagents and helpful discussions.
This work was supported by the Intramural Research Program of the
National Institutes of Health, National Cancer Institute.
NR 47
TC 34
Z9 34
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD APR 12
PY 2011
VL 29
IS 17
BP 3310
EP 3319
DI 10.1016/j.vaccine.2011.02.066
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 764BJ
UT WOS:000290603100032
PM 21382487
ER
PT J
AU Steinhagen, F
Kinjo, T
Bode, C
Klinman, DM
AF Steinhagen, Folkert
Kinjo, Takeshi
Bode, Christian
Klinman, Dennis M.
TI TLR-based immune adjuvants
SO VACCINE
LA English
DT Review
DE Toll-like receptor ligand; Vaccination; Adjuvant
ID T-CELL RESPONSES; HEPATITIS-B-VACCINE; DOUBLE-STRANDED-RNA;
POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID; HUMAN-PAPILLOMAVIRUS TYPE-16;
RANDOMIZED CONTROLLED-TRIAL; MONOPHOSPHORYL-LIPID-A;
TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTORS; ACTIVE-SPECIFIC
IMMUNOTHERAPY
AB This work describes the nature and strength of the immune response induced by various Toll-like receptor ligands and their ability to act as vaccine adjuvants. It reviews the various ligands capable of triggering individual TLRs, and then focuses on the efficacy and safety of those agents for which clinical results are available. Published by Elsevier Ltd.
C1 [Steinhagen, Folkert; Kinjo, Takeshi; Bode, Christian; Klinman, Dennis M.] NCI, Canc & Inflammat Program, Frederick, MD 21702 USA.
RP Klinman, DM (reprint author), NCI, Canc & Inflammat Program, Bldg 567,Rm 205, Frederick, MD 21702 USA.
EM klinmand@mail.nih.gov
FU Intramural NIH HHS [ZIA BC010852-03]
NR 261
TC 148
Z9 155
U1 4
U2 52
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD APR 12
PY 2011
VL 29
IS 17
BP 3341
EP 3355
DI 10.1016/j.vaccine.2010.08.002
PG 15
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 764BJ
UT WOS:000290603100037
PM 20713100
ER
PT J
AU Blanco, I
Lara, B
De Serres, F
AF Blanco, Ignacio
Lara, Beatriz
De Serres, Frederick
TI Efficacy of alpha1-antitrypsin augmentation therapy in conditions other
than pulmonary emphysema
SO ORPHANET JOURNAL OF RARE DISEASES
LA English
DT Review
ID ZZ ALPHA(1)-ANTITRYPSIN DEFICIENCY; PLASMA PROTEINASE-INHIBITORS;
ALPHA-1-ANTITRYPSIN DEFICIENCY; IN-VITRO; ALPHA(1)-PROTEINASE INHIBITOR;
ALPHA-1-PROTEINASE INHIBITOR; REPLACEMENT THERAPY; ANTITRYPSIN
DEFICIENCY; NEUTROPHIL ELASTASE; CELL PROLIFERATION
AB Up to now alpha 1-antitrypsin (AAT) augmentation therapy has been approved only for commercial use in selected adults with severe AAT deficiency-related pulmonary emphysema (i.e. PI*ZZ genotypes as well as combinations of Z, rare and null alleles expressing AAT serum concentrations <11 mu mol/L). However, the compassionate use of augmentation therapy in recent years has proven outstanding efficacy in small cohorts of patients suffering from uncommon AAT deficiency-related diseases other than pulmonary emphysema, such as fibromyalgia, systemic vasculitis, relapsing panniculitis and bronchial asthma. Moreover, a series of preclinical studies provide evidence of the efficacy of AAT augmentation therapy in several infectious diseases, diabetes mellitus and organ transplant rejection. These facts have generated an expanding number of medical applications and patents with claims for other indications of AAT besides pulmonary emphysema. The aim of the present study is to compile and analyze both clinical and histological features of the aforementioned published case studies and reports where AAT augmentation therapy was used for conditions other than pulmonary emphysema. Particularly, our research refers to ten case reports and two clinical trials on AAT augmentation therapy in patients with both AAT deficiency and, at least, one of the following diseases: fibromyalgia, vasculitis, panniculitis and bronchial asthma. In all the cases, AAT was successfully applied whereas previous maximal conventional therapies had failed. In conclusion, laboratory studies in animals and humans as well as larger clinical trials should be, thus, performed in order to determine both the strong clinical efficacy and security of AAT in the treatment of conditions other than pulmonary emphysema.
C1 [Blanco, Ignacio] Biomed Res Off OIB FICYT, Oviedo 33009, Principality As, Spain.
[Lara, Beatriz] Hosp Arnau Vilanova, Inst Recerca Biomed Lleida IRB, CIBERES Inst Salud Carlos III Madrid, Madrid, Spain.
[De Serres, Frederick] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC 27709 USA.
RP Blanco, I (reprint author), Biomed Res Off OIB FICYT, Rosal 7, Oviedo 33009, Principality As, Spain.
EM ignablanco@yahoo.com
NR 82
TC 28
Z9 31
U1 1
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1750-1172
J9 ORPHANET J RARE DIS
JI Orphanet J. Rare Dis.
PD APR 12
PY 2011
VL 6
AR 14
DI 10.1186/1750-1172-6-14
PG 11
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA 762MP
UT WOS:000290483400001
PM 21486454
ER
PT J
AU Cellmer, T
Buscaglia, M
Henry, ER
Hofrichter, J
Eaton, WA
AF Cellmer, Troy
Buscaglia, Marco
Henry, Eric R.
Hofrichter, James
Eaton, William A.
TI Making connections between ultrafast protein folding kinetics and
molecular dynamics simulations
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE tryptophan triplet lifetime; villin headpiece subdomain; downhill
protein folding; laser temperature jump
ID VILLIN HEADPIECE SUBDOMAIN; INTRAMOLECULAR CONTACT FORMATION; LASER
TEMPERATURE-JUMP; LOOP FORMATION; SPEED LIMIT; FAST EVENTS; TRYPTOPHAN;
PEPTIDE; MODEL; POLYPEPTIDES
AB Determining the rate of forming the truly folded conformation of ultrafast folding proteins is an important issue for both experiments and simulations. The double-norleucine mutant of the 35-residue villin subdomain is the focus of recent computer simulations with atomistic molecular dynamics because it is currently the fastest folding protein. The folding kinetics of this protein have been measured in laser temperature-jump experiments using tryptophan fluorescence as a probe of overall folding. The conclusion from the simulations, however, is that the rate determined by fluorescence is significantly larger than the rate of overall folding. We have therefore employed an independent experimental method to determine the folding rate. The decay of the tryptophan triplet-state in photoselection experiments was used to monitor the change in the unfolded population for a sequence of the villin subdomain with one amino acid difference from that of the laser temperature-jump experiments, but with almost identical equilibrium properties. Folding times obtained in a two-state analysis of the results from the two methods at denaturant concentrations varying from 1.5-6.0 M guanidinium chloride are in excellent agreement, with an average difference of only 20%. Polynomial extrapolation of all the data to zero denaturant yields a folding time of 220 (+100, -70) ns at 283 K, suggesting that under these conditions the barrier between folded and unfolded states has effectively disappeared-the so-called "downhill scenario."
C1 [Cellmer, Troy; Henry, Eric R.; Hofrichter, James; Eaton, William A.] NIDDKD, Lab Chem Phys, NIH, Bethesda, MD 20892 USA.
[Buscaglia, Marco] Univ Milan, Dipartimento Chim Biochim & Biotecnol Med, I-20090 Segrate, Italy.
RP Eaton, WA (reprint author), NIDDKD, Lab Chem Phys, NIH, Bethesda, MD 20892 USA.
EM eaton@helix.nih.gov
RI Henry, Eric/J-3414-2013; Buscaglia, Marco/C-2435-2008
OI Henry, Eric/0000-0002-5648-8696; Buscaglia, Marco/0000-0001-5010-0278
FU National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health
FX We thank Wai-Ming Yau for peptide synthesis, Thang Chiu for preparation
of Fig. 1, David Shaw for a preprint of his work, and Patrick Callis for
helpful discussion. This work was supported by the Intramural Research
Program of the National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health.
NR 54
TC 36
Z9 36
U1 1
U2 28
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 12
PY 2011
VL 108
IS 15
BP 6103
EP 6108
DI 10.1073/pnas.1019552108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 748SZ
UT WOS:000289413600039
PM 21441105
ER
PT J
AU Sanishvili, R
Yoder, DW
Pothineni, SB
Rosenbaum, G
Xu, SL
Vogt, S
Stepanova, S
Makarov, OA
Corcoran, S
Benn, R
Nagarajan, V
Smith, JL
Fischetti, RF
AF Sanishvili, Ruslan
Yoder, Derek W.
Pothineni, Sudhir Babu
Rosenbaum, Gerd
Xu, Shenglan
Vogt, Stefan
Stepanova, Sergey
Makarov (Oner Makapob), Oleg A.
Corcoran, Stephen
Benn, Richard
Nagarajan, Venugopalan
Smith, Janet L.
Fischetti, Robert F.
TI Radiation damage in protein crystals is reduced with a micron-sized
X-ray beam
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE microcrystallography; synchrotron radiation
ID DIFFRACTION DATA; MINI-BEAM; MACROMOLECULAR CRYSTALS;
SYNCHROTRON-RADIATION; GM/CA-CAT; CRYSTALLOGRAPHY; MICRODIFFRACTION;
BEAMLINES; RADDOSE
AB Radiation damage is a major limitation in crystallography of biological macromolecules, even for cryocooled samples, and is particularly acute in microdiffraction. For the X-ray energies most commonly used for protein crystallography at synchrotron sources, photoelectrons are the predominant source of radiation damage. If the beam size is small relative to the photoelectron path length, then the photoelectron may escape the beam footprint, resulting in less damage in the illuminated volume. Thus, it may be possible to exploit this phenomenon to reduce radiation-induced damage during data measurement for techniques such as diffraction, spectroscopy, and imaging that use X-rays to probe both crystalline and noncrystalline biological samples. In a systematic and direct experimental demonstration of reduced radiation damage in protein crystals with small beams, damage was measured as a function of micron-sized X-ray beams of decreasing dimensions. The damage rate normalized for dose was reduced by a factor of three from the largest (15.6 mu m) to the smallest (0.84 mu m) X-ray beam used. Radiation-induced damage to protein crystals was also mapped parallel and perpendicular to the polarization direction of an incident 1-mu m X-ray beam. Damage was greatest at the beam center and decreased monotonically to zero at a distance of about 4 mu m, establishing the range of photoelectrons. The observed damage is less anisotropic than photoelectron emission probability, consistent with photoelectron trajectory simulations. These experimental results provide the basis for data collection protocols to mitigate with micron-sized X-ray beams the effects of radiation damage.
C1 [Sanishvili, Ruslan; Yoder, Derek W.; Pothineni, Sudhir Babu; Xu, Shenglan; Stepanova, Sergey; Makarov (Oner Makapob), Oleg A.; Corcoran, Stephen; Benn, Richard; Nagarajan, Venugopalan; Smith, Janet L.; Fischetti, Robert F.] Argonne Natl Lab, Natl Inst Gen Med Sci, Biosci Div, Argonne, IL 60439 USA.
[Sanishvili, Ruslan; Yoder, Derek W.; Pothineni, Sudhir Babu; Xu, Shenglan; Stepanova, Sergey; Makarov (Oner Makapob), Oleg A.; Corcoran, Stephen; Benn, Richard; Nagarajan, Venugopalan; Smith, Janet L.; Fischetti, Robert F.] Argonne Natl Lab, Natl Canc Inst, Biosci Div, Collaborat Access Team, Argonne, IL 60439 USA.
[Rosenbaum, Gerd] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.
[Vogt, Stefan] Argonne Natl Lab, XRay Sci Div, Argonne, IL 60439 USA.
[Smith, Janet L.] Univ Michigan, Life Sci Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA.
RP Fischetti, RF (reprint author), Argonne Natl Lab, Natl Inst Gen Med Sci, Biosci Div, 9700 S Cass Ave, Argonne, IL 60439 USA.
EM rfischetti@anl.gov
RI Vogt, Stefan/B-9547-2009; Vogt, Stefan/J-7937-2013
OI Vogt, Stefan/0000-0002-8034-5513; Vogt, Stefan/0000-0002-8034-5513
FU National Institute of General Medical Sciences [Y1-GM-1104]; National
Cancer Institute of the US National Institutes of Health [Y1-CO-1020];
US Department of Energy, Basic Energy Sciences, Office of Science
[DE-AC02-06CH11357]
FX The authors thank Colin Nave, Elspeth Garman and Liz Duke for helpful
discussions. The National Institute of General Medical Sciences and
National Cancer Institute Collaborative Access Team is supported by the
National Institute of General Medical Sciences (Y1-GM-1104) and the
National Cancer Institute (Y1-CO-1020) of the US National Institutes of
Health. Use of the Advanced Photon Source was supported by the US
Department of Energy, Basic Energy Sciences, Office of Science, under
Contract DE-AC02-06CH11357.
NR 35
TC 45
Z9 45
U1 0
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 12
PY 2011
VL 108
IS 15
BP 6127
EP 6132
DI 10.1073/pnas.1017701108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 748SZ
UT WOS:000289413600043
PM 21444772
ER
PT J
AU Gordon, PV
Sample, C
Berezhkovskii, AM
Muratov, CB
Shvartsman, SY
AF Gordon, Peter V.
Sample, Christine
Berezhkovskii, Alexander M.
Muratov, Cyrill B.
Shvartsman, Stanislav Y.
TI Local kinetics of morphogen gradients
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE robustness; tissue regulation; concentration gradient
ID SONIC HEDGEHOG; POSITIONAL INFORMATION; DROSOPHILA EMBRYO; DORSAL
MORPHOGEN; XENOPUS EMBRYO; PATTERN; PROTEIN; LONG; ENDOCYTOSIS;
ROBUSTNESS
AB Some aspects of pattern formation in developing embryos can be described by nonlinear reaction-diffusion equations. An important class of these models accounts for diffusion and degradation of a locally produced single chemical species. At long times, solutions of such models approach a steady state in which the concentration decays with distance from the source of production. We present analytical results that characterize the dynamics of this process and are in quantitative agreement with numerical solutions of the underlying nonlinear equations. The derived results provide an explicit connection between the parameters of the problem and the time needed to reach a steady state value at a given position. Our approach can be used for the quantitative analysis of tissue patterning by morphogen gradients, a subject of active research in biophysics and developmental biology.
C1 [Gordon, Peter V.; Muratov, Cyrill B.] New Jersey Inst Technol, Dept Math Sci, Newark, NJ 07102 USA.
[Sample, Christine; Shvartsman, Stanislav Y.] Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA.
[Sample, Christine; Shvartsman, Stanislav Y.] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA.
[Sample, Christine] Univ Cambridge Emmanuel Coll, Boston, MA 02115 USA.
[Berezhkovskii, Alexander M.] Ctr Informat Technol, Math & Stat Comp Lab, Div Computat Biosci, NIH, Bethesda, MD 20892 USA.
RP Muratov, CB (reprint author), New Jersey Inst Technol, Dept Math Sci, Newark, NJ 07102 USA.
EM muratov@njit.edu; stas@princeton.edu
FU United States-Israel Binational Science Foundation [2006-151]; National
Institutes of Health, Center for Information Technology; National
Science Foundation (NSF) [DMS-0718027, DMS-0908279, DMS-0718604];
National Institutes of Health [GM078079]
FX The authors thank J. Briscoe for providing the image for Fig. 1. The
work of P.V.G. was supported, in part, by the United States-Israel
Binational Science Foundation Grant 2006-151. A.M.B. was supported by
the Intramural Research Program of the National Institutes of Health,
Center for Information Technology. C.B.M. acknowledges partial support
by National Science Foundation (NSF) via Grants DMS-0718027 and
DMS-0908279. S.Y.S. acknowledges partial support by NSF via Grant
DMS-0718604, by National Institutes of Health via Grant GM078079, and by
the NSF Career award.
NR 47
TC 25
Z9 25
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 12
PY 2011
VL 108
IS 15
BP 6157
EP 6162
DI 10.1073/pnas.1019245108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 748SZ
UT WOS:000289413600048
PM 21444770
ER
PT J
AU Venkova-Canova, T
Chattoraj, DK
AF Venkova-Canova, Tatiana
Chattoraj, Dhruba K.
TI Transition from a plasmid to a chromosomal mode of replication entails
additional regulators
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE replication control; DNA chaperone
ID VIBRIO-CHOLERAE CHROMOSOMES; ESCHERICHIA-COLI; NEGATIVE CONTROL;
DNA-REPLICATION; CELL-CYCLE; INITIATOR; BINDING; RCTB; COOPERATIVITY;
INACTIVATION
AB Plasmid origins of replication are rare in bacterial chromosomes, except in multichromosome bacteria. The replication origin of Vibrio cholerae chromosome II (chrII) closely resembles iteron-bearing plasmid origins. Iterons are repeated initiator binding sites in plasmid origins and participate both in replication initiation and its control. The control is mediated primarily by coupling of iterons via the bound initiators ("handcuffing"), which causes steric hindrance to the origin. The control in chrII must be different, since the timing of its replication is cell cycle-specific, whereas in plasmids it is random. Here we show that chrII uses, in addition to iterons, another kind of initiator binding site, named 39-mers. The 39-mers confer stringent control by increasing handcuffing of iterons, presumably via initiator remodeling. Iterons, although potential inhibitors of replication themselves, restrain the 39-mer-mediated inhibition, possibly by direct coupling ("heterohandcuffing"). We propose that the presumptive transition of a plasmid to a chromosomal mode of control requires additional regulators to increase the stringency of control, and as will be discussed, to gain the capacity to modulate the effectiveness of the regulators at different stages of the cell cycle.
C1 [Venkova-Canova, Tatiana; Chattoraj, Dhruba K.] NCI, Lab Biochem & Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Chattoraj, DK (reprint author), NCI, Lab Biochem & Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM chattoraj@nih.gov
FU Center for Cancer Research of the National Cancer Institute
FX We are grateful to our colleagues Michael Yarmolinsky, Michael Lichten,
and Yikang Rong, and one of the reviewers for suggestions to improve the
manuscript. This work was supported by the Intramural Research Program,
Center for Cancer Research of the National Cancer Institute.
NR 30
TC 17
Z9 17
U1 1
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 12
PY 2011
VL 108
IS 15
BP 6199
EP 6204
DI 10.1073/pnas.1013244108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 748SZ
UT WOS:000289413600055
PM 21444815
ER
PT J
AU Joyce, MG
Tran, P
Zhuravleva, MA
Jaw, J
Colonna, M
Sun, PD
AF Joyce, M. Gordon
Tran, Paul
Zhuravleva, Marina A.
Jaw, Jessica
Colonna, Marco
Sun, Peter D.
TI Crystal structure of human natural cytotoxicity receptor NKp30 and
identification of its ligand binding site
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE X-ray crystallography; BIAcore binding; NKp30 mutants; antibody epitope
mapping
ID KILLER-CELLS; INHIBITORY RECEPTOR; MOLECULAR-REPLACEMENT; ACTIVATING
RECEPTOR; COMPLEX; DOMAINS; RECOGNITION; RESEMBLES; NKP44; NKG2D
AB Natural killer (NK) cells are a group of innate immune cells that carry out continuous surveillance for the presence of virally infected or cancerous cells. The natural cytotoxicity receptor (NCR) NKp30 is critical for the elimination of a large group of tumor cell types. Although several ligands have been proposed for NKp30, the lack of a conserved structural feature among these ligands and their uncertain physiological relevance has contributed to confusion in the field and hampered a full understanding of the receptor. To gain insights into NKp30 ligand recognition, we have determined the crystal structure of the extracellular domain of human NKp30. The structure displays an I-type Ig-like fold structurally distinct from the other natural cytotoxicity receptors NKp44 and NKp46. Using cytolytic killing assays against a range of tumor cell lines and subsequent peptide epitope mapping of a NKp30 blocking antibody, we have identified a critical ligand binding region on NKp30 involving its F strand. Using different solution binding studies, we show that the N-terminal domain of B7-H6 is sufficient for NKp30 recognition. Mutations on NKp30 further confirm that residues in the vicinity of the F strand, including part of the C strand and the CD loop, affect binding to B7-H6. The structural comparison of NKp30 with CD28 family receptor and ligand complexes also supports the identified ligand binding site. This study provides insights into NKp30 ligand recognition and a framework for a potential family of unidentified ligands.
C1 [Joyce, M. Gordon; Tran, Paul; Zhuravleva, Marina A.; Jaw, Jessica; Sun, Peter D.] NIAID, Struct Immunol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
[Colonna, Marco] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
RP Sun, PD (reprint author), NIAID, Struct Immunol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
EM psun@nih.gov
OI Colonna, Marco/0000-0001-5222-4987
FU Department of Energy, Office of Science, Office of Basic Energy Sciences
[W-31-109-Eng-38]; National Institute of Allergy and Infectious Diseases
FX We thank Christine Foster and Julius Chung for preliminary work at the
beginning of this project. We also thank Greg Snyder and Tsan Xiao for
instruction and the use of a Mosquito crystallization robot for initial
high throughput crystallization screening. Use of the Advanced Photon
Source was supported by the Department of Energy, Office of Science,
Office of Basic Energy Sciences, under Contract W-31-109-Eng-38. This
research is supported by the intramural research funding from the
National Institute of Allergy and Infectious Diseases.
NR 43
TC 31
Z9 35
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 12
PY 2011
VL 108
IS 15
BP 6223
EP 6228
DI 10.1073/pnas.1100622108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 748SZ
UT WOS:000289413600059
PM 21444796
ER
PT J
AU Wang, WCH
Juan, AH
Panebra, A
Liggett, SB
AF Wang, Wayne C. H.
Juan, Aster H.
Panebra, Alfredo
Liggett, Stephen B.
TI MicroRNA let-7 establishes expression of beta(2)-adrenergic receptors
and dynamically down-regulates agonist-promoted down-regulation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE desensitization; airways; noncoding RNA; gene regulation
ID AIRWAY SMOOTH-MUSCLE; BETA-ADRENERGIC RECEPTORS; MESSENGER-RNA;
BETA-2-ADRENERGIC RECEPTOR; IN-VIVO; TARGETS; COMPLEX; PHOSPHORYLATION;
TRAFFICKING; PATHWAYS
AB Although beta(2)-adrenergic receptors (beta(2)AR) are expressed on most cell types, mechanisms that establish expression levels and regulate expression by chronic agonist remain unclear. The 3' UTR of ADRB2 has a conserved 8-nucleotide seed region that we hypothesized is targeted by the let-7 family of miRNAs leading to translational repression. In luciferase assays with transfected cells, luc-beta(2)WT3'UTR had decreased expression when cotransfected with let-7f, but a mutated luc-beta(2)3'UTR lacking the seed was unaffected by let-7f; a mutated let-7f also had no effect on luc-beta(2)WT3'UTR expression. ADRB2 mRNA was in greater abundance in immunoprecipitates of Ago2, a core component of the miRNA-induced silencing complex, when cells were transfected with let-7f, but not with a mutated let-7f, indicating a direct interaction with the silencing mechanism. H292 cells transfected with let-7f caused similar to 60% decrease in native beta(2)AR expression, but transfection with let-7f-specific locked nucleic acid anti-miRNA increased beta(2)AR expression by similar to twofold. We considered that an increase in let-7f leading to greater repression of translation contributes to agonist-promoted down-regulation. Paradoxically, in cells and in lungs from mice treated in vivo, an similar to 50% decrease in let-7f occurs during long-term agonist exposure, indicating a counterregulatory event. Consistent with this notion, let-7f locked nucleic acid transfection caused depressed agonist-promoted down-regulation. Thus, let-7f miRNA regulates baseline beta(2)AR expression and decreases in let-7f evoked by agonist attenuate down-regulation. This positive feedback loop has not previously been described for a G protein-coupled receptor and its miRNA. Methods to decrease let-7f expression in targeted cells may increase therapeutic responses to beta-agonist by increasing beta(2)AR expression or minimizing tachyphylaxis.
C1 [Wang, Wayne C. H.; Panebra, Alfredo; Liggett, Stephen B.] Univ Maryland, Sch Med, Dept Med, Cardiopulm Genom Program, Baltimore, MD 21201 USA.
[Juan, Aster H.] NIAMSD, Lab Muscle Stem Cells & Gene Regulat, NIH, Bethesda, MD 20892 USA.
RP Liggett, SB (reprint author), Univ Maryland, Sch Med, Dept Med, Cardiopulm Genom Program, Baltimore, MD 21201 USA.
EM sligg001@umaryland.edu
RI liggett, stephen/E-7453-2012
FU National Institutes of Health [HL104119, HL045967, HL071609, HL065899]
FX We thank Rachel Schillinger and Molly Malone for technical assistance,
and Esther Moses for manuscript preparation. This work was funded by
National Institutes of Health Grants HL104119 (to W.C.H.W.) and
HL045967, HL071609, and HL065899 (to S.B.L.).
NR 43
TC 23
Z9 24
U1 0
U2 0
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 12
PY 2011
VL 108
IS 15
BP 6246
EP 6251
DI 10.1073/pnas.1101439108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 748SZ
UT WOS:000289413600063
PM 21447718
ER
PT J
AU Fenichel, EP
Castillo-Chavez, C
Ceddia, MG
Chowell, G
Parra, PAG
Hickling, GJ
Holloway, G
Horan, R
Morin, B
Perrings, C
Springborn, M
Velazquez, L
Villalobos, C
AF Fenichel, Eli P.
Castillo-Chavez, Carlos
Ceddia, M. G.
Chowell, Gerardo
Parra, Paula A. Gonzalez
Hickling, Graham J.
Holloway, Garth
Horan, Richard
Morin, Benjamin
Perrings, Charles
Springborn, Michael
Velazquez, Leticia
Villalobos, Cristina
TI Adaptive human behavior in epidemiological models
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE susceptible-infected-recovered model; R-0; reproductive number;
bioeconomics
ID INFECTIOUS-DISEASES; PANDEMIC INFLUENZA; EPIDEMICS; CHOICE; AIDS
AB The science and management of infectious disease are entering a new stage. Increasingly public policy to manage epidemics focuses on motivating people, through social distancing policies, to alter their behavior to reduce contacts and reduce public disease risk. Person-to-person contacts drive human disease dynamics. People value such contacts and are willing to accept some disease risk to gain contact-related benefits. The cost-benefit trade-offs that shape contact behavior, and hence the course of epidemics, are often only implicitly incorporated in epidemiological models. This approach creates difficulty in parsing out the effects of adaptive behavior. We use an epidemiological-economic model of disease dynamics to explicitly model the trade-offs that drive person-to-person contact decisions. Results indicate that including adaptive human behavior significantly changes the predicted course of epidemics and that this inclusion has implications for parameter estimation and interpretation and for the development of social distancing policies. Acknowledging adaptive behavior requires a shift in thinking about epidemiological processes and parameters.
C1 [Fenichel, Eli P.; Perrings, Charles] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.
[Fenichel, Eli P.; Perrings, Charles] Arizona State Univ, EcoSERV Grp, Tempe, AZ 85287 USA.
[Castillo-Chavez, Carlos; Chowell, Gerardo; Morin, Benjamin] Arizona State Univ, Sch Human Evolut & Social Change, Tempe, AZ 85287 USA.
[Ceddia, M. G.; Holloway, Garth] Univ Reading, Sch Agr Policy & Dev, Dept Food Econ & Mkt, Reading RG6 6AR, Berks, England.
[Chowell, Gerardo] NIH, Div Epidemiol & Populat Studies, Fogarty Int Ctr, Bethesda, MD 20892 USA.
[Parra, Paula A. Gonzalez; Velazquez, Leticia] Univ Texas El Paso, Program Computat Sci, El Paso, TX 79968 USA.
[Hickling, Graham J.] Univ Tennessee, Dept Forestry Wildlife & Fisheries, Ctr Wildlife Hlth, Knoxville, TN 37996 USA.
[Hickling, Graham J.] Univ Tennessee, Natl Inst Math & Biol Synth, Knoxville, TN 37996 USA.
[Horan, Richard] Michigan State Univ, Dept Agr Food & Resource Econ, E Lansing, MI 48824 USA.
[Springborn, Michael] Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA.
[Villalobos, Cristina] Univ Texas Pan Amer, Dept Math, Edinburg, TX 78539 USA.
RP Fenichel, EP (reprint author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.
EM Eli.Fenichel@asu.edu
RI Chowell, Gerardo/F-5038-2012; Castillo-Chavez, Carlos/E-1412-2014
OI Chowell, Gerardo/0000-0003-2194-2251; Castillo-Chavez,
Carlos/0000-0002-1046-3901
FU National Institute for Mathematical and Biological Synthesis; National
Science Foundation; United States Department of Homeland Security; US
Department of Agriculture through National Science Foundation
[EF-0832858]; University of Tennessee, Knoxville; US Army Research
Laboratory, through the Army High Performance Computing Research Center
[W911NF-07-0027]; Early History Program
FX This manuscript is the result of the NIMBioS working group, in which all
authors participated. E.P.F. led the working group, the modeling, and
the writing. All authors, listed alphabetically following E.P.F.,
contributed to conception of the project, modeling, and writing. This
work was conducted by the Synthesizing and Predicting Infectious Disease
with Endogenous Risk work group supported by the National Institute for
Mathematical and Biological Synthesis, sponsored by the National Science
Foundation, United States Department of Homeland Security, and US
Department of Agriculture through National Science Foundation Award
EF-0832858. Additional support was from University of Tennessee,
Knoxville. P.A.G.P. and L.V. were supported in part by the US Army
Research Laboratory, through the Army High Performance Computing
Research Center, Cooperative Agreement W911NF-07-0027. G.C. was
supported in part by the Late Lessons from Early History Program.
NR 33
TC 85
Z9 88
U1 0
U2 33
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 12
PY 2011
VL 108
IS 15
BP 6306
EP 6311
DI 10.1073/pnas.1011250108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 748SZ
UT WOS:000289413600073
PM 21444809
ER
PT J
AU Mukhopadhyay, B
Cinar, R
Yin, S
Liu, J
Tam, J
Godlewski, G
Harvey-White, J
Mordi, I
Cravatt, BF
Lotersztajn, S
Gao, B
Yuan, QP
Schuebel, K
Goldman, D
Kunos, G
AF Mukhopadhyay, Bani
Cinar, Resat
Yin, Shi
Liu, Jie
Tam, Joseph
Godlewski, Grzegorz
Harvey-White, Judith
Mordi, Isioma
Cravatt, Benjamin F.
Lotersztajn, Sophie
Gao, Bin
Yuan, Qiaoping
Schuebel, Kornel
Goldman, David
Kunos, George
TI Hyperactivation of anandamide synthesis and regulation of cell-cycle
progression via cannabinoid type 1 (CB1) receptors in the regenerating
liver
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID ACID AMIDE HYDROLASE; PARTIAL-HEPATECTOMY; RAT-LIVER; 2-ARACHIDONOYL
GLYCEROL; TRANSCRIPTION FACTOR; ENZYMATIC-SYNTHESIS; ENDOGENOUS LIGAND;
MICE; BIOSYNTHESIS; EXPRESSION
AB The mammalian liver regenerates upon tissue loss, which induces quiescent hepatocytes to enter the cell cycle and undergo limited replication under the control of multiple hormones, growth factors, and cytokines. Endocannabinoids acting via cannabinoid type 1 receptors (CB1R) promote neural progenitor cell proliferation, and in the liver they promote lipogenesis. These findings suggest the involvement of CB1R in the control of liver regeneration. Here we report that mice lacking CB1R globally or in hepatocytes only and wild-type mice treated with a CB1R antagonist have a delayed proliferative response to two-thirds partial hepatectomy (PHX). In wild-type mice, PHX leads to increased hepatic expression of CB1R and hyperactivation of the biosynthesis of the endocannabinoid anandamide in the liver via an in vivo pathway involving conjugation of arachidonic acid and ethanolamine by fatty-acid amide hydrolase. In wild-type but not CB1R-/- mice, PHX induces robust up-regulation of key cell-cycle proteins involved in mitotic progression, including cyclin-dependent kinase 1(Cdk1), cyclin B2, and their transcriptional regulator forkhead box protein M1 (FoxM1), as revealed by ultrahigh-throughput RNA sequencing and pathway analysis and confirmed by real-time PCR and Western blot analyses. Treatment of wild-type mice with anandamide induces similar changes mediated via activation of the PI3K/Akt pathway. We conclude that activation of hepatic CB1R by newly synthesized anandamide promotes liver regeneration by controlling the expression of cell-cycle regulators that drive M phase progression.
C1 [Mukhopadhyay, Bani; Cinar, Resat; Liu, Jie; Tam, Joseph; Godlewski, Grzegorz; Harvey-White, Judith; Kunos, George] NIAAA, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA.
[Yin, Shi; Gao, Bin] NIAAA, Lab Liver Biol, NIH, Bethesda, MD 20892 USA.
[Mordi, Isioma; Yuan, Qiaoping; Schuebel, Kornel; Goldman, David] NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA.
[Cravatt, Benjamin F.] Scripps Inst, La Jolla, CA 92037 USA.
[Lotersztajn, Sophie] Univ Paris 12, Creteil, France.
RP Kunos, G (reprint author), NIAAA, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA.
EM george.kunos@nih.gov
RI Goldman, David/F-9772-2010;
OI Goldman, David/0000-0002-1724-5405; CINAR, RESAT/0000-0002-8597-7253
FU National Institute on Alcohol Abuse and Alcoholism
FX We thank Ken Mackie for the CB1 antibodies and Beat Lutz and Giovanni
Marsicano for the CB1 floxed mice used to generate
LCB1-/- mice. This work was funded by the
intramural program of the National Institute on Alcohol Abuse and
Alcoholism.
NR 51
TC 43
Z9 43
U1 1
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 12
PY 2011
VL 108
IS 15
BP 6323
EP 6328
DI 10.1073/pnas.1017689108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 748SZ
UT WOS:000289413600076
PM 21383171
ER
PT J
AU Abe, M
Schambra, H
Wassermann, EM
Luckenbaugh, D
Schweighofer, N
Cohen, LG
AF Abe, Mitsunari
Schambra, Heidi
Wassermann, Eric M.
Luckenbaugh, Dave
Schweighofer, Nicolas
Cohen, Leonardo G.
TI Reward Improves Long-Term Retention of a Motor Memory through Induction
of Offline Memory Gains
SO CURRENT BIOLOGY
LA English
DT Article
ID MONETARY REWARD; HUMAN BRAIN; DOPAMINE TRANSMISSION; SYNAPTIC
PLASTICITY; PREFRONTAL CORTEX; CONSOLIDATION; POTENTIATION; ADAPTATION;
MECHANISMS; PREDICTION
AB In humans, training in which good performance is rewarded or bad performance punished results in transient behavioral improvements [1-3]. The relative effects of reward and punishment on consolidation and long-term retention, critical behavioral stages for successful learning [4, 5], are not known. Here, we investigated the effects of reward and punishment on these different stages of human motor skill learning. Vie studied healthy subjects who trained on a motor task under rewarded, punished, or neutral control conditions. Performance was tested before and immediately, 6 hr, 24 hr, and 30 days after training in the absence of reward or punishment. Performance improvements immediately after training were comparable in the three groups. At 6 hr, the rewarded group maintained performance gains, whereas the other two groups experienced significant forgetting. At 24 hr, the reward group showed significant offline (post-training) improvements, whereas the other two groups did not. At 30 days, the rewarded group retained the gains identified at 24 hr, whereas the other two groups experienced significant forgetting. We conclude that training under rewarded conditions is more effective than training under punished or neutral conditions in eliciting lasting motor learning, an advantage driven by offline memory gains that persist over time.
C1 [Abe, Mitsunari; Schambra, Heidi; Cohen, Leonardo G.] NIMH, Human Cort Physiol & Stroke Neurorehabil Sect, NINDS, NIH, Bethesda, MD 20892 USA.
[Wassermann, Eric M.] NIMH, Behav Neurol Unit, NINDS, NIH, Bethesda, MD 20892 USA.
[Luckenbaugh, Dave] NIMH, Mood & Anxiety Disorders Program, NIH, Bethesda, MD 20892 USA.
[Schweighofer, Nicolas] Univ So Calif, Dept Biokinesiol & Phys Therapy, Los Angeles, CA 90089 USA.
RP Cohen, LG (reprint author), NIMH, Human Cort Physiol & Stroke Neurorehabil Sect, NINDS, NIH, Bethesda, MD 20892 USA.
EM cohenl@ninds.nih.gov
RI Schweighofer, Nicolas/A-3675-2008; Abe, Mitsunari/F-1373-2014
OI Abe, Mitsunari/0000-0002-3913-2292
FU National Institute of Neurological Disorders and Stroke; National
Science Foundation [BCS-1031899]
FX This work was supported by the Intramural Research Program of the
National Institute of Neurological Disorders and Stroke and by National
Science Foundation grant: BCS-1031899 to N.S. We thank Toyomi Abe,
Nitzan Censor, Mark Hallett, Eran Dayan, Ethan Buch, John Krakauer, and
Pablo Celnik for critical comments on earlier versions of this
manuscript.
NR 41
TC 71
Z9 71
U1 5
U2 27
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD APR 12
PY 2011
VL 21
IS 7
BP 557
EP 562
DI 10.1016/j.cub.2011.02.030
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 752BK
UT WOS:000289662600017
PM 21419628
ER
PT J
AU McKay, MM
Ritt, DA
Morrison, DK
AF McKay, Melissa M.
Ritt, Daniel A.
Morrison, Deborah K.
TI RAF Inhibitor-Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade
Signaling
SO CURRENT BIOLOGY
LA English
DT Article
ID KSR1 SCAFFOLD COMPLEX; B-RAF; KINASE SUPPRESSOR; ONCOGENIC RAS;
ACTIVATION; PHOSPHORYLATION; IDENTIFICATION; MECHANISM; PATHWAY; CELLS
AB RAF kinase inhibitors can induce ERK cascade signaling by promoting dimerization of RAF family members in the presence of oncogenic or normally activated RAS [1-3]. This interaction is mediated by a dimer interface region in the RAF kinase domain that is conserved in members of the ERK cascade scaffold family, kinase suppressor of RAS (KSR) [4,5]. In this study, we find that most RAF inhibitors also induce the binding of KSR1 to wild-type and oncogenic B-RAF proteins, including V600E B-RAF, but promote little complex formation between KSR1 and C-RAF. The inhibitor-induced KSR1/B-RAF interaction requires direct binding of the drug to B-RAF and is dependent on conserved dimer interface residues in each protein, but, unexpectedly, is not dependent on binding of B-RAF to activated RAS. Inhibitor-induced KSR/B-RAF complex formation can occur in the cytosol and is observed in normal mouse fibroblasts, as well as a variety of human cancer cell lines. Strikingly, we find that KSR1 competes with C-RAF for inhibitor-induced binding to B-RAF and, as a result, alters the effect of the inhibitors on ERK cascade signaling.
C1 [McKay, Melissa M.; Ritt, Daniel A.; Morrison, Deborah K.] NCI, Lab Cell & Dev Signaling, Ctr Canc Res, Frederick, MD 21702 USA.
RP Morrison, DK (reprint author), NCI, Lab Cell & Dev Signaling, Ctr Canc Res, Frederick, MD 21702 USA.
EM morrisod@mail.nih.gov
FU National Cancer Institute
FX We thank members of the Laboratory of Cell and Developmental Signaling
for helpful discussions. This project has been funded by federal funds
from the National Cancer Institute.
NR 20
TC 47
Z9 48
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD APR 12
PY 2011
VL 21
IS 7
BP 563
EP 568
DI 10.1016/j.cub.2011.02.033
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 752BK
UT WOS:000289662600018
PM 21458265
ER
PT J
AU Amaratunga, C
Lopera-Mesa, TM
Brittain, NJ
Cholera, R
Arie, T
Fujioka, H
Keefer, JR
Fairhurst, RM
AF Amaratunga, Chanaki
Lopera-Mesa, Tatiana M.
Brittain, Nathaniel J.
Cholera, Rushina
Arie, Takayuki
Fujioka, Hisashi
Keefer, Jeffrey R.
Fairhurst, Rick M.
TI A Role for Fetal Hemoglobin and Maternal Immune IgG in Infant Resistance
to Plasmodium falciparum Malaria
SO PLOS ONE
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; INFECTED ERYTHROCYTES; CEREBRAL MALARIA;
ACQUIRED-IMMUNITY; RED-CELLS; SEQUESTRATION; SURFACE; PROTECTION;
ANTIBODIES; CHILDREN
AB Background: In Africa, infant susceptibility to Plasmodium falciparum malaria increases substantially as fetal hemoglobin (HbF) and maternal immune IgG disappear from circulation. During the first few months of life, however, resistance to malaria is evidenced by extremely low parasitemias, the absence of fever, and the almost complete lack of severe disease. This resistance has previously been attributed in part to poor parasite growth in HbF-containing red blood cells (RBCs). A specific role for maternal immune IgG in infant resistance to malaria has been hypothesized but not yet identified.
Methods and Findings: We found that P. falciparum parasites invade and develop normally in fetal (cord blood, CB) RBCs, which contain up to 95% HbF. However, these parasitized CB RBCs are impaired in their binding to human microvascular endothelial cells (MVECs), monocytes, and nonparasitized RBCs -cytoadherence interactions that have been implicated in the development of high parasite densities and the symptoms of malaria. Abnormal display of the parasite's cytoadherence antigen P. falciparum erythrocyte membrane protein-1 (PfEMP-1) on CB RBCs accounts for these findings and is reminiscent of that on HbC and HbS RBCs. IgG purified from the plasma of immune Malian adults almost completely abolishes the adherence of parasitized CB RBCs to MVECs.
Conclusions: Our data suggest a model of malaria protection in which HbF and maternal IgG act cooperatively to impair the cytoadherence of parasitized RBCs in the first few months of life. In highly malarious areas of Africa, an infant's contemporaneous expression of HbC or HbS and development of an immune IgG repertoire may effectively reconstitute the waning protective effects of HbF and maternal immune IgG, thereby extending the malaria resistance of infancy into early childhood.
C1 [Amaratunga, Chanaki; Lopera-Mesa, Tatiana M.; Brittain, Nathaniel J.; Cholera, Rushina; Fairhurst, Rick M.] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.
[Arie, Takayuki] Osaka Prefecture Univ, Sch Engn, Dept Phys & Elect, Osaka, Japan.
[Fujioka, Hisashi] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
[Keefer, Jeffrey R.] Johns Hopkins Sch Med, Dept Pediat, Div Pediat Hematol, Baltimore, MD USA.
RP Amaratunga, C (reprint author), NIAID, Lab Malaria & Vector Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM rfairhurst@niaid.nih.gov
FU National Institutes of Health, National Institute of Allergy and
Infectious Diseases
FX This research was supported by the Intramural Research Program of the
National Institutes of Health, National Institute of Allergy and
Infectious Diseases. The funders had no role in the study design, data
collection, analysis, decision to publish or preparation of the
manuscript.
NR 47
TC 31
Z9 32
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 12
PY 2011
VL 6
IS 4
AR e14798
DI 10.1371/journal.pone.0014798
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 748QE
UT WOS:000289404700003
PM 21532754
ER
PT J
AU Zou, SG
Liedo, P
Altamirano-Robles, L
Cruz-Enriquez, J
Morice, A
Ingram, DK
Kaub, K
Papadopoulos, N
Carey, JR
AF Zou, Sige
Liedo, Pablo
Altamirano-Robles, Leopoldo
Cruz-Enriquez, Janeth
Morice, Amy
Ingram, Donald K.
Kaub, Kevin
Papadopoulos, Nikos
Carey, James R.
TI Recording Lifetime Behavior and Movement in an Invertebrate Model
SO PLOS ONE
LA English
DT Article
ID DIETARY-RESTRICTION; DROSOPHILA; SLEEP; FLY
AB Characterization of lifetime behavioral changes is essential for understanding aging and aging-related diseases. However, such studies are scarce partly due to the lack of efficient tools. Here we describe and provide proof of concept for a stereo vision system that classifies and sequentially recordsat an extremely fine scalesix different behaviors (resting, micro-movement, walking, flying, feeding and drinking) and the within-cage (3D) location of individualtephritidfruit flies by time-of-day throughout their lives. Using flies fed on two different diets, full sugar-yeast and sugar-only diets, we report for the first time their behavioral changes throughout their lives at a high resolution. We have found that the daily activity peaks at the age of 15-20 days and then gradually declines with age for flies on both diets. However, the overall daily activity is higher for flies on sugar-only diet than those on the full diet. Flies on sugar-only diet show a stronger diurnal localization pattern with higher preference to staying on the top of the cage during the period of light-off when compared to flies on the full diet. Clustering analyses of age-specific behavior patterns reveal three distinct young, middle-aged and old clusters for flies on each of the two diets. The middle-aged groups for flies on sugar-only diet consist of much younger age groups when compared to flies on full diet. This technology providesresearch opportunitiesfor using a behavioral informatics approach for understanding different ways in which behavior, movement, and aging in model organisms are mutually affecting.
C1 [Zou, Sige] NIA, Lab Expt Gerontol, Baltimore, MD 21224 USA.
[Liedo, Pablo] El Colegio Frontera Sur, Dept Entomol, Tapachula, Chiapas, Mexico.
[Altamirano-Robles, Leopoldo; Cruz-Enriquez, Janeth] Inst Nacl Astrofis Opt & Electr, Lab Vis Comp, Puebla, Mexico.
[Morice, Amy; Kaub, Kevin; Carey, James R.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.
[Ingram, Donald K.] Louisiana State Univ, Pennington Biomed Res Ctr, Nutrit Neurosci & Aging Lab, Baton Rouge, LA 70808 USA.
[Papadopoulos, Nikos] Univ Thessaly, Dept Agr Crop Prod & Rural Environm, Magnisias, Greece.
[Carey, James R.] Univ Calif Berkeley, Ctr Econ & Demog Aging, Berkeley, CA 94720 USA.
RP Zou, SG (reprint author), NIA, Lab Expt Gerontol, Baltimore, MD 21224 USA.
EM jrcarey@ucdavis.edu
RI Trejo, Yesenia/D-9257-2012; Liedo, Pablo/E-9313-2010; Papadopoulos,
Nikos/B-9156-2011
OI Liedo, Pablo/0000-0002-0004-1721; Papadopoulos,
Nikos/0000-0003-2480-8189
FU Ellison Medical Foundation; UC MEXUS; National Institute on
Aging/National Institutes of Health (NIA/NIH) [P01 AG022500-01, P01
AG08761-10]
FX Research funded by the Ellison Medical Foundation, UC MEXUS and National
Institute on Aging/National Institutes of Health (NIA/NIH) grants P01
AG022500-01 and P01 AG08761-10 to JRC, and the Intramural Research
Program of NIA, NIH to SZ. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 19
TC 16
Z9 16
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 12
PY 2011
VL 6
IS 4
AR e18151
DI 10.1371/journal.pone.0018151
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 748QE
UT WOS:000289404700007
PM 21559058
ER
PT J
AU Wang, DS
Zhang, Z
Dong, M
Sun, SH
Chapman, ER
Jackson, MB
AF Wang, Dongsheng
Zhang, Zhen
Dong, Min
Sun, Shihu
Chapman, Edwin R.
Jackson, Meyer B.
TI Syntaxin Requirement for Ca2+-Triggered Exocytosis in Neurons and
Endocrine Cells Demonstrated with an Engineered Neurotoxin
SO BIOCHEMISTRY
LA English
DT Article
ID VOLTAGE-GATED K+; BOTULINUM NEUROTOXIN; MEMBRANE-FUSION;
NEUROEXOCYTOSIS; CHANNELS; VESICLES; SNARES; C1; 1A
AB Botulinum neurotoxins cleave synaptic SNAREs and block exocytosis, demonstrating that these proteins function in neurosecretion. However, the function of the SNARE syntaxin remains less clear because no neurotoxin cleaves it selectively. Starting with a botulinum neurotoxin that cleaves both syntaxin and SNAP-25, we engineered a version that retains activity against syntaxin but spares SNAP-25. These mutants block synaptic release in neurons and norepinephrine release in neuroendocrine cells, thus establishing an essential role for syntaxin in Ca2+-triggered exocytosis. These mutants can generate syntaxin-free cells as a useful experimental system for research and may lead to pharmaceuticals that target syntaxin selectively.
C1 [Wang, Dongsheng; Jackson, Meyer B.] Univ Wisconsin, Dept Neurosci, Madison, WI 53706 USA.
[Zhang, Zhen] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA.
[Dong, Min; Sun, Shihu; Chapman, Edwin R.] Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA.
RP Jackson, MB (reprint author), Univ Wisconsin, Dept Neurosci, Madison, WI 53706 USA.
EM mbjackso@wisc.edu
RI Zhang, Zhen/F-8561-2011
FU National Institutes of Health [NS44057]; Howard Hughes Medical Institute
FX Funded by National Institutes of Health Grant NS44057 and the Howard
Hughes Medical Institute.
NR 24
TC 14
Z9 14
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD APR 12
PY 2011
VL 50
IS 14
BP 2711
EP 2713
DI 10.1021/bi200290p
PG 3
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 743OW
UT WOS:000289029200001
PM 21401123
ER
PT J
AU Gift, SK
Zentner, IJ
Schon, A
McFadden, K
Umashankara, M
Rajagopal, S
Contarino, M
Duffy, C
Courter, JR
Zhang, MY
Gershoni, JM
Cocklin, S
Dimitrov, DS
Smith, AB
Freire, E
Chaiken, IM
AF Gift, Syna Kuriakose
Zentner, Isaac J.
Schoen, Arne
McFadden, Karyn
Umashankara, M.
Rajagopal, Srivats
Contarino, Mark
Duffy, Caitlin
Courter, Joel R.
Zhang, Mei-Yun
Gershoni, Jonathan M.
Cocklin, Simon
Dimitrov, Dimiter S.
Smith, Amos B., III
Freire, Ernesto
Chaiken, Irwin M.
TI Conformational and Structural Features of HIV-1 gp120 Underlying the
Dual Receptor Antagonism by Cross-Reactive Neutralizing Antibody m18
SO BIOCHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; CD4
BINDING-SITE; EXTERIOR ENVELOPE GLYCOPROTEIN; POTENT NEUTRALIZATION;
ENTRY INHIBITORS; CD4-BINDING SITE; MEDIATED FUSION; CD4-BOUND STATE;
DISPLAY LIBRARY
AB We investigated the interaction between cross-reactive HIV-1 neutralizing human monoclonal antibody m18 and HIV-I(YU-2) gp120 in an effort to understand how this antibody inhibits the entry of virus into cells. m18 binds to gp120 with high affinity (K(D) approximate to 5 nM) as measured by surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC). SPR analysis further showed that m18 inhibits interactions of gp120 with both soluble CD4 and CD4-induced antibodies that have epitopes overlapping the coreceptor binding site. This dual receptor site antagonism, which occurs with equal potency for both inhibition effects, argues that m18 is not functioning as a mimic of CD4, in spite of the presence of a putative CD4-like loop formed by HCDR3 in the antibody. Consistent with this view, m18 was found to interact with gp120 in the presence of saturating concentrations of a CD4-mimicking small molecule gp120 inhibitor, suggesting that m18 does not require unoccupied CD4 Pbe43 binding cavity residues of gp120. Thermodynamic analysis of the m18 gp120 interaction suggests that m18 stabilizes a conformation of gp120 that is unique from and less structured than the CD4-stabilized conformation. Conformational mutants of gp120 were studied for their impact on m18 interaction. Mutations known to disrupt the coreceptor binding region and to lead to complete suppression of 17b binding had minimal effects on m18 binding. This argues that energetically important epitopes for m18 binding lie outside the disrupted bridging sheet region used for 17b and coreceptor binding. In contrast, mutations in the CD4 region strongly affected m18 binding. Overall, the results obtained in this work argue that m18, rather than mimicking CD4 directly, suppresses both receptor binding site functions of HIV-1 gp120 by stabilizing a nonproductive conformation of the envelope protein. These results can be related to prior findings about the importance of conformational entrapment as a common mode of action for neutralizing CD4bs antibodies, with differences mainly in epitope utilization and the extent of gp120 structuring.
C1 [Gift, Syna Kuriakose; Zentner, Isaac J.; McFadden, Karyn; Umashankara, M.; Rajagopal, Srivats; Contarino, Mark; Duffy, Caitlin; Cocklin, Simon; Chaiken, Irwin M.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.
[Gift, Syna Kuriakose; Zentner, Isaac J.; McFadden, Karyn; Chaiken, Irwin M.] Drexel Univ, Coll Med, Biochem Grad Program, Philadelphia, PA 19102 USA.
[Schoen, Arne; Freire, Ernesto] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
[Courter, Joel R.; Smith, Amos B., III] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
[Zhang, Mei-Yun] Univ Hong Kong, Dept Microbiol, AIDS Inst, Hong Kong, Hong Kong, Peoples R China.
[Gershoni, Jonathan M.] Tel Aviv Univ, IL-69978 Tel Aviv, Israel.
[Dimitrov, Dimiter S.] NCI, Ctr Canc Res Nanobiol Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
RP Chaiken, IM (reprint author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 11102 New Coll Bldg,MS 497,245N 15th St, Philadelphia, PA 19102 USA.
EM ichaiken@drexelmed.edu
FU National Institutes of Health (NIH) [P01 GM 56550, CHAVI
U19AI067854-04]; NIH, National Cancer Institute, Center for Cancer
Research
FX This research was supported by National Institutes of Health (NIH) Grant
P01 GM 56550 and CHAVI U19AI067854-04 and by the Intramural Research
Program of the NIH, National Cancer Institute, Center for Cancer
Research.
NR 81
TC 4
Z9 4
U1 1
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD APR 12
PY 2011
VL 50
IS 14
BP 2756
EP 2768
DI 10.1021/bi101160r
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 743OW
UT WOS:000289029200007
PM 21351734
ER
PT J
AU Gift, SK
McFadden, K
Zentner, IJ
Rajagopal, S
Zhang, MY
Dimitrov, DS
Chaiken, IM
AF Gift, Syna Kuriakose
McFadden, Karyn
Zentner, Isaac J.
Rajagopal, Srivats
Zhang, Mei-Yun
Dimitrov, Dimiter S.
Chaiken, Irwin M.
TI Monoclonal Antibody m18 Paratope Leading to Dual Receptor Antagonism of
HIV-1 gp120
SO BIOCHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; NEUTRALIZING
ANTIBODIES; STRUCTURAL BASIS; VACCINE DESIGN; BINDING-SITE; TYPE-1
GP120; ENV BINDING; EPITOPE; CD4
AB We sought to identify sequences in the monoclonal antibody m18 complementarity determining regions (CDRs) that are responsible for its interaction with HIV-1 gpI20 and inhibition of the envelope receptor binding sites. In the accompanying paper (DOI 10.1021/bi101160r), we reported that m18 inhibits CD4 binding through a nonactivating mechanism that, at the same time, induces conformational effects leading to inhibition of the coreceptor site. Here, we sought to define the structural elements in m18 responsible for these actions. Direct binding and competition analyses using surface plasmon resonance showed that YU-2 gp120 binding is stabilized by a broad paratope of residues in the m18 CDRs. Additionally, several m18 residues were identified for which mutants retained high affinity for gpI20 but had suppressed CD4 and 17b inhibition activities. A subset of these mutants did, however, neutralize HXBc2 viral infection. The results obtained in this work demonstrate that the combined m18 paratope contains subsets of residues that are differentially important for the binding and inhibition functions of the m18 neutralizing antibody. The data also add to prior observations that high-affinity antibodies that do not inhibit monomeric gp120 receptor site interactions may still exhibit significant antiviral activity.
C1 [Gift, Syna Kuriakose; McFadden, Karyn; Zentner, Isaac J.; Rajagopal, Srivats; Chaiken, Irwin M.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.
[Gift, Syna Kuriakose; Chaiken, Irwin M.] Drexel Univ, Coll Med, Biochem Grad Program, Philadelphia, PA 19102 USA.
[Zhang, Mei-Yun] Univ Hong Kong, Dept Microbiol, AIDS Inst, Hong Kong, Hong Kong, Peoples R China.
[Dimitrov, Dimiter S.] NCI, Ctr Canc Res Nanobiol Program, CCR, NIH, Frederick, MD 21702 USA.
RP Chaiken, IM (reprint author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 11102 New Coll Bldg,MS 497,245N 15th St, Philadelphia, PA 19102 USA.
EM ichaiken@drexelmed.edu
FU National Institutes of Health [P01 GM 56550, CHAVI UI9AI067854-04]; NIH,
National Cancer Institute, Center for Cancer Research
FX This research was supported by National Institutes of Health Grants P01
GM 56550 and CHAVI UI9AI067854-04 and by the Intramural Research Program
of the NIH, National Cancer Institute, Center for Cancer Research.
NR 43
TC 1
Z9 1
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD APR 12
PY 2011
VL 50
IS 14
BP 2769
EP 2779
DI 10.1021/bi101161j
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 743OW
UT WOS:000289029200008
PM 21417283
ER
PT J
AU Vunnam, N
Flint, J
Balbo, A
Schuck, P
Pedigo, S
AF Vunnam, Nagamani
Flint, Jon
Balbo, Andrea
Schuck, Peter
Pedigo, Susan
TI Dimeric States of Neural- and Epithelial-Cadherins are Distinguished by
the Rate of Disassembly
SO BIOCHEMISTRY
LA English
DT Article
ID CELL-CELL ADHESION; N-CADHERIN; SYNAPTIC PLASTICITY; CLASSICAL
CADHERINS; ANALYTICAL ULTRACENTRIFUGATION; CRYSTAL-STRUCTURE; STRUCTURAL
BASIS; NERVOUS-SYSTEM; SUPERFAMILY; MOLECULES
AB Epithelial- and neural-cadherins are specifically localized at synapses in neurons which can change the shape and contact surface on a time scale of seconds to months. We have focused our studies on the role of the extracellular domains of cadherins in the dynamics of synapses. The kinetics of dimer disassembly of the first two extracellular domains of E- and N-cadherin, ECAD12 and NCAD12, were studied with analytical size exclusion chromatography and sedimentation velocity. NCAD12 forms three different dimers that are distinguished by assembly conditions and kinetics of dissociation. ECAD12 dimer disassembles rapidly regardless of the calcium concentration, whereas the disassembly of NCAD12 dimers was strongly dependent on calcium concentration. In addition to the apo- and saturated-dimeric forms of NCAD12, there is a third dimeric form that is a slow exchange duller. This third dimeric form for NCAD12, formed by decalcification of the calcium-saturated dimer, was kinetically trapped in apo-conditions and did not disassemble over a period of months. Sedimentation velocity experiments showed that this dimer, upon addition of calcium, had similar weighted averages as a. calcium-saturated dimer. These studies provide evidence that the kinetics of dimer disassembly of the extracellular domains may be a major contributor to the morphological dynamics of synapses in vivo.
C1 [Vunnam, Nagamani; Flint, Jon; Pedigo, Susan] Univ Mississippi, Dept Chem & Biochem, University, MS 38677 USA.
[Balbo, Andrea; Schuck, Peter] NIBIB, Dynam Macromol Assembly LBPS, NIH, Bethesda, MD 20892 USA.
RP Pedigo, S (reprint author), Univ Mississippi, Dept Chem & Biochem, University, MS 38677 USA.
EM spedigo@olemiss.edu
OI Schuck, Peter/0000-0002-8859-6966
FU National Science Foundation [MCB 0950494]
FX This work was supported by Grant MCB 0950494 from the National Science
Foundation.
NR 73
TC 9
Z9 9
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD APR 12
PY 2011
VL 50
IS 14
BP 2951
EP 2961
DI 10.1021/bi2001246
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 743OW
UT WOS:000289029200026
PM 21375242
ER
PT J
AU Edgell, DR
Chalamcharla, VR
Belfort, M
AF Edgell, David R.
Chalamcharla, Venkata R.
Belfort, Marlene
TI Learning to live together: mutualism between self-splicing introns and
their hosts
SO BMC BIOLOGY
LA English
DT Review
ID GROUP-II INTRON; OPEN READING FRAMES; YEAST MITOCHONDRIAL-DNA; HOMING
ENDONUCLEASE; TRANSFER-RNA; IN-VIVO; ENCODED ENDONUCLEASE;
MESSENGER-RNA; REVERSE TRANSCRIPTASE/MATURASE; CHLAMYDOMONAS-REINHARDTII
AB Group I and II introns can be considered as molecular parasites that interrupt protein-coding and structural RNA genes in all domains of life. They function as self-splicing ribozymes and thereby limit the phenotypic costs associated with disruption of a host gene while they act as mobile DNA elements to promote their spread within and between genomes. Once considered purely selfish DNA elements, they now seem, in the light of recent work on the molecular mechanisms regulating bacterial and phage group I and II intron dynamics, to show evidence of co-evolution with their hosts. These previously underappreciated relationships serve the co-evolving entities particularly well in times of environmental stress.
C1 [Edgell, David R.] Univ Western Ontario, Dept Biochem, Schulich Sch Med & Dent, London, ON N6A 5C1, Canada.
[Chalamcharla, Venkata R.; Belfort, Marlene] New York State Dept Hlth, Ctr Med Sci, Wadsworth Ctr, Albany, NY 12208 USA.
[Chalamcharla, Venkata R.; Belfort, Marlene] SUNY Albany, Albany, NY 12208 USA.
[Chalamcharla, Venkata R.] NCI, NIH, Bethesda, MD 20892 USA.
RP Edgell, DR (reprint author), Univ Western Ontario, Dept Biochem, Schulich Sch Med & Dent, London, ON N6A 5C1, Canada.
EM dedgell@uwo.ca; belfort@wadsworth.org
OI Belfort, Marlene/0000-0002-1592-5618
FU CIHR [MOP-97780]; NIH [GM39422, GM44844]
FX We thank John Dansereau for assistance with figures, and Anna Pyle and
Steve Zimmerly for discussion. This work was supported by a CIHR
Operating Grant (MOP-97780) to DRE, a CIHR New Investigator Salary Award
to DRE, and by NIH Grants GM39422 and GM44844 to MB.
NR 95
TC 23
Z9 23
U1 1
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7007
J9 BMC BIOL
JI BMC Biol.
PD APR 11
PY 2011
VL 9
AR 22
DI 10.1186/1741-7007-9-22
PG 9
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 748QD
UT WOS:000289404600001
PM 21481283
ER
PT J
AU Kang, SS
Herz, J
Kim, JV
Nayak, D
Stewart-Hutchinson, P
Dustin, ML
McGavern, DB
AF Kang, Silvia S.
Herz, Jasmin
Kim, Jiyun V.
Nayak, Debasis
Stewart-Hutchinson, Phillip
Dustin, Michael L.
McGavern, Dorian B.
TI Migration of cytotoxic lymphocytes in cell cycle permits local MHC
I-dependent control of division at sites of viral infection
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID CD8(+) T-CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; TOLERANCE INDUCTION;
SYNAPSE FORMATION; ANTIGEN; ACTIVATION; MEMORY; EFFECTOR; NAIVE; VIVO
AB After virus infection, cytotoxic T lymphocytes (CTLs) divide rapidly to eradicate the pathogen and prevent the establishment of persistence. The magnitude of an antiviral CTL response is thought to be controlled by the initiation of a cell cycle program within lymphoid tissues. However, it is presently not known whether this division program proceeds during migration or is influenced locally at sites of viral infection. We demonstrate that antiviral CTLs remain in cell cycle while transiting to infected tissues. Up to one third of virus-specific CTLs within blood were found to be in cell cycle after infection with lymphocytic choriomeningitis virus or vesicular stomatitis virus. Using two-photon microscopy, we found that effector CTL divided rapidly upon arrest in the virus-infected central nervous system as well as in meningeal blood vessels. We also observed that MHC I-dependent interactions, but not costimulation, influenced the division program by advancing effector CTL through stages of the cell cycle. These results demonstrate that CTLs are poised to divide in transit and that their numbers can be influenced locally at the site of infection through interactions with cells displaying cognate antigen.
C1 [Kang, Silvia S.; Herz, Jasmin; Nayak, Debasis; McGavern, Dorian B.] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA.
[Kim, Jiyun V.; Stewart-Hutchinson, Phillip; Dustin, Michael L.] NYU, Mol Pathogenesis Program, Helen L & Martin S Kimmel Ctr Biol & Med, Skirball Inst Biomol Med,Sch Med, New York, NY 10016 USA.
RP McGavern, DB (reprint author), Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA.
EM mcgavernd@mail.nih.gov
OI McGavern, Dorian/0000-0001-9568-545X; Dustin,
Michael/0000-0003-4983-6389
FU National Institutes of Health (NIH) [AI075298-01, AI055037]; Dana
Foundation; New York State Spinal Cord; National Research Service Award
[NS061447-01]
FX This work was supported by National Institutes of Health (NIH)
intramural program as well as NIH grants AI075298-01 and AI055037 (M.L
Dustin), Dana Foundation Grant (M.L Dustin), and New York State Spinal
Cord Injury Research Grant (J.V. Kim). S.S. Kong is presently supported
by a National Research Service Award (NS061447-01).
NR 42
TC 22
Z9 22
U1 0
U2 4
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD APR 11
PY 2011
VL 208
IS 4
BP 747
EP 759
DI 10.1084/jem.20101295
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 748QF
UT WOS:000289404800010
PM 21464219
ER
PT J
AU Keszei, M
Detre, C
Rietdijk, ST
Munoz, P
Romero, X
Berger, SB
Calpe, S
Liao, GX
Castro, W
Julien, A
Wu, YY
Shin, DM
Sancho, J
Zubiaur, M
Morse, HC
Morel, L
Engel, P
Wang, NH
Terhorst, C
AF Keszei, Marton
Detre, Cynthia
Rietdijk, Svend T.
Munoz, Pilar
Romero, Xavier
Berger, Scott B.
Calpe, Silvia
Liao, Gongxian
Castro, Wilson
Julien, Aimee
Wu, Ying-Yu
Shin, Dong-Mi
Sancho, Jaime
Zubiaur, Mercedes
Morse, Herbert C., III
Morel, Laurence
Engel, Pablo
Wang, Ninghai
Terhorst, Cox
TI A novel isoform of the Ly108 gene ameliorates murine lupus
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID SPLICED 3'-UNTRANSLATED REGION; B-CELL TOLERANCE; SPONTANEOUS
AUTOIMMUNITY; SUSCEPTIBILITY LOCI; C57BL/6 MICE; TCR-ZETA; T-CELLS;
ERYTHEMATOSUS; FAMILY; EXPRESSION
AB Studies of human systemic lupus erythematosus patients and of murine congenic mouse strains associate genes in a DNA segment on chromosome 1 with a genetic predisposition for this disease. The systematic analysis of lupus-prone congenic mouse strains suggests a role for two isoforms of the Ly108 receptor in the pathogenesis of the disease. In this study, we demonstrate that Ly108 is involved in the pathogenesis of lupus-related auto-immunity in mice. More importantly, we identified a third protein isoform, Ly108-H1, which is absent in two lupus-prone congenic animals. Introduction of an Ly108-H1-expressing transgene markedly diminishes T cell-dependent autoimmunity in congenic B6.Sle1b mice. Thus, an immune response-suppressing isoform of Ly108 can regulate the pathogenesis of lupus.
C1 [Keszei, Marton; Detre, Cynthia; Rietdijk, Svend T.; Romero, Xavier; Berger, Scott B.; Calpe, Silvia; Liao, Gongxian; Castro, Wilson; Julien, Aimee; Wu, Ying-Yu; Wang, Ninghai; Terhorst, Cox] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Immunol, Dept Med,Med Sch, Boston, MA 02115 USA.
[Munoz, Pilar; Sancho, Jaime; Zubiaur, Mercedes] CSIC, Inst Parasitol & Biomed, Granada 18100, Spain.
[Shin, Dong-Mi; Morse, Herbert C., III] NIAID, Immunopathol Lab, NIH, Rockville, MD 20852 USA.
[Morel, Laurence] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.
[Engel, Pablo] Univ Barcelona, Sch Med, Dept Cellular Biol & Pathol, Immunol Unit, E-08036 Barcelona, Spain.
RP Terhorst, C (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Immunol, Dept Med,Med Sch, Boston, MA 02115 USA.
EM mkeszei@bidmc.harvard.edu; cterhors@bidmc.harvard.edu
RI Sancho, Jaime/O-3228-2013; Keszei, Marton/F-3295-2014; Zubiaur,
Mercedes/K-9390-2014;
OI Sancho, Jaime/0000-0003-3852-7951; Keszei, Marton/0000-0002-1158-2179;
Zubiaur, Mercedes/0000-0002-4127-3027; Morse,
Herbert/0000-0002-9331-3705
FU National Institutes of Health [DK073339, AI-065687]
FX This work was supported by grants from the National Institutes of Health
(DK073339 and AI-065687 to C. Terhorst).
NR 39
TC 29
Z9 30
U1 0
U2 5
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD APR 11
PY 2011
VL 208
IS 4
BP 811
EP 822
DI 10.1084/jem.20101653
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 748QF
UT WOS:000289404800015
PM 21422172
ER
PT J
AU Boelte, KC
Gordy, LE
Joyce, S
Thompson, MA
Yang, L
Lin, PC
AF Boelte, Kimberly C.
Gordy, Laura E.
Joyce, Sebastian
Thompson, Mary Ann
Yang, Li
Lin, P. Charles
TI Rgs2 Mediates Pro-Angiogenic Function of Myeloid Derived Suppressor
Cells in the Tumor Microenvironment via Upregulation of MCP-1
SO PLOS ONE
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; MESSENGER-RNA; EXPRESSION; FAMILY;
GENE; LOCALIZATION; LYMPHOCYTES; CHEMOTAXIS; ACTIVATION; CHEMOKINES
AB Background: Tumor growth is intimately linked with stromal interactions. Myeloid derived suppressor cells (MDSCs) are dramatically elevated in cancer patients and tumor bearing mice. MDSCs modulate the tumor microenvironment through attenuating host immune response and increasing vascularization.
Methodology/Principal Findings: In searching for molecular mediators responsible for pro-tumor functions, we found that regulator of G protein signaling-2 (Rgs2) is highly increased in tumor-derived MDSCs compared to control MDSCs. We further demonstrate that hypoxia, a common feature associated with solid tumors, upregulates the gene expression. Genetic deletion of Rgs2 in mice resulted in a significant retardation of tumor growth, and the tumors exhibit decreased vascular density and increased cell death. Interestingly, deletion of Rgs2 in MDSCs completely abolished their tumor promoting function, suggesting that Rgs2 signaling in MDSCs is responsible for the tumor promoting function. Cytokine array profiling identified that Rgs2-/- tumor MDSCs produce less MCP-1, leading to decreased angiogenesis, which could be restored with addition of recombinant MCP-1.
Conclusion: Our data reveal Rgs2 as a critical regulator of the pro-angiogenic function of MDSCs in the tumor microenvironment, through regulating MCP-1 production.
C1 [Boelte, Kimberly C.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37235 USA.
[Gordy, Laura E.; Joyce, Sebastian] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN USA.
[Thompson, Mary Ann] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA.
[Yang, Li; Lin, P. Charles] NIH, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Boelte, KC (reprint author), Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37235 USA.
EM p.lin@nih.gov
FU National Institutes of Health [CA108856, NS45888, AR053718, HL054977,
AI061721, AI042284, T32CA009582, T32HL069765, T32AI007611]
FX This work was supported in part by grants from National Institutes of
Health to PCL (CA108856, NS45888 and AR053718) and SJ (HL054977,
AI061721 and AI042284) as well as training grants to KCB (T32CA009582)
and LEG (T32HL069765 and T32AI007611). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 33
TC 26
Z9 27
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2011
VL 6
IS 4
AR e18534
DI 10.1371/journal.pone.0018534
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 747XH
UT WOS:000289354100019
PM 21494556
ER
PT J
AU Liu, SA
Piatigorsky, J
AF Liu, Shuang
Piatigorsky, Joram
TI Regulation of Mouse Small Heat Shock Protein alpha b-Crystallin Gene by
Aryl Hydrocarbon Receptor
SO PLOS ONE
LA English
DT Article
ID DIOXIN-RESPONSIVE ENHANCER; LIGANDED AH RECEPTOR; DEVELOPMENTAL
EXPRESSION; TRANSCRIPTION FACTORS; DNA INTERACTIONS; 2 MEMBERS; LENS;
IDENTIFICATION; PROMOTER; MICE
AB The stress-inducible small heat shock protein (shsp)/alpha B-crystallin gene is expressed highly in the lens and moderately in other tissues. Here we provide evidence that it is a target gene of the aryl hydrocarbon receptor (AhR) transcription factor. A sequence (-329/-323, CATGCGA) similar to the consensus xenobiotic responsive element (XRE), called here XRE-like, is present in the alpha BE2 region of alpha B-crystallin enhancer and can bind AhR in vitro and in vivo. alpha B-crystallin protein levels were reduced in retina, lens, cornea, heart, skeletal muscle and cultured muscle fibroblasts of AhR(-/-) mice; alpha B-crystallin mRNA levels were reduced in the eye, heart and skeletal muscle of AhR(-/-) mice. Increased AhR stimulated alpha B-crystallin expression in transfection experiments conducted in conjunction with the aryl hydrocarbon receptor nuclear translocator (ARNT) and decreased AhR reduced alpha B-crystallin expression. AhR effect on aB-crystallin promoter activity was cell-dependent in transfection experiments. AhR up-regulated alpha B-crystallin promoter activity in transfected HeLa, NIH3T3 and COS-7 cells in the absence of exogenously added ligand (TCDD), but had no effect on the alpha B-crystallin promoter in C(2)C(12), CV-1 or Hepa-1 cells with or without TCDD. TCDD enhanced AhR-stimulated alpha B-crystallin promoter activity in transfected alpha TN4 cells. AhR could bind to an XRE-like site in the alpha B-crystallin enhancer in vitro and in vivo. Finally, site-specific mutagenesis experiments showed that the XRE-like motif was necessary for both basal and maximal AhR-induction of alpha B-crystallin promoter activity. Our data strongly suggest that AhR is a regulator of alpha B-crystallin gene expression and provide new avenues of research for the mechanism of tissue-specific alpha B-crystallin gene regulation under normal and physiologically stressed conditions.
C1 [Liu, Shuang; Piatigorsky, Joram] NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA.
[Liu, Shuang] NCI, Expt Immunol Lab, NIH, Frederick, MD 21701 USA.
RP Liu, SA (reprint author), NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA.
EM liushuang1999@yahoo.com; joramp@nei.nih.gov
FU NIH, NEI
FX This research was supported by the Intramural Research Program of the
NIH, NEI. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 40
TC 10
Z9 10
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2011
VL 6
IS 4
AR e17904
DI 10.1371/journal.pone.0017904
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 747XH
UT WOS:000289354100003
PM 21494593
ER
PT J
AU Ide, S
Minami, M
Uhl, GR
Satoh, M
Sora, I
Ikeda, K
AF Ide, Soichiro
Minami, Masabumi
Uhl, George R.
Satoh, Masamichi
Sora, Ichiro
Ikeda, Kazutaka
TI (-)-Pentazocine induces visceral chemical antinociception, but not
thermal, mechanical, or somatic chemical antinociception, in mu-opioid
receptor knockout mice
SO MOLECULAR PAIN
LA English
DT Article
DE Opioid receptor Knockout mice; Pentazocine; Antinociception
ID MORPHINE-INDUCED ANALGESIA; POSTOPERATIVE PAIN; SEX-DIFFERENCES; KAPPA;
DELTA; GENE; PENTAZOCINE; NOCICEPTION; ANTAGONIST; WITHDRAWAL
AB Background: (-)-Pentazocine has been hypothesized to induce analgesia via the kappa-opioid (KOP) receptor, although the involvement of other opioid receptor subtypes in the effects of pentazocine remains unknown. In this study, we investigated the role of the mu-opioid (MOP) receptor in thermal, mechanical, and chemical antinociception induced by (-)-pentazocine using MOP receptor knockout (MOP-KO) mice.
Results: (-)-Pentazocine-induced thermal antinociception, assessed by the hot-plate and tail-flick tests, was significantly reduced in heterozygous and abolished in homozygous MOP-KO mice compared with wildtype mice. The results obtained from the (-)-pentazocine-induced mechanical and somatic chemical antinociception experiments, which used the hind-paw pressure and formalin tests, were similar to the results obtained from the thermal antinociception experiments in these mice. However, (-)-pentazocine retained its ability to induce significant visceral chemical antinociception, assessed by the writhing test, in homozygous MOP-KO mice, an effect that was completely blocked by pretreatment with nor-binaltorphimine, a KOP receptor antagonist. In vitro binding and cyclic adenosine monophosphate assays showed that (-)-pentazocine possessed higher affinity for KOP and MOP receptors than for delta-opioid receptors.
Conclusions: The present study demonstrated the abolition of the thermal, mechanical, and somatic chemical antinociceptive effects of (-)-pentazocine and retention of the visceral chemical antinociceptive effects of (-)-pentazocine in MOP-KO mice. These results suggest that the MOP receptor plays a pivotal role in thermal, mechanical, and somatic chemical antinociception induced by (-)-pentazocine, whereas the KOP receptor is involved in visceral chemical antinociception induced by (-)-pentazocine.
C1 [Ide, Soichiro; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Res Project Addict Subst, Tokyo 1568506, Japan.
[Ide, Soichiro; Minami, Masabumi] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido 0600812, Japan.
[Uhl, George R.; Sora, Ichiro] Natl Inst Drug Abuse, Baltimore, MD 21224 USA.
[Satoh, Masamichi] Yasuda Womens Univ, Dept Pharm, Hiroshima 7310153, Japan.
[Sora, Ichiro] Tohoku Univ, Grad Sch Med, Dept Neurosci, Div Psychobiol, Sendai, Miyagi 9808574, Japan.
RP Ikeda, K (reprint author), Tokyo Metropolitan Inst Med Sci, Res Project Addict Subst, Tokyo 1568506, Japan.
EM ikeda-kz@igakuken.or.jp
RI Ide, Soichiro/D-5472-2012; Minami, Masabumi/A-3883-2012; Ikeda,
Kazutaka/I-4694-2013
OI Minami, Masabumi/0000-0002-0144-0679; Ikeda,
Kazutaka/0000-0001-8342-0278
FU Japanese Ministry of Education, Culture, Sports, Science, and Technology
[21600018]; Japanese Ministry of Health, Labour and Welfare; National
Institutes of Health
FX This study was supported by research grants from the Japanese Ministry
of Education, Culture, Sports, Science, and Technology, a Grant-in-Aid
for Scientific Research (C) (21600018), the Japanese Ministry of Health,
Labour and Welfare, and the National Institute on Drug Abuse Intramural
Research Program from the National Institutes of Health. We thank Drs.
Yoko Hagino, Yukio Takamatsu, and Keiko Matsuoka for technical support
and animal care.
NR 37
TC 10
Z9 10
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1744-8069
J9 MOL PAIN
JI Mol. Pain
PD APR 10
PY 2011
VL 7
AR 23
DI 10.1186/1744-8069-7-23
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 762AK
UT WOS:000290444400001
PM 21477373
ER
PT J
AU Jaffe, ES
AF Jaffe, Elaine S.
TI Centralized Review Offers Promise for the Clinician, the Pathologist,
and the Patient With Newly Diagnosed Lymphoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
C1 NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Jaffe, ES (reprint author), NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
OI Jaffe, Elaine/0000-0003-4632-0301
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR 10
PY 2011
VL 29
IS 11
BP 1398
EP 1398
DI 10.1200/JCO.2010.34.2741
PG 1
WC Oncology
SC Oncology
GA 746VW
UT WOS:000289276900017
PM 21343557
ER
PT J
AU Kino, T
Chrousos, GP
AF Kino, Tomoshige
Chrousos, George P.
TI Acetylation-mediated epigenetic regulation of glucocorticoid receptor
activity: Circadian rhythm-associated alterations of glucocorticoid
actions in target tissues
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article; Proceedings Paper
CT 14th Biennial Adrenal Cortex Conference (Adrenal 2010)
CY JUN 16-18, 2010
CL San Diego, CA
DE Acetylation; Circadian rhythm; Clock; Histone acetyltransferase (HAT);
Histone deacetylase (HDAC); Hypothalamic-pituitary-adrenal (HPA) axis;
Sirt1
ID PITUITARY-ADRENAL AXIS; ANDROGEN RECEPTOR; TRANSCRIPTIONAL ACTIVITY;
MINERALOCORTICOID RECEPTOR; DNA-BINDING; CLINICAL-IMPLICATIONS;
GENE-EXPRESSION; STRESS SYSTEM; MAP KINASE; P38 MAPK
AB Glucocorticoids influence organ functions through the glucocorticoid receptor, a protein acetylated and deacetylated by several histone acetyltransferases and deacetylases. We reported that the circadian rhythm-related transcription factor "Clock", a key component of the biological CLOCK with inherent histone acetyltransferase activity, acetylates glucocorticoid receptor lysines within its hinge region-a "lysine cluster" containing a KXKK motif-and represses its transcriptional activity. This Clock-induced repression of the glucocorticoid receptor activity is inversely phased to the diurnally circulating glucocorticoids and may act as a local counter regulatory mechanism to the actions of these hormones. Importantly, uncoupling of the central CLOCK-regulated hypothalamic-pituitary-adrenal axis and peripheral CLOCK-mediated alterations of glucocorticoid action, such as chronic stress and frequent trans-time zone travel or night-shift work, may cause functional hypercortisolism and contribute to various pathologies. Thus, acetylation-mediated epigenetic regulation of the glucocorticoid receptor may be essential for the maintenance of proper time-integrated glucocorticoid action, significantly influencing human well-being and longevity. Published by Elsevier Ireland Ltd.
C1 [Kino, Tomoshige] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Unit Mol Hormone Act, Program Reprod & Adult Endocrinol, NIH,CRC, Bethesda, MD 20892 USA.
[Chrousos, George P.] Univ Athens, Sch Med, Aghia Sophia Childrens Hosp, Dept Pediat 1, GR-11527 Athens, Greece.
RP Kino, T (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Unit Mol Hormone Act, Program Reprod & Adult Endocrinol, NIH,CRC, Bldg 10,Rm 1-3140,10 Ctr Dr,MSC 1109, Bethesda, MD 20892 USA.
EM kinot@mail.nih.gov
FU Intramural NIH HHS [ZIA HD008732-09]
NR 93
TC 25
Z9 25
U1 4
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD APR 10
PY 2011
VL 336
IS 1-2
SI SI
BP 23
EP 30
DI 10.1016/j.mce.2010.12.001
PG 8
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 748HN
UT WOS:000289381400005
PM 21146585
ER
PT J
AU Almeida, MQ
Stratakis, CA
AF Almeida, Madson Q.
Stratakis, Constantine A.
TI How does cAMP/protein kinase A signaling lead to tumors in the adrenal
cortex and other tissues?
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article; Proceedings Paper
CT 14th Biennial Adrenal Cortex Conference (Adrenal 2010)
CY JUN 16-18, 2010
CL San Diego, CA
DE Adrenal cortex; Protein kinase A; Primary pigmented nodular
adrenocortical disease; ACTH-independent macronodular adrenal
hyperplasia; Adrenal tumor; Phosphodiesterase; Wnt signaling
ID DEPENDENT PROTEIN-KINASE; SUBUNIT TYPE 1A; ADRENOCORTICAL DISEASE PPNAD;
MCCUNE-ALBRIGHT SYNDROME; REGULATORY SUBUNIT; CARNEY COMPLEX;
BETA-CATENIN; NEUROFIBROMATOSIS TYPE-1; GENETIC-HETEROGENEITY; MOLECULAR
ANALYSIS
AB The overwhelming majority of benign lesions of the adrenal cortex leading to Cushing syndrome are linked to one or another abnormality of the cAMP signaling pathway. A small number of both massive macronodular adrenocortical disease and cortisol-producing adenomas harbor somatic GNAS mutations. Micronodular adrenocortical hyperplasias are either pigmented (the classic form being that of primary pigmented nodular adrenocortical disease) or non-pigmented: micronodular adrenocortical hyperplasias can be seen in the context of other conditions or isolated; for example, primary pigmented nodular adrenocortical disease usually occurs in the context of Carney complex, but isolated primary pigmented nodular adrenocortical disease has also been described. Both Carney complex and isolated primary pigmented nodular adrenocortical disease are caused by germline PRKAR1A mutations; somatic mutations of this gene that regulates cAMP-dependent protein kinase are also found in cortisol-producing adenomas, and abnormalities of PKA are present in most cases of massive macronodular adrenocortical disease. Micronodular adrenocortical hyperplasias and some cortisol-producing adenomas are associated with phosphodiesterase 11A and 8B defects, coded, respectively, by the PDE11A and PDE8B genes. Mouse models of Prkar1a deficiency also show that increased cAMP signaling leads to tumors in adrenal cortex and other tissues. In this review, we summarize all recent data from ours and other laboratories, supporting the view that Wnt-signaling acts as an important mediator of tumorigenicity induced by abnormal PRKAR1A function and aberrant cAMP signaling. Published by Elsevier Ireland Ltd.
C1 [Stratakis, Constantine A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, SEGEN, PDEGEN, NIH,CRC, Bethesda, MD 20892 USA.
[Stratakis, Constantine A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Endocrinol Interinst Training Program, NIH, Bethesda, MD 20892 USA.
RP Stratakis, CA (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, SEGEN, PDEGEN, NIH,CRC, Bldg 10,Room 1-3330,10 Ctr Dr,MSC1103, Bethesda, MD 20892 USA.
EM stratakc@mail.nih.gov
FU Intramural NIH HHS [ZIA HD000642-13]
NR 72
TC 31
Z9 32
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD APR 10
PY 2011
VL 336
IS 1-2
SI SI
BP 162
EP 168
DI 10.1016/j.mce.2010.11.018
PG 7
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 748HN
UT WOS:000289381400024
PM 21111774
ER
PT J
AU Fink-Jensen, A
Schmidt, LS
Dencker, D
Schulein, C
Wess, J
Wortwein, G
Woldbye, DPD
AF Fink-Jensen, Anders
Schmidt, Lene S.
Dencker, Ditte
Schulein, Christina
Wess, Jurgen
Wortwein, Gitta
Woldbye, David P. D.
TI Antipsychotic-induced catalepsy is attenuated in mice lacking the M-4
muscarinic acetylcholine receptor
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Muscarinic M-4 receptor; Catalepsy; Haloperidol; Risperidone; Dopamine;
Scopolamine; Motoric side effects
ID RAT STRIATAL NEURONS; D2 DOPAMINE; KNOCKOUT MICE; CHOLINERGIC NEURONS;
MESSENGER-RNAS; EXPRESSION; D1; PROTEINS; SUBTYPE; DRUGS
AB A delicate balance exists between the central dopaminergic and cholinergic neurotransmitter systems with respect to motor function. An imbalance can result in motor dysfunction as observed in Parkinson's disease patients and in patients treated with antipsychotic compounds. Cholinergic receptor antagonists can alleviate extrapyramidal symptoms in Parkinson's disease and motor side effects induced by antipsychotics. The effects of anticholinergics are mediated by muscarinic receptors of which five subtypes (M-1-M-5) exist. Muscarinic M-4 receptors are found at high concentrations in motor parts of the striatum, suggesting a role for muscarinic M-4 receptors in the motor side effects of antipsychotics, and in the alleviation of these side effects by anticholinergics. Here we investigated the potential role of the muscarinic M-4 receptor in catalepsy induced by antipsychotics (haloperidol and risperidone) as well as the anti-cataleptic effects of the non-selective anticholinergic drug scopolamine in fully backcrossed muscarinic M-4 receptor knockout mice. The drug-induced catalepsy was strongly attenuated, but not abolished, in M-4 knockout mice as compared to wild-type controls. Scopolamine further attenuated the cataleptic response in M-4 knockout mice, suggesting that non-M-4 muscarinic receptors also participate in the anti-cataleptic effects. In conclusion, these data indicate an important role for M-4 receptors in antipsychotic-induced motor side effects and suggest that M-4 receptors could be a target for future pharmacological treatment of antipsychotic-induced as well as idiopathic parkinsonism. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Fink-Jensen, Anders; Schmidt, Lene S.; Dencker, Ditte; Schulein, Christina; Wortwein, Gitta; Woldbye, David P. D.] Rigshosp Univ Hosp, Lab Neuropsychiat, Copenhagen, Denmark.
[Fink-Jensen, Anders] Univ Hosp Copenhagen, Psychiat Ctr Copenhagen, Copenhagen, Denmark.
[Wess, Jurgen] NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bethesda, MD USA.
[Wortwein, Gitta] Univ Copenhagen, Dept Publ Hlth, DK-2100 Copenhagen, Denmark.
[Woldbye, David P. D.] Univ Copenhagen, Dept Neurosci & Pharmacol, DK-2100 Copenhagen, Denmark.
RP Fink-Jensen, A (reprint author), Univ Copenhagen, Lab Neuropsychiat, Psychiat Ctr Copenhagen, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.
EM a.fink-jensen@dadlnet.dk
OI Wortwein, Gitta/0000-0001-6981-7885
FU Ivan Nielsen Foundation; 7 Lundbeck Foundation
FX This work was supported by grants from the Ivan Nielsen Foundation and
the 7 Lundbeck Foundation.
NR 35
TC 15
Z9 16
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD APR 10
PY 2011
VL 656
IS 1-3
BP 39
EP 44
DI 10.1016/j.ejphar.2011.01.018
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 742IO
UT WOS:000288935600007
PM 21269601
ER
PT J
AU Yoo, SH
Park, O
Henderson, LE
Abdelmegeed, MA
Moon, KH
Song, BJ
AF Yoo, Seong Ho
Park, Ogyi
Henderson, Lauren E.
Abdelmegeed, Mohamed A.
Moon, Kwan-Hoon
Song, Byoung-Joon
TI Lack of PPAR alpha exacerbates lipopolysaccharide-induced liver toxicity
through STAT1 inflammatory signaling and increased oxidative/nitrosative
stress
SO TOXICOLOGY LETTERS
LA English
DT Article
DE PPAR alpha; Lipopolysaccharide; Acute liver damage; Cytokines; STAT;
Oxidative/nitrosative stress
ID ACTIVATED RECEPTOR-GAMMA; OXIDATIVE STRESS; IFN-GAMMA; KAPPA-B; INJURY;
LIGANDS; APOPTOSIS; TRANSCRIPTION; DYSFUNCTION; METABOLISM
AB Peroxisome proliferator-activated receptor-alpha (PPAR alpha) has been implicated in a potent anti-inflammatory activity. However, no information is available on whether PPAR alpha can affect signal transducers and activator of transcription proteins (STATs) in acute liver damage. Thus, this study was aimed to investigate the in vivo role of PPAR alpha in elevating STATs as well as oxidative/nitrosative stress in a model of lipopolysaccharide (LPS)-induced acute hepatic inflammatory injury. Using age-matched Ppara-null and wild-type (WT) mice, we demonstrate that the deletion of PPAR alpha aggravates LPS-mediated liver injury through activating STAT1 and NF-KB-p65 accompanied by increased levels of pro-inflammatory cytokines. Furthermore, the activities of key anti-oxidant enzymes and mitochondrial complexes were significantly decreased while lipid peroxidation and protein nitration were elevated in LPS-exposed Ppara-null mice compared to WT. These results indicate that PPAR alpha is important in preventing LPS-induced acute liver damage by regulating STAT1 inflammatory signaling pathways and oxidative/nitrosative stress. Published by Elsevier Ireland Ltd.
C1 [Yoo, Seong Ho; Henderson, Lauren E.; Abdelmegeed, Mohamed A.; Moon, Kwan-Hoon; Song, Byoung-Joon] NIAAA, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD 20892 USA.
[Park, Ogyi] NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA.
[Yoo, Seong Ho] Seoul Natl Univ, Coll Med, Dept Forens Med, Seoul, South Korea.
[Yoo, Seong Ho] Seoul Natl Univ, Coll Med, Inst Forens Med, Seoul, South Korea.
RP Song, BJ (reprint author), NIAAA, Lab Membrane Biochem & Biophys, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM bj.song@nih.gov
RI Yoo, Sung Ho/J-5549-2012
FU National Institute on Alcohol Abuse and Alcoholism
FX This study was supported by the Intramural Research Fund of National
Institute on Alcohol Abuse and Alcoholism.
NR 31
TC 10
Z9 14
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0378-4274
J9 TOXICOL LETT
JI Toxicol. Lett.
PD APR 10
PY 2011
VL 202
IS 1
BP 23
EP 29
DI 10.1016/j.toxlet.2011.01.013
PG 7
WC Toxicology
SC Toxicology
GA 742HO
UT WOS:000288932400004
PM 21262334
ER
PT J
AU Wolfe, CL
Moss, B
AF Wolfe, Cindy L.
Moss, Bernard
TI Interaction between the G3 and L5 proteins of the vaccinia virus
entry-fusion complex
SO VIROLOGY
LA English
DT Article
DE Poxvirus; Protein interactions; Multisubunit complex;
Immunopurification; Mass spectrometry
ID VIRION MEMBRANE-PROTEIN; SURFACE HEPARAN-SULFATE; CELL-CELL FUSION;
MATURE VIRION; ESSENTIAL COMPONENT; POXVIRUS ENTRY; L1 PROTEIN; BINDS;
GENE; ENCODES
AB The vaccinia virus entry-fusion complex (EFC) consists of 10 to 12 proteins that are embedded in the viral membrane and individually required for fusion with the cell and entry of the core into the cytoplasm. The architecture of the EFC is unknown except for information regarding two pair-wise interactions: A28 with H2 and A16 with G9. Here we used a technique to destabilize the EFC by repressing the expression of individual components and identified a third pair-wise interaction: G3 with L5. These two proteins remained associated under several different EFC destabilization conditions and in each case were immunopurified together as demonstrated by Western blotting. Further evidence for the specific interaction of G3 and L5 was obtained by mass spectrometry. This interaction also occurred when G3 and L5 were expressed in uninfected cells, indicating that no other viral proteins were required. Thus, the present study extends our knowledge of the protein interactions important for EFC assembly and stability. Published by Elsevier Inc.
C1 [Wolfe, Cindy L.; Moss, Bernard] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
RP Moss, B (reprint author), NIAID, Viral Dis Lab, NIH, 33 North Dr, Bethesda, MD 20892 USA.
EM bmoss@nih.gov
FU Division of Intramural Research, NIAID, NIH
FX We thank Catherine Cotter for providing cells and other members of the
Laboratory of Viral Diseases for helpful discussions. The research was
supported by the Division of Intramural Research, NIAID, NIH.
NR 25
TC 8
Z9 12
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD APR 10
PY 2011
VL 412
IS 2
BP 278
EP 283
DI 10.1016/j.virol.2011.01.014
PG 6
WC Virology
SC Virology
GA 740DZ
UT WOS:000288773100004
PM 21295816
ER
PT J
AU Singer, M
Winocour, E
AF Singer, Maxine
Winocour, Ernest
TI SV40 host-substituted variants: a new look at the monkey DNA inserts and
recombinant junctions
SO VIROLOGY
LA English
DT Article
DE SV40 host-substituted variants; Microhomology-mediated end joining;
Monkey genome
ID SIMIAN-VIRUS 40; DEOXYRIBONUCLEIC ACID REPLICATION; VIABLE DELETION
MUTANTS; DOUBLE-STRAND BREAKS; CVP8-1-P2 ECORI RES; T-ANTIGEN;
VIRAL-DNA; ILLEGITIMATE RECOMBINATION; VIRUS-40-INFECTED CELLS;
EVOLUTIONARY VARIANTS
AB The available monkey genomic data banks were examined in order to determine the chromosomal locations of the host DNA inserts in 8 host-substituted SV40 variant DNAs. Five of the 8 variants contained more than one linked monkey DNA insert per tandem repeat unit and in all cases but one, the 19 monkey DNA inserts in the 8 variants mapped to different locations in the monkey genome. The 50 parental DNAs (32 monkey and 18 SV40 DNA segments) which spanned the crossover and flanking regions that participated in monkey/monkey and monkey/SV40 recombinations were characterized by substantial levels of microhomology of up to 8 nucleotides in length; the parental DNAs also exhibited direct and inverted repeats at or adjacent to the crossover sequences. We discuss how the host-substituted SV40 variants arose and the nature of the recombination mechanisms involved. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Singer, Maxine] Carnegie Inst Sci, Washington, DC 20005 USA.
[Singer, Maxine] NCI, Lab Biochem & Mol Biol, Bethesda, MD 20892 USA.
[Winocour, Ernest] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.
RP Singer, M (reprint author), Carnegie Inst Sci, 1530 P St NW, Washington, DC 20005 USA.
EM msinger@ciw.edu; ernest.winocour@weizmann.ac.il
NR 68
TC 1
Z9 1
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD APR 10
PY 2011
VL 412
IS 2
BP 325
EP 332
DI 10.1016/j.virol.2011.01.020
PG 8
WC Virology
SC Virology
GA 740DZ
UT WOS:000288773100009
PM 21316069
ER
PT J
AU Qi, L
Kash, JC
Dugan, VG
Jagger, BW
Lau, YF
Sheng, ZM
Crouch, EC
Hartshorn, KL
Taubenberger, JK
AF Qi, Li
Kash, John C.
Dugan, Vivien G.
Jagger, Brett W.
Lau, Yuk-Fai
Sheng, Zhong-Mei
Crouch, Erika C.
Hartshorn, Kevan L.
Taubenberger, Jeffery K.
TI The ability of pandemic influenza virus hemagglutinins to induce lower
respiratory pathology is associated with decreased surfactant protein D
binding
SO VIROLOGY
LA English
DT Article
DE Influenza A virus; Pandemic; Hemagglutinin; Pathology; Surfactant
Protein D; Mice
ID A VIRUSES; IN-VIVO; MORTALITY; INFECTION; IMMUNE; CELLS; SPECIFICITY;
CLEARANCE; RECEPTORS; EVOLUTION
AB Pandemic influenza viral infections have been associated with viral pneumonia. Chimeric influenza viruses with the hemagglutinin segment of the 1918, 1957, 1968, or 2009 pandemic influenza viruses in the context of a seasonal H1N1 influenza genome were constructed to analyze the role of hemagglutinin (HA) in pathogenesis and cell tropism in a mouse model. We also explored whether there was an association between the ability of lung surfactant protein D (SP-D) to bind to the HA and the ability of the corresponding chimeric virus to infect bronchiolar and alveolar epithelial cells of the lower respiratory tract. Viruses expressing the hemagglutinin of pandemic viruses were associated with significant pathology in the lower respiratory tract, including acute inflammation, and showed low binding activity for SP-D. In contrast, the virus expressing the HA of a seasonal influenza strain induced only mild disease with little lung pathology in infected mice and exhibited strong in vitro binding to SP-D. Published by Elsevier Inc.
C1 [Qi, Li; Kash, John C.; Dugan, Vivien G.; Jagger, Brett W.; Sheng, Zhong-Mei; Taubenberger, Jeffery K.] NIAID, Viral Pathogenesis & Evolut Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
[Lau, Yuk-Fai] NIAID, Emerging Resp Viruses Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
[Crouch, Erika C.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
[Hartshorn, Kevan L.] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Taubenberger, JK (reprint author), NIAID, Viral Pathogenesis & Evolut Sect, Infect Dis Lab, NIH, 33 N Dr,MSC 3203, Bethesda, MD 20892 USA.
EM taubenbergerj@niaid.nih.gov
OI Hartshorn, Kevan/0000-0002-7196-7433
FU NIH; NIAID
FX We thank Christian Sauder (CBER/FDA, Bethesda) for helpful discussions.
We are grateful for the help provided by the staff of the NIH Building
33 Animal Facility (NIAID/CMB). This work was supported by the
Intramural Research Program of the NIH and the NIAID.
NR 58
TC 38
Z9 38
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD APR 10
PY 2011
VL 412
IS 2
BP 426
EP 434
DI 10.1016/j.virol.2011.01.029
PG 9
WC Virology
SC Virology
GA 740DZ
UT WOS:000288773100020
PM 21334038
ER
PT J
AU Dobbin, KK
Simon, RM
AF Dobbin, Kevin K.
Simon, Richard M.
TI Optimally splitting cases for training and testing high dimensional
classifiers
SO BMC MEDICAL GENOMICS
LA English
DT Article
ID DNA MICROARRAY DATA; CLASS PREDICTION; EXPRESSION; CLASSIFICATION;
CANCER; SURVIVAL
AB Background: We consider the problem of designing a study to develop a predictive classifier from high dimensional data. A common study design is to split the sample into a training set and an independent test set, where the former is used to develop the classifier and the latter to evaluate its performance. In this paper we address the question of what proportion of the samples should be devoted to the training set. How does this proportion impact the mean squared error (MSE) of the prediction accuracy estimate?
Results: We develop a non-parametric algorithm for determining an optimal splitting proportion that can be applied with a specific dataset and classifier algorithm. We also perform a broad simulation study for the purpose of better understanding the factors that determine the best split proportions and to evaluate commonly used splitting strategies (1/2 training or 2/3 training) under a wide variety of conditions. These methods are based on a decomposition of the MSE into three intuitive component parts.
Conclusions: By applying these approaches to a number of synthetic and real microarray datasets we show that for linear classifiers the optimal proportion depends on the overall number of samples available and the degree of differential expression between the classes. The optimal proportion was found to depend on the full dataset size (n) and classification accuracy - with higher accuracy and smaller n resulting in more assigned to the training set. The commonly used strategy of allocating 2/3rd of cases for training was close to optimal for reasonable sized datasets (n >= 100) with strong signals (i.e. 85% or greater full dataset accuracy). In general, we recommend use of our nonparametric resampling approach for determing the optimal split. This approach can be applied to any dataset, using any predictor development method, to determine the best split.
C1 [Dobbin, Kevin K.] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA.
[Simon, Richard M.] NCI, Biometr Res Branch, NIH, Rockville, MD USA.
RP Dobbin, KK (reprint author), Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA.
EM dobbinke@uga.edu
FU Distinguished Cancer Clinicians and Scientists Program of the Georgia
Cancer Coalition
FX Kevin K. Dobbin's work was partially supported by the Distinguished
Cancer Clinicians and Scientists Program of the Georgia Cancer
Coalition.
NR 22
TC 15
Z9 15
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD APR 8
PY 2011
VL 4
AR 31
DI 10.1186/1755-8794-4-31
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 761XW
UT WOS:000290437300001
PM 21477282
ER
PT J
AU Parvez, MK
Purcell, RH
Emerson, SU
AF Parvez, Mohammad K.
Purcell, Robert H.
Emerson, Suzanne U.
TI Hepatitis E virus ORF2 protein over-expressed by baculovirus in hepatoma
cells, efficiently encapsidates and transmits the viral RNA to naive
cells
SO VIROLOGY JOURNAL
LA English
DT Article
ID CAPSID PROTEIN; INSECT CELLS; IN-VITRO; RECOMBINANT; PATHOGENESIS;
REPLICATION; RELEASE; CULTURE; HEV
AB A recombinant baculovirus(vBacORF2) that expressed the full-length ORF2 capsid protein of a genotype 1 strain of hepatitis E virus(HEV) was constructed. Transduction of S10-3 human hepatoma cells with this baculovirus led to large amounts of ORF2 protein production in similar to 50% of the cells as determined by immune fluorescence microscopy. The majority of the ORF2 protein detected by Western blot was 72 kDa, the size expected for the full-length protein. To determine if the exogenously-supplied ORF2 protein could transencapsidate viral genomes, S10-3 cell cultures that had been transfected the previous day with an HEV replicon of genotype 1 that contained the gene for green fluorescent protein(GFP), in place of that for ORF2 protein, were transduced with the vBacORF2 virus. Cell lysates were prepared 5 days later and tested for the ability to deliver the GFP gene to HepG2/C3A cells, another human hepatoma cell line. FACS analysis indicated that lysates from cell cultures receiving only the GFP replicon were incapable of introducing the replicon into the HepG2/C3A cells whereas similar to 2% of the HepG2/C3A cells that received lysate from cultures that had received both the replicon and the baculovirus produced GFP. Therefore, the baculovirus-expressed ORF2 protein was able to trans encapsidate the viral replicon and form a particle that could infect naive HepG2/C3A cells. This ex vivo RNA packaging system should be useful for studying many aspects of HEV molecular biology.
C1 [Parvez, Mohammad K.; Emerson, Suzanne U.] NIAID, Mol Hepatitis Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
[Purcell, Robert H.] NIAID, Hepatitis Viruses Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
[Parvez, Mohammad K.] King Saud Univ, Coll Pharm, Dept Pharmacognosy, Riyadh, Saudi Arabia.
RP Emerson, SU (reprint author), NIAID, Mol Hepatitis Sect, Infect Dis Lab, NIH, 50 South Dr, Bethesda, MD 20892 USA.
EM semerson@niaid.nih.gov
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health, USA
FX This work was supported by the Intramural Research Program of the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, USA. The technical support of Kristina Faulk in
flow cytometry and Danielle Burke in Western blot is acknowledged.
NR 21
TC 8
Z9 11
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD APR 8
PY 2011
VL 8
AR 159
DI 10.1186/1743-422X-8-159
PG 6
WC Virology
SC Virology
GA 755QP
UT WOS:000289951400001
PM 21477278
ER
PT J
AU Ghaedi, M
Tuleuova, N
Zern, MA
Wu, J
Revzin, A
AF Ghaedi, Mahboobe
Tuleuova, Nazgul
Zern, Mark A.
Wu, Jian
Revzin, Alexander
TI Bottom-up signaling from HGF-containing surfaces promotes hepatic
differentiation of mesenchymal stem cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Growth factor immobilization; Extracellular matrix; Hepatic
differentiation; Mesenchymal stem cells; Protein microarrays
ID HEPATOCYTE GROWTH-FACTOR; LIVER EPITHELIAL-CELLS; IN-VITRO; PRINTED
ARRAYS; TRANSPLANTATION; MATRIX; CULTURE; TYPE-1
AB The capacity of stem cells to differentiate into specific cell types makes them very promising in tissue regeneration and repair. However, realizing this promise requires novel methods for guiding lineage-specific differentiation of stem cells. In this study, hepatocyte growth factor (HGF), an important morphogen in liver development, was co-printed with collagen I (Col) to create arrays of protein spots on glass. Human adipose stem cells (ASCs) were cultured on top of the HGF/Col spots for 2 weeks. The effects of surface-immobilized HGF on hepatic differentiation of ASCs were analyzed using RT-PCR, ELISA and immunocytochemistry. Stimulation of stem cells with HGF from the bottom-up caused an upregulation in synthesis of alpha-fetoprotein and albumin, as determined by immunocytochemistry and ELISA. RT-PCR results showed that the mRNA levels for albumin, alpha-fetoprotein and alpha 1-antitrypsin were 10- to 20-fold higher in stem cells cultured on the HGF/Col arrays compared to stem cells on Col only spots. Our results show that surfaces containing HGF co-printed with ECM proteins may be used to differentiate mesenchymal stem cells such as ASCs into hepatocyte-like cells. These results underscore the utility of growth factor-containing culture surfaces for stem cell differentiation. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Ghaedi, Mahboobe; Tuleuova, Nazgul; Revzin, Alexander] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
[Zern, Mark A.; Wu, Jian] Univ Calif Davis, Med Ctr, Dept Med, Transplant Res Program, Sacramento, CA 95817 USA.
[Ghaedi, Mahboobe] NIGEB, Tehran, Iran.
[Tuleuova, Nazgul] Natl Biotechnol Ctr, Astana, Kazakhstan.
RP Revzin, A (reprint author), Univ Calif Davis, Dept Biomed Engn, 451 Hlth Sci,Dr 2519, Davis, CA 95616 USA.
EM arevzin@ucdavis.edu
FU NIH [R01DK079977]
FX We thank Prof. Jan Nolta for providing stem cells used in our
experiments. We gratefully acknowledge Drs. Yuyu Duan and Ji Youn Lee
for technical assistance. This work was supported by an NIH grant
(R01DK079977) awarded to A.R.
NR 36
TC 20
Z9 21
U1 1
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 8
PY 2011
VL 407
IS 2
BP 295
EP 300
DI 10.1016/j.bbrc.2011.03.005
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 753DU
UT WOS:000289746700005
PM 21382341
ER
PT J
AU Goessling, W
Allen, RS
Guan, X
Jin, P
Uchida, N
Dovey, M
Harris, JM
Metzger, ME
Bonifacino, AC
Stroncek, D
Stegner, J
Armant, M
Schlaeger, T
Tisdale, JF
Zon, LI
Donahue, RE
North, TE
AF Goessling, Wolfram
Allen, Robyn S.
Guan, Xiao
Jin, Ping
Uchida, Naoya
Dovey, Michael
Harris, James M.
Metzger, Mark E.
Bonifacino, Aylin C.
Stroncek, David
Stegner, Joseph
Armant, Myriam
Schlaeger, Thorsten
Tisdale, John F.
Zon, Leonard I.
Donahue, Robert E.
North, Trista E.
TI Prostaglandin E2 Enhances Human Cord Blood Stem Cell Xenotransplants and
Shows Long-Term Safety in Preclinical Nonhuman Primate Transplant Models
SO CELL STEM CELL
LA English
DT Article
ID BONE-MARROW; PROGENITOR CELLS; EXPANSION; MOBILIZATION; REPOPULATION;
ENGRAFTMENT; RECEPTOR; DONORS
AB Hematopoietic stem cells (HSCs) are used in transplantation therapy to reconstitute the hematopoietic system. Human cord blood (hCB) transplantation has emerged as an attractive alternative treatment option when traditional HSC sources are unavailable; however, the absolute number of hCB HSCE.; transplanted is significantly lower than bone marrow or mobilized peripheral blood stem cells (MPBSCs). We previously demonstrated that dimethyl-prostaglandin E2 (dmPGE2), increased HSCs in vertebrate models. Here, we describe preclinical analyses of the therapeutic potential of dmPGE2 treatment by using human and nonhuman primate HSCs. dmPGE2 significantly increased total human hematopoietic colony formation in vitro and enhanced engraftment of unfractionated and CD34(+) hCB after xenotransplantation. In nonhuman primate autologous transplantation, dmPGE2-treated CD34(+) MPBSCs showed stable multilineage engraftment over 1 year postinfusion. Together, our analyses indicated that dmPGE2 mediates conserved responses in HSCs from human and nonhuman primates and provided sufficient preclinical information to support proceeding to an FDA-approved phase 1 clinical trial.
C1 [Goessling, Wolfram; Zon, Leonard I.; North, Trista E.] Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Goessling, Wolfram; Zon, Leonard I.; North, Trista E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Goessling, Wolfram] Brigham & Womens Hosp, Dana Farber Canc Inst, Gastrointestinal Canc Ctr, Div Genet, Boston, MA 02115 USA.
[Goessling, Wolfram] Brigham & Womens Hosp, Dana Farber Canc Inst, Gastrointestinal Canc Ctr, Div Gastroenterol, Boston, MA 02115 USA.
[Allen, Robyn S.; Metzger, Mark E.; Bonifacino, Aylin C.; Donahue, Robert E.] NHLBI, Hematol Branch, NIH, Rockville, MD 20850 USA.
[Guan, Xiao; Schlaeger, Thorsten; Zon, Leonard I.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA.
[Jin, Ping; Stroncek, David] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.
[Uchida, Naoya; Tisdale, John F.] NIDDK, Mol & Clin Hematol Branch, NHLBI, NIH, Bethesda, MD 20892 USA.
[Dovey, Michael; Harris, James M.; North, Trista E.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA.
[Stegner, Joseph; Armant, Myriam] Immune Dis Inst, Ctr Human Cell Therapy, Boston, MA 02115 USA.
[Zon, Leonard I.] Howard Hughes Med Inst, Boston, MA 02115 USA.
RP North, TE (reprint author), Harvard Stem Cell Inst, Boston, MA 02115 USA.
EM tnorth@bidmc.harvard.edu
RI Guan, Xiao/D-5656-2013;
OI Goessling, Wolfram/0000-0001-9972-1569
FU Harvard Stern Cell Institute; NIH NIDDK; Howard Hughes Medical
Institute; National Institutes of Health, NHLBI; NIDDK; Department of
Transfusion Medicine at the NIH Clinical Center; FATE Therapeutics
FX The HMS researchers thank J. Trowbridge, C. Walkley, G.O. Daley J. Ritz,
L. Silberstein, G. Kao, J. Antin, R. Soiffer, K. Ballen, C. Cutler, and
the members of the Center for Human Cell Therapy at Harvard Medical
School, Dana-Farber Cancer Institute for helpful discussions and
guidance on the clinical application of dmPGE2 and the FDA application
process. We are grateful to the Carolinas Cord Blood Bank for providing
us with discarded cord blood units. The NIH researchers thank K.
Keyvanfar for cell-sorting assistance, Y. Tian for assisting with the
processing of the microarray data, and the veterinary and animal care
staff at 5 Research Court and Poolesville for maintaining the nonhuman
primates used in this study. This research was supported by the Harvard
Stern Cell Institute (VV.G., LIZ., T.E.N.), NIH NIDDK (W.G., LIZ.,
TEN.), Howard Hughes Medical Institute (LIZ.), the Intramural Research
Program of the National Institutes of Health, NHLBI, and/or NIDDK
(R.S.A., N.U., M.E.M., A.C.B., J.F.T., RED.), and the Department of
Transfusion Medicine at the NIH Clinical Center (P.J., D.S.). T.E.N. and
W.G. receive patent royalties and consulting fees from FATE
Therapeutics; L.I.Z. is a scientific founder and stockholder of and
receives patent royalties from FATE Therapeutics, which is currently
testing the use of prostaglandin E2 to enhance the efficacy of hCB
transplants in an independently conducted phase I clinical trial.
NR 32
TC 124
Z9 128
U1 0
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD APR 8
PY 2011
VL 8
IS 4
BP 445
EP 458
DI 10.1016/j.stem.2011.02.003
PG 14
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 752QI
UT WOS:000289707100016
PM 21474107
ER
PT J
AU Liu, YT
Munro, D
Layfield, D
Dellinger, A
Walter, J
Peterson, K
Rickman, CB
Allingham, RR
Hauser, MA
AF Liu, Yutao
Munro, Drew
Layfield, David
Dellinger, Andrew
Walter, Jeffrey
Peterson, Katherine
Rickman, Catherine Bowes
Allingham, R. Rand
Hauser, Michael A.
TI Serial analysis of gene expression (SAGE) in normal human trabecular
meshwork
SO MOLECULAR VISION
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; GENOMIC CONVERGENCE; MICROARRAY ANALYSIS; CANDIDATE
GENES; CELLS; IDENTIFICATION; DEXAMETHASONE; DISEASE; PROFILE;
TRANSCRIPTOME
AB Purpose: To identify the genes expressed in normal human trabecular meshwork tissue, a tissue critical to the pathogenesis of glaucoma.
Methods: Total RNA was extracted from human trabecular meshwork (HTM) harvested from 3 different donors. Extracted RNA was used to synthesize individual SAGE (serial analysis of gene expression) libraries using the I-SAGE Long kit from Invitrogen. Libraries were analyzed using SAGE 2000 software to extract the 17 base pair sequence tags. The extracted sequence tags were mapped to the genome using SAGE Genie map.
Results: A total of 298,834 SAGE tags were identified from all HTM libraries (96,842, 88,126, and 113,866 tags, respectively). Collectively, there were 107,325 unique tags. There were 10,329 unique tags with a minimum of 2 counts from a single library. These tags were mapped to known unique Unigene clusters. Approximately 29% of the tags (orphan tags) did not map to a known Unigene cluster. Thirteen percent of the tags mapped to at least 2 Unigene clusters. Sequence tags from many glaucoma-related genes, including myocilin, optineurin, and WD repeat domain 36, were identified.
Conclusions: This is the first time SAGE analysis has been used to characterize the gene expression profile in normal HTM. SAGE analysis provides an unbiased sampling of gene expression of the target tissue. These data will provide new and valuable information to improve understanding of the biology of human aqueous outflow.
C1 [Liu, Yutao; Layfield, David; Dellinger, Andrew; Walter, Jeffrey; Hauser, Michael A.] Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC USA.
[Munro, Drew; Rickman, Catherine Bowes; Allingham, R. Rand; Hauser, Michael A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
[Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
[Peterson, Katherine] NEI, Sect Mol Struct & Funct Genom, NIH, Bethesda, MD 20892 USA.
RP Hauser, MA (reprint author), 905 S LaSalle St,DUMC Box 3445, Durham, NC 27710 USA.
EM mike.hauser@duke.edu
FU NIH [R01EY013315, R01EY019126, R01EY015543, R01 EY019038, P30 EY005722];
Ruth and Milton Steinbach Fund; Macular Vision Research Foundation;
NCRR/NIH [1 UL1 RR024128-01]
FX We thank the study participants that make this work possible. We thank
Dr. Graeme Wistow for displaying our SAGE data through the NEIBank
genome browser. This research was supported by NIH grants R01EY013315
(M.A.H.), R01EY019126 (M.A.H.), R01EY015543 (R.R.A.), R01 EY019038
(C.B.R.), P30 EY005722 (Duke Eye Center), the Ruth and Milton Steinbach
Fund (C.B.R.), and the Macular Vision Research Foundation (C.B.R.). This
research was also supported in part by Duke University's CTSA grant 1
UL1 RR024128-01 from NCRR/NIH, as well as the research infrastructure of
the Duke Center for Human Genetics.
NR 45
TC 8
Z9 8
U1 1
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 8
PY 2011
VL 17
IS 98-100
BP 885
EP 893
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
SC Biochemistry & Molecular Biology; Ophthalmology
GA 749AN
UT WOS:000289434600002
PM 21528004
ER
PT J
AU Burns, KA
Li, Y
Arao, Y
Petrovich, RM
Korach, KS
AF Burns, Katherine A.
Li, Yin
Arao, Yukitomo
Petrovich, Robert M.
Korach, Kenneth S.
TI Selective Mutations in Estrogen Receptor alpha D-domain Alters Nuclear
Translocation and Non-estrogen Response Element Gene Regulatory
Mechanisms
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DEOXYRIBONUCLEIC-ACID-BINDING; BREAST-CANCER CELLS; ER-ALPHA; HINGE
REGION; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID-RECEPTOR; IN-VIVO;
LYSINE METHYLATION; PLASMA-MEMBRANE; EXPORT SIGNALS
AB The three main mechanisms of ER alpha action are: 1) nuclear, genomic, direct DNA binding, 2) nuclear, genomic, "tethered"-mediated, protein-protein interactions, and 3) non-nuclear, non-genomic, rapid action responses. Reports suggest the D-domain or hinge region of ER alpha plays an important role in mechanisms 1 and 2 above. Studies demonstrating the functionality of the ER alpha hinge region have resected the full D-domain; therefore, site directed mutations were made to attribute precise sequence functionality to this domain. This study focuses on the characterization and properties of three novel site directed ER alpha-D-domain mutants. The Hinge 1 (H1) ER alpha mutant has disrupted nuclear localization, can no longer perform tethered mediated responses and has lost interaction with c-Jun, but retains estrogen response element (ERE)-mediated functions as demonstrated by confocal microscopy, reporter assays, endogenous gene expression and co-immunoprecipitation. The H2 ER alpha mutant is non-nuclear, but translocates to the nucleus with estradiol (E-2) treatment and maintains ERE-mediated functionality. The H2 + NES ER alpha mutant does not maintain nuclear translocation with hormone binding, no longer activates ERE-target genes, functions in ERE-or tethered-mediated luciferase assays, but does retain the non-genomic, non-nuclear, rapid action response. These studies reveal the sequence(s) in the ER alpha hinge region that are involved in tethered-mediated actions as well as nuclear localization and attribute important functionality to this region of the receptor. In addition, the properties of these ER alpha mutants will allow future studies to further dissect and characterize the three main ER alpha mechanisms of action and determine the mechanistic role each action has in estrogen hormone regulation.
C1 [Burns, Katherine A.; Li, Yin; Arao, Yukitomo; Korach, Kenneth S.] Natl Inst Environm Hlth Sci, Lab Reprod & Dev Toxicol, NIH, Res Triangle Pk, NC 27709 USA.
[Petrovich, Robert M.] Natl Inst Environm Hlth Sci, Prot Express Core Facil, NIH, Res Triangle Pk, NC 27709 USA.
RP Korach, KS (reprint author), 111 TW Alexander Dr, Res Triangle Pk, NC 27790 USA.
EM Korach@niehs.nih.gov
OI Korach, Kenneth/0000-0002-7765-418X
FU National Institutes of Health [Z01ES70065, Z01ES102487-01]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants Z01ES70065 and Z01ES102487-01.
NR 56
TC 26
Z9 27
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 8
PY 2011
VL 286
IS 14
DI 10.1074/jbc.M110.187773
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 744EN
UT WOS:000289077500075
PM 21285458
ER
PT J
AU Hwang, JY
Huang, WW
Arnold, LA
Huang, RL
Attia, RR
Connelly, M
Wichterman, J
Zhu, FY
Augustinaite, I
Austin, CP
Inglese, J
Johnson, RL
Guy, RK
AF Hwang, Jong Yeon
Huang, Wenwei
Arnold, Leggy A.
Huang, Ruili
Attia, Ramy R.
Connelly, Michele
Wichterman, Jennifer
Zhu, Fangyi
Augustinaite, Indre
Austin, Christopher P.
Inglese, James
Johnson, Ronald L.
Guy, R. Kiplin
TI Methylsulfonylnitrobenzoates, a New Class of Irreversible Inhibitors of
the Interaction of the Thyroid Hormone Receptor and Its Obligate
Coactivators That Functionally Antagonizes Thyroid Hormone
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SMALL-MOLECULE INHIBITORS; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS;
LIGAND-BINDING; IN-VIVO; AMPHIBIAN METAMORPHOSIS; BIOLOGICAL EVALUATION;
HIGH-THROUGHPUT; DRUG DISCOVERY; ION CHANNELS
AB Thyroid hormone receptors (TRs) are members of the nuclear hormone receptor (NR) superfamily and regulate development, growth, and metabolism. Upon binding thyroid hormone, TR undergoes a conformational change that allows the release of corepressors and the recruitment of coactivators, which in turn regulate target gene transcription. Although a number of TR antagonists have been developed, most are analogs of the endogenous hormone that inhibit ligand binding. In a screen for inhibitors that block the association of TR beta with steroid receptor coactivator 2 (SRC2), we identified a novel methylsulfonylnitrobenzoate (MSNB)-containing series that blocks this interaction at micromolar concentrations. Here we have studied a series of MSNB analogs and characterized their structure activity relationships. MSNB members do not displace thyroid hormone T-3 but instead act by direct displacement of SRC2. MSNB series members are selective for the TR over the androgen, vitamin D, and PPAR gamma NR members, and they antagonize thyroid hormone-activated transcription action in cells. The methylsulfonylnitro group is essential for TR beta antagonism. Side-chain alkylamine substituents showed better inhibitory activity than arylamine substituents. Mass spectrum analysis suggested that MSNB inhibitors bind irreversibly to Cys-298 within the AF-2 cleft of TR beta to disrupt SRC2 association.
C1 [Hwang, Jong Yeon; Attia, Ramy R.; Connelly, Michele; Zhu, Fangyi; Augustinaite, Indre; Guy, R. Kiplin] St Jude Childrens Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA.
[Huang, Wenwei; Huang, Ruili; Wichterman, Jennifer; Austin, Christopher P.; Inglese, James; Johnson, Ronald L.] NHGRI, NIH Chem Genom Ctr, NIH, Bethesda, MD 20892 USA.
[Arnold, Leggy A.] Univ Wisconsin, Dept Chem & Biochem, Milwaukee, WI 53211 USA.
RP Guy, RK (reprint author), 262 Danny Thomas Pl,Mail Stop 1000, Memphis, TN 38105 USA.
EM kip.guy@stjude.org
RI Guy, Rodney/J-7107-2013
OI Guy, Rodney/0000-0002-9638-2060
FU National Institutes of Health [DK58080]; NIH Roadmap for Medical
Research; National Institutes of Health NHGRI; American Lebanese Syrian
Associated Charities (ALSAC); St. Jude Children's Research Hospital
(SJCRH)
FX This work was supported, in whole or in part, by National Institutes of
Health Grant DK58080, the NIH Roadmap for Medical Research, and the
National Institutes of Health NHGRI Intramural Research Program. This
work was also supported by the American Lebanese Syrian Associated
Charities (ALSAC) and the St. Jude Children's Research Hospital (SJCRH).
NR 78
TC 19
Z9 19
U1 2
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 8
PY 2011
VL 286
IS 14
DI 10.1074/jbc.M110.200436
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 744EN
UT WOS:000289077500003
PM 21321127
ER
PT J
AU Wu, YZ
Antony, S
Juhasz, A
Lu, JM
Ge, Y
Jiang, GJ
Roy, K
Doroshow, JH
AF Wu, Yongzhong
Antony, Smitha
Juhasz, Agnes
Lu, Jiamo
Ge, Yun
Jiang, Guojian
Roy, Krishnendu
Doroshow, James H.
TI Up-regulation and Sustained Activation of Stat1 Are Essential for
Interferon-gamma (IFN-gamma)-induced Dual Oxidase 2 (Duox2) and Dual
Oxidase A2 (DuoxA2) Expression in Human Pancreatic Cancer Cell Lines
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RESPIRATORY-TRACT EPITHELIUM; FAMILY NADPH OXIDASES; IFN-GAMMA; NOX
FAMILY; SER-727 PHOSPHORYLATION; TYROSINE PHOSPHATASES; DUCTAL
ADENOCARCINOMA; GENE-EXPRESSION; HOST-DEFENSE; TRANSCRIPTION
AB Dual oxidase 2 is a member of the NADPH oxidase (Nox) gene family that plays a critical role in the biosynthesis of thyroid hormone as well as in the inflammatory response of the upper airway mucosa and in wound healing, presumably through its ability to generate reactive oxygen species, including H2O2. The recently discovered overexpression of Duox2 in gastrointestinal malignancies, as well as our limited understanding of the regulation of Duox2 expression, led us to examine the effect of cytokines and growth factors on Duox2 in human tumor cells. We found that exposure of human pancreatic cancer cells to IFN-gamma (but not other agents) produced a profound up-regulation of the expression of Duox2, and its cognate maturation factor DuoxA2, but not other members of the Nox family. Furthermore, increased Duox2/DuoxA2 expression was closely associated with a significant increase in the production of both intracellular reactive oxygen species and extracellular H2O2. Examination of IFN-gamma-mediated signaling events demonstrated that in addition to the canonical Jak-Stat1 pathway, IFN-gamma activated the p38-MAPK pathway in pancreatic cancer cells, and both played an important role in the induction of Duox2 by IFN-gamma. Duox2 up-regulation following IFN-gamma exposure is also directly associated with the binding of Stat1 to elements of the Duox2 promoter. Our findings suggest that the pro-inflammatory cytokine IFN-gamma initiates a Duox2-mediated reactive oxygen cascade in human pancreatic cancer cells; reactive oxygen species production in this setting could contribute to the pathophysiologic characteristics of these tumors.
C1 [Wu, Yongzhong; Antony, Smitha; Juhasz, Agnes; Lu, Jiamo; Ge, Yun; Jiang, Guojian; Doroshow, James H.] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Roy, Krishnendu; Doroshow, James H.] NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA.
RP Doroshow, JH (reprint author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bldg 31,Rm 3A-44,31 Ctr Dr, Bethesda, MD 20892 USA.
EM doroshoj@mail.nih.gov
FU NCI, National Institutes of Health
FX This work was supported, in whole or in part, by a NCI, National
Institutes of Health, grant.
NR 53
TC 24
Z9 27
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 8
PY 2011
VL 286
IS 14
DI 10.1074/jbc.M110.191031
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 744EN
UT WOS:000289077500039
PM 21321110
ER
PT J
AU Zbidi, H
Jardin, I
Woodard, GE
Lopez, JJ
Berna-Erro, A
Salido, GM
Rosado, JA
AF Zbidi, Hanene
Jardin, Isaac
Woodard, Geoffrey E.
Lopez, Jose J.
Berna-Erro, Alejandro
Salido, Gines M.
Rosado, Juan A.
TI STIM1 and STIM2 Are Located in the Acidic Ca2+ Stores and Associates
with Orai1 upon Depletion of the Acidic Stores in Human Platelets
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ADENINE-DINUCLEOTIDE PHOSPHATE; VACUOLAR H+-ATPASES; CALCIUM-ENTRY; TRPC
CHANNELS; DIFFERENTIAL SENSITIVITY; OPERATED CHANNELS;
MEMBRANE-VESICLES; MAMMALIAN-CELLS; RELEASE; PROTEIN
AB Mammalian cells accumulate Ca2+ into agonist-sensitive acidic organelles, vesicles that possess a vacuolar proton-ATPase. Acidic Ca2+ stores include secretory granules and lysosome-related organelles. Current evidence clearly indicates that acidic Ca2+ stores participate in cell signaling and function, including the activation of store-operated Ca2+ entry in human platelets upon depletion of the acidic stores, although the mechanism underlying the activation of store-operated Ca2+ entry controlled by the acidic stores remains unclear. STIM1 has been presented as the endoplasmic reticulum Ca2+ sensor, but its role sensing intraluminal Ca2+ concentration in the acidic stores has not been investigated. Here we report that STIM1 and STIM2 are expressed in the lysosome-related organelles and dense granules in human platelets isolated by immunomagnetic sorting. Depletion of the acidic Ca2+ stores using the specific vacuolar proton-ATPase inhibitor, bafilomycin A1, enhanced the association between STIM1 and STIM2 as well as between these proteins and the plasma membrane channel Orai1. Depletion of the acidic Ca2+ stores also induces time-dependent co-immunoprecipitation of STIM1 with the TRPC proteins hTRPC1 and hTRPC6, as well as between Orai1 and both TRPC proteins. In addition, bafilomycin A1 enhanced the association between STIM2 and SERCA3. These findings demonstrate the location of STIM1 and STIM2 in the acidic Ca2+ stores and their association with Ca2+ channels and ATPases upon acidic stores discharge.
C1 [Zbidi, Hanene; Jardin, Isaac; Berna-Erro, Alejandro; Salido, Gines M.; Rosado, Juan A.] Univ Extremadura, Cell Physiol Res Grp, Dept Physiol, Caceres 10003, Spain.
[Woodard, Geoffrey E.] NIDDK, NIH, Bethesda, MD 20892 USA.
[Lopez, Jose J.] INSERM, Hemostase & Dynam Cellulaire Vasc U770, F-94276 Le Kremlin Bicetre, France.
RP Rosado, JA (reprint author), Univ Extremadura, Dept Physiol, Caceres 10071, Spain.
EM jarosado@unex.es
RI Salido, Gines/A-4292-2009; rosado, juan/H-3488-2015; Jardin,
Isaac/E-8310-2016; LOPEZ, JOSE/F-4602-2016
OI Salido, Gines/0000-0002-8687-2445; rosado, juan/0000-0002-9749-2325;
Jardin, Isaac/0000-0003-4575-8264; LOPEZ, JOSE/0000-0002-5234-1478
FU Ministerio de Ciencia e Innovacion [BFU2010-21043-C02-01,
BES-2008-002875]; Ministerio de Asuntos Exteriores y de Cooperacion
Proyecto Conjunto de Investigacion [A/023417/09]; Junta de
Extremadura-Fondo Europeo de Desarrollo Regional [GR10010]
FX This work was supported by Ministerio de Ciencia e Innovacion Grant
BFU2010-21043-C02-01, Ministerio de Asuntos Exteriores y de Cooperacion
Proyecto Conjunto de Investigacion Grant A/023417/09, and Junta de
Extremadura-Fondo Europeo de Desarrollo Regional Grant GR10010.;
Supported by Ministerio de Ciencia e Innovacion Fellowship
BES-2008-002875.
NR 64
TC 33
Z9 33
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 8
PY 2011
VL 286
IS 14
DI 10.1074/jbc.M110.190694
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 744EN
UT WOS:000289077500040
PM 21321120
ER
PT J
AU Nikolaitchik, OA
Galli, A
Moore, MD
Pathak, VK
Hu, WS
AF Nikolaitchik, Olga A.
Galli, Andrea
Moore, Michael D.
Pathak, Vinay K.
Hu, Wei-Shau
TI Multiple Barriers to Recombination between Divergent HIV-1 Variants
Revealed by a Dual-Marker Recombination Assay
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE GFP; Gag; group M; group O; reconstitution
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DEPENDENT DNA POLYMERASE;
GENETIC-RECOMBINATION; IN-VIVO; INITIATION SIGNAL; GROUP-O; REPLICATION;
INFECTION; SELECTION; IDENTIFICATION
AB Recombination is a major force for generating human immunodeficiency virus type 1 (HIV-1) diversity and produces numerous recombinants circulating in the human population. We previously established a cell-based system using green fluorescent protein gene (gfp) as a reporter to study the mechanisms of HIV-1 recombination. We now report an improved system capable of detecting recombination using authentic viral sequences. Frameshift mutations were introduced into the gag gene so that parental viruses do not express full-length Gag; however, recombination can generate a progeny virus that expresses a functional Gag. We demonstrate that this Gag reconstitution assay can be used to detect recombination between two group M HIV-1 variants of the same or of different subtypes. Using both gfp and gag assays, we found that, similar to group M viruses, group O viruses also recombine frequently. When recombination between a group M virus and a group O virus was examined, we found three distinct barriers for intergroup recombination. First, similar to recombination within group M viruses, intergroup recombination is affected by the identity of the dimerization initiation signal (DIS); variants with the same DIS recombined at a higher rate than those with different DIS. Second, using the gfp recombination assay, we showed that intergroup recombination occurs much less frequently than intragroup recombination, even though the gfp target sequence is identical in all viruses. Finally, Gag reconstitution between variants from different groups is further reduced compared with green fluorescent protein, indicating that sequence divergence interferes with recombination efficiency in the gag gene. Compared with identical sequences, we estimate that recombination rates are reduced by 3-fold and by 10- to 13-fold when the target regions in gag contain 91% and 72-73% sequence identities, respectively. These results show that there are at least three distinct mechanisms preventing exchange of genetic information between divergent HIV-1 variants from different groups. Published by Elsevier Ltd.
C1 [Nikolaitchik, Olga A.; Galli, Andrea; Moore, Michael D.; Pathak, Vinay K.; Hu, Wei-Shau] NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA.
RP Hu, WS (reprint author), NCI, HIV Drug Resistance Program, POB B,Bldg 535,Room 336, Frederick, MD 21702 USA.
EM Wei-Shau.Hu@nih.gov
OI Galli, Andrea/0000-0002-4404-430X
FU National Institutes of Health, National Cancer Institute, Center for
Cancer Research
FX We thank Hans-Georg Krausslich for group O molecular clone. This
research was supported by the Intramural Research Program of the
National Institutes of Health, National Cancer Institute, Center for
Cancer Research.
NR 38
TC 12
Z9 13
U1 1
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD APR 8
PY 2011
VL 407
IS 4
BP 521
EP 531
DI 10.1016/j.jmb.2011.01.052
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 742EX
UT WOS:000288925200004
PM 21295586
ER
PT J
AU Suto, N
Wise, RA
Vezina, P
AF Suto, Nobuyoshi
Wise, Roy A.
Vezina, Paul
TI Dorsal as well as ventral striatal lesions affect levels of intravenous
cocaine and morphine self-administration in rats
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Cocaine self-administration; Morphine self-administration; Striatum;
Caudate putamen; Nucleus accumbens; Electrolytic lesion
ID KAINIC ACID LESIONS; NUCLEUS-ACCUMBENS; CAUDATE-PUTAMEN; REWARD;
DOPAMINE; PIMOZIDE; SEEKING; REINFORCEMENT; AMPHETAMINE; DEPENDENCE
AB While the ventral striatum has long been implicated in the rewarding properties of psychomotor stimulants and opiates, little attention has been paid to the possible contribution of more dorsal regions of the striatum. We have thus examined the effects of lesions in three different striatal subregions on cocaine and morphine self-administration. Different groups of rats were trained to self-administer intravenous cocaine (1.0 mg/kg/infusion) or morphine (0.5 mg/kg/infusion) first under fixed ratio (FR) and then under progressive ratio (PR) schedules of reinforcement. Upon completion of the training, independent groups received bilateral electrolytic or sham lesions of the dorsal portion of the caudate-putamen (dCPu), the ventral portion of the caudate-putamen (vCPu) or the more ventral nucleus accumbens (NAS). Following recovery, they were tested for self-administration of cocaine (0.25, 0.5, 1.0 and 1.5 mg/kg/infusion) or morphine (0.125, 0.25, 0.5 and 0.75 mg/kg/infusion) under the PR schedule. The PR responding for each drug was significantly reduced in a dose-dependent manner following lesions of dCPu, vCPu and NAS. While the relative effectiveness of these lesions is likely to be specific to the conditions of this experiment. NAS lesions reduced self-administration of each drug to a greater extent than did dCPu or vCPu lesions. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Suto, Nobuyoshi; Vezina, Paul] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA.
[Suto, Nobuyoshi; Wise, Roy A.] NIDA, Behav Neurosci Branch, Intramural Res Program, NIH,DHHS, Baltimore, MD 21224 USA.
RP Suto, N (reprint author), Univ Maryland, Sch Med, Dept Psychiat, Maryland Psychiat Res Ctr, POB 21247, Baltimore, MD 21228 USA.
EM nsuto@mprc.umaryland.edu
RI Wise, Roy/A-6465-2012
FU National Institute on Drug Abuse, National Institutes of Health,
Department of Health and Human Services [R01-DA-09397]
FX Supported by grant R01-DA-09397 (PV) and funding from the Intramural
Research Program, National Institute on Drug Abuse, National Institutes
of Health, Department of Health and Human Services. We thank Dr. Stephan
Steidl for critical reading of this manuscript.
NR 39
TC 13
Z9 13
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD APR 8
PY 2011
VL 493
IS 1-2
BP 29
EP 32
DI 10.1016/j.neulet.2011.02.011
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA 745QN
UT WOS:000289180800006
PM 21315801
ER
PT J
AU Niu, SQ
Tan, ML
Ichiye, T
AF Niu, Shuqiang
Tan, Ming-Liang
Ichiye, Toshiko
TI The large quadrupole of water molecules
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article
ID LIQUID WATER; POTENTIAL FUNCTIONS; MULTIPOLE MOMENTS; CONDENSED PHASES;
AB-INITIO; MODEL; OCTUPOLE; SOLVATION; DYNAMICS; DENSITY
AB Many quantum mechanical calculations indicate water molecules in the gas and liquid phase have much larger quadrupole moments than any of the common site models of water for computer simulations. Here, comparisons of multipoles from quantum mechanical/molecular mechanical (QM/MM) calculations at the MP2/aug-cc-pVQZ level on a B3LYP/aug-cc-pVQZ level geometry of a water-like cluster and from various site models show that the increased square planar quadrupole can be attributed to the p-orbital character perpendicular to the molecular plane of the highest occupied molecular orbital as well as a slight shift of negative charge toward the hydrogens. The common site models do not account for the p-orbital type electron density and fitting partial charges of TIP4P- or TIP5P-type models to the QM/MM dipole and quadrupole give unreasonable higher moments. Furthermore, six partial charge sites are necessary to account reasonably for the large quadrupole, and polarizable site models will not remedy the problem unless they account for the p-orbital in the gas phase since the QM calculations show it is present there too. On the other hand, multipole models by definition can use the correct multipoles and the electrostatic potential from the QM/MM multipoles is much closer than that from the site models to the potential from the QM/MM electron density. Finally, Monte Carlo simulations show that increasing the quadrupole in the soft-sticky dipole-quadrupole-octupole multipole model gives radial distribution functions that are in good agreement with experiment. (C) 2011 American Institute of Physics. [doi: 10.1063/1.3569563]
C1 [Niu, Shuqiang; Tan, Ming-Liang; Ichiye, Toshiko] Georgetown Univ, Dept Chem, Washington, DC 20057 USA.
[Ichiye, Toshiko] NHLBI, Lab Computat Biol, NIH, Bethesda, MD 20892 USA.
RP Niu, SQ (reprint author), Georgetown Univ, Dept Chem, Washington, DC 20057 USA.
EM ti9@georgetown.edu
FU National Science Foundation [MCB-0544629]; William G. McGowan
Foundation; National Institutes of Health, National Heart, Lung, and
Blood Institute (Laboratory of Computational Biology)
FX The authors are grateful to the National Science Foundation for the
support of this work through Grant No. MCB-0544629. The calculations
were performed on facilities provided by Georgetown University and
administered by the division of Advanced Research Computing (ARC).
Support was also provided by the William G. McGowan Foundation. In
addition, this research was supported in part by the Intramural Research
Program of the National Institutes of Health, National Heart, Lung, and
Blood Institute (Laboratory of Computational Biology). T. I. also thanks
Professor Sylvio Canuto for helpful discussions on his calculations and
Professor Peter J. Rossky for insightful comments.
NR 46
TC 22
Z9 22
U1 1
U2 19
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
MELVILLE, NY 11747-4501 USA
SN 0021-9606
EI 1089-7690
J9 J CHEM PHYS
JI J. Chem. Phys.
PD APR 7
PY 2011
VL 134
IS 13
AR 134501
DI 10.1063/1.3569563
PG 11
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 746OH
UT WOS:000289256100022
PM 21476758
ER
PT J
AU Wu, XW
Brooks, BR
AF Wu, Xiongwu
Brooks, Bernard R.
TI Toward canonical ensemble distribution from self-guided Langevin
dynamics simulation
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article
ID PROGRAM; CHARMM
AB This work derives a quantitative description of the conformational distribution in self-guided Langevin dynamics (SGLD) simulations. SGLD simulations employ guiding forces calculated from local average momentums to enhance low-frequency motion. This enhancement in low-frequency motion dramatically accelerates conformational search efficiency, but also induces certain perturbations in conformational distribution. Through the local averaging, we separate properties of molecular systems into low-frequency and high-frequency portions. The guiding force effect on the conformational distribution is quantitatively described using these low-frequency and high-frequency properties. This quantitative relation provides a way to convert between a canonical ensemble and a self-guided ensemble. Using example systems, we demonstrated how to utilize the relation to obtain canonical ensemble properties and conformational distributions from SGLD simulations. This development makes SGLD not only an efficient approach for conformational searching, but also an accurate means for conformational sampling. [doi: 10.1063/1.3574397]
C1 [Wu, Xiongwu; Brooks, Bernard R.] NHLBI, Lab Computat Biol, NIH, Bethesda, MD 20892 USA.
RP Wu, XW (reprint author), NHLBI, Lab Computat Biol, NIH, 5635 Fishers Lane,Room T904, Bethesda, MD 20892 USA.
EM wuxw@nhlbi.nih.gov
NR 11
TC 19
Z9 19
U1 0
U2 11
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
MELVILLE, NY 11747-4501 USA
SN 0021-9606
EI 1089-7690
J9 J CHEM PHYS
JI J. Chem. Phys.
PD APR 7
PY 2011
VL 134
IS 13
AR 134108
DI 10.1063/1.3574397
PG 12
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 746OH
UT WOS:000289256100008
PM 21476744
ER
PT J
AU Chiang, J
Hodes, RJ
AF Chiang, Jeffrey
Hodes, Richard J.
TI Cbl Enforces Vav1 Dependence and a Restricted Pathway of T Cell
Development
SO PLOS ONE
LA English
DT Article
ID ADAPTER PROTEIN SLP-76; C-CBL; DIFFERENTIAL REQUIREMENT; TYROSINE
PHOSPHORYLATION; LYMPHOCYTE DEVELOPMENT; NEGATIVE REGULATION; RECEPTOR
SIGNALS; ACTIVATION; ZAP-70; FAMILY
AB Extensive studies of pre-TCR- and TCR-dependent signaling have led to characterization of a pathway deemed essential for efficient T cell development, and comprised of a cascade of sequential events involving phosphorylation of Lck and ZAP-70, followed by phosphorylation of LAT and SLP-76, and subsequent additional downstream events. Of interest, however, reports from our lab as well as others have indicated that the requirements for ZAP-70, LAT, and SLP-76 are partially reversed by inactivation of c-Cbl (Cbl), an E3 ubiquitin ligase that targets multiple molecules for ubiquitination and degradation. Analysis of signaling events in these Cbl knockout models, including the recently reported analysis of SLP-76 transgenes defective in interaction with Vav1, suggested that activation of Vav1 might be a critical event in alternative pathways of T cell development. To extend the analysis of signaling requirements for thymic development, we have therefore assessed the effect of Cbl inactivation on the T cell developmental defects that occur in Vav1-deficient mice. The defects in Vav1-deficient thymic development, including a marked defect in DN3-DN4 transition, were completely reversed by Cbl inactivation, accompanied by enhanced phosphorylation of PLC-gamma 1 and ERKs in response to pre-TCR/TCR cross-linking of Vav1(-/-)Cbl(-/-)DP thymocytes. Taken together, these results suggest a substantially modified paradigm for pre-TCR/TCR signaling and T cell development. The observed consensus pathways of T cell development, including requirements for ZAP-70, LAT, SLP-76, and Vav1, appear to reflect the restriction by Cbl of an otherwise much broader set of molecular pathways capable of mediating T cell development.
C1 [Chiang, Jeffrey; Hodes, Richard J.] NCI, NIH, Expt Immunol Branch, Bethesda, MD 20892 USA.
[Hodes, Richard J.] NIA, NIH, Bethesda, MD 20892 USA.
RP Chiang, J (reprint author), NCI, NIH, Expt Immunol Branch, Bethesda, MD 20892 USA.
EM chiangj@mail.nih.gov
FU National Institutes of Health (NIH), National Cancer Institute
FX This research was supported by the Intramural Research Program of the
National Institutes of Health (NIH), National Cancer Institute. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 29
TC 5
Z9 5
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 7
PY 2011
VL 6
IS 4
AR e18542
DI 10.1371/journal.pone.0018542
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 746IN
UT WOS:000289238700022
PM 21490975
ER
PT J
AU Liu, ZH
Naranjo, A
Thiele, CJ
AF Liu, Zhihui
Naranjo, Arlene
Thiele, Carol J.
TI CASZ1b, the Short Isoform of CASZ1 Gene, Coexpresses with CASZ1a during
Neurogenesis and Suppresses Neuroblastoma Cell Growth
SO PLOS ONE
LA English
DT Article
ID TUMOR-SUPPRESSOR; NERVOUS-SYSTEM; CASTOR; DROSOPHILA; EXPRESSION;
DIFFERENTIATION; IDENTITY
AB In Drosophila, the CASZ1 (castor) gene encodes a zinc finger transcription factor and is a neural fate-determination gene. In mammals, the CASZ1 gene encodes two major isoforms, CASZ1a with 11 zinc fingers and CASZ1b with 5 zinc fingers. CASZ1b is more evolutionally conserved since it is the only homologue found in drosophila and Xenopus. Our previous study showed that full length CASZ1 (CASZ1a) functions to suppress growth in neuroblastoma tumor. However, the function of CASZ1b isoform in mammals is unknown. In this study, realtime PCR analyses indicate that mouse CASZ1b (mCASZ1b) is dynamically expressed during neurogenesis. CASZ1b and CASZ1a co-exist in all the neuronal tissues but exhibit distinct expression patterns spatially and temporally during brain development. CASZ1b and CASZ1a expression is coordinately upregulated by the differentiation agent Retinoic Acid, as well as agents that modify the epigenome in neural crest derived neuroblastoma cell lines. In contrast CASZ1b is down regulated while CASZ1a is upregulated by agents that raise intracellular cAMP levels. CASZ1b and CASZ1a have no synergistic or antagonistic activities on the regulation of their target NGFR gene transcription. Specific restoration of CASZ1b in NB cells suppresses tumor growth in vitro and in vivo. Consistent with its function role, we find that low CASZ1b expression is significantly associated with decreased survival probability of neuroblastoma patients (p<0.02). This study indicates that although their mechanisms of regulation may be distinct, both CASZ1b and CASZ1a have largely redundant but critical roles in suppressing tumor cell growth.
C1 [Liu, Zhihui; Thiele, Carol J.] NCI, Ctr Canc Res, Pediat Oncol Branch, Bethesda, MD 20892 USA.
[Naranjo, Arlene] Univ Florida, Childrens Oncol Grp Stat, Gainesville, FL USA.
[Naranjo, Arlene] Univ Florida, Ctr Data, Gainesville, FL USA.
RP Liu, ZH (reprint author), NCI, Ctr Canc Res, Pediat Oncol Branch, Bethesda, MD 20892 USA.
EM ct47a@nih.gov
FU National Cancer Institute
FX This work was supported by grants from National Cancer Institute
intramural program. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 25
TC 5
Z9 5
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 7
PY 2011
VL 6
IS 4
AR e18557
DI 10.1371/journal.pone.0018557
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 746IN
UT WOS:000289238700023
PM 21490919
ER
PT J
AU Jun, HS
Lee, YM
Song, KD
Mansfield, BC
Chou, JY
AF Jun, Hyun Sik
Lee, Young Mok
Song, Ki Duk
Mansfield, Brian C.
Chou, Janice Y.
TI G-CSF improves murine G6PC3-deficient neutrophil function by modulating
apoptosis and energy homeostasis
SO BLOOD
LA English
DT Article
ID COLONY-STIMULATING FACTOR; DISEASE TYPE 1B; 11-BETA-HYDROXYSTEROID
DEHYDROGENASE TYPE-1; ENDOPLASMIC-RETICULUM STRESS; CELL-DEATH;
CONGENITAL NEUTROPENIA; GLUCOSE-TRANSPORT; HEXOSE-6-PHOSPHATE
DEHYDROGENASE; GLUCOSE-6-PHOSPHATE TRANSPORTER; OXIDATIVE STRESS
AB G6PC3 (or glucose-6-phosphatase-beta) deficiency underlies a congenital neutropenia syndrome in which neutrophils exhibit enhanced endoplasmic reticulum (ER) stress, increased apoptosis, impaired energy homeostasis, and impaired functionality. Here we show that murine G6pc3(-/-) neutrophils undergoing ER stress activate protein kinase-like ER kinase and phosphatidylinositol 3,4,5-trisphosphate/Akt signaling pathways, and that neutrophil apoptosis is mediated in part by the intrinsic mitochondrial pathway. In G6PC3-deficient patients, granulocyte colony-stimulating factor (G-CSF) improves neutropenia, but its impact on neutrophil apoptosis and dysfunction is unknown. We now show that G-CSF delays neutrophil apoptosis in vitro by modulating apoptotic mediators. However, G6pc3(-/-) neutrophils in culture exhibit accelerated apoptosis compared with wild-type neutrophils both in the presence or absence of G-CSF. Limiting glucose (0.6mM) accelerates apoptosis but is more pronounced for wild-type neutrophils, leading to similar survival profiles for both neutrophil populations. In vivo G-CSF therapy completely corrects neutropenia and normalizes levels of p-Akt, phosphatidylinositol 3,4,5-trisphosphate, and active caspase-3. Neutrophils from in vivo G-CSF-treated G6pc3(-/-) mice exhibit increased glucose uptake and elevated intracellular levels of G6P, lactate, and adenosine-5'-triphosphate, leading to improved functionality. Together, the results strongly suggest that G-CSF improves G6pc3(-/-) neutrophil survival by modulating apoptotic mediators and rectifies function by enhancing energy homeostasis. (Blood. 2011;117(14):3881-3892)
C1 [Jun, Hyun Sik; Lee, Young Mok; Mansfield, Brian C.; Chou, Janice Y.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular Differentiat, Program Dev Endocrinol & Genet, NIH, Bethesda, MD 20892 USA.
[Song, Ki Duk] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular & Dev Biol, Program Genom Differentiat, NIH, Bethesda, MD 20892 USA.
RP Chou, JY (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular Differentiat, Program Dev Endocrinol & Genet, NIH, 10 Ctr Dr,Bldg 10,Rm 9D42, Bethesda, MD 20892 USA.
EM chouja@mail.nih.gov
RI Jun, Hyun Sik/C-6799-2013;
OI Mansfield, Brian/0000-0002-8533-2789
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health
FX This work was supported by the Intramural Research Programs of the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health.
NR 49
TC 19
Z9 19
U1 1
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD APR 7
PY 2011
VL 117
IS 14
BP 3881
EP 3892
DI 10.1182/blood-2010-08-302059
PG 12
WC Hematology
SC Hematology
GA 746RV
UT WOS:000289265500023
PM 21292774
ER
PT J
AU Kelly, RJ
Lopez-Chavez, A
Citrin, D
Janik, JE
Morris, JC
AF Kelly, Ronan J.
Lopez-Chavez, Ariel
Citrin, Deborah
Janik, John E.
Morris, John C.
TI Impacting tumor cell-fate by targeting the inhibitor of apoptosis
protein survivin
SO MOLECULAR CANCER
LA English
DT Review
ID PROSTATE-CANCER CELLS; CHROMOSOMAL PASSENGER COMPLEX; RIBOZYME-MEDIATED
INHIBITION; ANTIAPOPTOSIS GENE SURVIVIN; NON-HODGKINS-LYMPHOMA;
LUNG-CANCER; RADIORESISTANCE FACTOR; MALIGNANT-MELANOMA; NUCLEAR
SURVIVIN; GASTRIC-CANCER
AB Survivin (BIRC5), a member of the inhibitor of apoptosis protein (IAP) family that inhibits caspases and blocks cell death is highly expressed in cancer and is associated with a poorer clinical outcome. Functioning simultaneously during cell division and apoptosis inhibition, survivin plays a pivotal role in determining cell survival. Survivin has consistently been identified by molecular profiling analysis to be associated with higher tumor grade, more advanced disease, abbreviated survival, accelerated rates of recurrence, and chemotherapy and radiation resistance. Survivin's differential expression in cancer compared to normal tissue and its role as a nodal protein in a number of cellular pathways make it a highly flexible therapeutic target, suitable for small-molecule inhibitiors, molecular antagonists, and vaccination-based therapies. By targeting survivin it is hoped that multiple tumor signaling circuitries may be simultaneously disabled. This effect may be applicable to many tumor histologies irrespective of specific genetic makeup. To date, survivin inhibitors have shown modest activity as single agents, but it is anticipated that when given in combination with cytotoxic chemotherapy or monoclonal antibodies they may exhibit enhanced efficacy. This review discusses the complex circuitry of survivin in human cancers and highlights clinical trials involving novel agents that target this important protein.
C1 [Morris, John C.] Univ Cincinnati, Dept Med, Div Hematol Oncol, Cincinnati, OH 45267 USA.
[Kelly, Ronan J.; Lopez-Chavez, Ariel] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Citrin, Deborah] NCI, Radiat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Janik, John E.] NCI, Metab Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Morris, JC (reprint author), Univ Cincinnati, Dept Med, Div Hematol Oncol, Cincinnati, OH 45267 USA.
EM morri2j7@uc.edu
FU NIH, National Cancer Institute, Center for Cancer Research
FX This research was supported in part by the Intramural Research Program
of the NIH, National Cancer Institute, Center for Cancer Research.
NR 136
TC 76
Z9 86
U1 1
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD APR 6
PY 2011
VL 10
AR 35
DI 10.1186/1476-4598-10-35
PG 11
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 755OE
UT WOS:000289941600001
PM 21470426
ER
PT J
AU Jang, H
Arce, FT
Mustata, M
Ramachandran, S
Capone, R
Nussinov, R
Lal, R
AF Jang, Hyunbum
Arce, Fernando Teran
Mustata, Mirela
Ramachandran, Srinivasan
Capone, Ricardo
Nussinov, Ruth
Lal, Ratnesh
TI Antimicrobial Protegrin-1 Forms Amyloid-Like Fibrils with Rapid Kinetics
Suggesting a Functional Link
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID ATOMIC-FORCE MICROSCOPY; ION CHANNELS; BETA-PROTEIN; ALZHEIMERS-DISEASE;
BILAYER-MEMBRANES; STRUCTURAL REQUIREMENTS; PEPTIDE PROTEGRIN-1;
BROAD-SPECTRUM; CONGO RED; MECHANISM
AB Protegrin-1 (PG-1) is an 18 residues long, cysteine-rich beta-sheet antimicrobial peptide (AMP). PG-1 induces strong cytotoxic activities on cell membrane and acts as a potent antibiotic agent. Earlier we reported that its cytotoxicity is mediated by its channel-forming ability. In this study, we have examined the amyloidogenic fibril formation properties of PG-1 in comparison with a well-defined amyloid, the amyloid-beta (A beta(1-42)) peptide. We have used atomic force microscopy (AFM) and thioflavin-T staining to investigate the kinetics of PG-1 fibrils growth and molecular dynamics simulations to elucidate the underlying mechanism. AFM images of PG-1 on a highly hydrophilic surface (mica) show fibrils with morphological similarities to A beta(1-42) fibrils. Real-time AFM imaging of fibril growth suggests that PG-1 fibril growth follows a relatively fast kinetics compared to the A beta(1-42) fibrils. The AFM results are in close agreement with results from thioflavin-T staining data. Furthermore, the results indicate that PG-1 forms fibrils in solution. Significantly, in contrast, we do not detect fibrillar structures of PG-1 on an anionic lipid bilayer 2-dioleoyl-sn-glycero-3-phospho-L-serine/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine; only small PG-1 oligomers can be observed. Molecular dynamics simulations are able to identify the presence of these small oligomers on the membrane bilayer. Thus, our current results show that cytotoxic AMP PG-1 is amyloidogenic and capable of forming fibrils. Overall, comparing beta-rich AMPs and amyloids such as A beta, in addition to cytotoxicity and amyloidogenicity, they share a common structural motif, and are channel forming. These combined properties support a functional relationship between amyloidogenic peptides and beta-sheet-rich cytolytic AMPs, suggesting that amyloids channels may have an antimicrobial function.
C1 [Jang, Hyunbum; Nussinov, Ruth] NCI, Ctr Canc Res, Nanobiol Program, SAIC Frederick, Frederick, MD 21701 USA.
[Arce, Fernando Teran; Ramachandran, Srinivasan; Capone, Ricardo; Lal, Ratnesh] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
[Arce, Fernando Teran; Ramachandran, Srinivasan; Capone, Ricardo; Lal, Ratnesh] Univ Calif San Diego, Dept Mech & Aerosp Engn, La Jolla, CA 92093 USA.
[Mustata, Mirela] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA.
[Nussinov, Ruth] Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, Sackler Inst Mol Med, IL-69978 Tel Aviv, Israel.
RP Nussinov, R (reprint author), NCI, Ctr Canc Res, Nanobiol Program, SAIC Frederick, Frederick, MD 21701 USA.
EM ruthnu@helix.nih.gov; rlal@ucsd.edu
RI Capone, Ricardo/D-1943-2010
OI Capone, Ricardo/0000-0002-7327-9837
FU National Cancer Institute, National Institutes of Health (NIH)
[HHSN261200800001E]; NIH, National Cancer Institute, Center for Cancer
Research; NIH [R01AG028709]
FX This project was funded in whole or in part with federal funds from the
National Cancer Institute, National Institutes of Health (NIH), under
contract No. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the U.S. government.
This research was supported (in part) by the Intramural Research Program
of the NIH, National Cancer Institute, Center for Cancer Research. This
research was supported by NIH grant No. R01AG028709 (R.L.). All
simulations had been performed using the high-performance computational
facilities of the Biowulf PC/Linux cluster at the National Institutes of
Health, Bethesda, MD (http://biowulf.nih.gov).
NR 67
TC 40
Z9 40
U1 1
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD APR 6
PY 2011
VL 100
IS 7
BP 1775
EP 1783
DI 10.1016/j.bpj.2011.01.072
PG 9
WC Biophysics
SC Biophysics
GA 749TU
UT WOS:000289494200023
PM 21463591
ER
PT J
AU Tang, JS
Kiyatkin, EA
AF Tang, Jeremy S.
Kiyatkin, Eugene A.
TI Fluctuations in central and peripheral temperatures induced by
intravenous nicotine: Central and peripheral contributions
SO BRAIN RESEARCH
LA English
DT Article
DE Nicotinic receptor; Vasoconstriction; Brain hyperthermia; Peripheral
sensory nerve; Nicotine pyrrolidine methiodide; Conditioning
ID RAT TRIGEMINAL GANGLION; SENSORY NERVE-ENDINGS; BODY-TEMPERATURE;
ACETYLCHOLINE-RECEPTORS; CEREBRAL VENTRICLES; HUMAN BRAIN; NEURONS;
ADDICTION; RESPONSES; DOPAMINE
AB Nicotine (NIC) is a highly addictive substance that interacts with different subtypes of nicotinic acetylcholine receptors widely distributed in the central and peripheral nervous systems. While the direct action of NIC on central neurons appears to be essential for its reinforcing properties, the role of peripheral actions of this drug remains a matter of controversy. In this study, we examined changes in locomotor activity and temperature fluctuations in the brain (nucleus accumbens and ventral tegmental area), temporal muscle, and skin induced by intravenous (iv) NIC at low human-relevant doses (10 and 30 mu g/kg) in freely moving rats. These effects were compared to those induced by social interaction, an arousing procedure that induces behavioral activation and temperature responses via pure neural mechanisms, and iv injections of a peripherally acting NIC analog, NIC pyrrolidine methiodide (NIC-PM) used at equimolar doses. We found that NIC at 30 mu g/kg induces a modest locomotor activation, rapid and strong decrease in skin temperature, and weak increases in brain and muscle temperature. While these effects were qualitatively similar to those induced by social interaction, they were much weaker and showed a tendency to increase with repeated drug administrations. In contrast, NIC-PM did not affect locomotion and induced much weaker than NIC increases in brain and muscle temperatures and decreases in skin temperature; these effects showed a tendency to be weaker with repeated drug administrations. Our data indicate that NIC's actions in the brain are essential to induce locomotor activation and brain and body hyperthermic responses. However, rapid peripheral action of NIC on sensory afferents could be an important factor in triggering its central effects, contributing to neural and physiological activation following repeated drug use. Published by Elsevier B.V.
C1 [Tang, Jeremy S.; Kiyatkin, Eugene A.] Natl Inst Drug Abuse, Behav Neurosci Branch, Intramural Res Program, NIH,DHHS, Baltimore, MD 21224 USA.
RP Kiyatkin, EA (reprint author), Natl Inst Drug Abuse, Behav Neurosci Branch, Intramural Res Program, NIH,DHHS, 333 Cassell Dr, Baltimore, MD 21224 USA.
EM ekiyatki@intra.nida.nih.gov
RI Reis, Aline/G-9573-2012
FU NIH, NIDA
FX This research was supported by the Intramural Research Program of the
NIH, NIDA. We wish to thank Dr. Bruce Vaupel for kindly providing us
with nicotine pyrrolidine methiodide.
NR 45
TC 2
Z9 2
U1 2
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD APR 6
PY 2011
VL 1383
BP 141
EP 153
DI 10.1016/j.brainres.2011.01.092
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 749UF
UT WOS:000289495600016
PM 21295014
ER
PT J
AU Li, Y
Xu, SQ
Mihaylova, MM
Zheng, B
Hou, XY
Jiang, BB
Park, O
Luo, ZJ
Lefai, E
Shyy, JYJ
Gao, B
Wierzbicki, M
Verbeuren, TJ
Shaw, RJ
Cohen, RA
Zang, MW
AF Li, Yu
Xu, Shanqin
Mihaylova, Maria M.
Zheng, Bin
Hou, Xiuyun
Jiang, Bingbing
Park, Ogyi
Luo, Zhijun
Lefai, Etienne
Shyy, John Y. -J.
Gao, Bin
Wierzbicki, Michel
Verbeuren, Tony J.
Shaw, Reuben J.
Cohen, Richard A.
Zang, Mengwei
TI AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic
Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice
SO CELL METABOLISM
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN-1; FATTY LIVER;
LIPID-METABOLISM; DEFICIENT MICE; LDL RECEPTOR; EXPRESSION; CELLS;
OVEREXPRESSION; TRANSCRIPTION
AB AMPK has emerged as a critical mechanism for salutary effects of polyphenols on lipid metabolic disorders in type 1 and type 2 diabetes. Here we demonstrate that AMPK interacts with and directly phosphorylates sterol regulatory element binding proteins (SREBP-1c and -2). Ser372 phosphorylation of SREBP-1c by AMPK is necessary for inhibition of proteolytic processing and transcriptional activity of SREBP-1c in response to polyphenols and metformin. AMPK stimulates Ser372 phosphorylation, suppresses SREBP-1c cleavage and nuclear translocation, and represses SREBP-1c target gene expression in hepatocytes exposed to high glucose, leading to reduced lipogenesis and lipid accumulation. Hepatic activation of AMPK by the synthetic polyphenol S17834 protects against hepatic steatosis, hyperlipidemia, and accelerated atherosclerosis in diet-induced insulin-resistant LDL receptor-deficient mice in part through phosphorylation of SREBP-1c Ser372 and suppression of SREBP-1c- and -2-dependent lipogenesis. AMPK-dependent phosphorylation of SREBP may offer therapeutic strategies to combat insulin resistance, dyslipidemia, and atherosclerosis.
C1 [Li, Yu; Xu, Shanqin; Hou, Xiuyun; Jiang, Bingbing; Luo, Zhijun; Cohen, Richard A.; Zang, Mengwei] Boston Univ, Sch Med, Vasc Biol Sect, Dept Med,Whitaker Cardiovasc Inst, Boston, MA 02481 USA.
[Mihaylova, Maria M.; Shaw, Reuben J.] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.
[Mihaylova, Maria M.; Shaw, Reuben J.] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA.
[Zheng, Bin] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.
[Park, Ogyi; Gao, Bin] NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA.
[Lefai, Etienne] Univ Lyon 1, INSERM, U1060, INRA,U1235,CarMeN Lab, F-69600 Oullins, France.
[Shyy, John Y. -J.] Univ Calif San Diego, Div Biomed Sci, La Jolla, CA 92093 USA.
[Wierzbicki, Michel; Verbeuren, Tony J.] Inst Rech Servier, F-92150 Suresnes, France.
RP Zang, MW (reprint author), Boston Univ, Sch Med, Vasc Biol Sect, Dept Med,Whitaker Cardiovasc Inst, Boston, MA 02481 USA.
EM mwzang1@bu.edu
RI Li, Yu/B-1071-2014;
OI Zang, Mengwei/0000-0002-2502-2586; Cohen, Richard/0000-0002-1070-6408;
Luo, Zhijun/0000-0003-3509-4046; li, yu/0000-0001-6910-5933
FU National Institutes of Health [RO1 DK076942, PO1 HL068758, RO1 DK080425,
DK59637, R01 DK080425]; American Diabetes Association [1-08-JF-47]
FX This work has been supported by the National Institutes of Health Grants
RO1 DK076942 (to M.Z.), PO1 HL068758 (to R.A.C.), RO1 DK080425 (to
R.J.S.), and DK59637 (Lipid, Lipoprotein, and Atherosclerosis Core of
the Vanderbilt Mouse Metabolic Phenotype Center), and the American
Diabetes Association Junior Faculty Award 1-08-JF-47 (to R.J.S.). M.Z.
and R.A.C. are recipients of Robert Dawson Evans Junior Faculty Merit
and Scholar Awards. M.Z. is also the recipient of the Wing Tat Lee Award
at Boston University School of Medicine. This work was also supported by
NIH R01 DK080425 (to R.J.S.). We are grateful to Dr. Benoit Viollet for
kindly providing AMPK+/+ and AMPK-/- MEFs. We
thank Jianxin Xie at Cell Signaling Technology for collaborating to
develop the phospho-Ser372 SREBP-1c antibody. We would like to thank Dr.
Vladimir R. Babaev for helping to perform FPLC analysis. We also thank
Kimberly Wong and Dr. Yuxia Cao for excellent technical assistance and
Karlene A. Maitland-Toolan and Robert M. Weisbrod for animal studies. We
would like to thank Dr. Kenneth Walsh, Dr. Sudha B. Biddinger, Dr. Dave
Pimental, and Dr. Haya Herscovitz for insightful discussion. Dr. Tony J.
Verbeuren and Dr. Michel Wierzbicki are employees and Dr. Richard A.
Cohen is a consultant of Servier Pharmaceutical Company.
NR 34
TC 373
Z9 398
U1 9
U2 78
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD APR 6
PY 2011
VL 13
IS 4
BP 376
EP 388
DI 10.1016/j.cmet.2011.03.009
PG 13
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 748HM
UT WOS:000289381300009
PM 21459323
ER
PT J
AU Gurley, SB
Riquier-Brison, ADM
Schnermann, J
Sparks, MA
Allen, AM
Haase, VH
Snouwaert, JN
Le, TH
McDonough, AA
Koller, BH
Coffman, TM
AF Gurley, Susan B.
Riquier-Brison, Anne D. M.
Schnermann, Jurgen
Sparks, Matthew A.
Allen, Andrew M.
Haase, Volker H.
Snouwaert, John N.
Le, Thu H.
McDonough, Alicia A.
Koller, Beverley H.
Coffman, Thomas M.
TI AT(1A) Angiotensin Receptors in the Renal Proximal Tubule Regulate Blood
Pressure
SO CELL METABOLISM
LA English
DT Article
ID II RECEPTOR; SODIUM-TRANSPORT; ESSENTIAL-HYPERTENSION;
MOLECULAR-MECHANISMS; CONVERTING ENZYME; IN-VIVO; KIDNEY; NEPHRON;
RENIN; MICE
AB Hypertension affects more than 1.5 billion people worldwide but the precise cause of elevated blood pressure (BP) cannot be determined in most affected individuals. Nonetheless, blockade of the renin-angiotensin system (RAS) lowers BP in the majority of patients with hypertension. Despite its apparent role in hypertension pathogenesis, the key cellular targets of the RAS that control BP have not been clearly identified. Here we demonstrate that RAS actions in the epithelium of the proximal tubule have a critical and nonredundant role in determining the level of BP. Abrogation of AT(1) angiotensin receptor signaling in the proximal tubule alone is sufficient to lower BP, despite intact vascular responses. Elimination of this pathway reduces proximal fluid reabsorption and alters expression of key sodium transporters, modifying pressure-natriuresis and providing substantial protection against hypertension. Thus, effectively targeting epithelial functions of the proximal tubule of the kidney should be a useful therapeutic strategy in hypertension.
C1 [Gurley, Susan B.; Sparks, Matthew A.; Coffman, Thomas M.] Duke Univ, Dept Med, Div Nephrol, Durham, NC 27710 USA.
[Gurley, Susan B.; Sparks, Matthew A.; Coffman, Thomas M.] VA Med Ctr, Durham, NC 27710 USA.
[Riquier-Brison, Anne D. M.; McDonough, Alicia A.] Univ So Calif, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA.
[Schnermann, Jurgen] NIDDK, NIH, Bethesda, MD 20892 USA.
[Allen, Andrew M.] Univ Melbourne, Dept Physiol, Melbourne, Vic 3010, Australia.
[Haase, Volker H.] Vanderbilt Univ, Dept Med, Div Nephrol & Hypertens, Nashville, TN 37232 USA.
[Snouwaert, John N.; Koller, Beverley H.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
[Le, Thu H.] Univ Virginia, Dept Med, Div Nephrol, Charlottesville, VA 22908 USA.
[Coffman, Thomas M.] Duke NUS Grad Med Sch, Cardiovasc & Metab Disorders Res Program, Singapore 169857, Singapore.
RP Coffman, TM (reprint author), Duke Univ, Dept Med, Div Nephrol, Durham, NC 27710 USA.
EM tcoffman@duke.edu
RI Haase, Volker Hans/A-6758-2013;
OI Haase, Volker Hans/0000-0002-7051-8994; Allen, Andrew
Mark/0000-0002-2183-5360; Sparks, Matthew/0000-0003-2075-2691
FU National Institutes of Health [TMC 2R01 HL056122 13, AAM DK083785];
American Heart Association [0475034N]; Veterans Affairs Research
Administration; Edna and Fred L. Mandel, Jr. Foundation
FX The authors gratefully acknowledge the technical support of Robert C.
Griffiths and Carrie L. Mach and funding from National Institutes of
Health (TMC 2R01 HL056122 13; AAM DK083785), American Heart Association
(SBG Fellow-to-Faculty Award 0475034N), Veterans Affairs Research
Administration, and the Edna and Fred L. Mandel, Jr. Foundation.
NR 42
TC 100
Z9 101
U1 0
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD APR 6
PY 2011
VL 13
IS 4
BP 469
EP 475
DI 10.1016/j.cmet.2011.03.001
PG 7
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 748HM
UT WOS:000289381300017
PM 21459331
ER
PT J
AU Li, YQ
Xue, YX
He, YY
Li, FQ
Xue, LF
Xu, CM
Sacktor, TC
Shaham, Y
Lu, L
AF Li, Yan-qin
Xue, Yan-xue
He, Ying-ying
Li, Fang-qiong
Xue, Li-fen
Xu, Chun-mei
Sacktor, Todd Charlton
Shaham, Yavin
Lu, Lin
TI Inhibition of PKM xi in Nucleus Accumbens Core Abolishes Long-Term Drug
Reward Memory
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID PROTEIN-KINASE-C; DOPAMINE D-1-FAMILY RECEPTORS; VENTRAL TEGMENTAL AREA;
AMPA RECEPTORS; HEROIN SEEKING; M-ZETA; BASOLATERAL AMYGDALA; SIGNALING
PATHWAY; COCAINE-SEEKING; LTP MAINTENANCE
AB During abstinence, memories of drug-associated cues persist for many months, and exposure to these cues often provokes relapse to drug use. The mechanisms underlying the maintenance of these memories are unknown. A constitutively active atypical protein kinase C (PKC) isozyme, protein kinase M xi (PKM xi), is required for maintenance of spatial memory, conditioned taste aversion, and other memory forms. We used conditioned place preference (CPP) and conditioned place aversion (CPA) procedures to study the role of nucleus accumbens PKM xi in the maintenance of drug reward and aversion memories in rats. Morphine CPP training (10 mg/kg, 4 pairings) increased PKM xi levels in accumbens core but not shell. Injections of the PKM xi inhibitor xi inhibitory peptide (ZIP) into accumbens core but not shell after CPP training blocked morphine CPP expression for up to 14 d after injections. This effect was mimicked by the PKC inhibitor chelerythrine, which inhibits PKM xi, but not by the conventional and novel PKC inhibitor staurosporine, which does not effectively inhibit PKM xi. ZIP injections into accumbens core after training also blocked the expression of cocaine (10 mg/kg) and high-fat food CPP but had no effect on CPA induced by naloxone-precipitated morphine withdrawal. Accumbens core injections of Tat-GluR2(3Y), which inhibits GluR2-dependent AMPA receptor endocytosis, prevented the impairment in morphine CPP induced by local ZIP injections, indicating that the persistent effect of PKM xi is on GluR2-containing AMPA receptors. Results indicate that PKM xi activity in accumbens core is a critical cellular substrate for the maintenance of memories of relapse-provoking reward cues during prolonged abstinence periods.
C1 [Li, Yan-qin; Xue, Yan-xue; He, Ying-ying; Li, Fang-qiong; Xue, Li-fen; Xu, Chun-mei; Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100191, Peoples R China.
[Sacktor, Todd Charlton] Suny Downstate Med Ctr, Dept Physiol & Pharmacol, New York, NY 11203 USA.
[Sacktor, Todd Charlton] Suny Downstate Med Ctr, Dept Neurol, New York, NY 11203 USA.
[Shaham, Yavin] Natl Inst Drug Abuse, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
RP Lu, L (reprint author), Peking Univ, Natl Inst Drug Dependence, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.
EM linlu@bjmu.edu.cn
RI shaham, yavin/G-1306-2014
FU National Basic Research Program of China [2009CB522004]; Natural Science
Foundation of China [30725016]; Natural Science Foundation of Beijing
Municipality [09G0762]; National Institute on Drug Abuse [National
Institutes of Health (NIH), Department of Health and Human Services];
National Institutes of Health [MH057068, MH53576]
FX This work was supported in part by the National Basic Research Program
of China (No. 2009CB522004), the Natural Science Foundation of China
(No. 30725016), Natural Science Foundation of Beijing Municipality (No.
09G0762), the Intramural Research Program of the National Institute on
Drug Abuse [National Institutes of Health (NIH), Department of Health
and Human Services], and National Institutes of Health Grants MH057068
and MH53576 (T.C.S.). We thank Dr. Emily Wentzell, Anna Stern, and Dr.
David Epstein for helpful comments.
NR 58
TC 66
Z9 67
U1 1
U2 13
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD APR 6
PY 2011
VL 31
IS 14
BP 5436
EP 5446
DI 10.1523/JNEUROSCI.5884-10.2011
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 746AO
UT WOS:000289213500029
PM 21471379
ER
PT J
AU Ramonet, D
Daher, JPL
Lin, BM
Stafa, K
Kim, J
Banerjee, R
Westerlund, M
Pletnikova, O
Glauser, L
Yang, LC
Liu, Y
Swing, DA
Beal, MF
Troncoso, JC
McCaffery, JM
Jenkins, NA
Copeland, NG
Galter, D
Thomas, B
Lee, MK
Dawson, TM
Dawson, VL
Moore, DJ
AF Ramonet, David
Daher, Joao Paulo L.
Lin, Brian M.
Stafa, Klodjan
Kim, Jaekwang
Banerjee, Rebecca
Westerlund, Marie
Pletnikova, Olga
Glauser, Liliane
Yang, Lichuan
Liu, Ying
Swing, Deborah A.
Beal, M. Flint
Troncoso, Juan C.
McCaffery, J. Michael
Jenkins, Nancy A.
Copeland, Neal G.
Galter, Dagmar
Thomas, Bobby
Lee, Michael K.
Dawson, Ted M.
Dawson, Valina L.
Moore, Darren J.
TI Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic
Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2
SO PLOS ONE
LA English
DT Article
ID FAMILIAL PARKINSONS-DISEASE; KINASE-ACTIVITY; ALPHA-SYNUCLEIN; R1441C
MUTATION; BETA PROMOTER; GTP-BINDING; GENE LRRK2; BRAIN;
LEUCINE-RICH-REPEAT-KINASE-2; LOCALIZATION
AB Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant familial Parkinson's disease (PD) and also contribute to idiopathic PD. LRRK2 mutations represent the most common cause of PD with clinical and neurochemical features that are largely indistinguishable from idiopathic disease. Currently, transgenic mice expressing wild-type or disease-causing mutants of LRRK2 have failed to produce overt neurodegeneration, although abnormalities in nigrostriatal dopaminergic neurotransmission have been observed. Here, we describe the development and characterization of transgenic mice expressing human LRRK2 bearing the familial PD mutations, R1441C and G2019S. Our study demonstrates that expression of G2019S mutant LRRK2 induces the degeneration of nigrostriatal pathway dopaminergic neurons in an age-dependent manner. In addition, we observe autophagic and mitochondrial abnormalities in the brains of aged G2019S LRRK2 mice and markedly reduced neurite complexity of cultured dopaminergic neurons. These new LRRK2 transgenic mice will provide important tools for understanding the mechanism(s) through which familial mutations precipitate neuronal degeneration and PD.
C1 [Ramonet, David; Stafa, Klodjan; Glauser, Liliane; Moore, Darren J.] Ecole Polytech Fed Lausanne, Sch Life Sci, Brain Mind Inst, Lausanne, Switzerland.
[Daher, Joao Paulo L.; Lin, Brian M.; Dawson, Ted M.; Dawson, Valina L.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, NeuroRegenerat Program, Baltimore, MD USA.
[Daher, Joao Paulo L.; Lin, Brian M.; Dawson, Ted M.; Dawson, Valina L.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Stem Cell Program, Baltimore, MD USA.
[Daher, Joao Paulo L.; Lin, Brian M.; Dawson, Ted M.; Dawson, Valina L.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
[Daher, Joao Paulo L.] Univ Fed Fluminense, Sch Med, Dept Pathol, Niteroi, RJ, Brazil.
[Kim, Jaekwang; Pletnikova, Olga; Liu, Ying; Troncoso, Juan C.; Lee, Michael K.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
[Kim, Jaekwang; Lee, Michael K.] Univ Minnesota, Dept Neurosci, Inst Translat Neurosci, Minneapolis, MN USA.
[Banerjee, Rebecca; Yang, Lichuan; Beal, M. Flint; Thomas, Bobby] Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA.
[Westerlund, Marie; Galter, Dagmar] Karolinska Inst, Dept Neurosci, Stockholm, Sweden.
[McCaffery, J. Michael] Johns Hopkins Univ, Integrated Imaging Ctr, Baltimore, MD USA.
[McCaffery, J. Michael] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
[Swing, Deborah A.; Jenkins, Nancy A.; Copeland, Neal G.] NCI, Mouse Canc Genet Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA.
[Dawson, Ted M.; Dawson, Valina L.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
[Dawson, Valina L.] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.
RP Ramonet, D (reprint author), Ecole Polytech Fed Lausanne, Sch Life Sci, Brain Mind Inst, Lausanne, Switzerland.
EM vdawson@jhmi.edu; darren.moore@epfl.ch
RI Galter, Dagmar/C-4826-2011; Lee, Michael/D-9491-2013;
OI Galter, Dagmar/0000-0001-6485-6244; Lee, Michael/0000-0001-5865-9682;
Dawson, Valina/0000-0002-2915-3970
FU National Parkinson Foundation; Swiss National Science Foundation
[310030_127478]; Parkinson Schweiz; American Parkinson Disease
Association; Ecole Polytechnique Federale de Lausanne; Swedish Research
Council; National Institutes of Health [NS060885, NS062165, NS03877]
FX This work was supported by the National Parkinson Foundation (D.J.M., V.
L. D.); Swiss National Science Foundation (grant no. 310030_127478 to
D.J.M.); Parkinson Schweiz (D.J.M.); American Parkinson Disease
Association (D.J.M.); Ecole Polytechnique Federale de Lausanne (D.J.M.);
Swedish Research Council (D.G.); and the National Institutes of Health
(grant no. NS060885 and NS062165 to B. T., and NS03877 to T. M. D. and
V. L. D.). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 61
TC 139
Z9 141
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 6
PY 2011
VL 6
IS 4
AR e18568
DI 10.1371/journal.pone.0018568
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 745UM
UT WOS:000289192400039
PM 21494637
ER
PT J
AU Subbiah, V
Naing, A
Brown, RE
Chen, H
Doyle, L
LoRusso, P
Benjamin, R
Anderson, P
Kurzrock, R
AF Subbiah, Vivek
Naing, Aung
Brown, Robert E.
Chen, Helen
Doyle, Laurence
LoRusso, Patricia
Benjamin, Robert
Anderson, Pete
Kurzrock, Razelle
TI Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with
Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors:
Response/Resistance Signatures
SO PLOS ONE
LA English
DT Article
ID FACTOR-I RECEPTOR; MONOCLONAL-ANTIBODY; TUMORS; RESISTANCE; PATHWAYS;
AKT/PKB; MTORC2; RICTOR; CELLS
AB Background: Insulin-like growth factor 1 receptor (IGF1R) targeted therapies have resulted in responses in a small number of patients with advanced metastatic Ewing's sarcoma. We performed morphoproteomic profiling to better understand response/resistance mechanisms of Ewing's sarcoma to IGF1R inhibitor-based therapy.
Methodology/Principal Findings: This pilot study assessed two patients with advanced Ewing's sarcoma treated with IGF1R antibody alone followed by combined IGF1R inhibitor plus mammalian target of rapamycin (mTOR) inhibitor treatment once resistance to single-agent IGF1R inhibitor developed. Immunohistochemical probes were applied to detect p-mTOR (Ser2448), p-Akt (Ser473), p-ERK1/2 (Thr202/Tyr204), nestin, and p-STAT3 (Tyr 705) in the original and recurrent tumor. The initial remarkable radiographic responses to IGF1R-antibody therapy was followed by resistance and then response to combined IGF1R plus mTOR inhibitor therapy in both patients, and then resistance to the combination regimen in one patient. In patient 1, upregulation of p-Akt and p-mTOR in the tumor that relapsed after initial response to IGF1R antibody might explain the resistance that developed, and the subsequent response to combined IGF1R plus mTOR inhibitor therapy. In patient 2, upregulation of mTOR was seen in the primary tumor, perhaps explaining the initial response to the IGF1R and mTOR inhibitor combination, while the resistant tumor that emerged showed activation of the ERK pathway as well.
Conclusion/Significance: Morphoproteomic analysis revealed that the mTOR pathway was activated in these two patients with advanced Ewing's sarcoma who showed response to combined IGF1R and mTOR inhibition, and the ERK pathway in the patient in whom resistance to this combination emerged. Our pilot results suggests that morphoproteomic assessment of signaling pathway activation in Ewing's sarcoma merits further investigation as a guide to understanding response and resistance signatures.
C1 [Subbiah, Vivek; Anderson, Pete] Univ Texas MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA.
[Subbiah, Vivek; Naing, Aung; Kurzrock, Razelle] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA.
[Brown, Robert E.] Univ Texas Houston, Sch Med, Dept Pathol & Lab Med, UT Hlth, Houston, TX 77030 USA.
[Chen, Helen; Doyle, Laurence] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA.
[LoRusso, Patricia] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA.
[Benjamin, Robert] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Sarcoma Med Oncol, Houston, TX 77030 USA.
RP Subbiah, V (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA.
EM vsubbiah@mdanderson.org
FU NCI-CTEP [R21-CA13763301A1]; National Center for Research Resources
(NCRR) [RR024148]; National Institutes of Health (NIH); NIH Roadmap for
Medical Research; NIH through Cancer Center [CA 016672]; [U01
CA062461-17]
FX This study was funded by in part by U01 CA062461-17 (RK) and NCI-CTEP
R21-CA13763301A1 (AN). This work was also supported by Grant RR024148
from the National Center for Research Resources (NCRR), National
Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its
contents are solely the responsibility of the authors and do not
necessarily represent the official view of NCRR or NIH. Information on
NCRR is available at http://www.ncrr.nih.gov/. Information on
Reengineering the Clinical Research Enterprise can be obtained from
http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp.
The University of Texas MD Anderson Cancer Center is supported in part
by the NIH through Cancer Center Support Grant no. CA 016672. Presented
in part as a platform presentation at the 16th Annual Meeting of the
Connective Tissue Oncologic Society, November 11-13, 2010, Paris,
France. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 27
TC 47
Z9 48
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 6
PY 2011
VL 6
IS 4
AR e18424
DI 10.1371/journal.pone.0018424
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 745UM
UT WOS:000289192400027
PM 21494688
ER
PT J
AU Volkow, ND
McLellan, TA
Cotto, JH
Karithanom, M
Weiss, SRB
AF Volkow, Nora D.
McLellan, Thomas A.
Cotto, Jessica H.
Karithanom, Meena
Weiss, Susan R. B.
TI Characteristics of Opioid Prescriptions in 2009
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID ADOLESCENTS; DEPENDENCE; ADULTS; ABUSE
C1 [Volkow, Nora D.; Cotto, Jessica H.; Karithanom, Meena; Weiss, Susan R. B.] NIDA, NIH, Bethesda, MD 20892 USA.
[McLellan, Thomas A.] Univ Penn, Sch Med, Ctr Subst Abuse Solut, Philadelphia, PA 19104 USA.
RP Volkow, ND (reprint author), NIDA, NIH, Bethesda, MD 20892 USA.
EM nvolkow@nida.nih.gov
FU Intramural NIH HHS [Z99 DA999999]
NR 6
TC 110
Z9 111
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 6
PY 2011
VL 305
IS 13
BP 1299
EP 1301
DI 10.1001/jama.2011.401
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 745JT
UT WOS:000289162400016
PM 21467282
ER
PT J
AU Volkow, ND
McLellan, TA
AF Volkow, Nora D.
McLellan, Thomas A.
TI Curtailing Diversion and Abuse of Opioid Analgesics Without Jeopardizing
Pain Treatment
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID CHRONIC NONCANCER PAIN
C1 [Volkow, Nora D.] NIDA, NIH, Bethesda, MD 20892 USA.
[McLellan, Thomas A.] Univ Penn, Sch Med, Ctr Subst Abuse Solut, Philadelphia, PA 19104 USA.
RP Volkow, ND (reprint author), NIDA, NIH, 6001 Execut Blvd,Room 5274,MSC 9581, Bethesda, MD 20892 USA.
EM nvolkow@nida.nih.gov
NR 10
TC 97
Z9 98
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 6
PY 2011
VL 305
IS 13
BP 1346
EP 1347
DI 10.1001/jama.2011.369
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 745JT
UT WOS:000289162400024
PM 21467287
ER
PT J
AU Blair, A
Marrett, L
Freeman, LB
AF Blair, Aaron
Marrett, Loraine
Freeman, Laura Beane
TI Occupational cancer in developed countries
SO ENVIRONMENTAL HEALTH
LA English
DT Article; Proceedings Paper
CT Conference on Environment and Cancer
CY JUN 04-05, 2009
CL Turin, ITALY
ID EXPOSURE; SMOKING
AB Studies of occupational exposures have made major contributions to our understanding of human carcinogenesis. About one third of the factors identified as definite or probable human carcinogens were first investigated in the workplace and these exposures exact a considerable toll on working populations. There are many additional workplace exposures that are suspect carcinogens that require further evaluation to ensure a safe work environment. Information from occupational investigations is also relevant to the general population because many occupational exposures can be found outside the workplace. Much of our understanding about occupational cancer has been obtained from studies largely composed of white men in developed countries. The movement of industry from developed to developing countries underscores the need for future investigations to include more diverse populations.
C1 [Blair, Aaron; Freeman, Laura Beane] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Blair, Aaron; Marrett, Loraine] Canc Care Ontario, Occupat Canc Res Ctr, Toronto, ON, Canada.
RP Blair, A (reprint author), NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
EM blaira@exchange.nih.gov
RI Beane Freeman, Laura/C-4468-2015
OI Beane Freeman, Laura/0000-0003-1294-4124
NR 15
TC 6
Z9 6
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-069X
J9 ENVIRON HEALTH-GLOB
JI Environ. Health
PD APR 5
PY 2011
VL 10
SU 1
AR S9
DI 10.1186/1476-069X-10-S1-S9
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA 759II
UT WOS:000290233600009
PM 21489219
ER
PT J
AU Melnick, RL
Huff, J
AF Melnick, Ronald L.
Huff, James
TI Lorenzo Tomatis and primary prevention of environmental cancer
SO ENVIRONMENTAL HEALTH
LA English
DT Article; Proceedings Paper
CT Conference on Environment and Cancer
CY JUN 04-05, 2009
CL Turin, ITALY
ID RISKS; IDENTIFICATION
AB The leading 20(th) century proponent for primary prevention of environmental cancer was Dr. Lorenzo Tomatis, the former Director of the International Agency for Research on Cancer and founder of the IARC Monographs program. This paper is dedicated to the memory of Dr. Tomatis - eminent scientist, scholar, teacher, humanitarian, and public health champion - and includes many perspectives that he promoted throughout his career, with original quotations from some of his scientific writings on primary prevention of environmental cancer. Any attempt by us to simply summarize his views would only detract from the power and logic of his language.
"Cancer still remains a mainly lethal disease. Primary prevention remains the most relevant approach to reduce mortality through a reduction in incidence" [1].
C1 [Melnick, Ronald L.] Ron Melnick Consulting LLC, Chapel Hill, NC 27514 USA.
[Huff, James] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC 27709 USA.
RP Melnick, RL (reprint author), Ron Melnick Consulting LLC, 111 Roundtree Rd, Chapel Hill, NC 27514 USA.
EM ron.melnick@gmail.com
NR 11
TC 4
Z9 4
U1 1
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-069X
J9 ENVIRON HEALTH-GLOB
JI Environ. Health
PD APR 5
PY 2011
VL 10
SU 1
AR S14
DI 10.1186/1476-069X-10-S1-S14
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA 759II
UT WOS:000290233600014
PM 21489210
ER
PT J
AU Tao, YG
Xi, SC
Shan, JG
Maunakea, A
Che, A
Briones, V
Lee, EY
Geiman, T
Huang, JQ
Stephens, R
Leighty, RM
Zhao, KJ
Muegge, K
AF Tao, Yongguang
Xi, Sichuan
Shan, Jigui
Maunakea, Alika
Che, Anney
Briones, Victorino
Lee, Eunice Y.
Geiman, Theresa
Huang, Jiaqiang
Stephens, Robert
Leighty, Robert M.
Zhao, Keji
Muegge, Kathrin
TI Lsh, chromatin remodeling family member, modulates genome-wide cytosine
methylation patterns at nonrepeat sequences
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE methylated DNA immunoprecipitation; chIP-sequencing; epigenetics
ID DE-NOVO METHYLATION; DNA METHYLATION; MAMMALIAN DEVELOPMENT; ARABIDOPSIS
GENE; SNF2 FAMILY; HUMAN-CELLS; HETEROCHROMATIN; TRANSCRIPTION;
MUTATION; ELEMENTS
AB DNA methylation is critical for normal development and plays important roles in genome organization and transcriptional regulation. Although DNA methyltransferases have been identified, the factors that establish and contribute to genome-wide methylation patterns remain elusive. Here, we report a high-resolution cytosine methylation map of the murine genome modulated by Lsh, a chromatin remodeling family member that has previously been shown to regulate CpG methylation at repetitive sequences. We provide evidence that Lsh also controls genome-wide cytosine methylation at nonrepeat sequences and relate those changes to alterations in H4K4me3 modification and gene expression. Deletion of Lsh alters the allocation of cytosine methylation in chromosomal regions of 50 kb to 2 Mb and, in addition, leads to changes in the methylation profile at the 5' end of genes. Furthermore, we demonstrate that loss of Lsh promotes-as well as prevents-cytosine methylation. Our data indicate that Lsh is an epigenetic modulator that is critical for normal distribution of cytosine methylation throughout the murine genome.
C1 [Tao, Yongguang; Xi, Sichuan; Briones, Victorino; Lee, Eunice Y.; Geiman, Theresa; Huang, Jiaqiang; Muegge, Kathrin] NCI, Basic Sci Program, Lab Canc Prevent, Frederick, MD 21702 USA.
[Shan, Jigui; Che, Anney; Stephens, Robert] NCI, Adv Biomed Comp Ctr, Frederick, MD 21702 USA.
[Leighty, Robert M.] NCI, Data Management Serv, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21702 USA.
[Maunakea, Alika; Zhao, Keji] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20817 USA.
RP Muegge, K (reprint author), NCI, Basic Sci Program, Lab Canc Prevent, Frederick, MD 21702 USA.
EM Kathrin.Muegge@nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]; National Institutes of Health, National Cancer
Institute, Center for Cancer Research
FX We thank Drs. Nancy Colburn, Amar Klar, and Michael Kuehn for critical
comments on the manuscript. This project has been funded in whole or in
part with federal funds from the National Cancer Institute, National
Institutes of Health (Contract HHSN261200800001E) and the Intramural
Research Program of the National Institutes of Health, National Cancer
Institute, Center for Cancer Research.
NR 37
TC 30
Z9 31
U1 0
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 5
PY 2011
VL 108
IS 14
BP 5626
EP 5631
DI 10.1073/pnas.1017000108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 746RT
UT WOS:000289265300030
PM 21427231
ER
PT J
AU Batorsky, R
Kearney, MF
Palmer, SE
Maldarelli, F
Rouzine, IM
Coffin, JM
AF Batorsky, Rebecca
Kearney, Mary F.
Palmer, Sarah E.
Maldarelli, Frank
Rouzine, Igor M.
Coffin, John M.
TI Estimate of effective recombination rate and average selection
coefficient for HIV in chronic infection
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE modeling; clonal interference; background selection; hitchhiking;
haplotype
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VIVO; ASEXUAL EVOLUTION;
GENE-SEQUENCES; POPULATION; DYNAMICS; RESISTANCE; ADAPTATION; TYPE-1;
INDIVIDUALS
AB HIV adaptation to a host in chronic infection is simulated by means of a Monte-Carlo algorithm that includes the evolutionary factors of mutation, positive selection with varying strength among sites, random genetic drift, linkage, and recombination. By comparing two sensitive measures of linkage disequilibrium (LD) and the number of diverse sites measured in simulation to patient data from one-time samples of pol gene obtained by single-genome sequencing from representative untreated patients, we estimate the effective recombination rate and the average selection coefficient to be on the order of 1% per genome per generation (10(-5) per base per generation) and 0.5%, respectively. The adaptation rate is twofold higher and fourfold lower than predicted in the absence of recombination and in the limit of very frequent recombination, respectively. The level of LD and the number of diverse sites observed in data also range between the values predicted in simulation for these two limiting cases. These results demonstrate the critical importance of finite population size, linkage, and recombination in HIV evolution.
C1 [Rouzine, Igor M.; Coffin, John M.] Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.
[Batorsky, Rebecca] Tufts Univ, Dept Phys & Astron, Medford, MA 02155 USA.
[Kearney, Mary F.; Palmer, Sarah E.; Maldarelli, Frank] NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA.
RP Rouzine, IM (reprint author), Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.
EM irouzine@tufts.edu; john.coffin@tufts.edu
OI batorsky, rebecca/0000-0003-4712-6500
FU National Institutes of Health [R01AI 063926, R37CA 089441]; F. M. Kirby
Foundation
FX We are grateful to Nick Barton for numerous comments and to Boris
Shraiman and Richard Neher for useful discussion. The work was supported
by National Institutes of Health grants R01AI 063926 (to I. M. R.) and
R37CA 089441 (to J.M.C.). J.M.C. was a Research Professor of the
American Cancer Society with support from the F. M. Kirby Foundation.
NR 51
TC 51
Z9 51
U1 3
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 5
PY 2011
VL 108
IS 14
BP 5661
EP 5666
DI 10.1073/pnas.1102036108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 746RT
UT WOS:000289265300036
PM 21436045
ER
PT J
AU Flatz, L
Roychoudhuri, R
Honda, M
Filali-Mouhim, A
Goulet, JP
Kettaf, N
Lin, M
Roederer, M
Haddad, EK
Sekaly, RP
Nabel, GJ
AF Flatz, Lukas
Roychoudhuri, Rahul
Honda, Mitsuo
Filali-Mouhim, Abdelali
Goulet, Jean-Philippe
Kettaf, Nadia
Lin, Min
Roederer, Mario
Haddad, Elias K.
Sekaly, Rafick P.
Nabel, Gary J.
TI Single-cell gene-expression profiling reveals qualitatively distinct CD8
T cells elicited by different gene-based vaccines
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE lymphocyte subsets; microarray; immune differentiation
ID SIMIAN IMMUNODEFICIENCY VIRUS; RHESUS-MONKEYS; MEMORY; PROTECTION;
CHALLENGE; IMMUNIZATION; REPLICATION; LYMPHOCYTES; RESPONSES;
IMMUNOGENICITY
AB CD8 T cells play a key role in mediating protective immunity against selected pathogens after vaccination. Understanding the mechanism of this protection is dependent upon definition of the heterogeneity and complexity of cellular immune responses generated by different vaccines. Here, we identify previously unrecognized subsets of CD8 T cells based upon analysis of gene-expression patterns within single cells and show that they are differentially induced by different vaccines. Three prime-boost vector combinations encoding HIV Env stimulated antigen-specific CD8 T-cell populations of similar magnitude, phenotype, and functionality. Remarkably, however, analysis of single-cell gene-expression profiles enabled discrimination of a majority of central memory ( CM) and effector memory ( EM) CD8 T cells elicited by the three vaccines. Subsets of T cells could be defined based on their expression of Eomes, Cxcr3, and Ccr7, or Klrk1, Klrg1, and Ccr5 in CM and EM cells, respectively. Of CM cells elicited by DNA prime-recombinant adenoviral (rAd) boost vectors, 67% were Eomes-Ccr7(+) Cxcr3(-), in contrast to only 7% and 2% stimulated by rAd5-rAd5 or rAd-LCMV, respectively. Of EM cells elicited by DNA-rAd, 74% were Klrk1(-) Klrg1(-)Ccr5(-) compared with only 26% and 20% for rAd5-rAd5 or rAd5-LCMV. Definition by single-cell gene profiling of specific CM and EM CD8 T-cell subsets that are differentially induced by different gene-based vaccines will facilitate the design and evaluation of vaccines, as well as enable our understanding of mechanisms of protective immunity.
C1 [Flatz, Lukas; Roychoudhuri, Rahul; Honda, Mitsuo; Roederer, Mario; Nabel, Gary J.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Flatz, Lukas] Univ Bern, Inst Infect Dis, CH-3010 Bern, Switzerland.
[Filali-Mouhim, Abdelali; Goulet, Jean-Philippe; Kettaf, Nadia; Haddad, Elias K.; Sekaly, Rafick P.] Ctr Hosp Univ Montreal, Ctr Rech, Immunol Lab, Montreal, PQ H2X 1P1, Canada.
[Lin, Min] Fluidigm Corp, San Francisco, CA 94080 USA.
[Haddad, Elias K.; Sekaly, Rafick P.] Vaccine & Gene Therapy Inst, Port St Lucie, FL 34987 USA.
RP Nabel, GJ (reprint author), NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
EM gnabel@nih.gov
RI Roychoudhuri, Rahul/A-7442-2010
OI Roychoudhuri, Rahul/0000-0002-5392-1853
FU Vaccine Research Center, National Institute of Allergy and Infectious
Diseases, National Institutes of Health; Schwyzer Stiftung
FX We thank Steve Perfetto, Richard Nguyen, David Ambrozak, Pratip
Chattopadhyay, Enrico Lugli, Yolanda Mahnke, and Carl Hogerkorp for help
and advice with cell sorting, microarray, and real time PCR; Jeff
Skinner for his advice regarding hierarchical clustering of gene
expression data; Derek Macallan and George Griffin, Martin Pieprzyk,
Tomer Kalisky, Daniel Danila, and Nicholas Restifo for their help and
advice; and Brenda Hartman for help with the figure preparation and Ati
Tislerics for support in manuscript editing. This research was supported
in part by the Intramural Research Program of the Vaccine Research
Center, National Institute of Allergy and Infectious Diseases, National
Institutes of Health. L. F. was supported by the Schwyzer Stiftung.
NR 28
TC 61
Z9 61
U1 0
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 5
PY 2011
VL 108
IS 14
BP 5724
EP 5729
DI 10.1073/pnas.1013084108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 746RT
UT WOS:000289265300047
PM 21422297
ER
PT J
AU Onda, M
Beers, R
Xiang, LM
Lee, B
Weldon, JE
Kreitman, RJ
Pastan, I
AF Onda, Masanori
Beers, Richard
Xiang, Laiman
Lee, Byungkook
Weldon, John E.
Kreitman, Robert J.
Pastan, Ira
TI Recombinant immunotoxin against B-cell malignancies with no
immunogenicity in mice by removal of B-cell epitopes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE protein engineering; SS1P; passive immunotherapy; target therapy/cancer
therapeutics
ID PHASE-I TRIAL; STAPHYLOKINASE VARIANTS; CYTOTOXIC ACTIVITY;
ANTITUMOR-ACTIVITY; ANIMAL TOXICITY; ALTERED IMMUNOREACTIVITY;
RFB4(DSFV)-PE38 BL22; PSEUDOMONAS EXOTOXIN; LEUKEMIA; SS1P
AB Many nonhuman proteins have useful pharmacological activities, but are infrequently effective in humans because of their high immunogenicity. A recombinant immunotoxin (HA22, CAT8015, moxetumomab pasudotox) composed of an anti-CD22 antibody variable fragment fused to PE38, a 38-kDa portion of Pseudomonas exotoxin A, has produced many complete remissions in drug-resistant hairy-cell leukemia when several cycles of the agent can be given, but has much less activity when antibodies develop. We have pursued a strategy to deimmunize recombinant immunotoxins by identifying and removing B-cell epitopes. We previously reported that we could eliminate most B-cell epitopes using a combination of point mutations and deletions. Here we show the location and amino acid composition of all of the B-cell epitopes in the remaining 25-kDa portion of Pseudomonas exotoxin. Using this information, we eliminated these epitopes to produce an immunotoxin (HA22-LR-8M) that is fully cytotoxic against malignant B-cell lines, has high cytotoxic activity against cells directly isolated from patients with chronic lymphocytic leukemia, and has excellent antitumor activity in mice. HA22-LR-8M does not induce antibody formation in mice when given repeatedly by intravenous injection and does not induce a secondary antibody response when given to mice previously exposed to HA22. HA22-LR-8M also has greatly reduced antigenicity when exposed to sera from patients who have produced antibodies to HA22. The properties of HA22-LR-8M make it an excellent candidate for further clinical development.
C1 [Onda, Masanori; Beers, Richard; Xiang, Laiman; Lee, Byungkook; Weldon, John E.; Kreitman, Robert J.; Pastan, Ira] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Pastan, I (reprint author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM pastani@mail.nih.gov
OI Weldon, John/0000-0002-6516-9064
FU National Institutes of Health, National Cancer Institute, Center for
Cancer Research; MedImmune, LLC.
FX We thank Dr. B. K. Sathyanaraya for making the structure drawings shown
in Figs. 1 and 3. This research was supported by the Intramural Research
Program of the National Institutes of Health, National Cancer Institute,
Center for Cancer Research, and by a Cooperative Research and
Development Agreement with MedImmune, LLC.
NR 31
TC 53
Z9 55
U1 0
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 5
PY 2011
VL 108
IS 14
BP 5742
EP 5747
DI 10.1073/pnas.1102746108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 746RT
UT WOS:000289265300050
PM 21436054
ER
PT J
AU Cullen, M
Elzarrad, MK
Seaman, S
Zudaire, E
Stevens, J
Yang, MY
Li, XJ
Chaudhary, A
Xu, LH
Hilton, MB
Logsdon, D
Hsiao, E
Stein, EV
Cuttitta, F
Haines, DC
Nagashima, K
Tessarollo, L
St Croix, B
AF Cullen, Mike
Elzarrad, Mohammed K.
Seaman, Steven
Zudaire, Enrique
Stevens, Janine
Yang, Mi Young
Li, Xiujie
Chaudhary, Amit
Xu, Lihong
Hilton, Mary Beth
Logsdon, Daniel
Hsiao, Emily
Stein, Erica V.
Cuttitta, Frank
Haines, Diana C.
Nagashima, Kunio
Tessarollo, Lino
St Croix, Brad
TI GPR124, an orphan G protein-coupled receptor, is required for
CNS-specific vascularization and establishment of the blood-brain
barrier
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; GLUCOSE-TRANSPORTER GLUT-1; ANGIOGENESIS;
MORPHOGENESIS; VEGF; PERMEABILITY; MICE; DIFFERENTIATION; VASCULATURE;
EXPRESSION
AB Every organ in the body requires blood vessels for efficient delivery of oxygen and nutrients, but independent vascular beds are highly specialized to meet the individual needs of specific organs. The vasculature of the brain is tightly sealed, with blood-brain barrier (BBB) properties developing coincident with neural vascularization. G protein-coupled receptor 124 (GPR124) (tumor endothelial marker 5, TEM5), an orphan member of the adhesion family of G protein-coupled receptors, was previously identified on the basis of its overexpression in tumor vasculature. Here, we show that global deletion or endothelial-specific deletion of GPR124 in mice results in embryonic lethality associated with abnormal angiogenesis of the forebrain and spinal cord. Expression of GPR124 was found to be required for invasion and migration of blood vessels into neuroepithelium, establishment of BBB properties, and expansion of the cerebral cortex. Thus, GPR124 is an important regulator of neurovasculature development and a potential drug target for cerebrovascular diseases.
C1 [Cullen, Mike; Elzarrad, Mohammed K.; Seaman, Steven; Stevens, Janine; Yang, Mi Young; Li, Xiujie; Chaudhary, Amit; Xu, Lihong; Hilton, Mary Beth; Hsiao, Emily; Stein, Erica V.; St Croix, Brad] NCI, Tumor Angiogenesis Sect, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA.
[Zudaire, Enrique; Cuttitta, Frank] NCI, Angiogenesis Core Facil, NIH, Gaithersburg, MD 20877 USA.
[Hilton, Mary Beth; Logsdon, Daniel] NCI, Basic Res Program, Frederick, MD 21702 USA.
[Haines, Diana C.] NCI, Vet Pathol Sect, Pathol Histotechnol Lab, Frederick, MD 21702 USA.
[Nagashima, Kunio] NCI, Image Anal Lab, Adv Technol Program, Sci Applicat Int Corp, Frederick, MD 21702 USA.
[Tessarollo, Lino] NCI, Neural Dev Sect, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA.
RP St Croix, B (reprint author), NCI, Tumor Angiogenesis Sect, Mouse Canc Genet Program, NIH, Frederick, MD 21702 USA.
EM stcroix@ncifcrf.gov
RI Seaman, Steven/A-2755-2013; Cuttitta, Frank/B-4758-2016;
OI Seaman, Steven/0000-0003-3349-3334; Stein, Erica/0000-0001-8778-8846
FU National Cancer Institute (NCI), National Institutes of Health;
Department of Health and Social Services (DHSS); NCI [HHSN261200800001E]
FX We thank Dr. Babette Weksler for the immortalized hCMEC (HCMEC/D3)
cells. We thank members of the Mouse Cancer Genetics Program for helpful
discussion and Dr. Neal Copeland for critical reading of the manuscript.
This research was supported by the intramural research program of the
National Cancer Institute (NCI), National Institutes of Health,
Department of Health and Social Services (DHSS), and with federal funds
from the NCI under Contract HHSN261200800001E. The content of this
publication does not necessarily reflect the views or policies of the
DHSS nor does mention of trade names, commercial products, or
organizations imply endorsement by the US government.
NR 38
TC 54
Z9 59
U1 3
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 5
PY 2011
VL 108
IS 14
BP 5759
EP 5764
DI 10.1073/pnas.1017192108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 746RT
UT WOS:000289265300053
PM 21421844
ER
PT J
AU Fernando, RN
Eleuteri, B
Abdelhady, S
Nussenzweig, A
Andang, M
Ernfors, P
AF Fernando, Ruani N.
Eleuteri, Boris
Abdelhady, Shaimaa
Nussenzweig, Andre
Andang, Michael
Ernfors, Patrik
TI Cell cycle restriction by histone H2AX limits proliferation of adult
neural stem cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE DNA damage response; subventricular zone astrocytes; self-repair
ID IN-VIVO; SONIC HEDGEHOG; PROGENITOR CELLS; MAMMALIAN BRAIN; DENTATE
GYRUS; NEUROGENESIS; ZONE; MAINTENANCE; VITRO; FATE
AB Adult neural stem cell proliferation is dynamic and has the potential for massive self-renewal yet undergoes limited cell division in vivo. Here, we report an epigenetic mechanism regulating proliferation and self-renewal. The recruitment of the PI3K-related kinase signaling pathway and histone H2AX phosphorylation following GABA(A) receptor activation limits subventricular zone proliferation. As a result, NSC self-renewal and niche size is dynamic and can be directly modulated in both directions pharmacologically or by genetically targeting H2AX activation. Surprisingly, changes in proliferation have long-lasting consequences on stem cell numbers, niche size, and neuronal output. These results establish a mechanism that continuously limits proliferation and demonstrates its impact on adult neurogenesis. Such homeostatic suppression of NSC proliferation may contribute to the limited self-repair capacity of the damaged brain.
C1 [Fernando, Ruani N.; Eleuteri, Boris; Abdelhady, Shaimaa; Andang, Michael; Ernfors, Patrik] Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, S-17177 Stockholm, Sweden.
[Nussenzweig, Andre] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.
RP Ernfors, P (reprint author), Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, S-17177 Stockholm, Sweden.
EM patrik.ernfors@ki.se
OI Ernfors, Patrik/0000-0002-1140-3986; Andang, Michael/0000-0002-2886-7891
FU Swedish Research Council; Swedish Cancer Foundation; Swedish Child
Cancer Foundation; Swedish Brain Foundation; Bertil Hallsten Research
Foundation; EU; KI Strategic Neuroscience Programme; Wallenberg Scholar
Award; ERC [232675]; Knut and Alice Wallenberg Foundation (Center for
Live Imaging of Cells at Karolinska Institutet); Federation of the
Societies of Biochemistry and Molecular Biology; Swedish Childhood
Cancer Foundation
FX We thank Prof. Magdalena Gotz for sharing the GLAST-CreERT2;CAG-GFP mice
and Helena Samuelsson for technical support. This work was supported by
Swedish Research Council Linne Grants (Developmental Biology for
Regenerative Medicine Grant), Swedish Cancer Foundation, Swedish Child
Cancer Foundation, Swedish Brain Foundation, Bertil Hallsten Research
Foundation, EU FP7 MOLPARK collaborative project, KI Strategic
Neuroscience Programme, Wallenberg Scholar Award, ERC Advanced Grant
232675 (to P.E.), and Knut and Alice Wallenberg Foundation (Center for
Live Imaging of Cells at Karolinska Institutet). R. F. was supported by
the Swedish Research Council. B.E was supported by the Federation of the
Societies of Biochemistry and Molecular Biology. M.A was supported by
the Swedish Research Council, Swedish Cancer Foundation, and Swedish
Childhood Cancer Foundation.
NR 44
TC 59
Z9 62
U1 1
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 5
PY 2011
VL 108
IS 14
BP 5837
EP 5842
DI 10.1073/pnas.1014993108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 746RT
UT WOS:000289265300066
PM 21436033
ER
PT J
AU Phillips, D
Aponte, AM
Covian, R
Balaban, RS
AF Phillips, Darci
Aponte, Angel M.
Covian, Raul
Balaban, Robert S.
TI Intrinsic Protein Kinase Activity in Mitochondrial Oxidative
Phosphorylation Complexes
SO BIOCHEMISTRY
LA English
DT Article
ID CYTOCHROME-C-OXIDASE; NUCLEOSIDE DIPHOSPHATE KINASE;
PYRUVATE-DEHYDROGENASE; CREATINE-KINASE; BOUND PHOSPHOHISTIDINE; NATIVE
ELECTROPHORESIS; MASS-SPECTROMETRY; ATP; AUTOPHOSPHORYLATION; MEMBRANE
AB Mitochondrial protein phosphorylation is a well-recognized metabolic control mechanism, with the classical example of pyruvate dehydrogenase (PDH) regulation by specific kinases and phosphatases of bacterial origin. However, despite the growing number of reported mitochondrial phosphoproteins, the identity of the protein kinases mediating these phosphorylation events remains largely unknown. The detection of mitochondrial protein kinases is complicated by the low concentration of kinase relative to that of the target protein, the lack of specific antibodies, and contamination from associated, but nonmatrix, proteins. In this study, we use blue native gel electrophoresis (BN-PAGE) to isolate rat and porcine heart mitochondrial complexes for screening of protein kinase activity. To detect kinase activity, one-dimensional BN-PAGE gels were exposed to [gamma-(32)P]ATP and then followed by sodium dodecyl sulfate gel electrophoresis. Dozens of mitochondrial proteins were labeled with (32)P in this setting, including all five complexes of oxidative phosphorylation and several citric acid cycle enzymes. The nearly ubiquitous (32)P protein labeling demonstrates protein kinase activity within each mitochondrial protein complex. The validity of this two-dimensional BN-PAGE method was demonstrated by detecting the known PDH kinases and phosphatases within the PDH complex band using Western blots and mass spectrometry. Surprisingly, these same approaches detected only a few additional conventional protein kinases, suggesting a major role for autophosphorylation in mitochondrial proteins. Studies on purified Complex V and creatine kinase confirmed that these proteins undergo autophosphorylation and, to a lesser degree, tenacious (32)P-metabolite association. In-gel Complex IV activity was shown to be inhibited by ATP, and partially reversed by phosphatase activity, consistent with an inhibitory role for protein phosphorylation in this complex. Collectively, this study proposes that many of the mitochondrial complexes contain an autophosphorylation mechanism, which may play a functional role in the regulation of these multiprotein units.
C1 [Phillips, Darci; Covian, Raul; Balaban, Robert S.] NHLBI, Cardiac Energet Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Aponte, Angel M.] NHLBI, Prote Core Facil, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
RP Balaban, RS (reprint author), NHLBI, Cardiac Energet Lab, NIH, Dept Hlth & Human Serv, 10 Ctr Dr,Room B1D416, Bethesda, MD 20892 USA.
EM rsb@nih.gov
FU National Institutes of Health Division of Intramural Research
FX These studies were funded by the National Institutes of Health Division
of Intramural Research.
NR 53
TC 20
Z9 20
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD APR 5
PY 2011
VL 50
IS 13
BP 2515
EP 2529
DI 10.1021/bi101434x
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 742UN
UT WOS:000288970800016
PM 21329348
ER
PT J
AU Daar, ES
Tierney, C
Fischl, MA
Sax, PE
Mollan, K
Budhathoki, C
Godfrey, C
Jahed, NC
Myers, L
Katzenstein, D
Farajallah, A
Rooney, JF
Pappa, KA
Woodward, WC
Patterson, K
Bolivar, H
Benson, CA
Collier, AC
AF Daar, Eric S.
Tierney, Camlin
Fischl, Margaret A.
Sax, Paul E.
Mollan, Katie
Budhathoki, Chakra
Godfrey, Catherine
Jahed, Nasreen C.
Myers, Laurie
Katzenstein, David
Farajallah, Awny
Rooney, James F.
Pappa, Keith A.
Woodward, William C.
Patterson, Kristine
Bolivar, Hector
Benson, Constance A.
Collier, Ann C.
CA AIDS Clinical Trials Grp Study A52
TI Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for
Initial Treatment of HIV-1
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID TWICE-DAILY LOPINAVIR/RITONAVIR; ONCE-DAILY ATAZANAVIR/RITONAVIR; NAIVE
HIV-1-INFECTED PATIENTS; RENAL-FUNCTION; ANTIRETROVIRAL TREATMENT;
TENOFOVIR DF; THERAPY; LAMIVUDINE; ABACAVIR; EMTRICITABINE
AB Background: Limited data compare once-daily options for initial therapy for HIV-1.
Objective: To compare time to virologic failure; first grade-3 or -4 sign, symptom, or laboratory abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir plus ritonavir with efavirenz-containing initial therapy for HIV-1.
Design: A randomized equivalence trial accrued from September 2005 to November 2007, with median follow-up of 138 weeks. Regimens were assigned by using a central computer, stratified by screening HIV-1 RNA level less than 100 000 copies/mL or 100 000 copies/mL or greater; blinding was known only to the site pharmacist. (ClinicalTrials.gov registration number: NCT00118898)
Setting: 59 AIDS Clinical Trials Group sites in the United States and Puerto Rico. Patients: Antiretroviral-naive patients.
Intervention: Open-label atazanavir plus ritonavir or efavirenz, each given with with placebo-controlled abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtricitabine.
Measurements: Primary outcomes were time to virologic failure, safety, and tolerability events. Secondary end points included proportion of patients with HIV-1 RNA level less than 50 copies/mL, emergence of drug resistance, changes in CD4 cell counts, calculated creatinine clearance, and lipid levels.
Results: 463 eligible patients were randomly assigned to receive atazanavir plus ritonavir and 465 were assigned to receive efavirenz, both with abacavir-lamivudine; 322 (70%) and 324 (70%), respectively, completed follow-up. The respective numbers of participants in each group who received tenofovir DF-emtricitabine were 465 and 464; 342 (74%) and 343 (74%) completed follow-up. Primary efficacy was similar in the group that received atazanavir plus ritonavir and and the group that received efavirenz and did not differ according to whether abacavir-lamivudine or tenofovir DF-emtricitabine was also given. Hazard ratios for time to virologic failure were 1.13 (95% CI, 0.82 to 1.56) and 1.01 (CI, 0.70 to 1.46), respectively, although CIs did not meet prespecified criteria for equivalence. The time to safety (P = 0.048) and tolerability (P < 0.001) events was longer in persons given atazanavir plus ritonavir than in those given efavirenz with abacavir-lamivudine but not with tenofovir DF-emtricitabine.
Limitations: Neither HLA-B*5701 nor resistance testing was the standard of care when A5202 enrolled patients. The third drugs, atazanavir plus ritonavir and efavirenz, were open-label; the nucleoside reverse transcriptase inhibitors were prematurely unblinded in the high viral load stratum; and 32% of patients modified or discontinued treatment with their third drug.
Conclusion: Atazanavir plus ritonavir and efavirenz have similar antiviral activity when used with abacavir-lamivudine or tenofovir DF-emtricitabine.
C1 Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Los Angeles, CA USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Univ Miami, Sch Med, Miami, FL 33136 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
NIAID, Bethesda, MD 20892 USA.
Social & Sci Syst, Silver Spring, MD 20910 USA.
Frontier Sci & Technol Res Fdn Inc, Amherst, NY 14226 USA.
Stanford Univ, Palo Alto, CA 94304 USA.
Bristol Myers Squibb Co, Plainsboro, NJ USA.
Gilead Sci Inc, Foster City, CA 94404 USA.
GlaxoSmithKline, Res Triangle Pk, NC 27709 USA.
Abbott Labs, Abbott Pk, IL 60064 USA.
Univ N Carolina, Chapel Hill, NC USA.
Univ Calif San Diego, San Diego, CA 92103 USA.
Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA.
RP Daar, ES (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, 1124 W Carson St,N-24, Torrance, CA 90502 USA.
EM EDaar@LABioMed.org
FU National Institutes of Health; National Institute of Allergy and
Infectious Diseases [U01AI068636]; AIDS Clinical Trials Group Central
Group [AI38858]; Statistical Data Management Center [AI38855, AI68634];
National Center for Research Resources
FX National Institutes of Health.; By award U01AI068636 from the National
Institute of Allergy and Infectious Diseases, along with the previous
grant for the AIDS Clinical Trials Group Central Group (AI38858) and the
Statistical Data Management Center grants (AI38855 and AI68634). The
study was supported in part by the General Clinical Research Center
Units, funded by the National Center for Research Resources.
NR 26
TC 183
Z9 183
U1 2
U2 11
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD APR 5
PY 2011
VL 154
IS 7
AR 445
DI 10.7326/0003-4819-154-7-201104050-00316
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 744EX
UT WOS:000289078700001
PM 21320923
ER
PT J
AU Lauer, MS
AF Lauer, Michael S.
TI How Will Exercise Capacity Gain Enough Respect?
SO CIRCULATION
LA English
DT Editorial Material
DE Editorials; cardiovascular diseases; classification; exercise;
mortality; risk
ID RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; SUDDEN CARDIAC
DEATH; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR-DISEASE; RISK;
PREDICTION; OVERWEIGHT; MORTALITY
C1 [Lauer, Michael S.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
RP Lauer, MS (reprint author), 6701 Rockledge Dr,Room 8128, Bethesda, MD 20892 USA.
EM lauerm@nhlbi.nih.gov
RI Lauer, Michael/L-9656-2013
OI Lauer, Michael/0000-0002-9217-8177
NR 23
TC 4
Z9 4
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD APR 5
PY 2011
VL 123
IS 13
BP 1364
EP 1366
DI 10.1161/CIRCULATIONAHA.111.023218
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 744FO
UT WOS:000289080500008
PM 21422388
ER
PT J
AU Burke, A
Zhang, R
Tavora, F
Li, L
Fowler, D
Oliveira, JB
AF Burke, Allen
Zhang, Richard
Tavora, Fabio
Li, Ling
Fowler, David
Oliveira, Joao Bosco
TI NOVEL PKP2 MUTATIONS IN ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY
AND SUDDEN ARRHYTHMIC DEATHS IN MORPHOLOGICALLY NORMAL HEARTS
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 60th Annual Scientific Session and Expo of the
American-College-of-Cardiology
CY APR 03-05, 2011
CL New Orleans, LA
SP Amer Coll Cardiol
C1 NIH, Bethesda, MD 20892 USA.
Univ Maryland, Med Ctr, Baltimore, MD 21201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 5
PY 2011
VL 57
IS 14
SU 1
BP E227
EP E227
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 778HR
UT WOS:000291695100228
ER
PT J
AU Hadnott, TN
Gould, H
Bondy, C
AF Hadnott, Tracy N.
Gould, Harley
Bondy, Carolyn
TI AORTIC DILATION IN THE PAROUS TURNER SYNDROME PATIENT: A CASE SERIES
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 60th Annual Scientific Session and Expo of the
American-College-of-Cardiology
CY APR 03-05, 2011
CL New Orleans, LA
SP Amer Coll Cardiol
C1 NIH, Bethesda, MD 20892 USA.
Howard Hughes Med Inst, Bethesda, MD 20817 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 5
PY 2011
VL 57
IS 14
SU 1
BP E1524
EP E1524
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 778HR
UT WOS:000291695101527
ER
PT J
AU Koh, KK
Quon, M
Park, Y
Han, S
Shin, E
Chung, WJ
Lee, K
AF Koh, Kwang K.
Quon, Michael
Park, Yae
Han, Seung
Shin, Eak
Chung, W-J
Lee, Kyoung
TI EFFECTS OF FENOFIBRATE THERAPY ON CIRCULATING ADIPOCYTOKINES IN PATIENTS
WITH PRIMARY HYPERTRIGLYCERIDEMIA
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 60th Annual Scientific Session and Expo of the
American-College-of-Cardiology
CY APR 03-05, 2011
CL New Orleans, LA
SP Amer Coll Cardiol
C1 Gachon Univ Gil Hosp, Inchon, South Korea.
NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 5
PY 2011
VL 57
IS 14
SU 1
BP E2024
EP E2024
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 778HR
UT WOS:000291695102029
ER
PT J
AU Sims, A
Frank, L
Cross, R
Clauss, S
Dimock, D
Purdy, J
Jacoub, I
Hazra, R
Hadigan, C
Sable, C
AF Sims, Amy
Frank, Lowell
Cross, Russell
Clauss, Sarah
Dimock, David
Purdy, Julia
Jacoub, Irene
Hazra, Rohan
Hadigan, Colleen
Sable, Craig
TI ABNORMAL CARDIAC STRAIN IN CHILDREN AND YOUNG ADULTS WITH HIV ACQUIRED
IN EARLY LIFE
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT 60th Annual Scientific Session and Expo of the
American-College-of-Cardiology
CY APR 03-05, 2011
CL New Orleans, LA
SP Amer Coll Cardiol
C1 Childrens Natl Med Ctr, Washington, DC 20010 USA.
NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD APR 5
PY 2011
VL 57
IS 14
SU 1
BP E446
EP E446
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 778HR
UT WOS:000291695100447
ER
PT J
AU Wang, H
Lafdil, F
Wang, L
Yin, S
Feng, DC
Gao, B
AF Wang, Hua
Lafdil, Fouad
Wang, Lei
Yin, Shi
Feng, Dechun
Gao, Bin
TI Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates
carbon tetrachloride-induced liver injury and fibrosis in mice:
involvement of hepatocyte STAT3 in TIMP-1 production
SO CELL AND BIOSCIENCE
LA English
DT Article
ID HEPATIC STELLATE CELLS; MATRIX METALLOPROTEINASES; SPECIAL EMPHASIS;
GENE-EXPRESSION; ONCOSTATIN-M; RAT; MECHANISMS; ACTIVATOR; PROTEIN; IL-6
AB Background: Tissue inhibitor of metalloproteinase 1 (TIMP-1), which is thought to be produced mainly by activated hepatic stellate cells and Kupffer cells in the liver, plays a pivotal role in matrix remodeling during liver injury and repair; while the effect of TIMP-1 on hepatocellular damage remains obscure.
Results: Hepatic expression of TIMP-1 mRNA and protein was up-regulated both in acute and chronic liver injury induced by carbon tetrachloride (CCl4). Compared with wild-type mice, TIMP-1 knockout mice were more susceptible to CCl4-induced acute and chronic liver injury, as shown by higher levels of serum alanine aminotransferase (ALT), greater number of apoptotic hepatocytes, and more extended necroinflammatory foci. TIMP-1 knockout mice also displayed greater degree of liver fibrosis after chronic CCl4 injection when compared with wild-type mice. In vitro treatment with TIMP-1 inhibited cycloheximide-induced cell death of primary mouse hepatocytes. Finally, up-regulation of TIMP-1 in the liver and serum after chronic CCl4 treatment was markedly diminished in hepatocyte-specific signal transducer and activator of transcription 3 (STAT3) knockout mice. In vitro treatment with interleukin-6 stimulated TIMP-1 production in primary mouse hepatocytes, but to a lesser extent in STAT3-deficient hepatocytes.
Conclusions: TIMP-1 plays an important role in protecting against acute and chronic liver injury and subsequently inhibiting liver fibrosis induced by CCl4. In addition to activated stellate cells and Kupffer cells, hepatocytes are also responsible for TIMP-1 production during liver injury via a STAT3-dependent manner.
C1 [Wang, Hua; Lafdil, Fouad; Wang, Lei; Yin, Shi; Feng, Dechun; Gao, Bin] NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA.
[Wang, Hua] Anhui Med Univ, Affiliated Prov Hosp, Dept Oncol, Hefei 230001, Anhui, Peoples R China.
[Lafdil, Fouad] Hop Henri Mondor, INSERM, U955, Lab Liver Pathophysiol, F-94010 Creteil, France.
RP Gao, B (reprint author), NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA.
EM bgao@mail.nih.gov
RI Feng, Dechun/Q-5962-2016
FU NIAAA, NIH; Natural Science Foundation of China [30973467/H1611]
FX This work was supported in part by the intramural program of NIAAA, NIH
(B Gao) and in part by the Natural Science Foundation of China (H Wang,
No. 30973467/H1611).
NR 32
TC 12
Z9 12
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2045-3701
J9 CELL BIOSCI
JI Cell Biosci.
PD APR 4
PY 2011
VL 1
AR 14
DI 10.1186/2045-3701-1-14
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 982OF
UT WOS:000307054300001
PM 21711826
ER
PT J
AU Yu, HP
Zhao, H
Wang, LE
Han, YH
Chen, WV
Amos, CI
Rafnar, T
Sulem, P
Stefansson, K
Landi, MT
Caporaso, N
Albanes, D
Thun, M
Mckay, JD
Brennan, P
Wang, YF
Houlston, RS
Spitz, MR
Wei, QY
AF Yu, Hongping
Zhao, Hui
Wang, Li-E
Han, Younghun
Chen, Wei V.
Amos, Christopher I.
Rafnar, Thorunn
Sulem, Patrick
Stefansson, Kari
Landi, Maria Teresa
Caporaso, Neil
Albanes, Demetrius
Thun, Michael
McKay, James D.
Brennan, Paul
Wang, Yufei
Houlston, Richard S.
Spitz, Margaret R.
Wei, Qingyi
TI An analysis of single nucleotide polymorphisms of 125 DNA repair genes
in the Texas genome-wide association study of lung cancer with a
replication for the XRCC4 SNPs
SO DNA REPAIR
LA English
DT Article
DE XRCC4; Variant; Genetic susceptibility; Genome-wide association study;
Replication study
ID DOUBLE-STRAND; SUSCEPTIBILITY LOCUS; SEQUENCE VARIANTS; BREAK REPAIR;
LIGASE IV; RISK; EPIDEMIOLOGY; RADIATION; DAMAGE; METAANALYSIS
AB DNA repair genes are important for maintaining genomic stability and limiting carcinogenesis. We analyzed all single nucleotide polymorphisms (SNPs) of 125 DNA repair genes covered by the Illumina HumanHap300 (v1.1) BeadChips in a previously conducted genome-wide association study (GWAS) of 1154 lung cancer cases and 1137 controls and replicated the top-hits of XRCC4 SNPs in an independent set of 597 cases and 611 controls in Texas populations. We found that six of 20 XRCC4 SNPs were associated with a decreased risk of lung cancer with a P-value of 0.01 or lower in the discovery dataset, of which the most significant SNP was rs10040363 (P for allelic test = 4.89 x 10(-4)). Moreover, the data in this region allowed us to impute a potentially functional SNP rs2075685 (imputed P for allelic test = 1.3 x 10(-3)). A luciferase reporter assay demonstrated that the rs2075685G > T change in the XRCC4 promoter increased expression of the gene. In the replication study of rs10040363, rs1478486, rs9293329, and rs2075685, however, only rs10040363 achieved a borderline association with a decreased risk of lung cancer in a dominant model (adjusted OR = 0.80. 95% CI = 0.62-1.03 and P = 0.079). In the final combined analysis of both the Texas GWAS discovery and replication datasets, the strength of the association was increased for rs10040363 (adjusted OR = 0.77.95% CI = 0.66-0.89, P-dominant = 5 x 10(-4) and P for trend = 5 x 10(-4)) and rs1478486 (adjusted OR = 0.82, 95% CI = 0.71-0.94, P-dominant = 6 x 10(-3) and P for trend = 3.5 x 10(-3)). Finally, we conducted a meta-analysis of these XRCC4 SNPs with available data from published GWA studies of lung cancer with a total of 12,312 cases and 47,921 controls, in which none of these XRCC4 SNPs was associated with lung cancer risk. It appeared that rs2075685, although associated with increased expression of a reporter gene and lung cancer risk in the Texas populations, did not have an effect on lung cancer risk in other populations. This study underscores the importance of replication using published data in larger populations. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Wei, Qingyi] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1365, Houston, TX 77030 USA.
[Rafnar, Thorunn; Sulem, Patrick; Stefansson, Kari] DeCODE Genet, IS-101 Reykjavik, Iceland.
[Landi, Maria Teresa; Caporaso, Neil; Albanes, Demetrius] NIH, Div Canc Epidemiol, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Thun, Michael] Amer Canc Soc, Dept Epidemiol, Atlanta, GA 30329 USA.
[McKay, James D.; Brennan, Paul] Int Agcy Res Canc, F-69372 Lyon, France.
[Wang, Yufei; Houlston, Richard S.] Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England.
RP Wei, QY (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Unit 1365, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM qwei@mdanderson.org
RI Yu, Hongping/F-3710-2011; Albanes, Demetrius/B-9749-2015;
OI Houlston, Richard/0000-0002-5268-0242
FU National Institutes of Health [ES11740, CA131274, CA86390, CA55769,
CA121197, CA 16672]
FX We thank Min Zhao, Jianzhong He and Kejing Xu for their laboratory
assistance, and Dakai Zhu for his technical support. This study was
supported in part by National Institutes of Health grants ES11740 and
CA131274 (to Q.W.), CA86390 and CA55769 (to M.R.S.), CA121197 (to C.A.),
and CA 16672 (to The University of Texas M.D. Anderson Cancer Center).
Its contents are solely the responsibility of the authors and do not
necessarily represent the official views of the National Institutes of
Health.
NR 44
TC 15
Z9 16
U1 1
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1568-7864
J9 DNA REPAIR
JI DNA Repair
PD APR 3
PY 2011
VL 10
IS 4
BP 398
EP 407
DI 10.1016/j.dnarep.2011.01.005
PG 10
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA 751CZ
UT WOS:000289596400006
PM 21296624
ER
PT J
AU Krijger, PHL
Lee, KY
Wit, N
van den Berk, PCM
Wu, XL
Roest, HP
Maas, A
Ding, H
Hoeijmakers, JHJ
Myung, K
Jacobs, H
AF Krijger, Peter H. L.
Lee, Kyoo-Young
Wit, Niek
van den Berk, Paul C. M.
Wu, Xiaoli
Roest, Henk P.
Maas, Alex
Ding, Hao
Hoeijmakers, Jan H. J.
Myung, Kyungjae
Jacobs, Heinz
TI HLTF and SHPRH are not essential for PCNA polyubiquitination, survival
and somatic hypermutation: Existence of an alternative E3 ligase
SO DNA REPAIR
LA English
DT Article
DE PCNA; RAD5; HLTF; SHPRH; Somatic hypermutation; Translesion synthesis
ID CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-ETA; IMMUNOGLOBULIN GENE
HYPERMUTATION; POSTREPLICATION REPAIR PATHWAY; CLASS-SWITCH
RECOMBINATION; SACCHAROMYCES-CEREVISIAE; TRANSLESION SYNTHESIS;
UBIQUITIN LIGASE; GENOMIC INSTABILITY; DAMAGE
AB DNA damage tolerance is regulated at least in part at the level of proliferating cell nuclear antigen (PCNA) ubiquitination. Monoubiquitination (PCNA-Ub) at lysine residue 164 (K164) stimulates error-prone translesion synthesis (US), Rad5-dependent polyubiquitination (PCNA-Ub(n)) stimulates error-free template switching (TS). To generate high affinity antibodies by somatic hypermutation (SHM), B cells profit from error-prone TLS polymerases. Consistent with the role of PCNA-Ub in stimulating TLS, hypermutated B cells of PCNA(K164R) mutant mice display a defect in generating selective point mutations. Two Rad5 orthologs, HLTF and SHPRH have been identified as alternative E3 ligases generating PCNA-Ub(n) in mammals. As PCNA-Ub and PCNA-Ub(n) both make use of K164, error-free PCNA-Ub(n)-dependent TS may suppress error-prone PCNA-Ub-dependent TLS. To determine a regulatory role of Shprh and Hltf in SHM, we generated Shprh/Hltf double mutant mice. Interestingly, while the formation of PCNA-Ub and PCNA-Ub(n) is prohibited in PCNA(K164R) MEFs, the formation of PCNA-Ub(n) is not abolished in Shprh/Hltf mutant MEFs. In line with these observations Shprh/Hltf double mutant B cells were not hypersensitive to DNA damage. Furthermore, SHM was normal in Shprh/Hltf mutant B cells. These data suggest the existence of an alternative E3 ligase in the generation of PCNA-Ub(n). (C) 2010 Elsevier B.V. All rights reserved.
C1 [Jacobs, Heinz] Antoni van Leeuwenhoek Ziekenhuis, Netherlands Canc Inst, NKI AVL, Div Immunol, NL-1066 CX Amsterdam, Netherlands.
[Lee, Kyoo-Young; Myung, Kyungjae] NHGRI, Genome Instabil Sect, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA.
[Wu, Xiaoli; Ding, Hao] Univ Manitoba, Dept Biochem & Med Genet, Fac Med, Winnipeg, MB R3E 0W3, Canada.
[Roest, Henk P.; Maas, Alex; Hoeijmakers, Jan H. J.] Erasmus MC, Canc Genom Ctr, Dept Cell Biol & Genet, CBG, NL-3015 GE Rotterdam, Netherlands.
RP Jacobs, H (reprint author), Antoni van Leeuwenhoek Ziekenhuis, Netherlands Canc Inst, NKI AVL, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
EM h.jacobs@nki.nl
OI Krijger, Peter/0000-0003-1702-348X; Jacobs, Heinz/0000-0001-6227-9850
FU NHGRI; NIH [HG012003-09]; Korean Government [KRF-2007-357-C00092];
Netherlands Organisation for Scientific Research; Dutch Cancer Society
[NWO 917.56.328, NKI-2008-4112, EUR99-2003]
FX We thank Frank van Diepen and Anita Pfauth for cell sortings, the
NKI-AVL mouse facility for assistance and the NKI-AVL sequence facility
for sequencing. An anti-SHPRH antibody was kindly provided by Dr. Sood
(NHGRI, NIH). We like to apologize everybody whose work could only be
cited indirectly due to space limitations. We also thank Vanessa-Leigh
van Zuylen for critically reading the manuscript. This research was
supported by the intramural research program of the NHGRI, NIH
(HG012003-09) to KM, by the Korea Research Foundation Grant
(KRF-2007-357-C00092) funded by the Korean Government to KL, the
Netherlands Organisation for Scientific Research and the Dutch Cancer
Society (VIDI program NWO 917.56.328 and KWF grant NKI-2008-4112 to HJ,
and EUR99-2003 to HR and JH).
NR 34
TC 22
Z9 23
U1 1
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1568-7864
EI 1568-7856
J9 DNA REPAIR
JI DNA Repair
PD APR 3
PY 2011
VL 10
IS 4
BP 438
EP 444
DI 10.1016/j.dnarep.2010.12.008
PG 7
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA 751CZ
UT WOS:000289596400010
PM 21269891
ER
PT J
AU Quinn, TC
Serwadda, D
AF Quinn, Thomas C.
Serwadda, David
TI The future of HIV/AIDS in Africa: a shared responsibility
SO LANCET
LA English
DT Editorial Material
C1 [Quinn, Thomas C.] NIAID, Bethesda, MD 20892 USA.
[Quinn, Thomas C.] Johns Hopkins Univ, Ctr Global Hlth, Baltimore, MD 21205 USA.
[Serwadda, David] Makerere Univ, Sch Publ Hlth, Kampala, Uganda.
RP Quinn, TC (reprint author), NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM tquinn@jhmi.edu
NR 2
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD APR 2
PY 2011
VL 377
IS 9772
BP 1133
EP 1134
DI 10.1016/S0140-6736(10)62183-6
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 750IH
UT WOS:000289539300008
PM 21126758
ER
PT J
AU Gavidia, T
Brune, MN
McCarty, KM
Pronczuk, J
Etzel, R
Neira, M
Carpenter, DO
Suk, WA
Arnold, RG
Ha, EH
Sly, PD
AF Gavidia, Tania
Brune, Marie-Noel
McCarty, Kathleen M.
Pronczuk, Jenny
Etzel, Ruth
Neira, Maria
Carpenter, David O.
Suk, William A.
Arnold, Robert G.
Ha, Eun Hee
Sly, Peter D.
TI Children's environmental health-from knowledge to action
SO LANCET
LA English
DT Editorial Material
C1 [Gavidia, Tania; Sly, Peter D.] WHO Collaborating Ctr Res Childrens Environm Hlth, Perth, WA, Australia.
[Brune, Marie-Noel; Pronczuk, Jenny; Etzel, Ruth; Neira, Maria] WHO, Dept Publ Hlth & Environm, CH-1211 Geneva, Switzerland.
[McCarty, Kathleen M.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Div Environm Hlth Sci, New Haven, CT 06510 USA.
[Pronczuk, Jenny] Univ Republica, Dept Toxicol, Montevideo, Uruguay.
[Carpenter, David O.] SUNY Albany, Inst Hlth & Environm, Rensselaer, NY USA.
[Suk, William A.] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA.
[Arnold, Robert G.] Univ Arizona, Chem & Environm Engn Dept, Tucson, AZ USA.
[Ha, Eun Hee] Ewha Womans Univ, Dept Prevent Med, Seoul, South Korea.
[Sly, Peter D.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld 4029, Australia.
RP Sly, PD (reprint author), WHO Collaborating Ctr Res Childrens Environm Hlth, Perth, WA, Australia.
EM p.sly@uq.edu.au
RI Sly, Peter/F-1486-2010
OI Sly, Peter/0000-0001-6305-2201
NR 5
TC 6
Z9 6
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD APR 2
PY 2011
VL 377
IS 9772
BP 1134
EP 1136
DI 10.1016/S0140-6736(10)60929-4
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 750IH
UT WOS:000289539300009
PM 20667587
ER
PT J
AU Gaiser, T
Camps, J
Meinhardt, S
Wangsa, D
Nguyen, QT
Varma, S
Dittfeld, C
Kunz-Schughart, LA
Kemmerling, R
Becker, MR
Heselmeyer-Haddad, K
Ried, T
AF Gaiser, Timo
Camps, Jordi
Meinhardt, Sandra
Wangsa, Danny
Quang Tri Nguyen
Varma, Sudhir
Dittfeld, Claudia
Kunz-Schughart, Leoni A.
Kemmerling, Ralf
Becker, Maria R.
Heselmeyer-Haddad, Kerstin
Ried, Thomas
TI Genome and Transcriptome Profiles of CD133-Positive Colorectal Cancer
Cells
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID PLASMA-MEMBRANE PROTRUSIONS; TUMOR-INITIATING CELLS; HUMAN COLON-CANCER;
STEM-CELLS; HEMATOPOIETIC STEM; EPITHELIAL-CELLS; SOLID TUMORS; CD133
EXPRESSION; DRUG-RESISTANCE; RECTAL-CANCER
AB Colorectal carcinomas (CRC) might be organized hierarchically and contain a subpopulation of tumorigenic, putative cancer stem cells that are CD133 positive. We studied the biological and genetic characteristics of such cells in CRC cell lines and primary tumors. Three CRC cell lines were sorted in CD133 positive and negative fractions. The respective genetic aberration profiles were studied using array comparative genomic hybridization (aCGH) and expression profiling. Tumorigenicity for each cellular population was tested by injection into nude mice. Additionally, we compared CD133+ and CD133- cells of 12 primary colorectal tumors using laser capture microdissection and aCGH. Three of five CRC cell lines displayed both CD133+ and CD133- cells, but tumorigenicity of these subfractions did not differ significantly and aCGH revealed essentially identical genomic imbalances. However, 96 genes were differentially expressed between the two populations. Array comparative genomic hybridization analysis after laser capture microdissection of CD133+ and CD133- areas in primary colorectal tumors revealed genetic differences in 7 of 12 cases. The use of cell lines for studying genomic alterations that define cancer stem cell characteristics, therefore, seems questionable. In contrast, CD133+ cells in primary cancer samples showed a unique genomic aberration profile. In conclusion, our data suggest that CD133 positivity defines a genetically distinct cellular compartment in primary CRC, which potentially includes tumor initiating cells. (Am J Pathol 2011, 178:1478-1488; DOI: 10.1016/j.ajpath.2010.12.036)
C1 [Gaiser, Timo; Camps, Jordi; Meinhardt, Sandra; Wangsa, Danny; Quang Tri Nguyen; Heselmeyer-Haddad, Kerstin; Ried, Thomas] NCI, Sect Canc Genom, NIH, Bethesda, MD 20892 USA.
[Varma, Sudhir] NIAID, Bioinformat & Computat Biosci Branch, NIH, Bethesda, MD 20892 USA.
[Dittfeld, Claudia; Kunz-Schughart, Leoni A.] Tech Univ Dresden, OncoRay Natl Ctr Radiat Res Oncol, Dresden, Germany.
[Kemmerling, Ralf] Paracelsus Med Univ, Inst Pathol, Salzburg, Austria.
[Becker, Maria R.] NCI, Dermatol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Ried, T (reprint author), NCI, Sect Canc Genom, NIH, Bldg 50,Room 1408,50 South Dr, Bethesda, MD 20892 USA.
EM riedt@mail.nih.gov
RI Varma, Sudhir/N-8763-2014
OI Varma, Sudhir/0000-0002-4096-4782
FU National Institutes of Health, National Cancer Institute; Mildred Scheel
Foundation; German Research Foundation (DFG) [KU 971/7-1];
Bundesministerium fuer Bildung und Forschung "Center for Innovation
Competence"
FX Supported by the Intramural Research Program of the National Institutes
of Health, National Cancer Institute. T.G. is supported by a fellowship
within the post doctorate program of the Mildred Scheel Foundation. The
work performed by the group of LAKS (Tumor Pathophysiology, OncoRay) was
supported by the German Research Foundation (DFG) through a grant (KU
971/7-1). OncoRay is funded by the Bundesministerium fuer Bildung und
Forschung in the program "Center for Innovation Competence."
NR 63
TC 15
Z9 15
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD APR
PY 2011
VL 178
IS 4
BP 1478
EP 1488
DI 10.1016/j.ajpath.2010.12.036
PG 11
WC Pathology
SC Pathology
GA 865JH
UT WOS:000298306700009
PM 21435437
ER
PT J
AU Wang, Y
Hancock, AM
Bradner, J
Chung, KA
Quinn, JF
Peskind, ER
Galasko, D
Jankovic, J
Zabetian, CP
Kim, HM
Leverenz, JB
Montine, TJ
Ginghina, C
Edwards, KL
Snapinn, KW
Goldstein, DS
Shi, M
Zhang, J
AF Wang, Yu
Hancock, Aneeka M.
Bradner, Joshua
Chung, Kathryn A.
Quinn, Joseph F.
Peskind, Elaine R.
Galasko, Douglas
Jankovic, Joseph
Zabetian, Cyrus P.
Kim, Hojoong M.
Leverenz, James B.
Montine, Thomas J.
Ginghina, Carmen
Edwards, Karen L.
Snapinn, Katherine W.
Goldstein, David S.
Shi, Min
Zhang, Jing
TI Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's
Disease, Alzheimer's Disease, and Multiple-System Atrophy
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID CSF AMYLOID-BETA; CONSENSUS STATEMENT; COGNITIVE DECLINE;
NERVOUS-SYSTEM; PHOSPHO-TAU; LEWY BODY; DEMENTIA; BIOMARKERS; DIAGNOSIS;
EXPRESSION
AB Complement activation, a key component of neuroinflammation, has been reported in both Parkinson's disease (PD) and Alzheimer's disease (AD). However, it is unclear whether complement activation and neuroinflammation in general are distinctly different from each another in major neurodegenerative disorders. In the present study, cerebrospinal fluid complement 3 (C3) and factor H (FH) were measured and evaluated together with amyloid-beta(42) (A beta(42)), which in recent investigations was decreased in patients with PD, in particular those with cognitive impairment. The study included 345 participants: 126 patients with PD at various stages with or without cognitive impairment, 50 with AD, and 32 with multiple-system atrophy, and 137 healthy control individuals. In addition to changes in A beta(42) concentrations, there were clear differences in the patterns of complement profiles among neurodegenerative disorders. The C3/FH ratio demonstrated high sensitivity and specificity in differentiating patients with multiple-system atrophy from those with AD or PD and control individuals. In addition, the C3/A beta(42) and FH/A beta(42) ratios not only correlated with PD severity approximated using the Unified Parkinson's Disease Rating Scale but also with the presence of cognitive impairment or dementia in PD. Both C3 and FH correlated with the severity of impairment in AD as indicated using Mini-Mental State Examination scores. (Am J Pathol 2011, 178:1509-1516; DOI: 10.1016/j.ajpath.2011.01.006)
C1 [Wang, Yu; Hancock, Aneeka M.; Bradner, Joshua; Montine, Thomas J.; Ginghina, Carmen; Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA.
[Peskind, Elaine R.; Leverenz, James B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA.
[Zabetian, Cyrus P.; Kim, Hojoong M.; Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA.
[Wang, Yu] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan 430074, Peoples R China.
[Chung, Kathryn A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Peskind, Elaine R.; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
[Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Kim, Hojoong M.] Vet Affairs Puget Sound Hlth Care Syst, Dept Neurol, Seattle, WA USA.
[Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.
[Jankovic, Joseph] Baylor Coll Med, Parkinsons Dis Ctr, Dept Neurol, Houston, TX 77030 USA.
[Jankovic, Joseph] Baylor Coll Med, Movement Disorders Clin, Dept Neurol, Houston, TX 77030 USA.
[Edwards, Karen L.; Snapinn, Katherine W.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Goldstein, David S.] NINDS, Clin Neurocardiol Sect, Clin Neurosci Program, Div Intramural Res,NIH, Bethesda, MD 20892 USA.
RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, HMC Box 359635,325 9th Ave, Seattle, WA 98104 USA.
EM zhangj@uw.edu
RI Shi, Min/G-6165-2012;
OI Shi, Min/0000-0002-6901-2558; Zabetian, Cyrus/0000-0002-7739-4306
FU National Institutes of Health [ES004696, NS057567, AG025327, AG033398,
NS060252, NS062684, AG005136, AG008017]; Michael J. Fox Foundation;
Cheng-Mei Shaw Endowment; Nancy and Buster Alvord Endowment
FX Supported by grants ES004696, NS057567, AG025327, AG033398, and NS060252
(J.Z.), NS062684 (T.J.M., C.P.Z., J.B.L., and J.Z.), AG005136 (ERR. and
T.J.M.), and AG008017 (K.A.C. and J.F.Q.) from the National Institutes
of Health, and grants from the Michael J. Fox Foundation and the
Cheng-Mei Shaw Endowment (J.Z.) and the Nancy and Buster Alvord
Endowment (T.J.M.).
NR 37
TC 38
Z9 41
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD APR
PY 2011
VL 178
IS 4
BP 1509
EP 1516
DI 10.1016/j.ajpath.2011.01.006
PG 8
WC Pathology
SC Pathology
GA 865JH
UT WOS:000298306700012
PM 21435440
ER
PT J
AU Yin, S
Wang, H
Park, O
Wei, W
Shen, JL
Gao, B
AF Yin, Shi
Wang, Hua
Park, Ogyi
Wei, Wei
Shen, Jilong
Gao, Bin
TI Enhanced Liver Regeneration in IL-10-Deficient Mice after Partial
Hepatectomy via Stimulating Inflammatory Response and Activating
Hepatocyte STAT3
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID INTEGRIN-LINKED KINASE; SIGNAL TRANSDUCER; TRANSCRIPTION 3; FACTOR
RECEPTOR; PROLIFERATION; CYTOKINE; MASS; INTERLEUKIN-10; HYPERTROPHY;
CONTRIBUTES
AB Emerging evidence suggests that proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), play a critical role in the initiation and progression of liver regeneration; however, relatively little is known about the role of anti-inflammatory cytokine IL-10 in liver regeneration after partial hepatectomy (PHx). Here, we examined the role of IL-10 in liver regeneration using a model of PHx in several strains of genetically modified mice. After PHx, expression of IL-10 mRNA in the liver and spleen was significantly elevated. Such elevation was diminished in TLR4 mutant mice. Compared with wild-type mice, IL-10(-/-) mice had higher levels of expression of proinflammatory cytokines (IL-6, TNF-alpha, and IFN-gamma) and inflamniatory markers (CCR2 and F4/80) in the liver, as well as higher serum levels of proinflammatory cytokines after PHx. The number of neutrophils and macrophages was also higher in the livers of IL-10(-/-) mice than in wild-type mice after PHx. Liver regeneration as determined by BrdU incorporation after PHx was higher in IL-10(-/-) mice than in wild-type mice, which was associated with higher levels of activation of IL-6 downstream signal STAT3 in the liver. An additional deletion of STAT3 in hepatocytes significantly reduced liver regeneration in IL-10(-/-) mice after PHx. Collectively, IL-10 plays an important role in negatively regulating liver regeneration via limiting inflammatory response and subsequently tempering hepatic STAT3 activation. (Am J Pathol 2011, 178:1614-1621; DOI: 10.1016/j.ajpath.2011.01.001)
C1 [Yin, Shi; Wang, Hua; Park, Ogyi; Gao, Bin] NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA.
[Yin, Shi; Shen, Jilong] Anhui Med Univ, Dept Microbiol & Parasitol, Hefei 230032, Anhui, Peoples R China.
[Wang, Hua] Anhui Med Univ, Dept Oncol, Hefei 230032, Anhui, Peoples R China.
[Yin, Shi; Shen, Jilong] Anhui Med Univ, Minist Educ, Prov Lab Microbiol & Parasitol, Hefei 230032, Anhui, Peoples R China.
[Yin, Shi; Wei, Wei; Shen, Jilong] Anhui Med Univ, Minist Educ, Inst Clin Pharmacol, Hefei 230032, Anhui, Peoples R China.
RP Gao, B (reprint author), NIAAA, Lab Liver Dis, NIH, Bethesda, MD 20892 USA.
EM jlshen@ahmu.edu.cn; bgao@mail.nih.gov
FU National Institute on Alcohol Abuse and Alcoholism of the National
Institutes of Health (NIH); Natural Science Foundation of China
[30973467/H1611]
FX Supported in part by the intramural program of National Institute on
Alcohol Abuse and Alcoholism of the National Institutes of Health (NIH)
(B.G.) and in part by the Natural Science Foundation of China (No.
30973467/H1611 to H.W.).
NR 35
TC 17
Z9 20
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD APR
PY 2011
VL 178
IS 4
BP 1614
EP 1621
DI 10.1016/j.ajpath.2011.01.001
PG 8
WC Pathology
SC Pathology
GA 865JH
UT WOS:000298306700021
PM 21435447
ER
PT J
AU Pincock, LL
Montello, MJ
Tarosky, MJ
Pierce, WF
Edwards, CW
AF Pincock, Laura L.
Montello, Michael J.
Tarosky, Matthew J.
Pierce, William F.
Edwards, Calvin W.
TI Pharmacist readiness roles for emergency preparedness
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Editorial Material
ID HURRICANE-KATRINA
C1 [Pierce, William F.] US FDA, Div Biol Oncol Prod, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA.
[Pincock, Laura L.] US FDA, Off Commun, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA.
[Montello, Michael J.] NCI, Clin Invest Branch, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, Rockville, MD USA.
[Tarosky, Matthew J.] US FDA, Div Biores Monitoring, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA.
[Tarosky, Matthew J.] US FDA, PHS Rapid Deployment Force 1, CDER, Planning Sect, Silver Spring, MD 20993 USA.
[Edwards, Calvin W.] US FDA, Off Regulatory Affairs, Silver Spring, MD 20993 USA.
RP Pierce, WF (reprint author), US FDA, Div Biol Oncol Prod, Off New Drugs, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave,Bldg 22,Room 5219, Silver Spring, MD 20993 USA.
EM william.pierce@fda.hhs.gov
NR 13
TC 3
Z9 3
U1 0
U2 5
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD APR 1
PY 2011
VL 68
IS 7
BP 620
EP 623
DI 10.2146/ajhp090659
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 858CF
UT WOS:000297772800014
PM 21411804
ER
PT J
AU Hartz, SM
Lin, P
Edenberg, HJ
Xuei, XL
Rochberg, N
Saccone, S
Berrettini, W
Nelson, E
Nurnberger, J
Bierut, LJ
Rice, JP
AF Hartz, Sarah M.
Lin, Peng
Edenberg, Howard J.
Xuei, Xiaoling
Rochberg, Nanette
Saccone, Scott
Berrettini, Wade
Nelson, Elliot
Nurnberger, John
Bierut, Laura J.
Rice, John P.
CA NIMH Genetics Initiative Bipolar D
TI Genetic association of bipolar disorder with the beta(3) nicotinic
receptor subunit gene
SO PSYCHIATRIC GENETICS
LA English
DT Article
DE analyses; CHRNA3; CHRNA5; CHRNA6; genetic association nicotine; tobacco
use disorder
ID GENOME-WIDE ASSOCIATION; EUROPEAN-ANCESTRY; ACETYLCHOLINE-RECEPTORS;
LINKAGE ANALYSES; TOBACCO SMOKING; CANDIDATE GENES; DEPENDENCE; SAMPLE;
SCHIZOPHRENIA; RISK
AB Objective Owing to the clinical relationship between bipolar disorder and nicotine dependence, we investigated two research questions: (i) are genetic associations with nicotine dependence different in individuals with bipolar disorder as compared with individuals without bipolar disorder, and (ii) do loci earlier associated with nicotine dependence have pleiotropic effects on these two diseases.
Method Our study consisted of 916 cases with bipolar disorder and 1028 controls. On the basis of known associations with nicotine dependence, we genotyped eight single-nucleotide polymorphisms (SNPs) on chromosome 8 (three bins) in the regions of CHRNB3 and CHRNA6, and six SNPs on chromosome 15 (three bins) in the regions of CHRNA5 and CHRNA3.
Results To determine whether the genetic associations with nicotine dependence are different in bipolar disorder than in the general population, we compared allele frequencies of candidate SNPs between individuals with nicotine dependence only and individuals with both nicotine dependence and bipolar disorder. There were no statistical differences between these frequencies, indicating that genetic association with nicotine dependence is similar in individuals with bipolar disorder as in the general population. In the investigation of pleiotropic effects of these SNPs on bipolar disorder, two highly correlated synonymous SNPs in CHRNB3, rs4952 and rs4953, were significantly associated with bipolar disorder (odds ratio 1.7, 95% confidence interval: 1.2-2.4, P = 0.001). This association remained significant both after adjusting for a smoking covariate and analyzing the association in nonsmokers only.
Conclusion Our results suggest that (i) bipolar disorder does not modify the association between nicotine dependence and nicotinic receptor subunit genes, and (ii) variants in CHRNB3/CHRNA6 are independently associated with bipolar disorder. Psychiatr Genet 21:77-84 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
C1 [Hartz, Sarah M.; Lin, Peng; Rochberg, Nanette; Saccone, Scott; Nelson, Elliot; Bierut, Laura J.; Rice, John P.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
NIMH, Clin Sci Lab, NIH, US Dept HHS, Bethesda, MD 20892 USA.
NIMH, Unit Genet Basis Mood & Anxiety Disorders, Mood & Anxiety Disorders Program, NIH,US Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
Univ Calif Irvine, Dept Psychiat, Irvine, CA 92717 USA.
Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Berrettini, Wade] Univ Penn, Philadelphia, PA 19104 USA.
Rush Univ, Med Ctr, Dept Psychiat, Chicago, IL 60612 USA.
Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA.
[Edenberg, Howard J.; Xuei, Xiaoling] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA.
[Nurnberger, John] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA.
[NIMH Genetics Initiative Bipolar D] Howard Univ, Dept Psychiat, Washington, DC 20059 USA.
RP Rice, JP (reprint author), Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
EM jrice@wustl.edu
RI Meyer, Eric/C-1029-2011; Lin, P/G-7702-2014;
OI Meyer, Eric/0000-0002-1998-7162; Lawson, William/0000-0002-9324-7090
FU National Cancer Institute, NIH [P50CA89392]; National Institute of Drug
Abuse, NIH [5K02DA021237]
FX This study was supported by the NIH grants P50CA89392 from the National
Cancer Institute and 5K02DA021237 National Institute of Drug Abuse.
NR 45
TC 4
Z9 4
U1 4
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0955-8829
J9 PSYCHIAT GENET
JI Psychiatr. Genet.
PD APR
PY 2011
VL 21
IS 2
BP 77
EP 84
DI 10.1097/YPG.0b013e32834135eb
PG 8
WC Genetics & Heredity; Neurosciences
SC Genetics & Heredity; Neurosciences & Neurology
GA 727ZK
UT WOS:000287841700003
PM 21191315
ER
PT J
AU Daniel, CR
Cross, AJ
Koebnick, C
Sinha, R
AF Daniel, Carrie R.
Cross, Amanda J.
Koebnick, Corinna
Sinha, Rashmi
TI Trends in meat consumption in the USA
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Red meat; Poultry; Processed meat; US diet; Chronic disease
ID CORONARY-HEART-DISEASE; COLORECTAL-CANCER RISK; BOVINE SPONGIFORM
ENCEPHALOPATHY; BREAST-CANCER; RED MEAT; CARDIOVASCULAR-DISEASE; BRITISH
VEGETARIANS; CARBOHYDRATE INTAKE; PROSPECTIVE COHORT; PANCREATIC-CANCER
AB Objective: To characterize the trends, distribution, potential determinants and public health implications of meat consumption within the USA.
Design: We examined temporal trends in meat consumption using food availability data from the FAO and US Department of Agriculture (USDA), and further evaluated the meat intake by type (red, white, processed) in the National Health and Nutrition Examination Surveys (NHANES) linked to the MyPyramid Equivalents Database (MPED).
Results: Overall meat consumption has continued to rise in the USA and the rest of the developed world. Despite a shift towards higher poultry consumption, red meat still represents the largest proportion of meat consumed in the USA (58%). Twenty-two per cent of the meat consumed in the USA is processed. According to the NHANES 2003-2004, total meat intake averaged 128 g/d. The type and quantities of meat reported varied by education, race, age and gender.
Conclusions: Given the plausible epidemiological evidence for red and processed meat intake in cancer and chronic disease risk, understanding the trends and determinants of meat consumption in the USA, where meat is consumed at more than three times the global average, should be particularly pertinent to researchers and other public health professionals aiming to reduce the global burden of chronic disease.
C1 [Daniel, Carrie R.; Cross, Amanda J.; Sinha, Rashmi] NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA.
[Koebnick, Corinna] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA.
RP Daniel, CR (reprint author), NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv,NIH, 6120 Execut Blvd, Bethesda, MD 20892 USA.
EM Carrie.Daniel@nih.hhs.gov
RI Sinha, Rashmi/G-7446-2015; Koebnick, Corinna/P-4767-2016
OI Sinha, Rashmi/0000-0002-2466-7462; Koebnick, Corinna/0000-0001-8274-0309
FU NIH, National Cancer Institute
FX The present study was supported by the Intramural Research Program of
the NIH, National Cancer Institute. None of the authors had a financial
or personal conflict of interest. C. R. D. contributed to the concept,
analysis, interpretation of results and writing of the manuscript;
A.J.C. contributed to the interpretation of results and writing of the
manuscript; C. K. helped the analysis and interpretation of the results;
R. S. contributed to the concept, interpretation of the results and
writing of the manuscript; and all authors contributed to the critical
review and approval of the final manuscript. The authors thank Jill
Reedy and Lisa Kahle for their contributions to this manuscript.
NR 78
TC 96
Z9 98
U1 18
U2 65
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD APR
PY 2011
VL 14
IS 4
BP 575
EP 583
DI 10.1017/S1368980010002077
PG 9
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA 740AH
UT WOS:000288763400004
PM 21070685
ER
PT J
AU Garcia-Closas, M
Hein, DW
Silverman, D
Malats, N
Yeager, M
Jacobs, K
Doll, MA
Figueroa, JD
Baris, D
Schwenn, M
Kogevinas, M
Johnson, A
Chatterjee, N
Moore, LE
Moeller, T
Real, FX
Chanock, S
Rothman, N
AF Garcia-Closas, Montserrat
Hein, David W.
Silverman, Debra
Malats, Nuria
Yeager, Meredith
Jacobs, Kevin
Doll, Mark A.
Figueroa, Jonine D.
Baris, Dalsu
Schwenn, Molly
Kogevinas, Manolis
Johnson, Alison
Chatterjee, Nilanjan
Moore, Lee E.
Moeller, Timothy
Real, Francisco X.
Chanock, Stephen
Rothman, Nathaniel
TI A single nucleotide polymorphism tags variation in the arylamine
N-acetyltransferase 2 phenotype in populations of European background
SO PHARMACOGENETICS AND GENOMICS
LA English
DT Article
DE bladder cancer; genome-wide scan; NAT2 phenotype; single nucleotide
polymorphism
ID URINARY-BLADDER CANCER; HUMAN N-ACETYLTRANSFERASE-2;
FUNCTIONAL-CHARACTERIZATION; MOLECULAR-GENETICS; HUMAN HEPATOCYTES;
ACETYLATION; RISK; GENOTYPE
AB The arylamine N-acetyltransferase 2 (NAT2) slow acetylation phenotype is an established risk factor for urinary bladder cancer. We reported earlier on this risk association using NAT2 phenotypic categories inferred from NAT2 haplotypes based on seven single nucleotide polymorphisms (SNPs) in a study in Spain. In a subsequent genome-wide scan, we have identified a single common tag SNP (rs1495741) located in the 3' end of NAT2 that is also associated with bladder cancer risk. The aim of this report is to evaluate the agreement between the common tag SNP and the 7-SNP NAT2 inferred phenotype. The agreement between the 7-SNP NAT2 inferred phenotype and the tag SNP, rs1495741, was initially assessed in 2174 individuals from the Spanish Bladder Cancer Study (SBCS), and confirmed in a subset of individuals from the Main and Vermont component the New England Bladder Cancer Study (NEBCS). We also investigated the association of rs1495741 genotypes with NAT2 catalytic activity in cryopreserved hepatocytes from 154 individuals of European background. We observed very strong agreement between rs1495741 and the 7-SNP inferred NAT2 phenotype: sensitivity and specificity for the NAT2 slow phenotype was 99 and 95%, respectively. Our findings were replicated in an independent population from the NEBCS. Estimates for the association between NAT2 slow phenotype and bladder cancer risk in the SBCS and its interaction with cigarette smoking were comparable for the 7-SNP inferred NAT2 phenotype and rs1495741. In addition, rs1495741 genotypes were strongly related to NAT2 activity measured in hepatocytes (P < 0.0001). A novel NAT2 tag SNP (rs1495741) predicts with high accuracy the 7-SNP inferred NAT2 phenotype, and thus can be used as a sole marker in pharmacogenetic or epidemiological studies of populations of European background. These findings illustrate the utility of tag SNPs, often used in genome-wide association studies (GWAS), to identify novel phenotypic markers. Further studies are required to determine the functional implications of rs1495741 and the structure and evolution of the haplotype on which it resides. Pharmacogenetics and Genomics 21: 231-236 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
C1 [Garcia-Closas, Montserrat; Silverman, Debra; Yeager, Meredith; Jacobs, Kevin; Figueroa, Jonine D.; Baris, Dalsu; Chatterjee, Nilanjan; Moore, Lee E.; Chanock, Stephen; Rothman, Nathaniel] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Yeager, Meredith; Jacobs, Kevin; Chanock, Stephen] NCI, Core Genotype Facil, Adv Technol Ctr, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
[Moeller, Timothy] Celsis Vitro Technol, Baltimore, MD USA.
[Hein, David W.; Doll, Mark A.] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.
[Hein, David W.; Doll, Mark A.] Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Louisville, KY 40292 USA.
[Schwenn, Molly] Maine Canc Registry, Augusta, ME USA.
[Johnson, Alison] Vermont Canc Registry, Burlington, VT USA.
[Kogevinas, Manolis] Univ Pompeu Fabra, Ctr Res Environm Epidemiol CREAL, Barcelona, Spain.
[Kogevinas, Manolis] Univ Pompeu Fabra, Hosp Mar, Municipal Inst Med Res, IMIM, Barcelona, Spain.
[Kogevinas, Manolis] Univ Pompeu Fabra, CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain.
[Real, Francisco X.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain.
[Malats, Nuria] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain.
[Garcia-Closas, Montserrat; Real, Francisco X.] Univ Cambridge, Dept Oncol, Cambridge, England.
[Kogevinas, Manolis] Natl Sch Publ Hlth, Athens, Greece.
RP Garcia-Closas, M (reprint author), Inst Canc Res, Epidemiol Sect, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.
EM Montse.GarciaClosas@icr.ac.uk
RI Hein, David/A-9707-2008; Garcia-Closas, Montserrat /F-3871-2015; Malats,
Nuria/H-7041-2015; Real Arribas, Francisco/H-5275-2015; Kogevinas,
Manolis/C-3918-2017
OI Garcia-Closas, Montserrat /0000-0003-1033-2650; Malats,
Nuria/0000-0003-2538-3784; Real Arribas, Francisco/0000-0001-9501-498X;
FU National Institute of Health, National Cancer Institute, Division of
Cancer Epidemiology and Genetics [N02-CP-11015, N02-CP-01037]; FIS/Spain
[00/0745]; Fundacio Marato [TV3]; Red Tematica Investigacion Cooperativa
en Cancer (RTICC) [G03/174, CA34627]; United States Public Health
Service, United States National Cancer Institute, National Institutes of
Health, Department of Health and Human Services [R01-CA034627]
FX The SBCS and NEBCS (Maine, Vermont) were supported by Intramural
Research Program of the National Institute of Health, National Cancer
Institute, Division of Cancer Epidemiology and Genetics (contract
numbers N02-CP-11015 for SBCS and N02-CP-01037 for NEBCS). The SBCS was
also funded by grants FIS/Spain 00/0745, Fundacio Marato TV3, Red
Tematica Investigacion Cooperativa en Cancer (RTICC), G03/174, and
CA34627. The work on NAT2 catalytic activity in human hepatocytes was
partially supported by United States Public Health Service grant
R01-CA034627 from the United States National Cancer Institute, National
Institutes of Health, Department of Health and Human Services.
NR 18
TC 46
Z9 48
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1744-6872
J9 PHARMACOGENET GENOM
JI Pharmacogenet. Genomics
PD APR
PY 2011
VL 21
IS 4
BP 231
EP 236
DI 10.1097/FPC.0b013e32833e1b54
PG 6
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
& Pharmacy
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology
& Pharmacy
GA 735UH
UT WOS:000288444500009
PM 20739907
ER
PT J
AU Yeo, L
Romero, R
Jodicke, C
Ogge, G
Lee, W
Kusanovic, JP
Vaisbuch, E
Hassan, S
AF Yeo, L.
Romero, R.
Jodicke, C.
Ogge, G.
Lee, W.
Kusanovic, J. P.
Vaisbuch, E.
Hassan, S.
TI Four-chamber view and 'swing technique' (FAST) echo: a novel and simple
algorithm to visualize standard fetal echocardiographic planes
SO ULTRASOUND IN OBSTETRICS & GYNECOLOGY
LA English
DT Article
DE congenital heart disease; fetal heart; four-dimensional; OmniView;
prenatal diagnosis; STIC; ultrasound
ID CONGENITAL HEART-DISEASE; SPATIOTEMPORAL IMAGE CORRELATION;
PRENATAL-DIAGNOSIS; 4-DIMENSIONAL ULTRASONOGRAPHY; GREAT-ARTERIES;
TOMOGRAPHIC ULTRASOUND; LOW-RISK; DEFECTS; TRANSPOSITION; POPULATION
AB Objective To describe a novel and simple algorithm (four-chamber view and 'swing technique' (FAST) echo) for visualization of standard diagnostic planes of fetal echocardiography from dataset volumes obtained with spatiotemporal image correlation (STIC) and applying a new display technology (OmniView).
Methods We developed an algorithm to image standard fetal echocardiographic planes by drawing four dissecting lines through the longitudinal view of the ductal arch contained in a STIC volume dataset. Three of the lines are locked to provide simultaneous visualization of targeted planes, and the fourth line (unlocked) 'swings' through the ductal arch image (swing technique), providing an infinite number of cardiac planes in sequence. Each line generates the following plane(s): (a) Line 1: three-vessels and trachea view; (b) Line 2: five-chamber view and long-axis view of the aorta (obtained by rotation of the five-chamber view on the y-axis); (c) Line 3: four-chamber view; and (d) 'swing line': three-vessels and trachea view, five-chamber view and/or long-axis view of the aorta, four-chamber view and stomach. The algorithm was then tested in 50 normal hearts in fetuses at 15.3-40 weeks' gestation and visualization rates for cardiac diagnostic planes were calculated. To determine whether the algorithm could identify planes that departed from the normal images, we tested the algorithm in five cases with proven congenital heart defects.
Results In normal cases, the FAST echo algorithm (three locked lines and rotation of the five-chamber view on the y-axis) was able to generate the intended planes (longitudinal view of the ductal arch, pulmonary artery, three-vessels and trachea view, five-chamber view, long-axis view of the aorta, four-chamber view) individually in 100% of cases (except for the three-vessels and trachea view, which was seen in 98% (49/50)) and simultaneously in 98% (49/50). The swing technique was able to generate the three-vessels and trachea view, five-chamber view and/or long-axis view of the aorta, four-chamber view and stomach in 100% of normal cases. In the abnormal cases, the FAST echo algorithm demonstrated the cardiac defects and displayed views that deviated from what was expected from the examination of normal hearts. The swing technique was useful for demonstrating the specific diagnosis due to visualization of an infinite number of cardiac planes in sequence.
Conclusions This novel and simple algorithm can be used to visualize standard fetal echocardiographic planes in normal fetal hearts. The FAST echo algorithm may simplify examination of the fetal heart and could reduce operator dependency. Using this algorithm, inability to obtain expected views or the appearance of abnormal views in the generated planes should raise the index of suspicion for congenital heart disease. Copyright (C) 2011 ISUOG. Published by John Wiley & Sons, Ltd.
C1 [Yeo, L.] Wayne State Univ, Hutzel Womens Hosp, Perinatol Res Branch, NICHD,NIH,DHHS, Detroit, MI 48201 USA.
[Yeo, L.; Romero, R.; Jodicke, C.; Ogge, G.; Lee, W.; Kusanovic, J. P.; Vaisbuch, E.; Hassan, S.] NICHD, Perinatol Res Branch, NIH, DHHS, Bethesda, MD USA.
[Yeo, L.; Romero, R.; Jodicke, C.; Lee, W.; Kusanovic, J. P.; Vaisbuch, E.; Hassan, S.] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48201 USA.
[Romero, R.] Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48201 USA.
[Lee, W.] William Beaumont Hosp, Dept Obstet & Gynecol, Div Fetal Imaging, Royal Oak, MI 48072 USA.
RP Yeo, L (reprint author), Wayne State Univ, Hutzel Womens Hosp, Perinatol Res Branch, NICHD,NIH,DHHS, 3990 John R,Box 4, Detroit, MI 48201 USA.
EM lyeo@med.wayne.edu; prbchiefstaff@med.wayne.edu
OI Vaisbuch, Edi/0000-0002-8400-9031
FU Perinatology Research Branch, Division of Intramural Research, Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, NIH, DHHS
FX This research was supported by the Perinatology Research Branch,
Division of Intramural Research, Eunice Kennedy Shriver National
Institute of Child Health and Human Development, NIH, DHHS.
NR 73
TC 16
Z9 21
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0960-7692
J9 ULTRASOUND OBST GYN
JI Ultrasound Obstet. Gynecol.
PD APR
PY 2011
VL 37
IS 4
BP 423
EP 431
DI 10.1002/uog.8840
PG 9
WC Acoustics; Obstetrics & Gynecology; Radiology, Nuclear Medicine &
Medical Imaging
SC Acoustics; Obstetrics & Gynecology; Radiology, Nuclear Medicine &
Medical Imaging
GA 741KB
UT WOS:000288861500007
PM 20878671
ER
PT J
AU Xie, R
Chung, JY
Ylaya, K
Williams, RL
Guerrero, N
Nakatsuka, N
Badie, C
Hewitt, SM
AF Xie, Ran
Chung, Joon-Yong
Ylaya, Kris
Williams, Reginald L.
Guerrero, Natalie
Nakatsuka, Nathan
Badie, Cortessia
Hewitt, Stephen M.
TI Factors Influencing the Degradation of Archival Formalin-Fixed
Paraffin-Embedded Tissue Sections
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Review
DE Antigenicity; formalin fixed; paraffin embedded; immunohistochemistry;
protein array; tissue processing
ID BREAST-CANCER; GENE-EXPRESSION; FIXATION; IMMUNOHISTOCHEMISTRY;
MICROARRAYS; ANTIGENICITY; PROTEIN; VALIDATION; INTENSITY; RETRIEVAL
AB The loss of antigenicity in archival formalin-fixed paraffin-embedded (FFPE) tissue sections negatively affects both diagnostic histopathology and advanced molecular studies. The mechanisms underlying antigenicity loss in FFPE tissues remain unclear. The authors hypothesize that water is a crucial contributor to protein degradation and decrement of immunoreactivity in FFPE tissues. To test their hypothesis, they examined fixation time, processing time, and humidity of storage environment on protein integrity and antigenicity by immunohistochemistry, Western blotting, and protein extraction. This study revealed that inadequate tissue processing, resulting in retention of endogenous water in tissue sections, results in antigen degradation. Exposure to high humidity during storage results in significant protein degradation and reduced immunoreactivity, and the effects of storage humidity are temperature dependent. Slides stored under vacuum with desiccant do not protect against the effects of residual water from inadequate tissue processing. These results support that the presence of water, both endogenously and exogenously, plays a central role in antigenicity loss. Optimal tissue processing is essential. The parameters of optimal storage of unstained slides remain to be defined, as they are directly affected by preanalytic variables. Nevertheless, minimization of exposure to water is required for antigen preservation in FFPE tissue sections. This article contains online supplemental material at http://www.jhc.org. Please visit this article online to view these materials. (J Histochem Cytochem 59:356-365, 2011)
C1 [Xie, Ran; Chung, Joon-Yong; Ylaya, Kris; Williams, Reginald L.; Guerrero, Natalie; Nakatsuka, Nathan; Badie, Cortessia; Hewitt, Stephen M.] NCI, Tissue Array Res Program, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.
RP Hewitt, SM (reprint author), Adv Technol Ctr, TARP AMPL, MSC 4605, Bethesda, MD 20892 USA.
EM genejock@helix.nih.gov
OI Hewitt, Stephen/0000-0001-8283-1788; Chung,
Joon-Yong/0000-0001-5041-5982
FU Center for Cancer Research, National Cancer Institute, NIH
FX The author(s) disclosed receipt of the following financial support for
the research and/or authorship of this article: This research was
supported by the Intramural Research Program of the NIH, National Cancer
Institute, Center for Cancer Research.
NR 26
TC 56
Z9 56
U1 2
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022-1554
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD APR
PY 2011
VL 59
IS 4
BP 356
EP 365
DI 10.1369/0022155411398488
PG 10
WC Cell Biology
SC Cell Biology
GA 805CF
UT WOS:000293703300001
PM 21411807
ER
PT J
AU Salit, RB
Bishop, MR
AF Salit, Rachel B.
Bishop, Michael R.
TI The Evolving World of Tumor Lysis Syndrome THE MUSLIMANI ET AL ARTICLE
REVIEWED
SO ONCOLOGY-NEW YORK
LA English
DT Editorial Material
ID RECOMMENDATIONS; GUIDELINES; MANAGEMENT; LEUKEMIA; LYMPHOMA
C1 [Salit, Rachel B.; Bishop, Michael R.] NCI, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA.
RP Salit, RB (reprint author), NCI, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA.
NR 8
TC 1
Z9 1
U1 0
U2 0
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890-9091
J9 ONCOLOGY-NY
JI Oncology-NY
PD APR
PY 2011
VL 25
IS 4
BP 378
EP 380
PG 2
WC Oncology
SC Oncology
GA 800ES
UT WOS:000293343200009
PM 21618961
ER
PT J
AU Rao, DB
Little, PB
Malarkey, DE
Herbert, RA
Sills, RC
AF Rao, Deepa B.
Little, Peter B.
Malarkey, David E.
Herbert, Ronald A.
Sills, Robert C.
TI Histopathological Evaluation of the Nervous System in National
Toxicology Program Rodent Studies: A Modified Approach
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE neuropathology; histopathology; brain; nervous system; NTP; nervous
system; screening
ID PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; ANIMAL-MODELS; UNITED-STATES;
DEVELOPMENTAL NEUROTOXICITY; INHALATION EXPOSURE; GLUCOSE-UTILIZATION;
MULTIPLE-SCLEROSIS; CARBONYL SULFIDE; ECONOMIC-IMPACT
AB This article outlines the changes and underlying rationale for modifications to the histopathological evaluation of the nervous system during toxicology and carcinogenesis studies conducted by the National Toxicology Program (NTP). In the past, routine evaluation of the nervous system was mostly limited to three sections of brain, and occasionally the spinal cord and peripheral nerves. Factors such as the increasing occurrence of human neurological diseases and associated economical cost burden, the role of unidentified environmental stressors in neurodegenerative disorders, multiple therapeutic drug-induced neuropathies noted in human clinical trials, and the exponential use of environmental chemicals with unknown neurotoxic potential necessitate a more extensive evaluation of the nervous system. The NTP has modified its protocol to include examination of key anatomic subsites related to neurodegenerative diseases such as Parkinson's disease. Modifications include four additional sections of the brain. Increasing the number of brain sections permits examination of a greater number of specific anatomic subsites with unique vulnerability. In addition, the spinal cord, peripheral nerves, trigeminal ganglion, and intestinal autonomic ganglia will be evaluated as needed. It is expected that this modified approach will increase the sensitivity of detecting neurotoxicants and neurocarcinogens important in human neurologic and neurodegenerative disorders.
C1 [Rao, Deepa B.; Malarkey, David E.; Herbert, Ronald A.; Sills, Robert C.] NIEHS, Natl Toxicol Program, Res Triangle Pk, NC 27709 USA.
[Rao, Deepa B.] Integrated Lab Syst Inc, Res Triangle Pk, NC USA.
[Little, Peter B.] Pathol Associates Inc, Charles River Labs, Durham, NC USA.
RP Sills, RC (reprint author), NIEHS, Natl Toxicol Program, POB 12233,MS B3-06,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.
EM sills@niehs.nih.gov
FU National Institutes of Health, National Institute of Environmental
Health Sciences
FX The authors thank fellow NTP colleagues Drs. Jean Harry, Joseph
Roycroft, and Raj Chhabra, and Dr. James P. Morrison of PAI, Charles
River, for their invaluable input during the development of this
modified protocol, and Drs. Gordon Flake and Mark Cesta for their
detailed internal review of this article. Also, the authors are deeply
grateful for the comments, opinions, and advice from many toxicologic
pathologists with experience and interest in neuropathology who have all
generously contributed throughout the process of establishing a modified
NTP approach for evaluating the nervous system. We thank Mr. David Sabio
(digital imaging), Ms. Stephanie Holmgren (library information
services), Ms. Beth Mahler and the National Institute of Environmental
Health Sciences histopathology core laboratory, and Mr. Shean Chiou
(software) for their technical expertise and assistance during the
preparation of this article. This research was supported (in part) by
the Intramural Research Program of the National Institutes of Health,
National Institute of Environmental Health Sciences.
NR 79
TC 10
Z9 10
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192-6233
EI 1533-1601
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD APR
PY 2011
VL 39
IS 3
BP 463
EP 470
DI 10.1177/0192623311401044
PG 8
WC Pathology; Toxicology
SC Pathology; Toxicology
GA 800QX
UT WOS:000293380100001
PM 21430177
ER
PT J
AU Hill, GD
Moore, AB
Kissling, GE
Flagler, ND
Ney, E
Cline, JM
Dixon, D
AF Hill, Georgette D.
Moore, Alicia B.
Kissling, Grace E.
Flagler, Norris D.
Ney, Elizabeth
Cline, J. Mark
Dixon, Darlene
TI Effects of Hormonally Active Agents on Steroid Hormone Receptor
Expression and Cell Proliferation in the Myometrium of Ovariectomized
Macaques
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE myometrium; macaques; conjugated equine estrogens (CEE);
medroxyprogesterone acetate (MPA); tamoxifen (TAM); steroid receptors;
Ki-67
ID CORONARY-ARTERY ATHEROSCLEROSIS; CONJUGATED EQUINE ESTROGENS; RECEIVING
TAMOXIFEN THERAPY; POSTMENOPAUSAL WOMEN; BREAST-CANCER;
PROGESTERONE-RECEPTOR; MEDROXYPROGESTERONE ACETATE; ENDOMETRIAL
HYPERPLASIA; UTERINE LEIOMYOMATA; CYNOMOLGUS MACAQUES
AB Hormone replacement therapy and selective estrogen receptor modulators have been controversial treatment options for postmenopausal women because of their potential health benefits and/or risks. In this study, we determine the effects of the hormonally active compounds, conjugated equine estrogens (CEE), medroxyprogesterone acetate (MPA), CEE + MPA, and tamoxifen (TAM) on the myometrium of ovariectomized macaques. Immunoexpression of estrogen receptor-alpha (ER alpha), progesterone receptor (PR), and Ki-67 in the myometrium is assessed. We found no significant difference in ER alpha myometrial expression in the CEE, MPA, and CEE + MPA treatment groups, but there was a significant decrease in expression in animals administered TAM versus controls. Conjugated equine estrogen-, TAM-, and CEE + MPA-treated animals had significantly increased expression of PR in myometrial cells and there was no difference in PR expression in cells from MPA-treated animals versus control animals. Myometrial cell proliferation did not significantly differ between the controls and any of the treatment groups, although normalized Ki-67 values were somewhat higher in the CEE and TAM groups. These data suggest that ERa and PR expression in the myometrium is influenced by treatment with hormonally active agents.
C1 [Moore, Alicia B.; Dixon, Darlene] NIEHS, Comparat Pathobiol Grp, Cellular & Mol Pathol Branch, NTP,NIH,DHHS, Res Triangle Pk, NC 27709 USA.
[Hill, Georgette D.] Integrated Syst Lab, Res Triangle Pk, NC USA.
[Kissling, Grace E.] NIEHS, Biostat Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA.
[Flagler, Norris D.; Ney, Elizabeth] NIEHS, Special Tech Grp, Cellular & Mol Pathol Branch, NTP,NIH,DHHS, Res Triangle Pk, NC 27709 USA.
[Cline, J. Mark] Wake Forest Univ, Comparat Med Sect, Dept Pathol, Sch Med, Winston Salem, NC 27109 USA.
RP Dixon, D (reprint author), NIEHS, Comparat Pathobiol Grp, Cellular & Mol Pathol Branch, NTP,NIH,DHHS, POB 12233,Bldg 101,MD B3-06,Rm B341, Res Triangle Pk, NC 27709 USA.
EM dixon@niehs.nih.gov
FU NIEHS [N01-ES-55548]; National Heart Lung and Blood Institute [HL490852,
HL45666]
FX The authors would like to thank Drs. Mark Hoenerhoff and Arun Pandiri
for their critical review of this manuscript, and Ms. Beth Mahler for
her expert assistance with imaging. This study was supported in part by
the Intramural Research Program of the NIEHS, and Dr. Hill's work was
supported by NIEHS contract #N01-ES-55548. In addition, this study was
supported in part by National Heart Lung and Blood Institute grants,
HL490852 and HL45666.
NR 49
TC 2
Z9 2
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192-6233
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD APR
PY 2011
VL 39
IS 3
BP 508
EP 515
DI 10.1177/0192623311401045
PG 8
WC Pathology; Toxicology
SC Pathology; Toxicology
GA 800QX
UT WOS:000293380100007
PM 21411722
ER
PT J
AU Trinchieri, G
AF Trinchieri, Giorgio
TI Inflammation in Cancer: a Therapeutic Target? THE KAMP, SHACTER, AND
WEITZMAN ARTICLE REVIEWED
SO ONCOLOGY-NEW YORK
LA English
DT Editorial Material
ID GENERATION; RESPONSES
C1 NCI, Canc & Inflammat Program, Ctr Canc Res, NIH, Frederick, MD 21701 USA.
RP Trinchieri, G (reprint author), NCI, Canc & Inflammat Program, Ctr Canc Res, NIH, Frederick, MD 21701 USA.
NR 17
TC 10
Z9 10
U1 0
U2 1
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890-9091
J9 ONCOLOGY-NY
JI Oncology-NY
PD APR
PY 2011
VL 25
IS 5
BP 418
EP 420
PG 3
WC Oncology
SC Oncology
GA 800EU
UT WOS:000293343400008
PM 21710837
ER
PT J
AU Stenholm, S
Metter, EJ
Roth, GS
Ingram, DK
Mattison, JA
Taub, DD
Ferrucci, L
AF Stenholm, Sari
Metter, E. Jeffrey
Roth, George S.
Ingram, Donald K.
Mattison, Julie A.
Taub, Dennis D.
Ferrucci, Luigi
TI Relationship between plasma ghrelin, insulin, leptin, interleukin 6,
adiponectin, testosterone and longevity in the Baltimore Longitudinal
Study of Aging
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Aging; biomarkers; caloric restriction; longevity
ID CALORIC RESTRICTION; OLDER MEN; DIETARY RESTRICTION; ANABOLIC HORMONES;
DECLINE; FRAILTY; HUMANS; WOMEN; AGE; BIOMARKERS
AB Background and aims: Caloric restriction (CR) is the most robust and reproducible intervention for slowing aging, and maintaining health and vitality in animals. Previous studies found that CR is associated with changes in specific biomarkers in monkeys that were also associated with reduced risk of mortality in healthy men. In this study we examine the association between other potential biomarkers related to CR and extended lifespan in healthy humans. Methods: Based on the Baltimore Longitudinal Study of Aging, "long-lived" participants who survived to at least 90 years of age (n=41, cases) were compared with "short-lived" participants who died between 72-76 years of age (n=31, controls) in the nested case control study. Circulating levels of ghrelin, insulin, leptin, interleukin 6, adiponectin and testosterone were measured from samples collected between the ages 58 to 70 years. Baseline differences between groups were examined with t-test or Wilcoxon test, and mixed effects general linear model was used for a logistic model to differentiate the two groups with multiple measurements on some subjects. Results: At the time of biomarkers evaluation (58-70 yrs), none of the single biomarker levels was significantly different between the two groups. However, after combining information from multiple biomarkers by adding the z-transformed values, the global score differentiated the long- and short-lived participants (p=0.05). Conclusions: In their sixties, long-lived and short-lived individuals do not differ in biomarkers that have been associated with CR in animals. However, difference between the groups was only obtained when multiple biomarker dysregulation was considered. (Aging Clin Exp Res 2011; 23: 153-158) (C)2011, Editrice Kurtis
C1 [Stenholm, Sari; Metter, E. Jeffrey; Ferrucci, Luigi] NIA, Clin Res Branch, Longitudinal Studies Sect, Baltimore, MD 21225 USA.
[Stenholm, Sari] Natl Inst Hlth & Welf, Turku, Finland.
[Roth, George S.] GeroScience Inc, Pylesville, MD USA.
[Ingram, Donald K.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Nutr Neurosci & Aging Lab, Baton Rouge, LA USA.
[Mattison, Julie A.] NIA, Lab Expt Gerontol, NIA Primate Aging Studies, Baltimore, MD 21225 USA.
[Taub, Dennis D.] NIA, Immunol Lab, Baltimore, MD 21225 USA.
RP Ferrucci, L (reprint author), NIA, Clin Res Branch, Longitudinal Studies Sect, Harbor Hosp 5th Floor,3001 S Hanover St, Baltimore, MD 21225 USA.
EM ferrucciLu@grc.nia.nih.gov
RI Stenholm, Sari/G-6940-2011
FU NIH, National Institute on Aging
FX This research was supported by the Intramural Research Program of the
NIH, National Institute on Aging. Data for these analyses were obtained
from the Baltimore Longitudinal Study of Aging, a study performed by the
National Institute on Aging.
NR 34
TC 6
Z9 6
U1 0
U2 1
PU EDITRICE KURTIS S R L
PI MILAN
PA VIA LUIGI ZOJA 30, 20153 MILAN, ITALY
SN 1594-0667
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD APR
PY 2011
VL 23
IS 2
BP 153
EP 158
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 793FM
UT WOS:000292805800012
PM 21743292
ER
PT J
AU Yu, M
Levine, SJ
AF Yu, Man
Levine, Stewart J.
TI Toll-like receptor 3, RIG-I-like receptors and the NLRP3 inflammasome:
Key modulators of innate immune responses to double-stranded RNA viruses
SO CYTOKINE & GROWTH FACTOR REVIEWS
LA English
DT Review
DE Double-stranded viral RNA; TLR3; RIG-1; NLRP3 inflammasome; Signal
transduction
ID NF-KAPPA-B; HUMAN DENDRITIC CELLS; OVARIAN-CANCER CELLS;
INFLUENZA-VIRUS; RHEUMATOID-ARTHRITIS; ANTIVIRAL RESPONSES;
PATTERN-RECOGNITION; AIRWAY EPITHELIUM; VIRAL-INFECTION; GENE INDUCTION
AB Double-stranded RNA (dsRNA), the genetic material for many RNA viruses, induces robust host immune responses via pattern recognition receptors, which include Toll-like receptor 3 (TLR3), retinoic acid-inducible gene-I-like receptors (RLRs) and the multi-protein NLRP3 inflammasome complex. The engagement of dsRNA receptors or inflammasome activation by viral dsRNA initiates complex intracellular signaling cascades that play essential roles in inflammation and innate immune responses, as well as the resultant development of adaptive immunity. This review focuses on signaling pathways mediated by TLR3, RLRs and the NLRP3 inflammasome, as well as the potential use of agonists and antagonists that target these pathways to treat disease. Published by Elsevier Ltd.
C1 [Yu, Man; Levine, Stewart J.] NHLBI, Cardiovasc & Pulm Branch, NIH, Bethesda, MD 20892 USA.
RP Levine, SJ (reprint author), NHLBI, Cardiovasc & Pulm Branch, NIH, 10 Ctr Dr,Room 6D16, Bethesda, MD 20892 USA.
EM levines@nhlbi.nih.gov
FU Division of Intramural Research, NHLBI, NIH
FX This work was supported by the Division of Intramural Research, NHLBI,
NIH.
NR 120
TC 71
Z9 74
U1 3
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6101
J9 CYTOKINE GROWTH F R
JI Cytokine Growth Factor Rev.
PD APR
PY 2011
VL 22
IS 2
BP 63
EP 72
DI 10.1016/j.cytogfr.2011.02.001
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 791KU
UT WOS:000292664900001
PM 21466970
ER
PT J
AU Sedriep, S
Xia, X
Marotta, F
Zhou, L
Yadav, H
Yang, H
Soresi, V
Catanzaro, R
Zhong, K
Polimeni, A
Chui, DH
AF Sedriep, S.
Xia, X.
Marotta, F.
Zhou, L.
Yadav, H.
Yang, H.
Soresi, V.
Catanzaro, R.
Zhong, K.
Polimeni, A.
Chui, D. H.
TI BENEFICIAL NUTRACEUTICAL MODULATION OF CEREBRAL ERYTHROPOIETIN
EXPRESSION AND OXIDATIVE STRESS: AN EXPERIMENTAL STUDY
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE erythropoietin; brain cognitive impairment; oxidative stress;
phycocyanins; prematurely senescent mice
ID BLOOD-BRAIN-BARRIER; RECEPTOR EXPRESSION; NEONATAL-RATS; C-PHYCOCYANIN;
IN-VITRO; ANTIOXIDANT; ISCHEMIA; DAMAGE; MICE; NEUROPROTECTION
AB The main object of this study is to examine the effect of Klamin (R), a nutraceutical containing phenylethylamine, phycocyanins, mycosporine-like aminoacids and aphanizomenon flos aquae-phytochrome on the learning and memory ability, the oxidative status and cerebral erythropoietin and its receptor EPO/EPOR system in prematurely senescent (PS) mice. A total of 28 PS mice, selected according to a prior T-maze test, and 26 non-prematurely senescent mice (NPS) mice were chosen. PS animals were divided into 3 groups and followed for 4 weeks: A) normal chow diet; B) added with Klamin (R) at 20 mg/kg/day (low dose); C) added with Klamin (R) at 100mg/kg/day (high dose). A further group of NPS mice given either normal food (group D) or high dose Klamin (R) (group E) was also considered. The behavioral procedures of spatial learning ability (Morris test) showed that PS mice had significantly longer learning time as compared to their NPS counterpart (p<0.01), but this effect was prevented especially in mice supplemented with high-dose Klamin (R) (p<0.05) which improved performances in NPS mice (p<0.05). High-dose Klamin (R) supplementation restored the depleted total thiol concentration in the brain observed in PS mice while normalizing their increased malonildialdehyde level (p<0.05). Moreover, the high-dosage only caused a significant upregulation of EPO/EPOR system both in PS and in NPS animals (p<0.05). Taken together, these data suggest that this specific alga Klamath extract has considerable antioxidant and adaptogenic properties, also through a stimulatory effect of cerebral EPO/EPO system.
C1 [Sedriep, S.] Biocell Unit Lab & Anal Ctr, Miyazaki, Japan.
[Xia, X.] Guilin Med Univ, Affiliated Hosp, Guilin, Guangxi, Peoples R China.
[Marotta, F.; Polimeni, A.] ReGenera Res Grp Aging Intervent, Milan, Italy.
[Zhou, L.; Yang, H.; Zhong, K.; Chui, D. H.] Peking Univ, Neurosci Res Inst, Beijing 100871, Peoples R China.
[Yadav, H.] NIDDK, NIH, Bethesda, MD USA.
[Soresi, V.] Octopus Sci Assoc Bioprevent, Milan, Italy.
[Catanzaro, R.] Univ Catania, Dept Internal Med, Gastroenterol Unit, I-95124 Catania, Italy.
RP Marotta, F (reprint author), Piazza Firenze 12, I-20154 Milan, Italy.
EM fmarchimede@libero.it
NR 35
TC 12
Z9 12
U1 1
U2 2
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393-974X
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD APR-JUN
PY 2011
VL 25
IS 2
BP 187
EP 194
PG 8
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
Experimental; Physiology
SC Endocrinology & Metabolism; Immunology; Research & Experimental
Medicine; Physiology
GA 793VS
UT WOS:000292852600006
PM 21880207
ER
PT J
AU Cooper, ID
AF Cooper, I. Diane
TI Research: the opportunity wheel keeps turning
SO JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION
LA English
DT Editorial Material
ID MEDICAL-LIBRARY-ASSOCIATION; INFORMATION-SCIENCE; POLICY
C1 [Cooper, I. Diane] NIH, Res Sect, Bethesda, MD 20892 USA.
[Cooper, I. Diane] NIH, NIH Lib, Bethesda, MD 20892 USA.
RP Cooper, ID (reprint author), NIH, Res Sect, Bldg 10,MSC 1150, Bethesda, MD 20892 USA.
EM cooperd@mail.nih.gov
RI Cooper, Diane/G-5826-2011
NR 14
TC 1
Z9 1
U1 0
U2 0
PU MEDICAL LIBRARY ASSOC
PI CHICAGO
PA 65 EAST WACKER PLACE, STE 1900, CHICAGO, IL 60601-7298 USA
SN 1536-5050
J9 J MED LIBR ASSOC
JI J. Med. Libr. Assoc.
PD APR
PY 2011
VL 99
IS 2
BP 107
EP 109
DI 10.3163/1536-5050.99.2.001
PG 3
WC Information Science & Library Science
SC Information Science & Library Science
GA 774EE
UT WOS:000291363300001
PM 21464847
ER
PT J
AU Ripple, AM
Mork, JG
Knecht, LS
Humphreys, BL
AF Ripple, Anna M.
Mork, James G.
Knecht, Lou S.
Humphreys, Betsy L.
TI A retrospective cohort study of structured abstracts in MEDLINE,
1992-2006
SO JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION
LA English
DT Article
ID INFORMATIVE ABSTRACTS; PROPOSAL; ARTICLES
C1 [Humphreys, Betsy L.] NIH, US Dept Hlth & Human Serv, Natl Lib Med, Bethesda, MD 20894 USA.
EM ripple@nlm.nih.gov; mork@nlm.nih.gov; knechtl@mail.nlm.nih.gov;
betsy_humphreys@nlm.nih.gov
FU Intramural NIH HHS
NR 15
TC 10
Z9 10
U1 0
U2 4
PU MEDICAL LIBRARY ASSOC
PI CHICAGO
PA 65 EAST WACKER PLACE, STE 1900, CHICAGO, IL 60601-7298 USA
SN 1536-5050
J9 J MED LIBR ASSOC
JI J. Med. Libr. Assoc.
PD APR
PY 2011
VL 99
IS 2
BP 160
EP 163
DI 10.3163/1536-5050.99.2.009
PG 4
WC Information Science & Library Science
SC Information Science & Library Science
GA 774EE
UT WOS:000291363300009
PM 21464855
ER
PT J
AU Cornell, A
Bushman, B
Womack, K
AF Cornell, Ada
Bushman, Barbara
Womack, Kristina
TI Analysis of journals that did not meet selection criteria for inclusion
in the National Library of Medicine collection but have manuscripts in
PubMed Central
SO JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION
LA English
DT Article
C1 [Cornell, Ada; Womack, Kristina] Natl Lib Med, Select & Acquisit Sect, Bethesda, MD 20894 USA.
[Bushman, Barbara] Natl Lib Med, Cataloging Sect, Bethesda, MD 20894 USA.
RP Cornell, A (reprint author), Natl Lib Med, Select & Acquisit Sect, 8600 Rockville Pike, Bethesda, MD 20894 USA.
EM ada.cornell@inova.org; bushmanb@mail.nlm.nih.gov;
womackk2@mail.nlm.nih.gov
NR 5
TC 0
Z9 0
U1 0
U2 6
PU MEDICAL LIBRARY ASSOC
PI CHICAGO
PA 65 EAST WACKER PLACE, STE 1900, CHICAGO, IL 60601-7298 USA
SN 1536-5050
J9 J MED LIBR ASSOC
JI J. Med. Libr. Assoc.
PD APR
PY 2011
VL 99
IS 2
BP 168
EP 170
DI 10.3163/1536-5050.99.2.011
PG 3
WC Information Science & Library Science
SC Information Science & Library Science
GA 774EE
UT WOS:000291363300011
PM 21464857
ER
PT J
AU Kulminski, AM
Arbeev, KG
Christensen, K
Mayeux, R
Newman, AB
Province, MA
Hadley, EC
Rossi, W
Perls, TT
Elo, IT
Yashin, AI
AF Kulminski, Alexander M.
Arbeev, Konstantin G.
Christensen, Kaare
Mayeux, Richard
Newman, Anne B.
Province, Michael A.
Hadley, Evan C.
Rossi, Winifred
Perls, Thomas T.
Elo, Irma T.
Yashin, Anatoli I.
TI Do gender, disability, and morbidity affect aging rate in the LLFS?
Application of indices of cumulative deficits
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE Aging rates; Longevity; Cumulative indices; Long-Life Family Study
ID LONG-LIFE FAMILY; LEIDEN LONGEVITY; NONAGENARIAN SIBLINGS; HEALTH
DISORDERS; ELDERLY-PEOPLE; FRAILTY INDEX; FOLLOW-UP; MORTALITY;
POPULATION; ACCUMULATION
AB We used an approach of cumulative deficits to evaluate the rate of aging in 4954 participants of the Long-Life Family Study (LLFS) recruited in the U.S. (Boston, New York, and Pittsburg) and Denmark. We used an array of 85 health-related deficits covering major health dimensions including depression, cognition, morbidity, physical performance, and disability to construct several deficit indices (DIs) with overlapping and complementary sets of deficits to test robustness of the estimates. Our study shows that the DI robustly characterize accelerated rates of aging irrespective of specific of deficits. When a wider spectrum of health dimensions is considered these rates are better approximated by quadratic law. Exponential rates are more characteristic for more severe health dimensions. The aging rates are the same for males and females. Individuals who contracted major diseases and those who were free of them exhibited the same aging rates as characterized by the DI constructed using mild deficits. Unlike health, disability can qualitatively alter the aging patterns of the LLFS participants. We report on systemic differences in health among the LLFS centenarians residing in New York and Boston. This study highlights importance of aggregated approaches to better understand systemic mechanisms of health deterioration in long-living individuals. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Kulminski, Alexander M.; Arbeev, Konstantin G.; Yashin, Anatoli I.] Duke Univ, Ctr Populat Hlth & Aging, Durham, NC 27708 USA.
[Christensen, Kaare] Univ So Denmark, Danish Aging Res Ctr, DK-5000 Odense C, Denmark.
[Mayeux, Richard] Columbia Univ, Div Hlth Sci, New York, NY 10032 USA.
[Newman, Anne B.] Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA 15213 USA.
[Province, Michael A.] Washington Univ, Sch Med, Div Stat Genom, St Louis, MO 63108 USA.
[Hadley, Evan C.; Rossi, Winifred] NIA, Bethesda, MD 20892 USA.
[Perls, Thomas T.] Boston Univ, Sch Med, Div Geriatr MED Geriatr, Boston, MA 02215 USA.
[Elo, Irma T.] Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA.
RP Kulminski, AM (reprint author), Duke Univ, Ctr Populat Hlth & Aging, Box 90408,Trent Hall,Room 002, Durham, NC 27708 USA.
EM Alexander.Kulminski@duke.edu
RI Christensen, Kaare/C-2360-2009; Newman, Anne/C-6408-2013;
OI Christensen, Kaare/0000-0002-5429-5292; Newman,
Anne/0000-0002-0106-1150; Perls, Thomas/0000-0002-2492-4334
FU National Institute on Aging (NIA) [U01AG023746, R01AG032319]
FX This work was supported by National Institute on Aging (NIA) grants
U01AG023746 and R01AG032319. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
NIA or the National Institutes of Health.
NR 46
TC 10
Z9 11
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0047-6374
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD APR
PY 2011
VL 132
IS 4
BP 195
EP 201
DI 10.1016/j.mad.2011.03.006
PG 7
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 777NI
UT WOS:000291628000008
PM 21463647
ER
PT J
AU Nielsen, L
Mather, M
AF Nielsen, Lisbeth
Mather, Mara
TI Emerging perspectives in social neuroscience and neuroeconomics of aging
SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE
LA English
DT Article
DE aging; life course
ID AGE-RELATED DIFFERENCES; FINANCIAL RISK-TAKING; ADULT LIFE-SPAN;
OLDER-ADULTS; DECISION-MAKING; EMOTION REGULATION; COGNITIVE CONTROL;
INDIVIDUAL-DIFFERENCES; SELF-CONTROL; LONGITUDINAL ANALYSES
AB This article introduces the special issue of 'Social Cognitive and Affective Neuroscience' on Aging Research, and offers a broad conceptual and methodological framework for considering advances in life course research in social neuroscience and neuroeconomics. The authors highlight key areas of inquiry where aging research is raising new insights about how to conceptualize and examine critical questions about the links between cognition, emotion and motivation in social and economic behavior, as well as challenges that need to be addressed when taking a life course perspective in these fields. They also point to several emerging approaches that hold the potential for addressing these challenges, through bridging approaches from laboratory and population-based science, bridging inquiry across life stages and expanding measurement of core psychological phenotypes.
C1 [Nielsen, Lisbeth] NIA, Div Behav & Social Res, NIH, Bethesda, MD 20892 USA.
[Mather, Mara] Univ So Calif, Davis Sch Gerontol, Los Angeles, CA USA.
[Mather, Mara] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA.
RP Nielsen, L (reprint author), NIA, Div Behav & Social Res, NIH, 7201 Wisconsin Ave,Suite 533, Bethesda, MD 20892 USA.
EM nielsenli@nia.nih.gov
RI Mather, Mara/E-3232-2010
OI Mather, Mara/0000-0003-4331-6112
FU National Institute on Aging under RFAs (Neuroeconomics of Aging)
[RFA-AG-06-011]; National Institute on Aging under RFAs (Neuroscience of
Aging) [RFA-AG-09-006]; Social Neuroscience RFAs from the National
Institute on Drug Abuse; Social Neuroscience RFAs from the National
Institute on Mental Health [RFA-DA-06-004, RFA-MH-08-070]
FX The National Institute on Aging has supported new research in Social
Neuroscience and Neuroeconomics of Aging under two institute-sponsored
RFAs (Neuroeconomics of Aging RFA-AG-06-011 and Social Neuroscience of
Aging RFA-AG-09-006) as well as through participation in Social
Neuroscience RFAs from the National Institute on Drug Abuse and the
National Institute on Mental Health (RFA-DA-06-004 and RFA-MH-08-070).
Several of the research recommendations from these previous
solicitations are echoed in this article.
NR 154
TC 10
Z9 11
U1 1
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1749-5016
EI 1749-5024
J9 SOC COGN AFFECT NEUR
JI Soc. Cogn. Affect. Neurosci.
PD APR
PY 2011
VL 6
IS 2
SI SI
BP 149
EP 164
DI 10.1093/scan/nsr019
PG 16
WC Neurosciences; Psychology; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA 776NT
UT WOS:000291543100001
PM 21482573
ER
PT J
AU Oesch, NW
Kothmann, WW
Diamond, JS
AF Oesch, Nicholas W.
Kothmann, W. Wade
Diamond, Jeffrey S.
TI Illuminating synapses and circuitry in the retina
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Article
ID STARBURST AMACRINE CELLS; RABBIT RETINA; GANGLION-CELL; DIRECTIONAL
SELECTIVITY; MAMMALIAN RETINA; BIPOLAR CELLS; SYNAPTIC-TRANSMISSION; ROD
PHOTORECEPTOR; KAINATE RECEPTORS; NMDA RECEPTORS
AB In the central nervous system, space is at a premium. This is especially true in the retina, where synapses, cells, and circuitry have evolved to maximize signal-processing capacity within a thin, optically transparent tissue. For example, at some retinal synapses, single presynaptic active zones contact multiple postsynaptic targets; some individual neurons perform completely different tasks depending on visual conditions, while others execute hundreds of circuit computations in parallel; and the retinal network adapts, at various levels, to the ever-changing visual world. Each of these features reflects efficient use of limited cellular resources to optimally encode visual information.
C1 [Oesch, Nicholas W.; Kothmann, W. Wade; Diamond, Jeffrey S.] Natl Inst Neurol Disorders & Stroke, Synapt Physiol Sect, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20824 USA.
RP Diamond, JS (reprint author), Natl Inst Neurol Disorders & Stroke, Synapt Physiol Sect, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20824 USA.
EM diamondj@ninds.nih.gov
RI Diamond, Jeffrey/C-1835-2015
OI Diamond, Jeffrey/0000-0002-1770-2629
FU NINDS
FX We thank Jonathan Demb and Gabe Murphy for critically reading the
manuscript. This work was supported by the NINDS Intramural Research
Program.
NR 50
TC 12
Z9 12
U1 1
U2 4
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD APR
PY 2011
VL 21
IS 2
BP 238
EP 244
DI 10.1016/j.conb.2011.01.008
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 771VI
UT WOS:000291188400006
PM 21349699
ER
PT J
AU Mayer, ML
AF Mayer, Mark L.
TI Structure and mechanism of glutamate receptor ion channel assembly,
activation and modulation
SO CURRENT OPINION IN NEUROBIOLOGY
LA English
DT Article
ID LIGAND-BINDING DOMAIN; AMINO-TERMINAL DOMAIN; GLUR2 AMPA RECEPTOR;
MOLECULAR-MECHANISM; POSITIVE MODULATORS; CRYSTAL-STRUCTURES; KAINATE
RECEPTORS; CORNICHON PROTEINS; DIMER INTERFACE; NMDA RECEPTORS
AB Ionotropic glutamate receptors (iGluRs) are ligand gated ion channels that mediate excitatory synaptic transmission in the brain of vertebrates. A rapidly growing body of crystal structures for isolated iGluR extracellular domains, and more recently a full length AMPA receptor, combined with data from electrophysiological experiments and MD simulations, provides a framework that makes it possible to investigate the molecular basis for assembly, gating and modulation. These unprecedented advances in structural biology are constantly challenged by novel functional properties that emerge despite decades of functional analysis, and by a growing family of auxiliary proteins that modulate iGluR activity and assembly.
C1 NICHD, Lab Cellular & Mol Neurophysiol, Porter Neurosci Res Ctr, NIH,DHHS, Bethesda, MD 20892 USA.
RP Mayer, ML (reprint author), NICHD, Lab Cellular & Mol Neurophysiol, Porter Neurosci Res Ctr, NIH,DHHS, Bethesda, MD 20892 USA.
EM mayerm@mail.nih.gov
RI Mayer, Mark/H-5500-2013
FU NICHD, NIH
FX I thank Pierre Paoletti for comments on the text, Teru Nakagawa for the
single particle EM maps, and Phil Biggin for the MD trajectories. Work
in my lab is supported by the intramural research program of NICHD, NIH.
NR 64
TC 42
Z9 42
U1 2
U2 15
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-4388
J9 CURR OPIN NEUROBIOL
JI Curr. Opin. Neurobiol.
PD APR
PY 2011
VL 21
IS 2
BP 283
EP 290
DI 10.1016/j.conb.2011.02.001
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 771VI
UT WOS:000291188400012
PM 21349697
ER
PT J
AU Roy, AK
Gotimer, K
Kelly, AMC
Castellanos, FX
Milham, MP
Ernst, M
AF Roy, Amy Krain
Gotimer, Kristin
Kelly, A. M. Clare
Castellanos, F. Xavier
Milham, Michael P.
Ernst, Monique
TI Uncovering putative neural markers of risk avoidance
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Decision-making; Precuneus; Risk; Striatum
ID ANTERIOR CINGULATE CORTEX; RIGHT PREFRONTAL CORTEX; TAKING
DECISION-MAKING; ANXIETY DISORDER; BRAIN IMAGES; RIGHT INSULA; REWARD;
FMRI; ACTIVATION; BEHAVIOR
AB Risk avoidance is a hallmark of psychopathological conditions such as anxiety disorders. Yet few studies have examined its neural basis. The present work sought to identify the neural correlates of risk avoidance. While functional MRI scans were acquired, healthy adults (N=23) played a Wheel of Fortune game during which they chose to bet or pass on each of 104 proposed gamble trials. Participants also completed the Cognitive Appraisal of Risky Events (CARE, Fromme et al., 1997), a self-report measure of "real world" risky behavior. As expected, decision-making was associated with activation, as measured by increased BOLD responses, of the striatum, insula, anterior cingulate cortex, dorsolateral prefrontal cortex, and parietal lobe. Risk avoidance during probabilistic trials (percent of trials passed) was significantly correlated with precuneus and striatal responses to trials with a certain outcome (No-Risk). Similarly, "real world" risk avoidance, as measured by the CARE, was significantly correlated with precuneus activity during No-Risk trials. Collectively, these data suggest that precuneus and striatal responses to decision-making under certainty represent putative neural markers of risk avoidance in the laboratory and in the "real world." Further, they underline the need to extend neuroimaging research on risk avoidance, and associated anxiety disorders, to posterior cortical regions. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Roy, Amy Krain] CUNY Brooklyn Coll, Dept Psychol, Brooklyn, NY 11210 USA.
[Roy, Amy Krain; Gotimer, Kristin; Kelly, A. M. Clare; Castellanos, F. Xavier; Milham, Michael P.] NYU, Sch Med, Ctr Child Study, Phyllis Green & Randolph Cowen Inst Pediat Neuros, New York, NY 10016 USA.
[Ernst, Monique] NIMH, Mood & Anxiety Disorders Program, NIH, US Dept HHS, Bethesda, MD 20892 USA.
RP Roy, AK (reprint author), CUNY Brooklyn Coll, Dept Psychol, Brooklyn, NY 11210 USA.
EM amy.roy@nyumc.org
RI Roy, Amy/J-7613-2013; Milham, Michael/K-9501-2014;
OI Castellanos, Francisco/0000-0001-9192-9437
FU National Institute of Mental Health [K23MH074821]; National Institute of
Mental Health, NIH, DHHS
FX This work was supported by the National Institute of Mental Health
(grant number K23MH074821 to A.K.R.) and the Intramural Research Program
of the National Institute of Mental Health, NIH, DHHS.
NR 39
TC 10
Z9 11
U1 1
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD APR
PY 2011
VL 49
IS 5
BP 937
EP 944
DI 10.1016/j.neuropsychologia.2011.02.038
PG 8
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 764RE
UT WOS:000290649200019
PM 21354189
ER
PT J
AU Zopf, R
Truong, S
Finkbeiner, M
Friedman, J
Williams, MA
AF Zopf, Regine
Truong, Sandra
Finkbeiner, Matthew
Friedman, Jason
Williams, Mark A.
TI Viewing and feeling touch modulates hand position for reaching
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Parietal cortex; Touch; Action; Human body; Body location; Rubber hand
illusion
ID GRASPING VISUAL ILLUSIONS; MULTISENSORY REPRESENTATION; PERIPERSONAL
SPACE; PREMOTOR CORTEX; PARIETAL CORTEX; BODY-OWNERSHIP; PERCEPTION;
PROPRIOCEPTION; DISSOCIATION; INTEGRATION
AB Action requires knowledge of our body location in space. Here we asked if interactions with the external world prior to a reaching action influence how visual location information is used. We investigated if the temporal synchrony between viewing and feeling touch modulates the integration of visual and proprioceptive body location information for action. We manipulated the synchrony between viewing and feeling touch in the Rubber Hand Illusion paradigm prior to participants performing a ballistic reaching task to a visually specified target. When synchronous touch was given, reaching trajectories were significantly shifted compared to asynchronous touch. The direction of this shift suggests that touch influences the encoding of hand position for action. On the basis of this data and previous findings, we propose that the brain uses correlated cues from passive touch and vision to update its own position for action and experience of self-location. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Zopf, Regine; Truong, Sandra; Finkbeiner, Matthew; Friedman, Jason; Williams, Mark A.] Macquarie Univ, Macquarie Ctr Cognit Sci, Inst Human Cognit & Brain Sci, Sydney, NSW 2109, Australia.
[Truong, Sandra] NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA.
RP Zopf, R (reprint author), Macquarie Univ, Macquarie Ctr Cognit Sci, Inst Human Cognt & Brain Sci, Sydney, NSW 2109, Australia.
EM regine.zopf@mq.edu.au; sandra.truong@nih.gov
RI Friedman, Jason/B-4690-2008;
OI Friedman, Jason/0000-0001-8845-5082; Zopf, Regine/0000-0002-1375-3832;
Williams, Mark/0000-0002-3897-5167
FU Australian Research Council
FX We would like to thank Glenn Carruthers for fruitful discussions and
Chris Baker, Dwight Kravitz and Anina Rich for their insightful comments
on an earlier version of this manuscript. MF is an Australian Research
Fellow and MAW is a Queen Elizabeth II Fellow, both funded by the
Australian Research Council.
NR 40
TC 16
Z9 17
U1 2
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD APR
PY 2011
VL 49
IS 5
BP 1287
EP 1293
DI 10.1016/j.neuropsychologia.2011.02.012
PG 7
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 764RE
UT WOS:000290649200054
PM 21320514
ER
PT J
AU Cornwell, BR
Alvarez, RP
Lissek, S
Kaplan, R
Ernst, M
Grillon, C
AF Cornwell, Brian R.
Alvarez, Ruben P.
Lissek, Shmuel
Kaplan, Raphael
Ernst, Monique
Grillon, Christian
TI Anxiety overrides the blocking effects of high perceptual load on
amygdala reactivity to threat-related distractors
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Amygdala; Anxiety; Attention; Fearful faces; Perceptual load; Prefrontal
cortices
ID SPATIAL ATTENTION; FEARFUL FACES; DISORDERS; STARTLE; BRAIN; SHOCK
AB Amygdala reactivity to threat-related distractor stimuli can be abolished in perceptually demanding contexts. Premised on the biological imperative to respond swiftly to threat, we demonstrate, however, that when participants are threatened by shock, greater amygdala responses to fearful compared to neutral distractor faces is preserved under conditions of high attentional demand. Lateral prefrontal cortices also showed selective responding to fearful distractor faces under these conditions, suggesting that threat-related distractor stimuli engaged attentional control mechanisms. We conclude that anxiety elicited by looming threat promotes neurocognitive processes that broaden attention and enhance sensitivity to potential danger cues, even when perceptual systems are taxed. Published by Elsevier Ltd.
C1 [Cornwell, Brian R.; Alvarez, Ruben P.; Lissek, Shmuel; Kaplan, Raphael; Ernst, Monique; Grillon, Christian] NIMH, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA.
[Cornwell, Brian R.; Alvarez, Ruben P.; Lissek, Shmuel; Kaplan, Raphael; Ernst, Monique; Grillon, Christian] NIH, Mood & Anxiety Disorders Program, Bethesda, MD 20892 USA.
RP Cornwell, BR (reprint author), NIMH, Mood & Anxiety Disorders Program, 15K North Dr,MSC 2670, Bethesda, MD 20892 USA.
EM cornwellb@mail.nih.gov
OI Kaplan, Raphael/0000-0002-5023-1566
FU National Institute of Mental Health (NIMH)
FX This research was supported by the Intramural Research Program of the
National Institute of Mental Health (NIMH). We wish to thank Katye Vytal
for helpful comments on an earlier draft.
NR 26
TC 20
Z9 21
U1 2
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD APR
PY 2011
VL 49
IS 5
BP 1363
EP 1368
DI 10.1016/j.neuropsychologia.2011.02.049
PG 6
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 764RE
UT WOS:000290649200065
PM 21376745
ER
PT J
AU Neumann, S
Gershengorn, MC
AF Neumann, S.
Gershengorn, M. C.
TI Small molecule TSHR agonists and antagonists
SO ANNALES D ENDOCRINOLOGIE
LA English
DT Article
DE Thyroid; Thyroid cancer; Graves' disease; TSH receptor; Small molecule
ligands
ID THYROTROPIN RECEPTOR
AB TSH activates the TSH receptor (TSHR) thereby stimulating the function of thyroid follicular cells (thyrocytes) leading to biosynthesis and secretion of thyroid hormones. Because TSHR is involved in several thyroid pathologies, there is a strong rationale for the design of small molecule "drug-like" ligands. Recombinant human TSH (rhTSH, Thyrogen (R)) has been used in the follow-up of patients with thyroid cancer to increase the sensitivity for detection of recurrence or metastasis. rhTSH is difficult to produce and must be administered by injection. A small molecule TSHR agonist could produce the same beneficial effects as rhTSH but with greater ease of oral administration. We developed a small molecule ligand that is a full agonist at TSHR. Importantly for its clinical potential, this agonist elevated serum thyroxine and stimulated thyroidal radioiodide uptake in mice after its absorption from the gastrointestinal tract following oral administration. Graves' disease (GD) is caused by persistent, unregulated stimulation of thyrocytes by thyroid-stimulating antibodies (TSAbs) that activate TSHR. We identified the first small molecule TSHR antagonists that inhibited TSH- and TSAb-stimulated signalling in primary cultures of human thyrocytes. Our results provide proof-of-principle for effectiveness of small molecule agonists and antagonists for TSHR. We suggest that these small molecule ligands are lead compounds for the development of higher potency ligands that can be used as probes of TSHR biology with therapeutic potential. Published by Elsevier Masson SAS.
C1 [Neumann, S.; Gershengorn, M. C.] NIDDK, NIH, CEB, Receptor & Hormone Act Sect, Bethesda, MD 20892 USA.
RP Neumann, S (reprint author), NIDDK, NIH, CEB, Receptor & Hormone Act Sect, Bldg 50,Room 4124,50 S Dr, Bethesda, MD 20892 USA.
EM susannen@intra.niddk.nih.gov
FU National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health
FX This work was supported by the Intramural Research Programs of the
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health.
NR 10
TC 7
Z9 9
U1 0
U2 3
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0003-4266
J9 ANN ENDOCRINOL-PARIS
JI Ann Endocrinol.
PD APR
PY 2011
VL 72
IS 2
BP 74
EP 76
DI 10.1016/j.ando.2011.03.002
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 767FP
UT WOS:000290841000006
PM 21511239
ER
PT J
AU Kazuki, Y
Hoshiya, H
Takiguchi, M
Abe, S
Iida, Y
Osaki, M
Katoh, M
Hiratsuka, M
Shirayoshi, Y
Hiramatsu, K
Ueno, E
Kajitani, N
Yoshino, T
Kazuki, K
Ishihara, C
Takehara, S
Tsuji, S
Ejima, F
Toyoda, A
Sakaki, Y
Larionov, V
Kouprina, N
Oshimura, M
AF Kazuki, Y.
Hoshiya, H.
Takiguchi, M.
Abe, S.
Iida, Y.
Osaki, M.
Katoh, M.
Hiratsuka, M.
Shirayoshi, Y.
Hiramatsu, K.
Ueno, E.
Kajitani, N.
Yoshino, T.
Kazuki, K.
Ishihara, C.
Takehara, S.
Tsuji, S.
Ejima, F.
Toyoda, A.
Sakaki, Y.
Larionov, V.
Kouprina, N.
Oshimura, M.
TI Refined human artificial chromosome vectors for gene therapy and animal
transgenesis
SO GENE THERAPY
LA English
DT Article
DE human artificial chromosome; animal transgenesis; microcell-mediated
chromosome transfer
ID TRANSFORMATION-ASSOCIATED RECOMBINATION; STEM-CELLS; GENOMIC LOCI; MICE;
GENERATION; CLONING; EXPRESSION; SEQUENCE; YEAST; HUMAN-CHROMOSOME-21
AB Human artificial chromosomes (HACs) have several advantages as gene therapy vectors, including stable episomal maintenance, and the ability to carry large gene inserts. We previously developed HAC vectors from the normal human chromosomes using a chromosome engineering technique. However, endogenous genes were remained in these HACs, limiting their therapeutic applications. In this study, we refined a HAC vector without endogenous genes from human chromosome 21 in homologous recombination-proficient chicken DT40 cells. The HAC was physically characterized using a transformation-associated recombination (TAR) cloning strategy followed by sequencing of TAR-bacterial artificial chromosome clones. No endogenous genes were remained in the HAC. We demonstrated that any desired gene can be cloned into the HAC using the Cre-loxP system in Chinese hamster ovary cells, or a homologous recombination system in DT40 cells. The HAC can be efficiently transferred to other type of cells including mouse ES cells via microcell-mediated chromosome transfer. The transferred HAC was stably maintained in vitro and in vivo. Furthermore, tumor cells containing a HAC carrying the suicide gene, herpes simplex virus thymidine kinase (HSV-TK), were selectively killed by ganciclovir in vitro and in vivo. Thus, this novel HAC vector may be useful not only for gene and cell therapy, but also for animal transgenesis. Gene Therapy (2011) 18, 384-393; doi:10.1038/gt.2010.147; published online 18 November 2010
C1 [Kazuki, Y.; Hoshiya, H.; Takiguchi, M.; Abe, S.; Iida, Y.; Osaki, M.; Hiramatsu, K.; Ueno, E.; Kajitani, N.; Kazuki, K.; Ishihara, C.; Takehara, S.; Tsuji, S.; Oshimura, M.] Tottori Univ, Grad Sch Med Sci, Dept Biomed Sci, Inst Regenerat Med & Biofunct, Tottori 6838503, Japan.
[Kazuki, Y.; Oshimura, M.] Tottori Univ, Chromosome Engn Res Ctr, Tottori 6838503, Japan.
[Katoh, M.] Tottori Univ, Div Human Genome Sci, Dept Mol & Cellular Biol, Sch Life Sci,Fac Med, Tottori 6838503, Japan.
[Shirayoshi, Y.] Tottori Univ, Div Regenerat Med & Therapeut, Dept Genet Med & Regenerat Therapeut, Inst Regenerat Med & Biofunct,Grad Sch Med Sci, Tottori 6838503, Japan.
[Yoshino, T.] Tottori Univ, Div Funct Genom, Res Ctr Biosci & Technol, Tottori 6838503, Japan.
[Ejima, F.; Toyoda, A.; Sakaki, Y.] RIKEN, Genom Sci Ctr, Sequence Technol Team, Yokohama, Kanagawa, Japan.
[Larionov, V.; Kouprina, N.] NCI, Mol Pharmacol Lab, Bethesda, MD 20892 USA.
[Oshimura, M.] CREST, JST, Tokyo, Japan.
RP Oshimura, M (reprint author), Tottori Univ, Grad Sch Med Sci, Dept Biomed Sci, Inst Regenerat Med & Biofunct, 86 Nishi Cho, Tottori 6838503, Japan.
EM oshimura@grape.med.tottori-u.ac.jp
FU JST, CREST; Ministry of Education, Culture, Sports, Science and
Technology of Japan
FX We thank Dr M Okabe at Osaka University for providing pCX-EGFP; Dr J
Toguchida at Kyoto University for providing hiMSC; Dr M Ikeno at Keio
University for providing p11-4; Dr G Felsenfeld, National Institute of
Health for providing pJC5-4; the technical staffs of the Sequence
Technology Team at RIKEN GSC for their assistance; Mr/Mrs Y Watanabe, Y
Kai, K Kawakami and C Igawa at Tottori University for technical
assistance; and Dr T Ohbayashi at Tottori University for critical
discussions. This study was supported in part by JST, CREST (MO and YK),
and the twenty-first Century Center of Excellence (COE) program from the
Ministry of Education, Culture, Sports, Science and Technology of Japan
(MO and YK).
NR 41
TC 37
Z9 37
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THER
JI Gene Ther.
PD APR
PY 2011
VL 18
IS 4
BP 384
EP 393
DI 10.1038/gt.2010.147
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Genetics & Heredity; Research & Experimental Medicine
GA 769YE
UT WOS:000291053400008
PM 21085194
ER
PT J
AU Ramella-Roman, JC
Nayak, A
Prahl, SA
AF Ramella-Roman, Jessica C.
Nayak, Amritha
Prahl, Scott A.
TI Spectroscopic sensitive polarimeter for biomedical applications
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE Stokes vector; spectroscopic polarimeter; Mueller matrix
ID TURBID MEDIA; SCATTERING; PHANTOMS; CELLS
AB We present the design and calibration of a spectroscopic sensitive polarimeter. The polarimeter can measure the full Stokes vector in the wavelength range 550 to 750 nm with 1-nm resolution and consists of a fiber-based spectrophotometer, a white light emitting diode light source, two liquid crystal retarders, and one polarizer. Calibration of the system is achieved with a scheme that does not require knowledge of the polarizing elements' orientation or retardation. Six intensity spectra are required to calculate the full spectrum Stokes vector. Error in the polarimeter is less than 5%. We report the Stokes vectors for light transmitted through nonscattering polarizing elements as well as a measurement of the depolarizing properties of chicken muscle at several wavelengths. (C) 2011 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.3561907]
C1 [Ramella-Roman, Jessica C.] Catholic Univ Amer, Dept Biomed Engn, Washington, DC 20064 USA.
[Nayak, Amritha] NICHD NICHD, Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20817 USA.
[Prahl, Scott A.] Providence St Vincent Med Ctr, Oregon Med Laser Ctr, Portland, OR 97225 USA.
RP Ramella-Roman, JC (reprint author), Catholic Univ Amer, Dept Biomed Engn, 620 Michigan Ave NE, Washington, DC 20064 USA.
EM ramella@cua.edu
FU Applied Physics Laboratory, Johns Hopkins, Laurel, Maryland; NIH/NIDCR
[1R21DE016758]
FX We acknowledge and appreciate the financial support of the Applied
Physics Laboratory, Johns Hopkins, Laurel, Maryland. Scott Prahl
acknowledges the support of NIH/NIDCR 1R21DE016758.
NR 22
TC 6
Z9 6
U1 1
U2 5
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD APR
PY 2011
VL 16
IS 4
AR 047001
DI 10.1117/1.3561907
PG 7
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA 769PX
UT WOS:000291031400029
PM 21529091
ER
PT J
AU Pchelina, SN
Emelyanov, AK
Yakimovskii, AF
Miller, DW
Shabalina, IG
Drozdova, AS
Schwarzman, AL
AF Pchelina, S. N.
Emelyanov, A. K.
Yakimovskii, A. F.
Miller, D. W.
Shabalina, I. G.
Drozdova, A. S.
Schwarzman, A. L.
TI Reduced Content of alpha-Synuclein in Peripheral Blood Leukocytes of
Patients with LRRK2-Associated Parkinson's Disease
SO BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Parkinson's disease; alpha-synuclein; lymphocytes; leucine-rich kinase 2
ID RUSSIA
AB Measurement of alpha-synuclein level in the peripheral blood was proposed as a diagnostic test for Parkinson's disease. However, the results of these studies remain contradictory, probably because the examined samples included patients with different etiology of Parkinson's disease. To verify this assumption we studied the levels of alpha-synuclein in peripheral blood leukocytes of patients with Parkinson's disease associated with mutations in the gene of leucine-rich kinase 2 (LRRK2). The mean alpha-synuclein level was significantly lower in patients with LRRK2-associated Parkinson's disease (N=8) than in patients with sporadic form of the disease (N=33; p<0.02) and in controls (N=18; p<0.05). On the other hand, we found no differences in the level of alpha-synuclein level between patients with sporadic form of the disease and controls. We hypothesize that the level of alpha-synuclein in the peripheral blood largely depends on the etiology of the disease and cannot be used as a universal diagnostic test for Parkinson's disease.
C1 [Pchelina, S. N.; Emelyanov, A. K.; Drozdova, A. S.; Schwarzman, A. L.] Russian Acad Sci, BP Konstantinov Petersburg Nucl Phys Inst, Moscow 117901, Russia.
[Pchelina, S. N.; Yakimovskii, A. F.; Shabalina, I. G.] St Petersburg State IP Pavlov Med Univ, Minist Hlth Care & Social Dev Russian Federat, St Petersburg, Russia.
[Miller, D. W.] NIA, NIH, Bethesda, MD 20892 USA.
RP Pchelina, SN (reprint author), Russian Acad Sci, BP Konstantinov Petersburg Nucl Phys Inst, Moscow 117901, Russia.
EM sopche-lina@hotmail.com
FU Russian Foundation for Basic Researches [09-04-00934-a]; Russian Academy
of Sciences
FX The study was supported by the Russian Foundation for Basic Researches
(grant No. 09-04-00934-a) and Russian Academy of Sciences (Fundamental
Sciences to Medicine, 2006).
NR 12
TC 3
Z9 3
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0007-4888
J9 B EXP BIOL MED+
JI Bull. Exp. Biol. Med.
PD APR
PY 2011
VL 150
IS 6
BP 679
EP 681
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 766VF
UT WOS:000290813900005
PM 22235415
ER
PT J
AU Ma, WJ
Chen, HL
Jiang, LL
Song, GX
Kan, HD
AF Ma, Wenjuan
Chen, Honglei
Jiang, Lili
Song, Guixiang
Kan, Haidong
TI Stock volatility as a risk factor for coronary heart disease death
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Coronary heart disease; Stock volatility; Time-series analysis
ID ACUTE MYOCARDIAL-INFARCTION; SUDDEN CARDIAC DEATH; TIME-SERIES; MENTAL
STRESS; AIR-POLLUTION; CARDIOVASCULAR-DISEASES; ARTERY-DISEASE; DAILY
MORTALITY; PUBLIC-HEALTH; GLOBAL BURDEN
AB Aims The volatility of financial markets may cause substantial emotional and physical stress among investors. We hypothesize that this may have adverse effects on cardiovascular health. The Chinese stock markets were extremely volatile between 2006 and 2008. We, therefore, examined the relationship between daily change of the Shanghai Stock Exchange (SSE) Composite Index (referred as the Index) and coronary heart disease (CHD) deaths from 1 January 2006 to 31 December 2008 in Shanghai, the financial capital of China.
Methods and results Daily death and stock performance data were collected from the Shanghai Center for Disease Control and Prevention and SSE, respectively. Data were analysed with over-dispersed generalized linear Poisson models, controlling for long-term and seasonal trends of CHD mortality, day of the week, Index closing value, weather conditions, and air pollution levels. We observed a U-shaped relationship between the Index change and CHD deaths: both rising and falling of the Index were associated with more deaths and the fewest deaths coincided with little or no change of the index. We also examined the absolute daily change of the Index in relation to CHD deaths: in a 1-day lag model, each 100-point change of the Index corresponded to 5.17% (95% confidence interval: 1.71, 8.63%) increase in CHD deaths. Further analysis showed that the association was stronger for out-of-hospital CHD death than for in-hospital death.
Conclusion We found that CHD deaths fluctuated with daily stock changes in Shanghai, suggesting that stock volatility may adversely affect cardiovascular health.
C1 [Ma, Wenjuan; Kan, Haidong] Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Minist Educ, Shanghai 200433, Peoples R China.
[Ma, Wenjuan; Kan, Haidong] Fudan Univ, Inst Global Environm Change Res, Shanghai 200433, Peoples R China.
[Chen, Honglei] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC USA.
[Jiang, Lili] Natl Univ Singapore, Fac Sci, Dept Stat, Singapore 117548, Singapore.
[Song, Guixiang] Shanghai Municipal Ctr Dis Control & Prevent, Shanghai, Peoples R China.
RP Kan, HD (reprint author), Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Minist Educ, Shanghai 200433, Peoples R China.
EM haidongkan@gmail.com
OI Chen, Honglei/0000-0003-3446-7779
FU National Basic Research Program (973 program) of China [2011CB503802];
Gong-Yi Program of China Ministry of Environmental Protection
[200809109]; National Natural Science Foundation of China [30800892];
Shanghai Pu Jiang Program [09PJ1401700]; Program for New Century
Excellent Talents in University [NCET-09-0314]; NIH; National Institute
of Environmental Health Sciences [Z01-ES-101986]
FX The study was supported by the National Basic Research Program (973
program) of China (2011CB503802), Gong-Yi Program of China Ministry of
Environmental Protection (200809109), National Natural Science
Foundation of China (30800892), Shanghai Pu Jiang Program (09PJ1401700),
and Program for New Century Excellent Talents in University
(NCET-09-0314). H. C. was supported by the Intramural Research Program
of the NIH, the National Institute of Environmental Health Sciences
(Z01-ES-101986).
NR 35
TC 11
Z9 11
U1 1
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
J9 EUR HEART J
JI Eur. Heart J.
PD APR
PY 2011
VL 32
IS 8
BP 1006
EP 1011
DI 10.1093/eurheartj/ehq495
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 750XN
UT WOS:000289581600022
PM 21196446
ER
PT J
AU Otto, M
AF Otto, Michael
TI Panton-Valentine leukocidin antibodies for the treatment of MRSA skin
infections?
SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
LA English
DT Article
DE drug development; MRSA; Panton-Valentine leukocidin; skin infections;
Staphylococcus aureus
ID RESISTANT STAPHYLOCOCCUS-AUREUS; COMMUNITY-ASSOCIATED MRSA; VIRULENCE
DETERMINANTS; NECROTIZING PNEUMONIA; ALPHA-HEMOLYSIN; GENES;
INFLAMMATION; EXPRESSION; SEVERITY; STRAINS
AB Methicillin-resistant Staphylococcus aureus (MRSA) has recently caused epidemic outbreaks of community-associated (CA) skin infections. The infecting strains frequently contain the genes encoding the staphylococcal toxin, Panton-Valentine leukocidin (PVL). On that ground, the use of PVL-based vaccines has been proposed for the treatment of CA-MRSA infections, despite experimental and epidemiological evidence that does not support a major role of the PVL toxin in CA-MRSA skin disease. Hermos et al. show that antibodies to PVL do not protect from CA-MRSA skin infections in children, strongly suggesting that PVL-based immunization is of little benefit for this most frequent disease caused by CA-MRSA.
C1 NIAID, Lab Human Bacterial Pathogenesis, NIH, Bethesda, MD 20926 USA.
RP Otto, M (reprint author), NIAID, Lab Human Bacterial Pathogenesis, NIH, Bethesda, MD 20926 USA.
EM motto@niaid.nih.gov
OI Otto, Michael/0000-0002-2222-4115
FU National Institute of Allergy and Infectious Diseases [Z01 AI000904-06]
FX Michael Otto has received funding from the Intramural Research Program
of the National Institute of Allergy and Infectious Diseases (Z01
AI000904-06). The author has no other relevant affiliations or financial
involvement with any organization or entity with a financial interest in
or financial conflict with the subject matter or materials discussed in
the manuscript apart from those disclosed.
NR 37
TC 3
Z9 3
U1 1
U2 2
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1478-7210
J9 EXPERT REV ANTI-INFE
JI Expert Rev. Anti-Infect. Ther.
PD APR
PY 2011
VL 9
IS 4
BP 389
EP 392
DI 10.1586/ERI.11.19
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 767FC
UT WOS:000290839700009
PM 21504395
ER
PT J
AU Bode, C
Zhao, G
Steinhagen, F
Kinjo, T
Klinman, DM
AF Bode, Christian
Zhao, Gan
Steinhagen, Folkert
Kinjo, Takeshi
Klinman, Dennis M.
TI CpG DNA as a vaccine adjuvant
SO EXPERT REVIEW OF VACCINES
LA English
DT Review
DE adjuvant; cancer; CpG oligodeoxynucleotide; immunity; infectious
disease; Toll-like receptor; vaccine
ID T-CELL RESPONSES; PLASMACYTOID DENDRITIC CELLS; B SURFACE-ANTIGEN;
SYSTEMIC-LUPUS-ERYTHEMATOSUS; INDUCE AUTOIMMUNE-DISEASE;
NECROSIS-FACTOR-ALPHA; HIV-INFECTED ADULTS; TOLL-LIKE RECEPTORS;
BACTERIAL-DNA; IN-VIVO
AB Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells that express Toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells) to mount an innate immune response characterized by the production of Th1 and proinflammatory cytokines. When used as vaccine adjuvants, CpG ODNs improve the function of professional antigen-presenting cells and boost the generation of humoral and cellular vaccine-specific immune responses. These effects are optimized by maintaining ODNs and vaccine in close proximity. The adjuvant properties of CpG ODNs are observed when administered either systemically or mucosally, and persist in immunocompromised hosts. Preclinical studies indicate that CpG ODNs improve the activity of vaccines targeting infectious diseases and cancer. Clinical trials demonstrate that CpG ODNs have a good safety profile and increase the immunogenicity of coadministered vaccines.
C1 [Bode, Christian; Zhao, Gan; Steinhagen, Folkert; Kinjo, Takeshi; Klinman, Dennis M.] NCI, Canc & Inflammat Program, Frederick, MD 21702 USA.
RP Klinman, DM (reprint author), NCI, Canc & Inflammat Program, Frederick, MD 21702 USA.
EM klinmand@mail.nih.gov
FU Intramural NIH HHS [ZIA BC010852-04]
NR 143
TC 183
Z9 195
U1 7
U2 62
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1476-0584
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD APR
PY 2011
VL 10
IS 4
SI SI
BP 499
EP 511
DI 10.1586/ERV.10.174
PG 13
WC Immunology
SC Immunology
GA 767DB
UT WOS:000290834400017
PM 21506647
ER
PT J
AU Ahren, E
AF Ahren, Eva
TI The Anatomy Murders: Being the True and Spectacular History of
Edinburgh's Notorious Burke and Hare and of the Man of Science Who
Abetted Them in the Commission of Their Most Heinous Crimes
SO JOURNAL OF THE HISTORY OF MEDICINE AND ALLIED SCIENCES
LA English
DT Book Review
C1 [Ahren, Eva] Uppsala Univ, Uppsala, Sweden.
[Ahren, Eva] NIH, Hist Off, Bethesda, MD 20892 USA.
RP Ahren, E (reprint author), Uppsala Univ, Uppsala, Sweden.
EM eva.ahren@idehist.uu.se
NR 1
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-5045
J9 J HIST MED ALL SCI
JI J. Hist. Med. Allied Sci.
PD APR
PY 2011
VL 66
IS 2
BP 251
EP 253
DI 10.1093/jhmas/jrq077
PG 3
WC Health Care Sciences & Services; History & Philosophy Of Science
SC Health Care Sciences & Services; History & Philosophy of Science
GA 764NL
UT WOS:000290637100005
ER
PT J
AU Pekkurnaz, G
Fera, A
Zimmerberg-Helms, J
Degiorgis, JA
Bezrukov, L
Blank, PS
Mazar, J
Reese, TS
Zimmerberg, J
AF Pekkurnaz, Gulcin
Fera, Andrea
Zimmerberg-Helms, Jessica
Degiorgis, Joseph A.
Bezrukov, Ludmila
Blank, Paul S.
Mazar, Julia
Reese, Thomas S.
Zimmerberg, Joshua
TI Isolation and Ultrastructural Characterization of Squid Synaptic
Vesicles
SO BIOLOGICAL BULLETIN
LA English
DT Article
ID ELECTRON-MICROSCOPY; PROTEINS; SYNAPTOSOMES; PURIFICATION
AB Synaptic vesicles contain a variety of proteins and lipids that mediate fusion with the pre-synaptic membrane. Although the structures of many synaptic vesicle proteins are known, an overall picture of how they are organized at the vesicle surface is lacking. In this paper, we describe a better method for the isolation of squid synaptic vesicles and characterize the results. For highly pure and intact synaptic vesicles from squid optic lobe, glycerol density gradient centrifugation was the key step. Different electron microscopic methods show that vesicle membrane surfaces are largely covered with structures corresponding to surface proteins. Each vesicle contains several stalked globular structures that extend from the vesicle surface and are consistent with the V-ATPase. BLAST search of a library of squid expressed sequence tags identifies 10 V-ATPase subunits, which are expressed in the squid stellate ganglia. Negative-stain tomography demonstrates directly that vesicles flatten during the drying step of negative staining, and furthermore shows details of individual vesicles and other proteins at the vesicle surface.
C1 [Pekkurnaz, Gulcin; Zimmerberg-Helms, Jessica; Bezrukov, Ludmila; Blank, Paul S.; Mazar, Julia; Zimmerberg, Joshua] NICHHD, NIH, Bethesda, MD 20892 USA.
[Pekkurnaz, Gulcin; Fera, Andrea; Zimmerberg-Helms, Jessica; Degiorgis, Joseph A.; Mazar, Julia; Reese, Thomas S.; Zimmerberg, Joshua] Marine Biol Lab, Woods Hole, MA 02543 USA.
[Fera, Andrea; Degiorgis, Joseph A.; Reese, Thomas S.] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA.
[Degiorgis, Joseph A.] Providence Coll, Dept Biol, Providence, RI 02918 USA.
RP Zimmerberg, J (reprint author), NICHHD, NIH, Bethesda, MD 20892 USA.
EM joshz@mail.nih.gov
FU National Center for Research Resources (NCRR), NIH [P20RR016457-10]
FX We are grateful to Jane Farrington for examining fractions in the
electron microscope, and Dr. Harish Pant for teaching us the optic lobe
dissection and homogenization. JAD is supported by the RI-INBRE program
award # P20RR016457-10 from the National Center for Research Resources
(NCRR), NIH.
NR 18
TC 3
Z9 3
U1 0
U2 2
PU MARINE BIOLOGICAL LABORATORY
PI WOODS HOLE
PA 7 MBL ST, WOODS HOLE, MA 02543 USA
SN 0006-3185
EI 1939-8697
J9 BIOL BULL-US
JI Biol. Bull.
PD APR
PY 2011
VL 220
IS 2
BP 89
EP 96
PG 8
WC Biology; Marine & Freshwater Biology
SC Life Sciences & Biomedicine - Other Topics; Marine & Freshwater Biology
GA 763YS
UT WOS:000290596200003
PM 21551445
ER
PT J
AU Chan, PYS
von Leupoldt, A
Bradley, MM
Lang, PJ
Davenport, PW
AF Chan, Pei-Ying S.
von Leupoldt, Andreas
Bradley, Margret M.
Lang, Peter J.
Davenport, Paul W.
TI The effect of anxiety on respiratory sensory gating measured by the
respiratory-related evoked potential (RREP)
SO BIOLOGICAL PSYCHOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Meeting of the
International-Society-for-the-Advancement-of-Respiratory-Psychophysiolog
y
CY SEP 26-27, 2010
CL New York, NY
SP Int Soc Advancement Respiratory Psychophysiol
C1 [Chan, Pei-Ying S.] Chang Gung Univ, Dept Occupat Therapy, Tao Yuan, Taiwan.
[Chan, Pei-Ying S.; von Leupoldt, Andreas; Davenport, Paul W.] Univ Florida, Coll Vet Med, Dept Physiol Sci, Gainesville, FL 32610 USA.
[von Leupoldt, Andreas] Univ Hamburg, Dept Psychol, Hamburg, Germany.
[von Leupoldt, Andreas; Bradley, Margret M.; Lang, Peter J.] Univ Florida, NIMH, Ctr Study Emot & Attent, Gainesville, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-0511
J9 BIOL PSYCHOL
JI Biol. Psychol.
PD APR
PY 2011
VL 87
IS 1
BP 175
EP 176
PG 2
WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology,
Experimental
SC Psychology; Behavioral Sciences
GA 758VL
UT WOS:000290195100045
ER
PT J
AU von Leupoldt, A
Chan, PYS
Bradley, MM
Lang, PJ
Davenport, PW
AF von Leupoldt, Andreas
Chan, Pei-Ying S.
Bradley, Margaret M.
Lang, Peter J.
Davenport, Paul W.
TI The impact of anxiety on the neural processing of short inspiratory
occlusions
SO BIOLOGICAL PSYCHOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Meeting of the
International-Society-for-the-Advancement-of-Respiratory-Psychophysiolog
y
CY SEP 26-27, 2010
CL New York, NY
SP Int Soc Advancement Respiratory Psychophysiol
C1 [von Leupoldt, Andreas; Chan, Pei-Ying S.; Davenport, Paul W.] Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA.
[von Leupoldt, Andreas] Univ Hamburg, Dept Psychol, Hamburg, Germany.
[von Leupoldt, Andreas] Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, Hamburg, Germany.
[von Leupoldt, Andreas; Bradley, Margaret M.; Lang, Peter J.] Univ Florida, NIMH, Ctr Study Emot & Attent, Gainesville, FL USA.
[Chan, Pei-Ying S.] Chang Gung Univ, Dept Occupat Therapy, Tao Yuan, Taiwan.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-0511
J9 BIOL PSYCHOL
JI Biol. Psychol.
PD APR
PY 2011
VL 87
IS 1
BP 175
EP 175
PG 1
WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology,
Experimental
SC Psychology; Behavioral Sciences
GA 758VL
UT WOS:000290195100044
ER
PT J
AU Baumann, MH
Williams, Z
Zolkowska, D
Rothman, RB
AF Baumann, Michael H.
Williams, Zakia
Zolkowska, Dorota
Rothman, Richard B.
TI Serotonin (5-HT) precursor loading with 5-hydroxy-L-tryptophan (5-HTP)
reduces locomotor activation produced by (+)-amphetamine in the rat
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Amphetamine; 5-Hydroxy-L-tryptophan; Cocaine; Drug addiction; Dopamine;
Serotonin
ID COCAINE-DEPENDENCE; NUCLEUS-ACCUMBENS; D-AMPHETAMINE; DOUBLE-BLIND;
AGONIST-LIKE; DOPAMINE; FENFLURAMINE; L-5-HYDROXYTRYPTOPHAN;
PHARMACOTHERAPY; RECEPTORS
AB Background: Evidence suggests that increases in synaptic serotonin (5-HT) can reduce the stimulant properties of amphetamine-type drugs. Here we tested the hypothesis that administration of the 5-HT precursor 5-hydroxy-L-tryptophan (5-HTP), along with the peripheral decarboxylase inhibitor benserazide, would decrease locomotor effects of (+)-amphetamine.
Methods: Drug treatments were administered to conscious male rats undergoing in vivo microdialysis in nucleus accumbens. During dialysis sampling, rats were housed in chambers equipped with photobeams to detect forward locomotion (i.e., ambulation) and repetitive movements (i.e., stereotypy). Extracellular concentrations of dopamine (DA) and 5-HT were measured by high-pressure liquid chromatography with electrochemical detection.
Results: 5-HIP (10 & 30 mg/kg, i.p.) plus benserazide (30 mg/kg, i.p.) caused dose-related increases in 5-HT but failed to alter other parameters. (+)-Amphetamine (0.3 & 1.0 mg/kg, i.p.) produced dose-related increases in DA, ambulation and stereotypy. Combined administration of 5-HTP and (+)-amphetamine evoked large elevations in extracellular DA and 5-HT, but caused significantly less ambulation than (+)amphetamine alone (similar to 50% reduction).
Conclusions: Our results confirm that 5-HIP can decrease hyperactivity produced by (+)-amphetamine, even in the presence of elevations in dialysate DA. The data suggest that 5-HTP and (+)-amphetamine may be useful to broadly enhance monoamine function in the clinical setting, while reducing undesirable effects of (+)-amphetamine. Published by Elsevier Ireland Ltd.
C1 [Baumann, Michael H.; Williams, Zakia; Zolkowska, Dorota; Rothman, Richard B.] NIDA, IRP, NIH, Clin Psychopharmacol Sect, Baltimore, MD 21224 USA.
RP Rothman, RB (reprint author), NIDA, IRP, NIH, Clin Psychopharmacol Sect, Suite 4500,Triad Bldg,333 Cassell Dr, Baltimore, MD 21224 USA.
EM rrothman@mail.nih.gov
FU National Institute on Drug Abuse (NIDA)
FX Funding for this study was generously provided by the Intramural
Research Program (IRP) of the National Institute on Drug Abuse (NIDA):
NIDA had no further role in study design, data collection, or analysis
and interpretation of the data; in writing the report; or in the
decision to submit the paper for publication.
NR 42
TC 11
Z9 12
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD APR 1
PY 2011
VL 114
IS 2-3
BP 147
EP 152
DI 10.1016/j.drugalcdep.2010.09.015
PG 6
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 759XO
UT WOS:000290283000008
PM 21071157
ER
PT J
AU Janssens, ACJW
Ioannidis, JPA
Bedrosian, S
Boffetta, P
Dolan, SM
Dowling, N
Fortier, I
Freedman, AN
Grimshaw, JM
Gulcher, J
Gwinn, M
Hlatky, MA
Janes, H
Kraft, P
Melillo, S
O'Donnell, CJ
Pencina, MJ
Ransohoff, D
Schully, SD
Seminara, D
Winn, DM
Wright, CF
van Duijn, CM
Little, J
Khoury, MJ
AF Janssens, A. Cecile J. W.
Ioannidis, John P. A.
Bedrosian, Sara
Boffetta, Paolo
Dolan, Siobhan M.
Dowling, Nicole
Fortier, Isabel
Freedman, Andrew N.
Grimshaw, Jeremy M.
Gulcher, Jeffrey
Gwinn, Marta
Hlatky, Mark A.
Janes, Holly
Kraft, Peter
Melillo, Stephanie
O'Donnell, Christopher J.
Pencina, Michael J.
Ransohoff, David
Schully, Sheri D.
Seminara, Daniela
Winn, Deborah M.
Wright, Caroline F.
van Duijn, Cornelia M.
Little, Julian
Khoury, Muin J.
TI Strengthening the reporting of genetic risk prediction studies (GRIPS):
explanation and elaboration
SO EUROPEAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Genetic; Risk prediction; Methodology; Guidelines; Reporting
ID GENOME-WIDE ASSOCIATION; HEART-DISEASE RISK; OPERATING CHARACTERISTIC
CURVE; TYPE-2 DIABETES RISK; RECLASSIFICATION MEASURES; MACULAR
DEGENERATION; DIAGNOSTIC-ACCURACY; CARDIOVASCULAR RISK;
CONTROLLED-TRIALS; PROSTATE-CANCER
AB The rapid and continuing progress in gene discovery for complex diseases is fuelling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but they vary widely in completeness of reporting and apparent quality. Transparent reporting of the strengths and weaknesses of these studies is important to facilitate the accumulation of evidence on genetic risk prediction. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS), building on the principles established by prior reporting guidelines. These recommendations aim to enhance the transparency, quality and completeness of study reporting, and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct or analysis.
C1 [Janssens, A. Cecile J. W.; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands.
[Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.
[Ioannidis, John P. A.] Fdn Res & Technol, Biomed Res Inst, Ioannina, Greece.
[Ioannidis, John P. A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA.
[Ioannidis, John P. A.] Tufts Med Ctr, Ctr Genet Epidemiol & Modeling, Inst Clin Res & Hlth Policy Studies, Boston, MA USA.
[Ioannidis, John P. A.] Tufts Med Ctr, Tufts CTSI, Inst Clin Res & Hlth Policy Studies, Boston, MA USA.
[Ioannidis, John P. A.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.
[Bedrosian, Sara; Dowling, Nicole; Gwinn, Marta; Melillo, Stephanie; Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA.
[Boffetta, Paolo] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
[Boffetta, Paolo] Int Prevent Res Inst, Lyon, France.
[Dolan, Siobhan M.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10467 USA.
[Fortier, Isabel] Publ Populat Project Genom P3G, Montreal, PQ, Canada.
[Freedman, Andrew N.; Schully, Sheri D.; Seminara, Daniela; Winn, Deborah M.] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA.
[Grimshaw, Jeremy M.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
[Grimshaw, Jeremy M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
[Gulcher, Jeffrey] DeCODE Genet, Reykjavik, Iceland.
[Hlatky, Mark A.] Stanford Univ, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA.
[Janes, Holly] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Inst, Seattle, WA 98104 USA.
[Janes, Holly] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[O'Donnell, Christopher J.] NHLBI, Framingham, MA USA.
[O'Donnell, Christopher J.] NHLBIs Framingham Heart Study, Framingham, MA USA.
[O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Pencina, Michael J.] Boston Univ, Dept Biostat, Boston, MA 02215 USA.
[Pencina, Michael J.] Harvard Clin Res Inst, Boston, MA USA.
[Ransohoff, David] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Wright, Caroline F.] PHG Fdn, Cambridge, England.
[Little, Julian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada.
RP Janssens, ACJW (reprint author), Erasmus MC, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM a.janssens@erasmusmc.nl
RI Ioannidis, John/G-9836-2011; janssens, cecile/L-1075-2015;
OI Janssens, A Cecile/0000-0002-6153-4976; Wright,
Caroline/0000-0003-2958-5076
FU NCI NIH HHS [U24 CA086368, U24 CA086368-11]
NR 93
TC 10
Z9 10
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0393-2990
J9 EUR J EPIDEMIOL
JI Eur. J. Epidemiol.
PD APR
PY 2011
VL 26
IS 4
BP 313
EP 337
DI 10.1007/s10654-011-9551-z
PG 25
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 760ON
UT WOS:000290333700009
PM 21424820
ER
PT J
AU Chernoff, N
Rogers, EH
Zehr, RD
Gage, MI
Malarkey, DE
Bradfield, CA
Liu, Y
Schmid, JE
Jaskot, RH
Richards, JH
Wood, CR
Rosen, MB
AF Chernoff, N.
Rogers, E. H.
Zehr, R. D.
Gage, M. I.
Malarkey, D. E.
Bradfield, C. A.
Liu, Y.
Schmid, J. E.
Jaskot, R. H.
Richards, J. H.
Wood, C. R.
Rosen, M. B.
TI Toxicity and recovery in the pregnant mouse after gestational exposure
to the cyanobacterial toxin, cylindrospermopsin
SO JOURNAL OF APPLIED TOXICOLOGY
LA English
DT Article
DE cylindrospermopsin; cyanobacteria; toxicity; mouse; serum chemistries;
gene expression
ID PROTEIN-SYNTHESIS INHIBITION; ISLAND MYSTERY DISEASE; FACTOR-X
DEFICIENCY; SWISS ALBINO MICE; 2 GERMAN LAKES; GENE-EXPRESSION;
RACIBORSKII CYANOBACTERIA; 1ST REPORT; IN-VIVO; CYANOTOXIN
CYLINDROSPERMOPSIN
AB Cylindrospermopsin (CYN) is a tricyclic alkaloid toxin produced by fresh water cyanobacterial species worldwide. CYN has been responsible for both livestock and human poisoning after oral exposure. This study investigated the toxicity of CYN to pregnant mice exposed during different segments of gestation. The course of recovery and individual responses to the toxin were evaluated. Adverse effects of CYN were monitored up to 7 weeks post-dosing by clinical examination, histopathology, biochemistry and gene expression. Exposure on gestational days (GD) 8-12 induced significantly more lethality than GD13-17 exposure. Periorbital, gastrointestinal and distal tail hemorrhages were seen in both groups. Serum markers indicative of hepatic injury (alanine amino transferase, aspartate amino transferase and sorbitol dehydrogenase) were increased in both groups; markers of renal dysfunction (blood urea nitrogen and creatinine) were elevated in the GD8-12 animals. Histopathology was observed in the liver (centrilobular necrosis) and kidney (interstitial inflammation) in groups exhibiting abnormal serum markers. The expression profiles of genes involved in ribosomal biogenesis, xenobiotic and lipid metabolism, inflammatory response and oxidative stress were altered 24 h after the final dose. One week after dosing, gross, histological and serum parameters had returned to normal, although increased liver/body weight ratio and one instance of gastrointestinal bleeding was found in the GD13-17 group. Gene expression changes persisted up to 2 weeks post-dosing and returned to normal by 4 weeks. Responses of individual animals to CYN exposure indicated highly significant inter-animal variability within the treated groups. Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [Chernoff, N.; Rogers, E. H.; Zehr, R. D.; Gage, M. I.; Schmid, J. E.; Jaskot, R. H.; Richards, J. H.; Wood, C. R.; Rosen, M. B.] US EPA, ORD, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA.
[Malarkey, D. E.] NIEHS, Cellular & Mol Pathol Branch, Res Triangle Pk, NC 27709 USA.
[Bradfield, C. A.; Liu, Y.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53711 USA.
RP Chernoff, N (reprint author), US EPA, ORD, Natl Hlth & Environm Effects Res Lab, MD 67, Res Triangle Pk, NC 27711 USA.
EM chernoff.neil@epa.gov
FU US Environmental Protection Agency; NIH [ES012752, CA014520]; NIH,
National Institute of Environmental Health Sciences
FX We would like to thank Dr Carin Vanderklok, North Carolina State
University School of Veterinary Medicine for assistance with the
histological analyses. The information in this document has been funded
by the US Environmental Protection Agency. It has been subject to review
by the National Health and Environmental Effects Research Laboratory and
approved for publication. Approval does not signify that the contents
reflect the views of the Agency, nor does mention of trade names or
commercial products constitute endorsement or recommendation for use.
Drs Bradfield and Liu are supported by NIH grant numbers ES012752 and
CA014520. The histological analysis was supported by the Intramural
Research Program of the NIH, National Institute of Environmental Health
Sciences.
NR 71
TC 12
Z9 12
U1 4
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0260-437X
J9 J APPL TOXICOL
JI J. Appl. Toxicol.
PD APR
PY 2011
VL 31
IS 3
BP 242
EP 254
DI 10.1002/jat.1586
PG 13
WC Toxicology
SC Toxicology
GA 759ZQ
UT WOS:000290290800006
PM 20936652
ER
PT J
AU Lee, JH
Lee, Y
Ryu, H
Kang, DW
Lee, J
Lazar, J
Pearce, LV
Pavlyukovets, VA
Blumberg, PM
Choi, S
AF Lee, Jin Hee
Lee, Yoonji
Ryu, HyungChul
Kang, Dong Wook
Lee, Jeewoo
Lazar, Jozsef
Pearce, Larry V.
Pavlyukovets, Vladimir A.
Blumberg, Peter M.
Choi, Sun
TI Structural insights into transient receptor potential vanilloid type 1
(TRPV1) from homology modeling, flexible docking, and mutational studies
SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
LA English
DT Article
DE Transient receptor potential vanilloid type 1 (TRPV1); Homology
modeling; Docking; Mutation; Capsaicin; Resiniferatoxin (RTX)
ID PROTEIN STRUCTURES; RESINIFERATOXIN; SENSITIVITY; ANTAGONISTS;
CAPSAICIN; CHANNEL; ANALGESICS; AGONISTS
AB The transient receptor potential vanilloid subtype 1 (TRPV1) is a non-selective cation channel composed of four monomers with six transmembrane helices (TM1-TM6). TRPV1 is found in the central and peripheral nervous system, and it is an important therapeutic target for pain relief. We describe here the construction of a tetrameric homology model of rat TRPV1 (rTRPV1). We experimentally evaluated by mutational analysis the contribution of residues of rTRPV1 contributing to ligand binding by the prototypical TRPV1 agonists, capsaicin and resiniferatoxin (RTX). We then performed docking analysis using our homology model. The docking results with capsaicin and RTX showed that our homology model was reliable, affording good agreement with our mutation data. Additionally, the binding mode of a simplified RTX (sRTX) ligand as predicted by the modeling agreed well with those of capsaicin and RTX, accounting for the high binding affinity of the sRTX ligand for TRPV1. Through the homology modeling, docking and mutational studies, we obtained important insights into the ligand-receptor interactions at the molecular level which should prove of value in the design of novel TRPV1 ligands.
C1 [Lee, Jin Hee; Lee, Yoonji; Choi, Sun] Ewha Womans Univ, Coll Pharm, Div Life & Pharmaceut Sci, Seoul 120750, South Korea.
[Lee, Jin Hee; Lee, Yoonji; Choi, Sun] Ewha Womans Univ, Natl Core Res Ctr Cell Signaling & Drug Discovery, Seoul 120750, South Korea.
[Ryu, HyungChul; Kang, Dong Wook; Lee, Jeewoo] Seoul Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, Seoul 151742, South Korea.
[Lazar, Jozsef; Pearce, Larry V.; Pavlyukovets, Vladimir A.; Blumberg, Peter M.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Choi, S (reprint author), Ewha Womans Univ, Coll Pharm, Div Life & Pharmaceut Sci, Seoul 120750, South Korea.
EM sunchoi@ewha.ac.kr
FU Ministry of Education, Science and Technology (MEST)
[R01-2007-000-20052-0]; National Research Foundation of Korea (NRF);
National Core Research Center (NCRC) of MEST; NRF through the Center for
Cell Signaling & Drug Discovery Research at Ewha Womans University;
National Institutes of Health, Center for Cancer Research, National
Cancer Institute
FX This research was supported by Grants R01-2007-000-20052-0 from the
Ministry of Education, Science and Technology (MEST) and National
Research Foundation of Korea (NRF) (to J. Lee and S. Choi), the National
Core Research Center (NCRC) program (R15-2006-020) of MEST and NRF
through the Center for Cell Signaling & Drug Discovery Research at Ewha
Womans University (to S. Choi), and the Intramural Research Program of
the National Institutes of Health, Center for Cancer Research, National
Cancer Institute (to P. M. Blumberg).
NR 25
TC 36
Z9 36
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-654X
J9 J COMPUT AID MOL DES
JI J. Comput.-Aided Mol. Des.
PD APR
PY 2011
VL 25
IS 4
BP 317
EP 327
DI 10.1007/s10822-011-9421-5
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Computer Science,
Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Computer Science
GA 763QZ
UT WOS:000290576100003
PM 21448716
ER
PT J
AU Deflorian, F
Jacobson, KA
AF Deflorian, Francesca
Jacobson, Kenneth A.
TI Comparison of three GPCR structural templates for modeling of the
P2Y(12) nucleotide receptor
SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
LA English
DT Article
DE G protein-coupled receptor; Nucleotides; Purines; Homology modeling;
Docking; Antithrombotic drugs
ID PROTEIN-COUPLED RECEPTORS; CRYSTAL-STRUCTURE; ACTIVE METABOLITE;
ACTIVATION; ANTAGONISTS; RECOGNITION; RHODOPSIN; THERAPY; AGONIST; CCR5
AB The P2Y(12) receptor (P2Y(12)R) is an ADP-activated G protein-coupled receptor (GPCR) that is an important target for antithrombotic drugs. Three homology models of P2Y(12)R were compared, based on different GPCR structural templates: bovine rhodopsin (bRHO), human A(2A) adenosine receptor (A(2A)AR), and human C-X-C chemokine receptor type 4 (CXCR4). By criteria of sequence analysis (25.6% identity in transmembrane region), deviation from helicity in the second transmembrane helix (TM2), docked poses of ligands highlighting the role of key residues, accessibility of a conserved disulfide bridge that is reactive toward irreversibly-binding antagonists, and the presence of a shared disulfide bridge between the third extracellular loop (EL3) and the N-terminus, the CXCR4-based model appeared to be the most consistent with known characteristics of P2Y(12)R. The docked poses of agonist 2MeSADP and charged anthraquinone antagonist PSB-0739 in the binding pocket of P2Y(12)R-CXC agree with previously published site-directed mutagenesis studies of Arg256 and Lys280. A sulfonate at position 2 of the anthraquinone core created a strong interaction with the Lys174(EL2) side chain. The docking poses of the irreversibly-binding, active metabolite (existing as two diastereoisomers in vivo) of the clinically utilized antagonist Clopidogrel were compared. The free thiol group of the 4S diastereoisomer, but not the 4R isomer, was found in close proximity (similar to 4.7 ) to the sulfur atom of a disulfide bridge involving Cys175, suggesting greater activity in covalent binding. Therefore, ligand docking to the CXCR4-based model of the P2Y(12)R predicted poses of both reversibly and irreversibly-binding small molecules, consistent with observed pharmacology and mutagenesis studies.
C1 [Deflorian, Francesca; Jacobson, Kenneth A.] NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
RP Jacobson, KA (reprint author), NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A 19, Bethesda, MD 20892 USA.
EM kajacobs@helix.nih.gov
RI Jacobson, Kenneth/A-1530-2009
OI Jacobson, Kenneth/0000-0001-8104-1493
FU NIH, NIDDK
FX We thank Dr. Stefano Costanzi (NIDDK) and Dr. David Erlinge (Lund
University, Lund, Sweden) for helpful discussion. This research was
supported by the Intramural Research Program of the NIH, NIDDK.
NR 34
TC 20
Z9 20
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-654X
J9 J COMPUT AID MOL DES
JI J. Comput.-Aided Mol. Des.
PD APR
PY 2011
VL 25
IS 4
BP 329
EP 338
DI 10.1007/s10822-011-9423-3
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Computer Science,
Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Computer Science
GA 763QZ
UT WOS:000290576100004
PM 21461952
ER
PT J
AU Sabunciyan, S
Mandelberg, N
Rabkin, CS
Yolken, R
Viscidi, R
AF Sabunciyan, Sarven
Mandelberg, Nataniel
Rabkin, Charles S.
Yolken, Robert
Viscidi, Raphael
TI No difference in antibody titers against xenotropic MLV related virus in
prostate cancer cases and cancer-free controls
SO MOLECULAR AND CELLULAR PROBES
LA English
DT Article
DE XMRV; Prostate cancer; Virus; Xenotropic murine leukemia; Virus-related
virus; ELISA; Epidemiology
ID TUMORS
AB New ELISA assays were developed to measure immunoreactivity for XMRV. Antibody titers were measured in a cohort of prostate cancer cases and cancer free controls from the central United States. No statistically significant differences were observed in immunoreactivity between cases and controls for either the XMRV-env or the XMRV-gag antigen. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Sabunciyan, Sarven; Mandelberg, Nataniel; Yolken, Robert; Viscidi, Raphael] Johns Hopkins Univ, Dept Pediat, Stanley Div Dev Virol, Baltimore, MD 21287 USA.
[Sabunciyan, Sarven] Johns Hopkins Univ, Sch Med, Ctr Epigenet, Baltimore, MD 21287 USA.
[Rabkin, Charles S.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
RP Sabunciyan, S (reprint author), Johns Hopkins Univ, Dept Pediat, Stanley Div Dev Virol, 600 N Wolfe St,Blalock 1147, Baltimore, MD 21287 USA.
EM ssabuncl@jhmi.edu
FU Stanley Medical Research Institute
FX The authors would like to thank Dr. William Switzer who kindly sent us
the anti-sera necessary for assay validation. This research was funded
by the Stanley Medical Research Institute.
NR 7
TC 7
Z9 9
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0890-8508
J9 MOL CELL PROBE
JI Mol. Cell. Probes
PD APR-JUN
PY 2011
VL 25
IS 2-3
BP 134
EP 136
DI 10.1016/j.mcp.2011.01.005
PG 3
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Biotechnology & Applied Microbiology; Cell Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Cell Biology
GA 764DR
UT WOS:000290609100011
PM 21281710
ER
PT J
AU Cornelis, MC
Monda, KL
Yu, K
Paynter, N
Azzato, EM
Bennett, SN
Berndt, SI
Boerwinkle, E
Chanock, S
Chatterjee, N
Couper, D
Curhan, G
Heiss, G
Hu, FB
Hunter, DJ
Jacobs, K
Jensen, MK
Kraft, P
Landi, MT
Nettleton, JA
Purdue, MP
Rajaraman, P
Rimm, EB
Rose, LM
Rothman, N
Silverman, D
Stolzenberg-Solomon, R
Subar, A
Yeager, M
Chasman, DI
van Dam, RM
Caporaso, NE
AF Cornelis, Marilyn C.
Monda, Keri L.
Yu, Kai
Paynter, Nina
Azzato, Elizabeth M.
Bennett, Siiri N.
Berndt, Sonja I.
Boerwinkle, Eric
Chanock, Stephen
Chatterjee, Nilanjan
Couper, David
Curhan, Gary
Heiss, Gerardo
Hu, Frank B.
Hunter, David J.
Jacobs, Kevin
Jensen, Majken K.
Kraft, Peter
Landi, Maria Teresa
Nettleton, Jennifer A.
Purdue, Mark P.
Rajaraman, Preetha
Rimm, Eric B.
Rose, Lynda M.
Rothman, Nathaniel
Silverman, Debra
Stolzenberg-Solomon, Rachael
Subar, Amy
Yeager, Meredith
Chasman, Daniel I.
van Dam, Rob M.
Caporaso, Neil E.
TI Genome-Wide Meta-Analysis Identifies Regions on 7p21 (AHR) and 15q24
(CYP1A2) As Determinants of Habitual Caffeine Consumption
SO PLOS GENETICS
LA English
DT Article
ID FOOD FREQUENCY QUESTIONNAIRE; ASSOCIATION; POLYMORPHISMS; RECEPTOR;
REPRODUCIBILITY; ACTIVATION; VALIDITY; HEALTH; COFFEE; GENES
AB We report the first genome-wide association study of habitual caffeine intake. We included 47,341 individuals of European descent based on five population-based studies within the United States. In a meta-analysis adjusted for age, sex, smoking, and eigenvectors of population variation, two loci achieved genome-wide significance: 7p21 (P = 2.4x10(-19)), near AHR, and 15q24 (P = 5.2x10(-14)), between CYP1A1 and CYP1A2. Both the AHR and CYP1A2 genes are biologically plausible candidates as CYP1A2 metabolizes caffeine and AHR regulates CYP1A2.
C1 [Cornelis, Marilyn C.; Hu, Frank B.; Hunter, David J.; Jensen, Majken K.; Rimm, Eric B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Monda, Keri L.; Heiss, Gerardo] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Yu, Kai; Azzato, Elizabeth M.; Berndt, Sonja I.; Chanock, Stephen; Chatterjee, Nilanjan; Jacobs, Kevin; Landi, Maria Teresa; Purdue, Mark P.; Rajaraman, Preetha; Rothman, Nathaniel; Silverman, Debra; Stolzenberg-Solomon, Rachael; Subar, Amy; Yeager, Meredith; Caporaso, Neil E.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Curhan, Gary] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Couper, David] Univ Washington, Dept Biostat, Collaborat Studies Coordinating Ctr, Seattle, WA 98195 USA.
[Boerwinkle, Eric; Nettleton, Jennifer A.] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol Human Genet & Environm Sci, Houston, TX USA.
[Kraft, Peter] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA.
[van Dam, Rob M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth, Singapore 117595, Singapore.
[van Dam, Rob M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore.
RP Cornelis, MC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
EM dchasman@rics.bwh.harvard.edu; ephrmvd@nus.edu.sg; caporasn@mail.nih.gov
RI van Dam, Rob/F-9674-2010; Purdue, Mark/C-9228-2016
OI van Dam, Rob/0000-0002-7354-8734; Purdue, Mark/0000-0003-1177-3108
FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-55015,
N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021,
N01-HC-55022, R01HL087641, R01HL59367, R01HL086694, HL 043851, HL69757];
National Human Genome Research Institute [U01HG004402]; NIH
[HSN268200625226C, UL1RR025005, HHSN268200782096C, HL35464, CA55075];
NCI [CA 40356, U01-CA98233, P01CA087969, P01CA055075, CA 047988]; NIH
Genes, Environment, and Health Initiative (GEI) [U01HG004402,
U01HG004738, U01HG004422, U01HG004729, U01HG004726, 01HG004735,
U01HG004415, U01HG004436, U01HG004423, U01HG004728, AHG006033,
U01HG004438]; NIH Institute, NIDCR [U01DE018993, U01DE018903]; NIH
Institute, NIAAA [U10AA008401]; NIH Institute, NIDA [P01CA089392,
01DA013423]; NIH Institute, NCI [CA63464, CA54281, CA136792,
Z01CP010200]; National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) [R01DK058845, 5P01DK070756]; Division of Cancer
Epidemiology and Genetics; Division of Cancer Prevention, National
Cancer Institute, NIH, DHHS; Donald W. Reynolds Foundation; Fondation
Leducq; Amgen; Canadian Institutes of Health Research
FX ARIC is carried out as a collaborative study supported by National
Heart, Lung, and Blood Institute (NHLBI) contracts N01-HC-55015,
N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021,
N01-HC-55022, R01HL087641, R01HL59367, and R01HL086694; National Human
Genome Research Institute contract U01HG004402; and NIH contract
HSN268200625226C. Infrastructure was partly supported by Grant Number
UL1RR025005, a component of the NIH and NIH Roadmap for Medical
Research. The NHS Breast Cancer GW scan was performed as part of the
Cancer Genetic Markers of Susceptibility initiative of the NCI. We
particularly acknowledge the contributions of R. Hoover, A. Hutchinson,
K. Jacobs, and G. Thomas. The current research is supported by CA 40356
and U01-CA98233 from the NCI. The NHS/HPFS type 2 diabetes GWAS
(U01HG004399) is a component of a collaborative project that includes 13
other GWAS funded as part of the Gene Environment-Association Studies
(GENEVA) under the NIH Genes, Environment, and Health Initiative (GEI)
(U01HG004738, U01HG004422, U01HG004402, U01HG004729, U01HG004726,
01HG004735, U01HG004415, U01HG004436, U01HG004423, U01HG004728,
AHG006033) with additional support from individual NIH Institutes
(NIDCR: U01DE018993, U01DE018903; NIAAA: U10AA008401; NIDA: P01CA089392,
01DA013423; NCI: CA63464, CA54281, CA136792, Z01CP010200). Assistance
with genotype cleaning and general study coordination, was provided by
the GENEVA Coordinating Center (U01HG004446). Assistance with data
cleaning was provided by the NCBI. Genotyping was performed at the Broad
Institute of MIT and Harvard, with funding support from the NIH GEI
(U01HG04424), and Johns Hopkins University Center for Inherited Disease
Research, with support from the NIH GEI (U01HG004438) and the NIH
contract "High throughput genotyping for studying the genetic
contributions to human disease" (HHSN268200782096C). Additional funding
for the current research was provided by the NCI (P01CA087969,
P01CA055075) and the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK, R01DK058845). The NHS/HPFS CHD GWAS was
supported by HL35464 and CA55075 from the NIH with additional support
for genotyping from Merck/Rosetta Research Laboratories, North Wales,
PA. The NHS/HPFS Kidney GWAS was supported by NIDDK: 5P01DK070756. PLCO
was supported the Intramural Research Program of the Division of Cancer
Epidemiology and Genetics and by contracts from the Division of Cancer
Prevention, National Cancer Institute, NIH, DHHS. The WGHS is supported
by HL 043851 and HL69757 from the NHLBI and CA 047988 from the NCI, the
Donald W. Reynolds Foundation, and the Fondation Leducq, with
collaborative scientific support and funding for genotyping provided by
Amgen. MCC is a recipient of a Canadian Institutes of Health Research
Fellowship. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 37
TC 71
Z9 73
U1 1
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7390
J9 PLOS GENET
JI PLoS Genet.
PD APR
PY 2011
VL 7
IS 4
AR e1002033
DI 10.1371/journal.pgen.1002033
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 755YI
UT WOS:000289977000023
PM 21490707
ER
PT J
AU Ma, WJ
Westmoreland, JW
Gordenin, DA
Resnick, MA
AF Ma, Wenjian
Westmoreland, Jim W.
Gordenin, Dmitry A.
Resnick, Mike A.
TI Alkylation Base Damage Is Converted into Repairable Double-Strand Breaks
and Complex Intermediates in G2 Cells Lacking AP Endonuclease
SO PLOS GENETICS
LA English
DT Article
ID SISTER-CHROMATID EXCHANGE; DNA METHYLATION DAMAGE;
SACCHAROMYCES-CEREVISIAE; ABASIC SITES; EXCISION-REPAIR; BIOLOGICAL
CONSEQUENCES; ESCHERICHIA-COLI; MAMMALIAN-CELLS; TOPOISOMERASE-I; YEAST
AB DNA double-strand breaks (DSBs) are potent sources of genome instability. While there is considerable genetic and molecular information about the disposition of direct DSBs and breaks that arise during replication, relatively little is known about DSBs derived during processing of single-strand lesions, especially for the case of single-strand breaks (SSBs) with 39-blocked termini generated in vivo. Using our recently developed assay for detecting end-processing at random DSBs in budding yeast, we show that single-strand lesions produced by the alkylating agent methyl methanesulfonate (MMS) can generate DSBs in G2-arrested cells, i.e., S-phase independent. These derived DSBs were observed in apn1/2 endonuclease mutants and resulted from aborted base excision repair leading to 39 blocked single-strand breaks following the creation of abasic (AP) sites. DSB formation was reduced by additional mutations that affect processing of AP sites including ntg1, ntg2, and, unexpectedly, ogg1, or by a lack of AP sites due to deletion of the MAG1 glycosylase gene. Similar to direct DSBs, the derived DSBs were subject to MRX (Mre11, Rad50, Xrs2)-determined resection and relied upon the recombinational repair genes RAD51, RAD52, as well as on the MCD1 cohesin gene, for repair. In addition, we identified a novel DNA intermediate, detected as slow-moving chromosomal DNA (SMD) in pulsed field electrophoresis gels shortly after MMS exposure in apn1/2 cells. The SMD requires nicked AP sites, but is independent of resection/recombination processes, suggesting that it is a novel structure generated during processing of 39-blocked SSBs. Collectively, this study provides new insights into the potential consequences of alkylation base damage in vivo, including creation of novel structures as well as generation and repair of DSBs in nonreplicating cells.
C1 [Ma, Wenjian; Westmoreland, Jim W.; Gordenin, Dmitry A.; Resnick, Mike A.] NIEHS, Chromosome Stabil Grp, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.
RP Ma, WJ (reprint author), NIEHS, Chromosome Stabil Grp, Mol Genet Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
EM resnick@niehs.nih.gov
RI Ma, Wenjian/C-1071-2012;
OI Gordenin, Dmitry/0000-0002-8399-1836
FU NIEHS (NIH, DHHS) [1Z01ES021016]
FX This work was supported by the Intramural Research Program of the NIEHS
(NIH, DHHS) under project 1Z01ES021016 to MAR. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 62
TC 17
Z9 17
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7390
J9 PLOS GENET
JI PLoS Genet.
PD APR
PY 2011
VL 7
IS 4
AR e1002059
DI 10.1371/journal.pgen.1002059
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA 755YI
UT WOS:000289977000005
PM 21552545
ER
PT J
AU Pare, G
Ridker, PM
Rose, L
Barbalic, M
Dupuis, J
Dehghan, A
Bis, JC
Benjamin, EJ
Shiffman, D
Parker, AN
Chasman, DI
AF Pare, Guillaume
Ridker, Paul M.
Rose, Lynda
Barbalic, Maja
Dupuis, Josee
Dehghan, Abbas
Bis, Joshua C.
Benjamin, Emelia J.
Shiffman, Dov
Parker, Alexander N.
Chasman, Daniel I.
TI Genome-Wide Association Analysis of Soluble ICAM-1 Concentration Reveals
Novel Associations at the NFKBIK, PNPLA3, RELA, and SH2B3 Loci
SO PLOS GENETICS
LA English
DT Article
ID INTERCELLULAR-ADHESION MOLECULE-1; NF-KAPPA-B; TRANSCRIPTIONAL
REGULATION; MYOCARDIAL-INFARCTION; CIRCULATING LEVELS; CHARGE
CONSORTIUM; SEQUENCE VARIANTS; SMOKING-BEHAVIOR; GENE; DISEASE
AB Soluble ICAM-1 (sICAM-1) is an endothelium-derived inflammatory marker that has been associated with diverse conditions such as myocardial infarction, diabetes, stroke, and malaria. Despite evidence for a heritable component to sICAM-1 levels, few genetic loci have been identified so far. To comprehensively address this issue, we performed a genome-wide association analysis of sICAM-1 concentration in 22,435 apparently healthy women from the Women's Genome Health Study. While our results confirm the previously reported associations at the ABO and ICAM1 loci, four novel associations were identified in the vicinity of NFKBIK (rs3136642, P = 5.4x10(-9)), PNPLA3 (rs738409, P = 5.8x10(-9)), RELA (rs1049728, P = 2.7x10(-16)), and SH2B3 (rs3184504, P = 2.9x10(-17)). Two loci, NFKBIB and RELA, are involved in NFKB signaling pathway; PNPLA3 is known for its association with fatty liver disease; and SH3B2 has been associated with a multitude of traits and disease including myocardial infarction. These associations provide insights into the genetic regulation of sICAM-1 levels and implicate these loci in the regulation of endothelial function.
C1 [Pare, Guillaume; Ridker, Paul M.; Rose, Lynda; Chasman, Daniel I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA.
[Pare, Guillaume; Ridker, Paul M.; Rose, Lynda; Chasman, Daniel I.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Donald W Reynolds Ctr Cardiovasc Res, Boston, MA 02115 USA.
[Pare, Guillaume] McMaster Univ, Hamilton, ON, Canada.
[Barbalic, Maja] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX USA.
[Barbalic, Maja] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX USA.
[Dupuis, Josee; Benjamin, Emelia J.] NHLBI, Framingham, MA USA.
[Dupuis, Josee; Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Framingham, MA USA.
[Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Dehghan, Abbas] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[Dehghan, Abbas] NCHA, Leiden, Netherlands.
[Bis, Joshua C.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med, Prevent Med & Epidemiol Sect, Dept Med, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Shiffman, Dov] Celera, Alameda, CA USA.
[Parker, Alexander N.] Amgen Inc, Cambridge, MA USA.
RP Pare, G (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA.
EM pareg@McMaster.ca
OI Dupuis, Josee/0000-0003-2871-3603; Benjamin, Emelia/0000-0003-4076-2336;
Dehghan, Abbas/0000-0001-6403-016X
FU National Heart, Lung, and Blood Institute; National Cancer Institute
(Bethesda, MD); Donald W. Reynolds Foundation (Las Vegas, NV); Doris
Duke Charitable Foundation; Foundation Leducq (Paris, FR); Amgen
FX This study was supported by grants from the National Heart, Lung, and
Blood Institute and the National Cancer Institute (Bethesda, MD), the
Donald W. Reynolds Foundation (Las Vegas, NV), the Doris Duke Charitable
Foundation, and the Foundation Leducq (Paris, FR), with collaborative
scientific and genotypic support provided by Amgen. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 44
TC 37
Z9 38
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7390
J9 PLOS GENET
JI PLoS Genet.
PD APR
PY 2011
VL 7
IS 4
AR e1001374
DI 10.1371/journal.pgen.1001374
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 755YI
UT WOS:000289977000022
PM 21533024
ER
PT J
AU Pasaniuc, B
Zaitlen, N
Lettre, G
Chen, GK
Tandon, A
Kao, WHL
Ruczinski, I
Fornage, M
Siscovick, DS
Zhu, XF
Larkin, E
Lange, LA
Cupples, LA
Yang, Q
Akylbekova, EL
Musani, SK
Divers, J
Mychaleckyj, J
Li, MY
Papanicolaou, GJ
Millikan, RC
Ambrosone, CB
John, EM
Bernstein, L
Zheng, W
Hu, JJ
Ziegler, RG
Nyante, SJ
Bandera, EV
Ingles, SA
Press, MF
Chanock, SJ
Deming, SL
Rodriguez-Gil, JL
Palmer, CD
Buxbaum, S
Ekunwe, L
Hirschhorn, JN
Henderson, BE
Myers, S
Haiman, CA
Reich, D
Patterson, N
Wilson, JG
Price, AL
AF Pasaniuc, Bogdan
Zaitlen, Noah
Lettre, Guillaume
Chen, Gary K.
Tandon, Arti
Kao, W. H. Linda
Ruczinski, Ingo
Fornage, Myriam
Siscovick, David S.
Zhu, Xiaofeng
Larkin, Emma
Lange, Leslie A.
Cupples, L. Adrienne
Yang, Qiong
Akylbekova, Ermeg L.
Musani, Solomon K.
Divers, Jasmin
Mychaleckyj, Joe
Li, Mingyao
Papanicolaou, George J.
Millikan, Robert C.
Ambrosone, Christine B.
John, Esther M.
Bernstein, Leslie
Zheng, Wei
Hu, Jennifer J.
Ziegler, Regina G.
Nyante, Sarah J.
Bandera, Elisa V.
Ingles, Sue A.
Press, Michael F.
Chanock, Stephen J.
Deming, Sandra L.
Rodriguez-Gil, Jorge L.
Palmer, Cameron D.
Buxbaum, Sarah
Ekunwe, Lynette
Hirschhorn, Joel N.
Henderson, Brian E.
Myers, Simon
Haiman, Christopher A.
Reich, David
Patterson, Nick
Wilson, James G.
Price, Alkes L.
TI Enhanced Statistical Tests for GWAS in Admixed Populations: Assessment
using African Americans from CARe and a Breast Cancer Consortium
SO PLOS GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GENOTYPE-IMPUTATION; LINKAGE DISEQUILIBRIUM;
SUSCEPTIBILITY LOCI; RACIAL-DIFFERENCES; PROSTATE-CANCER; RISK;
ADMIXTURE; DISEASE; EPIDEMIOLOGY
AB While genome-wide association studies (GWAS) have primarily examined populations of European ancestry, more recent studies often involve additional populations, including admixed populations such as African Americans and Latinos. In admixed populations, linkage disequilibrium (LD) exists both at a fine scale in ancestral populations and at a coarse scale (admixture-LD) due to chromosomal segments of distinct ancestry. Disease association statistics in admixed populations have previously considered SNP association (LD mapping) or admixture association (mapping by admixture-LD), but not both. Here, we introduce a new statistical framework for combining SNP and admixture association in case-control studies, as well as methods for local ancestry-aware imputation. We illustrate the gain in statistical power achieved by these methods by analyzing data of 6,209 unrelated African Americans from the CARe project genotyped on the Affymetrix 6.0 chip, in conjunction with both simulated and real phenotypes, as well as by analyzing the FGFR2 locus using breast cancer GWAS data from 5,761 African-American women. We show that, at typed SNPs, our method yields an 8% increase in statistical power for finding disease risk loci compared to the power achieved by standard methods in case-control studies. At imputed SNPs, we observe an 11% increase in statistical power for mapping disease loci when our local ancestry-aware imputation framework and the new scoring statistic are jointly employed. Finally, we show that our method increases statistical power in regions harboring the causal SNP in the case when the causal SNP is untyped and cannot be imputed. Our methods and our publicly available software are broadly applicable to GWAS in admixed populations.
C1 [Pasaniuc, Bogdan; Zaitlen, Noah; Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Pasaniuc, Bogdan; Zaitlen, Noah; Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Pasaniuc, Bogdan; Zaitlen, Noah; Tandon, Arti; Palmer, Cameron D.; Hirschhorn, Joel N.; Reich, David; Patterson, Nick; Price, Alkes L.] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA USA.
[Lettre, Guillaume] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Lettre, Guillaume] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.
[Chen, Gary K.; Ingles, Sue A.; Press, Michael F.; Henderson, Brian E.; Haiman, Christopher A.] Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90089 USA.
[Tandon, Arti; Hirschhorn, Joel N.; Reich, David] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Kao, W. H. Linda] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA.
[Kao, W. H. Linda] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA.
[Ruczinski, Ingo] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
[Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Sch Publ Hlth, Houston, TX USA.
[Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol, Sch Publ Hlth, Houston, TX USA.
[Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA USA.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Zhu, Xiaofeng] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
[Larkin, Emma] Vanderbilt Univ, Dept Med, Div Allergy Pulm & Crit Care, Nashville, TN USA.
[Lange, Leslie A.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
[Cupples, L. Adrienne; Yang, Qiong] Boston Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Boston, MA USA.
[Akylbekova, Ermeg L.; Buxbaum, Sarah; Ekunwe, Lynette] Jackson State Univ, Jackson Heart Study, Jackson, MS USA.
[Musani, Solomon K.; Wilson, James G.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA.
[Divers, Jasmin] Wake Forest Univ, Div Publ Hlth Sci, Dept Biostat Sci, Winston Salem, NC 27109 USA.
[Mychaleckyj, Joe] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA.
[Li, Mingyao] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Papanicolaou, George J.] NHLBI, Div Cardiovasc Sci, NIH, Bethesda, MD 20892 USA.
[Millikan, Robert C.] Gillings Sch Global Publ Hlth Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA.
[Millikan, Robert C.; Nyante, Sarah J.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Ambrosone, Christine B.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
[John, Esther M.] No Calif Canc Ctr, Fremont, CA USA.
[John, Esther M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[John, Esther M.] Stanford Canc Ctr, Stanford, CA USA.
[Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA USA.
[Zheng, Wei] Vanderbilt Epidemiol Ctr, Dept Med, Div Epidemiol, Nashville, TN USA.
[Zheng, Wei] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA.
[Hu, Jennifer J.; Rodriguez-Gil, Jorge L.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
[Hu, Jennifer J.; Rodriguez-Gil, Jorge L.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
[Ziegler, Regina G.] NCI, Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Bandera, Elisa V.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA.
[Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Deming, Sandra L.] Vanderbilt Epidemiol Ctr, Inst Med & Publ Hlth, Nashville, TN USA.
[Palmer, Cameron D.; Hirschhorn, Joel N.] Childrens Hosp Boston, Div Genet, Boston, MA USA.
[Palmer, Cameron D.; Hirschhorn, Joel N.] Childrens Hosp Boston, Div Endocrinol, Boston, MA USA.
[Palmer, Cameron D.; Hirschhorn, Joel N.] Childrens Hosp Boston, Program Genom, Boston, MA USA.
[Myers, Simon] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
[Wilson, James G.] VA Med Ctr, Jackson, MS USA.
RP Pasaniuc, B (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
EM bpasaniu@hsph.harvard.edu; aprice@hsph.harvard.edu
RI Pasaniuc, Bogdan/E-9310-2012; Yang, Qiong/G-5438-2014; Bandera,
Elisa/M-4169-2014; Myers, Simon/A-6792-2015; Buxbaum, Sarah/E-1970-2013;
OI Bandera, Elisa/0000-0002-8789-2755; Myers, Simon/0000-0002-2585-9626;
Buxbaum, Sarah/0000-0002-4886-3564; Cupples, L.
Adrienne/0000-0003-0273-7965
FU NIH [RC1 GM091332-01, 5T32ES007142-27]; Department of Defense; Norris
Foundation; National Heart, Lung, and Blood Institute; NHLBI
[HHSN268200960009C]; Broad Institute [N01-HC-65226]; University of North
Carolina at Chapel Hill [N01-HC-55015]; Baylor Medical College
[N01-HC-55016]; University of Mississippi Medical Center [N01-HC-55021];
University of Minnesota [N01-HC-55019, N01-HC48048, N01-HC-95163, U01
HL053934]; Johns Hopkins University [N01-HC-55020, N01-HC-85081, N01
HC-15103, N01-HC-95162, N01-HC-95168, U01 HL053937]; University of Texas
Houston [N01-HC-55017]; University of North Carolina Forsyth County
[N01-HC-55018]; Cardiovascular Health Study (CHS): University of
Washington [N01-HC-85079]; Wake Forest University [N01-HC-85080,
N01-HC-45205, N01-HC-95165]; University of Pittsburgh [N01-HC-85082, U01
HL077813]; University of California Davis [N01-HC-85083, U01 HL053916];
University of California Irvine [N01-HC-85084, N01-HC-45134,
N01-HC-95100]; New England Medical Center [N01-HC-85085, N01-HC-95167];
University of Vermont [N01-HC-85086, N01-HC-95166]; Georgetown
University [N01-HC-35129]; University of Wisconsin [N01-HC-75150];
Geisinger Clinic [N01-HC-45133]; University of Washington [N01 HC-55222,
U01 HL080295]; Cleveland Family Study (CFS): Case Western Reserve
University [RO1 HL46380-01-16]; Cooperative Study of Sickle Cell Disease
(CSSCD): University of Illinois [N01-HB-72982, N01-HB-97062]; Howard
University [N01-HB-72991, N01-HB-97061]; University of Miami
[N01-HB-72992, N01-HB-97064]; Duke University [N01-HB-72993]; George
Washington University [N01-HB-72994]; University of Tennessee
[N01-HB-72995, N01-HB-97070]; Yale University [N01-HB-72996,
N01-HB-97072]; Children's Hospital-Philadelphia [N01-HB-72997,
N01-HB-97056]; University of Chicago [N01-HB-72998, N01-HB-97053];
Medical College of Georgia [N01-HB-73000, N01-HB-97060]; Washington
University [N01-HB-73001, N01-HB-97071]; Jewish Hospital and Medical
Center of Brooklyn [N01-HB-73002]; Trustees of Health and Hospitals of
the City of Boston, Inc. [N01-HB-73003]; Children's Hospital-Oakland
[N01-HB-73004, N01-HB-97054]; University of Mississippi [N01-HB-73005,
N01-HC-95171]; St. Luke's Hospital-New York [N01-HB-73006]; Alta
Bates-Herrick Hospital [N01-HB-97051]; Columbia University
[N01-HB-97058, N01-HC-95161]; St. Jude's Children's Research Hospital
[N01-HB-97066]; Research Foundation - State University of New
York-Albany [N01-HB-97068, N01-HB-97069]; New England Research Institute
[N01-HB-97073]; Interfaith Medical Center-Brooklyn [N01-HB-97085];
Coronary Artery Risk in Young Adults (CARDIA): University of Alabama at
Birmingham [N01-HC-48047]; Northwestern University [N01-HC-48049,
N01-HC-95164]; Kaiser Foundation Research Institute [N01-HC-48050];
University of Alabama at Birmingham [N01-HC-95095]; Tufts-New England
Medical Center [N01-HC-45204]; Harbor-UCLA Research and Education
Institute [N01-HC-05187, N01-HC-95169]; Framingham Heart Study (FHS):
Boston University [N01-HC-25195]; Jackson Heart Study (JHS): Jackson
State University [N01-HC-95170]; Tougaloo College [N01-HC-95172];
Multi-Ethnic Study of Atherosclerosis (MESA): University of Washington
[N01-HC-95159]; Regents of the University of California [N01-HC-95160];
Sleep Heart Health Study (SHHS): Johns Hopkins University [U01
HL064360]; Case Western University [U01 HL063463]; University of Arizona
[U01 HL053938]; Boston University [U01 HL053941]; MedStar Research
Institute [U01 HL063429]; MEC (National Institutes of Health)
[R01-CA63464, R37-CA54281]; CARE (National Institute for Child Health
and Development) [NO1-HD-3-3175]; WCHS (U.S. Army Medical Research and
Material Command (USAMRMC)) [DAMD-17-01-0-0334]; National Institutes of
Health [R01-CA100598]; Breast Cancer Research Foundation; SFBC (National
Institutes of Health) [R01-CA77305]; United States Army Medical Research
Program [DAMD17-96-6071]; NC-BCFR (National Institutes of Health)
[U01-CA69417]; NHBS (National Institutes of Health); WFBC (National
Institutes of Health); National Cancer Institute, National Institutes of
Health; National Cancer Institute; Clinical and Translational Science
Awards (CTSA); NCI; Florida Bankhead-Coley Cancer Research Program;
NIH/NHGRI; [R01-CA100374]; [R01-CA73629]; [RFA CA-95-011];
[5K99CA126978-02]; [R01CA073629]; [10BG-04]; [U01 HG004726-01]
FX This work was funded by NIH grant RC1 GM091332-01 (BP, DR, NP, JGW, ALP)
and by NIH fellowship 5T32ES007142-27 (NZ), using data from NHLBI's
Candidate Gene Association Resource (CARe) project and by a Department
of Defense Breast Cancer Research Program Era of Hope Scholar Award to
CAH and the Norris Foundation. The Candidate gene Association Resource
(CARe) wishes to acknowledge the support of the National Heart, Lung,
and Blood Institute and the contributions of the research institutions,
study investigators, field staff, and study participants in creating
this resource for biomedical research (NHLBI contract number
HHSN268200960009C). The following nine parent studies have contributed
parent study data, ancillary study data, and DNA samples through the
Broad Institute (N01-HC-65226) to create this genotype/phenotype
database for wide dissemination to the biomedical research community:
Atherosclerotic Risk in Communities (ARIC): The University of North
Carolina at Chapel Hill (N01-HC-55015), Baylor Medical College
(N01-HC-55016), University of Mississippi Medical Center (N01-HC-55021),
University of Minnesota (N01-HC-55019), Johns Hopkins University
(N01-HC-55020), University of Texas Houston (N01-HC-55017), University
of North Carolina Forsyth County (N01-HC-55018); Cardiovascular Health
Study (CHS): University of Washington (N01-HC-85079), Wake Forest
University (N01-HC-85080), Johns Hopkins University (N01-HC-85081),
University of Pittsburgh (N01-HC-85082), University of California Davis
(N01-HC-85083), University of California Irvine (N01-HC-85084), New
England Medical Center (N01-HC-85085), University of Vermont
(N01-HC-85086), Georgetown University (N01-HC-35129), Johns Hopkins
University (N01 HC-15103), University of Wisconsin (N01-HC-75150),
Geisinger Clinic (N01-HC-45133), University of Washington (N01 HC-55222,
U01 HL080295); Cleveland Family Study (CFS): Case Western Reserve
University (RO1 HL46380-01-16); Cooperative Study of Sickle Cell Disease
(CSSCD): University of Illinois (N01-HB-72982, N01-HB-97062), Howard
University (N01-HB-72991, N01-HB-97061), University of Miami
(N01-HB-72992, N01-HB-97064), Duke University (N01-HB-72993), George
Washington University (N01-HB-72994), University of Tennessee
(N01-HB-72995, N01-HB-97070), Yale University (N01-HB-72996,
N01-HB-97072), Children's Hospital-Philadelphia (N01-HB-72997,
N01-HB-97056), University of Chicago (N01-HB-72998, N01-HB-97053),
Medical College of Georgia (N01-HB-73000, N01-HB-97060), Washington
University (N01-HB-73001, N01-HB-97071), Jewish Hospital and Medical
Center of Brooklyn (N01-HB-73002), Trustees of Health and Hospitals of
the City of Boston, Inc., (N01-HB-73003), Children's Hospital-Oakland
(N01-HB-73004, N01-HB-97054), University of Mississippi (N01-HB-73005),
St. Luke's Hospital-New York (N01-HB-73006), Alta Bates-Herrick Hospital
(N01-HB-97051), Columbia University (N01-HB-97058), St.; Jude's
Children's Research Hospital (N01-HB-97066), Research Foundation - State
University of New York-Albany (N01-HB-97068, N01-HB-97069), New England
Research Institute (N01-HB-97073), Interfaith Medical Center-Brooklyn
(N01-HB-97085); Coronary Artery Risk in Young Adults (CARDIA):
University of Alabama at Birmingham (N01-HC-48047), University of
Minnesota (N01-HC48048), Northwestern University (N01-HC-48049), Kaiser
Foundation Research Institute (N01-HC-48050), University of Alabama at
Birmingham (N01-HC-95095), Tufts-New England Medical Center
(N01-HC-45204), Wake Forest University (N01-HC-45205), Harbor-UCLA
Research and Education Institute (N01-HC-05187), Univesity of California
Irvine (N01-HC-45134, N01-HC-95100); Framingham Heart Study (FHS):
Boston University (N01-HC-25195); Jackson Heart Study (JHS): Jackson
State University (N01-HC-95170), University of Mississippi
(N01-HC-95171), Tougaloo College (N01-HC-95172); Multi-Ethnic Study of
Atherosclerosis (MESA): University of Washington (N01-HC-95159), Regents
of the University of California (N01-HC-95160), Columbia University
(N01-HC-95161), Johns Hopkins University (N01-HC-95162), University of
Minnesota (N01-HC-95163), Northwestern University (N01-HC-95164), Wake
Forest University (N01-HC-95165), University of Vermont (N01-HC-95166),
New England Medical Center (N01-HC-95167), Johns Hopkins University
(N01-HC-95168), Harbor-UCLA Research and Education Institute
(N01-HC-95169); Sleep Heart Health Study (SHHS): Johns Hopkins
University (U01 HL064360), Case Western University (U01 HL063463),
University of California Davis (U01 HL053916), University of Arizona
(U01 HL053938), University of Minnesota (relocating in 2006 to Univ
Arizona) (U01 HL053934), University of Pittsburgh (U01 HL077813), Boston
University (U01 HL053941), MedStar Research Institute (U01 HL063429),
Johns Hopkins University (U01 HL053937). The studies that provided the
Breast Cancer data were supported by the following grants: MEC (National
Institutes of Health grants R01-CA63464 and R37-CA54281); CARE (National
Institute for Child Health and Development grant NO1-HD-3-3175), WCHS
(U.S. Army Medical Research and Material Command (USAMRMC) grant
DAMD-17-01-0-0334, the National Institutes of Health grant R01-CA100598,
and the Breast Cancer Research Foundation, SFBC (National Institutes of
Health grant R01-CA77305 and United States Army Medical Research Program
grant DAMD17-96-6071), NC-BCFR (National Institutes of Health grant
U01-CA69417), CBCS (National Institutes of Health Specialized Program of
Research Excellence in Breast Cancer, grant number P50-CA58223, and
Center for Environmental Health and Susceptibility, National Institute
of Environmental Health Sciences, National Institutes of Health, grant
number P30-ES10126), PLCO (Intramural Research Program, National Cancer
Institute, National Institutes of Health (, NHBS (National Institutes of
Health grant R01-CA100374), WFBC (National Institutes of Health grant
R01-CA73629). The Breast Cancer Family Registry (BCFR) was supported by
the National Cancer Institute, National Institutes of Health under RFA
CA-95-011 and through cooperative agreements with members of the Breast
Cancer Family Registry and Principal Investigators. The content of this
manuscript does not necessarily reflect the views or policies of the
National Cancer Institute or any of the collaborating centers in the
BCFR, nor does mention of trade names, commercial products, or
organizations imply endorsement by the U. S. Government or the BCFR.;
SLD is supported by a grant from the National Cancer nstitute:
5K99CA126978-02. WHLK and IR are supported by a Clinical and
Translational Science Awards (CTSA) grant to the Johns Hopkins Medical
Institutions. JJH and JLR-G were supported by grants funded by NCI
(R01CA073629) and Florida Bankhead-Coley Cancer Research Program
(10BG-04). CH, DR, NP, and AT were supported by NIH/NHGRI grant U01
HG004726-01. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 65
TC 46
Z9 46
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7390
J9 PLOS GENET
JI PLoS Genet.
PD APR
PY 2011
VL 7
IS 4
AR e1001371
DI 10.1371/journal.pgen.1001371
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA 755YI
UT WOS:000289977000015
PM 21541012
ER
PT J
AU Smedby, KE
Foo, JN
Skibola, CF
Darabi, H
Conde, L
Hjalgrim, H
Kumar, V
Chang, ET
Rothman, N
Cerhan, JR
Brooks-Wilson, AR
Rehnberg, E
Irwan, ID
Ryder, LP
Brown, PN
Bracci, PM
Agana, L
Riby, J
Cozen, W
Davis, S
Hartge, P
Morton, LM
Severson, RK
Wang, SS
Slager, SL
Fredericksen, ZS
Novak, AJ
Kay, NE
Habermann, TM
Armstrong, B
Kricker, A
Milliken, S
Purdue, MP
Vajdic, CM
Boyle, P
Lan, Q
Zahm, SH
Zhang, YW
Zheng, TZ
Leach, S
Spinelli, JJ
Smith, MT
Chanock, SJ
Padyukov, L
Alfredsson, L
Klareskog, L
Glimelius, B
Melbye, M
Liu, ET
Adami, HO
Humphreys, K
Liu, JJ
AF Smedby, Karin E.
Foo, Jia Nee
Skibola, Christine F.
Darabi, Hatef
Conde, Lucia
Hjalgrim, Henrik
Kumar, Vikrant
Chang, Ellen T.
Rothman, Nathaniel
Cerhan, James R.
Brooks-Wilson, Angela R.
Rehnberg, Emil
Irwan, Ishak D.
Ryder, Lars P.
Brown, Peter N.
Bracci, Paige M.
Agana, Luz
Riby, Jacques
Cozen, Wendy
Davis, Scott
Hartge, Patricia
Morton, Lindsay M.
Severson, Richard K.
Wang, Sophia S.
Slager, Susan L.
Fredericksen, Zachary S.
Novak, Anne J.
Kay, Neil E.
Habermann, Thomas M.
Armstrong, Bruce
Kricker, Anne
Milliken, Sam
Purdue, Mark P.
Vajdic, Claire M.
Boyle, Peter
Lan, Qing
Zahm, Shelia H.
Zhang, Yawei
Zheng, Tongzhang
Leach, Stephen
Spinelli, John J.
Smith, Martyn T.
Chanock, Stephen J.
Padyukov, Leonid
Alfredsson, Lars
Klareskog, Lars
Glimelius, Bengt
Melbye, Mads
Liu, Edison T.
Adami, Hans-Olov
Humphreys, Keith
Liu, Jianjun
TI GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and
Suggests Shared Genetic Susceptibility with Diffuse Large B-cell
Lymphoma
SO PLOS GENETICS
LA English
DT Article
ID NON-HODGKIN-LYMPHOMA; GENOME-WIDE ASSOCIATION; NECROSIS-FACTOR TNF;
RHEUMATOID-ARTHRITIS; INTERLYMPH-CONSORTIUM; STATISTICAL-METHOD; RISK
LOCUS; CANCER; HAPLOTYPE; HLA
AB Non-Hodgkin lymphoma (NHL) represents a diverse group of hematological malignancies, of which follicular lymphoma (FL) is a prevalent subtype. A previous genome-wide association study has established a marker, rs10484561 in the human leukocyte antigen (HLA) class II region on 6p21.32 associated with increased FL risk. Here, in a three-stage genome-wide association study, starting with a genome-wide scan of 379 FL cases and 791 controls followed by validation in 1,049 cases and 5,790 controls, we identified a second independent FL-associated locus on 6p21.32, rs2647012 (OR(combined) = 0.64, P(combined)= 2x10(-21)) located 962 bp away from rs10484561 (r(2)< 0.1 in controls). After mutual adjustment, the associations at the two SNPs remained genome-wide significant (rs2647012: OR(adjusted) = 0.70, P(adjusted)= 4x10(-12); rs10484561: OR(adjusted) = 1.64, P(adjusted)= 5x10(-15)). Haplotype and coalescence analyses indicated that rs2647012 arose on an evolutionarily distinct haplotype from that of rs10484561 and tags a novel allele with an opposite (protective) effect on FL risk. Moreover, in a follow-up analysis of the top 6 FL-associated SNPs in 4,449 cases of other NHL subtypes, rs10484561 was associated with risk of diffuse large B-cell lymphoma (OR(combined) = 1.36, P(combined) = 1.4x10(-7)). Our results reveal the presence of allelic heterogeneity within the HLA class II region influencing FL susceptibility and indicate a possible shared genetic etiology with diffuse large B-cell lymphoma. These findings suggest that the HLA class II region plays a complex yet important role in NHL.
C1 [Smedby, Karin E.] Karolinska Inst, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden.
[Foo, Jia Nee; Kumar, Vikrant; Irwan, Ishak D.; Liu, Edison T.; Liu, Jianjun] ASTAR, Genome Inst Singapore, Singapore, Singapore.
[Skibola, Christine F.; Conde, Lucia; Agana, Luz; Riby, Jacques; Smith, Martyn T.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA.
[Darabi, Hatef; Rehnberg, Emil; Adami, Hans-Olov; Humphreys, Keith] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Hjalgrim, Henrik; Melbye, Mads] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.
[Chang, Ellen T.] Canc Prevent Inst Calif, Fremont, CA USA.
[Chang, Ellen T.] Stanford Univ, Div Epidemiol, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA.
[Rothman, Nathaniel; Hartge, Patricia; Morton, Lindsay M.; Wang, Sophia S.; Purdue, Mark P.; Lan, Qing; Zahm, Shelia H.; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Cerhan, James R.; Slager, Susan L.; Fredericksen, Zachary S.; Novak, Anne J.; Kay, Neil E.; Habermann, Thomas M.] Mayo Clin, Coll Med, Rochester, MN USA.
[Brooks-Wilson, Angela R.; Spinelli, John J.] British Columbia Canc Agcy, British Columbia Canc Res Ctr, Vancouver, BC V5Z 4E6, Canada.
[Brooks-Wilson, Angela R.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC V5A 1S6, Canada.
[Ryder, Lars P.] Univ Copenhagen Hosp, Dept Clin Immunol, DK-2100 Copenhagen, Denmark.
[Brown, Peter N.] Univ Copenhagen Hosp, Dept Haematol, DK-2100 Copenhagen, Denmark.
[Bracci, Paige M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Cozen, Wendy] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Davis, Scott] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Davis, Scott] Univ Washington, Seattle, WA 98195 USA.
[Severson, Richard K.] Wayne State Univ, Dept Family Med & Publ Hlth Sci, Detroit, MI USA.
[Severson, Richard K.] Karmanos Canc Inst, Detroit, MI USA.
[Wang, Sophia S.] Beckman Res Inst, Div Etiol, Duarte, CA USA.
[Wang, Sophia S.] City Hope Natl Med Ctr, Duarte, CA USA.
[Armstrong, Bruce; Kricker, Anne] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia.
[Milliken, Sam] St Vincents Hosp, Dept Haematol, Sydney, NSW 2010, Australia.
[Vajdic, Claire M.] Univ New S Wales, Canc Res Ctr, Prince Wales Clin Sch, Sydney, NSW, Australia.
[Boyle, Peter] Int Prevent Res Inst, Lyon, France.
[Zhang, Yawei; Zheng, Tongzhang] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[Leach, Stephen] British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada.
[Spinelli, John J.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada.
[Padyukov, Leonid; Klareskog, Lars] Karolinska Inst, Rheumatol Unit, Dept Med, Stockholm, Sweden.
[Padyukov, Leonid; Klareskog, Lars] Karolinska Univ Hosp Solna, Stockholm, Sweden.
[Alfredsson, Lars] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden.
[Glimelius, Bengt] Karolinska Inst, Dept Pathol & Oncol, S-10401 Stockholm, Sweden.
[Glimelius, Bengt] Uppsala Univ, Dept Radiol Oncol & Radiat Sci, Uppsala, Sweden.
[Adami, Hans-Olov] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Smedby, KE (reprint author), Karolinska Inst, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden.
EM liuj3@gis.a-star.edu.sg
RI Conde, Lucia/D-9295-2011; Spinelli, John/B-6210-2013; Boyle,
Peter/A-4380-2014; Tang, Macy/B-9798-2014; ryder, lars/Q-2060-2015;
Purdue, Mark/C-9228-2016; Foo, Jia Nee/D-6069-2014; Brooks-Wilson,
Angela/E-9399-2012; Zahm, Shelia/B-5025-2015; Morton,
Lindsay/B-5234-2015; Armstrong, Bruce/K-9464-2015
OI Klareskog, Lars/0000-0001-9601-6186; Cerhan, James/0000-0002-7482-178X;
Alfredsson, Lars/0000-0003-1688-6697; Padyukov,
Leonid/0000-0003-2950-5670; Boyle, Peter/0000-0001-6251-0610; ryder,
lars/0000-0002-4744-3496; Purdue, Mark/0000-0003-1177-3108; Foo, Jia
Nee/0000-0001-9899-2308; Vajdic, Claire/0000-0002-3612-8298;
Brooks-Wilson, Angela/0000-0003-1009-6408; Morton,
Lindsay/0000-0001-9767-2310; Armstrong, Bruce/0000-0001-8940-7525
FU Agency for Science and Technology and Research of Singapore (A*STAR);
Swedish Cancer Society [090659]; Swedish Research Council
[K2008-64X-20737-01-2, 523-2006-972]; Danish Medical Research Council
[FSS 09-63424]; National Cancer Institute (NCI) [CA069269-01]; Swedish
Council for Working life [2008-0567]; AFA insurance company; Vinnova;
NCI, National Institutes of Health (NIH) [CA122663, CA104682, CA45614,
CA89745]; NIH (NCI) [N01-PC-65064, N01-PC-67008, N01-PC-67009,
N01-PC-67010, N02-PC-71105, R01-CA91253, R01-CA118444, CA62006]; Public
Health Service; National Health and Medical Research Council of
Australia; Cancer Council NSW; University of Sydney Medical Foundation;
US NIH (NCI); Canadian Cancer Society; Canadian Institutes of Health
Research
FX This work was funded by the Agency for Science and Technology and
Research of Singapore (A*STAR), the Swedish Cancer Society (090659), the
Swedish Research Council (K2008-64X-20737-01-2, 523-2006-972), and the
Danish Medical Research Council (FSS 09-63424). The collection of blood
samples in the founding case-control study was supported by the National
Cancer Institute (NCI) (CA069269-01). Sample collection in EIRA was
supported by the Swedish Council for Working life (2008-0567), the AFA
insurance company, and by the Combine project founded by Vinnova. The
SF1 and SF2 studies were supported by the NCI, National Institutes of
Health (NIH) (CA122663, CA104682, CA45614, CA89745). The NCI-SEER study
was supported by the Intramural Research Program of the NIH (NCI) and by
Public Health Service contracts N01-PC-65064, N01-PC-67008,
N01-PC-67009, N01-PC-67010, and N02-PC-71105. The Mayo study was
supported by the NIH (NCI) (R01-CA91253, R01-CA118444). The NSW study
was supported by a National Health and Medical Research Council of
Australia project grant, Cancer Council NSW, a University of Sydney
Medical Foundation Program Grant, and the Intramural Research Program of
the US NIH (NCI). The Yale study was supported by grant CA62006 from NIH
(NCI) and the Intramural Research Program of the National Institutes of
Health (NCI). The BC study was funded from the Canadian Cancer Society
and the Canadian Institutes of Health Research. ARB-W is a Senior
Scholar of the Michael Smith Foundation for Health Research. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 31
TC 54
Z9 56
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7390
J9 PLOS GENET
JI PLoS Genet.
PD APR
PY 2011
VL 7
IS 4
AR e1001378
DI 10.1371/journal.pgen.1001378
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 755YI
UT WOS:000289977000026
PM 21533074
ER
PT J
AU Stirling, PC
Bloom, MS
Solanki-Patil, T
Smith, S
Sipahimalani, P
Li, ZJ
Kofoed, M
Ben-Aroya, S
Myung, K
Hieter, P
AF Stirling, Peter C.
Bloom, Michelle S.
Solanki-Patil, Tejomayee
Smith, Stephanie
Sipahimalani, Payal
Li, Zhijian
Kofoed, Megan
Ben-Aroya, Shay
Myung, Kyungjae
Hieter, Philip
TI The Complete Spectrum of Yeast Chromosome Instability Genes Identifies
Candidate CIN Cancer Genes and Functional Roles for ASTRA Complex
Components
SO PLOS GENETICS
LA English
DT Article
ID SACCHAROMYCES-CEREVISIAE; INTERACTION NETWORK; GENOME INSTABILITY;
STABILITY; SCREEN; TEL2; LOCALIZATION; KINASE; MTOR; CELL
AB Chromosome instability (CIN) is observed in most solid tumors and is linked to somatic mutations in genome integrity maintenance genes. The spectrum of mutations that cause CIN is only partly known and it is not possible to predict a priori all pathways whose disruption might lead to CIN. To address this issue, we generated a catalogue of CIN genes and pathways by screening,2,000 reduction-of-function alleles for 90% of essential genes in Saccharomyces cerevisiae. Integrating this with published CIN phenotypes for other yeast genes generated a systematic CIN gene dataset comprised of 692 genes. Enriched gene ontology terms defined cellular CIN pathways that, together with sequence orthologs, created a list of human CIN candidate genes, which we cross-referenced to published somatic mutation databases revealing hundreds of mutated CIN candidate genes. Characterization of some poorly characterized CIN genes revealed short telomeres in mutants of the ASTRA/TTT components TTI1 and ASA1. High-throughput phenotypic profiling links ASA1 to TTT (Tel2-Tti1-Tti2) complex function and to TORC1 signaling via Tor1p stability, consistent with the role of TTT in PI3-kinase related kinase biogenesis. The comprehensive CIN gene list presented here in principle comprises all conserved eukaryotic genome integrity pathways. Deriving human CIN candidate genes from the list allows direct cross-referencing with tumor mutational data and thus candidate mutations potentially driving CIN in tumors. Overall, the CIN gene spectrum reveals new chromosome biology and will help us to understand CIN phenotypes in human disease.
C1 [Stirling, Peter C.; Solanki-Patil, Tejomayee; Sipahimalani, Payal; Kofoed, Megan; Ben-Aroya, Shay; Hieter, Philip] Univ British Columbia, Michael Smith Labs, Vancouver, BC V5Z 1M9, Canada.
[Bloom, Michelle S.; Smith, Stephanie; Myung, Kyungjae] NHGRI, Genome Instabil Sect, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA.
[Li, Zhijian] Univ Toronto, Banting & Best Dept Med Res, Terrence Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada.
RP Stirling, PC (reprint author), Univ British Columbia, Michael Smith Labs, Vancouver, BC V5Z 1M9, Canada.
EM Hieter@msl.ubc.ca
FU Terry Fox Foundation [700044]; Michael Smith Foundation for Health
Research (MSFHR); National Institutes of Health (NIH); Canadian
Institutes for Health Research (CIHR); NHGRI, NIH; Human Frontier
Science Program (HFSP); Killam trust
FX PCS is a Research Fellow of the Terry Fox Foundation (Award # 700044;
www.terryfox.org/) with additional support from the Michael Smith
Foundation for Health Research (MSFHR; www.msfhr.org/). PH is supported
by the National Institutes of Health (NIH; www.nih.gov/) and the
Canadian Institutes for Health Research (CIHR;
http://www.cihr-irsc.gc.ca/e/193.html). KM is supported by the
intramural research program of the NHGRI, NIH. SB-A was supported by a
Human Frontier Science Program (HFSP) long-term fellowship
(www.hfsp.org/) and by a research grant from the Killam trust
(http://www.killamtrusts.ca/). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 39
TC 52
Z9 52
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7390
J9 PLOS GENET
JI PLoS Genet.
PD APR
PY 2011
VL 7
IS 4
AR e1002057
DI 10.1371/journal.pgen.1002057
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 755YI
UT WOS:000289977000042
PM 21552543
ER
PT J
AU Zhai, GJ
Teumer, A
Stolk, L
Perry, JRB
Vandenput, L
Coviello, AD
Koster, A
Bell, JT
Bhasin, S
Eriksson, J
Eriksson, A
Ernst, F
Ferrucci, L
Frayling, TM
Glass, D
Grundberg, E
Haring, R
Hedman, AK
Hofman, A
Kiel, DP
Kroemer, HK
Liu, YM
Lunetta, KL
Maggio, M
Lorentzon, M
Mangino, M
Melzer, D
Miljkovic, I
Nica, A
Penninx, BWJH
Vasan, RS
Rivadeneira, F
Small, KS
Soranzo, N
Uitterlinden, AG
Volzke, H
Wilson, SG
Xi, L
Zhuang, WV
Harris, TB
Murabito, JM
Ohlsson, C
Murray, A
de Jong, FH
Spector, TD
Wallaschofski, H
AF Zhai, Guangju
Teumer, Alexander
Stolk, Lisette
Perry, John R. B.
Vandenput, Liesbeth
Coviello, Andrea D.
Koster, Annemarie
Bell, Jordana T.
Bhasin, Shalender
Eriksson, Joel
Eriksson, Anna
Ernst, Florian
Ferrucci, Luigi
Frayling, Timothy M.
Glass, Daniel
Grundberg, Elin
Haring, Robin
Hedman, Asa K.
Hofman, Albert
Kiel, Douglas P.
Kroemer, Heyo K.
Liu, Yongmei
Lunetta, Kathryn L.
Maggio, Marcello
Lorentzon, Mattias
Mangino, Massimo
Melzer, David
Miljkovic, Iva
Nica, Alexandra
Penninx, Brenda W. J. H.
Vasan, Ramachandran S.
Rivadeneira, Fernando
Small, Kerrin S.
Soranzo, Nicole
Uitterlinden, Andre G.
Voelzke, Henry
Wilson, Scott G.
Xi, Li
Zhuang, Wei Vivian
Harris, Tamara B.
Murabito, Joanne M.
Ohlsson, Claes
Murray, Anna
de Jong, Frank H.
Spector, Tim D.
Wallaschofski, Henri
CA MuTHER Consortium
TI Eight Common Genetic Variants Associated with Serum DHEAS Levels Suggest
a Key Role in Ageing Mechanisms
SO PLOS GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; DEHYDROEPIANDROSTERONE-SULFATE LEVELS;
POLYCYSTIC-OVARY-SYNDROME; BONE-MINERAL DENSITY; XENOBIOTIC METABOLISM;
SUSCEPTIBILITY LOCI; RISK LOCI; CARDIOVASCULAR-DISEASE;
INSULIN-RESISTANCE; ACID-METABOLISM
AB Dehydroepiandrosterone sulphate (DHEAS) is the most abundant circulating steroid secreted by adrenal glands-yet its function is unknown. Its serum concentration declines significantly with increasing age, which has led to speculation that a relative DHEAS deficiency may contribute to the development of common age-related diseases or diminished longevity. We conducted a meta-analysis of genome-wide association data with 14,846 individuals and identified eight independent common SNPs associated with serum DHEAS concentrations. Genes at or near the identified loci include ZKSCAN5 (rs11761528; p = 3.15610(-36)), SULT2A1 (rs2637125; p = 2.61610(-19)), ARPC1A (rs740160; p = 1.56610(-16)), TRIM4 (rs17277546; p = 4.50610(-11)), BMF (rs7181230; p = 5.44610(-11)), HHEX (rs2497306; p = 4.64610(-9)), BCL2L11 ( rs6738028; p = 1.72610(-8)), and CYP2C9 (rs2185570; p = 2.29610(-8)). These genes are associated with type 2 diabetes, lymphoma, actin filament assembly, drug and xenobiotic metabolism, and zinc finger proteins. Several SNPs were associated with changes in gene expression levels, and the related genes are connected to biological pathways linking DHEAS with ageing. This study provides much needed insight into the function of DHEAS.
C1 [Zhai, Guangju; Bell, Jordana T.; Glass, Daniel; Grundberg, Elin; Mangino, Massimo; Small, Kerrin S.; Soranzo, Nicole; Wilson, Scott G.; Spector, Tim D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England.
[Teumer, Alexander; Ernst, Florian] Ernst Moritz Arndt Univ Greifswald, Interfac Inst Genet & Funct Genom, Greifswald, Germany.
[Stolk, Lisette; Rivadeneira, Fernando; Uitterlinden, Andre G.; de Jong, Frank H.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
[Stolk, Lisette; Hofman, Albert; Rivadeneira, Fernando; Uitterlinden, Andre G.] Netherlands Consortium Hlth Ageing, Rotterdam, Netherlands.
[Perry, John R. B.; Frayling, Timothy M.; Melzer, David; Murray, Anna] Univ Exeter, Peninsula Med Sch, Exeter, Devon, England.
[Perry, John R. B.; Bell, Jordana T.; Hedman, Asa K.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[Vandenput, Liesbeth; Eriksson, Joel; Eriksson, Anna; Lorentzon, Mattias; Ohlsson, Claes] Univ Gothenburg, Dept Internal Med, Inst Med, Sahlgrenska Acad, Gothenburg, Sweden.
[Coviello, Andrea D.; Vasan, Ramachandran S.; Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA.
[Coviello, Andrea D.; Vasan, Ramachandran S.; Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Sect Prevent Med, Boston, MA 02118 USA.
[Coviello, Andrea D.; Vasan, Ramachandran S.; Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Cardiol Sect, Boston, MA 02118 USA.
[Coviello, Andrea D.; Vasan, Ramachandran S.; Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA.
[Koster, Annemarie; Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
[Bhasin, Shalender] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Claude Pepper Older Amer Independence Ctr, Boston, MA 02118 USA.
[Ferrucci, Luigi] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[Grundberg, Elin; Nica, Alexandra; Small, Kerrin S.; Soranzo, Nicole] Wellcome Trust Sanger Inst, Hixton, WI USA.
[Haring, Robin; Wallaschofski, Henri] Ernst Moritz Arndt Univ Greifswald, Inst Clin Chem & Lab Med, Greifswald, Germany.
[Hofman, Albert; Uitterlinden, Andre G.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[Kiel, Douglas P.] Hebrew Senior Life Inst Aging Res, Boston, MA USA.
[Kiel, Douglas P.] Harvard Univ, Sch Med, Boston, MA USA.
[Kroemer, Heyo K.] Ernst Moritz Arndt Univ Greifswald, Ctr Pharmacol & Expt Therapeut, Dept Pharmacol, Greifswald, Germany.
[Liu, Yongmei] Wake Forest Univ Hlth Sci, Dept Epidemiol & Prevent, Winston Salem, NC USA.
[Lunetta, Kathryn L.; Zhuang, Wei Vivian] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Maggio, Marcello] Univ Parma, Dept Internal Med & Biomed Sci, Sect Geriatr, I-43100 Parma, Italy.
[Miljkovic, Iva] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Nica, Alexandra] Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva, Switzerland.
[Penninx, Brenda W. J. H.] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands.
[Vasan, Ramachandran S.; Murabito, Joanne M.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Voelzke, Henry] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, Greifswald, Germany.
[Wilson, Scott G.] Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia.
[Wilson, Scott G.] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia.
[Xi, Li] Pfizer Worldwide R&D, Mol Med Computat Biol, Groton, CT USA.
RP Zhai, GJ (reprint author), Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England.
EM tim.spector@kcl.ac.uk
RI Koster, Annemarie/E-7438-2010; Rivadeneira, Fernando/O-5385-2015;
mangino, massimo/F-5134-2011;
OI Rivadeneira, Fernando/0000-0001-9435-9441; mangino,
massimo/0000-0002-2167-7470; Murabito, Joanne/0000-0002-0192-7516;
Lunetta, Kathryn/0000-0002-9268-810X; Miljkovic,
Iva/0000-0002-3155-9777; Ramachandran, Vasan/0000-0001-7357-5970;
Soranzo, Nicole/0000-0003-1095-3852; Kiel, Douglas/0000-0001-8474-0310;
Melzer, David/0000-0002-0170-3838; Hedman, Asa/0000-0001-5413-204X;
Vandenput, Liesbeth/0000-0002-1712-6131; Small,
Kerrin/0000-0003-4566-0005
FU Wellcome Trust; Arthritis Research Campaign; European Community
[HEALTH-F2-2008-201865-GEFOS, HEALTH-F4-2007-201413,
QLG2-CT-2002-01254]; UK Department of Health via the National Institute
for Health Research (NIHR); Biotechnology and Biological Sciences
Research Council [G20234]; National Eye Institute (NEI) via an
NIH/Center for Inherited Disease Research (CIDR); Federal Ministry of
Education and Research [01ZZ9603, 01ZZ0103, 01ZZ0403, 03ZIK012];
Ministry of Cultural Affairs; Social Ministry of the Federal State of
Mecklenburg West Pomerania; Siemens Healthcare, Erlangen, Germany;
Federal State of Mecklenburg West Pomerania; Ministry of Cultural
Affairs of the Federal State of Mecklenburg - West Pomerania
[03IS2061A]; Siemens Healthcare Diagnostics, Eschborn; DPC Biermann
GmbH, Bad Nauheim, Germany; Novo Nordisc; National Institute on Aging
[N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [1R01AG032098-01A1];
National Institutes of Health [HHSN268200782096C]; NIH, National
Institute on Aging; Netherlands Organisation of Scientific Research NWO
[175.010.2005.011, 911-03-012]; Research Institute for Diseases in the
Elderly (RIDE2) [014-93-015]; Netherlands Genomics Initiative (NGI)
Netherlands Consortium of Healthy Aging (NCHA) [050-060-810]; European
Commision [HEALTH-F2-2008-201865, HEALTH-F2-2008-35627]; Erasmus Medical
Center; Erasmus University, Rotterdam; Netherlands Organization for the
Health Research and Development (ZonMw); Research Institute for Diseases
in the Elderly (RIDE); Ministry of Education, Culture and Science;
Ministry for Health, Welfare and Sports; European Commission
[HEALTH-F2-2008-201865-GEFOS]; Municipality of Rotterdam; German
Bundesministerium fuer Forschung und Technology [01 AK 803 A-H, 01 IG
07015 G]; National Institute of Aging [R21AG032598]; National Heart,
Lung and Blood Institute [N01-HC-25195]; Affymetrix, Inc
[N02-HL-6-4278]; Robert Dawson Evans Endowment of the Department of
Medicine at Boston University School of Medicine and Boston Medical
Center; NIH [R01 AR/AG 41398]; Swedish Research Council
[K2010-54X-09894-19-3, 2006-3832]; Swedish Foundation for Strategic
Research; ALF/LUA; Lundberg Foundation; Torsten and Ragnar Soderberg's
Foundation; Petrus and Augusta Hedlunds Foundation; Vastra Gotaland
Foundation; Goteborg Medical Society; Novo Nordisk foundation; Italian
Ministry of Health [ICS110.1/RF97.71]; U.S. National Institute on Aging
[263 MD 9164, 263 MD 821336, N.1-AG-1-1, N.1-AG-1-2111, N01-AG-5-0002];
National Institute on Aging, National Institutes of Health, Baltimore,
Maryland; Sir Henry Wellcome Postdoctoral Fellowship [092447/Z/10/Z]
FX TwinsUK: The study was funded by the Wellcome Trust, Arthritis Research
Campaign, European Community's Seventh Framework Programme
(FP7/2007-2013)/grant agreement HEALTH-F2-2008-201865-GEFOS and Seventh
Framework Programme grant 200800 Treat OA/(FP7/2007-2013), ENGAGE
project grant agreement HEALTH-F4-2007-201413, and the FP-5 GenomEUtwin
Project (QLG2-CT-2002-01254). The study also receives support from the
UK Department of Health via the National Institute for Health Research
(NIHR) comprehensive Biomedical Research Centre award to Guy's & St
Thomas' NHS Foundation Trust in partnership with King's College London.
TDS is an NIHR senior investigator. The project also received support
from a Biotechnology and Biological Sciences Research Council project
grant (G20234). The authors acknowledge the funding and support of the
National Eye Institute (NEI) via an NIH/Center for Inherited Disease
Research (CIDR) genotyping project. We thank the staff from the
Genotyping Facilities at the Wellcome Trust Sanger Institute for sample
preparation, quality control, and genotyping; Le Centre National de
Genotypage, France, for genotyping; Duke University, NC, USA, for
genotyping; and the Finnish Institute of Molecular Medicine, Finnish
Genome Center, University of Helsinki. Genotyping was also done by CIDR
as part of an NEI/NIH project grant.; SHIP: Computing resources have
been made available by the Leibniz Supercomputing Centre of the Bavarian
Academy of Sciences and Humanities (HLRB project h1231). SHIP is part of
the Community Medicine Research net of the University of Greifswald,
Germany, which is funded by the Federal Ministry of Education and
Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of
Cultural Affairs as well as the Social Ministry of the Federal State of
Mecklenburg West Pomerania. Genome-wide data have been supported by the
Federal Ministry of Education and Research (grant no. 03ZIK012) and a
joint grant from Siemens Healthcare, Erlangen, Germany and the Federal
State of Mecklenburg West Pomerania. This work is also part of the
research project Greifswald Approach to Individualized Medicine
(GANI_MED). The GANI_MED consortium is funded by the Federal Ministry of
Education and Research and the Ministry of Cultural Affairs of the
Federal State of Mecklenburg - West Pomerania (03IS2061A). The
University of Greifswald is a member of the 'Center of Knowledge
Interchange' program of the Siemens AG. The DHEAS reagents used were
sponsored by Siemens Healthcare Diagnostics, Eschborn, formerly DPC
Biermann GmbH, Bad Nauheim, Germany. Novo Nordisc provided partial grant
support for the determination of serum samples and data analysis.;
Health ABC: This study was supported by National Institute on Aging
contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106. The
genome-wide association study was funded by NIA grant 1R01AG032098-01A1
to Wake Forest University Health Sciences and genotyping services were
provided by the Center for Inherited Disease Research (CIDR). CIDR is
fully funded through a federal contract from the National Institutes of
Health to The Johns Hopkins University, contract number
HHSN268200782096C.'' This research was supported (in part) by the
Intramural Research Program of the NIH, National Institute on Aging.;
RS1: The generation and management of GWAS genotype data for the
Rotterdam Study is supported by the Netherlands Organisation of
Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012).
This study is funded by the Research Institute for Diseases in the
Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)
Netherlands Consortium of Healthy Aging (NCHA) project nr. 050-060-810,
and funding from the European Commision (HEALTH-F2-2008-201865, GEFOS;
HEALTH-F2-2008-35627, TREAT-OA). The Rotterdam Study is funded by
Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands
Organization for the Health Research and Development (ZonMw), the
Research Institute for Diseases in the Elderly (RIDE), the Ministry of
Education, Culture and Science, the Ministry for Health, Welfare and
Sports, the European Commission (DG XII), and the Municipality of
Rotterdam. We thank Pascal Arp, Mila Jhamai, Dr Michael Moorhouse,
Marijn Verkerk, and Sander Bervoets for their help in creating the GWAS
database. The authors are grateful to the study participants, the staff
from the Rotterdam Study and the participating general practioners and
pharmacists. We would like to thank Dr. Tobias A. Knoch, Karol Estrada,
Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their
institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and
especially the national German MediGRID and Services@MediGRID part of
the German D-Grid, both funded by the German Bundesministerium fuer
Forschung und Technology under grants #01 AK 803 A-H and # 01 IG 07015 G
for access to their grid resources.; FHS: DHEAS-genotype genome-wide
association analyses were supported by the National Institute of Aging
(Genetics of Reproductive Life Period and Health Outcomes, R21AG032598;
JMM, KL, DPK, WVZ). "The Framingham Heart Study of the National Heart
Lung and Blood Institute of the National Institutes of Health and Boston
University School of Medicine was supported by the National Heart, Lung
and Blood Institute's Framingham Heart Study Contract No. N01-HC-25195
and its contract with Affymetrix, Inc for genotyping services (Contract
No. N02-HL-6-4278). Analyses reflect intellectual input and resource
development from the Framingham Heart Study investigators participating
in the SNP Health Association Resource (SHARe) project. A portion of
this research was conducted using the Linux Cluster for Genetic Analysis
(LinGA-II) funded by the Robert Dawson Evans Endowment of the Department
of Medicine at Boston University School of Medicine and Boston Medical
Center." DPK received support from NIH (Grant R01 AR/AG 41398).; GOOD:
Financial support was received from the Swedish Research Council
(K2010-54X-09894-19-3, 2006-3832), the Swedish Foundation for Strategic
Research, the ALF/LUA research grant in Gothenburg, the Lundberg
Foundation, the Torsten and Ragnar Soderberg's Foundation, Petrus and
Augusta Hedlunds Foundation, the Vastra Gotaland Foundation, the
Goteborg Medical Society, the Novo Nordisk foundation and the European
Commission grant HEALTH-F2-2008-201865-GEFOS. We would like to thank Dr.
Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as
well as their institutions the Erasmus Computing Grid, Rotterdam, The
Netherlands, and especially the national German MediGRID and
Services@MediGRID part of the German D-Grid, both funded by the German
Bundesministerium fuer Forschung und Technology under grants #01 AK 803
A-H and # 01 IG 07015 G for access to their grid resources. We would
also like to thank Karol Estrada, Department of Internal Medicine,
Erasmus MC, Rotterdam, The Netherlands for advice regarding the grid
resources.; InCHIANTI: The InCHIANTI study baseline (1998-2000) was
supported as a "targeted project" (ICS110.1/RF97.71) by the Italian
Ministry of Health and in part by the U.S. National Institute on Aging
(Contracts: 263 MD 9164 and 263 MD 821336); the InCHIANTI Followup 1
(2001-2003) was funded by the U.S. National Institute on Aging
(Contracts: N.1-AG-1-1 and N.1-AG-1-2111); the InCHIANTI Follow-ups 2
and 3 studies (2004-2010) were financed by the U.S. National Institute
on Aging (Contract: N01-AG-5-0002); supported in part by the Intramural
research program of the National Institute on Aging, National Institutes
of Health, Baltimore, Maryland. JRBP is funded by a Sir Henry Wellcome
Postdoctoral Fellowship (092447/Z/10/Z).
NR 61
TC 40
Z9 42
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD APR
PY 2011
VL 7
IS 4
AR e1002025
DI 10.1371/journal.pgen.1002025
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 755YI
UT WOS:000289977000014
PM 21533175
ER
PT J
AU Brosh, RM
AF Brosh, Robert M., Jr.
TI Put on your thinking cap: G-quadruplexes, helicases, and telomeres
SO AGING-US
LA English
DT Article
ID GUANINE-RICH DNA; SACCHAROMYCES-CEREVISIAE; SEQUENCES; CELLS; SGS1;
REPLICATION; MAINTENANCE; PROTEIN; WERNER; ROLES
C1 NIA, Lab Mol Gerontol, NIH, NIH Biomed Res Ctr, Baltimore, MD 21224 USA.
RP Brosh, RM (reprint author), NIA, Lab Mol Gerontol, NIH, NIH Biomed Res Ctr, Baltimore, MD 21224 USA.
EM broshr@mail.nih.gov
NR 31
TC 4
Z9 4
U1 1
U2 2
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD APR
PY 2011
VL 3
IS 4
BP 332
EP 335
PG 4
WC Cell Biology
SC Cell Biology
GA 759HH
UT WOS:000290230800002
PM 21732565
ER
PT J
AU Howard, VJ
Kleindorfer, DO
Judd, SE
McClure, LA
Safford, MM
Rhodes, JD
Cushman, M
Moy, CS
Soliman, EZ
Kissela, BM
Howard, G
AF Howard, Virginia J.
Kleindorfer, Dawn O.
Judd, Suzanne E.
McClure, Leslie A.
Safford, Monika M.
Rhodes, J. David
Cushman, Mary
Moy, Claudia S.
Soliman, Elsayed Z.
Kissela, Brett M.
Howard, George
TI Disparities in Stroke Incidence Contributing to Disparities in Stroke
Mortality
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID NORTHERN MANHATTAN STROKE; BLACK-WHITE DIFFERENCES; UNITED-STATES;
FOLLOW-UP; RACIAL-DIFFERENCES; RISK-FACTORS; DISEASE; HYPERTENSION;
COMMUNITIES; POPULATION
AB Objective: While black-white and regional disparities in U. S. stroke mortality rates are well documented, the contribution of disparities in stroke incidence is unknown. We provide national estimates of stroke incidence by race and region, contrasting these to publicly available stroke mortality data.
Methods: This analysis included 27,744 men and women without prevalent stroke (40.4% black), aged >= 45 years from the REasons for Geographic And Racial Differences in Stroke (REGARDS) national cohort study, enrolled 2003-2007. Incident stroke was defined as first occurrence of stroke over 4.4 years of follow-up. Age-sex-adjusted stroke mortality rates were calculated using data from the Centers for Disease Control and Prevention (CDC) Wide-Ranging Online Data for Epidemiological Research (WONDER) System.
Results: There were 460 incident strokes over 113,469 person-years of follow-up. Relative to the rest of the United States, incidence rate ratios (IRRs) of stroke in the southeastern stroke belt and stroke buckle were 1.06 (95% confidence interval [CI], 0.87-1.29) and 1.19 (95% CI, 0.96-1.47), respectively. The age-sex-adjusted black/white IRR(black) was 1.51 (95% CI, 1.26-1.81), but for ages 45-54 years the IRR(black) was 4.02 (95% CI, 1.23-13.11) while for ages 85+ it was 0.86 (95% CI, 0.33-2.20). Generally, the IRRs(black) were less than the mortality rate ratios (MRRs) across age groups; however, only in ages 55-64 years and 65-74 years did the 95% CIs of IRRs(black) not include the MRR(black). The MRRs for regions were within 95% CIs for IRRs.
Interpretation: National patterns of black-white and regional differences in stroke incidence are similar to those for stroke mortality; however, the magnitude of differences in incidence appear smaller. ANN NEUROL 2011; 69: 619-627
C1 [Howard, Virginia J.] Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
[Judd, Suzanne E.; McClure, Leslie A.; Rhodes, J. David; Howard, George] Univ Alabama, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA.
[Safford, Monika M.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA.
[Kleindorfer, Dawn O.; Kissela, Brett M.] Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH USA.
[Cushman, Mary] Univ Vermont, Dept Med, Burlington, VT USA.
[Cushman, Mary] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA.
[Moy, Claudia S.] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA.
[Soliman, Elsayed Z.] Wake Forest Univ, Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA.
RP Howard, VJ (reprint author), Univ Alabama, Sch Publ Hlth, Dept Epidemiol, 1665 Univ Blvd, Birmingham, AL 35294 USA.
EM vjhoward@uab.edu
RI Soliman, Elsayed/D-8124-2011; McClure, Leslie/P-2929-2015;
OI Soliman, Elsayed/0000-0001-5632-8150; Kissela, Brett/0000-0002-9773-4013
FU National Institutes of Health (National Institute of Neurological
Disorders and Stroke) [U01 NS041588, NINDS R-01 NS039987, NCRR 1UL1
RR026314]; Allergan; Boehringer Ingelheim; NINDS; NIH
FX This research was supported by a grant from the National Institutes of
Health (National Institute of Neurological Disorders and Stroke
cooperative agreement U01 NS041588) to GH.; D.R., G. H., and V.J.H. have
received grant(s) from the NIH National Institute of Neurological
Disorders and Stroke (NINDS) for the REGARDS Study. G. H. has grant(s)
pending from the NIH-NINDS. B. K. has received funding from NIH-NINDS
for the REGARDS study for travel to study meetings, effort for
adjudication of stroke events, and authorship; has grant(s) pending
(NINDS R-01 NS039987, NCRR 1UL1 RR026314); has consulted for Allergan;
has developed educational presentations for and has been paid for travel
from Allergan; and has provided expert testimony for various entities.
D.O.K. has been paid travel expenses for meetings from NINDS REGARDS
funding; has been paid for lectures from the Boehringer Ingelheim
Speaker's Bureau; and has grant(s) pending from NINDS. M. C. has
received grant(s) from the NIH and has been reimbursed travel expenses
for meetings from the NIH. L. M. has received grant(s), has grant(s)
pending, and has received consulting fees (as a DSMB member) from NINDS.
S.J. has received grant(s) and has received support for travel to
meetings from NIH-NINDS.
NR 31
TC 121
Z9 121
U1 0
U2 6
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD APR
PY 2011
VL 69
IS 4
BP 619
EP 627
DI 10.1002/ana.22385
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 758HV
UT WOS:000290155800007
PM 21416498
ER
PT J
AU Harford, JB
Otero, IV
Anderson, BO
Cazap, E
Gradishar, WJ
Gralow, JR
Kane, GM
Niens, LM
Porter, PL
Reeler, AV
Rieger, PT
Shockney, LD
Shulman, LN
Soldak, T
Thomas, DB
Thompson, B
Winchester, DP
Zelle, SG
Badwe, RA
AF Harford, Joe B.
Otero, Isabel V.
Anderson, Benjamin O.
Cazap, Eduardo
Gradishar, William J.
Gralow, Julie R.
Kane, Gabrielle M.
Niens, Laurens M.
Porter, Peggy L.
Reeler, Anne V.
Rieger, Paula T.
Shockney, Lillie D.
Shulman, Lawrence N.
Soldak, Tanya
Thomas, David B.
Thompson, Beti
Winchester, David P.
Zelle, Sten G.
Badwe, Rajendra A.
TI Problem solving for breast health care delivery in low and middle
resource countries (LMCs): consensus statement from the Breast Health
Global Initiative
SO BREAST
LA English
DT Article
DE Implementation science; Cost-effectiveness research; Situational
analysis; Mortality-to-incidence ratio; Patient navigation; Advocacy
ID REDUCE CANCER DISPARITIES; INCOME COUNTRIES; GUIDELINE IMPLEMENTATION; 5
CONTINENTS; MORTALITY; ERADICATION; ALLOCATION; POLICIES; SCIENCE;
DISEASE
AB International collaborations like the Breast Health Global Initiative (BHGI) can help low and middle income countries (LMCs) to establish or improve breast cancer control programs by providing evidence-based, resource-stratified guidelines for the management and control of breast cancer. The Problem Solving Working Group of the BHGI 2010 Global Summit met to develop a consensus statement on problem-solving strategies addressing breast cancer in LMCs. To better assess breast cancer burden in poorly studied populations, countries require accurate statistics regarding breast cancer incidence and mortality. To better identify health care system strengths and weaknesses, countries require reasonable indicators of true health system quality and capacity. Using qualitative and quantitative research methods, countries should formulate cancer control strategies to identify both system inefficiencies and patient barriers. Patient navigation programs linked to public advocacy efforts feed and strengthen functional early detection and treatment programs. Cost-effectiveness research and implementation science are tools that can guide and expand successful pilot programs. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Anderson, Benjamin O.] Univ Washington, Fred Hutchinson Canc Res Ctr, Breast Hlth Global Initiat, Seattle, WA 98195 USA.
[Harford, Joe B.; Otero, Isabel V.] NCI, Off Int Affairs, NIH, Bethesda, MD 20892 USA.
[Cazap, Eduardo] SLACOM Soc Latinoamer & Caribe Oncol Med, Buenos Aires, DF, Argentina.
[Gradishar, William J.] Northwestern Univ, Feinberg Sch Med, NW Mem Hosp, Evanston, IL USA.
[Gralow, Julie R.] Seattle Canc Care Alliance, Seattle, WA USA.
[Anderson, Benjamin O.; Gralow, Julie R.; Kane, Gabrielle M.] Univ Washington, Sch Med, Seattle, WA 98195 USA.
[Niens, Laurens M.] Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands.
[Reeler, Anne V.] Axios Int, Paris, France.
[Rieger, Paula T.] Oncol Nursing Soc, Pittsburgh, PA USA.
[Shockney, Lillie D.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA.
[Shulman, Lawrence N.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Soldak, Tanya] Resource & Policy Exchange, Delhi, NY USA.
[Thomas, David B.] Amer Coll Surg, Natl Accreditat Program Breast Ctr, Chicago, IL USA.
[Zelle, Sten G.] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands.
[Badwe, Rajendra A.] Tata Mem Hosp, Dept Surg, Bombay 400012, Maharashtra, India.
RP Anderson, BO (reprint author), Univ Washington, Fred Hutchinson Canc Res Ctr, Breast Hlth Global Initiat, Box 356410, Seattle, WA 98195 USA.
EM banderso@u.washington.edu
FU Breast Health Global Initiative (BHGI); Bayer Schering Pharma; Breast
Cancer Research Foundation (BCRF); ASCO; UICC; ESMO; BCRF; Genetech;
Amgen; Norvartis; Roche; Susan G. Komen for the CureRegistered; Fogarty
International
FX BOA received funding from Breast Health Global Initiative (BHGI); EC
received consultancy funding from Bayer Schering Pharma, grants from the
Breast Cancer Research Foundation (BCRF) and Poniard Pharmaceuticals,
was on the speakers bureaus for Bayer and Bristol Meyers Squibb, and
received travel expenses from ASCO, UICC, ESMO, and BCRF; DBT and PP
have received funding from BHGI for travel; JRG received funding from
Genetech, Amgen, Norvartis, and Roche; LMN and SGZ received funding from
BHGI and Susan G. Komen for the Cure (R); BT received travel funding or
other support from Fogarty International. All other authors and working
group members reported no conflict of interest.
NR 70
TC 17
Z9 17
U1 0
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
J9 BREAST
JI Breast
PD APR
PY 2011
VL 20
SU 2
BP S20
EP S29
DI 10.1016/j.breast.2011.02.007
PG 10
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 758VB
UT WOS:000290194000004
PM 21376593
ER
PT J
AU Yip, CH
Cazap, E
Anderson, BO
Bright, KL
Caleffi, M
Cardoso, F
Elzawawy, AM
Harford, JB
Krygier, GD
Masood, S
Murillo, R
Muse, IM
Otero, IV
Passman, LJ
Santini, LA
da Silva, RCF
Thomas, DB
Torres, S
Zhengs, Y
Khaled, HM
AF Yip, Cheng-Har
Cazap, Eduardo
Anderson, Benjamin O.
Bright, Kristin L.
Caleffi, Maira
Cardoso, Fatima
Elzawawy, Ahmed M.
Harford, Joe B.
Krygier, Gabriel D.
Masood, Shahla
Murillo, Raul
Muse, Ignacio M.
Otero, Isabel V.
Passman, Leigh J.
Santini, Luiz A.
Ferreira da Silva, Ronaldo Correa
Thomas, David B.
Torres, Soledad
Zhengs, Ying
Khaled, Hussein M.
TI Breast cancer management in middle-resource countries (MRCs): Consensus
statement from the Breast Health Global Initiative
SO BREAST
LA English
DT Article
DE Breast cancer; Middle resource countries; Early detection; Treatment;
Multidisciplinary services; Health care financing
ID OF-AMERICAN-PATHOLOGISTS; INCOME COUNTRIES; GUIDELINE IMPLEMENTATION;
QUALITY-ASSURANCE; LATIN-AMERICA; CARE; TRIAL; ALLOCATION; SOCIETY;
WOMEN
AB In middle resource countries (MRCs), cancer control programs are becoming a priority as the pattern of disease shifts from infectious diseases to non-communicable diseases such as breast cancer, the most common cancer among women in MRCs. The Middle Resource Scenarios Working Group of the BHGI 2010 Global Summit met to identify common issues and obstacles to breast cancer detection, diagnosis and treatment in MRCs. They concluded that breast cancer early detection programs continue to be important, should include clinical breast examination (CBE) with or without mammography, and should be coupled with active awareness programs. Mammographic screening is usually opportunistic and early detection programs are often hampered by logistical and financial problems, as well as socio-cultural barriers, despite improved public educational efforts. Although multidisciplinary services for treatment are available, geographical and economic limitations to these services can lead to an inequity in health care access. Without adequate health insurance coverage, limited personal finances can be a significant barrier to care for many patients. Despite the improved availability of services (surgery, pathology, radiology and radiotherapy), quality assurance programs remain a challenge. Better access to anticancer drugs is needed to improve outcomes, as are rehabilitation programs for survivors. Focused and sustained government health care financing in MRCs is needed to improve early detection and treatment of breast cancer. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Anderson, Benjamin O.] Univ Washington, Fred Hutchinson Canc Res Ctr, Breast Hlth Global Initiat, Seattle, WA 98195 USA.
[Yip, Cheng-Har] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia.
[Cazap, Eduardo] SLACOM Soc Latinoamer & Caribe Oncol Med, Buenos Aires, DF, Argentina.
[Bright, Kristin L.] NYU, NYU Canc Inst, New York, NY USA.
[Bright, Kristin L.] NYU, NYU Sch Med, New York, NY USA.
[Caleffi, Maira] Hosp Moinhos Venta, Porto Alegre, RS, Brazil.
[Cardoso, Fatima] European Sch Oncol, Milan, Italy.
[Cardoso, Fatima] Champalimaud Canc Ctr, Lisbon, Portugal.
[Elzawawy, Ahmed M.] ICEDOC, Port Said, Egypt.
[Harford, Joe B.; Otero, Isabel V.] NCI, Off Int Affairs, NIH, Bethesda, MD 20892 USA.
[Krygier, Gabriel D.] Acad Univ Clin Hosp Montevideo, Montevideo, Uruguay.
[Krygier, Gabriel D.] Natl Breast Canc Program, Montevideo, Uruguay.
[Masood, Shahla] Univ Florida, Coll Med, Jacksonville, FL USA.
[Murillo, Raul] Inst Nacl Cancerol Colombia, Bogota, Colombia.
[Muse, Ignacio M.] Natl Canc Program, Montevideo, Uruguay.
[Passman, Leigh J.; Santini, Luiz A.; Ferreira da Silva, Ronaldo Correa] Inst Nacl Canc, Rio De Janeiro, Brazil.
[Torres, Soledad] Clin Las Condes Breast Ctr, Santiago, Chile.
[Ferreira da Silva, Ronaldo Correa; Zhengs, Ying] Shanghai Municipal Ctr Dis Control & Prevent, Shanghai, Peoples R China.
[Khaled, Hussein M.] Cairo Univ, Natl Canc Inst, Cairo, Egypt.
RP Anderson, BO (reprint author), Univ Washington, Fred Hutchinson Canc Res Ctr, Breast Hlth Global Initiat, Box 356410, Seattle, WA 98195 USA.
EM banderso@u.washington.edu
RI Yip, Cheng-Har/B-1909-2010;
OI Cardoso, Fatima/0000-0002-6692-2249
FU Breast Health Global Initiative (BHGI); Bayer Sherling Pharma; Breast
Cancer Research Foundation (BCRF); ASCO; UICC; ESMO; GSK; U.S.
Department of Defense [W81XWH-04-1-0905]; Fred Hutchinson Cancer
Research Center; Susan G. Komen for the CureRegistered
[SG09-0605-01-BHGI]; U.S. Office of International Affairs, National
Cancer Institute; European School of Oncology; Pan American Health
Organization; Sheikh Mohammed Hussein Al-Amoudi Center of Excellence in
Breast Cancer; American Society of Clinical Oncology; LIVESTRONG; U.S.
Centers for Disease Control and Prevention; U.S. Office of Women's
Health, Department of Health and Human Services; U.S. Office of Science
Planning and Assessment, National Cancer Institute; U.S. Office of
Research on Women's Health, National Institutes of Health; GE
Healthcare; Sanofi-Aventis
FX BOA received funding from Breast Health Global Initiative (BHGI), EC
received consultancy funding from Bayer Sherling Pharma, grants from
Breast Cancer Research Foundation (BCRF) and Poniard Pharmaceuticals,
was on the speakers bureaus for Bayer and Bristol Meyers Squibb, and
received travel expenses from ASCO, UICC, ESMO, and BCRF; CHY was on an
expert panel and received research funding from GSK and was on the
speakers bureaus for Sanofi-Aventis and Roche. DBT has received funding
from BHGI for travel. KB received funding from U.S. Department of
Defense Breast Cancer Research Program Center of Excellence
(#W81XWH-04-1-0905). All other authors and working group members
reported no conflict of interest.; BHGI received (2010 Global Summit)
grants and contributions from Fred Hutchinson Cancer Research Center;
Susan G. Komen for the Cure (R) (Grant Award SG09-0605-01-BHGI); U.S.
Office of International Affairs, National Cancer Institute; European
School of Oncology; Pan American Health Organization; Sheikh Mohammed
Hussein Al-Amoudi Center of Excellence in Breast Cancer; American
Society of Clinical Oncology; LIVESTRONG; U.S. Centers for Disease
Control and Prevention; U.S. Office of Women's Health, Department of
Health and Human Services; U.S. Office of Science Planning and
Assessment, National Cancer Institute; U.S. Office of Research on
Women's Health, National Institutes of Health and unrestricted
educational grants from GE Healthcare and Sanofi-Aventis.
NR 66
TC 17
Z9 18
U1 2
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
J9 BREAST
JI Breast
PD APR
PY 2011
VL 20
SU 2
BP S12
EP S19
DI 10.1016/j.breast.2011.02.015
PG 8
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 758VB
UT WOS:000290194000003
PM 21388811
ER
PT J
AU Kothapalli, NR
Fugmann, SD
AF Kothapalli, Naga Rama
Fugmann, Sebastian D.
TI Targeting of AID-mediated sequence diversification to immunoglobulin
genes
SO CURRENT OPINION IN IMMUNOLOGY
LA English
DT Review
ID INDUCED CYTIDINE DEAMINASE; CLASS-SWITCH RECOMBINATION;
SINGLE-STRANDED-DNA; SOMATIC HYPERMUTATION; B-CELLS; REGULATORY REGION;
IG; CONVERSION; TRANSCRIPTION; ENHANCER
AB Activation-induced cytidine deaminase (AID) is a key enzyme for antibody-mediated immune responses. Antibodies are encoded by the immunoglobulin genes and AID acts as a transcription-dependent DNA mutator on these genes to improve antibody affinity and effector functions. An emerging theme in field is that many transcribed genes are potential targets of AID, presenting an obvious danger to genomic integrity. Thus there are mechanisms in place to ensure that mutagenic outcomes of AID activity are specifically restricted to the immunoglobulin loci. Cis-regulatory targeting elements mediate this effect and their mode of action is probably a combination of immunoglobulin gene specific activation of AID and a perversion of faithful DNA repair towards error-prone outcomes.
C1 [Kothapalli, Naga Rama; Fugmann, Sebastian D.] NIA, Mol Immunol Unit, Lab Mol Biol & Immunol, NIH,Biomed Res Ctr, Baltimore, MD 21224 USA.
RP Fugmann, SD (reprint author), NIA, Mol Immunol Unit, Lab Mol Biol & Immunol, NIH,Biomed Res Ctr, 251 Bayview Blvd, Baltimore, MD 21224 USA.
EM fugmanns@mail.nih.gov
OI Kothapalli, Naga Rama/0000-0001-7993-8525
FU NIH, National Institute on Aging
FX We thank Drs. Nina Papavasiliou and Shu Yuan Yang for helpful comments
and suggestions. This work was supported entirely by the Intramural
Research Program of the NIH, National Institute on Aging.
NR 46
TC 11
Z9 11
U1 0
U2 1
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0952-7915
J9 CURR OPIN IMMUNOL
JI Curr. Opin. Immunol.
PD APR
PY 2011
VL 23
IS 2
BP 184
EP 189
DI 10.1016/j.coi.2010.12.009
PG 6
WC Immunology
SC Immunology
GA 758VW
UT WOS:000290196200006
PM 21295456
ER
PT J
AU Hobbs, EC
Fontaine, F
Yin, XF
Storz, G
AF Hobbs, Errett C.
Fontaine, Fanette
Yin, Xuefeng
Storz, Gisela
TI An expanding universe of small proteins
SO CURRENT OPINION IN MICROBIOLOGY
LA English
DT Review
ID CYTOCHROME B(6)F COMPLEX; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; INHIBITOR
SDA; SMALL RNA; MEMBRANE; PEPTIDES; BACTERIA; TOXIN; NISIN
AB Historically, small proteins (sproteins) of less than 50 amino acids, in their final processed forms or genetically encoded as such, have been understudied. However, both serendipity and more recent focused efforts have led to the identification of a number of new sproteins in both Gram-negative and Gram-positive bacteria. Increasing evidence demonstrates that sproteins participate in a wide array of cellular processes and exhibit great diversity in their mechanisms of action, yet general principles of sprotein function are emerging. This review highlights examples of sproteins that participate in cell signaling, act as antibiotics and toxins, and serve as structural proteins. We also describe roles for sproteins in detecting and altering membrane features, acting as chaperones, and regulating the functions of larger proteins.
C1 [Hobbs, Errett C.; Fontaine, Fanette; Yin, Xuefeng; Storz, Gisela] NICHD, Cell Biol & Metab Program, NIH, Bethesda, MD 20892 USA.
[Yin, Xuefeng] Peking Univ, Sch Basic Life Sci, Beijing 100191, Peoples R China.
RP Storz, G (reprint author), NICHD, Cell Biol & Metab Program, NIH, Bldg 181,Room 101,18 Lib Dr MSC 5430, Bethesda, MD 20892 USA.
EM storz@helix.nih.gov
OI Storz, Gisela/0000-0001-6698-1241
FU NICHD; NIGMS
FX This work was supported by the Intramural Research Program of NICHD and
a fellowship from the Pharmacology Research Associate Training program
of NIGMS (ECH). We thank AB Blanc-Potard, M Goulian, MR Hemm, DB Kearns,
MT Laub, KS Ramamurthi, and members of the Storz lab for helpful
comments and discussions.
NR 43
TC 46
Z9 48
U1 0
U2 15
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1369-5274
J9 CURR OPIN MICROBIOL
JI Curr. Opin. Microbiol.
PD APR
PY 2011
VL 14
IS 2
BP 167
EP 173
DI 10.1016/j.mib.2011.01.007
PG 7
WC Microbiology
SC Microbiology
GA 760YC
UT WOS:000290359700009
PM 21342783
ER
PT J
AU Sultana, A
Nakaya, N
Senatorov, VV
Tomarev, SI
AF Sultana, Afia
Nakaya, Naoki
Senatorov, Vladimir V.
Tomarev, Stanislav I.
TI Olfactomedin 2: Expression in the Eye and Interaction with Other
Olfactomedin Domain-Containing Proteins
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; MUTATED MOUSE;
MYOCILIN; GENE; CELLS; GLYCOPROTEIN; MUTATIONS; ZEBRAFISH
AB PURPOSE. Olfactomedin 2 (OLFM2) belongs to the family of olfactomedin domain-containing proteins. Genetic data suggest its association with glaucoma in Japanese patients. However, its functions are still elusive. In this study, the properties of mammalian OLFM2 were investigated.
METHODS. Expression of the rat and mouse Olfm2 gene was studied by using real-time PCR and in situ hybridization. Substitutions were introduced into OLFM2 by mutagenesis in vitro. Intracellular localization of OLFM2 was studied by confocal microscopy after transient transfection in HEK293 cells. Interaction of OLFM2 with olfactomedin 1 (Olfm1), olfactomedin 3 (Olfm3), myocilin, and gliomedin was studied by using co-immunoprecipitation.
RESULTS. Two major human OLFM2 mRNAs encode secreted proteins with a length of 454 and 478 amino acids. OLFM2 is more closely related to OLFM1 and -3 than to any other family members. Olfm2 showed the most dynamic expression pattern compared with Olfm1 and -3 during mouse eye development and was expressed preferentially in the developing retinal ganglion cell layer. Among three OLFM2 substitutions tested (T86M, R144Q, and L420S), only L420S completely blocked secretion of the protein. OLFM2 interacted with Olfm1 and -3, but not with myocilin and gliomedin. Co-transfection of the L420S mutant with wild-type Olfm1 and -3 significantly inhibited secretion of Olfm1 and -3.
CONCLUSIONS. Highly conserved OLFM2 protein may play an important role in the course of retinal and eye development. Severe mutations in one of the closely related olfactomedin domain-containing proteins (Olfm1-3) may block the secretion and probably the activity of all three family members, leading to more pronounced diseases of the retina than the knockout of individual genes. (Invest Ophthalmol Vis Sci. 2011;52:2584-2592) DOI:10.1167/iovs.10-6356
C1 [Sultana, Afia; Nakaya, Naoki; Senatorov, Vladimir V.; Tomarev, Stanislav I.] NEI, Mol Mech Glaucoma Sect, Lab Mol & Dev Biol, NIH, Bethesda, MD 20892 USA.
RP Tomarev, SI (reprint author), NEI, Mol Mech Glaucoma Sect, Lab Mol & Dev Biol, NIH, 5635 Fishers Lane,Room 1124, Bethesda, MD 20892 USA.
EM tomarevs@nei.nih.gov
FU National Eye Institute, National Institutes of Health
FX Supported by the Intramural Research Program of the National Eye
Institute, National Institutes of Health.
NR 45
TC 9
Z9 13
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2011
VL 52
IS 5
BP 2584
EP 2592
DI 10.1167/iovs.10-6356
PG 9
WC Ophthalmology
SC Ophthalmology
GA 757TQ
UT WOS:000290111000011
PM 21228389
ER
PT J
AU Czobor, P
Skolnick, P
AF Czobor, Pal
Skolnick, Phil
TI The Secrets of a Successful Clinical Trial: Compliance, Compliance, and
Compliance
SO MOLECULAR INTERVENTIONS
LA English
DT Editorial Material
ID MEDICATION; BICIFADINE; ADHERENCE; INHIBITOR; WEIGHT; MODELS; PAIN
C1 [Skolnick, Phil] NIDA, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, Bethesda, MD 20892 USA.
[Czobor, Pal] Semmelweis Univ, Dept Psychiat & Psychotherapy, Budapest, Hungary.
[Czobor, Pal] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA.
RP Skolnick, P (reprint author), NIDA, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, Bethesda, MD 20892 USA.
EM czo-bor@psych.sote.hu; Phil.Skolnick@nih.gov
NR 19
TC 16
Z9 16
U1 0
U2 0
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 1534-0384
J9 MOL INTERV
JI Mol. Interv.
PD APR
PY 2011
VL 11
IS 2
BP 107
EP 110
DI 10.1124/mi.11.2.8
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 758GN
UT WOS:000290151400008
PM 21540470
ER
PT J
AU Myers, RM
Stamatoyannopoulos, J
Snyder, M
Dunham, I
Hardison, RC
Bernstein, BE
Gingeras, TR
Kent, WJ
Birney, E
Wold, B
Crawford, GE
Bernstein, BE
Epstein, CB
Shoresh, N
Ernst, J
Mikkelsen, TS
Kheradpour, P
Zhang, XL
Wang, L
Issner, R
Coyne, MJ
Durham, T
Ku, MC
Truong, T
Ward, LD
Altshuler, RC
Lin, MF
Kellis, M
Gingeras, TR
Davis, CA
Kapranov, P
Dobin, A
Zaleski, C
Schlesinger, F
Batut, P
Chakrabortty, S
Jha, S
Lin, W
Drenkow, J
Wang, HE
Bell, K
Gao, H
Bell, I
Dumais, E
Dumais, J
Antonarakis, SE
Ucla, C
Borel, C
Guigo, R
Djebali, S
Lagarde, J
Kingswood, C
Ribeca, P
Sammeth, M
Alioto, T
Merkel, A
Tilgner, H
Carninci, P
Hayashizaki, Y
Lassmann, T
Takahashi, H
Abdelhamid, RF
Hannon, G
Fejes-Toth, K
Preall, J
Gordon, A
Sotirova, V
Reymond, A
Howald, C
Graison, EAY
Chrast, J
Ruan, YJ
Ruan, XA
Shahab, A
Poh, WT
Wei, CL
Crawford, GE
Furey, TS
Boyle, AP
Sheffield, NC
Song, LY
Shibata, Y
Vales, T
Winter, D
Zhang, ZC
London, D
Wang, TY
Birney, E
Keefe, D
Iyer, VR
Lee, BK
McDaniell, RM
Liu, Z
Battenhouse, A
Bhinge, AA
Lieb, JD
Grasfeder, LL
Showers, KA
Giresi, PG
Kim, SKC
Shestak, C
Myers, RM
Pauli, F
Reddy, TE
Gertz, J
Partridge, EC
Jain, P
Sprouse, RO
Bansal, A
Pusey, B
Muratet, MA
Varley, KE
Bowling, KM
Newberry, KM
Nesmith, AS
Dilocker, JA
Parker, SL
Waite, LL
Thibeault, K
Roberts, K
Absher, DM
Wold, B
Mortazavi, A
Williams, B
Marinov, G
Trout, D
Pepke, S
King, B
McCue, K
Kirilusha, A
DeSalvo, G
Fisher-Aylor, K
Amrhein, H
Vielmetter, J
Sherlock, G
Sidow, A
Batzoglou, S
Rauch, R
Kundaje, A
Libbrecht, M
Margulies, EH
Parker, SCJ
Elnitski, L
Green, ED
Hubbard, T
Harrow, J
Searle, S
Kokocinski, F
Aken, B
Frankish, A
Hunt, T
Despacio-Reyes, G
Kay, M
Mukherjee, G
Bignell, A
Saunders, G
Boychenko, V
Brent, M
Van Baren, MJ
Brown, RH
Gerstein, M
Khurana, E
Balasubramanian, S
Zhang, ZD
Lam, H
Cayting, P
Robilotto, R
Lu, Z
Guigo, R
Derrien, T
Tanzer, A
Knowles, DG
Mariotti, M
Kent, WJ
Haussler, D
Harte, R
Diekhans, M
Kellis, M
Lin, M
Kheradpour, P
Ernst, J
Reymond, A
Howald, C
Graison, EAY
Chrast, J
Valencia, A
Tress, M
Rodriguez, JM
Snyder, M
Landt, SG
Raha, D
Shi, MY
Euskirchen, G
Grubert, F
Kasowski, M
Lian, J
Cayting, P
Lacroute, P
Xu, YH
Monahan, H
Patacsil, D
Slifer, T
Yang, XQ
Charos, A
Reed, B
Wu, LF
Auerbach, RK
Habegger, L
Hariharan, M
Rozowsky, J
Abyzov, A
Weissman, SM
Gerstein, M
Struhl, K
Lamarre-Vincent, N
Lindahl-Allen, M
Miotto, B
Moqtaderi, Z
Fleming, JD
Newburger, P
Farnham, PJ
Frietze, S
O'Geen, H
Xu, XQ
Blahnik, KR
Cao, AR
Iyengar, S
Stamatoyannopoulos, JA
Kaul, R
Thurman, RE
Wang, H
Navas, PA
Sandstrom, R
Sabo, PJ
Weaver, M
Canfield, T
Lee, K
Neph, S
Roach, V
Reynolds, A
Johnson, A
Rynes, E
Giste, E
Vong, S
Neri, J
Frum, T
Johnson, EM
Nguyen, ED
Ebersol, AK
Sanchez, ME
Sheffer, HH
Lotakis, D
Haugen, E
Humbert, R
Kutyavin, T
Shafer, T
Dekker, J
Lajoie, BR
Sanyal, A
Kent, WJ
Rosenbloom, KR
Dreszer, TR
Raney, BJ
Barber, GP
Meyer, LR
Sloan, CA
Malladi, VS
Cline, MS
Learned, K
Swing, VK
Zweig, AS
Rhead, B
Fujita, PA
Roskin, K
Karolchik, D
Kuhn, RM
Haussler, D
Birney, E
Dunham, I
Wilder, SP
Keefe, D
Sobral, D
Herrero, J
Beal, K
Lukk, M
Brazma, A
Vaquerizas, JM
Luscombe, NM
Bickel, PJ
Boley, N
Brown, JB
Li, QH
Huang, HY
Gerstein, M
Habegger, L
Sboner, A
Rozowsky, J
Auerbach, RK
Yip, KY
Cheng, C
Yan, KK
Bhardwaj, N
Wang, J
Lochovsky, L
Jee, J
Gibson, T
Leng, J
Du, J
Hardison, RC
Harris, RS
Song, G
Miller, W
Haussler, D
Roskin, K
Suh, B
Wang, T
Paten, B
Noble, WS
Hoffman, MM
Buske, OJ
Weng, ZP
Dong, XJ
Wang, J
Xi, HL
Tenenbaum, SA
Doyle, F
Penalva, LO
Chittur, S
Tullius, TD
Parker, SCJ
White, KP
Karmakar, S
Victorsen, A
Jameel, N
Bild, N
Grossman, RL
Snyder, M
Landt, SG
Yang, XQ
Patacsil, D
Slifer, T
Dekker, J
Lajoie, BR
Sanyal, A
Weng, ZP
Whitfield, TW
Wang, J
Collins, PJ
Trinklein, ND
Partridge, EC
Myers, RM
Giddings, MC
Chen, X
Khatun, J
Maier, C
Yu, YB
Gunawardena, H
Risk, B
Feingold, EA
Lowdon, RF
Dillon, LAL
Good, PJ
AF Myers, Richard M.
Stamatoyannopoulos, John
Snyder, Michael
Dunham, Ian
Hardison, Ross C.
Bernstein, Bradley E.
Gingeras, Thomas R.
Kent, W. James
Birney, Ewan
Wold, Barbara
Crawford, Gregory E.
Bernstein, Bradley E.
Epstein, Charles B.
Shoresh, Noam
Ernst, Jason
Mikkelsen, Tarjei S.
Kheradpour, Pouya
Zhang, Xiaolan
Wang, Li
Issner, Robbyn
Coyne, Michael J.
Durham, Timothy
Ku, Manching
Thanh Truong
Ward, Lucas D.
Altshuler, Robert C.
Lin, Michael F.
Kellis, Manolis
Gingeras, Thomas R.
Davis, Carrie A.
Kapranov, Philipp
Dobin, Alexander
Zaleski, Christopher
Schlesinger, Felix
Batut, Philippe
Chakrabortty, Sudipto
Jha, Sonali
Lin, Wei
Drenkow, Jorg
Wang, Huaien
Bell, Kim
Gao, Hui
Bell, Ian
Dumais, Erica
Dumais, Jacqueline
Antonarakis, Stylianos E.
Ucla, Catherine
Borel, Christelle
Guigo, Roderic
Djebali, Sarah
Lagarde, Julien
Kingswood, Colin
Ribeca, Paolo
Sammeth, Micha
Alioto, Tyler
Merkel, Angelika
Tilgner, Hagen
Carninci, Piero
Hayashizaki, Yoshihide
Lassmann, Timo
Takahashi, Hazuki
Abdelhamid, Rehab F.
Hannon, Gregory
Fejes-Toth, Katalin
Preall, Jonathan
Gordon, Assaf
Sotirova, Vihra
Reymond, Alexandre
Howald, Cedric
Graison, Emilie Ait Yahya
Chrast, Jacqueline
Ruan, Yijun
Ruan, Xiaoan
Shahab, Atif
Poh, Wan Ting
Wei, Chia-Lin
Crawford, Gregory E.
Furey, Terrence S.
Boyle, Alan P.
Sheffield, Nathan C.
Song, Lingyun
Shibata, Yoichiro
Vales, Teresa
Winter, Deborah
Zhang, Zhancheng
London, Darin
Wang, Tianyuan
Birney, Ewan
Keefe, Damian
Iyer, Vishwanath R.
Lee, Bum-Kyu
McDaniell, Ryan M.
Liu, Zheng
Battenhouse, Anna
Bhinge, Akshay A.
Lieb, Jason D.
Grasfeder, Linda L.
Showers, Kimberly A.
Giresi, Paul G.
Kim, Seul K. C.
Shestak, Christopher
Myers, Richard M.
Pauli, Florencia
Reddy, Timothy E.
Gertz, Jason
Partridge, E. Christopher
Jain, Preti
Sprouse, Rebekka O.
Bansal, Anita
Pusey, Barbara
Muratet, Michael A.
Varley, Katherine E.
Bowling, Kevin M.
Newberry, Kimberly M.
Nesmith, Amy S.
Dilocker, Jason A.
Parker, Stephanie L.
Waite, Lindsay L.
Thibeault, Krista
Roberts, Kevin
Absher, Devin M.
Wold, Barbara
Mortazavi, Ali
Williams, Brian
Marinov, Georgi
Trout, Diane
Pepke, Shirley
King, Brandon
McCue, Kenneth
Kirilusha, Anthony
DeSalvo, Gilberto
Fisher-Aylor, Katherine
Amrhein, Henry
Vielmetter, Jost
Sherlock, Gavin
Sidow, Arend
Batzoglou, Serafim
Rauch, Rami
Kundaje, Anshul
Libbrecht, Max
Margulies, Elliott H.
Parker, Stephen C. J.
Elnitski, Laura
Green, Eric D.
Hubbard, Tim
Harrow, Jennifer
Searle, Stephen
Kokocinski, Felix
Aken, Browen
Frankish, Adam
Hunt, Toby
Despacio-Reyes, Gloria
Kay, Mike
Mukherjee, Gaurab
Bignell, Alexandra
Saunders, Gary
Boychenko, Veronika
Brent, Michael
Van Baren, M. J.
Brown, Randall H.
Gerstein, Mark
Khurana, Ekta
Balasubramanian, Suganthi
Zhang, Zhengdong
Lam, Hugo
Cayting, Philip
Robilotto, Rebecca
Lu, Zhi
Guigo, Roderic
Derrien, Thomas
Tanzer, Andrea
Knowles, David G.
Mariotti, Marco
Kent, W. James
Haussler, David
Harte, Rachel
Diekhans, Mark
Kellis, Manolis
Lin, Mike
Kheradpour, Pouya
Ernst, Jason
Reymond, Alexandre
Howald, Cedric
Graison, Emilie Ait Yahya
Chrast, Jacqueline
Valencia, Alfonso
Tress, Michael
Manuel Rodriguez, Jose
Snyder, Michael
Landt, Stephen G.
Raha, Debasish
Shi, Minyi
Euskirchen, Ghia
Grubert, Fabian
Kasowski, Maya
Lian, Jin
Cayting, Philip
Lacroute, Phil
Xu, Youhan
Monahan, Hannah
Patacsil, Dorrelyn
Slifer, Teri
Yang, Xinqiong
Charos, Alexandra
Reed, Brian
Wu, Linfeng
Auerbach, Raymond K.
Habegger, Lukas
Hariharan, Manoj
Rozowsky, Joel
Abyzov, Alexej
Weissman, Sherman M.
Gerstein, Mark
Struhl, Kevin
Lamarre-Vincent, Nathan
Lindahl-Allen, Marianne
Miotto, Benoit
Moqtaderi, Zarmik
Fleming, Joseph D.
Newburger, Peter
Farnham, Peggy J.
Frietze, Seth
O'Geen, Henriette
Xu, Xiaoqin
Blahnik, Kim R.
Cao, Alina R.
Iyengar, Sushma
Stamatoyannopoulos, John A.
Kaul, Rajinder
Thurman, Robert E.
Wang, Hao
Navas, Patrick A.
Sandstrom, Richard
Sabo, Peter J.
Weaver, Molly
Canfield, Theresa
Lee, Kristen
Neph, Shane
Roach, Vaughan
Reynolds, Alex
Johnson, Audra
Rynes, Eric
Giste, Erika
Vong, Shinny
Neri, Jun
Frum, Tristan
Johnson, Ericka M.
Nguyen, Eric D.
Ebersol, Abigail K.
Sanchez, Minerva E.
Sheffer, Hadar H.
Lotakis, Dimitra
Haugen, Eric
Humbert, Richard
Kutyavin, Tanya
Shafer, Tony
Dekker, Job
Lajoie, Bryan R.
Sanyal, Amartya
Kent, W. James
Rosenbloom, Kate R.
Dreszer, Timothy R.
Raney, Brian J.
Barber, Galt P.
Meyer, Laurence R.
Sloan, Cricket A.
Malladi, Venkat S.
Cline, Melissa S.
Learned, Katrina
Swing, Vanessa K.
Zweig, Ann S.
Rhead, Brooke
Fujita, Pauline A.
Roskin, Krishna
Karolchik, Donna
Kuhn, Robert M.
Haussler, David
Birney, Ewan
Dunham, Ian
Wilder, Steven P.
Keefe, Damian
Sobral, Daniel
Herrero, Javier
Beal, Kathryn
Lukk, Margus
Brazma, Alvis
Vaquerizas, Juan M.
Luscombe, Nicholas M.
Bickel, Peter J.
Boley, Nathan
Brown, James B.
Li, Qunhua
Huang, Haiyan
Gerstein, Mark
Habegger, Lukas
Sboner, Andrea
Rozowsky, Joel
Auerbach, Raymond K.
Yip, Kevin Y.
Cheng, Chao
Yan, Koon-Kiu
Bhardwaj, Nitin
Wang, Jing
Lochovsky, Lucas
Jee, Justin
Gibson, Theodore
Leng, Jing
Du, Jiang
Hardison, Ross C.
Harris, Robert S.
Song, Giltae
Miller, Webb
Haussler, David
Roskin, Krishna
Suh, Bernard
Wang, Ting
Paten, Benedict
Noble, William S.
Hoffman, Michael M.
Buske, Orion J.
Weng, Zhiping
Dong, Xianjun
Wang, Jie
Xi, Hualin
Tenenbaum, Scott A.
Doyle, Frank
Penalva, Luiz O.
Chittur, Sridar
Tullius, Thomas D.
Parker, Stephen C. J.
White, Kevin P.
Karmakar, Subhradip
Victorsen, Alec
Jameel, Nader
Bild, Nick
Grossman, Robert L.
Snyder, Michael
Landt, Stephen G.
Yang, Xinqiong
Patacsil, Dorrelyn
Slifer, Teri
Dekker, Job
Lajoie, Bryan R.
Sanyal, Amartya
Weng, Zhiping
Whitfield, Troy W.
Wang, Jie
Collins, Patrick J.
Trinklein, Nathan D.
Partridge, E. Christopher
Myers, Richard M.
Giddings, Morgan C.
Chen, Xian
Khatun, Jainab
Maier, Chris
Yu, Yanbao
Gunawardena, Harsha
Risk, Brian
Feingold, Elise A.
Lowdon, Rebecca F.
Dillon, Laura A. L.
Good, Peter J.
CA ENCODE Project Consortium
TI A User's Guide to the Encyclopedia of DNA Elements (ENCODE)
SO PLOS BIOLOGY
LA English
DT Article
ID EMBRYONIC STEM-CELLS; CHROMOSOME CONFORMATION CAPTURE; TRANSCRIPTION
FACTOR-BINDING; MESSENGER-RNA SUBSETS; UCSC GENOME BROWSER;
COLORECTAL-CANCER; IN-VIVO; COPY-NUMBER; RIBONUCLEOPROTEIN COMPLEXES;
DEVELOPMENTAL REGULATORS
AB The mission of the Encyclopedia of DNA Elements (ENCODE) Project is to enable the scientific and medical communities to interpret the human genome sequence and apply it to understand human biology and improve health. The ENCODE Consortium is integrating multiple technologies and approaches in a collective effort to discover and define the functional elements encoded in the human genome, including genes, transcripts, and transcriptional regulatory regions, together with their attendant chromatin states and DNA methylation patterns. In the process, standards to ensure high-quality data have been implemented, and novel algorithms have been developed to facilitate analysis. Data and derived results are made available through a freely accessible database. Here we provide an overview of the project and the resources it is generating and illustrate the application of ENCODE data to interpret the human genome.
C1 [Pauli, Florencia; Partridge, E. Christopher; Bansal, Anita; Pusey, Barbara; Nesmith, Amy S.; Dilocker, Jason A.; Absher, Devin M.] HudsonAlpha Inst Biotechnol, Huntsville, AL USA.
[Stamatoyannopoulos, John; Stamatoyannopoulos, John A.; Kaul, Rajinder; Thurman, Robert E.; Wang, Hao; Navas, Patrick A.; Sandstrom, Richard; Sabo, Peter J.; Weaver, Molly; Canfield, Theresa; Lee, Kristen; Neph, Shane; Roach, Vaughan; Reynolds, Alex; Johnson, Audra; Rynes, Eric; Giste, Erika; Vong, Shinny; Neri, Jun; Frum, Tristan; Johnson, Ericka M.; Nguyen, Eric D.; Ebersol, Abigail K.; Sanchez, Minerva E.; Sheffer, Hadar H.; Lotakis, Dimitra; Haugen, Eric; Humbert, Richard; Kutyavin, Tanya; Shafer, Tony; Noble, William S.; Hoffman, Michael M.; Buske, Orion J.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
[Snyder, Michael; Sherlock, Gavin; Sidow, Arend; Rauch, Rami; Cayting, Philip; Landt, Stephen G.; Shi, Minyi; Euskirchen, Ghia; Grubert, Fabian; Lacroute, Phil; Patacsil, Dorrelyn; Slifer, Teri; Yang, Xinqiong; Wu, Linfeng; Hariharan, Manoj] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.
[Dunham, Ian; Birney, Ewan; Keefe, Damian; Wilder, Steven P.; Sobral, Daniel; Herrero, Javier; Beal, Kathryn; Lukk, Margus; Brazma, Alvis; Vaquerizas, Juan M.; Luscombe, Nicholas M.] European Bioinformat Inst EBI, Cambridge, England.
[Hardison, Ross C.; Harris, Robert S.; Song, Giltae; Miller, Webb] Penn State Univ, Dept Biochem & Mol Biol, Ctr Comparat Genom & Bioinformat, University Pk, PA 16802 USA.
[Bernstein, Bradley E.; Epstein, Charles B.; Shoresh, Noam; Ernst, Jason; Mikkelsen, Tarjei S.; Kheradpour, Pouya; Zhang, Xiaolan; Wang, Li; Issner, Robbyn; Coyne, Michael J.; Durham, Timothy; Ku, Manching; Ward, Lucas D.; Lin, Michael F.; Kellis, Manolis; Sidow, Arend; Lin, Mike] Broad Inst MT & Harvard, Cambridge, MA USA.
Howard Hughes Med Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Lian, Jin; Weissman, Sherman M.] Harvard Univ, Sch Med, Boston, MA USA.
[Gingeras, Thomas R.; Davis, Carrie A.; Dobin, Alexander; Zaleski, Christopher; Schlesinger, Felix; Batut, Philippe; Chakrabortty, Sudipto; Jha, Sonali; Lin, Wei; Drenkow, Jorg; Wang, Huaien; Bell, Kim; Fejes-Toth, Katalin; Preall, Jonathan; Gordon, Assaf; Sotirova, Vihra] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
[Haussler, David; Rosenbloom, Kate R.; Raney, Brian J.; Barber, Galt P.; Sloan, Cricket A.; Zweig, Ann S.; Rhead, Brooke; Suh, Bernard; Paten, Benedict] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA.
[Wold, Barbara; Mortazavi, Ali; Kirilusha, Anthony; Reynolds, Alex; Ebersol, Abigail K.] CALTECH, Div Biol, Pasadena, CA 91125 USA.
[Mortazavi, Ali] CALTECH, Beckman Inst, Pasadena, CA 91125 USA.
[Crawford, Gregory E.; Boyle, Alan P.; Winter, Deborah; London, Darin] Duke Univ, Inst Genome Sci & Policy, Durham, NC USA.
Duke Univ, Dept Pediat, Durham, NC 27706 USA.
MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
[Kapranov, Philipp; Bell, Ian; Dumais, Erica; Dumais, Jacqueline] Affymetrix, Santa Clara, CA USA.
[Gao, Hui] Karolinska Inst, Huddinge, Sweden.
[Antonarakis, Stylianos E.; Ucla, Catherine; Borel, Christelle] Univ Geneva, Geneva, Switzerland.
[Guigo, Roderic; Lagarde, Julien; Kingswood, Colin; Ribeca, Paolo; Sammeth, Micha; Merkel, Angelika; Tilgner, Hagen; Tanzer, Andrea; Knowles, David G.; Mariotti, Marco] Ctr Regulacio Genom, Barcelona, Spain.
[Carninci, Piero; Hayashizaki, Yoshihide; Lassmann, Timo; Takahashi, Hazuki; Abdelhamid, Rehab F.] RIKEN Yokohama Inst, Omics Sci Ctr, Kanagawa, Japan.
[Hannon, Gregory] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA.
[Reymond, Alexandre] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland.
[Iyer, Vishwanath R.; Lee, Bum-Kyu; McDaniell, Ryan M.; Liu, Zheng; Battenhouse, Anna; Bhinge, Akshay A.] Univ Texas Austin, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, Ctr Syst & Synthet Biol, Austin, TX 78712 USA.
[Lieb, Jason D.; Grasfeder, Linda L.; Showers, Kimberly A.; Giresi, Paul G.; Kim, Seul K. C.; Shestak, Christopher] Univ N Carolina, Carolina Ctr Genome Sci, Dept Biol, Chapel Hill, NC USA.
[Lieb, Jason D.; Grasfeder, Linda L.; Showers, Kimberly A.; Giresi, Paul G.; Kim, Seul K. C.; Shestak, Christopher] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
[Pepke, Shirley] CALTECH, Ctr Adv Comp Res, Pasadena, CA 91125 USA.
[Sidow, Arend; Kundaje, Anshul] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.
[Batzoglou, Serafim; Kundaje, Anshul; Libbrecht, Max] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA.
[Margulies, Elliott H.; Parker, Stephen C. J.; Parker, Stephen C. J.] NHGRI, Div Intramural Res, NIH, Bethesda, MD 20892 USA.
[Elnitski, Laura] NHGRI, Genome Technol Branch, NIH, Rockville, MD USA.
[Green, Eric D.] NHGRI, NIH Intramural Sequencing Ctr, NIH, Bethesda, MD 20892 USA.
[Hubbard, Tim; Harrow, Jennifer; Searle, Stephen; Kokocinski, Felix; Aken, Browen; Frankish, Adam; Hunt, Toby; Despacio-Reyes, Gloria; Kay, Mike; Mukherjee, Gaurab; Bignell, Alexandra; Saunders, Gary; Boychenko, Veronika] Wellcome Trust Sanger Inst, Hinxton, Cambs, England.
[Boyle, Alan P.; Bhinge, Akshay A.; Frankish, Adam; Bignell, Alexandra; Khurana, Ekta; Lam, Hugo; Valencia, Alfonso; Charos, Alexandra; Rozowsky, Joel; Abyzov, Alexej; Ebersol, Abigail K.; Brown, James B.; Sboner, Andrea; Cheng, Chao; Wang, Jing; Leng, Jing] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA.
[Khurana, Ekta; Lam, Hugo; Abyzov, Alexej; Sboner, Andrea; Cheng, Chao; Wang, Jing; Leng, Jing] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT USA.
[Gerstein, Mark; Du, Jiang] Yale Univ, Dept Comp Sci, New Haven, CT 06520 USA.
Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA.
[Valencia, Alfonso; Tress, Michael; Manuel Rodriguez, Jose] Ctr Nacl Invest Oncol, Madrid, Spain.
[Raha, Debasish; Kasowski, Maya; Xu, Youhan; Monahan, Hannah; Charos, Alexandra; Reed, Brian] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA.
[Lian, Jin; Weissman, Sherman M.] Yale Univ, Dept Genet, New Haven, CT USA.
[Newburger, Peter; Farnham, Peggy J.] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA USA.
[Frietze, Seth; O'Geen, Henriette] Univ So Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA USA.
[Frietze, Seth; O'Geen, Henriette; Xu, Xiaoqin; Blahnik, Kim R.; Cao, Alina R.; Iyengar, Sushma] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA.
[Sanyal, Amartya] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Program Gene Funct & Express, Worcester, MA USA.
[Bickel, Peter J.; Li, Qunhua; Huang, Haiyan] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA.
[Wang, Ting] Washington Univ, Dept Genet, St Louis, MO 63110 USA.
[Noble, William S.] Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA.
[Wang, Jie] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Program Bioinformat & Integrat Biol, Worcester, MA USA.
[Xi, Hualin] Boston Univ, Bioinformat Program, Boston, MA 02215 USA.
[Tenenbaum, Scott A.; Doyle, Frank; Chittur, Sridar] SUNY Albany, Coll Nanoscale Sci & Engn, Albany, NY 12222 USA.
[Penalva, Luiz O.] Childrens Canc Res Inst, Dept Cellular & Struct Biol, San Antonio, TX USA.
[Tullius, Thomas D.; Parker, Stephen C. J.] Boston Univ, Dept Chem, Boston, MA 02215 USA.
[Tullius, Thomas D.; Parker, Stephen C. J.] Boston Univ, Program Bioinformat, Boston, MA 02215 USA.
[White, Kevin P.; Karmakar, Subhradip; Victorsen, Alec; Jameel, Nader; Bild, Nick; Grossman, Robert L.] Univ Chicago, Inst Genom & Syst Biol, Chicago, IL 60637 USA.
[Collins, Patrick J.; Trinklein, Nathan D.] SwitchGear Genom, Menlo Pk, CA USA.
[Giddings, Morgan C.; Khatun, Jainab; Maier, Chris] Boise State Univ, Biomol Res Ctr, Boise, ID 83725 USA.
[Giddings, Morgan C.; Risk, Brian] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA.
[Giddings, Morgan C.; Yu, Yanbao; Gunawardena, Harsha] Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA.
[Chen, Xian; Feingold, Elise A.; Lowdon, Rebecca F.; Dillon, Laura A. L.; Good, Peter J.] NHGRI, NIH, Bethesda, MD 20892 USA.
RP Myers, RM (reprint author), HudsonAlpha Inst Biotechnol, Huntsville, AL USA.
RI Alioto, Tyler/K-7267-2015; Hubbard, Tim/C-2567-2008; Tanzer,
Andrea/L-3147-2015; Valencia, Alfonso/I-3127-2015; Hariharan,
Manoj/N-2855-2015; Boyle, Alan/I-1848-2014; Hoffman,
Michael/I-1924-2012; Khurana, Ekta/C-4933-2013; Yan,
Koon-Kiu/A-5940-2009; Yu, Yanbao/G-3035-2010; Schlesinger,
Felix/E-2143-2011; Vaquerizas, Juan/F-2676-2011; Wang, Jie/F-9747-2011;
Frankish, Adam/G-6545-2011; Liu, Zheng/G-2612-2011; Sboner,
Andrea/C-6487-2008; Sincan, Murat /A-3794-2010; Dong,
Xianjun/B-5334-2012; Mikkelsen, Tarjei/A-1306-2007; Sherlock,
Gavin/E-9110-2012; Lassmann, Timo/A-8271-2008; Tullius,
Thomas/A-9685-2008; Abyzov, Alexej/M-4284-2013; Sobral,
Daniel/B-4786-2014; Sammeth, Michael/C-1157-2014; Carninci,
Piero/K-1568-2014; Dong, Xianjun/N-3867-2014; Antonarakis,
Stylianos/N-8866-2014; Djebali, Sarah/O-9817-2014; SANYAL,
AMARTYA/D-7240-2015; Brown, James/H-2971-2015; cheng, yong/I-4270-2012;
Guigo, Roderic/D-1303-2010; Hardison, Ross/G-1142-2010;
OI Alioto, Tyler/0000-0002-2960-5420; Hubbard, Tim/0000-0002-1767-9318;
Tanzer, Andrea/0000-0003-2873-4236; Valencia,
Alfonso/0000-0002-8937-6789; Hariharan, Manoj/0000-0002-1006-5372;
Boyle, Alan/0000-0002-2081-1105; Marinov, Georgi/0000-0003-1822-7273;
Gingeras, Thomas/0000-0001-9106-3573; Hunt, Toby/0000-0001-8377-0841;
Song, Giltae/0000-0001-8796-4678; Sheffield, Nathan/0000-0001-5643-4068;
Hoffman, Michael/0000-0002-4517-1562; Yu, Yanbao/0000-0003-2994-1974;
Vaquerizas, Juan/0000-0002-6583-6541; Sboner,
Andrea/0000-0001-6915-3070; Mikkelsen, Tarjei/0000-0002-8133-3135;
Saunders, Gary/0000-0002-7468-0008; Furey, Terry/0000-0001-5546-9672;
Merkel, Angelika/0000-0001-5164-6803; Ward, Lucas/0000-0002-8017-809X;
Dunham, Ian/0000-0003-2525-5598; Aken, Bronwen/0000-0002-3032-4095;
Grossman, Robert/0000-0003-3741-5739; Lassmann,
Timo/0000-0002-0138-2691; Tullius, Thomas/0000-0003-4425-796X; Sobral,
Daniel/0000-0003-3955-0117; Sammeth, Michael/0000-0002-6528-9883;
Carninci, Piero/0000-0001-7202-7243; Dong, Xianjun/0000-0002-8052-9320;
Antonarakis, Stylianos/0000-0001-8907-5823; Djebali,
Sarah/0000-0002-0599-1267; SANYAL, AMARTYA/0000-0002-2109-4478; Guigo,
Roderic/0000-0002-5738-4477; Hardison, Ross/0000-0003-4084-7516;
Herrero, Javier/0000-0001-7313-717X; Haugen, Eric/0000-0001-7444-8981;
Wilder, Steven/0000-0001-8049-2559; Newburger,
Peter/0000-0002-8615-673X; Winter, Deborah/0000-0003-1806-673X; Birney,
Ewan/0000-0001-8314-8497; Sherlock, Gavin/0000-0002-1692-4983; Rozowsky,
Joel/0000-0002-3565-0762; Farnham, Peggy/0000-0003-4469-7914; Brazma,
Alvis/0000-0001-5988-7409
FU National Human Genome Research Institute, National Institutes of Health,
Bethesda, MD, USA
FX Funded by the National Human Genome Research Institute, National
Institutes of Health, Bethesda, MD, USA. The role of the NIH Project
Management Group in the preparation of this paper was limited to
coordination and scientific management of the ENCODE Consortium.
NR 121
TC 156
Z9 161
U1 11
U2 96
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1544-9173
J9 PLOS BIOL
JI PLoS. Biol.
PD APR
PY 2011
VL 9
IS 4
AR e1001046
DI 10.1371/journal.pbio.1001046
PG 21
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics
GA 755NM
UT WOS:000289938900014
ER
PT J
AU McCormack, LA
Treiman, K
Rupert, D
Williams-Piehota, P
Nadler, E
Arora, NK
Lawrence, W
Street, RL
AF McCormack, Lauren A.
Treiman, Katherine
Rupert, Douglas
Williams-Piehota, Pamela
Nadler, Eric
Arora, Neeraj K.
Lawrence, William
Street, Richard L., Jr.
TI Measuring patient-centered communication in cancer care: A literature
review and the development of a systematic approach
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Review
DE Patient-centered communication; Conceptual framework; Measurement;
Cancer care; Review; USA
ID SELF-DETERMINATION THEORY; SHARED DECISION-MAKING; BREAST-CANCER;
PHYSICIAN COMMUNICATION; PATIENTS PERSPECTIVES; STANDARDIZED PATIENTS;
PATIENTS PREFERENCES; PATIENTS PERCEPTIONS; AFRICAN-AMERICAN; HUMAN
CONNECTION
AB Patient-centered communication (PCC) is a critical element of patient-centered care, which the Institute of Medicine (Committee on Quality of Health Care in America, 2001) promulgates as essential to improving healthcare delivery. Consequently, the US National Cancer Institute's Strategic Plan for Leading the Nation (2006) calls for assessing the delivery of PCC in cancer care. However, no comprehensive measure of PCC exists, and stakeholders continue to embrace different conceptualizations and assumptions about how to measure it. Our approach was grounded in the PCC conceptual framework presented in a recent US National Cancer Institute monograph (Epstein & Street, 2007). In this study, we developed a comprehensive inventory of domains and subdomains for PCC by reviewing relevant literature and theories, interviewing a limited number of cancer patients, and consulting experts. The resulting measurement domains are organized under the six core functions specified in the PCC conceptual framework: exchanging information, fostering healing relationships, recognizing and responding to emotions, managing uncertainty, making decisions, and enabling patient self-management. These domains represent a promising platform for operationalizing the complicated PCC construct. Although this study focused specifically on cancer care, the PCC measurements are relevant to other clinical contexts and illnesses, given that patient-centered care is a goal across all healthcare. Finally, we discuss considerations for developing PCC measures for research, quality assessment, and surveillance purposes.
United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute (2006). The NCI Strategic Plan for Leading the Nation: To Eliminate the Suffering and Death Due to Cancer. NIH Publication No. 06-5773. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [McCormack, Lauren A.; Rupert, Douglas; Williams-Piehota, Pamela] RTI Int, Hlth Commun Program, Res Triangle Pk, NC 27709 USA.
[Treiman, Katherine] RTI Int, Hlth Commun Program, Rockville, MD 20852 USA.
[Nadler, Eric] Baylor Univ, Med Ctr, Charles Sammons Canc Ctr, Dallas, TX 75246 USA.
[Arora, Neeraj K.] NCI, Outcomes Res Branch, ARP, DCCPS, Bethesda, MD 20892 USA.
[Lawrence, William] Agcy Healthcare Res & Qual, Ctr Outcomes & Evidence, Rockville, MD 20850 USA.
[Street, Richard L., Jr.] Texas A&M Univ, Dept Commun, College Stn, TX 77843 USA.
RP McCormack, LA (reprint author), RTI Int, Hlth Commun Program, 3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA.
EM Lmac@rti.org; Ktreiman@rti.org; drupert@rti.org; ppiehota@rti.org;
Eric.Nadler@oncologytoday.com; aroran@mail.nih.gov;
william.lawrence@ahrq.hhs.gov; r-street@tamu.edu
NR 84
TC 63
Z9 63
U1 4
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD APR
PY 2011
VL 72
IS 7
BP 1085
EP 1095
DI 10.1016/j.socscimed.2011.01.020
PG 11
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 757DN
UT WOS:000290065000011
PM 21376443
ER
PT J
AU Anthis, NJ
Campbell, ID
AF Anthis, Nicholas J.
Campbell, Iain D.
TI The tail of integrin activation
SO TRENDS IN BIOCHEMICAL SCIENCES
LA English
DT Review
ID BINDING-LIKE DOMAIN; STRUCTURAL BASIS; CELL-MIGRATION; CYTOPLASMIC
DOMAIN; FILAMIN BINDING; TALIN HEAD; THERAPEUTIC TARGETS;
CRYSTAL-STRUCTURE; FOCAL ADHESIONS; TRANSMEMBRANE
AB Integrins are essential adhesion receptors found on the surfaces of all metazoan cells. As regulators of cell migration and extracellular matrix assembly, these membrane-spanning heterodimers are critical for embryonic development, tissue repair and immune responses. Signals transmitted by integrins from outside to inside the cell promote cell survival and proliferation, but integrin affinity for extracellular ligands can also be controlled by intracellular cues. This bidirectional signaling is mediated by the short cytoplasmic tails of the two integrin subunits. Recent structural and functional studies of various integrin fragments and complexes between the cytoplasmic tails and intracellular proteins, such as talin, have provided new insight into the signaling processes centered around the tails, particularly inside-out integrin activation.
C1 [Campbell, Iain D.] Univ Oxford, Dept Biochem, Oxford OX1 3DR, England.
[Anthis, Nicholas J.] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
RP Campbell, ID (reprint author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3DR, England.
EM iain.campbell@bioch.ox.ac.uk
FU BBSRC; MRC; NIH cell migration consortium; NIH
FX IDC thanks BBSRC, MRC and the NIH cell migration consortium for
financial support. NJA is currently supported by an NIH post-doctoral
grant.
NR 85
TC 78
Z9 78
U1 4
U2 36
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0968-0004
J9 TRENDS BIOCHEM SCI
JI Trends Biochem.Sci.
PD APR
PY 2011
VL 36
IS 4
BP 191
EP 198
DI 10.1016/j.tibs.2010.11.002
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 757XH
UT WOS:000290121400003
PM 21216149
ER
PT J
AU Cortez, KJ
Maldarelli, F
AF Cortez, Karoll J.
Maldarelli, Frank
TI Clinical Management of HIV Drug Resistance
SO VIRUSES-BASEL
LA English
DT Review
DE HIV; drug resistance testing; clinical management
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY;
REVERSE-TRANSCRIPTASE INHIBITORS; NON-B SUBTYPES; SUSTAINED VIROLOGICAL
SUPPRESSION; TREATMENT-EXPERIENCED PATIENTS; RANDOMIZED
CONTROLLED-TRIAL; TREATMENT-NAIVE PATIENTS; SINGLE-DOSE NEVIRAPINE;
ROCHE COBAS AMPLICOR
AB Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug toxicity and the emergence of drug resistance. Management of clinical drug resistance requires in depth evaluation, and includes extensive history, physical examination and laboratory studies. Appropriate use of resistance testing provides valuable information useful in constructing regimens for treatment-experienced individuals with viremia during therapy. This review outlines the emergence of drug resistance in vivo, and describes clinical evaluation and therapeutic options of the individual with rebound viremia during therapy.
C1 [Cortez, Karoll J.; Maldarelli, Frank] NCI, HIV Drug Resistance Program, NIH, Bethesda, MD 20892 USA.
RP Maldarelli, F (reprint author), NCI, HIV Drug Resistance Program, NIH, Bldg 10 Rm 5A06, Bethesda, MD 20892 USA.
EM karoll.cortez@fda.hhs.gov; fmalli@mail.nih.gov
NR 176
TC 28
Z9 29
U1 0
U2 3
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD APR
PY 2011
VL 3
IS 4
BP 347
EP 378
DI 10.3390/v3040347
PG 32
WC Virology
SC Virology
GA 760FE
UT WOS:000290309100006
PM 21994737
ER
PT J
AU Reznick, JS
AF Reznick, Jeffrey S.
TI Reconstructing the Body: Classicism, Modernism, and the First World War
SO AMERICAN HISTORICAL REVIEW
LA English
DT Book Review
C1 [Reznick, Jeffrey S.] US Natl Lib Med, Bethesda, MD USA.
RP Reznick, JS (reprint author), US Natl Lib Med, Bethesda, MD USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-8762
J9 AM HIST REV
JI Am. Hist. Rev.
PD APR
PY 2011
VL 116
IS 2
BP 418
EP 419
PG 2
WC History
SC History
GA 751HE
UT WOS:000289607300021
ER
PT J
AU Kim, TH
Jiang, HH
Lee, S
Youn, YS
Park, CW
Byun, Y
Chen, XY
Lee, KC
AF Kim, Tae Hyung
Jiang, Hai Hua
Lee, Seulki
Youn, Yu Seok
Park, Chan Woong
Byun, Youngro
Chen, Xiaoyuan
Lee, Kang Choon
TI Mono-PEGylated Dimeric Exendin-4 as High Receptor Binding and
Long-Acting Conjugates for Type 2 Anti-Diabetes Therapeutics
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID GLUCAGON-LIKE PEPTIDE-1; SYNTHETIC EXENDIN-4; GLYCEMIC CONTROL; DB/DB
MICE; IN-VIVO; EXENATIDE; GLUCOSE; CHAIN; INHIBITORS; RELEASE
AB Dimerization is viewed as the most effective means of increasing receptor binding affinity, and both dimerization and PEGylation effectively prolong the life spans of short-lived peptides and proteins in vivo by delaying excretion via the renal route. Here, we describe the high binding affinities of two long-acting exendin-4 (Ex4) conjugates, dimerized Ex4 (Di-Ex4) and PEGylated Di-Ex-4 (PEG-Di-Ex4). Di-Ex4 and PEG-Di-Ex4 were prepared using cysteine and amine residue specific coupling reactions using Ex4-Cys, bisMal-NH(2), and activated PEG. The Ex4 conjugates produced were of high purity (>98.5%), as determined by size-exclusion chromatography and MALDI-TOF mass spectrometry. The receptor binding affinity of Di-Ex4 on RIN-m5F cells was 3.5-fold higher than that of Ex4, and the in vivo antihyperglycemic efficacy of Di-Ex4 was also greater than that of native Ex4 in type 2 diabetic db/db mice. Furthermore, Di-Ex4 and PEG-Di-Ex4 were found to have greater blood circulating t(1/2) and AUC(inf) values than native Ex4 by 2.7- and 13.7-fold, and by 4.0- and 17.3-fold, respectively. Accordingly, hypoglycemic durations were greatly increased to 15.0 and 40.1 h, respectively, at a dose of 25 nmol/kg; (native Ex4 7.3 h). The results of this study show that combined dimerization and PEGylation are effective when applied to Ex4, and suggest that PEG-Di-Ex4 has considerable potential as a type 2 anti-diabetic agent.
C1 [Kim, Tae Hyung; Jiang, Hai Hua; Park, Chan Woong; Lee, Kang Choon] Sungkyunkwan Univ, Coll Pharm, Suwon 440746, South Korea.
[Lee, Seulki; Chen, Xiaoyuan] NIBIB, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA.
[Youn, Yu Seok] Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea.
[Byun, Youngro] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.
RP Lee, KC (reprint author), Sungkyunkwan Univ, Coll Pharm, 300 Chonchon Dong, Suwon 440746, South Korea.
EM kclee@skku.edu
RI BYUN, YOUNG RO/D-5735-2013
NR 34
TC 19
Z9 19
U1 0
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD APR
PY 2011
VL 22
IS 4
BP 625
EP 632
DI 10.1021/bc100404x
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 751JM
UT WOS:000289613400013
PM 21401109
ER
PT J
AU Zhou, Y
Kim, YS
Shi, JY
Jacobson, O
Chen, XY
Liu, S
AF Zhou, Yang
Kim, Young-Seung
Shi, Jiyun
Jacobson, Orit
Chen, Xiaoyuan
Liu, Shuang
TI Evaluation of Cu-64-Labeled Acridinium Cation: A PET Radiotracer
Targeting Tumor Mitochondria
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID TRIPHENYLPHOSPHONIUM CATIONS; MULTIDRUG-RESISTANCE; LIPOPHILIC CATIONS;
CARCINOMA-CELLS; GLIOMA-CELLS; LIVING CELLS; RHODAMINE-123; RETENTION;
COMPLEXES; METABOLITE
AB This report presents the synthesis and evaluation of Cu-64(DO3A-xy-ACR) (DO3A-xy-ACR = 2,6-bis(dimethylamino)-10-(4-((4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclodo-decan-1-yl)methyl)benzyl)acridin-10-ium) as a radiotracer for imaging tumors in athymic nude mice bearing U87MG glioma xenografts by PET (positron emission tomography). The biodistribution data suggested that Cu-64(DO3A-xy-ACR) was excreted mainly through the renal system with >65% of injected radioactivity being recovered from urine samples at 1 h post-injection (p.i.). The tumor uptake of Cu-64(DO3A-xy-ACR) was 1.07 +/- 0.23, 1.58 +/- 0.55, 2.71 +/- 0.66, 3.47 +/- 1.19, and 3.52 +/- 1.72%ID/g at 0.5,, 1, 2, 4, and 24 h p.i., respectively. Cu-64(DO3A-xy-ACR) had very high liver uptake (31.90 +/- 3.98, 24.95 +/- 5.64, 15.20 +/- 4.29, 14.09 +/- 6.82, and 8.18 +/- 1.27%ID/g at 0.5, 1, 2, 4, and 24 h p.i., respectively) with low tumor/liver ratios. MicroPET studies showed that the tumors were clearly visualized as early as 30 min pi in the glioma-bearing mouse administered with Cu-64(DO3A-xy-ACR). The high liver radioactivity accumulation was also seen. Cu-64(DO3A-xy-ACR) had a relatively high metabolic stability during excretion via both renal and hepatobiliary routes, but it was completely decomposed in the liver homogenate. We explored the localization mechanism of Cu(DO3A-xy-ACR) using both U87MG human glioma and the cultured primary U87MG glioma cells. The results from the cellular staining assays showed that Cu-64(DO3A-xy-ACR) is able to localize in the mitochondria of living U87MG glioma cells due to the enhanced negative mitochondrial potential as compared to normal cells. Although Cu-64(DO3A-xy-ACR) is not an ideal PET radiotracer for tumor imaging due to its high liver uptake, the results from this study strongly suggest that Cu-64-labeled acridinium cations are indeed able to localize in the energized mitochondria of tumor cells.
C1 [Zhou, Yang; Kim, Young-Seung; Shi, Jiyun; Liu, Shuang] Purdue Univ, Sch Hlth Sci, W Lafayette, IN 47907 USA.
[Jacobson, Orit; Chen, Xiaoyuan] NIBIB, LOMIN, NIH, Bethesda, MD USA.
RP Liu, S (reprint author), Purdue Univ, Sch Hlth Sci, 550 Stadium Mall Dr, W Lafayette, IN 47907 USA.
EM liu100@purdue.edu
FU Purdue University; National Cancer Institute (NCI) [R01 CA115883]
FX This work is supported, in part, by Purdue University and the research
grant: R01 CA115883 from the National Cancer Institute (NCI).
NR 33
TC 5
Z9 5
U1 1
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD APR
PY 2011
VL 22
IS 4
BP 700
EP 708
DI 10.1021/bc100458p
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 751JM
UT WOS:000289613400021
PM 21413736
ER
PT J
AU Traini, R
Kreitman, RJ
AF Traini, Roberta
Kreitman, Robert J.
TI Renal Excretion of Recombinant Immunotoxins Containing Pseudomonas
Exotoxin
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID HAIRY-CELL LEUKEMIA; RFB4(DSFV)-PE38 BL22; TRIAL; RESPONSES; RECEPTOR;
TOXIN
AB Recombinant immunotoxins BL22 (CAT-3888) and LMB-2, composed of Fv fragments of anti-CD22 and CD25 MAbs, respectively, have produced major responses in patients with hematologic malignancies, and are also associated with renal toxicity, particularly with BL22. Characterization of the renal excretion of recombinant immunotoxins, which have 2-4 h half-lives in plasma, has not been reported in humans. To study the renal excretion of recombinant immunotoxins, urine from patients treated with BL22 was collected and the recombinant protein visualized after trichloroacetic acid (TCA) precipitation or anion exchange chromatography. BL22 viewed by immunoblot was found in the urine of patients within 8 h after dosing as an intact protein, and progressively degraded to fragments of <20 kDa within 1 day. We studied the stability of BL22 and LMB-2 added to urine at different time points and pH. When exposed to urine ex vivo, BL22 time-dependent proteolysis was similar to that observed in treated patients. By N-terminal sequencing, proteolysis was documented at positions 348-349 and 350-351 of BL22, and 339-340 and 341-342 of LMB-2, and other proteolytic sites were observed as well. Our data suggest that BL22 is excreted into the urine in a potentially cytotoxic form, even after its plasma level declines, and may remain intact long enough to cause renal toxicity.
C1 [Traini, Roberta; Kreitman, Robert J.] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Kreitman, RJ (reprint author), NIH, Bldg 37,Room 5124B,9000 Rockville Pike, Bethesda, MD 20854 USA.
EM kreitmar@mail.nih.gov
FU NCI; MedImmune, LLC
FX We also thank Drs. David FitzGerald and Ira Pastan for helpful
suggestions and for reviewing the manuscript. This work was supported in
part by the NCI, intramural program, and MedImmune, LLC.
NR 15
TC 6
Z9 6
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD APR
PY 2011
VL 22
IS 4
BP 736
EP 740
DI 10.1021/bc1005152
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 751JM
UT WOS:000289613400025
PM 21410247
ER
PT J
AU Yoon, HY
Kales, SC
Luo, RB
Lipkowitz, S
Randazzo, PA
AF Yoon, Hye-Young
Kales, Stephen C.
Luo, Ruibai
Lipkowitz, Stanley
Randazzo, Paul A.
TI ARAP1 association with CIN85 affects epidermal growth factor receptor
endocytic trafficking
SO BIOLOGY OF THE CELL
LA English
DT Article
DE ADP-ribosylation factor GTPase-activating protein (ArfGAP); ARAP1;
Cbl-interacting protein of 85 kDa (CIN85); endocytosis; epidermal growth
factor receptor; membrane traffic
ID ADAPTER PROTEIN; ACTIN CYTOSKELETON; SIGNALING NETWORK; TYROSINE
KINASES; DOWN-REGULATION; SH3 DOMAINS; C-CBL; EGFR; DEGRADATION;
UBIQUITIN
AB Background information. ARAP1 is an Arf (ADP-ribosylation factor)-directed GAP (GTPase-activating protein) that inhibits the trafficking of EGFR (epidermal growth factor receptor) to the early endosome. To further understand the function of ARAP1, we sought to identify proteins that interact with ARAP1.
Results. Here we report that ARAP1 associates with the CIN85 (Cbl-interacting protein of 85 kDa). Arg(86) and Arg(90) of AIRAP1 and the SH3 (Src homology 3) domains of CIN85 are necessary for the interaction. We found that a mutant of ARAP1 with reduced affinity for CIN85 does not efficiently rescue the effect of reduced ARAP1 expression on EGFR trafficking to the early endosome. Reduced expression of CIN85 has a similar effect as reduced expression of ARAP1 on traffic of the EGFR. Cbl proteins regulate the endocytic trafficking of the EGFR by mediating ubiquitination of the EGFR. Overexpression of ARAP1 reduced ubiquitination of the EGFR by Cbl and slowed Cbl-dependent degradation of the EGFR. Reduced expression of ARAP1 accelerated degradation of EGFR but did not affect the level of ubiquitination of the receptor that was detected.
Conclusion. ARAP1 interaction with CIN85 regulates endocytic trafficking of the EGFR and affects ubiquitination of EGFR. We propose a model in which the ARAP1 CIN85 complex drives exit of EGF-EGFR-Cbl complex from a pre-early endosome into a pathway distinct from the early endosome/lysosome pathway.
C1 [Yoon, Hye-Young; Kales, Stephen C.; Luo, Ruibai; Lipkowitz, Stanley; Randazzo, Paul A.] NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA.
RP Randazzo, PA (reprint author), NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA.
EM randazzp@mail.nih.gov
FU National Cancer Institute; National Institutes of Health, Bethesda, MD,
U.S.A. [ZIA BC 007365]
FX This work was supported by the National Cancer Institute, National
Institutes of Health Intramural Program (project number ZIA BC 007365),
Bethesda, MD, U.S.A.
NR 40
TC 7
Z9 7
U1 0
U2 4
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0248-4900
J9 BIOL CELL
JI Biol. Cell
PD APR
PY 2011
VL 103
IS 4
BP 171
EP 184
DI 10.1042/BC20100154
PG 14
WC Cell Biology
SC Cell Biology
GA 755UN
UT WOS:000289964200002
PM 21275903
ER
PT J
AU Zhou, B
Zhu, YB
Lin, L
Cai, Q
Sheng, ZH
AF Zhou, Bing
Zhu, Yi-Bing
Lin, Lin
Cai, Qian
Sheng, Zu-Hang
TI Snapin deficiency is associated with developmental defects of the
central nervous system
SO BIOSCIENCE REPORTS
LA English
DT Article
DE apoptotic cell death; autophagy; late endocytic trafficking; lysosome;
neuronal development; ubiquitin
ID CELL-DEATH; PROTEIN-DEGRADATION; AUTOPHAGOSOME FORMATION; DISEASE; MICE;
NEURODEGENERATION; INHIBITION; HUNTINGTIN; LYSOSOMES; TRANSPORT
AB The autophagy-lysosomal pathway is an intracellular degradation process essential for maintaining neuronal homoeostasis. Defects in this pathway have been directly linked to a growing number of neurodegenerative disorders. We recently revealed that Snapin plays a critical role in co-ordinating dynein-driven retrograde transport and late encosomal-lysosomal trafficking, thus maintaining efficient autophagy-lysosomal function. Deleting snapin in neurons impairs lysosomal proteolysis and reduces the clearance of autolysosomes. The role of the autophagy-lysosomal system in neuronal development is, however, largely uncharacterized. Here, we report that snapin deficiency leads to developmental defects in the central nervous system. Embryonic snapin(-/-) mouse brain showed reduced cortical plates and intermediate zone cell density, increased apoptotic death in the cortex and third ventricle, enhanced membrane-bound LC3-II staining associated with autophagic vacuoles and an accumulation of polyubiquitinated proteins in the cortex and hippocampus. Thus our results provide in vivo evidence for the essential role of late endocytic transport and autophagy-lysosomal function in maintaining neuronal survival and development of the mammalian central nervous system. In addition, our study supports the existence of a functional interplay between the autophagy-lysosome and ubiquitin-proteasome systems in the protein quality-control process.
C1 [Zhou, Bing; Zhu, Yi-Bing; Cai, Qian; Sheng, Zu-Hang] Natl Inst Neurol Disorders & Stroke, Synapt Funct Sect, NIH, Bethesda, MD 20892 USA.
[Zhou, Bing; Zhu, Yi-Bing; Lin, Lin] Shanghai Jiao Tong Univ, Sch Med, Dept Neurobiol, Shanghai 200030, Peoples R China.
RP Sheng, ZH (reprint author), Natl Inst Neurol Disorders & Stroke, Synapt Funct Sect, NIH, 35 Convent Dr, Bethesda, MD 20892 USA.
EM shengz@ninds.nih.gov
FU National Institute of Neurological Disorders and Stroke, National
Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Institute of Neurological Disorders and Stroke, National
Institutes of Health (to Z.-H.S.).
NR 41
TC 7
Z9 7
U1 1
U2 4
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0144-8463
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD APR
PY 2011
VL 31
IS 2
BP 151
EP 158
DI 10.1042/BSR20100110
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 756IM
UT WOS:000290004900009
PM 20946101
ER
PT J
AU Emmorey, K
Xu, J
Braun, A
AF Emmorey, Karen
Xu, Jiang
Braun, Allen
TI Neural responses to meaningless pseudosigns: Evidence for sign-based
phonetic processing in superior temporal cortex
SO BRAIN AND LANGUAGE
LA English
DT Article
DE Sign language; Deaf signers; fMRI; Pseudowords; Phonology
ID VERBAL WORKING-MEMORY; LANGUAGE; PERCEPTION; BRAIN; COMPREHENSION; FMRI
AB To identify neural regions that automatically respond to linguistically structured, but meaningless manual gestures, 14 deaf native users of American Sign Language (ASL) and 14 hearing non-signers passively viewed pseudosigns (possible but non-existent ASL signs) and non-iconic ASL signs, in addition to a fixation baseline. For the contrast between pseudosigns and baseline, greater activation was observed in left posterior superior temporal sulcus (STS), but not in left inferior frontal gyrus (BA 44145), for deaf signers compared to hearing non-signers, based on VOI analyses. We hypothesize that left STS is more engaged for signers because this region becomes tuned to human body movements that conform the phonological constraints of sign language. For deaf signers, the contrast between pseudosigns and known ASL signs revealed increased activation for pseudosigns in left posterior superior temporal gyrus (STG) and in left inferior frontal cortex, but no regions were found to be more engaged for known signs than for pseudosigns. This contrast revealed no significant differences in activation for hearing non-signers. We hypothesize that left STG is involved in recognizing linguistic phonetic units within a dynamic visual or auditory signal, such that less familiar structural combinations produce increased neural activation in this region for both pseudosigns and pseudowords. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Emmorey, Karen] San Diego State Univ, Lab Language & Cognit Neurosci, San Diego, CA 92120 USA.
[Xu, Jiang; Braun, Allen] NIH, Bethesda, MD 20892 USA.
RP Emmorey, K (reprint author), San Diego State Univ, Lab Language & Cognit Neurosci, 6495 Alvarado Rd,Suite 200, San Diego, CA 92120 USA.
EM kemmorey@mail.sdsu.edu
FU NIH [R01 DC010997]; NIDCD
FX This research was supported in part by NIH Grant R01 DC010997 (K.E.) and
by the NIDCD Intramural Research Program. We would like to thank Franco
Korpics for help recruiting Deaf participants, Jeannette Vincent for
help with stimuli development, Helsa Borinstein for help with the
gesture norming study, and all of the Deaf and hearing individuals who
participated in the study.
NR 28
TC 11
Z9 11
U1 1
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0093-934X
J9 BRAIN LANG
JI Brain Lang.
PD APR
PY 2011
VL 117
IS 1
BP 34
EP 38
DI 10.1016/j.bandl.2010.10.003
PG 5
WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences;
Psychology, Experimental
SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences &
Neurology; Psychology
GA 752PB
UT WOS:000289703500005
PM 21094525
ER
PT J
AU Mumford, SL
Dasharathy, S
Pollack, AZ
Schisterman, EF
AF Mumford, Sunni L.
Dasharathy, Sonya
Pollack, Anna Z.
Schisterman, Enrique F.
TI Variations in lipid levels according to menstrual cycle phase: clinical
implications
SO CLINICAL LIPIDOLOGY
LA English
DT Review
DE cholesterol; estrogen; lipoprotein; menstrual cycle
ID HEALTHY-YOUNG WOMEN; DENSITY-LIPOPROTEIN CHOLESTEROL; ESTROGEN PLUS
PROGESTIN; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; PLASMA-LIPIDS;
ORAL-CONTRACEPTIVES; SERUM-LIPOPROTEINS; CARDIOVASCULAR-DISEASE;
APOLIPOPROTEIN LEVELS
AB Understanding variations in lipoprotein cholesterol levels throughout the menstrual cycle is important because there may be clinical implications regarding the appropriate timing of measurement and implications on the design and interpretation of studies in women of reproductive age. Our objective was to review the evidence comparing lipoprotein cholesterol levels throughout the menstrual cycle among premenopausal women. Overall, lipoprotein cholesterol levels were observed to vary in response to changing estrogen levels. Taken together, the evidence suggests that total cholesterol and LDL-C tend to be highest during the follicular phase and to decline during the luteal phase, with HDL-C highest around ovulation. Based on these findings, the menstrual cycle phase should be taken into account when evaluating lipoprotein cholesterol levels among reproductive-aged women. Measuring cholesterol levels during menses is recommended for consistent comparisons as this phase can be more reliably identified than other phases, although women within National Cholesterol Education Program acceptable ranges, but near the boundaries when tested during menses, should undergo additional tests.
C1 [Mumford, Sunni L.; Dasharathy, Sonya; Pollack, Anna Z.; Schisterman, Enrique F.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, NIH, Rockville, MD 20852 USA.
RP Mumford, SL (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Div Epidemiol Stat & Prevent Res, NIH, 6100 Execut Blvd,7B03, Rockville, MD 20852 USA.
EM mumfords@mail.nih.gov
RI Pollack, Anna/F-2021-2011;
OI Pollack, Anna/0000-0002-4313-3298; Schisterman,
Enrique/0000-0003-3757-641X
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development, NIH
FX This work was supported by the Intramural Research Program of the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, NIH. The authors have no other relevant affiliations or
financial involvement with any organization or entity with a financial
interest in or financial conflict with the subject matter or materials
discussed in the manuscript apart from those disclosed.
NR 50
TC 11
Z9 13
U1 0
U2 4
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1758-4299
J9 CLIN LIPIDOL
JI Clin. Lipidol.
PD APR
PY 2011
VL 6
IS 2
BP 225
EP 234
DI 10.2217/CLP.11.9
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 754CE
UT WOS:000289828700013
PM 21743815
ER
PT J
AU Veenstra, TD
AF Veenstra, Timothy D.
TI Proteomics research in breast cancer: balancing discovery and
hypothesis-driven studies
SO EXPERT REVIEW OF PROTEOMICS
LA English
DT Editorial Material
DE biomarker; discovery; liquid chromatography; mass spectrometry;
validation
C1 SAIC Frederick Inc, Natl Canc Inst Frederick, Adv Technol Program, Lab Prote & Analyt Technol, Frederick, MD 21702 USA.
RP Veenstra, TD (reprint author), SAIC Frederick Inc, Natl Canc Inst Frederick, Adv Technol Program, Lab Prote & Analyt Technol, Frederick, MD 21702 USA.
EM veenstra@ncifcrf.gov
NR 8
TC 3
Z9 3
U1 0
U2 2
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1478-9450
J9 EXPERT REV PROTEOMIC
JI Expert Rev. Proteomics
PD APR
PY 2011
VL 8
IS 2
BP 139
EP 141
DI 10.1586/EPR.11.9
PG 3
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 754SN
UT WOS:000289877400001
PM 21501004
ER
PT J
AU Hoffert, JD
Pisitkun, T
Knepper, MA
AF Hoffert, Jason D.
Pisitkun, Trairak
Knepper, Mark A.
TI Phosphoproteomics of vasopressin signaling in the kidney
SO EXPERT REVIEW OF PROTEOMICS
LA English
DT Review
DE aquaporin; collecting duct; kidney; LC-MS/MS; tandem mass spectrometry;
vasopressin; water transport
ID RENAL COLLECTING DUCT; SCALE PHOSPHORYLATION ANALYSIS;
MASS-SPECTROMETRY; QUANTITATIVE PHOSPHOPROTEOMICS;
SACCHAROMYCES-CEREVISIAE; AQUAPORIN-2 ABUNDANCE; STIMULATED INCREASE;
WATER PERMEABILITY; PROTEOMIC ANALYSIS; SITE LOCALIZATION
AB Protein phosphorylation plays a critical role in the signaling pathways regulating water and solute transport in the distal renal tubule (i.e., renal collecting duct). A central mediator in this process is the antidiuretic peptide hormone arginine vasopressin, which regulates a number of transport proteins including water channel aquaporin-2 and urea transporters (UT-A1 and UT-A3). Within the past few years, tandem mass spectrometry-based proteomics has played a pivotal role in revealing global changes in the phosphoproteome in response to vasopressin signaling in the renal collecting duct. This type of large-scale 'shotgun' approach has resulted in an exponential increase in the number of phosphoproteins known to be regulated by vasopressin and has expanded on the established signaling mechanisms and kinase pathways regulating collecting duct physiology. This article will provide a brief background on vasopressin action, will highlight a number of recent quantitative phosphoproteomic studies in both native rat kidney and cultured collecting duct cells, and will conclude with a perspective focused on emerging trends in the field of phosphoproteomics.
C1 [Hoffert, Jason D.; Pisitkun, Trairak; Knepper, Mark A.] NHLBI, Epithelial Syst Biol Lab, Bethesda, MD 20892 USA.
RP Hoffert, JD (reprint author), NHLBI, Epithelial Syst Biol Lab, Bldg 10, Bethesda, MD 20892 USA.
EM hoffertj@nhlbi.nih.gov
OI Pisitkun, Trairak/0000-0001-6677-2271
FU Intramural NIH HHS [ZIA HL001285-24, Z01 HL001285-21, Z01 HL001285-22,
Z99 HL999999, ZIA HL001285-23]
NR 53
TC 7
Z9 8
U1 0
U2 6
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1478-9450
J9 EXPERT REV PROTEOMIC
JI Expert Rev. Proteomics
PD APR
PY 2011
VL 8
IS 2
BP 157
EP 163
DI 10.1586/EPR.11.14
PG 7
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 754SN
UT WOS:000289877400009
PM 21501009
ER
PT J
AU Theron, GB
Shapiro, DE
Van Dyke, R
Cababasay, MP
Louw, J
Watts, DH
Smith, E
Bulterys, M
Maupin, R
AF Theron, Gerhard B.
Shapiro, David E.
Van Dyke, Russell
Cababasay, Mae P.
Louw, Jeanne
Watts, D. Heather
Smith, Elizabeth
Bulterys, Marc
Maupin, Robert
TI Rapid intrapartum or postpartum HIV testing at a midwife obstetric unit
and a district hospital in South Africa
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Labor; Rapid testing; Unknown HIV status
ID POSTEXPOSURE PROPHYLAXIS; PREGNANT-WOMEN; TRANSMISSION; TRIAL;
NEVIRAPINE; LABOR
AB Objective: To compare the prepartum and postpartum feasibility and acceptance of voluntary counseling and rapid testing (VCT) among women with unknown HIV status in South Africa. Methods: Eligible women were randomized according to the calendar week of presentation to receive VCT either while in labor or after delivery. Results: Of 7238 women approached, 542 (7.5%) were eligible, 343 (63%) were enrolled, and 45 (13%) were found to be HIV infected. The proportions of eligible women who accepted VCT were 66.8% (161 of 241) in the intrapartum arm and 60.5% (182 of 301) in the postpartum arm, and the difference of 6.3% (95% CI, -1.8% to 14.5%) was not significant. The median times (44 and 45 minutes) required to conduct VCT were also similar in the 2 arms. In the intrapartum arm, all women in true labor received their test results before delivery and all those found to be HIV positive accepted prophylaxis with nevirapine before delivery. Conclusions: Rapid testing in labor wards for women with an unknown HIV status is feasible and well accepted, and allows for a more timely antiretroviral prophylaxis than postpartum testing. (C) 2010 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Theron, Gerhard B.] Univ Stellenbosch, Fac Hlth Sci, Dept Obstet & Gynaecol, ZA-7600 Stellenbosch, South Africa.
[Theron, Gerhard B.] Tygerberg Hosp, Stellenbosch, South Africa.
[Shapiro, David E.; Cababasay, Mae P.] Harvard Univ, Harvard Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
[Van Dyke, Russell] Tulane Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70118 USA.
[Louw, Jeanne] Univ Stellenbosch, Fac Hlth Sci, Dept Pediat & Child Hlth, ZA-7600 Stellenbosch, South Africa.
[Watts, D. Heather] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Bethesda, MD USA.
[Smith, Elizabeth] NIH, Div Aids, Bethesda, MD 20892 USA.
[Bulterys, Marc] China US Ctr Dis Control & Prevent, Ctr Dis Control Global AIDS Program, Beijing, Peoples R China.
[Maupin, Robert] Louisiana State Univ, Hlth Sci Ctr, Pediat AIDS Clin Trials Unit New Orleans, New Orleans, LA USA.
RP Theron, GB (reprint author), Fac Hlth Sci, Dept Obstet & Gynaecol, POB 19063, ZA-7505 Tygerberg, South Africa.
EM gbth@sun.ac.za
FU National Institute of Allergy and Infectious Diseases [U01 AI068632];
Eunice Kennedy Shriver National Institute of Child Health and Human
Development; National Institute of Mental Health [AI068632]; Harvard
School of Public Health Statistical and Data Analysis Center, under
National Institute of Allergy and Infectious Diseases [5 U01 AI41110, 1
U01 AI068616]; Child Health and Human Development
[N01-DK-9-001/HHSN267200800001C]
FX Support for the International Maternal Pediatric Adolescent AIDS
Clinical Trials Group (IMPAACT) was provided by the National Institute
of Allergy and Infectious Diseases (grant U01 AI068632), the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, and the National Institute of Mental Health (grant
AI068632). The content is the sole responsibility of the authors and
does not necessarily represent the official views of the National
Institutes of Health. This work was supported by the Harvard School of
Public Health Statistical and Data Analysis Center, under National
Institute of Allergy and Infectious Diseases cooperative agreement No. 5
U01 AI41110 with the Pediatric AIDS Clinical Trials Group and No. 1 U01
AI068616 with the IMPAACT Group. Support for the study sites was
provided by the National Institute of Allergy and Infectious Diseases,
the International and Domestic Pediatric and Maternal HIV Clinical
Trials Network funded by Child Health and Human Development (contract
No. N01-DK-9-001/HHSN267200800001C).
NR 12
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0020-7292
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD APR
PY 2011
VL 113
IS 1
BP 44
EP 49
DI 10.1016/j.ijgo.2010.10.011
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 756KL
UT WOS:000290010000009
PM 21251654
ER
PT J
AU Rodriguez-Garcia, M
Porichis, F
de Jong, OG
Levi, K
Diefenbach, TJ
Lifson, JD
Freeman, GJ
Walker, BD
Kaufmann, DE
Kavanagh, DG
AF Rodriguez-Garcia, Marta
Porichis, Filippos
de Jong, Olivier G.
Levi, Karen
Diefenbach, Thomas J.
Lifson, Jeffrey D.
Freeman, Gordon J.
Walker, Bruce D.
Kaufmann, Daniel E.
Kavanagh, Daniel G.
TI Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by
HIV-1 and differentially modulated by IL-10
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE B7-H1; B7-DC
ID T-CELL-ACTIVATION; PROGRAMMED DEATH-1; DENDRITIC CELLS; DISEASE
PROGRESSION; INFECTION; MONOCYTES; IMMUNITY; LIGANDS; B7-H1; B7-DC
AB PD-1 plays an important role in T cell exhaustion during HIV infection. PD-1 has two ligands: PD-L1, expressed on hematopoietic and nonhematopoietic cells, and PD-L2, limited to DCs and macrophages. Little is known about PD-L1 expression and regulation in human macrophages. Previous reports have found few immediate effects of macrophage exposure to HIV, suggesting that macrophages lack PRRs for this virus. Using quantitative confocal microscopy and a multiplexed cytokine bead array, we measured induction of PD-L1, PD-L2, and innate response cytokines in human MDMs in response to chemically inactivated HIV virions. Consistent with previous reports, no cytokines were induced by HIV virion exposure. Whereas PD-L1 and PD-L2 had low baseline expression, TLR ligands (LPS and CL097) up-regulated PD-L1 but not PD-L2. Unlike what we found for cytokine expression, PD-L1 and PD-L2 were up-regulated in response to exposure with inactivated HIV virions or with replication-competent HIV. Expression of PD-L1 was differentially modulated by IL-10, which induced up-regulation of PD-L1 but not of PD-L2, and IL-10 blockade enhanced only PD-L2 expression. We discuss implications for innate recognition of HIV by macrophages and potential, different roles for PD-L1 and PD-L2 in immunity and pathogenesis. J. Leukoc. Biol. 89: 507-515; 2011.
C1 [Rodriguez-Garcia, Marta; Porichis, Filippos; de Jong, Olivier G.; Levi, Karen; Diefenbach, Thomas J.; Walker, Bruce D.; Kaufmann, Daniel E.; Kavanagh, Daniel G.] MIT, Ragon Inst MGH, Charlestown, MA 02129 USA.
[Rodriguez-Garcia, Marta; Porichis, Filippos; de Jong, Olivier G.; Levi, Karen; Diefenbach, Thomas J.; Walker, Bruce D.; Kaufmann, Daniel E.; Kavanagh, Daniel G.] Harvard Univ, Charlestown, MA 02129 USA.
[Walker, Bruce D.] Howard Hughes Med Inst, Charlestown, MA USA.
[Lifson, Jeffrey D.] SAIC Frederick Inc, AIDS & Canc Virus Program, Natl Canc Inst Frederick, Frederick, MD USA.
[Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med,Dept Med Oncol, Boston, MA 02115 USA.
[Kaufmann, Daniel E.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Kavanagh, DG (reprint author), MIT, Ragon Inst MGH, 149 13th St, Charlestown, MA 02129 USA.
EM dkavanagh@partners.org
FU National Institutes of Health [1U19A1082630, A108080192, HL92565];
National Cancer Institute, National Institutes of Health
[HHSN261200800001E]; [1P01AI080192-0]
FX This work was supported by grant 1P01AI080192-0 and grants 1U19A1082630,
A108080192, and HL92565 from the National Institutes of Health. The work
was supported in part with federal funds from the National Cancer
Institute, National Institutes of Health, under contract no.
HHSN261200800001E. We thank Marcus Altfeld, Judy Chang, and Angela Meier
for their comments and suggestions.
NR 40
TC 43
Z9 43
U1 0
U2 6
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD APR
PY 2011
VL 89
IS 4
BP 507
EP 515
DI 10.1189/jlb.0610327
PG 9
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 757OZ
UT WOS:000290098900004
PM 21097698
ER
PT J
AU Murray, PJ
Wynn, TA
AF Murray, Peter J.
Wynn, Thomas A.
TI Obstacles and opportunities for understanding macrophage polarization
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Review
DE Toll-like receptors; cytokine; chemokine; interferon
ID MARROW-DERIVED MACROPHAGES; HEMATOPOIETIC STEM-CELLS; NITRIC-OXIDE
SYNTHESIS; GENE-EXPRESSION; ALTERNATIVE ACTIVATION; ARGINASE-I; TYPE-2
INFLAMMATION; HELMINTH INFECTION; TUMOR PROGRESSION; DENDRITIC CELLS
AB Macrophages are now routinely categorized into phenotypic subtypes based on gene expression induced in response to cytokine and pathogen-derived stimulation. In the broadest division, macrophages are described as being CAMs (M1 macrophages) or AAMs (M2 macrophages) based on their exposure to TLR and IFN signals or Th2 cytokines, respectively. Despite the prolific use of this simple classification scheme, little is known about the precise functions of effector molecules produced by AAMs, especially how representative the CAM and AAM subtypes are of tissue macrophages in homeostasis, infection, or tissue repair and how plasticity in gene expression regulates macrophage function in vivo. Furthermore, correlations between mouse and human tissue macrophages and their representative subtypes are lacking and are a major barrier to understanding human immunity. Here, we briefly summarize current features of macrophage polarization and discuss the roles of various macrophage subpopulations and macrophage-associated genes in health and disease. J. Leukoc. Biol. 89: 557-563; 2011.
C1 [Murray, Peter J.] St Jude Childrens Hosp, Dept Infect Dis, Memphis, TN 38105 USA.
[Murray, Peter J.] St Jude Childrens Hosp, Dept Immunol, Memphis, TN 38105 USA.
[Wynn, Thomas A.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.
RP Murray, PJ (reprint author), St Jude Childrens Hosp, Dept Infect Dis, 262 Danny Thomas Pl,MS320,Room E8078, Memphis, TN 38105 USA.
EM peter.murray@stjude.org
RI Wynn, Thomas/C-2797-2011
NR 78
TC 176
Z9 181
U1 3
U2 50
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD APR
PY 2011
VL 89
IS 4
BP 557
EP 563
DI 10.1189/jlb.0710409
PG 7
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 757OZ
UT WOS:000290098900008
PM 21248152
ER
PT J
AU Vilar, S
Karpiak, J
Berk, B
Costanzi, S
AF Vilar, Santiago
Karpiak, Joel
Berk, Barkin
Costanzi, Stefano
TI In silico analysis of the binding of agonists and blockers to the
beta(2)-adrenergic receptor
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE G protein-coupled receptor; Agonists; Blockers; Induced Fit; Docking;
Linear discriminant analysis; Molecular dynamics
ID PROTEIN-COUPLED RECEPTORS; 2ND EXTRACELLULAR LOOP; STRUCTURE-BASED
DISCOVERY; BETA-2-ADRENERGIC RECEPTOR; CONFORMATIONAL-CHANGES; BETA(2)
ADRENOCEPTOR; MOLECULAR-DYNAMICS; HOMOLOGY MODELS; DRUG DISCOVERY;
LIGAND
AB Activation of G protein-coupled receptors (GPCRs) is a complex phenomenon. Here, we applied Induced Fit Docking (IFD) in tandem with linear discriminant analysis (LDA) to generate hypotheses on the conformational changes induced to the beta(2)-adrenergic receptor by agonist binding, preliminary to the sequence of events that characterize activation of the receptor. This analysis, corroborated by a follow-up molecular dynamics study, suggested that agonists induce subtle movements to the fifth transmembrane domain (TM5) of the receptor. Furthermore, molecular dynamics also highlighted a correlation between movements of TM5 and the second extracellular loop (EL2), suggesting that freedom of motion of EL2 is required for the agonist-induced TM5 displacement. Importantly, we also showed that the IFD/LDA procedure can be used as a computational means to distinguish agonists from blockers on the basis of the differential conformational changes induced to the receptor. In particular, the two most predictive models obtained are based on the RMSD induced to Ser207 and on the counterclockwise rotation induced to TM5. Published by Elsevier Inc.
C1 [Vilar, Santiago; Karpiak, Joel; Berk, Barkin; Costanzi, Stefano] NIDDK, Lab Biol Modeling, NIH, DHHS, Bethesda, MD 20892 USA.
RP Costanzi, S (reprint author), NIDDK, Lab Biol Modeling, NIH, DHHS, Bethesda, MD 20892 USA.
EM stefanoc@mail.nih.gov
RI Costanzi, Stefano/G-8990-2013; berk, barkin/P-2088-2014;
OI Costanzi, Stefano/0000-0003-3183-7332; Vilar Varela,
Santiago/0000-0003-2663-4370
FU NIH, NIDDK
FX This research was supported by the Intramural Research Program of the
NIH, NIDDK. We thank Nels Thorsteinson of Chemical Computing Group for
providing the SVL script for the clustering of the docking poses.
NR 59
TC 27
Z9 28
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1093-3263
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD APR
PY 2011
VL 29
IS 6
BP 809
EP 817
DI 10.1016/j.jmgm.2011.01.005
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
Science, Interdisciplinary Applications; Crystallography; Mathematical &
Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
Mathematical & Computational Biology
GA 755IO
UT WOS:000289922900005
PM 21334234
ER
PT J
AU Bassig, BA
Inskip, PD
Burdette, L
Shapiro, WR
Selker, RG
Fine, HA
Loeffler, JS
Black, PM
Dubrow, R
Brenner, AV
AF Bassig, Bryan A.
Inskip, Peter D.
Burdette, Laurie
Shapiro, William R.
Selker, Robert G.
Fine, Howard A.
Loeffler, Jay S.
Black, Peter M.
Dubrow, Robert
Brenner, Alina V.
TI Selected human leukocyte antigen class II polymorphisms and risk of
adult glioma
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE Glioma; Brain tumors; HLA polymorphisms; DQB1; DRB1
AB Few studies have examined the relationship between human leukocyte antigen (HLA) polymorphisms and adult glioma, particularly at class II loci. We evaluated the association between selected HLA class II polymorphisms and adult glioma in a large, hospital-based case-control study, using unconditional logistic regression. DQB1*06 (OR=1.67, 95% CI=1.17-2.39) and DRB1*13 (OR=1.69, 95% CI=1.08-2.64) alleles were associated with an increased risk of glioma, while the DQB1*05 allele showed an inverse association (OR=0.63, 95% CI=0.43-0.93). These results, which were of borderline significance once controlled for the false discovery rate, suggest a potential role for the DQB1*06, DQB1*05, and DRB1*13 alleles in glioma susceptibility. (C) 2010 Published by Elsevier B.V.
C1 [Inskip, Peter D.; Brenner, Alina V.] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Bassig, Bryan A.; Dubrow, Robert] Yale Univ, Sch Med, Yale Sch Publ Hlth, New Haven, CT 06510 USA.
[Burdette, Laurie] NCI Frederick, Core Genotyping Facil, Adv Technol Program, SAIC Frederick Inc, Ft Detrick, MD 21702 USA.
[Shapiro, William R.] St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ 85013 USA.
[Selker, Robert G.] Western Penn Hosp, Div Neurosurg, Pittsburgh, PA 15224 USA.
[Fine, Howard A.] NCI, Neurooncol Branch, Bethesda, MD 20892 USA.
[Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Black, Peter M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Brenner, AV (reprint author), NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,MSC 7362, Bethesda, MD 20892 USA.
EM brennera@mail.nih.gov
FU National Institutes of Health (National Cancer Institute, Division of
Cancer Epidemiology and Genetics)
FX This study was supported by Intramural Research program of the National
Institutes of Health (National Cancer Institute, Division of Cancer
Epidemiology and Genetics).
NR 1
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD APR
PY 2011
VL 233
IS 1-2
BP 185
EP 191
DI 10.1016/j.jneuroim.2010.11.005
PG 7
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 757FD
UT WOS:000290070000024
PM 21195488
ER
PT J
AU Glaser, R
York, AE
Dimitrakakis, C
AF Glaser, Rebecca
York, Anne E.
Dimitrakakis, Constantine
TI Beneficial effects of testosterone therapy in women measured by the
validated Menopause Rating Scale (MRS)
SO MATURITAS
LA English
DT Article
DE Testosterone; Implant; Health-related quality of life; Menopause;
Pre-menopause
ID HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; BREAST-CANCER;
ANDROGEN LEVELS; SAFETY; SYMPTOMS; IMPLANTS; ESTROGEN; RISK; AGE
AB Objectives: This study was designed to measure the beneficial effects of continuous testosterone therapy, delivered by subcutaneous implant, in the relief of somatic, psychological and urogenital symptoms in both pre- and post-menopausal patients, utilizing the validated Health Related Quality of Life (HRQOL), Menopause Rating Scale (MRS).
Study design: 300 pre- and post-menopausal women with symptoms of relative androgen deficiency, were asked to self-administer the 11-item MRS, at baseline and 3 months after their first insertion of the subcutaneous testosterone implant. Baseline hormone measurements, menopausal status and BMI, were assessed to determine correlation with symptoms and clinical outcome. Main outcome measurements: Changes related to therapy were determined. Total MRS scores as well as psychological, somatic and urogenital subscale scores were compared prior to therapy and following testosterone implant therapy.
Results: Pre-menopausal and post-menopausal females reported similar hormone deficiency symptoms. Both groups demonstrated similar improvement in total score, as well as psychological, somatic and urogenital subscale scores with testosterone therapy. Better effect was noted in women with more severe complaints. Higher doses of testosterone correlated with greater improvement in symptoms.
Conclusion: Continuous testosterone alone, delivered by subcutaneous implant, was effective for the relief of hormone deficiency symptoms in both pre- and post-menopausal patients. The validated, HRQOL questionnaire, Menopause Rating Scale (MRS), proved a valuable tool in the measurement of the beneficial effects of testosterone therapy in both cohorts. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Glaser, Rebecca] Millennium Wellness Ctr, Dayton, OH 45458 USA.
[Glaser, Rebecca] Wright State Univ, Boonshoft Sch Med, Dept Surg, Dayton, OH 45435 USA.
[York, Anne E.] York Data Anal, Seattle, WA 98107 USA.
[Dimitrakakis, Constantine] Univ Athens, Sch Med, Dept Ob Gyn 1, Athens 11528, Greece.
[Dimitrakakis, Constantine] NICHD, NIH, Bethesda, MD 20892 USA.
RP Glaser, R (reprint author), Millennium Wellness Ctr, 228 E Spring Valley Rd, Dayton, OH 45458 USA.
EM rglaser@wohsr.com; anne.york@gmail.com; dimitrac@mail.nih.gov
NR 30
TC 15
Z9 18
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0378-5122
EI 1873-4111
J9 MATURITAS
JI Maturitas
PD APR
PY 2011
VL 68
IS 4
BP 355
EP 361
DI 10.1016/j.maturitas.2010.12.001
PG 7
WC Geriatrics & Gerontology; Obstetrics & Gynecology
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA 756JP
UT WOS:000290007800010
PM 21177051
ER
PT J
AU Yan, H
Sun, LG
Oppo, DW
Wang, YH
Liu, ZH
Xie, ZQ
Liu, XD
Cheng, WH
AF Yan, Hong
Sun, Liguang
Oppo, Delia W.
Wang, Yuhong
Liu, Zhonghui
Xie, Zhouqing
Liu, Xiaodong
Cheng, Wenhan
TI South China Sea hydrological changes and Pacific Walker Circulation
variations over the last millennium
SO NATURE COMMUNICATIONS
LA English
DT Article
ID INTERTROPICAL CONVERGENCE ZONE; EL-NINO/SOUTHERN-OSCILLATION; TROPICAL
PACIFIC; SURFACE TEMPERATURES; YUCATAN PENINSULA; MAYA LOWLANDS;
ICE-AGE; CLIMATE; HOLOCENE; RECORD
AB The relative importance of north-south migrations of the intertropical convergence zone (ITCZ) versus El Nino-Southern Oscillation and its associated Pacific Walker Circulation (PWC) variability for past hydrological change in the western tropical Pacific is unclear. Here we show that north-south ITCZ migration was not the only mechanism of tropical Pacific hydrologic variability during the last millennium, and that PWC variability profoundly influenced tropical Pacific hydrology. We present hydrological reconstructions from Cattle Pond, Dongdao Island of the South China Sea, where multi-decadal rainfall and downcore grain size variations are correlated to the Southern Oscillation Index during the instrumental era. Our downcore grain size reconstructions indicate that this site received less precipitation during relatively warm periods, AD 1000-1400 and AD 1850-2000, compared with the cool period (AD 1400-1850). Including our new reconstructions in a synthesis of tropical Pacific records results in a spatial pattern of hydrologic variability that implicates the PWC.
C1 [Yan, Hong; Sun, Liguang; Xie, Zhouqing; Liu, Xiaodong; Cheng, Wenhan] Univ Sci & Technol China, Dept Earth & Space Sci, Inst Polar Environm, Hefei 230026, Anhui, Peoples R China.
[Oppo, Delia W.] Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA.
[Wang, Yuhong] NIH, Bethesda, MD 20892 USA.
[Liu, Zhonghui] Univ Hong Kong, Dept Earth Sci, Hong Kong, Hong Kong, Peoples R China.
RP Sun, LG (reprint author), Univ Sci & Technol China, Dept Earth & Space Sci, Inst Polar Environm, Hefei 230026, Anhui, Peoples R China.
EM slg@ustc.edu.cn
RI Liu, Zhonghui/D-3163-2009; Ma, Wentao/A-8800-2010; Yan, Hong/I-8970-2014
OI Liu, Zhonghui/0000-0002-2168-8305;
FU Natural Science Foundation of China (NSFC) [40730107]; Major State Basic
Research Development Program of China (973 Program) [2010CB428902]; US
NSF
FX This work was supported by the Natural Science Foundation of China
(NSFC) (40730107) and the Major State Basic Research Development Program
of China (973 Program) (No.2010CB428902). DWO acknowledges support from
the US NSF. We wish to thank Chengyun Yang, Yi Liu, Nan Jia, Sanping
Zhao, Xin He and Shican Qiu for their help in sampling and analyses.
NR 29
TC 38
Z9 45
U1 6
U2 35
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR
PY 2011
VL 2
AR 293
DI 10.1038/ncomms1297
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 756AN
UT WOS:000289983800031
PM 21522137
ER
PT J
AU Millau, JF
Bandele, OJ
Perron, J
Bastien, N
Bouchard, EF
Gaudreau, L
Bell, DA
Drouin, R
AF Millau, Jean-Francois
Bandele, Omari J.
Perron, Josiann
Bastien, Nathalie
Bouchard, Eric F.
Gaudreau, Luc
Bell, Douglas A.
Drouin, Regen
TI Formation of stress-specific p53 binding patterns is influenced by
chromatin but not by modulation of p53 binding affinity to response
elements(dagger)
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID CELL-CYCLE ARREST; TRANSCRIPTION-FACTOR; APOPTOTIC FUNCTION;
GENE-EXPRESSION; DNA-BINDING; TRANSACTIVATION; P21(WAF1/CIP1);
ACETYLATION; ACTIVATION; INHIBITOR
AB The p53 protein is crucial for adapting programs of gene expression in response to stress. Recently, we revealed that this occurs partly through the formation of stress-specific p53 binding patterns. However, the mechanisms that generate these binding patterns remain largely unknown. It is not established whether the selective binding of p53 is achieved through modulation of its binding affinity to certain response elements (REs) or via a chromatin-dependent mechanism. To shed light on this issue, we used a microsphere assay for protein-DNA binding to measure p53 binding patterns on naked DNA. In parallel, we measured p53 binding patterns within chromatin using chromatin immunoprecipitation and DNase I coupled to ligation-mediated polymerase chain reaction footprinting. Through this experimental approach, we revealed that UVB and Nutlin-3 doses, which lead to different cellular outcomes, induce similar p53 binding patterns on naked DNA. Conversely, the same treatments lead to stress-specific p53 binding patterns on chromatin. We show further that altering chromatin remodeling using an histone acetyltransferase inhibitor reduces p53 binding to REs. Altogether, our results reveal that the formation of p53 binding patterns is not due to the modulation of sequence-specific p53 binding affinity. Rather, we propose that chromatin and chromatin remodeling are required in this process.
C1 [Millau, Jean-Francois; Perron, Josiann; Bastien, Nathalie; Bouchard, Eric F.; Drouin, Regen] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pediat, Div Genet, Sherbrooke, PQ J1H 5N4, Canada.
[Bandele, Omari J.; Bell, Douglas A.] NIEHS, Environm Genom Grp, Mol Genet Lab, Res Triangle Pk, NC 27709 USA.
[Gaudreau, Luc] Univ Sherbrooke, Fac Sci, Dept Biol, Sherbrooke, PQ J1K 2R1, Canada.
RP Drouin, R (reprint author), Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pediat, Div Genet, Sherbrooke, PQ J1H 5N4, Canada.
EM regen.drouin@usherbrooke.ca
FU Canada Research Chair Program; Canadian Institutes of Health Research;
National Institute of Environmental Health Sciences, National Institutes
of Health [ZO1-ES-100475, Z01 ES065079]; Foundation of Stars; Canadian
Foundation for Innovation; Centre de Recherche Clinique Etienne-Le Bel
of the CHUS
FX The Canada Research Chair Program ('Genetics, Mutagenesis and Cancer' to
R. D. and 'Mechanisms of Gene Transcription' to L. G.); the Canadian
Institutes of Health Research (to L. G.); and the Intramural Research
Program of the National Institute of Environmental Health Sciences,
National Institutes of Health (ZO1-ES-100475 and Z01 ES065079 to O.J.B.
and D. A. B.); Foundation of Stars, post-doctoral fellowship (to
J.-F.M.); Parts of the research were carried out in facilities funded by
grants from the Canadian Foundation for Innovation and from the Centre
de Recherche Clinique Etienne-Le Bel of the CHUS. Funding for open
access charge: Canada Research Chair Program ('Genetics, Mutagenesis and
Cancer' to R. D.).
NR 47
TC 7
Z9 7
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR
PY 2011
VL 39
IS 8
BP 3053
EP 3063
DI 10.1093/nar/gkq1209
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 757AD
UT WOS:000290055200012
PM 21177650
ER
PT J
AU Kim, KK
Kim, YC
Adelstein, RS
Kawamoto, S
AF Kim, Kee K.
Kim, Yong C.
Adelstein, Robert S.
Kawamoto, Sachiyo
TI Fox-3 and PSF interact to activate neural cell-specific alternative
splicing
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID PRE-MESSENGER-RNA; HEAVY CHAIN-B; NONMUSCLE MYOSIN; COMPLEX-FORMATION;
NERVOUS-SYSTEM; PROTEIN; EXON; EXPRESSION; CLONING; ISOFORM
AB Fox-1 family (Fox) proteins, which consist of Fox-1 (A2BP1), Fox-2 (Rbm9) and Fox-3 (NeuN) in mammals, bind to the RNA element UGCAUG and regulate alternative pre-mRNA splicing. However the mechanisms for Fox-regulated splicing are largely unknown. We analyzed the expression pattern of the three Fox proteins as well as neural cell-specific alternative splicing of a cassette exon N30 of nonmuscle myosin heavy chain (NMHC) II-B in the mouse central nervous system. Histological and biochemical analyses following fluorescence-activated cell sorting demonstrate a positive correlation of N30 inclusion and Fox-3 expression. Further, we identified polypyrimidine tract binding protein-associated splicing factor (PSF) as an interacting protein with Fox-3 by affinity-chromatography. In cultured cells, enhancement of N30 inclusion by Fox-3 depends on the presence of PSF. PSF enhances N30 inclusion in a UGCAUG-dependent manner, although it does not bind directly to this element. Fox-3 is recruited to the UGCAUG element downstream of N30 in the endogenous NMHC II-B transcript in a PSF-dependent manner. This study is the first to identify PSF as a coactivator of Fox proteins and provides evidence that the Fox-3 and PSF interaction is an integral part of the mechanism by which Fox proteins regulate activation of alternative exons via a downstream intronic enhancer.
C1 [Kim, Kee K.; Adelstein, Robert S.; Kawamoto, Sachiyo] NHLBI, Mol Cardiol Lab, Bethesda, MD 20892 USA.
[Kim, Yong C.] NIAID, Cellular Immunol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
RP Kawamoto, S (reprint author), NHLBI, Mol Cardiol Lab, Bethesda, MD 20892 USA.
EM kawamots@mail.nih.gov
RI Kim, Kee/F-8784-2011;
OI Adelstein, Robert/0000-0002-8683-2144
FU Division of Intramural Research, National Heart, Lung, and Blood
Institute, National Institutes of Health, USA
FX Funding for open access charge: Division of Intramural Research,
National Heart, Lung, and Blood Institute, National Institutes of
Health, USA.
NR 55
TC 38
Z9 40
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR
PY 2011
VL 39
IS 8
BP 3064
EP 3078
DI 10.1093/nar/gkq1221
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 757AD
UT WOS:000290055200013
PM 21177649
ER
PT J
AU Zhang, F
Hinnebusch, AG
AF Zhang, Fan
Hinnebusch, Alan G.
TI An upstream ORF with non-AUG start codon is translated in vivo but
dispensable for translational control of GCN4 mRNA
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID AMINO-ACID CONTROL; EIF2-ALPHA KINASE GCN2; SACCHAROMYCES-CEREVISIAE;
EUKARYOTIC TRANSLATION; MAMMALIAN-CELLS; GENE-EXPRESSION; INITIATION;
PROTEIN; YEAST; REINITIATION
AB Genome-wide analysis of ribosome locations in mRNAs of Saccharomyces cerevisiae has revealed the translation of upstream open reading frames that initiate with near-cognate start codons in many transcripts. Two such non-translation initiation codon (AUG)-initiated upstream open reading frames (uORFs) (nAuORFs 1 and 2) occur in GCN4 mRNA upstream of the four AUG-initiated uORFs (uORFs 1-4) that regulate GCN4 translation. We verified that nAuORF2 is translated in vivo by demonstrating beta-galactosidase production from lacZ coding sequences fused to nAuORF2, in a manner abolished by replacing its non-AUG initiation codon (AUA) start codon with the non-cognate triplet AAA, whereas translation of nAuORF1 was not detected. Importantly, replacing the near-cognate start codons of both nAuORFs with non-cognate triplets had little or no effect on the repression of GCN4 translation in non-starved cells, nor on its derepression in response to histidine limitation, nutritional shift-down or treatment with rapamycin, hydrogen peroxide or methyl methanesulfonate. Additionally, we found no evidence that initiation from the AUA codon of nAuORF2 is substantially elevated, or dependent on Gcn2, the sole eIF2 alpha kinase of yeast, in histidine-deprived cells. Thus, although nAuORF2 is translated in vivo, it appears that this event is not stimulated by eIF2 alpha phosphorylation nor significantly influences GCN4 translational induction under various starvation or stress conditions.
C1 [Zhang, Fan; Hinnebusch, Alan G.] Eunice K Shriver Natl Inst Child Hlth & Human Dev, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA.
RP Hinnebusch, AG (reprint author), Eunice K Shriver Natl Inst Child Hlth & Human Dev, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA.
EM ahinnebusch@nih.gov
FU National Institutes of Health
FX The research was supported by the Intramural Research Program of the
National Institutes of Health.
NR 38
TC 12
Z9 12
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR
PY 2011
VL 39
IS 8
BP 3128
EP 3140
DI 10.1093/nar/gkq1251
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 757AD
UT WOS:000290055200018
PM 21227927
ER
PT J
AU Prokesch, A
Bogner-Strauss, JG
Hackl, H
Rieder, D
Neuhold, C
Walenta, E
Krogsdam, A
Scheideler, M
Papak, C
Wong, WC
Vinson, C
Eisenhaber, F
Trajanoski, Z
AF Prokesch, Andreas
Bogner-Strauss, Juliane G.
Hackl, Hubert
Rieder, Dietmar
Neuhold, Claudia
Walenta, Evelyn
Krogsdam, Anne
Scheideler, Marcel
Papak, Christine
Wong, Wing-Cheong
Vinson, Charles
Eisenhaber, Frank
Trajanoski, Zlatko
TI Arxes: retrotransposed genes required for adipogenesis
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID MICROSOMAL SIGNAL PEPTIDASE; PPAR-GAMMA; HUMAN GENOME; PROCESSED
PSEUDOGENES; EXPRESSION; BINDING; PROTEIN; CELLS; ADIPOCYTES; SEQUENCES
AB Retrotransposed sequences arise from messenger RNAs (mRNAs) that have been reinserted into genomic DNA by reverse transcription. Usually, these sequences are embedded in dormant regions, collect missense mutations over time and constitute processed, nonfunctional pseudogenes. There are thousands of processed pseudogenes in the mouse and human genome. Here, we report evidence for two paralog genes (termed Arxes1 and Arxes2), which arose by retrotransposition of the signal peptidase Spcs3 followed by a segmental duplication event. They gained a functional promoter that we show to be transactivated by adipogenic transcription factors. We further show that the Arxes mRNAs are highly expressed in adipose tissue and strongly upregulated during adipogenesis in different cell models. Additionally, their expression is elevated by an anti-diabetic agent in vitro and in vivo. Importantly, we provide evidence that the Arxes genes are translated and that the proteins are located in the endoplasmic reticulum. Although the sequence similarity and subcellular location are reminiscent of their parental gene, our data suggest that the Arxes have developed a different function, since their expression is required for adipogenesis, whereas Spcs3 is dispensable. In summary, we report retrotransposed-duplicated genes that evolved from a parental gene to function in a tissue and adipogenesis-specific context.
C1 [Prokesch, Andreas; Bogner-Strauss, Juliane G.; Neuhold, Claudia; Walenta, Evelyn; Scheideler, Marcel; Papak, Christine] Graz Univ Technol, Inst Genom & Bioinformat, A-8010 Graz, Austria.
[Hackl, Hubert; Rieder, Dietmar; Krogsdam, Anne; Trajanoski, Zlatko] Innsbruck Med Univ, Div Bioinformat, Bioctr, Innsbruck, Austria.
[Wong, Wing-Cheong; Eisenhaber, Frank] ASTAR, Bioinformat Inst, Singapore, Singapore.
[Vinson, Charles] NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Eisenhaber, Frank] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore.
[Eisenhaber, Frank] Nanyang Technol Univ, Sch Comp Engn, Singapore, Singapore.
RP Prokesch, A (reprint author), Univ Penn, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.
EM andreas.prokesch@tugraz.at; zlatko.trajanoski@i-med.ac.at
OI Bogner-Strauss, Juliane/0000-0003-2459-0124; Hackl,
Hubert/0000-0003-4055-3841
FU Austrian Federal Ministry for Science and Research; Austrian Science
Fund
FX The GEN-AU projects BIN and GOLD from the Austrian Federal Ministry for
Science and Research; SFB Project Lipotoxicity from the Austrian Science
Fund. Funding for open access charge: Austrian Federal Ministry for
Science and Research, GEN-AU project BIN.
NR 45
TC 10
Z9 11
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR
PY 2011
VL 39
IS 8
BP 3224
EP 3239
DI 10.1093/nar/gkq1289
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 757AD
UT WOS:000290055200025
PM 21177646
ER
PT J
AU Baar, C
d'Abbadie, M
Vaisman, A
Arana, ME
Hofreiter, M
Woodgate, R
Kunkel, TA
Holliger, P
AF Baar, Claudia
d'Abbadie, Marc
Vaisman, Alexandra
Arana, Mercedes E.
Hofreiter, Michael
Woodgate, Roger
Kunkel, Thomas A.
Holliger, Philipp
TI Molecular breeding of polymerases for resistance to environmental
inhibitors
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID COMPARTMENTALIZED SELF-REPLICATION; ANCIENT DNA EXTRACTION;
DIRECTED-EVOLUTION; TAQ POLYMERASE; PCR INHIBITORS; CHAIN-REACTION;
HUMIC-ACID; AMPLIFICATION; PURIFICATION; COMPOST
AB Potent inhibitors limit the use of PCR assays in a wide spectrum of specimens. Here, we describe the engineering of polymerases with a broad resistance to complex environmental inhibitors using molecular breeding of eight different polymerase orthologues from the genus Thermus and directed evolution by CSR in the presence of inhibitors. Selecting for resistance to the inhibitory effects of Neomylodon bone powder, we isolated 2D9, a chimeric polymerase comprising sequence elements derived from DNA polymerases from Thermus aquaticus, Thermus oshimai, Thermus thermophilus and Thermus brockianus. 2D9 displayed a striking resistance to a broad spectrum of complex inhibitors of highly divergent composition including humic acid, bone dust, coprolite, peat extract, clay-rich soil, cave sediment and tar. The selected polymerase promises to have utility in PCR-based applications in a wide range of fields including palaeobiology, archaeology, conservation biology, forensic and historic medicine.
C1 [Baar, Claudia; d'Abbadie, Marc; Holliger, Philipp] MRC Lab Mol Biol, Cambridge CB2 0QH, England.
[Vaisman, Alexandra; Woodgate, Roger] NICHHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA.
[Arana, Mercedes E.; Kunkel, Thomas A.] NIEHS, Mol Genet Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA.
[Arana, Mercedes E.; Kunkel, Thomas A.] NIEHS, Struct Biol Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA.
[Hofreiter, Michael] Max Planck Inst Mol Anthropol, Res Grp Mol Ecol, D-04103 Leipzig, Germany.
RP Holliger, P (reprint author), MRC Lab Mol Biol, Hills Rd, Cambridge CB2 0QH, England.
EM ph1@mrc-lmb.cam.ac.uk
RI Vaisman, Alexandra/C-3766-2013; Hofreiter, Michael/A-3996-2017
OI Vaisman, Alexandra/0000-0002-2521-1467; Hofreiter,
Michael/0000-0003-0441-4705
FU MRC (Medical Research Council) [MC_US_A024_0014]; DFG (Deutsche
Forschungsgemeinschaft) [BA 3572/1-1]; MRC; Trinity College, Cambridge;
NICHD (National Institute of Child Health and Human Development)/NIH;
Division of Intramural Research of the NIH, NIEHS (National Institute of
Environmental Health Sciences) [Z01 ES065070]
FX MRC (Medical Research Council) program grant MC_US_A024_0014 (to P. H.)
and DFG (Deutsche Forschungsgemeinschaft) (grant BA 3572/1-1 to C. B.);
MRC studentship and a Junior Research Fellowship from Trinity College,
Cambridge (to M.d'A.); NICHD (National Institute of Child Health and
Human Development)/NIH Intramural Research Program (to R. W. and A. V.).
The work of M. E. A. and T. A. K. was supported in part by Project Z01
ES065070 (to T. A. K.) from the Division of Intramural Research of the
NIH, NIEHS (National Institute of Environmental Health Sciences).
Funding for open access charge: MRC.
NR 42
TC 26
Z9 26
U1 3
U2 30
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR
PY 2011
VL 39
IS 8
AR e51
DI 10.1093/nar/gkq1360
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 757AD
UT WOS:000290055200003
PM 21297114
ER
PT J
AU Szabo, R
Rasmussen, AL
Moyer, AB
Kosa, P
Schafer, JM
Molinolo, AA
Gutkind, JS
Bugge, TH
AF Szabo, R.
Rasmussen, A. L.
Moyer, A. B.
Kosa, P.
Schafer, J. M.
Molinolo, A. A.
Gutkind, J. S.
Bugge, T. H.
TI c-Met-induced epithelial carcinogenesis is initiated by the serine
protease matriptase
SO ONCOGENE
LA English
DT Article
DE hepatocyte growth factor; head and neck carcinoma; mTor;
protease-activated signaling; cell surface proteases
ID HEPATOCYTE GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA;
PLASMINOGEN-ACTIVATOR; IN-VIVO; FACTOR/SCATTER FACTOR; BARRIER FUNCTION;
CANCER; MICE; RAPAMYCIN; RECEPTOR
AB The progression and negative outcome of a variety of human carcinomas are intimately associated with aberrant activity of the c-Met oncogene. The underlying cause of this dysregulation, however, remains a subject of discussion, as the majority of cancer patients do not present with activating mutations in c-Met receptor itself. In this study, we show that the oncogenic protease matriptase is ubiquitously co-expressed with the c-Met in human squamous cell carcinomas and amplifies migratory and proliferative responses of primary epithelial cells to the cognate ligand for c-Met, pro-hepatocyte growth factor/scatter factor (proHGF/SF), through c-Met and Gab1 signaling. Furthermore, the selective genetic ablation of c-Met from matriptase-expressing keratinocytes completely negates the oncogenic potential of matriptase. In addition, matriptase-dependent carcinoma formation could be blocked by the pharmacological inhibition of the Akt-mammalian target of Rapamycin (mTor) pathway. Our data identify matriptase as an initiator of c-Met-Akt-mTor-dependent signaling axis in tumors and reveal mTor activation as an essential component of matriptase/ c-Met-induced carcinogenesis. The study provides a specific example of how epithelial transformation can be promoted by epigenetic acquisition of the capacity to convert a widely available paracrine growth factor precursor to its signaling competent state. Oncogene (2011) 30, 2003-2016; doi:10.1038/onc.2010.586; published online 10 January 2011
C1 [Szabo, R.; Rasmussen, A. L.; Moyer, A. B.; Kosa, P.; Schafer, J. M.; Molinolo, A. A.; Gutkind, J. S.; Bugge, T. H.] NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.
RP Bugge, TH (reprint author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.
EM thomas.bugge@nih.gov
RI Gutkind, J. Silvio/A-1053-2009
FU NIDCR
FX We thank Dr Snorri Thorgeirsson for floxed Hgfr mice. Supported by NIDCR
Intramural Research Program. We thank Dr Mary Jo Danton for critically
reviewing this manuscript.
NR 50
TC 36
Z9 37
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD APR
PY 2011
VL 30
IS 17
BP 2003
EP 2016
DI 10.1038/onc.2010.586
PG 14
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 755YL
UT WOS:000289977400004
PM 21217780
ER
PT J
AU Munir, S
Hillyer, P
Le Nouen, C
Buchholz, UJ
Rabin, RL
Collins, PL
Bukreyev, A
AF Munir, Shirin
Hillyer, Philippa
Le Nouen, Cyril
Buchholz, Ursula J.
Rabin, Ronald L.
Collins, Peter L.
Bukreyev, Alexander
TI Respiratory Syncytial Virus Interferon Antagonist NS1 Protein Suppresses
and Skews the Human T Lymphocyte Response
SO PLOS PATHOGENS
LA English
DT Article
ID NF-KAPPA-B; DENDRITIC CELLS; I INTERFERON; IFN-ALPHA; NONSTRUCTURAL
PROTEINS; CLONAL EXPANSION; EPITHELIAL-CELLS; ALPHA(E)BETA(7) INTEGRIN;
REGULATORY FACTOR-3; PRIMARY INFECTION
AB We recently demonstrated that the respiratory syncytial virus (RSV) NS1 protein, an antagonist of host type I interferon (IFN-I) production and signaling, has a suppressive effect on the maturation of human dendritic cells (DC) that was only partly dependent on released IFN-I. Here we investigated whether NS1 affects the ability of DC to activate CD8+ and CD4+ T cells. Human DC were infected with RSV deletion mutants lacking the NS1 and/or NS2 genes and assayed for the ability to activate autologous T cells in vitro, which were analyzed by multi-color flow cytometry. Deletion of the NS1, but not NS2, protein resulted in three major effects: (i) an increased activation and proliferation of CD8+ T cells that express CD103, a tissue homing integrin that directs CD8+ T cells to mucosal epithelial cells of the respiratory tract and triggers cytolytic activity; (ii) an increased activation and proliferation of Th17 cells, which have recently been shown to have anti-viral effects and also indirectly attract neutrophils; and (iii) decreased activation of IL-4-producing CD4+ T cells - which are associated with enhanced RSV disease - and reduced proliferation of total CD4+ T cells. Except for total CD4+ T cell proliferation, none of the T cell effects appeared to be due to increased IFN-I signaling. In the infected DC, deletion of the NS1 and NS2 genes strongly up-regulated the expression of cytokines and other molecules involved in DC maturation. This was partly IFN-I-independent, and thus might account for the T cell effects. Taken together, these data demonstrate that the NS1 protein suppresses proliferation and activation of two of the protective cell populations (CD103+ CD8+ T cells and Th17 cells), and promotes proliferation and activation of Th2 cells that can enhance RSV disease.
C1 [Munir, Shirin; Le Nouen, Cyril; Buchholz, Ursula J.; Collins, Peter L.; Bukreyev, Alexander] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
[Hillyer, Philippa; Rabin, Ronald L.] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA.
RP Munir, S (reprint author), NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
EM alexander.bukreyev@utmb.edu
FU NIAID, NIH
FX This project was funded by the NIAID, NIH, Intramural Program. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 89
TC 44
Z9 44
U1 3
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2011
VL 7
IS 4
AR e1001336
DI 10.1371/journal.ppat.1001336
PG 17
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 755ZE
UT WOS:000289979900008
PM 21533073
ER
PT J
AU Triyatni, M
Berger, EA
Saunier, B
AF Triyatni, Miriam
Berger, Edward A.
Saunier, Bertrand
TI A New Model to Produce Infectious Hepatitis C Virus without the
Replication Requirement
SO PLOS PATHOGENS
LA English
DT Article
ID WEST-NILE-VIRUS; PRIMARY HUMAN HEPATOCYTES; DOUBLE-STRANDED-RNA; B
TYPE-I; CELL-CULTURE; ASIALOGLYCOPROTEIN RECEPTOR; KUNJIN VIRUS;
EFFICIENT REPLICATION; MEDIATED ENDOCYTOSIS; STRUCTURAL PROTEINS
AB Numerous constraints significantly hamper the experimental study of hepatitis C virus (HCV). Robust replication in cell culture occurs with only a few strains, and is invariably accompanied by adaptive mutations that impair in vivo infectivity/replication. This problem complicates the production and study of authentic HCV, including the most prevalent and clinically important genotype 1 (subtypes 1a and 1b). Here we describe a novel cell culture approach to generate infectious HCV virions without the HCV replication requirement and the associated cell-adaptive mutations. The system is based on our finding that the intracellular environment generated by a West-Nile virus (WNV) subgenomic replicon rendered a mammalian cell line permissive for assembly and release of infectious HCV particles, wherein the HCV RNA with correct 5' and 3' termini was produced in the cytoplasm by a plasmid-driven dual bacteriophage RNA polymerase-based transcription/amplification system. The released particles preferentially contained the HCV-based RNA compared to the WNV subgenomic RNA. Several variations of this system are described with different HCV-based RNAs: (i) HCV bicistronic particles (HCVbp) containing RNA encoding the HCV structural genes upstream of a cell-adapted subgenomic replicon, (ii) HCV reporter particles (HCVrp) containing RNA encoding the bacteriophage SP6 RNA polymerase in place of HCV nonstructural genes, and (iii) HCV wild-type particles (HCVwt) containing unmodified RNA genomes of diverse genotypes (1a, strain H77; 1b, strain Con1; 2a, strain JFH-1). Infectivity was assessed based on the signals generated by the HCV RNA molecules introduced into the cytoplasm of target cells upon virus entry, i. e. HCV RNA replication and protein production for HCVbp in Huh-7.5 cells as well as for HCVwt in HepG2-CD81 cells and human liver slices, and SP6 RNA polymerase-driven firefly luciferase for HCVrp in target cells displaying candidate HCV surface receptors. HCV infectivity was inhibited by pre-incubation of the particles with anti-HCV antibodies and by a treatment of the target cells with leukocyte interferon plus ribavirin. The production of authentic infectious HCV particles of virtually any genotype without the adaptive mutations associated with in vitro HCV replication represents a new paradigm to decipher the requirements for HCV assembly, release, and entry, amenable to analyses of wild type and genetically modified viruses of the most clinically significant HCV genotypes.
C1 [Triyatni, Miriam; Berger, Edward A.; Saunier, Bertrand] NIAID, Mol Struct Sect, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
[Saunier, Bertrand] Paris Descartes Univ, Fac Med, Paris, France.
[Saunier, Bertrand] Inst Cochin Genet Mol, F-75014 Paris, France.
[Saunier, Bertrand] INSERM, U1016, Paris, France.
RP Triyatni, M (reprint author), Hoffmann La Roche Inc, 340 Kingsland St, Nutley, NJ 07110 USA.
EM bertrand.saunier@inserm.fr
FU NIH, NIAID
FX This research was funded in part by the Intramural Program of the NIH,
NIAID. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 75
TC 8
Z9 10
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2011
VL 7
IS 4
AR e1001333
DI 10.1371/journal.ppat.1001333
PG 19
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 755ZE
UT WOS:000289979900005
PM 21533214
ER
PT J
AU Wurtz, RH
McAlonan, K
Cavanaugh, J
Berman, RA
AF Wurtz, Robert H.
McAlonan, Kerry
Cavanaugh, James
Berman, Rebecca A.
TI Thalamic pathways for active vision
SO TRENDS IN COGNITIVE SCIENCES
LA English
DT Review
ID MONKEY SUPERIOR COLLICULUS; SACCADIC EYE-MOVEMENTS; BRAIN-STEM TELLS;
SPATIAL ATTENTION; FRONTAL-CORTEX; COROLLARY DISCHARGE; EXTRASTRIATE
CORTEX; RETICULAR NUCLEUS; RECEPTIVE FIELDS; BEHAVING MONKEY
AB Active vision requires the integration of information coming from the retina with that generated internally within the brain, especially by saccadic eye movements. Just as visual information reaches cortex via the lateral geniculate nucleus of the thalamus, this internal information reaches the cerebral cortex through other higher-order nuclei of the thalamus. This review summarizes recent work on four of these thalamic nuclei. The first two pathways convey internal information about up-coming saccades (a corollary discharge) and probably contribute to the neuronal mechanisms that underlie stable visual perception. The second two pathways might contribute to the neuronal mechanisms underlying visual spatial attention in cortex and in the thalamus itself.
C1 [Wurtz, Robert H.; McAlonan, Kerry; Cavanaugh, James; Berman, Rebecca A.] NEI, Lab Sensorimotor Res, NIH, Bethesda, MD 20892 USA.
RP Wurtz, RH (reprint author), NEI, Lab Sensorimotor Res, NIH, Bethesda, MD 20892 USA.
EM bob@lsr.nei.nih.gov
FU Intramural NIH HHS [ZIA EY000109-30]
NR 70
TC 44
Z9 44
U1 1
U2 18
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1364-6613
J9 TRENDS COGN SCI
JI TRENDS COGN. SCI.
PD APR
PY 2011
VL 15
IS 4
BP 177
EP 184
DI 10.1016/j.tics.2011.02.004
PG 8
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 753DY
UT WOS:000289747100006
PM 21414835
ER
PT J
AU Colsch, B
Jackson, SN
Dutta, S
Woods, AS
AF Colsch, Benoit
Jackson, Shelley N.
Dutta, Sucharita
Woods, Amina S.
TI Molecular Microscopy of Brain Gangliosides: Illustrating their
Distribution in Hippocampal Cell Layers
SO ACS CHEMICAL NEUROSCIENCE
LA English
DT Article
DE gangliosides; MALDI-imaging; molecular mapping; brain; hippocampus
ID DESORPTION/IONIZATION MASS-SPECTROMETRY; CENTRAL-NERVOUS-SYSTEM;
MOUSE-BRAIN; TISSUE SECTIONS; SIALIC ACIDS; MATRIX; GLYCOSPHINGOLIPIDS;
CHROMATOGRAPHY; LOCALIZATION; RECOGNITION
AB Gangliosides are amphiphilic molecules found in the outer layer of plasma membranes of all vertebrate cells. They play a major role in cell recognition and signaling and are involved in diseases affecting the central nervous system (CNS). We are reporting the differential distribution of ganglioside specie; in the rat brain's cerebrum, based on their ceramide associated core, and for the first time the presence of acetylation detected by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry, which was used to map and image gangliosides with detailed structural information and histological accuracy. In the hippocampus, localization of the major species GM1, GD1, O-acetylGD1, GT1, and O-acetylGT1 depends on the sphingoid base (d18:1 sphingosine or d20:1 eicosasphingosine) in the molecular layer of the dentate gyrus (ML), which is made up of three distinct layers, the inner molecular layer (IML), which contains sphingosine exclusively, and the middle molecular layer (MML) and the outer molecular layer (0 ML) where eicosasphingosine is the only sphingoid base. These results demonstrate that there is a different distribution of gangliosides in neuronal axons and dendrites depending on the ceramide core of each layer. GM3, GM2, GD3, and GD2 contain sphingosine predominantly and are mainly present in body cell layers, which are made up of the pyramidal cell layer (Py) and the granular layer of the dentate gyrus (GL), in contrast with GQ1 and the O-acetylated forms of GD1, GT1, and GQ1 gangliosides, which contain both sphingoid bases. However their distribution is based on the sialylated and acetylated oligosaccharide chains in the neuronal cell bodies.
C1 [Colsch, Benoit; Jackson, Shelley N.; Woods, Amina S.] NIDA IRP, Struct Biol Unit, Cellular Neurobiol Sect, NIH, Baltimore, MD 21224 USA.
[Dutta, Sucharita] Thermo Fisher Sci, San Jose, CA USA.
RP Woods, AS (reprint author), NIDA IRP, Struct Biol Unit, Cellular Neurobiol Sect, NIH, Baltimore, MD 21224 USA.
EM awoods@mail.nih.gov
FU National Institute on Drug Abuse, NIH; Office of National Drug Control
Policy (ONDCP)
FX This research was supported by the Intramural Research Program of the
National Institute on Drug Abuse, NIH. We thank the Office of National
Drug Control Policy (ONDCP) for instrumentation funding, without which
this and other projects could net have been accomplished.
NR 38
TC 32
Z9 34
U1 2
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7193
J9 ACS CHEM NEUROSCI
JI ACS Chem. Neurosci.
PD APR
PY 2011
VL 2
IS 4
BP 213
EP 222
DI 10.1021/cn100096h
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences
& Neurology
GA 753HF
UT WOS:000289762200005
PM 21961052
ER
PT J
AU Huang, KP
Huang, FL
AF Huang, Kuo-Ping
Huang, Freesia L.
TI Calcium-Sensitive Translocation of Calmodulin and Neurogranin between
Soma and Dendrites of Mouse Hippocampal CA1 Neurons
SO ACS CHEMICAL NEUROSCIENCE
LA English
DT Article
DE Calmodulin; neurogranin; calcium; translocation; hippocampus; epileptic
activity
ID PROTEIN-KINASE-C; ACTIVE-CHEMICAL SYNAPSES; RAT-BRAIN; SYNAPTIC
PLASTICITY; IN-VIVO; PHOSPHORYLATION; TRANSMISSION; SUBSTRATE; SLICES;
EPILEPTOGENESIS
AB Calmodulin (CaM) and neurogranin (Ng) are two abundant neuronal proteins whose interactions are implicated in the regulation of synaptic responses and plasticity. We employed the "low-calcium" model of epilepsy in hippocampal slices to investigate the mobilization of these two proteins in CA1 pyramidal neurons. Perfusion of mouse hippocampal slices with Ca(2+)-free artificial CSF (ACSF) caused a suppression of synaptic transmission and generation of epileptic activity; these responses could be reversed by normal Ca(2+)-containing ACSF. Fluorescence immunochemical staining of control hippocampal slices bathed in normal ACSF revealed that CaM and Ng were more concentrated in soma than in dendrites; especially for CaM, it was concentrated in the nucleus. Perfusion of hippocampal slices with Ca(2+)-free ACSF caused translocation of these two proteins from soma to dendrites, and this trafficking was also reversed by Ca(2+)-containing buffer. A reduction of similar to 15 and 40 nM intracellular Ca(2+), [Ca(2+)](i), caused half-maximum translocation of Ng and CaM, respectively. Hippocampal CA1 pyramidal neurons were the most responsive to this Ca(2+)-sensitive translocation as compared to those from other areas of the hippocampus. These results illustrated the unique feature of hippocampal CA1 pyramidal neurons in sequestering high concentrations of CaM and Ng in soma and releasing them to distal dendrites at reducing level of [Ca(2+)](i).
C1 [Huang, Kuo-Ping; Huang, Freesia L.] NICHHD, Program Dev Neurobiol, NIH, Bethesda, MD 20892 USA.
RP Huang, KP (reprint author), NICHHD, Program Dev Neurobiol, NIH, Bldg 49,Room 6A10,49 Convent Dr,MSC 4510, Bethesda, MD 20892 USA.
EM huangk@mail.nih.gov
FU NICHD, NIH
FX This work was supported by the Intramural Program of NICHD, NIH.
NR 38
TC 1
Z9 2
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7193
J9 ACS CHEM NEUROSCI
JI ACS Chem. Neurosci.
PD APR
PY 2011
VL 2
IS 4
BP 223
EP 230
DI 10.1021/cn200003f
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences
& Neurology
GA 753HF
UT WOS:000289762200006
ER
PT J
AU Xie, J
Zhang, F
Aronova, M
Zhu, L
Lin, X
Quan, QM
Liu, G
Zhang, GF
Choi, KY
Kim, K
Sun, XL
Lee, S
Sun, SH
Leapman, R
Chen, XY
AF Xie, Jin
Zhang, Fan
Aronova, Maria
Zhu, Lei
Lin, Xin
Quan, Qimeng
Liu, Gang
Zhang, Guofeng
Choi, Ki-Young
Kim, Kwangmeyung
Sun, Xiaolian
Lee, Seulki
Sun, Shouheng
Leapman, Richard
Chen, Xiaoyuan
TI Manipulating the Power of an Additional Phase: A Flower-like Au-Fe3O4
Optical Nanosensor for Imaging Protease Expressions In vivo
SO ACS NANO
LA English
DT Article
DE composite nanoparticles; Au-Fe3O4; matrix metalloproteinase; activatable
probes; near-infrared fluorescence imaging
ID IRON-OXIDE NANOPARTICLES; GOLD NANOPARTICLES; MAGNETIC NANOPARTICLES;
HETEROSTRUCTURED NANOPARTICLES; FUNCTIONAL MOLECULES; PROBES; DELIVERY
AB We and others have recently proposed the synthesis of composite nanoparticles that offer strongly enhanced functionality. Here we have used a flower-shaped Au-Fe3O4 nanoparticle as a template to construct an optical probe containing Cy5.5-GPLGVRG-TDOPA on the iron oxide surface and SH-PEG(5000) on the gold surface, that can be specifically activated by matrix metalloproteinases expressed in tumors. Gold nanoparticles have excellent quenching properties, but labile surface chemistry in vivo; on the other hand, iron oxide nanoparticles afford robust surface chemistry, but are suboptimal as energy receptors. By a marriage of the two, we have produced a unified structure with performance that Is unachievable with the separate components. Our results are a further demonstration that the architecture of nanoparticles can be modulated to tailor their function as molecular imaging/therapeutic agents.
C1 [Xie, Jin; Zhang, Fan; Zhu, Lei; Lin, Xin; Quan, Qimeng; Liu, Gang; Lee, Seulki; Chen, Xiaoyuan] NIBIB, LOMIN, NIH, Bethesda, MD 20892 USA.
[Aronova, Maria; Leapman, Richard] NIBIB, Lab Cellular Imaging & Macromol Biophys, NIH, Bethesda, MD 20892 USA.
[Choi, Ki-Young; Kim, Kwangmeyung] Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 136791, South Korea.
[Sun, Xiaolian; Sun, Shouheng] Brown Univ, Dept Chem, Providence, RI 02912 USA.
RP Lee, S (reprint author), NIBIB, LOMIN, NIH, Bethesda, MD 20892 USA.
EM Seulki.Lee@nih.gov; Shawn.Chen@nih.gov
RI Xie, Jin/E-8193-2010; Zhu, Lei/P-9786-2016; CHOI, KI YOUNG/Q-7177-2016
OI Zhu, Lei/0000-0002-1820-4795;
FU National Institute of Biomedical Imaging and Bioengineering (NIBIB),
NIH; National Science Foundation of China (NSFC) [81028009]; NIH
[K99/R00]; National Institute of Standards and Technology (NIST)
FX This work was supported by the Intramural Research Program (IRP) of the
National Institute of Biomedical Imaging and Bioengineering (NIBIB),
NIH, and the International Cooperative Program of National Science
Foundation of China (NSFC) (81028009). J.X. is partially supported by an
NIH Pathway to Independence Grant (K99/R00). S.L. acknowledges a
National Research Council Research Associateship Award funded by the
National Institute of Standards and Technology (NIST) and the IRP of
NIBIB, NIH. We thank Dr. H. S. Eden for proofreading the manuscript.
NR 28
TC 60
Z9 62
U1 6
U2 139
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD APR
PY 2011
VL 5
IS 4
BP 3043
EP 3051
DI 10.1021/nn200161v
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 753CJ
UT WOS:000289742100073
PM 21366330
ER
PT J
AU Burruss, S
Shen, XD
Baibakov, B
Gao, F
Semiletova, NV
AF Burruss, S.
Shen, X. -D.
Baibakov, B.
Gao, F.
Semiletova, N. V.
TI Soluble Donor-Like MHC Class I Proteins Induce
CD4(+)CD25(+)CD8(+)FoxP3(+) Cells with Potential To Ameliorate Graft
Chronic Injury.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY 2011
CL Philadelphia, PA
C1 [Burruss, S.; Shen, X. -D.; Gao, F.; Semiletova, N. V.] UCLA Med Sch, Los Angeles, CA USA.
[Baibakov, B.] NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2011
VL 11
SU 2
MA 42
BP 41
EP 41
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 747KJ
UT WOS:000289318400042
ER
PT J
AU Yusen, RD
Hong, B
Murray, SK
Messersmith, E
Lopez, B
Brown, KL
Ojo, A
Odim, J
Merion, RM
Barr, M
AF Yusen, R. D.
Hong, B.
Murray, S. K.
Messersmith, E.
Lopez, B.
Brown, K. L.
Ojo, A.
Odim, J.
Merion, R. M.
Barr, M.
CA RELIVE Study Grp
TI Morbidity and Mortality of 369 Live Lung Donors.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY 2011
CL Philadelphia, PA
C1 [Yusen, R. D.; Hong, B.; Brown, K. L.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Murray, S. K.; Ojo, A.; Merion, R. M.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Lopez, B.; Barr, M.] NIAID, NIH, Bethesda, MD USA.
[Odim, J.] Univ So Calif, Los Angeles, CA 90089 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2011
VL 11
SU 2
MA 69
BP 49
EP 49
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 747KJ
UT WOS:000289318400069
ER
PT J
AU Chakkera, H
Dueck, A
Weil, E
Cook, C
Swanson, C
Heilman, R
Reddy, K
Hamawi, K
Moss, A
Mulligan, D
Knowler, W
AF Chakkera, H.
Dueck, A.
Weil, E.
Cook, C.
Swanson, C.
Heilman, R.
Reddy, K.
Hamawi, K.
Moss, A.
Mulligan, D.
Knowler, W.
TI Pre-Transplant Risk Score Predicts Development of New Onset Diabetes
Mellitus after Kidney Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY 2011
CL Philadelphia, PA
C1 [Chakkera, H.; Dueck, A.; Cook, C.; Swanson, C.; Heilman, R.; Reddy, K.; Hamawi, K.; Moss, A.; Mulligan, D.] Mayo Clin, Phoenix, AZ USA.
[Weil, E.; Knowler, W.] NIH NIDDK Phoenix, Phoenix, AZ USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2011
VL 11
SU 2
MA 231
BP 100
EP 101
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 747KJ
UT WOS:000289318400231
ER
PT J
AU Engels, EA
Lin, M
AF Engels, E. A.
Lin, M.
TI Cancer Risk in US Transplant Recipients: The Transplant Cancer Match
Study
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY 2011
CL Philadelphia, PA
C1 [Engels, E. A.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Lin, M.] US Hlth Resources & Serv Adm, Div Transplantat, Rockville, MD 20857 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2011
VL 11
SU 2
MA 244
BP 105
EP 105
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 747KJ
UT WOS:000289318400244
ER
PT J
AU Roland, M
Barin, B
Huprikar, S
Wong, M
Fox, L
Diego, J
Blumberg, E
Simon, D
Shoham, S
Stock, P
AF Roland, M.
Barin, B.
Huprikar, S.
Wong, M.
Fox, L.
Diego, J.
Blumberg, E.
Simon, D.
Shoham, S.
Stock, P.
TI HIV-Related Predictors and Outcomes in 275 Liver and/or Kidney
Transplant Recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY 2011
CL Philadelphia, PA
C1 [Roland, M.; Stock, P.] UCSF, San Francisco, CA USA.
[Fox, L.] NIAID, NIH, Bethesda, MD USA.
[Diego, J.] U Miami, Miami, FL USA.
[Blumberg, E.] U Penn, Philadelphia, PA USA.
[Shoham, S.] Washington Hosp Ctr, Washington, DC USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2011
VL 11
SU 2
MA 377
BP 143
EP 144
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 747KJ
UT WOS:000289318400377
ER
PT J
AU Taler, SJ
Gillespie, B
Ibrahim, H
Kew, CE
Guidinger, MS
Leichtman, A
Kremer, W
Matas, A
Odim, J
Merion, RM
AF Taler, S. J.
Gillespie, B.
Ibrahim, H.
Kew, C. E.
Guidinger, M. S.
Leichtman, A.
Kremer, W.
Matas, A.
Odim, J.
Merion, R. M.
CA RELIVE Study Grp
TI Predictors of End Stage Renal Disease in Live Kidney Donors at Three US
Kidney Transplant Centers.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY 2011
CL Philadelphia, PA
C1 [Gillespie, B.; Leichtman, A.; Merion, R. M.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Taler, S. J.; Kremer, W.] Mayo Clin, Rochester, MN USA.
[Ibrahim, H.; Matas, A.] Univ Minnesota, Minneapolis, MN 55455 USA.
[Kew, C. E.] Univ Alabama, Birmingham, AL USA.
[Odim, J.] NIAID, NIH, Bethesda, MD 20892 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2011
VL 11
SU 2
MA 419
BP 156
EP 156
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 747KJ
UT WOS:000289318400419
ER
PT J
AU Roland, M
Barin, B
Blumberg, E
Feinberg, J
Fox, L
Huprikar, S
Wong, M
Diego, J
Simon, I
Stock, P
AF Roland, M.
Barin, B.
Blumberg, E.
Feinberg, J.
Fox, L.
Huprikar, S.
Wong, M.
Diego, J.
Simon, I.
Stock, P.
TI Tenofovir Is Not Associated with Renal Dysfunction Following Solid Organ
Transplantation.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY 2011
CL Philadelphia, PA
C1 [Feinberg, J.] U Cincinnati, Cincinnati, OH USA.
[Fox, L.] NIAID, NIH, Bethesda, MD 20892 USA.
[Diego, J.] U Miami, Miami, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2011
VL 11
SU 2
MA 857
BP 285
EP 285
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 747KJ
UT WOS:000289318401064
ER
PT J
AU Taler, SJ
Gillespie, B
Ibrahim, H
Kew, CE
Patel, U
Leichtman, A
Kremers, WK
Matas, A
Odim, J
Merion, RM
AF Taler, S. J.
Gillespie, B.
Ibrahim, H.
Kew, C. E.
Patel, U.
Leichtman, A.
Kremers, W. K.
Matas, A.
Odim, J.
Merion, R. M.
CA RELIVE Study Grp
TI Prevalence of Pre-Donation Hypertension and Metabolic Abnormalities
among Live Kidney Donors at Three US Centers: Trends over 45 Years
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY 2011
CL Philadelphia, PA
C1 [Taler, S. J.; Kremers, W. K.] Mayo Clin, Rochester, MN 55905 USA.
[Gillespie, B.; Leichtman, A.; Merion, R. M.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Ibrahim, H.; Matas, A.] Univ Minnesota, Minneapolis, MN 55455 USA.
[Kew, C. E.] Univ Alabama, Birmingham, AL USA.
[Odim, J.] NIAID, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2011
VL 11
SU 2
MA 963.5
BP 316
EP 316
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 747KJ
UT WOS:000289318401173
ER
PT J
AU Carpenter, M
Bostom, A
Hunsicker, L
Ivanova, A
Kasiske, B
Kusek, J
Levey, A
Markell, M
Pesavento, T
Smith, S
Weir, M
AF Carpenter, M.
Bostom, A.
Hunsicker, L.
Ivanova, A.
Kasiske, B.
Kusek, J.
Levey, A.
Markell, M.
Pesavento, T.
Smith, S.
Weir, M.
TI Higher Systolic Blood Pressure Is Associated with Increased
Cardiovascular Risk in Patients with Hypertension in the Folic Acid for
Vascular Outcome Reduction in Transplantation Trial.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY 2011
CL Philadelphia, PA
C1 [Carpenter, M.; Ivanova, A.] Univ N Carolina, Chapel Hill, NC USA.
[Bostom, A.] Rhode Isl Hosp, Providence, RI USA.
[Hunsicker, L.] Univ Iowa, Iowa City, IA USA.
[Kasiske, B.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
[Kusek, J.] NIDDK, NIH, Bethesda, MD USA.
[Levey, A.] Tufts Med Ctr, Boston, MA USA.
[Markell, M.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA.
[Pesavento, T.] Ohio State Univ, Columbus, OH 43210 USA.
[Smith, S.] Duke Univ, Durham, NC USA.
[Weir, M.] Univ Maryland, Baltimore, MD 21201 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2011
VL 11
SU 2
MA 1178
BP 375
EP 375
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 747KJ
UT WOS:000289318401393
ER
PT J
AU Putheti, P
Ding, R
Naqvi, R
Medeiros, M
Sharma, VK
Liu, J
Lin, G
Williams, NM
Bridges, ND
Strom, TB
Suthanthiran, M
Harmon, W
AF Putheti, P.
Ding, R.
Naqvi, R.
Medeiros, M.
Sharma, V. K.
Liu, J.
Lin, G.
Williams, N. M.
Bridges, N. D.
Strom, T. B.
Suthanthiran, M.
Harmon, W.
TI Gene-Expression Profiles of Peripheral Blood Cells and Urinary Cells Are
Diagnostic of Acute Rejection in Renal Allograft Recipients.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT American Transplant Congress
CY 2011
CL Philadelphia, PA
C1 [Putheti, P.; Strom, T. B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Transplant Inst, Boston, MA 02215 USA.
[Ding, R.; Naqvi, R.; Medeiros, M.; Sharma, V. K.; Suthanthiran, M.] Cornell Univ, Med Ctr, New York, NY 10021 USA.
[Liu, J.; Lin, G.] PPD Inc, Raleigh, NC USA.
[Williams, N. M.; Bridges, N. D.] NIAID, Transplantat Immunobiol Branch, Bethesda, MD 20892 USA.
[Harmon, W.] Childrens Hosp, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2011
VL 11
SU 2
MA 1430
BP 446
EP 446
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 747KJ
UT WOS:000289318401648
ER
PT J
AU Agurs-Collins, T
Perna, F
Oh, A
Chriqui, JF
Masse, LC
AF Agurs-Collins, Tanya
Perna, Frank
Oh, April
Chriqui, Jamie F.
Masse, Louise C.
TI FIVE-YEAR CHANGE IN US STATE COMPETITIVE FOOD LAWS AFFECTING MIDDLE
SCHOOLS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Agurs-Collins, Tanya; Perna, Frank; Oh, April] NCI, Rockville, MD 20852 USA.
[Chriqui, Jamie F.] Univ Illinois, Chicago, IL USA.
[Masse, Louise C.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
EM collinsta@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S132
EP S132
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701008
ER
PT J
AU Beckjord, EB
Rechis, R
Moser, RP
Hesse, BW
AF Beckjord, Ellen B.
Rechis, Ruth
Moser, Richard P.
Hesse, Bradford W.
TI METHODS FOR INCREASING BROAD PARTICIPATION IN BEHAVIORAL SCIENCE:
EXAMPLES OF CONSTRUCTING, FIELDING, AND HARMONIZING USE OF BEHAVIORAL
MEASURES
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Beckjord, Ellen B.] Univ Pittsburgh, Pittsburgh, PA USA.
[Rechis, Ruth] LIVESTRONG, Austin, TX USA.
[Moser, Richard P.; Hesse, Bradford W.] NCI, Bethesda, MD 20892 USA.
EM ebeckjor@rand.org
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S144
EP S144
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701051
ER
PT J
AU Beckjord, EB
Moser, RP
Rutten, LJF
Blake, K
Hesse, BW
AF Beckjord, Ellen B.
Moser, Richard P.
Rutten, Lila J. Finney
Blake, Kelly
Hesse, Bradford W.
TI USING SCIENCE 2.0 TO CONSTRUCT A SURVEILLANCE TOOL: BUILDING A BETTER
HEALTH INFORMATION NATIONAL TRENDS SURVEY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Beckjord, Ellen B.] Univ Pittsburgh, Pittsburgh, PA USA.
[Moser, Richard P.; Blake, Kelly; Hesse, Bradford W.] NCI, Bethesda, MD 20892 USA.
[Rutten, Lila J. Finney] SAIC Frederick, Frederick, MD USA.
EM ebeckjor@rand.org
NR 0
TC 0
Z9 0
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S144
EP S144
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701052
ER
PT J
AU Bellizzi, K
Breslau, E
AF Bellizzi, Keith
Breslau, Erica
TI PREVALENCE OF CANCER SCREENING AND PHYSICIAN RECOMMENDATIONS FOR
SCREENING IN OLDER ADULTS FROM MINORITY BACKGROUNDS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Bellizzi, Keith] UConn, Storrs, CT 06269 USA.
[Breslau, Erica] NCI, Bethesda, MD 20892 USA.
EM keith.m.bellizzi@uconn.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S239
EP S239
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701425
ER
PT J
AU Bergman, HE
Scholl, S
Moser, RP
Reeve, BB
Klein, WM
AF Bergman, Hannah E.
Scholl, Sarah
Moser, Richard P.
Reeve, Bryce B.
Klein, William M.
TI DEVELOPMENT OF A COMPREHENSIVE HEART DISEASE KNOWLEDGE QUESTIONNAIRE
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Bergman, Hannah E.; Moser, Richard P.; Klein, William M.] NCI, Div Canc Control & Populat Sci, Rockville, MD 20852 USA.
[Scholl, Sarah] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
[Reeve, Bryce B.] Univ N Carolina, Lineberger Canc Ctr, Chapel Hill, NC USA.
[Reeve, Bryce B.] Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC USA.
EM bergmanhe@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S89
EP S89
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700348
ER
PT J
AU Biesecker, BB
Erby, L
Woolford, S
Reeve, B
AF Biesecker, Barbara B.
Erby, Lori
Woolford, Samuel
Reeve, Bryce
TI DEVELOPMENT AND EVALUATION OF AN ADAPTATION SCALE: USE IN SIX STUDIES ON
LIVING WITH OR BEING AT RISK FOR A GENETIC CONDITION
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Biesecker, Barbara B.] NIH, Social & Behav Res Inst, Bethesda, MD 20892 USA.
[Biesecker, Barbara B.; Erby, Lori] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Woolford, Samuel] Bentley Univ, Boston, MA USA.
[Reeve, Bryce] Univ N Carolina, Chapel Hill, NC USA.
EM barbarab@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S22
EP S22
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700082
ER
PT J
AU Caccavale, LJ
Nansel, T
Haynie, D
Laffel, L
Mehta, S
AF Caccavale, Laura J.
Nansel, Tonja
Haynie, Denise
Laffel, Lori
Mehta, Sanjeev
TI DISORDERED EATING AMONG ADOLESCENTS WITH TYPE 1 DIABETES: RELATIONS WITH
FAMILY ENVIRONMENT AND QUALITY OF LIFE
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Caccavale, Laura J.; Nansel, Tonja; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
[Laffel, Lori; Mehta, Sanjeev] Joslin Diabet Ctr, Boston, MA 02215 USA.
EM caccavalel@mail.nih.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S206
EP S206
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701294
ER
PT J
AU Caccavale, LJ
Farhat, T
Iannotti, RJ
AF Caccavale, Laura J.
Farhat, Tilda
Iannotti, Ronald J.
TI THE EFFECT OF PARENT COMMUNICATION ON WEIGHT CONTROL BEHAVIORS IN
OVERWEIGHT ADOLESCENTS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Caccavale, Laura J.; Farhat, Tilda; Iannotti, Ronald J.] NICHD, NIH, Bethesda, MD USA.
EM caccavalel@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S174
EP S174
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701165
ER
PT J
AU Chambers, D
AF Chambers, David
TI A DYNAMIC APPROACH TO SUSTAINABILITY OF EFFECTIVE INTERVENTIONS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Chambers, David] NIMH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S131
EP S131
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701001
ER
PT J
AU Czajkowski, SM
Riley, W
Pilkonis, PA
Weinfurt, KP
AF Czajkowski, Susan M.
Riley, William
Pilkonis, Paul A.
Weinfurt, Kevin P.
TI PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): USING
NEW THEORY AND TECHNOLOGY TO IMPROVE MEASUREMENT OF PATIENT-REPORTED
OUTCOMES IN CLINICAL RESEARCH
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Czajkowski, Susan M.; Riley, William] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
[Pilkonis, Paul A.] Univ Pittsburgh, Sch Med, Dept Psychiat & Behav Sci, Pittsburgh, PA USA.
[Weinfurt, Kevin P.] Duke Clin Res Inst, Dept Psychiat & Behav Sci, Durham, NC USA.
EM czajkows@nhlbi.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S145
EP S145
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701055
ER
PT J
AU de Heer, DH
McBride, C
AF de Heer, Dirk H.
McBride, Colleen
TI GENOMICS-INFORMED INTERVENTIONS & GLOBAL HEALTH: WHAT DO WE KNOW?
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [de Heer, Dirk H.; McBride, Colleen] NHGRI, Social & Behav Res Branch, Silver Spring, MD 20910 USA.
EM dirk.deheer@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S55
EP S55
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700216
ER
PT J
AU Farhat, T
Iannotti, R
Caccavale, L
AF Farhat, Tilda
Iannotti, Ronald
Caccavale, Laura
TI ADOLESCENT OBESITY AND CHRONIC DISEASE-RELATED HEALTH PRACTICES:
MEDIATION BY BODY IMAGE
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Farhat, Tilda; Iannotti, Ronald; Caccavale, Laura] NIH, Bethesda, MD 20892 USA.
EM farhatti@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S215
EP S215
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701331
ER
PT J
AU Ferrer, R
Stipelman, B
Hall, K
Shmueli, D
Greenberg, D
Tesauro, G
O'Connell, M
Bergman, H
Roberson, G
Klein, W
AF Ferrer, Rebecca
Stipelman, Brooke
Hall, Kara
Shmueli, Dikla
Greenberg, Deborah
Tesauro, Gina
O'Connell, Mary
Bergman, Hannah
Roberson, Gary
Klein, William
TI WHO, WHAT, AND WHERE IN THE WORLD OF FUNDING: ANALYSIS OF THE PAST FIVE
YEARS OF THE NCI BEHAVIORAL RESEARCH PROGRAM RESEARCH PORTFOLIO
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Ferrer, Rebecca; Stipelman, Brooke; Hall, Kara; Shmueli, Dikla; Greenberg, Deborah; Tesauro, Gina; O'Connell, Mary; Bergman, Hannah; Roberson, Gary; Klein, William] NCI, NIH, Rockville, MD 20852 USA.
EM stipelmanba@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S129
EP S129
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700507
ER
PT J
AU George, SM
Alfano, CM
Smith, AW
Irwin, ML
McTiernan, A
Bernstein, L
Ballard-Barbash, R
AF George, Stephanie M.
Alfano, Catherine M.
Smith, Ashley W.
Irwin, Melinda L.
McTiernan, Anne
Bernstein, Leslie
Ballard-Barbash, Rachel
TI SEDENTARY BEHAVIOR, HEALTH-RELATED QUALITY OF LIFE, AND SYMPTOM OUTCOMES
AMONG EARLY-STAGE BREAST CANCER SURVIVORS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [George, Stephanie M.; Alfano, Catherine M.; Smith, Ashley W.; Ballard-Barbash, Rachel] NCI, Rockville, CT USA.
[Irwin, Melinda L.] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA.
EM materess@mail.nih.gov
NR 0
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S114
EP S114
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700446
ER
PT J
AU Glasgow, R
Kaplan, R
AF Glasgow, Russ
Kaplan, Robert
TI SUSTAINABILITY: WHAT DOES IT MEAN?
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Glasgow, Russ] NCI, DCCPS, Rockville, MD 20852 USA.
[Kaplan, Robert] Univ Calif San Diego, Los Angeles, CA USA.
EM russg@re-aim.net
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S130
EP S130
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700510
ER
PT J
AU Glasgow, R
AF Glasgow, Russ
TI A RE-[vertical bar#16#vertical bar]AIM PERSPECTIVE ON SUSTAINABILITY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Glasgow, Russ] NCI, DCCPS, Rockville, MD 20852 USA.
EM russg@re-aim.net
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S130
EP S130
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700511
ER
PT J
AU Glasgow, R
AF Glasgow, Russ
TI THE NEED FOR PRACTICAL PATIENT CENTERED MEASURES OF HEALTH BEHAVIORS AND
PSYCHOSOCIAL ISSUES
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Glasgow, Russ] NCI, DCCPS, Rockville, MD 20852 USA.
EM russg@re-aim.net
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S52
EP S52
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700202
ER
PT J
AU Hamilton, JG
Wu, LS
Austin, J
Valdimarsdottir, H
Basmajian, K
Vu, A
Rowley, S
Isola, L
Redd, W
Rini, C
AF Hamilton, Jada G.
Wu, Lisa
Austin, Jane
Valdimarsdottir, Heiddis
Basmajian, Katie
Vu, AnnaMarie
Rowley, Scott
Isola, Luis
Redd, William
Rini, Christine
TI MISERY LOVES COMPANY?: TIMING OF THE FINANCIAL CRISIS MODERATES THE
ASSOCIATION BETWEEN FINANCIAL STRESS AND QUALITY OF LIFE AMONG STEM CELL
TRANSPLANT SURVIVORS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Hamilton, Jada G.] NCI, Canc Prevent Fellowship Program, Rockville, MD 20892 USA.
[Wu, Lisa; Valdimarsdottir, Heiddis; Basmajian, Katie; Vu, AnnaMarie; Isola, Luis; Redd, William; Rini, Christine] Mt Sinai Sch Med, New York, NY USA.
[Austin, Jane] William Paterson Univ, Wayne, NJ USA.
[Rowley, Scott] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Rini, Christine] Univ N Carolina, Chapel Hill, NC USA.
EM hamiltonjg@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S201
EP S201
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701274
ER
PT J
AU Han, PK
Klein, WM
Killam, B
Lehman, T
Massett, H
Freedman, AN
AF Han, Paul K.
Klein, William M.
Killam, Bill
Lehman, Thomas
Massett, Holly
Freedman, Andrew N.
TI REPRESENTING RANDOMNESS IN THE COMMUNICATION OF INDIVIDUALIZED CANCER
RISK ESTIMATES: EFFECTS ON CANCER RISK PERCEPTIONS, WORRY, AND
SUBJECTIVE UNCERTAINTY ABOUT RISK
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Han, Paul K.] Maine Med Ctr, Ctr Outcomes Res, Portland, ME 04101 USA.
[Han, Paul K.; Klein, William M.; Massett, Holly; Freedman, Andrew N.] NCI, Bethesda, MD 20892 USA.
[Killam, Bill] User Ctr Design, Ashburn, VA USA.
[Lehman, Thomas] Acad Educ Dev, Washington, DC USA.
EM hanp@mmc.org
NR 0
TC 0
Z9 0
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S115
EP S115
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700451
ER
PT J
AU Hesse, B
Nelson, D
Kwon, H
AF Hesse, Brad
Nelson, David
Kwon, Harry
TI STIMULATING DATA: RECOVERY ACT INVESTMENTS IN COMMUNICATING DATA
EFFECTIVELY IN HEALTH AND HEALTH CARE
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Hesse, Brad] NCI, Hlth Commun & Informat Res Branch, Bethesda, MD 20892 USA.
[Nelson, David] NCI, Canc Prevent Fellowship Program, Bethesda, MD 20892 USA.
[Kwon, Harry] NCI, Off Commun & Educ, Bethesda, MD 20892 USA.
EM hesseb@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S53
EP S53
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700205
ER
PT J
AU Hesse, B
Rutten, LJ
Shaikh, AR
AF Hesse, Brad
Rutten, Lila J.
Shaikh, Abdul R.
TI EMPOWERING COMMUNITIES WITH DIRECT ACCESS TO HEALTH DATA
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Hesse, Brad; Rutten, Lila J.; Shaikh, Abdul R.] NCI, Hlth Commun & Informat Res Branch, Bethesda, MD 20892 USA.
[Rutten, Lila J.] SAIC Frederick Inc, Clin Monitoring Res Program, Frederick, MD USA.
EM hesseb@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S53
EP S53
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700207
ER
PT J
AU Hunt, Y
Augustson, E
Yaroch, A
Rutten, L
Moser, R
AF Hunt, Yvonne
Augustson, Erik
Yaroch, Amy
Rutten, Lila
Moser, Richard
TI SUN EXPOSURE, SUN PROTECTION, AND SMOKING
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Hunt, Yvonne; Augustson, Erik; Moser, Richard] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Yaroch, Amy] Ctr Human Nutr, Omaha, NE USA.
[Rutten, Lila] NCI, SAIC Inc, Frederick, MD 21701 USA.
EM huntym@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S140
EP S140
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701039
ER
PT J
AU Hunt, Y
Bergman, H
Shmueli, D
Roberson, G
AF Hunt, Yvonne
Bergman, Hannah
Shmueli, Dikla
Roberson, Gary
TI TOBACCO-RELATED RESEARCH FUNDING WITHIN THE NATIONAL CANCER INSTITUTE'S
BEHAVIORAL RESEARCH PROGRAM
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Hunt, Yvonne; Bergman, Hannah; Shmueli, Dikla] NCI, NIH, Bethesda, MD 20892 USA.
[Roberson, Gary] Williams Coll, Williamstown, MA 01267 USA.
EM huntym@mail.nih.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S129
EP S129
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700508
ER
PT J
AU Iannotti, R
Wang, J
AF Iannotti, Ronald
Wang, Jing
TI INTERNATIONAL PATTERNS IN ADOLESCENT PHYSICAL ACTIVITY, SEDENTARY
BEHAVIOR AND DIET: LATENT CLASS ANALYSES OF THE HEALTH BEHAVIOR IN
SCHOOL-AGED CHILDREN SURVEY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Iannotti, Ronald; Wang, Jing] NICHHD, Prevent Res Branch, Bethesda, MD 20892 USA.
EM iannottr@mail.nih.gov
NR 0
TC 0
Z9 0
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S226
EP S226
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701372
ER
PT J
AU Kaphingst, KA
Goodman, MS
Cheng, MR
Stafford, JD
Lachance, CR
AF Kaphingst, Kimberly A.
Goodman, Melody S.
Cheng, Meng-Ru
Stafford, Jewel D.
Lachance, Christina R.
TI RESPONSES TO GENETIC TEST RESULTS VS. FAMILY HISTORY INFORMATION AMONG
COMMUNITY HEALTH CENTER PATIENTS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Kaphingst, Kimberly A.; Cheng, Meng-Ru] Washington Univ, St Louis, MO 63112 USA.
[Goodman, Melody S.; Stafford, Jewel D.] SUNY Stony Brook, Stony Brook, NY 11794 USA.
[Lachance, Christina R.] NHGRI, NIH, Bethesda, MD 20892 USA.
EM kkaphingst@gwbmail.wustl.edu
RI Goodman, Melody/F-6768-2011
OI Goodman, Melody/0000-0001-8932-624X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S73
EP S73
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700286
ER
PT J
AU Kaufman, A
Augustson, E
AF Kaufman, Annette
Augustson, Erik
TI THE INFLUENCE OF SEDENTARY ACTIVITY ON THE RELATIONSHIP BETWEEN
CIGARETTE SMOKING AND BODY WEIGHT: RESULTS FROM THE NATIONAL HEALTH AND
NUTRITION EXAMINATION SURVEY (1999-2008)
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Kaufman, Annette; Augustson, Erik] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
EM kaufmana@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S140
EP S140
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701038
ER
PT J
AU Kenney, MK
Wang, J
Iannotti, R
Yongpradit, D
AF Kenney, Mary Kay
Wang, Jing
Iannotti, Ronald
Yongpradit, Daranee
TI URBAN/RURAL DIFFERENCES IN ADOLESCENT OBESITY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Kenney, Mary Kay] US Hlth Resources & Serv Adm, Rockville, MD 20857 USA.
[Wang, Jing; Iannotti, Ronald; Yongpradit, Daranee] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
EM mkenney@hrsa.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S215
EP S215
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701329
ER
PT J
AU Kent, EE
Montoya, MJ
Sender, LS
Morris, RA
Ziogas, A
Anton-Culver, H
AF Kent, Erin E.
Montoya, Michael J.
Sender, Leonard S.
Morris, Rebecca A.
Ziogas, Argyrios
Anton-Culver, Hoda
TI A COMPARISON OF ATTITUDES TOWARD CANCER CLINICAL TRIAL PARTICIPATION
BETWEEN ADOLESCENTS AND YOUNG ADULTS WITH LEUKEMIA AND LYMPHOMA AND
COLLEGE STUDENTS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Kent, Erin E.] NCI, Rockville, MD 20852 USA.
[Kent, Erin E.; Montoya, Michael J.; Sender, Leonard S.; Ziogas, Argyrios; Anton-Culver, Hoda] Univ Calif Irvine, Irvine, CA USA.
[Sender, Leonard S.; Morris, Rebecca A.] CHOC Childrens Hosp, Orange, CA USA.
EM Erin.Kent@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S5
EP S5
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700014
ER
PT J
AU Keogh, LA
Fisher, D
Schully, S
Lowery, J
Ahnen, D
Maskiell, J
Lindor, N
Hopper, J
Burnett, T
Holter, S
Gorin, SS
Sinicrope, P
AF Keogh, Louise A.
Fisher, Douglass
Schully, Sheri
Lowery, Jan
Ahnen, Dennis
Maskiell, Judi
Lindor, Noralane
Hopper, John
Burnett, Terrilea
Holter, Spring
Gorin, Sheri Sheinfeld
Sinicrope, Pam
TI DISCLOSING GENETIC RESEARCH RESULTS: EXPERIENCES OF THE COLON CANCER
FAMILY REGISTRY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Keogh, Louise A.; Maskiell, Judi; Hopper, John] Univ Melbourne, Ctr Womens Hlth Gender & Soc, Melbourne, Vic 3010, Australia.
[Fisher, Douglass] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Schully, Sheri] NIH, Bethesda, MD 20892 USA.
[Lowery, Jan] Univ Colorado, Sch Publ Hlth, Aurora, CO USA.
[Ahnen, Dennis] Univ Colorado, Denver, CO 80202 USA.
[Lindor, Noralane; Sinicrope, Pam] Mayo Clin, Rochester, MN USA.
[Burnett, Terrilea] Univ Hawaii, Honolulu, HI 96822 USA.
[Holter, Spring] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Gorin, Sheri Sheinfeld] Columbia Univ, New York, NY USA.
EM l.keogh@unimelb.edu.au
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S128
EP S128
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700501
ER
PT J
AU Kepka, DL
Ulrich, A
Coronado, G
AF Kepka, Deanna L.
Ulrich, Angela
Coronado, Gloria
TI CORRELATES OF HPV VACCINE UPTAKE AMONG RURAL LATINA MOTHERS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Kepka, Deanna L.] NCI, Div Canc Control & Populat Sci, Rockville, MD 20892 USA.
[Ulrich, Angela] Univ Washington, Seattle, WA 98195 USA.
[Coronado, Gloria] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
EM deanna.kepka@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S257
EP S257
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701496
ER
PT J
AU Kepka, DL
Coronado, G
Rodriguez, HP
Thompson, B
AF Kepka, Deanna L.
Coronado, Gloria
Rodriguez, Hector P.
Thompson, Beti
TI EVALUATION OF A RADIONOVELA TO PROMOTE HPV VACCINE AWARENESS AND
KNOWLEDGE AMONG HISPANIC PARENTS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Kepka, Deanna L.] NCI, Div Canc Control & Populat Sci, Rockville, MD 20892 USA.
[Coronado, Gloria; Thompson, Beti] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Rodriguez, Hector P.] Univ Calif Los Angeles, Los Angeles, CA USA.
EM deanna.kepka@nih.gov
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S243
EP S243
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701439
ER
PT J
AU Klein, W
Kara, H
Stipelman, B
Shmueli, D
Kobrin, S
Hunt, Y
AF Klein, William
Kara, Hall
Stipelman, Brooke
Shmueli, Dikla
Kobrin, Sarah
Hunt, Yvonne
TI BEHAVIORAL RESEARCH AT NCI: OUR PORTFOLIO UNMASKED
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Klein, William; Kara, Hall; Stipelman, Brooke; Shmueli, Dikla; Kobrin, Sarah; Hunt, Yvonne] NCI, NIH, Rockville, MD 20852 USA.
EM stipelmanba@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S129
EP S129
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700506
ER
PT J
AU Kobrin, S
Rothman, A
Meissner, H
Tiro, J
Hall, K
Ferrer, R
Shmueli, D
AF Kobrin, Sarah
Rothman, Alex
Meissner, Helen
Tiro, Jasmin
Hall, Kara
Ferrer, Rebecca
Shmueli, Dikla
TI USE OF BEHAVIORAL THEORY IN GRANT APPLICATIONS: WHAT CAN WE LEARN FROM
FUNDED CANCER SCREENING INTERVENTION RESEARCH?
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Kobrin, Sarah; Hall, Kara; Ferrer, Rebecca; Shmueli, Dikla] NCI, NIH, Rockville, MD 20852 USA.
[Rothman, Alex] UMN, Minneapolis, MN USA.
[Tiro, Jasmin] UT SW Med Ctr, Dallas, TX USA.
[Meissner, Helen] NIH, OBSSR, Bethesda, MD 20892 USA.
EM kobrins@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S130
EP S130
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700509
ER
PT J
AU Koehly, LM
Wilkinson, AV
AF Koehly, Laura M.
Wilkinson, Anna V.
TI PROJECT RAMA: USING FAMILY HEALTH HISTORY FEEDBACK TO PROMOTE HEALTH IN
MEXICAN ORIGIN FAMILIES
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Koehly, Laura M.] NHGRI, Social & Behav Res Branch, NIH, Bethesda, MD 20892 USA.
[Wilkinson, Anna V.] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Austin, TX USA.
EM koehlyl@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S55
EP S55
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700214
ER
PT J
AU Leviton, LC
Ory, M
Dowdy, D
Wilcox, S
Griffin, SF
Ottoson, JM
Martinez, DJ
Glasgow, R
AF Leviton, Laura C.
Ory, Marcia
Dowdy, Diane
Wilcox, Sara
Griffin, Sarah F.
Ottoson, Judith M.
Martinez, Diane J.
Glasgow, Russell
TI IMPACT OF A PROGRAM AND ITS EVALUATION: ACTIVE FOR LIFE (R)
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Leviton, Laura C.; Martinez, Diane J.] Robert Wood Johnson Fdn, Princeton, NJ 08543 USA.
[Wilcox, Sara] Univ S Carolina, Dept Exercise Sci, Columbia, SC 29208 USA.
[Ory, Marcia; Dowdy, Diane] Texas A&M Univ, College Stn, TX USA.
[Griffin, Sarah F.] Clemson Univ, Clemson, SC USA.
[Ottoson, Judith M.] San Francisco State Univ, San Francisco, CA 94132 USA.
[Glasgow, Russell] NCI, Div Canc Control & Populat Sci, Rockville, MD USA.
EM llevito@rwjf.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S54
EP S54
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700209
ER
PT J
AU Lipsky, L
Nansel, T
Haynie, D
Laffel, L
Mehta, S
AF Lipsky, Leah
Nansel, Tonja
Haynie, Denise
Laffel, Lori
Mehta, Sanjeev
TI CONCORDANCE OF DIETARY INTAKE AND QUALITY BETWEEN CHILDREN WITH TYPE-1
DIABETES (T1D) AND THEIR PARENTS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Lipsky, Leah; Nansel, Tonja; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
[Laffel, Lori; Mehta, Sanjeev] Joslin Diabet Ctr, Boston, MA 02215 USA.
EM lipskylm@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S22
EP S22
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700084
ER
PT J
AU Lombardero, A
Parascandola, M
AF Lombardero, Anayansi
Parascandola, Mark
TI STRATEGIES USED BY MULTINATIONAL TOBACCO COMPANIES IN EMERGING MARKETS:
A CASE STUDY OF TARGETED MARKETING AND LEGISLATION INFLUENCE IN SPAIN
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Lombardero, Anayansi] Univ Montana, Missoula, MT 59812 USA.
[Parascandola, Mark] NCI, Tobacco Control Res Branch, Bethesda, MD 20892 USA.
EM anayansi.lombardero@umontana.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S191
EP S191
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701236
ER
PT J
AU Loria, C
Arteaga, SS
Belle, S
Signore, C
Riley, W
AF Loria, Catherine
Arteaga, S. Sonia
Belle, Steven
Signore, Caroline
Riley, William
TI EARLY ADULT REDUCTION OF WEIGHT THROUGH LIFESTYLE INTERVENTION (EARLY)
TRIALS; USING INNOVATIVE TECHNOLOGIES IN RANDOMIZED CONTROLLED TRIALS
TARGETING WEIGHT CONTROL AMONG YOUNG ADULTS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Loria, Catherine; Arteaga, S. Sonia; Riley, William] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
[Belle, Steven] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Signore, Caroline] Kennedy Shriver Natl Inst Child Hlth & Human Dev, Pregnancy & Perinatol Branch, Bethesda, MD USA.
EM arteagass@nhlbi.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S133
EP S133
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701011
ER
PT J
AU McBride, C
Winch, P
AF McBride, Colleen
Winch, Peter
TI GENOMICS APPLICATIONS TO ADDRESS CHALLENGES FOR BEHAVIORAL MEDICINE IN
THE US AND ABROAD
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [McBride, Colleen] NHGRI, Bethesda, MD 20892 USA.
[Winch, Peter] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
EM cmcbride@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S55
EP S55
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700213
ER
PT J
AU McBride, C
Ottman, R
Figueiro, M
Bryan, A
Wanke, K
AF McBride, Colleen
Ottman, Ruth
Figueiro, Mariana
Bryan, Angela
Wanke, Kay
TI GENE-ENVIRONMENT INTERPLAY IN HEALTH BEHAVIOR: FROM MECHANISMS TO
TRANSLATION
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [McBride, Colleen] NIH, Social & Behav Res Branch, Bethesda, MD 20892 USA.
[Ottman, Ruth] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
[Figueiro, Mariana] Rensselaer Polytech Inst, Troy, NY USA.
[Bryan, Angela] Univ New Mexico, Albuquerque, NM 87131 USA.
[Wanke, Kay] NIH, Off Behav & Social Sci Res, Bethesda, MD 20892 USA.
EM wankek@mail.nih.gov
RI Ottman, Ruth/O-2371-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S3
EP S3
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700009
ER
PT J
AU Moser, RP
Hesse, BW
Shaikh, AR
Courtney, P
Morgan, G
Auguston, E
Levin, K
Helba, C
Garner, D
Dunn, M
AF Moser, Richard P.
Hesse, Bradford W.
Shaikh, Abdul R.
Courtney, Paul
Morgan, Glen
Auguston, Erik
Levin, Kerry
Helba, Cynthia
Garner, David
Dunn, Marsha
TI PROMOTING THE USE OF HARMONIZED MEASURES AND SHARING DATA TO CATALYZE
PROGRESS IN BEHAVIORAL SCIENCE: THE NATIONAL CANCER INSTITUTE'S
GRID-ENABLED MEASURES (GEM) PORTAL
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Moser, Richard P.; Hesse, Bradford W.; Shaikh, Abdul R.; Morgan, Glen; Auguston, Erik] NCI, Bethesda, MD 20892 USA.
[Levin, Kerry; Helba, Cynthia; Garner, David; Dunn, Marsha] Westat Corp, Rockville, MD USA.
[Courtney, Paul] SAIC Frederick, Frederick, MD USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S145
EP S145
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701054
ER
PT J
AU Nansel, TR
Lipsky, L
Haynie, D
Mehta, S
Laffel, L
AF Nansel, Tonja R.
Lipsky, Leah
Haynie, Denise
Mehta, Sanjeev
Laffel, Lori
TI RELATIONS AMONG PARENT AND YOUTH SOCIAL COGNITIVE CONSTRUCTS AND DIETARY
INTAKE IN YOUTH WITH TYPE 1 DIABETES
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Nansel, Tonja R.; Lipsky, Leah; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, Bethesda, MD USA.
[Mehta, Sanjeev; Laffel, Lori] Joslin Diabet Ctr, Boston, MA 02215 USA.
EM nanselt@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S213
EP S213
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701322
ER
PT J
AU Nansel, TR
Weaver, N
Williams, J
Willson, K
Tse, J
AF Nansel, Tonja R.
Weaver, Nancy
Williams, Janice
Willson, Katherine
Tse, Julia
TI IMPLEMENTATION OF A KIOSK-BASED PEDIATRIC INJURY PREVENTION PROGRAM IN
PRIMARY CARE
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Nansel, Tonja R.; Willson, Katherine; Tse, Julia] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
[Weaver, Nancy] St Louis Univ, St Louis, MO 63103 USA.
[Williams, Janice] Carolinas HealthCare Syst, Charlotte, NC USA.
EM nanselt@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S180
EP S180
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701191
ER
PT J
AU Nilsen, W
AF Nilsen, Wendy
TI WIRELESS MONITORING AND SUPPORT FOR ENHANCING ADHERENCE
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Nilsen, Wendy] NIH, Off Behav & Social Sci Res, Bethesda, MD 20892 USA.
EM nilsenwj@od.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S142
EP S142
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701046
ER
PT J
AU Norton, WE
Glanz, K
Collins, CB
Mittman, BS
Glasgow, RE
AF Norton, Wynne E.
Glanz, Karen
Collins, Charles B.
Mittman, Brian S.
Glasgow, Russell E.
TI SCALING-UP EVIDENCE-BASED HEALTH PROMOTION/DISEASE PREVENTION
INTERVENTIONS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Norton, Wynne E.] Univ Alabama, Birmingham, AL 35293 USA.
[Glanz, Karen] Univ Penn, Philadelphia, PA 19104 USA.
[Collins, Charles B.] Ctr Dis Control & Prevent, Capac Bldg Branch, Atlanta, GA USA.
[Mittman, Brian S.] VA Greater Los Angeles Healthcare Syst, Ctr Implementat Practice & Res Support, Los Angeles, CA USA.
[Glasgow, Russell E.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
EM wenorton@uab.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S152
EP S152
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701080
ER
PT J
AU O'Neill, S
Zikmund-Fisher, BJ
Hoffman, RM
Sepucha, KR
Knight, SJ
Klein, WM
Spring, B
AF O'Neill, Suzanne
Zikmund-Fisher, Brian J.
Hoffman, Richard M.
Sepucha, Karen R.
Knight, Sara J.
Klein, William M.
Spring, Bonnie
TI OPPORTUNITIES FOR TRANSLATIONAL RESEARCH USING THE DECISIONS STUDY: A
CONVERSATION BETWEEN SBM'S DECISION MAKING SIG AND THE SOCIETY FOR
MEDICAL DECISION MAKING
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [O'Neill, Suzanne] Georgetown Univ, Washington, DC 20007 USA.
[Zikmund-Fisher, Brian J.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Hoffman, Richard M.] Univ New Mexico, Albuquerque, NM 87131 USA.
[Sepucha, Karen R.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Knight, Sara J.] San Francisco VA UCSF, San Francisco, CA USA.
[Klein, William M.] NCI, Bethesda, MD 20892 USA.
[Spring, Bonnie] Northwestern Univ, Chicago, IL 60611 USA.
EM sco4@georgetown.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S150
EP S150
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701076
ER
PT J
AU Oh, A
Patrick, H
Berrigan, D
Perna, FM
AF Oh, April
Patrick, Heather
Berrigan, David
Perna, Frank M.
TI ADHERENCE TO MULTIPLE HEALTH BEHAVIORS: EXAMINATION OF TOBACCO USE AND
PATTERNS OF ADHERENCE IN US HISPANICS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Oh, April; Patrick, Heather; Berrigan, David; Perna, Frank M.] NCI, NIH, Rockville, MD 20852 USA.
EM ohay@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S141
EP S141
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701040
ER
PT J
AU Oh, A
Perna, FM
Agurs-Collins, T
Nebeling, L
AF Oh, April
Perna, Frank M.
Agurs-Collins, Tanya
Nebeling, Linda
TI CLASSIFICATION OF LAWS ASSOCIATED WITH SCHOOL STUDENTS (CLASS): AN
EVALUATION TOOL OF STATE PHYSICAL EDUCATION AND NUTRITION POLICY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Oh, April; Perna, Frank M.; Agurs-Collins, Tanya; Nebeling, Linda] NCI, NIH, Rockville, MD 20852 USA.
EM ohay@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S133
EP S133
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701010
ER
PT J
AU Oh, A
Erinosho, T
Dunton, G
Perna, FM
Berrigan, D
AF Oh, April
Erinosho, Temitope
Dunton, Genevieve
Perna, Frank M.
Berrigan, David
TI PHYSICAL AND SOCIAL CONTEXTS OF EATING AND DRINKING EPISODES IN US
ADULTS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Oh, April; Perna, Frank M.; Berrigan, David] NCI, NIH, Rockville, MD 20852 USA.
[Erinosho, Temitope] Univ N Carolina, Chapel Hill, NC USA.
[Dunton, Genevieve] Univ So Cali, Chapel Hill, NC USA.
EM ohay@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S24
EP S24
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700092
ER
PT J
AU Okamoto, J
Johnson, CA
Leventhal, A
Milam, J
Pentz, MA
Schwartz, D
Valente, TW
AF Okamoto, Janet
Johnson, C. Anderson
Leventhal, Adam
Milam, Joel
Pentz, Mary Ann
Schwartz, David
Valente, Thomas W.
TI THE CLASSROOM SOCIAL NETWORK AND DEPRESSIVE SYMPTOMS: DO NETWORK
COMPOSITION AND CHARACTERISTICS INFLUENCE ADOLESCENT DEPRESSION?
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Okamoto, Janet] NCI, DCCPS, BRP, Rockville, MD 20852 USA.
[Johnson, C. Anderson] Claremont Grad Univ, Claremont, CA USA.
[Leventhal, Adam; Milam, Joel; Pentz, Mary Ann; Schwartz, David; Valente, Thomas W.] Univ So Calif, Los Angeles, CA USA.
EM okamotojm@mail.nih.gov
NR 0
TC 0
Z9 0
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S68
EP S68
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700265
ER
PT J
AU Patrick, H
Augustson, EM
AF Patrick, Heather
Augustson, Erik M.
TI HEALTH RISK AND HEALTH PROMOTION: DO PEOPLE PERCEIVE RISK-ENHANCING AND
RISK-PROTECTIVE BEHAVIORS SIMILARLY?
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Patrick, Heather; Augustson, Erik M.] NCI, Div Canc Control & Populat Sci, Rockville, MD 20852 USA.
EM patrickha@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S141
EP S141
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701041
ER
PT J
AU Patrick, H
Nigg, CR
AF Patrick, Heather
Nigg, Claudio R.
TI UNDERSTANDING PATTERNS IN HEALTH RISK AND HEALTH PROMOTION BEHAVIORS:
PERSPECTIVES FROM NATIONALLY-REPRESENTATIVE SURVEYS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Patrick, Heather] NCI, Div Canc Control & Populat Sci, Rockville, MD 20852 USA.
[Nigg, Claudio R.] Univ Hawaii, Dept Publ Hlth Sci, Honolulu, HI 96822 USA.
EM patrickha@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S140
EP S140
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701037
ER
PT J
AU Pentz, MA
Alfonzo, M
Durand, C
Dunton, G
Meyer, A
Sallis, J
AF Pentz, Mary Ann
Alfonzo, Mariela
Durand, Casey
Dunton, Genevieve
Meyer, Aleta
Sallis, James
TI EVALUATING THE IMPACT OF SMART GROWTH PLANNING ON PHYSICAL ACTIVITY:
EFFECTS OF CONTEXT
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Pentz, Mary Ann; Durand, Casey; Dunton, Genevieve] Univ So Calif, Inst Hlth Promot & Dis Prevent Res, Alhambra, CA 91803 USA.
[Alfonzo, Mariela] Virginia Tech, Blacksburg, VA USA.
[Meyer, Aleta] NIDA, Bethesda, MD 20892 USA.
[Sallis, James] San Diego State Univ, San Diego, CA 92182 USA.
EM pentz@usc.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S139
EP S139
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701033
ER
PT J
AU Perna, FM
Oh, A
Agurs-Collins, T
Chriqui, J
Masse, LM
AF Perna, Frank M.
Oh, April
Agurs-Collins, Tanya
Chriqui, Jamie
Masse, Louise Masse
TI FIVE-YEAR CHANGE IN STATE PHYSICAL EDUCATION LAWS AND CONCORDANCE WITH
COMPETITIVE FOODS LAWS IN US MIDDLE SCHOOLS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Perna, Frank M.; Oh, April; Agurs-Collins, Tanya] NCI, Rockville, MD 20852 USA.
[Masse, Louise Masse] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Chriqui, Jamie] Univ Illinois, Chicago, IL USA.
EM pernafm@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S133
EP S133
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701009
ER
PT J
AU Perna, FM
Oh, A
Agurs-Collins, T
Chriqui, JF
Lee, SM
Masse, LC
AF Perna, Frank M.
Oh, April
Agurs-Collins, Tanya
Chriqui, Jamie F.
Lee, Sarah M.
Masse, Louise C.
TI POLICY AS A TOOL TO CHANGE SCHOOL NUTRITION AND PHYSICAL EDUCATION
ENVIRONMENTS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Perna, Frank M.; Oh, April; Agurs-Collins, Tanya] NCI, Div Canc Control & Populat Sci, Rockville, MD 20852 USA.
[Chriqui, Jamie F.] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA.
[Masse, Louise C.] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada.
[Lee, Sarah M.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA.
EM pernafm@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S132
EP S132
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701006
ER
PT J
AU Persky, S
Kaphingst, KA
Allen, VC
Senay, I
AF Persky, Susan
Kaphingst, Kimberly A.
Allen, Vincent C.
Senay, Ibrahim
TI THE EFFECT OF RACIAL DISCORDANCE WITH A VIRTUAL DOCTOR ON LUNG CANCER
RISK PERCEPTION AMONG AFRICAN AMERICANS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Persky, Susan] NHGRI, Bethesda, MD 20892 USA.
[Kaphingst, Kimberly A.] Washington Univ, St Louis, MO USA.
[Allen, Vincent C.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Senay, Ibrahim] Univ Illinois, Urbana, IL 61801 USA.
EM perskys@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S81
EP S81
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700316
ER
PT J
AU Pilkonis, PA
Choi, SW
Reise, SP
Stover, AM
Riley, WT
Cella, D
AF Pilkonis, Paul A.
Choi, Seung W.
Reise, Steven P.
Stover, Angela M.
Riley, William T.
Cella, David
TI ITEM BANKS FOR MEASURING EMOTIONAL DISTRESS FROM THE PATIENT-REPORTED
OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS): DEPRESSION, ANXIETY,
AND ANGER
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Pilkonis, Paul A.; Stover, Angela M.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Choi, Seung W.; Cella, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Reise, Steven P.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Riley, William T.] NHLBI, Bethesda, MD 20892 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S145
EP S145
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701057
ER
PT J
AU Riley, WT
Cella, D
AF Riley, William T.
Cella, David
TI PROMIS OVERVIEW: DEVELOPMENT OF NEW TOOLS FOR MEASURING HEALTH-RELATED
QUALITY OF LIFE AND RELATED OUTCOMES IN PATIENTS WITH CHRONIC DISEASES
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Riley, William T.] NHLBI, Bethesda, MD 20892 USA.
[Cella, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S145
EP S145
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701056
ER
PT J
AU Rutten, LJ
Hesse, B
Martinez, APO
Luna, GT
Kornfeld, J
AF Rutten, Lila J.
Hesse, Bradford
Martinez, Ana Patricia Ortiz
Luna, Guillermo Tortolero
Kornfeld, Julie
TI USE OF THE INTERNET FOR HEALTH AND CANCER INFORMATION SEEKING IN PUERTO
RICO
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Hesse, Bradford] NCI, Bethesda, MD 20892 USA.
[Rutten, Lila J.] NCI, SAIC Inc, Frederick, MD 21701 USA.
[Martinez, Ana Patricia Ortiz; Luna, Guillermo Tortolero] Univ Puerto Rico, San Juan, PR 00936 USA.
[Kornfeld, Julie] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
EM finney1@mail.nih.gov
NR 0
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S7
EP S7
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700023
ER
PT J
AU Ryan, B
Theodore, M
Mehta, S
Butler, D
Haynie, D
Nansel, T
Laffel, L
AF Ryan, Brittany
Theodore, Miranda
Mehta, Sanjeev
Butler, Deborah
Haynie, Denise
Nansel, Tonja
Laffel, Lori
TI DIABETES-SPECIFIC FAMILY CONFLICT, ADHERENCE AND GLYCEMIC CONTROL IN
YOUTH WITH TYPE 1 DIABETES
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Ryan, Brittany; Theodore, Miranda; Mehta, Sanjeev; Butler, Deborah; Laffel, Lori] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Haynie, Denise; Nansel, Tonja] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
EM brittany.ryan@joslin.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S92
EP S92
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700358
ER
PT J
AU Sanderson, S
McClure, J
Holm, A
McBride, C
AF Sanderson, Saskia
McClure, Jennifer
Holm, Amanda
McBride, Colleen
TI UNDERSTANDING EVER-SMOKERS' UPTAKE OF AND REACTIONS TO PERSONALIZED
GENETIC SUSCEPTIBILITY TESTING IN THE MULTIPLEX INITIATIVE
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Sanderson, Saskia] Mt Sinai Sch Med, New York, NY 10029 USA.
[McClure, Jennifer] Grp Hlth Res Inst, Seattle, WA USA.
[Holm, Amanda] Natl Human Genom Res Inst, Social & Behav Res Branch, Bethesda, MD USA.
[McBride, Colleen] Henry Ford Hlth Syst, Detroit, MI USA.
EM saskia.sanderson@mssm.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S74
EP S74
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700287
ER
PT J
AU Stoney, CM
Blumenthal, JA
Spring, B
Johnston, DW
Bonds, D
AF Stoney, Catherine M.
Blumenthal, James A.
Spring, Bonnie
Johnston, Derek W.
Bonds, Denise
TI COMPARATIVE EFFECTIVENESS RESEARCH IN CARDIOVASCULAR BEHAVIORAL MEDICINE
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Stoney, Catherine M.; Bonds, Denise] NHLBI, NIH, Bethesda, MD 20892 USA.
[Blumenthal, James A.] Duke Univ, Dept Psychiat, Durham, NC 27706 USA.
[Spring, Bonnie] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA.
[Johnston, Derek W.] Univ Aberdeen, Aberdeen, Scotland.
EM stoneyc@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S131
EP S131
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297701002
ER
PT J
AU Tse, J
Nansel, T
Haynie, D
Laffel, L
Mehta, S
AF Tse, Julia
Nansel, Tonja
Haynie, Denise
Laffel, Lori
Mehta, Sanjeev
TI THE RELATIONSHIP OF DIET QUALITY AND DISORDERED EATING BEHAVIORS IN
ADOLESCENTS WITH TYPE 1 DIABETES (T1D)
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Tse, Julia; Nansel, Tonja; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA.
[Laffel, Lori; Mehta, Sanjeev] Joslin Diabet Ctr, Boston, MA 02215 USA.
EM tsej2@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S60
EP S60
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700235
ER
PT J
AU Yaroch, AL
Rutten, LJ
Colon-Ramos, U
Johnson-Askew, W
Story, M
AF Yaroch, Amy L.
Rutten, Lila J.
Colon-Ramos, Uriyoan
Johnson-Askew, Wendy
Story, Mary
TI POVERTY, FOOD INSECURITY, AND OBESITY: A CONCEPTUAL FRAMEWORK FOR
RESEARCH, PRACTICE, AND POLICY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Rutten, Lila J.] Natl Canc Inst Frederick, SAIC Inc, HCIRB, Bethesda, MD 20892 USA.
[Yaroch, Amy L.; Rutten, Lila J.; Colon-Ramos, Uriyoan] Ctr Human Nutr, Omaha, NE USA.
[Johnson-Askew, Wendy] NIH, Div Nutr Res & Coordinat, Bethesda, MD 20892 USA.
[Story, Mary] Univ MN, Div Epidemiol, Sch Publ Hlth, Minneapolis, MN USA.
EM finneyl@mail.nih.gov
NR 0
TC 0
Z9 0
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR
PY 2011
VL 41
SU 1
BP S99
EP S99
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA 747CK
UT WOS:000289297700388
ER
PT J
AU White, LK
Suway, JG
Pine, DS
Bar-Haim, Y
Fox, NA
AF White, Lauren K.
Suway, Jenna G.
Pine, Daniel S.
Bar-Haim, Yair
Fox, Nathan A.
TI Cascading effects: The influence of attention bias to threat on the
interpretation of ambiguous information
SO BEHAVIOUR RESEARCH AND THERAPY
LA English
DT Article
DE Anxiety; Attention bias; Attention training; Information processing;
Interpretive bias
ID SELECTIVE ATTENTION; COGNITIVE BIASES; ANXIETY; INDIVIDUALS; PLASTICITY;
MODERATOR; CHILDREN
AB Both attention bias to threat and negative interpretive bias have been implicated in the emergence and maintenance of anxiety disorders. However, relations between attention and interpretive biases remain poorly understood. The current study experimentally manipulated attention bias to threat and examined the effects of attention training on the way ambiguous information was interpreted. Results suggest that the preferential allocation of attention towards threat affects the manner in which ambiguous information is interpreted. Individuals trained to attend to threat were more likely than individuals in a placebo training group to interpret ambiguous information in a threat-related manner. These data suggest that perturbations in the initial stages of information processing associated with anxiety may lead to a cascade of subsequent processing biases. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [White, Lauren K.; Suway, Jenna G.; Fox, Nathan A.] Univ Maryland, Dept Human Dev, Child Dev Lab, College Pk, MD 20742 USA.
[Pine, Daniel S.] NIMH, Mood & Anxiety Program, Sect Dev & Affect Neurosci, Bethesda, MD 20892 USA.
[Bar-Haim, Yair] Tel Aviv Univ, Dept Psychol, Adler Ctr Res Child Dev & Psychopathol, IL-69978 Tel Aviv, Israel.
RP White, LK (reprint author), Univ Maryland, Dept Human Dev, Child Dev Lab, College Pk, MD 20742 USA.
EM lwhite5@umd.edu
FU NIMH NIH HHS [F31 MH085424, F31 MH085424-02, 1F31MH085424]
NR 26
TC 33
Z9 37
U1 1
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0005-7967
EI 1873-622X
J9 BEHAV RES THER
JI Behav. Res. Ther.
PD APR
PY 2011
VL 49
IS 4
BP 244
EP 251
DI 10.1016/j.brat.2011.01.004
PG 8
WC Psychology, Clinical
SC Psychology
GA 749HD
UT WOS:000289454000004
PM 21353663
ER
PT J
AU Batra, J
Nagle, CM
O'Mara, T
Higgins, M
Dong, Y
Tan, OL
Lose, F
Skeie, LM
Srinivasan, S
Bolton, KL
Song, H
Ramus, SJ
Gayther, SA
Pharoah, PDP
Kedda, MA
Spurdle, AB
Clements, JA
AF Batra, Jyotsna
Nagle, Christina M.
O'Mara, Tracy
Higgins, Melanie
Dong, Ying
Tan, Olivia L.
Lose, Felicity
Skeie, Lene Marie
Srinivasan, Srilakshmi
Bolton, Kelly L.
Song, Honglin
Ramus, Susan J.
Gayther, Simon A.
Pharoah, Paul D. P.
Kedda, Mary-Anne
Spurdle, Amanda B.
Clements, Judith A.
TI A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to
a novel exon shows evidence of association with poor ovarian cancer
survival
SO BMC CANCER
LA English
DT Article
DE Kallikrein 15 single nucleotide polymorphisms; ovarian cancer; splice
variants
ID GENOME-WIDE ASSOCIATION; PROSTATE-CANCER; BREAST-CANCER; MESSENGER-RNA;
TISSUE KALLIKREIN; EXPRESSION; GENE; SUSCEPTIBILITY; PROTEIN; VARIANTS
AB Background: KLK15 over-expression is reported to be a significant predictor of reduced progression-free survival and overall survival in ovarian cancer. Our aim was to analyse the KLK15 gene for putative functional single nucleotide polymorphisms (SNPs) and assess the association of these and KLK15 HapMap tag SNPs with ovarian cancer survival.
Results: In silico analysis was performed to identify KLK15 regulatory elements and to classify potentially functional SNPs in these regions. After SNP validation and identification by DNA sequencing of ovarian cancer cell lines and aggressive ovarian cancer patients, 9 SNPs were shortlisted and genotyped using the Sequenom iPLEX Mass Array platform in a cohort of Australian ovarian cancer patients (N = 319). In the Australian dataset we observed significantly worse survival for the KLK15 rs266851 SNP in a dominant model (Hazard Ratio (HR) 1.42, 95% CI 1.02-1.96). This association was observed in the same direction in two independent datasets, with a combined HR for the three studies of 1.16 (1.00-1.34). This SNP lies 15bp downstream of a novel exon and is predicted to be involved in mRNA splicing. The mutant allele is also predicted to abrogate an HSF-2 binding site.
Conclusions: We provide evidence of association for the SNP rs266851 with ovarian cancer survival. Our results provide the impetus for downstream functional assays and additional independent validation studies to assess the role of KLK15 regulatory SNPs and KLK15 isoforms with alternative intracellular functional roles in ovarian cancer survival.
C1 [Batra, Jyotsna; O'Mara, Tracy; Higgins, Melanie; Dong, Ying; Tan, Olivia L.; Skeie, Lene Marie; Srinivasan, Srilakshmi; Kedda, Mary-Anne; Clements, Judith A.] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4059, Australia.
[Batra, Jyotsna; O'Mara, Tracy; Higgins, Melanie; Dong, Ying; Tan, Olivia L.; Skeie, Lene Marie; Srinivasan, Srilakshmi; Kedda, Mary-Anne; Clements, Judith A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
[Batra, Jyotsna; O'Mara, Tracy; Higgins, Melanie; Lose, Felicity; Spurdle, Amanda B.] Queensland Inst Med Res, Mol Canc Epidemiol Lab, Brisbane, Qld 4006, Australia.
[Nagle, Christina M.] Queensland Inst Med Res, Gynaecol Canc Grp, Brisbane, Qld 4006, Australia.
[Bolton, Kelly L.; Song, Honglin; Pharoah, Paul D. P.] Univ Cambridge, Strangeways Res Lab, Canc Res UK Dept Oncol, Cambridge, England.
[Bolton, Kelly L.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Ramus, Susan J.; Gayther, Simon A.] UCL, Inst Womens Hlth, Dept Gynecol Oncol, London, England.
RP Clements, JA (reprint author), Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4059, Australia.
EM j.clements@qut.edu.au
RI Song, H/C-9965-2011; Dong, Ying/C-3511-2012; Batra, Jyotsna/B-4130-2011;
O'Mara, Tracy/M-7508-2016; Spurdle, Amanda/A-4978-2011;
OI O'Mara, Tracy/0000-0002-5436-3232; Lose, Felicity/0000-0001-8337-3547;
Ramus, Susan/0000-0003-0005-7798; Spurdle, Amanda/0000-0003-1337-7897;
Clements, Judith/0000-0001-6026-1964
FU NHMRC; Institute of Health and Biomedical Innovation; Australian
Postgraduate Award; IHBI; QLD; Cancer Research UK; National Health and
Medical Research Council of Australia (NHMRC) [390123]
FX ABS and JAC are NHMRC Senior and Principal Research Fellows
respectively. CMN is supported by an NHMRC Career Development Award. JB
and OLT are supported by Institute of Health and Biomedical Innovation
Postdoctoral Fellowships. TOM is supported by an Australian Postgraduate
Award complemented with an IHBI and QLD Government Smart State
Postgraduate Awards. SEARCH is funded through a program grant from
Cancer Research UK. This work was supported by funding from the National
Health and Medical Research Council of Australia (NHMRC) grant 390123.
NR 36
TC 17
Z9 18
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD APR 1
PY 2011
VL 11
AR 119
DI 10.1186/1471-2407-11-119
PG 11
WC Oncology
SC Oncology
GA 752TT
UT WOS:000289718100001
PM 21457553
ER
PT J
AU Deola, S
Cavattoni, I
Pusceddu, I
Negri, G
Kasal, A
Svaldi, M
Langes, M
Gambato, R
Morello, E
Casini, M
Bondanza, A
Introna, M
Marincola, FM
Cortelazzo, S
AF Deola, S.
Cavattoni, I.
Pusceddu, I.
Negri, G.
Kasal, A.
Svaldi, M.
Langes, M.
Gambato, R.
Morello, E.
Casini, M.
Bondanza, A.
Introna, M.
Marincola, F. M.
Cortelazzo, S.
TI B- and T-cell interactions in graft-versus-host disease
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of
the EBMT Nurses Group/10th Meeting of the EBMT Management Group
CY APR 03-06, 2011
CL Paris, FRANCE
SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp
C1 [Deola, S.; Cavattoni, I.; Pusceddu, I.; Negri, G.; Kasal, A.; Svaldi, M.; Langes, M.; Gambato, R.; Casini, M.; Cortelazzo, S.] Cent Hosp, Bolzano, Italy.
[Morello, E.] Spedali Civil Brescia, I-25125 Brescia, Italy.
[Bondanza, A.] Hosp San Raffaele, I-20132 Milan, Italy.
[Introna, M.] United Hosp Bergamo, Bergamo, Italy.
[Marincola, F. M.] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2011
VL 46
SU 1
BP S327
EP S327
PG 1
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 745VC
UT WOS:000289195402221
ER
PT J
AU Fleischhauer, K
Spellman, SR
Wang, T
Haagenson, M
Battiwalla, M
Baxter-Lowe, LA
Dehn, JW
Gajewski, JL
Hale, GA
Heemskerk, MB
Lee, SJ
McCarthy, P
Miklos, D
Oudshoorn, M
Pollack, MS
Marino, S
Reddy, V
Senitzer, D
Shaw, B
Waller, EK
Fernandez-Vina, M
AF Fleischhauer, K.
Spellman, S. R.
Wang, T.
Haagenson, M.
Battiwalla, M.
Baxter-Lowe, L. A.
Dehn, J. W.
Gajewski, J. L.
Hale, G. A.
Heemskerk, M. B.
Lee, S. J.
McCarthy, P.
Miklos, D.
Oudshoorn, M.
Pollack, M. S.
Marino, S.
Reddy, V.
Senitzer, D.
Shaw, B.
Waller, E. K.
Fernandez-Vina, M.
TI Non-permissive HLA-DPB1 T-cell epitope disparities are associated with
non-relapse mortality after unrelated stem cell transplantation and are
not dependent on HLA-DPA1
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of
the EBMT Nurses Group/10th Meeting of the EBMT Management Group
CY APR 03-06, 2011
CL Paris, FRANCE
SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp
C1 [Fleischhauer, K.] Ist Sci San Raffaele, I-20132 Milan, Italy.
[Spellman, S. R.; Haagenson, M.] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA.
[Wang, T.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Battiwalla, M.] NHLBI, NIH, Bethesda, MD 20892 USA.
[Baxter-Lowe, L. A.] Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA.
[Dehn, J. W.] Natl Marrow Donor Program, Minneapolis, MN USA.
[Gajewski, J. L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Hale, G. A.] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA.
[Heemskerk, M. B.] Dutch Transplant Fdn, Leiden, Netherlands.
[Lee, S. J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[McCarthy, P.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Miklos, D.] Stanford Hosp & Clin, Stanford, CA USA.
[Oudshoorn, M.] Europdonor Fdn, Leiden, Netherlands.
[Pollack, M. S.] UTHSC Vet Hlth Care Syst, San Antonio, TX USA.
[Marino, S.] Univ Chicago, Chicago, IL 60637 USA.
[Reddy, V.] Florida Ctr Cellular Therapy, Orlando, FL USA.
[Senitzer, D.] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Shaw, B.] Anthony Nolan Res Inst, London, England.
[Waller, E. K.] Emory Univ Hosp, Atlanta, GA 30322 USA.
[Fernandez-Vina, M.] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2011
VL 46
SU 1
BP S74
EP S74
PG 1
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 745VC
UT WOS:000289195400170
ER
PT J
AU Fujiwara, H
Nagai, K
Ochi, T
An, J
Shirakata, T
Mineno, J
Kuzushima, K
Shiku, H
Melenhorst, J
Gostic, E
Price, D
Yasukawa, M
AF Fujiwara, H.
Nagai, K.
Ochi, T.
An, J.
Shirakata, T.
Mineno, J.
Kuzushima, K.
Shiku, H.
Melenhorst, J.
Gostic, E.
Price, D.
Yasukawa, M.
TI Engineered T-lymphocytes using a novel anti-leukaemia antigen, aurora-A
kinase-specific T-cell receptor gene transfer successfully displayed
anti-leukaemia reactivity
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of
the EBMT Nurses Group/10th Meeting of the EBMT Management Group
CY APR 03-06, 2011
CL Paris, FRANCE
SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp
C1 [Fujiwara, H.; Nagai, K.; Ochi, T.; An, J.; Shirakata, T.; Yasukawa, M.] Ehime Univ, Toon, Japan.
[Mineno, J.] Takara Bio Inc, Otsu, Shiga, Japan.
[Kuzushima, K.] Aichi Canc Ctr, Nagoya, Aichi 464, Japan.
[Shiku, H.] Mie Univ, Tsu, Mie 514, Japan.
[Melenhorst, J.] NHLBI, Bethesda, MD 20892 USA.
[Gostic, E.; Price, D.] Cardiff Univ, Cardiff, S Glam, Wales.
RI Price, David/C-7876-2013
OI Price, David/0000-0001-9416-2737
NR 0
TC 0
Z9 0
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2011
VL 46
SU 1
BP S1
EP S1
PG 1
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 745VC
UT WOS:000289195400002
ER
PT J
AU Reddy, P
Toubai, T
Matzinger, P
Tawara, I
Sun, Y
Friedman, T
Korngold, R
AF Reddy, P.
Toubai, T.
Matzinger, P.
Tawara, I.
Sun, Y.
Friedman, T.
Korngold, R.
TI Contribution of sex-mismatched HY antigen expression and its
cross-presentation in the induction of GvHD despite the absence of
epitope spreading
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of
the EBMT Nurses Group/10th Meeting of the EBMT Management Group
CY APR 03-06, 2011
CL Paris, FRANCE
SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp
C1 [Reddy, P.; Toubai, T.; Tawara, I.; Sun, Y.] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA.
[Matzinger, P.] NIH, Bethesda, MD 20892 USA.
[Friedman, T.; Korngold, R.] Hackensack Canc Ctr, Hackensack, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2011
VL 46
SU 1
BP S238
EP S238
PG 1
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 745VC
UT WOS:000289195401394
ER
PT J
AU Switzer, G
Harrington, D
Haagenson, M
Drexler, R
Foley, A
Confer, D
Bishop, M
Anderlini, P
Rowley, S
Leitman, S
Anasetti, C
Wingard, JR
AF Switzer, G.
Harrington, D.
Haagenson, M.
Drexler, R.
Foley, A.
Confer, D.
Bishop, M.
Anderlini, P.
Rowley, S.
Leitman, S.
Anasetti, C.
Wingard, J. R.
TI Early post-donation health-related quality-of-life and recovery among
adult unrelated stem cell donors: a planned subgroup analysis of a
randomized trial of marrow versus PBSC donation
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of
the EBMT Nurses Group/10th Meeting of the EBMT Management Group
CY APR 03-06, 2011
CL Paris, FRANCE
SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp
C1 [Switzer, G.; Harrington, D.] Univ Pittsburgh, Pittsburgh, PA USA.
[Haagenson, M.; Drexler, R.; Foley, A.; Confer, D.] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA.
[Wingard, J. R.] Univ Florida, Coll Med, Gainesville, FL USA.
[Anderlini, P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Rowley, S.] John Theurer Canc Ctr, Hackensack, NJ USA.
[Leitman, S.] NIH, Ctr Canc, Bethesda, MD 20892 USA.
[Anasetti, C.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2011
VL 46
SU 1
BP S72
EP S73
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 745VC
UT WOS:000289195400167
ER
PT J
AU Bottino, MC
Cerliani, JP
Rojas, P
Giulianelli, S
Soldati, R
Mondillo, C
Gorostiaga, MA
Pignataro, OP
Calvo, JC
Gutkind, JS
Amornphimoltham, P
Molinolo, AA
Luthy, IA
Lanari, C
AF Cecilia Bottino, Maria
Pablo Cerliani, Juan
Rojas, Paola
Giulianelli, Sebastian
Soldati, Rocio
Mondillo, Carolina
Alicia Gorostiaga, Maria
Pignataro, Omar P.
Carlos Calvo, Juan
Gutkind, J. Silvio
Amornphimoltham, Panomwat
Molinolo, Alfredo A.
Luethy, Isabel A.
Lanari, Claudia
TI Classical membrane progesterone receptors in murine mammary carcinomas:
agonistic effects of progestins and RU-486 mediating rapid non-genomic
effects
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Membrane progesterone receptors; Mammary carcinomas; Progesterone
receptor isoforms: membrane-initiated steroid signaling; Antiprogestins;
Breast cancer treatment; Non-genomic effects; Progestins
ID ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; EPIDERMAL-GROWTH-FACTOR;
ESTROGEN-RECEPTOR; MEDROXYPROGESTERONE ACETATE; SIGNALING PATHWAYS;
BINDING-SITES; IN-VITRO; METASTATIC PHENOTYPE; CYCLE PROGRESSION
AB In this article, we demonstrate the expression of functional progesterone binding sites at the cell membrane in murine mammary carcinomas that are stimulated by progestins and inhibited by antiprogestins. Using confocal immunofluorescence, ligand binding and cell compartment-specific western blots, we were able to identify the presence of the classical progesterone receptors. Medroxyprogesterone acetate (MPA) and RU-486 (1 x 10(-11) and 1 x 10(-8) M) behaved as agonists activating extracellular signal-regulated kinases (ERKs) and progestin-regulated proteins, except for Cyclin D1 and Tissue factor which failed to increase with 1 x 10(-8) M RU-486, an experimental condition that allows PR to bind DNA. These results predicted a full agonist effect at low concentrations of RU-486. Accordingly, at concentrations lower than 1 x 10(-11) M, RU-486 increased cell proliferation in vitro. This effect was abolished by incubation with the ERK kinase inhibitor PD 98059 or by OH-tamoxifen. In vivo, at a daily dose of 1.2 mu g/kg body weight RU-486 increased tumor growth, whereas at 12 mg/kg induces tumor regression. Our results indicate that low concentrations of MPA and RU-486 induce similar agonistic non-genomic effects, whereas RU-486 at higher concentrations may inhibit cell proliferation by genomic-induced effects. This suggests that RU-486 should be therapeutically administered at doses high enough to guarantee its genomic inhibitory effect.
C1 [Cecilia Bottino, Maria; Pablo Cerliani, Juan; Rojas, Paola; Giulianelli, Sebastian; Soldati, Rocio; Mondillo, Carolina; Alicia Gorostiaga, Maria; Lanari, Claudia] Consejo Nacl Invest Cient & Tecn CONICET, Lab Carcinogenesis Hormonal, Inst Biol & Med Expt, Buenos Aires, DF, Argentina.
[Luethy, Isabel A.] Consejo Nacl Invest Cient & Tecn CONICET, Lab Hormonas & Canc, Inst Biol & Med Expt, Buenos Aires, DF, Argentina.
[Pignataro, Omar P.; Carlos Calvo, Juan] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Buenos Aires, DF, Argentina.
[Gutkind, J. Silvio; Amornphimoltham, Panomwat; Molinolo, Alfredo A.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA.
RP Lanari, C (reprint author), Consejo Nacl Invest Cient & Tecn CONICET, Lab Carcinogenesis Hormonal, Inst Biol & Med Expt, Vuelta Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina.
EM clanari@dna.uba.ar
RI Gutkind, J. Silvio/A-1053-2009;
OI Luthy, Isabel/0000-0001-7603-6649
FU ANPCyT [PICT 07-932, PICT 05-38302]; CONICET [PIP 5351]; Institute of
Dental and Craniofacial Research, National Institutes of Health,
Bethesda, MD; UICC; Avon Foundation; Fundacion Sales
FX This work was supported by Fundacion Sales, ANPCyT (PICT 07-932 and PICT
05-38302), CONICET (PIP 5351). Drs. Gutkind, Amornphimoltham and
Molinolo are supported by the Intramural Research Program of the
Institute of Dental and Craniofacial Research, National Institutes of
Health, Bethesda, MD. We are very grateful to Dr. Elisa Bal de Kier
Joffe for providing LM3 cells, to Julieta Bolado and to Pablo Do Campo
for excellent technical assistance, and to Laboratorios Craveri, Buenos
Aires for providing MPA depot and to Bayer Schering Pharma AG for the
ZK230211. We also wish to thank Avon Foundation for an AACR travel award
to MC Bottino and the UICC for an ICRETT fellowship to MC Bottino.
NR 79
TC 11
Z9 11
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD APR
PY 2011
VL 126
IS 3
BP 621
EP 636
DI 10.1007/s10549-010-0971-3
PG 16
WC Oncology
SC Oncology
GA 735VP
UT WOS:000288449000007
PM 20535544
ER
PT J
AU Simila, ME
Valsta, LM
Kontto, JP
Albanes, D
Virtamo, J
AF Simila, Minna E.
Valsta, Liisa M.
Kontto, Jukka P.
Albanes, Demetrius
Virtamo, Jarmo
TI Low-, medium- and high-glycaemic index carbohydrates and risk of type 2
diabetes in men
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Glycaemic index; Glycaemic load; Carbohydrates; Type 2 diabetes;
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study
ID IMPAIRED GLUCOSE-TOLERANCE; DIETARY FIBER INTAKE; LOAD; WOMEN; MELLITUS;
PREVENTION; INSULIN; DISEASE; CONSUMPTION; CANCER
AB Findings on dietary glycaemic index (GI) and glycaemic load (GL) as risk factors for type 2 diabetes have been controversial. We examined the associations of dietary GI and GL and the associations of substitution of lower-GI carbohydrates for higher-GI carbohydrates with diabetes risk in a cohort of Finnish men. The cohort consisted of 25 943 male smokers aged 50-69 years. Diet was assessed, at baseline, using a validated diet history questionnaire. During a 12-year follow-up, 1098 incident diabetes cases were identified from a national register. Cox proportional hazard modelling was used to estimate the risk of diabetes, and multivariate nutrient density models were used to examine the effects of substitution of different carbohydrates. Dietary GI and GL were not associated with diabetes risk; multivariate relative risk (RR) for highest v. lowest quintile for GI was 0.87 (95% CI 0.71, 1.07) and for GL 0.88 (95% CI 0.65, 1.17). Substitution of medium-GI carbohydrates for high-GI carbohydrates was inversely associated with diabetes risk (multivariate RR for highest v. lowest quintile 0.75, 95% CI 0.59, 0.96), but substitution of low-GI carbohydrates for medium-or high-GI carbohydrates was not associated with the risk. In conclusion, dietary GI and GL were not associated with diabetes risk, and substitutions of lower-GI carbohydrates for higher-GI carbohydrates were not consistently associated with a lower diabetes risk. The associations of dietary GI and GL with diabetes risk should be interpreted by considering nutritional correlates, as foods may have different properties that affect risk.
C1 [Simila, Minna E.; Valsta, Liisa M.; Kontto, Jukka P.; Virtamo, Jarmo] Natl Inst Hlth & Welf, Div Welf & Hlth Promot, FI-00271 Helsinki, Finland.
[Albanes, Demetrius] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
RP Simila, ME (reprint author), Natl Inst Hlth & Welf, Div Welf & Hlth Promot, POB 30, FI-00271 Helsinki, Finland.
EM minna.simila@thl.fi
RI Albanes, Demetrius/B-9749-2015;
OI Kontto, Jukka/0000-0003-3899-9852
FU Academy of Finland [111420]; Ministry of Agriculture and Forestry;
Finnish Cultural Foundation; Kyllikki and Uolevi Lehikoinen Foundation;
Juho Vainio Foundation; Yrjo Jahnsson Foundation; National Cancer
Institute [N01-CN-45165, N01-RC-45035, N01-RC-37004]
FX The present study was supported by the Academy of Finland (grant no.
111420), the Ministry of Agriculture and Forestry, Doctoral Programmes
in Public Health, the Finnish Cultural Foundation, the Kyllikki and
Uolevi Lehikoinen Foundation, the Juho Vainio Foundation and the Yrjo
Jahnsson Foundation. The ATBC Study was supported by US Public Health
Service contracts (N01-CN-45165, N01-RC-45035 and N01-RC-37004) from the
National Cancer Institute. M. E. S., L. M. V. and J. V. contributed to
the conception and design of the present study. M. E. S. and J. P. K.
performed the statistical analysis. M. E. S. wrote the manuscript. All
authors participated in the critical revision of the manuscript. None of
the authors had any personal or financial conflict of interest.
NR 33
TC 9
Z9 9
U1 1
U2 10
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD APR
PY 2011
VL 105
IS 8
BP 1258
EP 1264
DI 10.1017/S000711451000485X
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 739VS
UT WOS:000288748700017
PM 21114892
ER
PT J
AU Anderson, CD
Nalls, MA
Biffi, A
Rost, NS
Greenberg, SM
Singleton, AB
Meschia, JF
Rosand, J
AF Anderson, Christopher D.
Nalls, Michael A.
Biffi, Alessandro
Rost, Natalia S.
Greenberg, Steven M.
Singleton, Andrew B.
Meschia, James F.
Rosand, Jonathan
TI The Effect of Survival Bias on Case-Control Genetic Association Studies
of Highly Lethal Diseases
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE stroke; hemorrhage; myocardial infarction; genetics; epidemiology
ID UNRECOGNIZED MYOCARDIAL-INFARCTION; CASE-FATALITY; STROKE INCIDENCE;
GENOMEWIDE ASSOCIATION; POPULATION; EPIDEMIOLOGY; REGISTRY; RISK;
PREVALENCE; ROTTERDAM
AB Background-Survival bias is the phenomenon by which individuals are excluded from analysis of a trait because of mortality related to the expression of that trait. In genetic association studies, variants increasing risk for disease onset as well as risk of disease-related mortality (lethality) could be difficult to detect in genetic association case-control designs, possibly leading to underestimation of a variant's effect on disease risk.
Methods and Results-We modeled cohorts for 3 diseases of high lethality (intracerebral hemorrhage, ischemic stroke, and myocardial infarction) using existing longitudinal data. Based on these models, we simulated case-control genetic association studies for genetic risk factors of varying effect sizes, lethality, and minor allele frequencies. For each disease, erosion of detected effect size was larger for case-control studies of individuals of advanced age (age >75 years) and/or variants with very high event-associated lethality (genotype relative risk for event-related death >2.0). We found that survival bias results in no more than 20% effect size erosion for cohorts with mean age <75 years, even for variants that double lethality risk. Furthermore, we found that increasing effect size erosion was accompanied by depletion of minor allele frequencies in the case population, yielding a "signature" of the presence of survival bias.
Conclusions-Our simulation provides formulas to allow estimation of effect size erosion given a variant's odds ratio of disease, odds ratio of lethality, and minor allele frequencies. These formulas will add precision to power calculation and replication efforts for case-control genetic studies. Our approach requires validation using prospective data. (Circ Cardiovasc Genet. 2011;4:188-196.)
C1 [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Hemorrhag Stroke Res Grp, Dept Neurol, Boston, MA 02114 USA.
[Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Rosand, Jonathan] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Nalls, Michael A.; Singleton, Andrew B.] NIA, Neurogenet Lab, Intramural Res Program, Bethesda, MD 20892 USA.
[Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
RP Rosand, J (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St,CPZN 6818, Boston, MA 02114 USA.
EM jrosand@partners.org
RI Singleton, Andrew/C-3010-2009;
OI Anderson, Christopher/0000-0002-0053-2002
FU American Heart Association/Bugher Foundation Centers for Stroke
Prevention Research [0775011N, 0755984T]; Deane Institute for
Integrative Study of Atrial Fibrillation and Stroke; National Institute
for Neurologic Disorders and Stroke [R01 NS063925, R01 NS059727, P50
NS051343, K23NS064052-01A1]; National Institute of Health, National
Institute on Aging [Z01-AG000954-06:2007]
FX This work was supported by funding from the American Heart
Association/Bugher Foundation Centers for Stroke Prevention Research
(0775011N, 0755984T), Deane Institute for Integrative Study of Atrial
Fibrillation and Stroke, and the National Institute for Neurologic
Disorders and Stroke (R01 NS063925, R01 NS059727, P50 NS051343,
K23NS064052-01A1). This research was also supported in part by the
Intramural Research Program of the National Institute of Health,
National Institute on Aging, under Annual Report No.
Z01-AG000954-06:2007.
NR 33
TC 15
Z9 18
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD APR
PY 2011
VL 4
IS 2
BP 188
EP U265
DI 10.1161/CIRCGENETICS.110.957928
PG 19
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA 752SA
UT WOS:000289712700015
PM 21292865
ER
PT J
AU Robey, RW
Ierano, C
Zhan, ZR
Bates, SE
AF Robey, Robert W.
Ierano, Caterina
Zhan, Zhirong
Bates, Susan E.
TI The Challenge of Exploiting ABCG2 in the Clinic
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Review
DE ABCG2/BCRP; blood-brain barrier; CNS penetration; drug resistance; gout;
oral bioavailability; Q141K; single nucleotide polymorphism
ID CANCER-RESISTANCE-PROTEIN; ACUTE-MYELOID-LEUKEMIA; ACUTE
LYMPHOBLASTIC-LEUKEMIA; BINDING CASSETTE TRANSPORTER; TYROSINE KINASE
INHIBITOR; REVERSES MULTIDRUG-RESISTANCE; MESSENGER-RNA EXPRESSION; CELL
LUNG-CANCER; HIGH-AFFINITY INTERACTION; CALCIUM-CHANNEL BLOCKERS
AB ABCG2, or breast cancer resistance protein (BCRP), is an ATP-binding cassette half-transporter that has been shown to transport a wide range of substrates including chemotherapeutics, antivirals, antibiotics and flavonoids. Given its wide range of substrates, much work has been dedicated to developing ABCG2 as a clinical target. But where can we intervene clinically and how can we avoid the mistakes made in past clinical trials targeting P-glycoprotein? This review will summarize the normal tissue distribution, cancer tissue expression, substrates and inhibitors of ABCG2, and highlight the challenges presented in exploiting ABCG2 in the clinic. We discuss the possibility of inhibiting ABCG2, so as to increase oral bioavailability or increase drug penetration into sanctuary sites, especially the central nervous system; and at the other end of the spectrum, the possibility of improving ABCG2 function, in the case of gout caused by a single nucleotide polymphism. Together, these aspects of ABCG2/BCRP make the protein a target of continuing interest for oncologists, biologists, and pharmacologists.
C1 [Robey, Robert W.; Ierano, Caterina; Zhan, Zhirong; Bates, Susan E.] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA.
RP Bates, SE (reprint author), NCI, Med Oncol Branch, NIH, 9000 Rockville Pike,Bldg 10,Rm 12N226, Bethesda, MD 20892 USA.
EM sebates@helix.nih.gov
RI Ierano, Caterina/K-1676-2016
OI Ierano, Caterina/0000-0003-3138-1873
FU Intramural NIH HHS [Z99 CA999999]
NR 178
TC 34
Z9 35
U1 0
U2 16
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1389-2010
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PD APR
PY 2011
VL 12
IS 4
BP 595
EP 608
PG 14
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 753JZ
UT WOS:000289770000013
PM 21118093
ER
EF